

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM protein - protein search, using sw model

Run on: February 17, 2006, 16:58:02 ; Search time 23 Seconds
(without alignments)
16.733 Million cell updates/sec

Title: US-10-821-256-2
Perfect score: 19
Sequence: 1 AOGV 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 4989

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 80:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	19	100.0	12	H41946	T-cell receptor ga
2	19	100.0	20	S21244	H+-transporting tw
3	16	84.2	23	S54339	cytochrome P450 cy
4	15	78.9	11	PH1600	Ig H chain V-D-J r
5	15	78.9	12	C33099	146k exocantigen -
6	15	78.9	12	PH0920	T-cell receptor be
7	15	78.9	12	PH1467	T-cell receptor be
8	15	78.9	14	S23376	collagen alpha cha
9	15	78.9	14	PH0804	T-cell receptor al
10	15	78.9	14	A39703	tubulin beta-3 cha
11	15	78.9	15	PS0382	Ig heavy chain U r
12	15	78.9	15	S05700	insulin-like growt
13	15	78.9	15	B56046	urinary tract ston
14	15	78.9	15	S05699	insulin-like growt
15	15	78.9	17	S28839	RNA-binding protei
16	15	78.9	18	A36133	hypothetical prote
17	15	78.9	20	PC4385	GroEL protein homo
18	15	78.9	20	PC4386	GroEL protein homo
19	15	78.9	20	A42865	Ca2+/calmodulin-b
20	15	78.9	20	S48746	beta tubulin b-det
21	15	78.9	20	A40198	N-acetylneuraminate
22	15	78.9	22	JUN0911	N4-(beta-N-acetyl)g
23	15	78.9	22	A56868	heat shock protein
24	15	78.9	22	A48365	methanol-induced c
25	15	78.9	25	A60741	insulin-like growt
26	14	73.7	15	I65478	c-Ki-ras - hamster
27	14	73.7	15	PH1377	T antigen variant
28	14	73.7	16	PH1346	Ig heavy chain DJ
29	14	73.7	16	G49037	Tcr delta chain V-

30	14	73.7	19	2	PH1624	Ig H chain V-D-J r
31	14	73.7	20	2	S06802	outer membrane pro
32	14	73.7	21	2	S21772	lipoygenase (EC 1
33	14	73.7	21	2	P00257	microbial serine p
34	14	73.7	22	2	S68900	xanthine dehydroge
35	14	73.7	23	2	PK0011	glutamate-ammonia
36	14	73.7	23	2	B61079	listeriolysin O -
37	14	73.7	24	2	S53749	histone H4 - rat
38	13	68.4	4	2	PT0633	T-cell receptor be
39	13	68.4	5	2	PT0572	T-cell receptor be
40	13	68.4	8	2	A35180	neutral proteinase
41	13	68.4	12	2	PH0936	T-cell receptor be
42	13	68.4	12	2	PN0160	ribosomal protein
43	13	68.4	12	2	P00786	NADH2 dehydrogens
44	13	68.4	14	2	S17766	beta-glucosidase (
45	13	68.4	14	2	PS0249	porin - rice (stra

ALIGNMENTS

RESULT 1
H41946
T-cell receptor gamma chain (St.12) - mouse (fragment)
C:Species: Mus musculus (house mouse)
C:Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 07-May-1999
C:Accession: H41946
R:Whetsell, M.; Mosley, R.L.; Whetsell, L.; Schaefer, F.V.; Miller, K.S.; Klein, J.R.
Mol. Cell. Biol. 11, 5902-5909, 1991
A>Title: Rearrangement and junctional-site sequence analyses of T-cell receptor gamma ge
A:Reference number: H41946; MUID:92049316; PMID:1658619
A:Accession: H41946
A:Status: preliminary; not compared with conceptual translation
A:Molecule type: DNA
A:Residues: 1-12 <WH>
A:Cross-references: UNIPARC:UPI000017C86B
C:Keywords: T-cell receptor

Query Match 100.0%; Score 19; DB 2; Length 12;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
DB 4 AOGV 7

RESULT 2
S21244
H+-transporting two-sector ATPase (EC 3.6.3.14) delta chain - spinach mitochondrion (Ira
C:Species: mitochondrion Spinacia oleracea (spinach)
C:Date: 19-Mar-1997 #sequence_revision 01-Aug-1997 #text_change 09-Jul-2004
C:Accession: S21244
R:Hammar, B.; Glaser, E.
Eur. J. Biochem. 205, 409-416, 1992
A>Title: Plant mitochondrial F(0)F(1) ATP synthase. Identification of the individual sub
A:Reference number: S21204; MUID:92209531; PMID:1313368
A:Accession: S21244
A:Status: preliminary
A:Molecule type: protein
A:Residues: 1-20 <HAM>
A:Cross-references: UNIPROT:P80085; UNIPARC:UPI00001262D3
C:Keywords: ATP biosynthesis; hydrolase; membrane-associated complex; mitochondrion

Query Match 100.0%; Score 19; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 78;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
DB 9 AOGV 12

RESULT 3
 S54339
 Cytochrome P450 CYP2A7A5 - human
 C/Species: Homo sapiens (man)
 C/Date: 27-Oct-1995 #sequence_revision 03-Nov-1995 #text_change 07-May-1999
 C/Accession: S54339
 R/Ding, S.; Lake, B.G.; Friedberg, T.; Wolf, C.R.
 Biochem. J. 306, 161-166, 1995
 A/Title: Expression and alternative splicing of the cytochrome P-450 CYP2A7.
 A/Reference number: S54338; MUID:95165049; PMID:7864805
 A/Accession: S54339
 A/Status: preliminary
 A/Molecule type: mRNA
 A/Residues: 1-23 <DIN>
 A/Cross-references: UNIPARC:UPI000017C0D9

Query Match 84.2%; Score 16; DB 2; Length 23;
 Best Local Similarity 75.0%; Pred. No. 6.7e+02;
 Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
 |||
 Db 12 SQGV 15

RESULT 4
 PH1600
 Ig H chain V-D-J region (wild-type clone 310) - mouse (fragment)
 C/Species: Mus musculus (house mouse)
 C/Date: 02-Jun-1994 #sequence_revision 02-Jun-1994 #text_change 17-Mar-1999
 C/Accession: PH1600
 R/Levinson, D.A.; Campos-Torres, J.; Leder, P.
 J. Exp. Med. 178, 317-329, 1993
 A/Title: Molecular characterization of transgene-induced immunodeficiency in B-lees mice
 A/Reference number: PH1580; MUID:93301609; PMID:8315387
 A/Molecule type: DNA
 A/Residues: 1-11 <LEV>
 A/Cross-references: UNIPARC:UPI000017C6BD
 A/Experimental source: Bone marrow pre-B lymphocyte
 C/Keywords: Immunoglobulin

Query Match 78.9%; Score 15; DB 2; Length 11;
 Best Local Similarity 75.0%; Pred. No. 6.5e+02;
 Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
 |||
 Db 2 ARGV 5

RESULT 5
 C33099
 148K exoantigen - malaria parasite (Plasmodium falciparum) (fragments)
 C/Species: Plasmodium falciparum
 C/Date: 24-Aug-1990 #sequence_revision 24-Aug-1990 #text_change 09-Jun-2000
 C/Accession: C33099
 R/Nichols, J.H.; Hager, L.P.
 submitted to the Protein Sequence Database, May 1990
 A/Reference number: A33098
 A/Accession: C33099
 A/Status: preliminary
 A/Molecule type: protein
 A/Residues: 1-12 <NIC>
 A/Cross-references: UNIPARC:UPI000017B5DE

Query Match 78.9%; Score 15; DB 2; Length 12;
 Best Local Similarity 100.0%; Pred. No. 7e+02;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 OGV 4
 |||
 Db 3 QGV 5

RESULT 6
 PH0920
 T-cell receptor beta chain V-D-J region (isolate 6) - rat (fragment)
 C/Species: Rattus norvegicus (Norway rat)
 C/Date: 09-Oct-1992 #sequence_revision 09-Oct-1992 #text_change 30-May-1997
 C/Accession: PH0920
 R/Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.
 J. Exp. Med. 174, 1467-1476, 1991
 A/Title: Analysis of T cell receptor beta chains in Lewis rats with experimental allergic
 A/Reference number: PH0911; MUID:92078857; PMID:1836012
 A/Accession: PH0920
 A/Molecule type: mRNA
 A/Residues: 1-12 <GOL>
 A/Cross-references: UNIPARC:UPI000017C9FA
 A/Experimental source: concanavalin A-activated lymphoblast
 A/Note: the authors translated the codon CAG for residue 12 as Glu
 C/Keywords: T-cell receptor

Query Match 78.9%; Score 15; DB 2; Length 12;
 Best Local Similarity 100.0%; Pred. No. 7e+02;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOG 3
 |||
 Db 5 AOG 7

RESULT 7
 PH1467
 T-cell receptor beta chain (clone 223/27) - mouse (fragment)
 C/Species: Mus musculus (house mouse)
 C/Date: 10-Mar-1994 #sequence_revision 10-Mar-1994 #text_change 15-Mar-2004
 C/Accession: PH1467
 R/Casanova, J.L.; Martinon, F.; Gournier, H.; Barra, C.; Panretler, C.; Regnault, A.; Koi
 J. Exp. Med. 177, 811-820, 1993
 A/Title: T cell receptor selection by and recognition of two class I major histocompatibility
 A/Reference number: PH1430; MUID:931171821; PMID:8436911
 A/Accession: PH1467
 A/Molecule type: mRNA
 A/Residues: 1-12 <CAS>
 A/Cross-references: UNIPARC:UPI000017C794
 A/Experimental source: cytolytic T-lymphocyte
 C/Keywords: receptor; T-cell

Query Match 78.9%; Score 15; DB 2; Length 12;
 Best Local Similarity 100.0%; Pred. No. 7e+02;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 OGV 4
 |||
 Db 7 QGV 9

RESULT 8
 S23376
 collagen alpha chain - polychaete (Alvinella pompejana) (fragment)
 C/Species: Alvinella pompejana
 C/Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 29-May-1998
 C/Accession: S23376
 R/Gaill, F.; Wiedemann, H.; Mann, K.; Kuehn, K.; Timpl, R.; Engel, J.
 J. Mol. Biol. 221, 209-223, 1991
 A/Title: Molecular characterization of cuticle and interstitial collagens from worms col
 A/Reference number: S17581; MUID:92015209; PMID:1920405
 A/Accession: S23376
 A/Molecule type: protein
 A/Residues: 1-14 <GAI>
 A/Cross-references: UNIPARC:UPI000017BD70

Query Match 78.9%; Score 15; DB 2; Length 14;
 Best Local Similarity 100.0%; Pred. No. 8.2e+02;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOG 3
 DB 3 AOG 5

RESULT 9

PH0804
 T-cell receptor alpha chain (L4) - mouse (fragment)
 C/Species: Mus musculus (house mouse)
 C/Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 30-May-1997
 C/Accession: PH0804
 R/Casanova, J.L.; Romero, P.; Widmann, C.; Kourilsky, P.; Marjanek, J.L.
 J. Exp. Med. 174, 1371-1383, 1991
 A/Title: T cell receptor genes in a series of class I major histocompatibility complex-II allelic exclusion and antigen-specific repertoire.
 A/Reference number: PH0746; MUID:92078846; PMID:1836010
 A/Accession: PH0804
 A/Molecule type: mRNA
 A/Residues: 1-14 <CAS>
 A/Cross-references: UNIPARC:UPI000017C77A; EMBL:X60913
 A/Experimental source: T lymphocyte
 C/Keywords: T-cell receptor

Query Match 78.9%; Score 15; DB 2; Length 14;
 Best Local Similarity 100.0%; Pred. No. 8.2e+02;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOG 3
 DB 5 AOG 7

RESULT 10

A39703
 tubulin beta-3 chain - bovine (fragment)
 C/Species: Bos primigenius taurus (cattle)
 C/Date: 08-Nov-1991 #sequence_revision 08-Nov-1991 #text_change 09-Jul-2004
 C/Accession: A39703
 R/Alexander, J.E.; Hunt, D.F.; Lee, M.K.; Shabanowitz, J.; Michel, H.; Berlin, S.C.; Mac
 Proc. Natl. Acad. Sci. U.S.A. 88, 4685-4689, 1991
 A/Title: Characterization of posttranslational modifications in neuron-specific class II
 A/Reference number: A39703; MUID:91271258; PMID:2052551
 A/Accession: A39703
 A/Status: preliminary
 A/Molecule type: protein
 A/Residues: 1-14 <ALC>
 A/Cross-references: UNIPROT:Q7M2L3; UNIPARC:UPI000017C586

Query Match 78.9%; Score 15; DB 2; Length 14;
 Best Local Similarity 100.0%; Pred. No. 8.2e+02;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOG 3
 DB 10 AOG 12

RESULT 11

PS0382
 Ig heavy chain J region 2 - rat (fragment)
 C/Species: Rattus norvegicus (Norway rat)
 C/Date: 09-Oct-1992 #sequence_revision 09-Oct-1992 #text_change 06-Jun-1997
 C/Accession: PS0382
 R/Lang, P.; Mocikat, R.
 Gene 102, 261-264, 1991
 A/Title: Immunoglobulin heavy-chain joining genes in the rat: comparison with mouse and
 A/Accession: PS0382
 A/Reference number: JH0666; MUID:91340162; PMID:1908401
 A/Molecule type: DNA
 A/Residues: 1-15 <LAN>
 A/Cross-references: UNIPARC:UPI000017693B; EMBL:X56791
 C/Superfamily: Immunoglobulin V region; Immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

Query Match 78.9%; Score 15; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 8.7e+02;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 QGV 4
 DB 7 QGV 9

RESULT 12

S05700
 insulin-like growth factor-binding protein, adult - human (fragment)
 C/Species: Homo sapiens (man)
 C/Date: 30-Sep-1991 #sequence_revision 30-Sep-1991 #text_change 18-Jun-1993
 C/Accession: S05700
 R/Roghani, M.; Hossenlopp, P.; Lepage, P.; Bolland, A.; Binoux, M.
 FEBS Lett. 255, 253-258, 1989
 A/Title: Isolation from human cerebrospinal fluid of a new insulin-like growth factor-bi
 A/Reference number: S05699; MUID:90005986; PMID:2551732
 A/Accession: S05700
 A/Molecule type: protein
 A/Residues: 1-15 <ROG>
 A/Cross-references: UNIPARC:UPI000017C274

Query Match 78.9%; Score 15; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 8.7e+02;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 QGV 4
 DB 7 QGV 9

RESULT 13

B56046
 urinary tract stone matrix protein 2, 21K - human (fragment)
 C/Species: Homo sapiens (man)
 C/Date: 12-Apr-1995 #sequence_revision 12-Apr-1995 #text_change 12-Apr-1995
 C/Accession: B56046
 R/Binette, J.P.; Binette, M.B.; Gawinowicz, M.A.; Kendrick, N.
 submitted to the Protein Sequence Database, February 1995
 A/Description: Isolation, characterization and sequence of stone proteins.
 A/Reference number: A56046
 A/Accession: B56046
 A/Status: preliminary
 A/Molecule type: protein
 A/Residues: 1-15 <BIN>
 A/Cross-references: UNIPARC:UPI000017C408

Query Match 78.9%; Score 15; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 8.7e+02;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 QGV 4
 DB 5 QGV 7

RESULT 14

S05699
 insulin-like growth factor-binding protein, juvenile - human (fragment)
 C/Species: Homo sapiens (man)
 C/Date: 30-Sep-1991 #sequence_revision 30-Sep-1991 #text_change 09-Jul-2004
 C/Accession: S05699
 R/Roghani, M.; Hossenlopp, P.; Lepage, P.; Bolland, A.; Binoux, M.
 FEBS Lett. 255, 253-258, 1989
 A/Title: Isolation from human cerebrospinal fluid of a new insulin-like growth factor-bi
 A/Reference number: S05699; MUID:90005986; PMID:2551732
 A/Accession: S05699
 A/Molecule type: protein
 A/Residues: 1-15 <ROG>

A;Cross-references: UNIPROT:P24592; UNIPARC:UPI000017C276

Query Match 78.9%; Score 15; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 8.7e+02;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 QGV 4
 |||
 Db 7 QGV 9

RESULT 15

S28839

RNA-binding protein, 28K - garden pea (fragment)

C;Species: Pisum sativum (garden pea)

C;Date: 19-Mar-1997 #sequence_revision 10-Oct-1997 #text_change 09-Jul-2004

C;Accession: S28839

R;Subbatah, C.C.; Tewart, K.K.

Eur. J. Biochem. 211, 171-179, 1993

A;Title: Purification and characterization of ribonucleoproteins from pea chloroplasts.

A;Reference number: S28837; MUID:91145944; PMID:8425527

A;Accession: S28839

A;Molecule type: protein

A;Residues: 1-17 <SUB>

A;Cross-references: UNIPROT:Q9T2K3; UNIPARC:UPI0000096D45

A;Experimental source: cv. Arkel

C;Function:

A;Description: may be involved in post-transcriptional regulation of plastid genes

C;Keywords: chloroplast; transcription regulation

Query Match 78.9%; Score 15; DB 2; Length 17;

Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOG 3
 |||
 Db 2 AOG 4

Search completed: February 17, 2006, 17:03:28
 Job time : 24 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: February 17, 2006, 16:53:37 ; Search time 144.5 Seconds
(without alignments)
19.530 Million cell updates/sec

Title: US-10-821-256-2
Perfect score: 19
Sequence: 1 AGGV 4

Scoring table: BIOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 21620

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Uniprot 05.80:*
1: uniprot_sprot:*
2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	100.0	20	1	ATP4_SPTOL	P80085 spinach ol
2	94.7	15	2	065177_MESCR	065177 mesembryant
3	94.7	20	2	Q9R4C7_MYCAV	Q9R4C7 mycobacteri
4	94.7	22	2	Q9TRB1_BOVIN	Q9TRB1 bos taurus
5	84.2	10	2	Q75SW3_ECOLI	Q75SW3 escherichia
6	84.2	18	2	06LC88_MOUSE	06LC88 mus musculus
7	84.2	19	2	Q9PS70_CHICK	Q9PS70 gallus gall
8	84.2	20	2	P82666_BOVIN	P82666 bos taurus
9	84.2	23	2	Q9UCS1_HUMAN	Q9UCS1 homo sapien
10	78.9	8	2	Q28866_MEGNO	Q28866 megaphera n
11	78.9	10	1	TRP5_LEUUA	P81737 leucophaea
12	78.9	11	2	Q9X9S6_STRLI	Q9X9S6 streptomyce
13	78.9	11	2	065207_MOUSE	065207 mus musculu
14	78.9	12	2	Q7Y7W2_SGARY	Q7Y7W2 suaeda pros
15	78.9	12	2	Q7Y7W3_SGARY	Q7Y7W3 suaeda fals
16	78.9	12	2	Q7Y7W4_SGARY	Q7Y7W4 suaeda ifni
17	78.9	12	2	Q7Y7W5_SGARY	Q7Y7W5 suaeda hete
18	78.9	12	2	Q7Y7W6_SGARY	Q7Y7W6 suaeda frut
19	78.9	12	2	Q7Y7W7_SGARY	Q7Y7W7 suaeda corn
20	78.9	12	2	Q7Y7W8_SGARY	Q7Y7W8 suaeda corn
21	78.9	12	2	Q7Y7W9_SGARY	Q7Y7W9 suaeda corn
22	78.9	12	2	Q7Y7W10_SGARY	Q7Y7W10 suaeda corn
23	78.9	12	2	Q7Y7W11_SGARY	Q7Y7W11 suaeda corn
24	78.9	12	2	Q7Y7W12_SGARY	Q7Y7W12 suaeda corn
25	78.9	12	2	Q7Y7W13_SGARY	Q7Y7W13 suaeda corn
26	78.9	12	2	Q7Y7W14_SGARY	Q7Y7W14 suaeda corn
27	78.9	12	2	Q7Y7W15_SGARY	Q7Y7W15 suaeda corn
28	78.9	12	2	Q7Y7W16_SGARY	Q7Y7W16 suaeda corn
29	78.9	12	2	Q7Y7W17_SGARY	Q7Y7W17 suaeda corn
30	78.9	12	2	Q7Y7W18_SGARY	Q7Y7W18 suaeda corn
31	78.9	12	2	Q7Y7W19_SGARY	Q7Y7W19 suaeda corn

32	15	78.9	12	2	Q7Y7W20_SGARY	Q7Y7W20 suaeda corn
33	15	78.9	12	2	Q7Y7W21_SGARY	Q7Y7W21 suaeda corn
34	15	78.9	12	2	Q7Y7W22_SGARY	Q7Y7W22 suaeda corn
35	15	78.9	12	2	Q7Y7W23_SGARY	Q7Y7W23 suaeda corn
36	15	78.9	12	2	Q7Y7W24_SGARY	Q7Y7W24 suaeda corn
37	15	78.9	12	2	Q7Y7W25_SGARY	Q7Y7W25 suaeda corn
38	15	78.9	12	2	Q7Y7W26_SGARY	Q7Y7W26 suaeda corn
39	15	78.9	12	2	Q7Y7W27_SGARY	Q7Y7W27 suaeda corn
40	15	78.9	12	2	Q7Y7W28_SGARY	Q7Y7W28 suaeda corn
41	15	78.9	12	2	Q7Y7W29_SGARY	Q7Y7W29 suaeda corn
42	15	78.9	12	2	Q7Y7W30_SGARY	Q7Y7W30 suaeda corn
43	15	78.9	12	2	Q7Y7W31_SGARY	Q7Y7W31 suaeda corn
44	15	78.9	12	2	Q7Y7W32_SGARY	Q7Y7W32 suaeda corn
45	15	78.9	12	2	Q7Y7W33_SGARY	Q7Y7W33 suaeda corn

ALIGNMENTS

RESULT 1
ATP4_SPTOL STANDARD, PRT, 20 AA.
ID ATP4_SPTOL
AC P80085;
DT 01-MAY-1992 (Rel. 22, Created)
DT 01-MAY-1992 (Rel. 22, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE ATP synthase delta, chain, mitochondrial (EC 3.6.3.14) (Fragment).
OS Spinacia oleracea (Spinach).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
OC Caryophyllales; Amaranthaceae; Spinacia.
NC NCBI_TaxID=3562;
LN [1]
RN PROTEIN SEQUENCE.
RP STRAIN=cv. Medania; TISSUE=leaf mesophyll;
RX MEDLINE=92209531; PubMed=1313368;
RA Haneaur B., Glaeser E.;
RT "Plant mitochondrial FOF1 ATP synthase. Identification of the
RT individual subunits and properties of the purified spinach leaf
RT mitochondrial ATP synthase."
RL Eur. J. Biochem. 205:409-416(1992).
CC -1- FUNCTION: Produces ATP from ADP in the presence of a proton
CC gradient across the membrane.
CC -1- FUNCTION: This is one of the 5 chains of the enzymatic component
CC (coupling factor CF(1)) of the mitochondrial ATPase complex.
CC -1- CATALYTIC ACTIVITY: ATP + H(2)O + H(+) (In) = ADP + phosphate +
CC H(+) (Out).
CC -1- SUBUNIT: F-type ATPases have 2 components, CF(1) - the catalytic
CC core - and CF(0) - the membrane proton channel. CF(1) has five
CC subunits: alpha(3), beta(3), gamma(1), delta(1), epsilon(1). CF(0)
CC has three main subunits: a, b and c.
CC -1- SUBCELLULAR LOCATION: Mitochondrial.
CC -1- SIMILARITY: Belongs to the ATPase epsilon chain family.
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC PIR: S21244; S21244.
KW ATP synthase; CF(1); Direct protein sequencing;
KW Hydrogen ion transport; Hydrolyase; Ion transport; Mitochondrion;
KW Transport.
FT NON TER 20
SQ SEQUENCE 20 AA: 2025A964CAB991A3 CRC64;
Query Match 100.0%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 AGGV 4
||||

Db 9 ACGV 12

RESULT 2

065177 MESCR PRELIMINARY; PRT; 15 AA.

AC 065177;

DT 01-AUG-1998 (TReMBLrel. 07, Last sequence update)

DT 01-DEC-2001 (TReMBLrel. 19, Last annotation update)

DE Thigot responsive protein homolog (Fragment).

OS Mesembryanthemum crystallinum (Common ice plant).

OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

OC Caryophyllales; Magnoliophyta; eudicotyledons; core eudicots;

OC NCBI_TaxID=3544;

OK [1]

RP NUCLEOTIDE SEQUENCE.

RC TISSUE=Root;

RA Michalowski C.B., Bohnert H.J.;

RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.

DR EMBL; AF054444; AAC14178.1; -, mRNA.

FT NON TER 1

SO SEQUENCE 15 AA; 1607 MW; 4137EDD9B3FC21 CRC64;

Query Match 94.7%; Score 18; DB 2; Length 15;

Best Local Similarity 75.0%; Pred. No. 9.9e+02;

Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 ACGV 4

Db 9 ACGI 12

RESULT 3

09R4C7 MYCAV PRELIMINARY; PRT; 20 AA.

AC 09R4C7;

DT 01-MAY-2000 (TReMBLrel. 13, Created)

DT 01-MAY-2000 (TReMBLrel. 13, Last sequence update)

DE 35 kDa EGF-binding protein (Fragment).

OS Mycobacterium avium.

OC Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;

OC Corynebacterineae; Mycobacteriaceae; Mycobacterium;

OC NCBI_TaxID=1764;

OK [1]

RP PROTEIN SEQUENCE.

RX MEDLINE=66333319; PubMed=8757813;

RA Bermudez L.E., Petrofsky M., Shelton K.;

RT "Epidermal growth factor-binding protein in mycobacterium avium and

mycobacterium tuberculosis: a possible role in the mechanism of

infection."

RL Infect. Immun. 64:2917-2922(1996).

SO SEQUENCE 20 AA; 2174 MW; BEA563671F69778 CRC64;

Query Match 94.7%; Score 18; DB 2; Length 20;

Best Local Similarity 75.0%; Pred. No. 1.3e+03;

Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 ACGV 4

Db 1 ACGI 4

RESULT 4

09TRB1 BOVIN PRELIMINARY; PRT; 22 AA.

AC 09TRB1;

DT 01-MAY-2000 (TReMBLrel. 13, Created)

DT 01-MAY-2000 (TReMBLrel. 13, Last sequence update)

DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)

DE ATP-dependent 20 S proteasome activator (Fragment).

OS Bos taurus (Bovine).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;

OC Pecora; Bovidae; Bovinae; Bos.

OK NCBI_TaxID=9913;

OK [1]

RP PROTEIN SEQUENCE.

RX MEDLINE=94342244; PubMed=8063704;

RA Demarino G.N., Mooney C.R., Zagnitko O.P., Proske R.J., Chu-Ping M.,

Atendino S.J., Swatfield J.C., Slaughter C.A.;

RT "PA700, an ATP-dependent activator of the 20 S proteasome, is an

ATPase containing multiple members of a nucleotide-binding protein

family."

RL J. Biol. Chem. 269:20878-20884(1994).

SO SEQUENCE 22 AA; 2195 MW; FE139DACP4AE9BE CRC64;

Query Match 94.7%; Score 18; DB 2; Length 22;

Best Local Similarity 75.0%; Pred. No. 1.4e+03;

Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 ACGV 4

Db 6 ACGI 9

RESULT 5

075SW3_ECOLI PRELIMINARY; PRT; 10 AA.

AC 075SW3;

DT 05-JUL-2004 (TReMBLrel. 27, Created)

DT 05-JUL-2004 (TReMBLrel. 27, Last sequence update)

DT 10-MAY-2005 (TReMBLrel. 30, Last annotation update)

DE Sigma F factor (Fragment).

GN Name=Fla1;

OS Escherichia coli.

OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;

OC Enterobacteriaceae; Escherichia.

OK NCBI_TaxID=562;

OK [1]

RP NUCLEOTIDE SEQUENCE.

RC STRAIN=E480-68, E223-69, and B17327-41;

RX PubMed=15056931; DOI=10.1266/99s.79.1;

RA Tominga A.;

RT "Characterization of six flagellin genes in the H3, H53 and H54

standard strains of Escherichia coli."

RL Genes Genet. Syst. 79:1-8(2004).

DR EMBL; AB128920; BAD14981.1; -, Genomic DNA.

DR EMBL; AB128921; BAD14982.1; -, Genomic DNA.

DR EMBL; AB128919; BAD14979.1; -, Genomic DNA.

FT NON TER 10

SO SEQUENCE 10 AA; 1084 MW; 8161421DC1BB5735 CRC64;

Query Match 84.2%; Score 16; DB 2; Length 10;

Best Local Similarity 75.0%; Pred. No. 2.5e+03;

Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 ACGV 4

Db 7 ACGV 10

RESULT 6

06LCB8_MOUSE PRELIMINARY; PRT; 18 AA.

AC 06LCB8;

DT 05-JUL-2004 (TReMBLrel. 27, Created)

DT 05-JUL-2004 (TReMBLrel. 27, Last sequence update)

DT 05-JUL-2004 (TReMBLrel. 27, Last annotation update)

DE TATA-binding protein (Fragment).

GN Name=TBP;

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
 OC Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RC STRAIN=C57BL/6;
 RL Truchetel Z., Vincet J., Forejt J., Klein J.;
 RL Submitted (JUL-1996) to the EMBL/GenBank/DBJ databases.
 DR EMBL, U63729; AA80845.1; -; Genomic_DNA.
 FT NON_TER
 SQ SEQUENCE 18 AA; 1931 MW; CC4051C3EDABCC6F CRC64;

Query Match 84.2%; Score 16; DB 2; Length 18;
 Best Local Similarity 75.0%; Pred. No. 4.4e+03;
 Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
 |||:
 Db 11 AOGU 14

RESULT 7
 Q9PS70 CHICK PRELIMINARY; PRT; 19 AA.
 AC Q9PS70;
 DT 01-MAY-2000 (TREMBLrel. 13, Created)
 DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)
 DT 01-JUN-2002 (TREMBLrel. 21, Last annotation update)
 DE Low density lipoprotein receptor-related protein (Fragment).
 OS Gallus gallus (Chicken).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
 OC Gallus.
 OX NCBI_TaxID=9031;
 RN [1]
 RP PROTEIN SEQUENCE.
 RX MEDLINE=92011685; PubMed=1918027;
 RA Steifant S., Barber D.L., Abersold R., Steyrer E., Shen X., Nimpf J.,
 RA Schneider W.J.;
 RT "The laying hen expresses two different low density lipoprotein
 RT receptor-related proteins.";
 RL J. Biol. Chem. 266:19079-19087(1991).
 FT NON_TER
 FT NON_TER
 SQ SEQUENCE 19 AA; 1861 MW; 4BEC931205620608 CRC64;

Query Match 84.2%; Score 16; DB 2; Length 19;
 Best Local Similarity 75.0%; Pred. No. 4.7e+03;
 Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
 |||:
 Db 3 AOGU 6

RESULT 8
 P82666 BOVIN PRELIMINARY; PRT; 20 AA.
 AC P82666;
 DT 01-MAR-2001 (TREMBLrel. 16, Created)
 DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)
 DT 01-JUN-2003 (TREMBLrel. 24, Last annotation update)
 DE Mitochondrial 28S ribosomal protein S23 (MRP-S23) (Fragments).
 OS Bos taurus (Bovine).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
 OC Pecora; Bovidae; Bovinae; Bos.
 OX NCBI_TaxID=9913;
 RN [1]
 RP PROTEIN SEQUENCE.
 RC TISSUE=Liver;
 RX MEDLINE=20490686; PubMed=10938081; DOI=10.1074/jbc.M003596200;
 RA Koc E.C., Burkhardt W., Blackburn K., Mosely A., Koc H.,

RA Spremulli L.L.;
 RT "A proteomics approach to the identification of mammalian
 RT mitochondrial small subunit ribosomal proteins.";
 RL J. Biol. Chem. 275:32585-32591(2000).
 CC -1- SUBCELLULAR LOCATION: Mitochondrial.
 DR GO: GO:0005739; C:mitochondrion; IEA.
 DR GO: GO:0003735; F:structural constituent of ribosome; IEA.
 KW Mitochondrion; Ribosomal protein.
 FT NON_CONS
 FT NON_TER
 FT NON_TER
 SQ SEQUENCE 20 AA; 2249 MW; EC7FE3CA50071EE4 CRC64;

Query Match 84.2%; Score 16; DB 2; Length 20;
 Best Local Similarity 75.0%; Pred. No. 4.9e+03;
 Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
 |||:
 Db 4 AEGV 7

RESULT 9
 Q9UCS1 HUMAN PRELIMINARY; PRT; 23 AA.
 AC Q9UCS1;
 DT 01-MAY-2000 (TREMBLrel. 13, Created)
 DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)
 DT 25-OCT-2004 (TREMBLrel. 28, Last annotation update)
 DE TROPOMYOSIN=33 kDa calcium binding protein fragment A (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominiidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP PROTEIN SEQUENCE.
 RA Crabos W., Yamakado T., Heizmann C.W., Cerletti N., Buhler F.R.,
 RA Erbe P.;
 RT "The calcium binding protein tropomyosin in human platelets and
 RT cardiac tissue: elevation in hypertensive cardiac hypertrophy.";
 RL Submitted (AUG-1992) to the EMBL/GenBank/DBJ databases.
 FT NON_TER
 FT NON_TER
 SQ SEQUENCE 23 AA; 2475 MW; EBD4B463017E7716 CRC64;

Query Match 84.2%; Score 16; DB 2; Length 23;
 Best Local Similarity 75.0%; Pred. No. 5.6e+03;
 Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
 |||:
 Db 20 AOGU 23

RESULT 10
 Q28866 MEGNO PRELIMINARY; PRT; 8 AA.
 AC Q28866;
 DT 01-NOV-1996 (TREMBLrel. 01, Created)
 DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)
 DT 01-MAY-1999 (TREMBLrel. 10, Last annotation update)
 DE Actin protein (Fragment).
 GN Name=actin;
 OS Megaptera novaeangliae (Humpback whale).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Cetacea;
 OC Mysticeti; Balaeopteridae; Megaptera.
 OX NCBI_TaxID=9773;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=94285813; PubMed=7912407;
 RA Palumbi S.R., Baker C.S.;

RT "Contrasting population structure from nuclear intron sequences and
 RT mRNA of humpback whales.";
 RL Mol. Biol. Evol. 11:426-435(1994).
 DR EMBL: S73467; AAD14118.1; -; Genomic_DNA.
 FT NON_TER 8
 SQ SEQUENCE 8 AA; 906 MW; 69C866D1F4177408 CRC64;

Query Match 78.9%; Score 15; DB 2; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2.2e+06; Indels 0; Gaps 0;
 Matches 3; Conservative 0; Mismatches 0;

Qy 2 QGV 4
 Db 6 QGV 8

RESULT 11
 TRPS LEUNA STANDARD; PRT; 10 AA.

AC 30-MAY-2000 (Rel. 39, Created)
 DT 30-MAY-2000 (Rel. 39, Last sequence update)
 DT 05-JUL-2004 (Rel. 44, Last annotation update)
 DE Tachykinin-related peptide 5 (LeuTRP 5).
 OS Leucophaea maderae (Madeira cockroach).
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Preyrgota;
 OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blaberoidea;
 OC Blaberidae; Leucophaea.
 OX NCBI_TaxID=6988;
 RN [1]
 RP PROTEIN SEQUENCE.
 RC TISSUE=Midgut;
 RX MEDLINE=97053012; PubMed=8897641;
 RA Muren J.B., Naessel D.R.;
 RT "Isolation of five tachykinin-related peptides from the midgut of the
 RT cockroach Leucophaea maderae: existence of N-terminally extended
 RT isoforms.";
 RL Regul. Pept. 65:185-196(1996).
 RN [2]
 RP PROTEIN SEQUENCE, AND MASS SPECTROMETRY.
 RC TISSUE=Brain;
 RX MEDLINE=97269266; PubMed=9114447; DOI=10.1016/S0196-9781(96)00243-4;
 RA Muren J.B., Naessel D.R.;
 RT "Seven tachykinin-related peptides isolated from the brain of the
 RT Madeira cockroach: evidence for tissue-specific expression of
 RT isoforms.";
 RL Peptides 18:7-15(1997).
 CC -1- FUNCTION: Myoactive peptide. Increases the amplitude and frequency
 CC of spontaneous contractions and tonus of hindgut muscle.
 CC -1- SUBCELLULAR LOCATION: Secreted.
 CC -1- TISSUE SPECIFICITY: Midgut and brain.
 CC -1- MASS SPECTROMETRY: MW=1033.2; METHOD=MALDI; RANGE=1-10;
 CC NOTE=Ref. 2.

CC -----
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.

CC Annotation: Direct protein sequencing; Neuropeptide; Tachykinin.
 FT MOD RES 10 10 Arginine amide.
 SQ SEQUENCE 10 AA; 1033 MW; C453CDB6D9C8769D CRC64;

Query Match 78.9%; Score 15; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 4.9e+03; Indels 0; Gaps 0;
 Matches 3; Conservative 0; Mismatches 0;

Qy 2 QGV 4
 Db 7 QGV 9

RESULT 12
 ID Q9X9S6_STRLI PRELIMINARY; PRT; 11 AA.

AC Q9X9S6;
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)
 DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Hypothetical protein ORF9 (Fragment).
 GN Name=ORF9;

OS Streptomyces lividans.
 OC Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;
 OC Streptomycineae; Streptomycetaceae; Streptomyces.
 OX NCBI_TaxID=1916;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.

RC STRAIN=TK21;
 RX MEDLINE=99328982; PubMed=10400594;
 RA Martinez-Costra O.H., Martin-Triana A.J., Martinez E.,
 RA Fernandez-Moreno M.A., Malpartida F.;
 RT "An additional regulatory gene for actinorhodin production in
 RT Streptomyces lividans involves a *lygR*-type transcriptional
 RT regulator.";
 RL J. Bacteriol. 181:4353-4364(1999).
 DR EMBL: Y18818; CAB51138.1; -; Genomic_DNA.
 KW Hypothetical protein.

FT NON_TER 1
 SQ SEQUENCE 11 AA; 1160 MW; D1BABA8EC1EDC412 CRC64;

Query Match 78.9%; Score 15; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 5.3e+03; Indels 0; Gaps 0;
 Matches 3; Conservative 0; Mismatches 0;

Qy 2 QGV 4
 Db 2 QGV 4

RESULT 13
 ID Q62207_MOUSE PRELIMINARY; PRT; 11 AA.

AC Q62207;
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Schwannomin (Fragment).
 GN Name=NF2; Synonyms=NF2;
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
 OC Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.

RC TISSUE=Brain;
 RX MEDLINE=95072570; PubMed=7981675;
 RA Huynh D.P., Nechiporuk T., Puls S.M.;
 RT "Alternative transcripts in the mouse neurofibromatosis type 2 (NF2)
 RT gene are conserved and code for schwannomins with distinct C-terminal
 RT domains.";

RL Hum. Mol. Genet. 3:1075-1079(1994).
 DR EMBL: L28838; AAA57151.1; -; mRNA.
 DR PIR: I54368; I54368.
 DR MGI: MGI:97307; NF2.

DR GO: GO:0005912; C:adherens junction; IMP.
 DR GO: GO:0005515; P:protein binding; IPI.
 DR GO: GO:004516; P:intercellular junction assembly and/or main. . .; IMP.
 DR GO: GO:0006469; P:negative regulation of protein kinase activity; IDA.
 DR GO: GO:0042127; P:regulation of cell proliferation; IMP.

FT NON_TER 1
 SQ SEQUENCE 11 AA; 1238 MW; C51FA05774140866 CRC64;

Query Match 78.9%; Score 15; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 5.3e+03; Indels 0; Gaps 0;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGG 3
|||

Db 3 AGG 5

RESULT 14

Q7Y7W2_9CARY PRELIMINARY; PRT; 12 AA.

AC Q7Y7W2; 01-OCT-2003 (TRENBLrel. 25, Last created)

DT 01-OCT-2003 (TRENBLrel. 25, Last sequence update)

DE 10-MAY-2005 (TRENBLrel. 30, Last annotation update)

GN Name=psbB;

OS Sueda prostrata.

OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

OC Caryophyllales; Amaranthaceae; Sueda.

OX NCBI_TaxID=224187;

RN [1]

RP NUCLEOTIDE SEQUENCE.

RA Schuetze P., Freitag H., Weising K.;

RT "An integrated molecular and morphological study of the subfamily

RL Suedoideae Uibr. (Chenopodiaceae).";

DR EMBL; AY181894; AA066039.1; -; Genomic DNA.

DR EMBL; AY181895; AA066042.1; -; Genomic DNA.

DR EMBL; AY181896; AA066045.1; -; Genomic DNA.

DR EMBL; AY181897; AA066048.1; -; Genomic DNA.

DR EMBL; AY181898; AA066051.1; -; Genomic DNA.

DR GO; GO:0009507; C:chloroplast; IEA.

DR KW Chloroplast.

FT NON TER

SQ SEQUENCE 12 AA; 1328 MM; 26CBA7B1B311B1B7 CRC64;

Query Match 78.9%; Score 15; DB 2; Length 12;

Best Local Similarity 100.0%; Pred. No. 5.8e+03;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 QGV 4
|||

Db 10 QGV 12

RESULT 15

Q7Y7W3_9CARY PRELIMINARY; PRT; 12 AA.

AC Q7Y7W3; 01-OCT-2003 (TRENBLrel. 25, Created)

DT 01-OCT-2003 (TRENBLrel. 25, Last sequence update)

DE 10-MAY-2005 (TRENBLrel. 30, Last annotation update)

GN Name=psbB;

OS Sueda salsa.

OC Chloroplast.

OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

OC Caryophyllales; Amaranthaceae; Sueda.

OX NCBI_TaxID=126914;

RN [1]

RP NUCLEOTIDE SEQUENCE.

RA Schuetze P., Freitag H., Weising K.;

RT "An integrated molecular and morphological study of the subfamily

SQ SEQUENCE 12 AA; 1328 MM; 26CBA7B1B311B1B7 CRC64;

Query Match 78.9%; Score 15; DB 2; Length 12;

Best Local Similarity 100.0%; Pred. No. 5.8e+03;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 QGV 4
|||

Db 10 QGV 12

Search completed: February 17, 2006, 17:02:36

Job time : 145.5 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: February 17, 2006, 17:18:43 ; Search time 10.5 Seconds

(Without alignments)
5.415 Million cell updates/sec

Title: US-10-821-256-2

Perfect score: 19

Sequence: 1 AGGV 4

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 107819 seqs, 14214640 residues

Total number of hits satisfying chosen parameters: 59776

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

Published Applications AA New:*

- 1: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
- 2: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
- 3: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
- 4: /cgn2_6/ptodata/1/pubpaa/PCR_NEW_PUB.pep.*
- 5: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
- 6: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
- 7: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
- 8: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	100.0	19	6	US-10-503-575-304	Sequence 304, App
2	100.0	24	7	US-11-054-515-2176	Sequence 2176, Ap
3	100.0	24	7	US-11-054-515-2969	Sequence 2969, Ap
4	94.7	16	6	US-10-939-890-111	Sequence 111, App
5	94.7	20	7	US-11-127-601-29	Sequence 29, App1
6	94.7	20	7	US-11-127-601-30	Sequence 30, App1
7	94.7	20	7	US-11-127-601-31	Sequence 31, App1
8	94.7	20	7	US-11-127-601-32	Sequence 32, App1
9	94.7	20	7	US-11-127-601-33	Sequence 33, App1
10	94.7	20	7	US-11-127-601-34	Sequence 34, App1
11	94.7	20	7	US-11-127-601-35	Sequence 35, App1
12	94.7	20	7	US-11-127-601-36	Sequence 36, App1
13	84.2	8	7	US-11-045-024-1476	Sequence 1476, Ap
14	84.2	8	7	US-11-045-024-1478	Sequence 1478, Ap
15	84.2	8	7	US-11-045-024-1479	Sequence 1479, Ap
16	84.2	8	7	US-11-045-024-1765	Sequence 1765, Ap
17	84.2	8	7	US-11-045-024-5309	Sequence 5309, Ap
18	84.2	8	7	US-11-045-024-6482	Sequence 6482, Ap
19	84.2	8	7	US-11-045-024-7882	Sequence 7882, Ap
20	84.2	8	7	US-11-045-024-7944	Sequence 7944, Ap
21	84.2	8	7	US-11-045-024-9347	Sequence 9347, Ap
22	84.2	8	7	US-11-045-024-9458	Sequence 9458, Ap
23	84.2	9	7	US-11-202-330-33	Sequence 33, App1
24	84.2	9	7	US-11-045-024-1498	Sequence 1498, Ap
25	84.2	9	7	US-11-045-024-1502	Sequence 1502, Ap

26	16	84.2	9	7	US-11-045-024-5267	Sequence 5267, Ap
27	16	84.2	9	7	US-11-045-024-6454	Sequence 6454, Ap
28	16	84.2	9	7	US-11-045-024-6468	Sequence 6468, Ap
29	16	84.2	9	7	US-11-045-024-6768	Sequence 6768, Ap
30	16	84.2	10	7	US-11-045-024-1523	Sequence 1523, Ap
31	16	84.2	10	7	US-11-045-024-2201	Sequence 2201, Ap
32	16	84.2	10	7	US-11-045-024-5376	Sequence 5376, Ap
33	16	84.2	10	7	US-11-045-024-7412	Sequence 7412, Ap
34	16	84.2	10	7	US-11-045-024-7890	Sequence 7890, Ap
35	16	84.2	10	7	US-11-045-024-1552	Sequence 1552, Ap
36	16	84.2	11	7	US-11-045-024-3432	Sequence 3432, Ap
37	16	84.2	11	7	US-11-045-024-5408	Sequence 5408, Ap
38	16	84.2	11	7	US-11-045-024-5409	Sequence 5409, Ap
39	16	84.2	11	7	US-11-045-024-7897	Sequence 7897, Ap
40	16	84.2	11	7	US-11-045-024-7948	Sequence 7948, Ap
41	16	84.2	11	7	US-11-045-024-7988	Sequence 7988, Ap
42	16	84.2	11	7	US-11-045-024-9342	Sequence 9342, Ap
43	16	84.2	11	7	US-11-045-024-10140	Sequence 10140, A
44	16	84.2	11	7		
45	16	84.2	11	7		

ALIGNMENTS

RESULT 1
US-10-503-575-304
; Sequence 304, Application US/10503575
; Publication No. US20050244823A1
; GENERAL INFORMATION:
; APPLICANT: Drifhout, Jan Mouter
; APPLICANT: van Veele, Petrus Antonius
; APPLICANT: Konig, Frits
; TITLE OF INVENTION: NOVEL EPITOPES FOR CELIAC DISEASE AND AUTOIMMUNE DISEASES, METHOD
; FILE REFERENCE: 2299/72843-PCR-US
; CURRENT APPLICATION NUMBER: US/10/503,575
; PRIOR FILING DATE: 2004-08-04
; PRIOR APPLICATION NUMBER: PCT/NL03/00077
; PRIOR FILING DATE: 2003-02-04
; PRIOR APPLICATION NUMBER: EP 02075456.0
; PRIOR FILING DATE: 2002-02-04
; NUMBER OF SEQ ID NOS: 340
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 304
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-503-575-304
Query Match 100.0%; Score 19; DB 6; Length 19;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 AGGV 4
|||
Db 9 AGGV 12
RESULT 2
US-11-054-515-2176
; Sequence 2176, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PFS23P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; PRIOR FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18

PRIOR APPLICATION NUMBER: 10/293,418
PRIOR FILING DATE: 2002-11-14
PRIOR APPLICATION NUMBER: 60/331,469
PRIOR FILING DATE: 2001-11-16
PRIOR APPLICATION NUMBER: 60/340,817
PRIOR FILING DATE: 2001-12-19
PRIOR APPLICATION NUMBER: 09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 3247
SEQ ID NO 2176
LENGTH: 24
TYPE: PRT
ORGANISM: Homo sapiens
US-11-054-515-2176

Query Match 100.0%; Score 19; DB 7; Length 24;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 ACGV 4
|||
Db 17 ACGV 20

RESULT 3
US-11-054-515-2969

Sequence 2969, Application US/11054515
Publication No. US2005025532A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PPS23P3
CURRENT APPLICATION NUMBER: US/11/054,515
CURRENT FILING DATE: 2005-02-10
PRIOR APPLICATION NUMBER: 60/543,296
PRIOR FILING DATE: 2004-02-11
PRIOR APPLICATION NUMBER: 60/580,347
PRIOR FILING DATE: 2004-06-18
PRIOR APPLICATION NUMBER: 10/293,418
PRIOR FILING DATE: 2002-11-14
PRIOR APPLICATION NUMBER: 60/331,469
PRIOR FILING DATE: 2001-11-16
PRIOR APPLICATION NUMBER: 60/340,817
PRIOR FILING DATE: 2001-12-19
PRIOR APPLICATION NUMBER: 09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 3247
SEQ ID NO 2969
LENGTH: 24
TYPE: PRT
ORGANISM: Homo sapiens
US-11-054-515-2969

Query Match 100.0%; Score 19; DB 7; Length 24;
Best Local Similarity 100.0%; Pred. No. 22;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 ACGV 4
|||
Db 17 ACGV 20

RESULT 4
US-10-939-890-111

Sequence 111, Application US/10939890
Publication No. US20050250700A1
GENERAL INFORMATION:
APPLICANT: Sato, Aaron K.
APPLICANT: Sexton, Daniel J.
APPLICANT: Dranefield, Daniel T.
APPLICANT: Ladner, Robert C.
APPLICANT: Arbogast, Christophe
APPLICANT: Bussat, Philippe
APPLICANT: Pan, Hong
APPLICANT: Khurana, Sudha
APPLICANT: Linder, Karen E.
APPLICANT: Marinelli, Edmund R.
APPLICANT: Nanjappan, Palaniappa
APPLICANT: Nunn, Adrian D.
APPLICANT: Pillai, Radhakrishna
APPLICANT: Pochon, Sibylle
APPLICANT: Ramalingam, Kondaredidhar
APPLICANT: Shrivastava, Kjay
APPLICANT: Song, Bo
APPLICANT: Swenson, Rolf E.
APPLICANT: Von Wronski, Mathew A.
TITLE OF INVENTION: KDR AND VEGF/KDR BINDING PEPTIDES
FILE REFERENCE: D0617.70014US00
CURRENT APPLICATION NUMBER: US/10/939,890
CURRENT FILING DATE: 2004-09-13
PRIOR APPLICATION NUMBER: US 10/661,156
PRIOR FILING DATE: 2003-09-11
PRIOR APPLICATION NUMBER: US 10/382,082
PRIOR FILING DATE: 2003-03-03
PRIOR APPLICATION NUMBER: PCT/US03/06731
PRIOR FILING DATE: 2003-03-03
PRIOR APPLICATION NUMBER: US 60/440,411
PRIOR FILING DATE: 2003-01-15
PRIOR APPLICATION NUMBER: US 60/360,851
PRIOR FILING DATE: 2002-03-01
NUMBER OF SEQ ID NOS: 883
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 111
LENGTH: 16
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Library Isolate
US-10-939-890-111

Query Match 94.7%; Score 18; DB 6; Length 16;
Best Local Similarity 75.0%; Pred. No. 26;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 ACGV 4
|||
Db 7 ACGI 10

RESULT 5

US-11-127-601-29
Sequence 29, Application US/11127601
Publication No. US2005026019A1
GENERAL INFORMATION:
APPLICANT: Compton, Teresa
APPLICANT: Felire, Adam
TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
FILE REFERENCE: 09820.380

```

; CURRENT APPLICATION NUMBER: US/11/127,601
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: US 60/570,260
; PRIOR FILING DATE: 2004-05-12
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Human cytomegalovirus
US-11-127-601-29
```

```

Query Match          94.7%; Score 18; DB 7; Length 20;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```

Qy      1 AOGV 4
        |||:
        6 AOGI 9
Db
```

```

RESULT 6
US-11-127-601-30
; Sequence 30, Application US/11/127601
; Publication No. US20050260199A1
; GENERAL INFORMATION:
; APPLICANT: Compton, Teresa
; APPLICANT: Feite, Adam
; TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
; FILE REFERENCE: 09820.380
; CURRENT APPLICATION NUMBER: US/11/127,601
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: US 60/570,260
; PRIOR FILING DATE: 2004-05-12
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 30
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Human cytomegalovirus
US-11-127-601-30
```

```

Query Match          94.7%; Score 18; DB 7; Length 20;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```

Qy      1 AOGV 4
        |||:
        6 AOGI 9
Db
```

```

RESULT 7
US-11-127-601-31
; Sequence 31, Application US/11/127601
; Publication No. US20050260199A1
; GENERAL INFORMATION:
; APPLICANT: Compton, Teresa
; APPLICANT: Feite, Adam
; TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
; FILE REFERENCE: 09820.380
; CURRENT APPLICATION NUMBER: US/11/127,601
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: US 60/570,260
; PRIOR FILING DATE: 2004-05-12
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 31
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Human cytomegalovirus
US-11-127-601-31
```

```

Query Match          94.7%; Score 18; DB 7; Length 20;
```

```

Best Local Similarity 75.0%; Pred. No. 34;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 AOGV 4
        |||:
        6 AOGI 9
Db
```

```

RESULT 8
US-11-127-601-32
; Sequence 32, Application US/11/127601
; Publication No. US20050260199A1
; GENERAL INFORMATION:
; APPLICANT: Compton, Teresa
; APPLICANT: Feite, Adam
; TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
; FILE REFERENCE: 09820.380
; CURRENT APPLICATION NUMBER: US/11/127,601
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: US 60/570,260
; PRIOR FILING DATE: 2004-05-12
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Human cytomegalovirus
US-11-127-601-32
```

```

Query Match          94.7%; Score 18; DB 7; Length 20;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```

Qy      1 AOGV 4
        |||:
        6 AOGI 9
Db
```

```

RESULT 9
US-11-127-601-33
; Sequence 33, Application US/11/127601
; Publication No. US20050260199A1
; GENERAL INFORMATION:
; APPLICANT: Compton, Teresa
; APPLICANT: Feite, Adam
; TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
; FILE REFERENCE: 09820.380
; CURRENT APPLICATION NUMBER: US/11/127,601
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: US 60/570,260
; PRIOR FILING DATE: 2004-05-12
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Human cytomegalovirus
US-11-127-601-33
```

```

Query Match          94.7%; Score 18; DB 7; Length 20;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```

Qy      1 AOGV 4
        |||:
        6 AOGI 9
Db
```

```

RESULT 10
US-11-127-601-34
; Sequence 34, Application US/11/127601
; Publication No. US20050260199A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Compton, Teresa
; APPLICANT: Feire, Adam
; TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
; FILE REFERENCE: 09820.380
; CURRENT APPLICATION NUMBER: US/11/127,601
; PRIOR FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: US 60/570,260
; PRIOR FILING DATE: 2004-05-12
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 34
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Human cytomegalovirus
US-11-127-601-34
```

```
Query Match          94.7%; Score 18; DB 7; Length 20;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 ACGV 4
        |||:
Db       6 ACGI 9
```

```
RESULT 11
US-11-127-601-35
; Sequence 35, Application US/11127601
; Publication No. US20050260199A1
; GENERAL INFORMATION:
; APPLICANT: Compton, Teresa
; APPLICANT: Feire, Adam
; TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
; FILE REFERENCE: 09820.380
; CURRENT APPLICATION NUMBER: US/11/127,601
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: US 60/570,260
; PRIOR FILING DATE: 2004-05-12
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 35
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Human cytomegalovirus
US-11-127-601-35
```

```
Query Match          94.7%; Score 18; DB 7; Length 20;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 ACGV 4
        |||:
Db       6 ACGI 9
```

```
RESULT 12
US-11-127-601-36
; Sequence 36, Application US/11127601
; Publication No. US20050260199A1
; GENERAL INFORMATION:
; APPLICANT: Compton, Teresa
; APPLICANT: Feire, Adam
; TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
; FILE REFERENCE: 09820.380
; CURRENT APPLICATION NUMBER: US/11/127,601
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: US 60/570,260
; PRIOR FILING DATE: 2004-05-12
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 36
; LENGTH: 20
; TYPE: PRT
```

```
; ORGANISM: Human cytomegalovirus
US-11-127-601-36
```

```
Query Match          94.7%; Score 18; DB 7; Length 20;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 ACGV 4
        |||:
Db       6 ACGI 9
```

```
RESULT 13
US-11-045-024-1476
; Sequence 1476, Application US/11045024
; Publication No. US20050271676A1
; GENERAL INFORMATION:
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert
; APPLICANT: Baker, Denise Marie
; APPLICANT: Celis, Bateban
; APPLICANT: Kubo, Ralph
; APPLICANT: Grey, Howard M.
; APPLICANT: BiImmune Inc.
; TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency
; TITLE OF INVENTION: Virus-1 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060.0040007
; CURRENT APPLICATION NUMBER: US/11/045,024
; CURRENT FILING DATE: 2005-01-28
; PRIOR APPLICATION NUMBER: US 09/412,863
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/103,396
; PRIOR FILING DATE: 1993-08-06
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/159,339
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/347,610
; PRIOR FILING DATE: 1994-12-01
; NUMBER OF SEQ ID NOS: 14528
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1476
; LENGTH: 8
; TYPE: PRT
; ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
US-11-045-024-1476
```

```
Query Match          84.2%; Score 16; DB 7; Length 8;
Best Local Similarity 75.0%; Pred. No. 7.7e+04;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 ACGV 4
        |||:
Db       3 AEGV 6
```

```
RESULT 14
US-11-045-024-1478
; Sequence 1478, Application US/11045024
; Publication No. US20050271676A1
; GENERAL INFORMATION:
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
```

APPLICANT: Livingston, Brian
APPLICANT: Cheenut, Robert
APPLICANT: Baker, Denise Marie
APPLICANT: Cells, Esteban
APPLICANT: Kudo, Ralph
APPLICANT: Grey, Howard M.
APPLICANT: EpiImmune Inc.
TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency
FILE REFERENCE: 2060.0040007
CURRENT FILING DATE: 2005-01-28
PRIOR APPLICATION NUMBER: US 09/412,863
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: US 08/027,146
PRIOR FILING DATE: 1993-03-05
PRIOR APPLICATION NUMBER: US 08/073,205
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/103,396
PRIOR FILING DATE: 1993-08-06
PRIOR APPLICATION NUMBER: US 08/159,184
PRIOR FILING DATE: 1993-11-29
PRIOR APPLICATION NUMBER: US 08/159,339
PRIOR FILING DATE: 1993-11-29
PRIOR APPLICATION NUMBER: US 08/205,713
PRIOR FILING DATE: 1994-03-04
PRIOR APPLICATION NUMBER: US 08/347,610
PRIOR FILING DATE: 1994-12-01
NUMBER OF SEQ ID NOS: 14528
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 1478
LENGTH: 8
TYPE: PRT
ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
US-11-045-024-1478

Query Match 84.2%; Score 16; DB 7; Length 8;
Best Local Similarity 75.0%; Pred. No. 7.7e+04;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGV 4
|:|
Db 2 AGV 5

RESULT 15
US-11-045-024-1479
Sequence 1479, Application US/11045024
Publication No. US20050271676A1
GENERAL INFORMATION:
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Livingston, Brian
APPLICANT: Cheenut, Robert
APPLICANT: Baker, Denise Marie
APPLICANT: Cells, Esteban
APPLICANT: Kudo, Ralph
APPLICANT: Grey, Howard M.
APPLICANT: EpiImmune Inc.
TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency
FILE REFERENCE: 2060.0040007
CURRENT FILING DATE: US/11/045,024
CURRENT FILING DATE: 2005-01-28
PRIOR APPLICATION NUMBER: US 09/412,863
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: US 08/027,146
PRIOR FILING DATE: 1993-03-05
PRIOR APPLICATION NUMBER: US 08/073,205
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/103,396
PRIOR FILING DATE: 1993-08-06

PRIOR APPLICATION NUMBER: US 08/159,184
PRIOR FILING DATE: 1993-11-29
PRIOR APPLICATION NUMBER: US 08/159,339
PRIOR FILING DATE: 1993-11-29
PRIOR APPLICATION NUMBER: US 08/205,713
PRIOR FILING DATE: 1994-03-04
PRIOR APPLICATION NUMBER: US 08/347,610
PRIOR FILING DATE: 1994-12-01
NUMBER OF SEQ ID NOS: 14528
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 1479
LENGTH: 8
TYPE: PRT
ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
US-11-045-024-1479

Query Match 84.2%; Score 16; DB 7; Length 8;
Best Local Similarity 75.0%; Pred. No. 7.7e+04;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGV 4
|:|
Db 2 AGV 5

Search completed: February 17, 2006, 17:22:50
Job time : 11.5 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM protein - protein search, using sw model

Run on: February 21, 2006, 09:03:03 ; Search time 119 Seconds
(Without alignments)
14.045 Million cell updates/sec

Title: US-10-821-256-2
Perfect score: 19
Sequence: 1 AGGV 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 6317

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%
Maximum Match 100%

Listing first 500 summaries

Database : Published Applications AA Main:*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	19	100.0	4	US-10-028-075B-2	Sequence 2, Appli
2	19	100.0	4	US-10-029-206A-2	Sequence 15, Appli
3	19	100.0	4	US-10-262-522A-15	Sequence 2, Appli
4	19	100.0	4	US-10-409-630-2	Sequence 2, Appli
5	19	100.0	4	US-10-409-027-2	Sequence 2, Appli
6	19	100.0	4	US-10-409-032-2	Sequence 2, Appli
7	19	100.0	4	US-10-409-642-2	Sequence 2, Appli
8	19	100.0	4	US-10-409-654-2	Sequence 2, Appli
9	19	100.0	4	US-10-409-659-2	Sequence 2, Appli
10	19	100.0	4	US-10-409-671-2	Sequence 2, Appli
11	19	100.0	4	US-10-409-694-2	Sequence 2, Appli
12	19	100.0	4	US-10-409-657-2	Sequence 2, Appli
13	19	100.0	4	US-10-409-668-2	Sequence 2, Appli
14	19	100.0	4	US-10-753-510-2	Sequence 2, Appli
15	19	100.0	4	US-10-821-240A-2	Sequence 2, Appli
16	19	100.0	4	US-10-817-756A-12	Sequence 12, Appli
17	19	100.0	4	US-10-821-256-2	Sequence 2, Appli
18	19	100.0	9	US-10-946-647-184	Sequence 184, Appli
19	19	100.0	9	US-10-946-647-558	Sequence 855, App
20	19	100.0	9	US-10-946-647-855	Sequence 855, App
21	19	100.0	9	US-10-946-647-954	Sequence 954, App
22	19	100.0	10	US-10-122-675-28	Sequence 115, Appl
23	19	100.0	13	US-09-957-806A-115	Sequence 28, Appli
24	19	100.0	19	US-10-394-980-6	Sequence 6, Appli
25	19	100.0	19	US-10-952-557-6	Sequence 430, App
26	19	100.0	20	US-09-397-945-430	Sequence 401, App
27	19	100.0	20	US-10-280-066-401	

28	19	100.0	20	US-10-653-595-430	Sequence 430, App
29	19	100.0	20	US-10-241-814-13	Sequence 13, Appl
30	19	100.0	21	US-10-377-134-8	Sequence 8, Appli
31	19	100.0	21	US-10-872-770-12	Sequence 12, Appl
32	19	100.0	23	US-10-097-065-597	Sequence 597, App
33	19	100.0	23	US-10-372-876-597	Sequence 597, App
34	19	100.0	24	US-09-880-748-2176	Sequence 2176, App
35	19	100.0	24	US-09-880-748-2369	Sequence 2369, App
36	19	100.0	24	US-10-293-418-2176	Sequence 2176, App
37	19	100.0	24	US-10-293-418-2369	Sequence 2369, App
38	19	100.0	25	US-09-864-761-45997	Sequence 45997, A
39	19	100.0	25	US-10-269-806-80	Sequence 80, Appl
40	19	100.0	25	US-10-029-386-13755	Sequence 33755, A
41	19	100.0	25	US-10-424-599-169158	Sequence 169158, A
42	19	100.0	29	US-10-424-599-281150	Sequence 281150, A
43	19	100.0	30	US-10-800-023-1	Sequence 1, Appli
44	19	100.0	33	US-10-424-599-261845	Sequence 261845, A
45	19	100.0	34	US-10-425-115-199464	Sequence 199464, A
46	19	100.0	35	US-10-424-599-242322	Sequence 242322, A
47	19	100.0	37	US-10-252-773-11	Sequence 11, Appl
48	19	100.0	38	US-10-120-319-22	Sequence 22, Appl
49	19	100.0	38	US-10-189-977-22	Sequence 22, Appl
50	19	100.0	38	US-10-392-098-22	Sequence 22, Appl
51	19	100.0	38	US-10-029-386-13511	Sequence 33511, A
52	19	100.0	40	US-10-425-115-195035	Sequence 195035, A
53	19	100.0	41	US-10-282-122A-45229	Sequence 45229, A
54	19	100.0	41	US-10-425-115-257966	Sequence 257966, A
55	19	100.0	41	US-10-773-446-115	Sequence 115, App
56	19	100.0	43	US-10-425-115-256443	Sequence 256443, A
57	19	100.0	44	US-10-425-115-280416	Sequence 280416, A
58	19	100.0	48	US-09-397-945-424	Sequence 424, App
59	19	100.0	48	US-10-424-599-203996	Sequence 203996, A
60	19	100.0	48	US-10-424-599-216178	Sequence 216178, A
61	19	100.0	48	US-10-653-595-424	Sequence 424, App
62	19	100.0	48	US-10-425-115-339468	Sequence 339468, A
63	19	100.0	49	US-10-029-386-17682	Sequence 27682, A
64	19	100.0	49	US-10-424-599-225119	Sequence 225119, A
65	19	100.0	51	US-09-866-066-35	Sequence 35, Appl
66	19	100.0	51	US-10-424-599-193989	Sequence 193989, A
67	19	100.0	51	US-10-969-677-35	Sequence 35, Appl
68	19	100.0	52	US-10-425-115-114288	Sequence 314288, A
69	19	100.0	53	US-09-925-302-824	Sequence 824, App
70	19	100.0	53	US-09-925-302-824	Sequence 824, App
71	19	100.0	54	US-10-016-768-3	Sequence 3, Appli
72	19	100.0	55	US-09-764-877-1474	Sequence 1474, App
73	19	100.0	55	US-10-242-515-1474	Sequence 1474, App
74	19	100.0	55	US-10-425-115-279298	Sequence 279298, A
75	19	100.0	56	US-09-864-761-44380	Sequence 44380, A
76	19	100.0	56	US-10-116-235-32	Sequence 32, Appl
77	19	100.0	56	US-10-264-049-3884	Sequence 3884, App
78	19	100.0	56	US-10-424-599-279039	Sequence 279039, A
79	19	100.0	56	US-10-425-115-263648	Sequence 263648, A
80	19	100.0	57	US-10-424-599-182978	Sequence 182978, A
81	19	100.0	57	US-10-424-599-249716	Sequence 249716, A
82	19	100.0	58	US-10-029-386-33617	Sequence 33617, A
83	19	100.0	58	US-10-425-115-192059	Sequence 192059, A
84	19	100.0	58	US-10-425-115-197211	Sequence 197211, A
85	19	100.0	58	US-10-425-115-336290	Sequence 336290, A
86	19	100.0	59	US-09-925-298-590	Sequence 590, App
87	19	100.0	59	US-10-102-806-590	Sequence 590, App
88	19	100.0	59	US-10-029-386-28279	Sequence 28279, A
89	19	100.0	59	US-10-425-115-278273	Sequence 278273, A
90	19	100.0	60	US-09-864-408A-2276	Sequence 2276, App
91	19	100.0	60	US-10-424-599-198924	Sequence 198924, A
92	19	100.0	62	US-10-424-599-189118	Sequence 189118, A
93	19	100.0	62	US-10-424-599-189377	Sequence 189377, A
94	19	100.0	62	US-10-425-114-11256	Sequence 11256, A
95	19	100.0	62	US-10-425-115-188418	Sequence 188418, A
96	19	100.0	63	US-10-029-386-11780	Sequence 11780, A
97	19	100.0	63	US-10-424-599-262885	Sequence 262885, A
98	19	100.0	63	US-10-424-599-270368	Sequence 270368, A
99	19	100.0	63	US-10-425-115-251637	Sequence 251637, A
100	19	100.0	63	US-10-450-763-26831	Sequence 26831, A

101	19	100.0	64	4	US-10-424-599-177860	Sequence 177860,	174	19	100.0	87	4	US-10-424-599-283838	Sequence 283838,
102	19	100.0	64	4	US-10-425-115-197187	Sequence 197187,	175	19	100.0	87	4	US-10-437-963-123960	Sequence 123960,
103	19	100.0	64	4	US-10-425-115-219280	Sequence 219280,	176	19	100.0	86	3	US-09-989-920-196	Sequence 196, App
104	19	100.0	65	4	US-10-437-963-106625	Sequence 106625,	177	19	100.0	88	4	US-10-437-963-148663	Sequence 148663,
105	19	100.0	65	4	US-10-425-115-240290	Sequence 240290,	178	19	100.0	88	4	US-10-425-115-199844	Sequence 199844,
106	19	100.0	65	4	US-10-425-115-357026	Sequence 357026,	179	19	100.0	88	4	US-10-425-115-353524	Sequence 353524,
107	19	100.0	66	4	US-10-424-599-257517	Sequence 257517,	180	19	100.0	89	4	US-10-424-599-173797	Sequence 173797,
108	19	100.0	67	4	US-10-437-963-106620	Sequence 106620,	181	19	100.0	89	4	US-10-693-367-14	Sequence 14, App1
109	19	100.0	67	4	US-10-437-963-158436	Sequence 158436,	182	19	100.0	89	4	US-10-425-115-232359	Sequence 232359,
110	19	100.0	67	4	US-10-425-115-200989	Sequence 200989,	183	19	100.0	90	4	US-10-425-115-221841	Sequence 221841,
111	19	100.0	67	4	US-10-425-115-331718	Sequence 331718,	184	19	100.0	91	4	US-10-424-599-282811	Sequence 282811,
112	19	100.0	67	6	US-11-097-143-3966	Sequence 39666, A	185	19	100.0	91	4	US-10-767-701-58893	Sequence 58893, A
113	19	100.0	68	4	US-10-425-115-354448	Sequence 354429, A	186	19	100.0	91	4	US-10-425-115-215363	Sequence 215363,
114	19	100.0	69	3	US-09-782-142-1	Sequence 1, Appli	187	19	100.0	91	5	US-10-450-763-35010	Sequence 35010, A
115	19	100.0	69	4	US-10-300-257-1	Sequence 1, Appli	188	19	100.0	92	4	US-10-424-599-152428	Sequence 152428,
116	19	100.0	69	4	US-10-424-599-255403	Sequence 255403,	189	19	100.0	92	4	US-10-425-115-255856	Sequence 255856,
117	19	100.0	69	4	US-10-437-963-191908	Sequence 191908,	190	19	100.0	93	5	US-10-609-055-4	Sequence 4, Appl1
118	19	100.0	69	4	US-10-767-701-34429	Sequence 34429, A	191	19	100.0	93	4	US-10-424-599-176284	Sequence 176284,
119	19	100.0	69	4	US-10-425-115-324687	Sequence 324687,	192	19	100.0	93	4	US-10-425-115-245408	Sequence 245408,
120	19	100.0	70	4	US-10-424-599-242839	Sequence 242839,	193	19	100.0	93	4	US-10-425-115-280821	Sequence 280821,
121	19	100.0	70	4	US-10-437-963-134195	Sequence 134195,	194	19	100.0	93	5	US-10-484-148-23	Sequence 23, Appl
122	19	100.0	70	4	US-10-425-115-321591	Sequence 321591,	195	19	100.0	94	4	US-10-425-115-341122	Sequence 341122,
123	19	100.0	71	5	US-10-926-683-1548	Sequence 1548, Ap	196	19	100.0	95	4	US-10-156-761-11115	Sequence 11115, A
124	19	100.0	72	4	US-10-131-406-6	Sequence 6, Appl1	197	19	100.0	95	4	US-10-425-115-298069	Sequence 298069,
125	19	100.0	72	4	US-10-424-599-182197	Sequence 182197,	198	19	100.0	95	4	US-10-425-115-314568	Sequence 314568,
126	19	100.0	72	4	US-10-424-599-234373	Sequence 234373,	199	19	100.0	96	4	US-10-425-115-348114	Sequence 348114,
127	19	100.0	72	4	US-10-425-115-202113	Sequence 202113,	200	19	100.0	96	4	US-10-424-599-220040	Sequence 220040,
128	19	100.0	72	4	US-10-425-115-348682	Sequence 348682,	201	19	100.0	96	4	US-10-437-963-186534	Sequence 186534,
129	19	100.0	72	5	US-10-989-992-6	Sequence 6, Appl1	202	19	100.0	96	4	US-10-767-701-48580	Sequence 48580, A
130	19	100.0	74	3	US-09-864-408A-2882	Sequence 2882, Ap	203	19	100.0	96	4	US-10-425-115-220279	Sequence 220279,
131	19	100.0	74	4	US-10-424-599-178691	Sequence 178691,	204	19	100.0	97	4	US-10-437-963-199150	Sequence 199150,
132	19	100.0	75	3	US-09-867-550-1124	Sequence 1124, Ap	205	19	100.0	97	4	US-10-425-115-358132	Sequence 358132,
133	19	100.0	75	4	US-10-424-599-154365	Sequence 154365,	206	19	100.0	97	5	US-10-501-282-1482	Sequence 1482, Ap
134	19	100.0	75	4	US-10-437-963-147518	Sequence 147518,	207	19	100.0	98	4	US-10-424-599-189929	Sequence 189929,
135	19	100.0	75	4	US-10-425-115-222854	Sequence 222854,	208	19	100.0	98	4	US-10-424-599-194380	Sequence 194380,
136	19	100.0	76	4	US-10-029-386-30198	Sequence 30198, A	209	19	100.0	99	5	US-10-617-320-5200	Sequence 5200, Ap
137	19	100.0	76	4	US-10-425-115-221278	Sequence 221278,	210	19	100.0	100	4	US-10-080-170-56	Sequence 56, Appl
138	19	100.0	76	4	US-10-425-115-292142	Sequence 292142,	211	19	100.0	100	4	US-10-080-170-56	Sequence 56, Appl
139	19	100.0	76	4	US-10-425-115-355384	Sequence 355384,	212	19	100.0	100	4	US-10-468-356-56	Sequence 222178,
140	19	100.0	77	4	US-10-425-115-271573	Sequence 271573,	213	19	100.0	100	4	US-10-425-115-222178	Sequence 222178,
141	19	100.0	77	4	US-10-425-115-289812	Sequence 289812,	214	19	100.0	100	4	US-10-425-115-289173	Sequence 289173,
142	19	100.0	77	4	US-10-425-115-319654	Sequence 319654,	215	19	100.0	101	3	US-09-864-408A-2292	Sequence 2292, Ap
143	19	100.0	77	4	US-10-425-115-330336	Sequence 330336,	216	19	100.0	101	4	US-10-437-963-121960	Sequence 121960,
144	19	100.0	78	4	US-10-425-115-343630	Sequence 343630,	217	19	100.0	101	5	US-10-450-763-32365	Sequence 32365, A
145	19	100.0	78	5	US-10-450-763-358928	Sequence 358928, A	218	19	100.0	101	5	US-10-450-763-34397	Sequence 34397, A
146	19	100.0	79	4	US-10-437-963-195350	Sequence 195350,	219	19	100.0	102	4	US-10-101-464A-659	Sequence 659, App
147	19	100.0	79	4	US-10-425-115-364068	Sequence 364068,	220	19	100.0	102	4	US-10-080-170-301	Sequence 301, App
148	19	100.0	81	4	US-10-424-599-277301	Sequence 277301,	221	19	100.0	102	4	US-10-424-599-155264	Sequence 155264,
149	19	100.0	81	4	US-10-437-963-137515	Sequence 137515,	222	19	100.0	102	4	US-10-080-170-301	Sequence 301, App
150	19	100.0	81	4	US-10-425-115-263146	Sequence 263146,	223	19	100.0	102	4	US-10-468-356-301	Sequence 301, App
151	19	100.0	81	4	US-10-425-115-306230	Sequence 306230,	224	19	100.0	102	4	US-10-425-115-265628	Sequence 265628,
152	19	100.0	82	4	US-10-424-599-163460	Sequence 163460,	225	19	100.0	102	5	US-10-864-252-699	Sequence 699, App
153	19	100.0	82	4	US-10-424-599-227097	Sequence 227097,	226	19	100.0	103	4	US-10-424-599-173799	Sequence 173799,
154	19	100.0	82	4	US-10-425-115-236419	Sequence 236419,	227	19	100.0	103	4	US-10-424-599-261546	Sequence 261546,
155	19	100.0	83	4	US-10-424-599-270384	Sequence 270384,	228	19	100.0	104	4	US-10-424-599-244826	Sequence 244826,
156	19	100.0	83	4	US-10-437-963-180416	Sequence 180416,	229	19	100.0	104	4	US-10-424-599-244826	Sequence 244826,
157	19	100.0	83	4	US-10-425-115-205887	Sequence 205887,	230	19	100.0	104	4	US-10-425-115-205212	Sequence 205212,
158	19	100.0	83	4	US-10-425-115-241812	Sequence 241812,	231	19	100.0	104	4	US-10-425-115-273311	Sequence 273311,
159	19	100.0	83	4	US-10-425-115-289244	Sequence 289244,	232	19	100.0	105	4	US-10-424-599-258231	Sequence 258231,
160	19	100.0	84	3	US-09-731-872-330	Sequence 330, App	233	19	100.0	105	4	US-10-437-963-187330	Sequence 187330,
161	19	100.0	84	3	US-09-876-997-330	Sequence 330, App	234	19	100.0	106	4	US-10-424-599-207947	Sequence 207947,
162	19	100.0	84	4	US-10-425-115-364443	Sequence 364443,	235	19	100.0	106	4	US-10-437-963-124557	Sequence 124557,
163	19	100.0	84	5	US-10-643-836-330	Sequence 330, App	236	19	100.0	106	4	US-10-425-115-197558	Sequence 197558,
164	19	100.0	84	5	US-10-450-763-35681	Sequence 35681, A	237	19	100.0	106	4	US-10-425-115-354333	Sequence 354333,
165	19	100.0	84	6	US-11-097-143-21975	Sequence 21975, A	238	19	100.0	106	5	US-10-775-481A-55	Sequence 55, Appl
166	19	100.0	85	4	US-10-425-114-68442	Sequence 68442, A	239	19	100.0	107	3	US-09-800-095A-104	Sequence 104, App
167	19	100.0	85	4	US-10-363-616-365	Sequence 365, App	240	19	100.0	107	3	US-09-833-245-1848	Sequence 1848, App
168	19	100.0	85	4	US-10-335-977-8250	Sequence 8250, Ap	241	19	100.0	107	4	US-10-424-599-161119	Sequence 161119,
169	19	100.0	85	4	US-10-425-115-368000	Sequence 368000, Ap	242	19	100.0	107	4	US-10-424-599-177891	Sequence 177891,
170	19	100.0	86	3	US-09-955-502-4	Sequence 4, Appl1	243	19	100.0	107	4	US-10-425-115-291283	Sequence 291283,
171	19	100.0	86	3	US-09-864-408A-2696	Sequence 2696, Ap	244	19	100.0	108	4	US-10-425-115-294264	Sequence 294264,
172	19	100.0	86	4	US-10-335-977-8249	Sequence 8249, Ap	245	19	100.0	109	4	US-10-437-963-180999	Sequence 180999,
173	19	100.0	86	5	US-10-799-514-13	Sequence 13, Appl	246	19	100.0	109	4	US-10-425-115-260668	Sequence 260668,

247	19	100.0	109	4	US-10-425-115-280327	Sequence 280327,	320	19	100.0	127	4	US-10-425-115-289211	Sequence 289211,
248	19	100.0	109	4	US-10-425-115-361658	Sequence 361658,	321	19	100.0	127	5	US-10-450-763-53377	Sequence 53377, A
249	19	100.0	110	4	US-10-424-599-164976	Sequence 164976,	322	19	100.0	128	3	US-09-925-299-698	Sequence 899, App
250	19	100.0	110	4	US-10-425-115-352048	Sequence 352048,	323	19	100.0	128	3	US-09-925-299-698	Sequence 898, App
251	19	100.0	111	4	US-10-424-599-193076	Sequence 193076,	324	19	100.0	128	4	US-10-424-599-176293	Sequence 176293,
252	19	100.0	111	4	US-10-335-977-6860	Sequence 6860, Ap	325	19	100.0	128	4	US-10-425-114-50582	Sequence 50582, A
253	19	100.0	111	4	US-10-767-701-52353	Sequence 52353, A	326	19	100.0	129	4	US-10-425-115-252447	Sequence 252447,
254	19	100.0	111	4	US-10-425-115-350889	Sequence 350889,	327	19	100.0	129	4	US-10-425-115-351484	Sequence 351484,
255	19	100.0	112	4	US-10-767-701-35668	Sequence 35668, A	328	19	100.0	129	4	US-10-425-115-352840	Sequence 352840,
256	19	100.0	112	4	US-10-425-115-287837	Sequence 287837,	329	19	100.0	130	4	US-10-282-122A-61474	Sequence 61474, A
257	19	100.0	113	4	US-10-156-761-11142	Sequence 11142, A	330	19	100.0	131	4	US-10-437-963-136208	Sequence 136208,
258	19	100.0	113	4	US-10-080-170-8	Sequence 8, Appl1	331	19	100.0	131	4	US-10-425-115-250272	Sequence 250272,
259	19	100.0	113	4	US-10-424-599-203422	Sequence 203422,	332	19	100.0	131	4	US-10-425-115-250272	Sequence 250272,
260	19	100.0	113	4	US-10-424-599-258229	Sequence 258229,	333	19	100.0	131	5	US-10-926-663-1521	Sequence 1521, Ap
261	19	100.0	113	4	US-10-080-170-8	Sequence 8, Appl1	334	19	100.0	132	4	US-10-424-599-152396	Sequence 152396,
262	19	100.0	113	4	US-10-437-963-191861	Sequence 191861,	335	19	100.0	132	4	US-10-424-599-200500	Sequence 200500,
263	19	100.0	113	4	US-10-468-356-8	Sequence 8, Appl1	336	19	100.0	132	4	US-10-424-599-202559	Sequence 202559,
264	19	100.0	113	4	US-10-425-115-211125	Sequence 211125,	337	19	100.0	132	4	US-10-424-599-258234	Sequence 258234,
265	19	100.0	113	4	US-10-425-115-316206	Sequence 316206,	338	19	100.0	132	4	US-10-437-963-156826	Sequence 156826,
266	19	100.0	114	4	US-10-437-963-167613	Sequence 167613,	339	19	100.0	132	4	US-10-437-963-165385	Sequence 165385,
267	19	100.0	114	4	US-10-767-701-46385	Sequence 46385, A	340	19	100.0	132	5	US-10-762-107-88	Sequence 88, Appl1
268	19	100.0	114	4	US-10-425-115-230329	Sequence 230329,	341	19	100.0	133	3	US-09-864-761-35106	Sequence 35106, A
269	19	100.0	114	4	US-10-425-115-269209	Sequence 269209,	342	19	100.0	133	3	US-09-738-626-6551	Sequence 6551, Ap
270	19	100.0	114	5	US-10-732-923-6358	Sequence 6358, Ap	343	19	100.0	133	4	US-10-424-599-146459	Sequence 146459,
271	19	100.0	114	5	US-10-450-763-38060	Sequence 38060, A	344	19	100.0	133	4	US-10-424-599-279320	Sequence 279320,
272	19	100.0	115	3	US-09-833-245-709	Sequence 709, App	345	19	100.0	133	4	US-10-437-963-181680	Sequence 181680,
273	19	100.0	115	4	US-10-230-331-34	Sequence 331, Appl1	346	19	100.0	133	4	US-10-425-115-359239	Sequence 359239,
274	19	100.0	115	4	US-10-437-963-106605	Sequence 106605,	347	19	100.0	134	3	US-10-425-115-213301	Sequence 213301,
275	19	100.0	115	4	US-10-437-963-130842	Sequence 130842,	348	19	100.0	134	3	US-09-855-604-120	Sequence 120, App
276	19	100.0	115	4	US-10-437-963-154724	Sequence 154724,	349	19	100.0	134	3	US-10-425-115-253088	Sequence 253088,
277	19	100.0	115	4	US-10-437-963-163186	Sequence 163186,	350	19	100.0	134	4	US-10-425-115-270514	Sequence 270514,
278	19	100.0	115	4	US-10-425-115-358687	Sequence 358687,	351	19	100.0	134	4	US-10-425-115-359239	Sequence 359239,
279	19	100.0	116	4	US-10-108-260A-4532	Sequence 4532, Ap	352	19	100.0	135	4	US-10-097-065-596	Sequence 596, App
280	19	100.0	116	4	US-10-424-599-250303	Sequence 250303,	353	19	100.0	135	4	US-10-372-876-596	Sequence 596, App
281	19	100.0	116	4	US-10-437-963-134757	Sequence 134757,	354	19	100.0	135	4	US-10-424-599-250888	Sequence 250888,
282	19	100.0	117	4	US-10-437-963-135657	Sequence 135657,	355	19	100.0	135	4	US-10-437-963-155403	Sequence 155403,
283	19	100.0	118	4	US-10-424-599-253142	Sequence 253142,	356	19	100.0	135	4	US-10-425-115-215369	Sequence 215369,
284	19	100.0	118	4	US-10-425-115-311566	Sequence 311566,	357	19	100.0	136	4	US-10-282-112A-49569	Sequence 49569, A
285	19	100.0	119	4	US-10-190-435-241	Sequence 241, App	358	19	100.0	138	4	US-10-286-421-21	Sequence 21, Appl1
286	19	100.0	119	4	US-10-425-115-292750	Sequence 292750,	359	19	100.0	138	4	US-10-286-421-21	Sequence 21, Appl1
287	19	100.0	119	4	US-10-425-115-337575	Sequence 337575,	360	19	100.0	138	4	US-10-282-122A-60639	Sequence 60639, A
288	19	100.0	120	3	US-09-867-550-634	Sequence 634, App	361	19	100.0	138	4	US-10-424-599-152994	Sequence 152994,
289	19	100.0	120	4	US-10-437-963-133900	Sequence 133900,	362	19	100.0	138	4	US-10-424-599-258721	Sequence 258721,
290	19	100.0	120	4	US-10-425-115-299755	Sequence 299755,	363	19	100.0	138	4	US-10-437-963-168302	Sequence 168302,
291	19	100.0	120	4	US-10-425-115-326962	Sequence 326962,	364	19	100.0	140	4	US-10-156-761-7616	Sequence 7616, Ap
292	19	100.0	120	5	US-10-856-499-2171	Sequence 2171, Ap	365	19	100.0	140	4	US-10-276-774-1424	Sequence 1424, App
293	19	100.0	121	3	US-09-974-879-484	Sequence 484, App	366	19	100.0	140	5	US-10-450-763-122271	Sequence 122271, A
294	19	100.0	121	3	US-09-305-736-485	Sequence 485, App	367	19	100.0	141	4	US-10-040-895-4	Sequence 4, Appl1
295	19	100.0	121	3	US-09-818-683-485	Sequence 485, App	368	19	100.0	141	4	US-10-029-386-3367	Sequence 3367, A
296	19	100.0	121	3	US-09-818-683-485	Sequence 485, App	369	19	100.0	141	4	US-10-108-260A-3939	Sequence 3939, Ap
297	19	100.0	121	4	US-10-424-599-260152	Sequence 260152,	370	19	100.0	141	4	US-10-282-122A-53067	Sequence 53067, A
298	19	100.0	121	4	US-10-621-401-484	Sequence 484, App	371	19	100.0	141	4	US-10-767-701-199530	Sequence 199530, A
299	19	100.0	122	4	US-10-291-172-305	Sequence 305, App	372	19	100.0	141	4	US-10-767-701-53785	Sequence 53785, A
300	19	100.0	122	4	US-10-424-599-212313	Sequence 212313,	373	19	100.0	141	4	US-10-425-115-185028	Sequence 185028,
301	19	100.0	122	4	US-10-221-278-305	Sequence 305, App	374	19	100.0	141	6	US-11-057-143-10363	Sequence 30363, A
302	19	100.0	122	4	US-10-425-114-389922	Sequence 38922, A	375	19	100.0	142	3	US-09-789-561-191	Sequence 191, App
303	19	100.0	122	4	US-10-408-765A-2161	Sequence 2161, Ap	376	19	100.0	142	4	US-10-424-599-185556	Sequence 185556,
304	19	100.0	122	4	US-10-437-963-183338	Sequence 183338,	377	19	100.0	142	4	US-10-425-114-42633	Sequence 42633, A
305	19	100.0	122	4	US-10-767-701-58817	Sequence 58817, A	378	19	100.0	142	4	US-10-425-115-164754	Sequence 164754,
306	19	100.0	122	4	US-10-425-115-312000	Sequence 312000,	379	19	100.0	142	5	US-10-883-936-191	Sequence 191, App
307	19	100.0	123	4	US-10-276-774-2424	Sequence 2424, Ap	380	19	100.0	143	4	US-10-282-122A-57897	Sequence 57897, A
308	19	100.0	123	4	US-10-767-701-54912	Sequence 54912, A	381	19	100.0	143	4	US-10-424-599-192151	Sequence 192151,
309	19	100.0	124	4	US-10-289-762-1155	Sequence 1155, Ap	382	19	100.0	143	4	US-10-296-115-1363	Sequence 1363, Ap
310	19	100.0	124	4	US-10-425-115-103432	Sequence 103432,	383	19	100.0	143	4	US-10-767-701-114448	Sequence 114448,
311	19	100.0	125	4	US-10-425-115-255481	Sequence 255481,	384	19	100.0	143	4	US-10-425-115-257969	Sequence 257969,
312	19	100.0	125	4	US-10-282-122A-77481	Sequence 77481, A	385	19	100.0	144	4	US-10-424-599-231893	Sequence 231893,
313	19	100.0	126	4	US-10-424-599-274218	Sequence 274218,	386	19	100.0	144	4	US-10-425-114-42759	Sequence 42759, A
314	19	100.0	126	4	US-10-767-701-37075	Sequence 37075, A	387	19	100.0	144	5	US-10-450-763-18846	Sequence 18846, A
315	19	100.0	127	4	US-10-424-599-215284	Sequence 215284,	388	19	100.0	145	4	US-10-425-114-56492	Sequence 56492, A
316	19	100.0	127	4	US-10-437-963-160818	Sequence 160818,	389	19	100.0	145	4	US-10-425-115-207074	Sequence 207074,
317	19	100.0	127	4	US-10-437-963-192729	Sequence 192729,	390	19	100.0	145	4	US-10-425-115-207850	Sequence 207850,
318	19	100.0	127	4	US-10-456-242-7	Sequence 7, Appl1	391	19	100.0	145	4	US-10-425-115-207850	Sequence 307850,
319	19	100.0	127	4	US-10-425-115-217543	Sequence 217543,	392	19	100.0	146	4	US-10-424-599-204568	Sequence 204568,

393	19	100.0	146	4	US-10-424-599-204570	Sequence 204570,
394	19	100.0	146	4	US-10-425-114-42380	Sequence 42380, A
395	19	100.0	146	4	US-10-335-977-7236	Sequence 7236, App
396	19	100.0	146	4	US-10-437-963-115335	Sequence 115335,
397	19	100.0	146	4	US-10-437-963-702884	Sequence 202884,
398	19	100.0	146	4	US-10-425-115-191100	Sequence 121100,
399	19	100.0	146	4	US-10-425-115-233009	Sequence 233009,
400	19	100.0	146	4	US-10-425-115-240137	Sequence 240137,
401	19	100.0	146	5	US-10-732-923-6396	Sequence 6396, App
402	19	100.0	146	5	US-10-450-763-59772	Sequence 59772, A
403	19	100.0	147	4	US-10-012-542-658	Sequence 458, App
404	19	100.0	147	4	US-10-115-123-458	Sequence 458, App
405	19	100.0	147	4	US-10-424-599-225582	Sequence 225582,
406	19	100.0	147	4	US-10-437-963-141415	Sequence 141415,
407	19	100.0	147	4	US-10-437-963-162770	Sequence 162770,
408	19	100.0	147	4	US-10-800-834-458	Sequence 458, App
409	19	100.0	148	3	US-09-738-626-5513	Sequence 5513, App
410	19	100.0	148	4	US-10-156-761-9414	Sequence 9414, App
411	19	100.0	148	4	US-10-369-493-12669	Sequence 12669, A
412	19	100.0	148	4	US-10-369-493-12669	Sequence 107135,
413	19	100.0	148	4	US-10-425-115-295634	Sequence 295634,
414	19	100.0	148	4	US-10-425-115-312425	Sequence 312425,
415	19	100.0	149	4	US-10-767-701-60218	Sequence 40218, A
416	19	100.0	149	4	US-10-425-115-223420	Sequence 223420,
417	19	100.0	149	4	US-10-425-115-308365	Sequence 308365,
418	19	100.0	149	5	US-10-732-923-6391	Sequence 6391, App
419	19	100.0	150	3	US-09-799-777-25	Sequence 25, App1
420	19	100.0	150	3	US-10-337-699-4	Sequence 4, App1
421	19	100.0	150	4	US-10-425-114-70920	Sequence 70920, A
422	19	100.0	150	4	US-10-437-963-147629	Sequence 147629,
423	19	100.0	151	4	US-10-424-599-197953	Sequence 197953,
424	19	100.0	151	4	US-10-424-599-236391	Sequence 236391,
425	19	100.0	151	4	US-10-437-963-120202	Sequence 120202,
426	19	100.0	151	4	US-10-767-701-39347	Sequence 39347, A
427	19	100.0	151	4	US-10-767-701-41378	Sequence 41378, A
428	19	100.0	152	3	US-09-925-300-1734	Sequence 1734, App
429	19	100.0	152	4	US-10-437-963-198231	Sequence 198231,
430	19	100.0	152	5	US-10-732-923-6357	Sequence 6357, App
431	19	100.0	152	5	US-10-450-763-46998	Sequence 46998, A
432	19	100.0	153	3	US-09-939-980-514	Sequence 514, App
433	19	100.0	153	3	US-09-905-176-22	Sequence 22, App1
434	19	100.0	153	4	US-10-078-929-58	Sequence 58, App1
435	19	100.0	153	4	US-10-213-880-6	Sequence 86, App1
436	19	100.0	153	4	US-10-177-293-286	Sequence 286, App
437	19	100.0	153	4	US-10-094-749-2408	Sequence 2408, App
438	19	100.0	153	4	US-10-401-403-182	Sequence 182, App
439	19	100.0	153	4	US-10-335-977-6504	Sequence 6504, App
440	19	100.0	153	4	US-10-767-701-39142	Sequence 39142, A
441	19	100.0	153	4	US-10-425-115-261370	Sequence 261370,
442	19	100.0	153	5	US-10-739-930-10655	Sequence 10655, A
443	19	100.0	153	5	US-10-732-923-2213	Sequence 2213, App
444	19	100.0	153	5	US-10-732-923-2214	Sequence 2214, App
445	19	100.0	153	5	US-10-450-763-58009	Sequence 58009, A
446	19	100.0	154	4	US-10-282-122A-50893	Sequence 50893, A
447	19	100.0	154	4	US-10-335-977-4792	Sequence 4792, App
448	19	100.0	154	4	US-10-335-977-7337	Sequence 7337, App
449	19	100.0	154	4	US-10-437-963-129993	Sequence 129993,
450	19	100.0	154	4	US-10-437-963-143040	Sequence 143040,
451	19	100.0	154	4	US-10-425-115-288937	Sequence 288937,
452	19	100.0	155	4	US-10-425-114-42206	Sequence 42206, A
453	19	100.0	155	4	US-10-335-977-4791	Sequence 4791, App
454	19	100.0	155	4	US-10-437-963-197465	Sequence 197465,
455	19	100.0	155	4	US-10-781-014-88	Sequence 88, App1
456	19	100.0	156	4	US-10-437-963-122605	Sequence 122605,
457	19	100.0	157	4	US-10-080-170-226	Sequence 226, App
458	19	100.0	157	4	US-10-425-114-59233	Sequence 59233, A
459	19	100.0	157	4	US-10-080-170-226	Sequence 226, App
460	19	100.0	157	4	US-10-468-356-226	Sequence 226, App
461	19	100.0	157	4	US-10-425-115-276031	Sequence 276031,
462	19	100.0	157	4	US-10-425-115-32287	Sequence 32287,
463	19	100.0	158	3	US-09-071-035-348	Sequence 348, App
464	19	100.0	158	3	US-09-890-688-12	Sequence 12, App1
465	19	100.0	158	4	US-10-206-576-348	Sequence 348, App

466

19

100.0

158

4

US-10-043-487-233

Sequence 233, App

467

19

100.0

158

4

US-10-043-487-346

Sequence 346, App

468

19

100.0

158

4

US-10-767-701-62314

Sequence 62314, A

469

19

100.0

158

4

US-10-425-115-256315

Sequence 256315,

470

19

100.0

158

4

US-10-425-115-256315

Sequence 256315,

471

19

100.0

158

5

US-10-912-362-348

Sequence 348, App

472

19

100.0

159

4

US-10-156-761-13786

Sequence 13786, A

473

19

100.0

159

5

US-10-799-514-23

Sequence 23, App1

474

19

100.0

160

4

US-10-451-667A-62

Sequence 62, App1

475

19

100.0

161

4

US-10-156-761-11117

Sequence 11117, A

476

19

100.0

161

4

US-10-029-386-32368

Sequence 32368, A

477

19

100.0

161

4

US-10-425-114-43119

Sequence 43119, A

478

19

100.0

161

4

US-10-296-115-968

Sequence 968, App

479

19

100.0

161

4

US-10-437-963-189946

Sequence 189946,

480

19

100.0

161

4

US-10-451-667A-382

Sequence 382, App

481

19

100.0

161

4

US-10-767-701-49916

Sequence 49916, A

482

19

100.0

161

4

US-10-767-701-61985

Sequence 61985, A

483

19

100.0

161

4

US-10-425-115-330445

Sequence 330445,

484

19

100.0

161

4

US-10-425-115-356208

Sequence 356208,

485

19

100.0

162

4

US-10-080-170-243

Sequence 243, App

486

19

100.0

162

4

US-10-461-990-31

Sequence 31, App1

487

19

100.0

162

4

US-10-080-170-243

Sequence 243, App

488

19

100.0

162

4

US-10-767-701-56786

Sequence 56786, A

489

19

100.0

162

4

US-10-468-356-243

Sequence 243, App

490

19

100.0

162

4

US-10-425-115-251896

Sequence 251896,

491

19

100.0

162

4

US-10-425-115-254077

Sequence 254077,

492

19

100.0

163

4

US-10-094-749-2612

Sequence 2612, App

493

19

100.0

163

4

US-10-289-762-103

Sequence 103, App

494

19

100.0

163

4

US-10-424-599-226266

Sequence 226266,

495

19

100.0

163

4

US-10-424-599-256875

Sequence 256875,

496

19

100.0

163

4

US-10-424-599-276381

Sequence 276381,

497

19

100.0

163

4

US-10-437-963-124774

Sequence 124774,

498

19

100.0

163

4

US-10-425-115-215847

Sequence 215847,

499

19

100.0

163

4

US-10-425-115-251012

Sequence 251012,

500

19

100.0

163

6

US-11-057-143-39597

Sequence 39597, A

RESULT 1

US-10-028-075B-2

Sequence 2, Application US/10028075B

Publication No. US2003011373A1

GENERAL INFORMATION:

APPLICANT: Khan, Nisier A.

APPLICANT: Benner, Robert

TITLE OF INVENTION: Gene regulator

FILE REFERENCE: 2183-5223US

CURRENT APPLICATION NUMBER: US/10/028, 075B

PRIOR FILING DATE: 2001-12-21

PRIOR APPLICATION NUMBER: EP 01203748.7

NUMBER OF SEQ ID NOS: 175

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 2

LENGTH: 4

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURES:

OTHER INFORMATION: Description of Artificial Sequence: oligopeptide

US-10-028-075B-2

Query Match 100.0%; Score 19; DB 4; Length 4;

Best Local Similarity 100.0%; Pred. No. 1.7e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4

DB 1 AOCV 4

RESULT 2

US-10-029-206A-2
; Sequence 2, Application US/10029206A
; Publication No. US20030119720A1
; GENERAL INFORMATION:
; APPLICANT: Khan, Nisar A.
; TITLE OF INVENTION: Oligopeptide treatment of anthrax
; FILE REFERENCE: 2183-522US
; CURRENT APPLICATION NUMBER: US/10/029,206A
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 09/821,380
; PRIOR FILING DATE: 2001-03-29
; NUMBER OF SEQ ID NOS: 175
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: oligopeptide
US-10-029-206A-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||
Db 1 AOGV 4

RESULT 3
US-10-262-522A-15
; Sequence 15, Application US/10262522A
; Publication No. US20030166556A1
; GENERAL INFORMATION:
; APPLICANT: Khan, Nisar A.
; APPLICANT: Benner, Robert
; TITLE OF INVENTION: Immunoregulator
; FILE REFERENCE: P52912US00
; CURRENT APPLICATION NUMBER: US/10/262,522A
; CURRENT FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: PCT/NL01/00259
; PRIOR FILING DATE: 2001-03-29
; PRIOR APPLICATION NUMBER: EP 00201139.3
; PRIOR FILING DATE: 2000-03-29
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (1)..(4)
; OTHER INFORMATION: Ala-replacement in peptide LQGV
US-10-262-522A-15

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||
Db 1 AOGV 4

RESULT 4
US-10-409-630-2
; Sequence 2, Application US/10409630
; Publication No. US2003021543A1
; GENERAL INFORMATION:
; APPLICANT: KHAN, NISAR A.

; APPLICANT: BENNER, ROBERT
; TITLE OF INVENTION: TREATMENT OF MULTIPLE SCLEROSIS (MS)
; FILE REFERENCE: 3077-5953US
; CURRENT APPLICATION NUMBER: US/10/409,630
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 10/028,075
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-409-630-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||
Db 1 AOGV 4

RESULT 5
US-10-409-027-2
; Sequence 2, Application US/10409027
; Publication No. US20030219425A1
; GENERAL INFORMATION:
; APPLICANT: KHAN, NISAR A.
; APPLICANT: BENNER, ROBERT
; APPLICANT: YZERMAN, JOHANNES N.M.
; TITLE OF INVENTION: TREATMENT OF TRANSPLANT SURVIVAL
; FILE REFERENCE: 3077-5957US
; CURRENT APPLICATION NUMBER: US/10/409,027
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 10/028,075
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-409-027-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||
Db 1 AOGV 4

RESULT 6
US-10-409-032-2
; Sequence 2, Application US/10409032
; Publication No. US20030220257A1
; GENERAL INFORMATION:
; APPLICANT: KHAN, NISAR AHMED
; APPLICANT: BENNER, ROBERT
; TITLE OF INVENTION: TREATMENT OF TRAUMA
; FILE REFERENCE: 3077-5952US
; CURRENT APPLICATION NUMBER: US/10/409,032
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 10/028,075

; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-409-032-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
Db 1 AOCV 4

RESULT 7
US-10-409-642-2
; Sequence 2, Application US/10409642
; Publication No. US20030220258A1
; GENERAL INFORMATION:
; APPLICANT: KHAN, NISAR A.
; APPLICANT: BENNER, ROBERT
; APPLICANT: JACOBS, BARTHOLOMEUS C.
; TITLE OF INVENTION: TREATMENT OF ISCHEMIC EVENTS
; FILE REFERENCE: 3077-5957US
; CURRENT APPLICATION NUMBER: US/10/409,642
; CURRENT FILING DATE: 2003-04-08
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-409-642-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
Db 1 AOCV 4

RESULT 8
US-10-409-654-2
; Sequence 2, Application US/10409654
; Publication No. US20030220259A1
; GENERAL INFORMATION:
; APPLICANT: KHAN, NISAR A.
; APPLICANT: BENNER, ROBERT
; APPLICANT: WENSVOORT, GERT
; TITLE OF INVENTION: TREATMENT OF NEUROLOGICAL DISORDERS
; FILE REFERENCE: 3077-5958US
; CURRENT APPLICATION NUMBER: US/10/409,654
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 10/028,075
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4

; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-409-654-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
Db 1 AOCV 4

RESULT 9
US-10-409-659-2
; Sequence 2, Application US/10409659
; Publication No. US20030220260A1
; GENERAL INFORMATION:
; APPLICANT: KHAN, NISAR A.
; APPLICANT: BENNER, ROBERT
; TITLE OF INVENTION: PEPTIDE COMPOSITIONS
; FILE REFERENCE: 3077-5956US
; CURRENT APPLICATION NUMBER: US/10/409,659
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 10/028,075
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-409-659-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
Db 1 AOCV 4

RESULT 10
US-10-409-671-2
; Sequence 2, Application US/10409671
; Publication No. US20030220261A1
; GENERAL INFORMATION:
; APPLICANT: KHAN, NISAR A.
; APPLICANT: BENNER, ROBERT
; TITLE OF INVENTION: TREATMENT OF IATROGENIC DISEASE
; FILE REFERENCE: 3077-5955US
; CURRENT APPLICATION NUMBER: US/10/409,671
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 10/028,075
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-409-671-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 1 AOGV 4

RESULT 11
US-10-409-694-2
; Sequence 2, Application US/10409694
; Publication No. US20030224955A1
; GENERAL INFORMATION:
; APPLICANT: KHAN, NISAR A.
; APPLICANT: WENSVOORT, GERT
; APPLICANT: BENNER, ROBERT
; TITLE OF INVENTION: TREATMENT OF BURNS
; FILE REFERENCE: 3077-5954US
; CURRENT APPLICATION NUMBER: US/10/409,694
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 10/028,075
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURES:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Peptide
US-10-409-694-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 1 AOGV 4

RESULT 12
US-10-409-657-2
; Sequence 2, Application US/10409657
; Publication No. US2004001361A1
; GENERAL INFORMATION:
; APPLICANT: WENSVOORT, GERT
; APPLICANT: KHAN, NISAR A.
; APPLICANT: BENNER, ROBERT
; TITLE OF INVENTION: STRATIFICATION
; FILE REFERENCE: 3077-5960US
; CURRENT APPLICATION NUMBER: US/10/409,657
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 10/028,075
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURES:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Peptide
US-10-409-657-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4

Db 1 AOGV 4
|||

RESULT 13
US-10-409-668-2
; Sequence 2, Application US/10409668
; Publication No. US20040202645A1
; GENERAL INFORMATION:
; APPLICANT: Khan, Nisar A.
; APPLICANT: Benner, Robert
; TITLE OF INVENTION: Treatment of Transplant Survival
; FILE REFERENCE: 3077-5958US
; CURRENT APPLICATION NUMBER: US/10/409,668
; CURRENT FILING DATE: 2003-04-08
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURES:
; OTHER INFORMATION: Synthetic peptide
US-10-409-668-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 1 AOGV 4

RESULT 14
US-10-753-510-2
; Sequence 2, Application US/10753510
; Publication No. US20040208855A1
; GENERAL INFORMATION:
; APPLICANT: Khan, Nisar A.
; APPLICANT: Benner, Robert
; TITLE OF INVENTION: Gene regulator
; FILE REFERENCE: 2183-5223US
; CURRENT APPLICATION NUMBER: US/10/753,510
; CURRENT FILING DATE: 2004-01-07
; PRIOR APPLICATION NUMBER: US/10/028,075B
; PRIOR FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: EP 01203748.7
; PRIOR FILING DATE: 2001-10-04
; NUMBER OF SEQ ID NOS: 175
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURES:
; OTHER INFORMATION: Description of Artificial Sequence: oligopeptide
US-10-753-510-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 1 AOGV 4

RESULT 15
US-10-821-240A-2
; Sequence 2, Application US/10821240A
; Publication No. US20050037430A1
; GENERAL INFORMATION:

; APPLICANT: Khan, Nisar A.
; APPLICANT: Benner, Robert
; TITLE OF INVENTION: Gene regulator
; FILE REFERENCE: 2183-5223US
; CURRENT APPLICATION NUMBER: US/10/821,240A
; CURRENT FILING DATE: 2004-04-08
; PRIOR APPLICATION NUMBER: 10/028,075
; PRIOR FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: EP 01203748.7
; PRIOR FILING DATE: 2001-10-04
; NUMBER OF SEQ ID NOS: 312
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Derivative of SEQ ID NO:1
; US-10-821-240A-2

Query Match 100.0%; Score 19; DB 5; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 1 ACGV 4

RESULT 16
US-10-817-756A-12
; Sequence 12, Application US/10817756A
; Publication No. US20050214943A1
; GENERAL INFORMATION:
; APPLICANT: Khan, Nisar A.
; APPLICANT: Benner, Robert
; APPLICANT: Erasmus Universiteit Rotterdam
; TITLE OF INVENTION: Gene regulatory peptides
; FILE REFERENCE: 2183-6400US
; CURRENT APPLICATION NUMBER: US/10/817,756A
; CURRENT FILING DATE: 2004-04-02
; PRIOR APPLICATION NUMBER: PCT/NL02/00639
; PRIOR FILING DATE: 2002-10-04
; PRIOR APPLICATION NUMBER: EP 01203748.7
; PRIOR FILING DATE: 2001-10-04
; PRIOR APPLICATION NUMBER: US 10/028,075
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Chemically synthesized peptide
; NAME/KEY: SITE
; LOCATION: (1)..(4)
; US-10-817-756A-12

Query Match 100.0%; Score 19; DB 5; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 1 ACGV 4

RESULT 17
US-10-821-256-2
; Sequence 2, Application US/10821256
; Publication No. US20050227925A1

; GENERAL INFORMATION:
; APPLICANT: Khan, Nisar A.
; APPLICANT: Benner, Robert
; TITLE OF INVENTION: Compositions Capable of Reducing Elevated Blood Urea
; FILE REFERENCE: 3077-6420
; CURRENT APPLICATION NUMBER: US/10/821,256
; CURRENT FILING DATE: 2004-04-08
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthesized Peptide
; US-10-821-256-2

Query Match 100.0%; Score 19; DB 5; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 1 ACGV 4

RESULT 18
US-10-946-647-184
; Sequence 184, Application US/10946647
; Publication No. US20050186217A1
; GENERAL INFORMATION:
; APPLICANT: EMERY, DARYL A.
; APPLICANT: STRAUB, DARREN E.
; APPLICANT: WONDERLING, LAURA
; TITLE OF INVENTION: COMPOSITIONS PRODUCED USING ENTERIC PATHOGENS AND METHODS OF USE
; FILE REFERENCE: 293.00340101
; CURRENT APPLICATION NUMBER: US/10/946,647
; CURRENT FILING DATE: 2004-09-20
; PRIOR APPLICATION NUMBER: 60/504,119
; PRIOR FILING DATE: 2003-09-19
; NUMBER OF SEQ ID NOS: 1448
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 184
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Salmonella enterica
; US-10-946-647-184

Query Match 100.0%; Score 19; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 1 ACGV 4

RESULT 19
US-10-946-647-558
; Sequence 558, Application US/10946647
; Publication No. US20050186217A1
; GENERAL INFORMATION:
; APPLICANT: EMERY, DARYL A.
; APPLICANT: STRAUB, DARREN E.
; APPLICANT: WONDERLING, LAURA
; TITLE OF INVENTION: COMPOSITIONS PRODUCED USING ENTERIC PATHOGENS AND METHODS OF USE
; FILE REFERENCE: 293.00340101
; CURRENT APPLICATION NUMBER: US/10/946,647
; CURRENT FILING DATE: 2004-09-20
; PRIOR APPLICATION NUMBER: 60/504,119
; PRIOR FILING DATE: 2003-09-19
; NUMBER OF SEQ ID NOS: 1448

SOFTWARE: PatentIn version 3.3
; SEQ ID NO 558
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Salmonella enteritidis
US-10-946-647-558

Query Match 100.0%; Score 19; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 1 ACGV 4

RESULT 20
US-10-946-647-855
; Sequence 855, Application US/10946647
; Publication No. US20050186217A1
; GENERAL INFORMATION:
; APPLICANT: EMERY, DARYL A.
; APPLICANT: STRAUB, DARREN E.
; APPLICANT: WONDERLING, LAURA
; TITLE OF INVENTION: COMPOSITIONS PRODUCED USING ENTERIC PATHOGENS AND METHODS OF USE
; FILE REFERENCE: 293.00340101
; CURRENT APPLICATION NUMBER: US/10/946,647
; CURRENT FILING DATE: 2004-09-20
; PRIOR APPLICATION NUMBER: 60/504,119
; PRIOR FILING DATE: 2003-09-19
; NUMBER OF SEQ ID NOS: 1448
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 855
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Escherichia coli
US-10-946-647-855

Query Match 100.0%; Score 19; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 1 ACGV 4

RESULT 21
US-10-946-647-954
; Sequence 954, Application US/10946647
; Publication No. US20050186217A1
; GENERAL INFORMATION:
; APPLICANT: EMERY, DARYL A.
; APPLICANT: STRAUB, DARREN E.
; APPLICANT: WONDERLING, LAURA
; TITLE OF INVENTION: COMPOSITIONS PRODUCED USING ENTERIC PATHOGENS AND METHODS OF USE
; FILE REFERENCE: 293.00340101
; CURRENT APPLICATION NUMBER: US/10/946,647
; CURRENT FILING DATE: 2004-09-20
; PRIOR APPLICATION NUMBER: 60/504,119
; PRIOR FILING DATE: 2003-09-19
; NUMBER OF SEQ ID NOS: 1448
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 954
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Escherichia coli
US-10-946-647-954

Query Match 100.0%; Score 19; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 1 ACGV 4

RESULT 22
US-10-122-675-28
; Sequence 28, Application US/10122675
; Publication No. US20030194712A1
; GENERAL INFORMATION:
; APPLICANT: Anderson, David
; APPLICANT: Li, Henry
; APPLICANT: Lu, Henry
; APPLICANT: Rigel Pharmaceuticals, Inc.
; TITLE OF INVENTION: Methods for Identifying Polypeptide Factors Interacting
; FILE REFERENCE: 021044-002000US
; CURRENT APPLICATION NUMBER: US/10/122,675
; CURRENT FILING DATE: 2002-10-31
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: inosine
; OTHER INFORMATION: monophosphate dehydrogenase (IMPDH) peptide
US-10-122-675-28

Query Match 100.0%; Score 19; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 4 ACGV 7

RESULT 23
US-09-957-806A-115
; Sequence 115, Application US/09957806A
; Publication No. US20050181446A1
; GENERAL INFORMATION:
; APPLICANT: Roggen, Erwin
; APPLICANT: Ernst, Steffen
; APPLICANT: Svendsen, Allan
; APPLICANT: Friis, Ebben
; APPLICANT: Osten, Claus
; TITLE OF INVENTION: PROTEIN VARIANTS HAVING MODIFIED IMMUNOGENICITY
; FILE REFERENCE: 10021.204-US
; CURRENT APPLICATION NUMBER: US/09/957,806A
; CURRENT FILING DATE: 2001-09-21
; NUMBER OF SEQ ID NOS: 248
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 115
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Thermomyces
US-09-957-806A-115

Query Match 100.0%; Score 19; DB 3; Length 13;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 6 ACGV 9

RESULT 24
US-10-394-980-6
; Sequence 6, Application US/10394980

```
; Publication No. US20040005633A1
; GENERAL INFORMATION:
; APPLICANT: Vandekerckhove, Joel
; TITLE OF INVENTION: METHODS AND APPARATUS FOR GEL-FREE QUALITATIVE AND
; FILE REFERENCE: YAV-001
; CURRENT APPLICATION NUMBER: US/10/394,980
; PRIOR FILING DATE: 2003-03-21
; PRIOR APPLICATION NUMBER: PCT/EP02/03368
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: US60/278,171
; PRIOR FILING DATE: 2001-03-22
; PRIOR APPLICATION NUMBER: US60/318,749
; PRIOR FILING DATE: 2001-09-12
; PRIOR APPLICATION NUMBER: US60/323,999
; PRIOR FILING DATE: 2001-09-20
; NUMBER OF SEQ ID NOS: 473
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MISC FEATURE
; OTHER INFORMATION: part of AMBP_HUMAN ((P02760) alphae-1-microglobulin)
US-10-394-980-6
```

```
Query Match          100.0%; Score 19; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 ACGV 4
        ||||
Db       3 ACGV 6
```

```
RESULT 25
US-10-952-557-6
; Sequence 6, Application US/10952557
; Publication No. US20050196823A1
; GENERAL INFORMATION:
; APPLICANT: Vandekerckhove, Joel
; TITLE OF INVENTION: METHODS AND APPARATUS FOR GEL-FREE QUALITATIVE AND
; FILE REFERENCE: YAV-001
; CURRENT APPLICATION NUMBER: US/10/952,557
; PRIOR FILING DATE: 2004-09-28
; PRIOR APPLICATION NUMBER: US/10/394,980
; PRIOR FILING DATE: 2003-03-21
; PRIOR APPLICATION NUMBER: PCT/EP02/03368
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: US60/278,171
; PRIOR FILING DATE: 2001-03-22
; PRIOR APPLICATION NUMBER: US60/318,749
; PRIOR FILING DATE: 2001-09-12
; PRIOR APPLICATION NUMBER: US60/323,999
; PRIOR FILING DATE: 2001-09-20
; NUMBER OF SEQ ID NOS: 473
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MISC FEATURE
; OTHER INFORMATION: part of AMBP_HUMAN ((P02760) alphae-1-microglobulin)
US-10-952-557-6
```

```
Query Match          100.0%; Score 19; DB 5; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 ACGV 4
        ||||
Db       3 ACGV 6
```

```
RESULT 26
US-09-397-945-430
; Sequence 430, Application US/09397945
; Publication No. US200301065139A1
; GENERAL INFORMATION:
; APPLICANT: Human Genome Sciences, Inc., et al.
; TITLE OF INVENTION: 95 Human secreted proteins
; FILE REFERENCE: P2027P1
; CURRENT APPLICATION NUMBER: US/09/397,945
; PRIOR FILING DATE: 1999-09-17
; PRIOR APPLICATION NUMBER: PCT/US99/05804
; PRIOR FILING DATE: 1999-03-18
; PRIOR APPLICATION NUMBER: 60/078,566
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,576
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,573
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,574
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,579
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/080,314
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080,312
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/078,578
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,581
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,577
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,563
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/080,313
; PRIOR FILING DATE: 1998-04-01
; NUMBER OF SEQ ID NOS: 470
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 430
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-397-945-430
```

```
Query Match          100.0%; Score 19; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 ACGV 4
        ||||
Db       5 ACGV 8
```

```
RESULT 27
US-10-280-066-401
; Sequence 401, Application US/10280066
; Publication No. US20030180718A1
; GENERAL INFORMATION:
; APPLICANT: Pillutla, Renuka C.
; APPLICANT: Brissette, Renee
; APPLICANT: Spruyt, Michael
; APPLICANT: Dedova, Olga
; APPLICANT: Blume, Arthur J.
; APPLICANT: Prendergast, John
; APPLICANT: Goldstein, Neil I.
; TITLE OF INVENTION: TARGET SPECIFIC SCREENING AND ITS USE FOR IDENTIFYING TARGET BINDI
; FILE REFERENCE: 2598-4009US1
```


CURRENT APPLICATION NUMBER: US/10/280,066
CURRENT FILING DATE: 2002-10-24
PRIOR APPLICATION NUMBER: 60/345,471
PRIOR FILING DATE: 2001-10-24
NUMBER OF SEQ ID NOS: 537
SOFTWARE: PatentIn version 3.1
SEQ ID NO 401
LENGTH: 20
TYPE: PRT
ORGANISM: Escherichia coli
FEATURE:
NAME/KEY: MISC FEATURE
OTHER INFORMATION: VEGFR1-20F-3-B6
US-10-280-066-401

Query Match 100.0%; Score 19; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
DB 6 AOGV 9

RESULT 28
US-10-653-595-430
Sequence 430, Application US/10653595
Publication No. US20040048304A1
GENERAL INFORMATION:
APPLICANT: Ruben et. al.
TITLE OF INVENTION: 95 Human secreted proteins
FILE REFERENCE: P2027P1C1
CURRENT APPLICATION NUMBER: US/10/653,595
CURRENT FILING DATE: 2003-09-03
PRIOR APPLICATION NUMBER: US 09/397945
PRIOR FILING DATE: 1999-09-17
PRIOR APPLICATION NUMBER: PCT/US99/05804
PRIOR FILING DATE: 1999-03-18
PRIOR APPLICATION NUMBER: 60/078,566
PRIOR FILING DATE: 1998-03-19
PRIOR APPLICATION NUMBER: 60/078,576
PRIOR FILING DATE: 1998-03-19
PRIOR APPLICATION NUMBER: 60/078,573
PRIOR FILING DATE: 1998-03-19
PRIOR APPLICATION NUMBER: 60/078,574
PRIOR FILING DATE: 1998-03-19
PRIOR APPLICATION NUMBER: 60/078,579
PRIOR FILING DATE: 1998-03-19
PRIOR APPLICATION NUMBER: 60/080,314
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080,312
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/078,578
PRIOR FILING DATE: 1998-03-19
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 470
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 430
LENGTH: 20
TYPE: PRT
ORGANISM: Homo sapiens
US-10-653-595-430

Query Match 100.0%; Score 19; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
DB 5 AOGV 8

RESULT 29

US-10-241-814-13
Sequence 13, Application US/10241814
Publication No. US20040053391A1
GENERAL INFORMATION:
APPLICANT: Katholieke Universiteit Nijmegen
TITLE OF INVENTION: Renal cell carcinoma antigen G-250-derived peptides that
elicit both CD4 and CD8 T-cell responses
FILE REFERENCE: 470-021777
CURRENT APPLICATION NUMBER: US/10/241,814
CURRENT FILING DATE: 2002-09-11
NUMBER OF SEQ ID NOS: 16
SEQ ID NO 13
LENGTH: 20
TYPE: PRT
ORGANISM: Homo sapiens
US-10-241-814-13

Query Match 100.0%; Score 19; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
DB 1 AOGV 4

RESULT 30
US-10-377-134-8
Sequence 8, Application US/10377134
Publication No. US20040096938A1
GENERAL INFORMATION:
APPLICANT: XU, Ming-Qun
APPLICANT: EVANS, Thomas C.
APPLICANT: PRADHAN, Srinarsa
APPLICANT: COMB, Donald G.
APPLICANT: PAULUS, Henry
APPLICANT: SUN, Luo
APPLICANT: CHEN, Lixin
APPLICANT: GHOSH, Inca
TITLE OF INVENTION: METHOD FOR GENERATING SPLIT, NON-TRANSFERABLE GENES
THAT ARE ABLE TO EXPRESS AN ACTIVE PROTEIN PRODUCT
FILE REFERENCE: NEB-219
CURRENT APPLICATION NUMBER: US/10/377,134
CURRENT FILING DATE: 2003-02-28
PRIOR APPLICATION NUMBER: 09/936,588
PRIOR FILING DATE: 2002-03-29
PRIOR APPLICATION NUMBER: PCT/US00/14122
PRIOR FILING DATE: 2000-05-23
PRIOR APPLICATION NUMBER: 60/135,677
PRIOR FILING DATE: 1999-05-24
NUMBER OF SEQ ID NOS: 138
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 8
LENGTH: 21
TYPE: PRT
ORGANISM: Escherichia coli
US-10-377-134-8

Query Match 100.0%; Score 19; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.1e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
DB 11 AOGV 14

RESULT 31
US-10-872-770-12
Sequence 12, Application US/10872770
Publication No. US20050164362A1
GENERAL INFORMATION:
APPLICANT: EDWARDS, ALED

APPLICANT: DHARMSI, AKIL
APPLICANT: DOMAGALIA, MEGAN
APPLICANT: PINDER, BENJAMIN
APPLICANT: ALAM, MUHAMMAD ZAHOO
APPLICANT: VEDADI, MASOOD
APPLICANT: WREZEL, OLGA
APPLICANT: HOUSTON, SIMON
APPLICANT: KIMBER, MATTHEW
APPLICANT: VALLEE, FRANCOIS
APPLICANT: AMREY, DONALD E.
APPLICANT: BEATTIE, BRYAN
TITLE OF INVENTION: NOVEL PRIPRIED POLYPEPTIDES FROM PSEUDOMONAS AERUGINOSA
FILE REFERENCE: IPT-191.01
CURRENT APPLICATION NUMBER: US/10/872,770
CURRENT FILING DATE: 2004-06-21
PRIOR APPLICATION NUMBER: PCT/CA02/01977
PRIOR FILING DATE: 2002-12-20
PRIOR APPLICATION NUMBER: 60/370,755
PRIOR FILING DATE: 2002-04-08
PRIOR APPLICATION NUMBER: 60/344,112
PRIOR FILING DATE: 2001-12-21
NUMBER OF SEQ ID NOS: 19
SOFTWARE: PatentIn Ver. 3.2
SEQ ID NO 12
LENGTH: 21
TYPE: PRT
ORGANISM: Pseudomonas aeruginosa
US-10-872-770-12

Query Match 100.0%; Score 19; DB 5; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.1e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
1111
DB 12 ACGV 15

RESULT 32
US-10-097-065-597
Sequence 597, Application US/10097065
Publication No. US2003005236A1
GENERAL INFORMATION:
APPLICANT: Moore, Paul A. et al.
TITLE OF INVENTION: 110 Human Secreted Proteins
FILE REFERENCE: P2021P1
CURRENT APPLICATION NUMBER: US/10/097,065
CURRENT FILING DATE: 2002-03-14
PRIOR APPLICATION NUMBER: PCT/US98/27059
PRIOR FILING DATE: 1998-12-17
PRIOR APPLICATION NUMBER: 60/070,923
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,007
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,057
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,006
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,369
PRIOR FILING DATE: 1997-12-19
PRIOR APPLICATION NUMBER: 60/068,367
PRIOR FILING DATE: 1997-12-19
PRIOR APPLICATION NUMBER: 60/068,368
PRIOR FILING DATE: 1997-12-19
PRIOR APPLICATION NUMBER: 60/068,169
PRIOR FILING DATE: 1997-12-19
PRIOR APPLICATION NUMBER: 60/068,053
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,064
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,054
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,008

PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,365
PRIOR FILING DATE: 1997-12-19
NUMBER OF SEQ ID NOS: 672
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 597
LENGTH: 23
TYPE: PRT
ORGANISM: Homo sapiens
US-10-097-065-597

Query Match 100.0%; Score 19; DB 4; Length 23;
Best Local Similarity 100.0%; Pred. No. 7.8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
1111
DB 3 ACGV 6

RESULT 33
US-10-372-876-597
Sequence 597, Application US/10372876
Publication No. US20030204071A1
GENERAL INFORMATION:
APPLICANT: Moore, Paul A. et al.
TITLE OF INVENTION: 110 Human Secreted Proteins
FILE REFERENCE: P2021P1
CURRENT APPLICATION NUMBER: US/10/372,876
CURRENT FILING DATE: 2003-02-26
PRIOR APPLICATION NUMBER: 09/334,595
PRIOR FILING DATE: 1999-06-17
PRIOR APPLICATION NUMBER: PCT/US98/27059
PRIOR FILING DATE: 1998-12-17
PRIOR APPLICATION NUMBER: 60/070,923
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,007
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,057
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,006
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,369
PRIOR FILING DATE: 1997-12-19
PRIOR APPLICATION NUMBER: 60/068,367
PRIOR FILING DATE: 1997-12-19
PRIOR APPLICATION NUMBER: 60/068,368
PRIOR FILING DATE: 1997-12-19
PRIOR APPLICATION NUMBER: 60/068,169
PRIOR FILING DATE: 1997-12-19
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 672
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 597
LENGTH: 23
TYPE: PRT
ORGANISM: Homo sapiens
US-10-372-876-597

Query Match 100.0%; Score 19; DB 4; Length 23;
Best Local Similarity 100.0%; Pred. No. 7.8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
1111
DB 3 ACGV 6

RESULT 34
US-09-880-748-2176
Sequence 2176, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:

```

; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2176
; LENGTH: 24
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-2176

Query Match      100.0%; Score 19; DB 3; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.1e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db      17 ACGV 20

RESULT 35
US-09-880-748-2969
; Sequence 2969, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2969
; LENGTH: 24
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-2969

Query Match      100.0%; Score 19; DB 3; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.1e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db      17 ACGV 20

RESULT 36
US-10-293-418-2176
; Sequence 2176, Application US/10293418
; Publication No. US20030223996A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 2176
; LENGTH: 24
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-2176

Query Match      100.0%; Score 19; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.1e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db      17 ACGV 20

RESULT 37
US-10-293-418-2969
; Sequence 2969, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 2969
; LENGTH: 24
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-2969

Query Match      100.0%; Score 19; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.1e+02;
```

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGCV 4
Db 17 AGCV 20

RESULT 38

US-09-864-761-45997
Sequence 45997, Application US/09864761
Patent No. US20020048763A1
GENERAL INFORMATION:
APPLICANT: Penn, Sharon G.
APPLICANT: Rank, David R.
APPLICANT: Hanzel, David K.
APPLICANT: Chen, Wenheng
TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
FILE REFERENCE: A601ca-X-1
CURRENT APPLICATION NUMBER: US/09/864,761
PRIOR FILING DATE: 2001-05-23,312
PRIOR APPLICATION NUMBER: US 60/180,312
PRIOR FILING DATE: 2000-02-04
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 09/632,366
PRIOR FILING DATE: 2000-08-03
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 09/608,408
PRIOR FILING DATE: 2000-06-30
PRIOR APPLICATION NUMBER: US 09/774,203
PRIOR FILING DATE: 2001-01-29
NUMBER OF SEQ ID NOS: 49117
SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
SEQ ID NO 45997
LENGTH: 25
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: MAP TO AC012614.3
OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.7
OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.7
OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 50
OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1.7
OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.7
OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 1.8
US-09-864-761-45997

Query Match 100.0%; Score 19; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 8.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCV 4
Db 16 AGCV 19

RESULT 39

US-10-269-806-80
Sequence 80, Application US/10269806
Publication No. US20030176352A1
GENERAL INFORMATION:
APPLICANT: Min, Housung
APPLICANT: Sitney, Karen
APPLICANT: Hartley, Cynthia
TITLE OF INVENTION: Peptides and Related Compounds Having Thrombopoietic Activity
FILE REFERENCE: A-750
CURRENT APPLICATION NUMBER: US/10/269,806
CURRENT FILING DATE: 2002-10-10
NUMBER OF SEQ ID NOS: 199
SOFTWARE: PatentIn version 3.1
SEQ ID NO 80
LENGTH: 25
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthesized Peptide Sequence
US-10-269-806-80

Query Match 100.0%; Score 19; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 8.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCV 4
Db 1 AGCV 4

RESULT 40
US-10-029-386-33755
Sequence 33755, Application US/10029386
Publication No. US20030194704A1
GENERAL INFORMATION:
APPLICANT: Penn, Sharon G.
APPLICANT: Rank, David R.
APPLICANT: Hanzel, David K.
TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR GI
FILE REFERENCE: A601ca-X-2
CURRENT APPLICATION NUMBER: US/10/029,386
CURRENT FILING DATE: 2001-12-20
NUMBER OF SEQ ID NOS: 34288
SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
SEQ ID NO 33755
LENGTH: 25
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: MAP TO AC007869.2
OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 0.4
US-10-029-386-33755

Query Match 100.0%; Score 19; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 8.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCV 4
Db 1 AGCV 4

```
RESULT 41
US-10-424-599-169158
; Sequence 169158, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovallik David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 169158
; LENGTH: 29
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_123764C.1.pep
US-10-424-599-169158

Query Match          100.0%; Score 19; DB 4; Length 29;
Best Local Similarity 100.0%; Pred. No. 9.8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
    |||
Db 20 AOGV 23

RESULT 42
US-10-424-599-281150
; Sequence 281150, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovallik David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 281150
; LENGTH: 29
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_95900C.1.pep
US-10-424-599-281150

Query Match          100.0%; Score 19; DB 4; Length 29;
Best Local Similarity 100.0%; Pred. No. 9.8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
    |||
Db 7 AOGV 10

RESULT 43
US-10-800-023-1
; Sequence 1, Application US/10800023
; Publication No. US2004025868A1
; GENERAL INFORMATION:
; APPLICANT: Steinman, Ralph
; APPLICANT: Nussenzweig, Michel
; APPLICANT: Hawiger, Daniel
; APPLICANT: Bonifaz, Laura
```

```
; TITLE OF INVENTION: Enhanced Antigen Delivery and Modulation
; TITLE OF INVENTION: of the Immune Response Therefrom
; FILE REFERENCE: 600-1-081CONC1P1
; CURRENT APPLICATION NUMBER: US/10/800,023
; CURRENT FILING DATE: 2004-03-14
; PRIOR APPLICATION NUMBER: 09/925,284
; PRIOR FILING DATE: 2001-08-09
; PRIOR APPLICATION NUMBER: 09/586,704
; PRIOR FILING DATE: 2000-06-05
; PRIOR APPLICATION NUMBER: PCT/US96/01383
; PRIOR FILING DATE: 1996-01-31
; PRIOR APPLICATION NUMBER: 08/381,528
; PRIOR FILING DATE: 1995-01-31
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 30
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-800-023-1

Query Match          100.0%; Score 19; DB 5; Length 30;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
    |||
Db 15 AOGV 18

RESULT 44
US-10-424-599-261845
; Sequence 261845, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovallik David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 261845
; LENGTH: 33
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_78469C.1.pep
US-10-424-599-261845

Query Match          100.0%; Score 19; DB 4; Length 33;
Best Local Similarity 100.0%; Pred. No. 1.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
    |||
Db 26 AOGV 29

RESULT 45
US-10-425-115-199464
; Sequence 199464, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovallik, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
```

FILE REFERENCE: 38-21(53222)B
CURRENT APPLICATION NUMBER: US/10/425,115
CURRENT FILING DATE: 2003-04-28
NUMBER OF SEQ ID NOS: 369326
SEQ ID NO 199464
LENGTH: 34
TYPE: PRT
ORGANISM: Zea mays
FEATURE:
NAME/KEY: unsure
LOCATION: (1)..(34)
OTHER INFORMATION: unsure at all Xaa locations
FEATURE:
OTHER INFORMATION: Clone ID: MRT4577_113486C.1.pep
US-10-425-115-199464

Query Match 100.0%; Score 19; DB 4; Length 34;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 14 ACGV 17

RESULT 46
US-10-424-599-242322
Sequence 242322, Application US/10424599
Publication No. US20040031072A1
GENERAL INFORMATION:
APPLICANT: La Rosa Thomas J
APPLICANT: Kovalic David K
APPLICANT: Zhou Yihua
APPLICANT: Cao Yongwei
TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
FILE REFERENCE: 38-21(53223)B
CURRENT APPLICATION NUMBER: US/10/424,599
CURRENT FILING DATE: 2003-04-28
NUMBER OF SEQ ID NOS: 285684
SEQ ID NO 242322
LENGTH: 35
TYPE: PRT
ORGANISM: Glycine max
FEATURE:
OTHER INFORMATION: Clone ID: PAT_MRT3847_60845C.1.pep
US-10-424-599-242322

Query Match 100.0%; Score 19; DB 4; Length 35;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 13 ACGV 16

RESULT 47
US-10-252-773-11
Sequence 11, Application US/10252773
Publication No. US20030131383A1
GENERAL INFORMATION:
APPLICANT: EVERETT, NICHOLAS P.
APPLICANT: LI, QUNIGSHUN
APPLICANT: LAWRENCE, CHRISTOPHER
APPLICANT: DAVIES, MAELOR H.
TITLE OF INVENTION: PEPTIDES WITH ENHANCED STABILITY TO PROTEASE
TITLE OF INVENTION: DEGRADATION
FILE REFERENCE: INTERLINK 3.0-003
CURRENT APPLICATION NUMBER: US/10/252,773
CURRENT FILING DATE: 2002-09-23
PRIORITY APPLICATION NUMBER: 60/106,373
PRIORITY FILING DATE: 1998-10-30

PRIOR APPLICATION NUMBER: 60/106,573
PRIOR FILING DATE: 1998-11-02
NUMBER OF SEQ ID NOS: 27
SOFTWARE: Patent Ver. 2.1
SEQ ID NO 11
LENGTH: 37
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-252-773-11

Query Match 100.0%; Score 19; DB 4; Length 37;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 6 ACGV 9

RESULT 48
US-10-120-319-22
Sequence 22, Application US/10120319
Publication No. US20020164749A1
GENERAL INFORMATION:
APPLICANT: Taylor, Diane E.
APPLICANT: Ge, Zhongming
TITLE OF INVENTION: ALPHA-1, 3-FUCOSYLTRANSFERASE
FILE REFERENCE: 07254/049001
CURRENT APPLICATION NUMBER: US/10/120,319
CURRENT FILING DATE: 2002-04-09
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/092,315
PRIOR FILING DATE: EARLIER FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/048,857
PRIOR FILING DATE: EARLIER FILING DATE: 1997-06-06
NUMBER OF SEQ ID NOS: 22
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 22
LENGTH: 38
TYPE: PRT
ORGANISM: Helicobacter pylori
US-10-120-319-22

Query Match 100.0%; Score 19; DB 4; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 35 ACGV 38

RESULT 49
US-10-189-977-22
Sequence 22, Application US/10189977
Publication No. US20030166211A1
GENERAL INFORMATION:
APPLICANT: Taylor, Diane E.
APPLICANT: Ge, Zhongming
TITLE OF INVENTION: ALPHA-1, 3-FUCOSYLTRANSFERASE
FILE REFERENCE: 07254/049001
CURRENT APPLICATION NUMBER: US/10/189,977
CURRENT FILING DATE: 2002-07-03
PRIOR APPLICATION NUMBER: US/09/092,315
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: US 60/048,857
PRIOR FILING DATE: 1997-06-06
NUMBER OF SEQ ID NOS: 22
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 22
LENGTH: 38

```

; TYPE: PRT
; ORGANISM: Helicobacter pylori
US-10-189-977-22
Query Match          100.0%; Score 19; DB 4; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db       35 ACGV 38

RESULT 50
US-10-392-098-22
; Sequence 22, Application US/10392098
; Publication No. US20030166212A1
; GENERAL INFORMATION:
; APPLICANT: Taylor, Diane B.
; TITLE OF INVENTION: NUCLEIC ACIDS ENCODING ALPHA-1,3
; TITLE OF INVENTION: FUCOSYLTRANSFERASES AND EXPRESSION SYSTEMS FOR MAKING AND
; TITLE OF INVENTION: EXPRESSING THEM (amended)
; FILE REFERENCE: 07254-049002
; CURRENT APPLICATION NUMBER: US/10/392,098
; CURRENT FILING DATE: 2003-03-17
; PRIOR APPLICATION NUMBER: US/09/733,524A
; PRIOR FILING DATE: 2000-12-07
; PRIOR APPLICATION NUMBER: US 09/092,315
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: US 60/048,857
; PRIOR FILING DATE: 1997-06-06
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 38
; TYPE: PRT
; ORGANISM: Helicobacter pylori
US-10-392-098-22
Query Match          100.0%; Score 19; DB 4; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db       35 ACGV 38

RESULT 51
US-10-029-386-33511
; Sequence 33511, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharon G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AECOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 33511
; LENGTH: 38
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AC003955.1
; OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 0.43
US-10-029-386-33511
```

```

Query Match          100.0%; Score 19; DB 4; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db       24 ACGV 27

RESULT 52
US-10-425-115-195035
; Sequence 195035, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovacic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(5322)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 195035
; LENGTH: 40
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_109461C.1.pdp
US-10-425-115-195035
Query Match          100.0%; Score 19; DB 4; Length 40;
Best Local Similarity 100.0%; Pred. No. 1.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db       22 ACGV 25

RESULT 53
US-10-282-122A-45229
; Sequence 45229, Application US/10282122A
; Publication No. US20040029129A1
; GENERAL INFORMATION:
; APPLICANT: Wang, Liangsu
; APPLICANT: Zamudio, Carlos
; APPLICANT: Malone, Cheryl
; APPLICANT: Haselbeck, Robert
; APPLICANT: Zyskind, Kari
; APPLICANT: Wall, Daniel
; APPLICANT: Trawick, John
; APPLICANT: Carr, Grant
; APPLICANT: Yamamoto, Robert
; APPLICANT: Forsyth, R.
; APPLICANT: Xu, H.
; TITLE OF INVENTION: Identification of Essential Genes in Microorganisms
; FILE REFERENCE: EUTRA.034A
; CURRENT APPLICATION NUMBER: US/10/282,122A
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: 60/191,078
; PRIOR FILING DATE: 2000-03-21
; PRIOR APPLICATION NUMBER: 60/206,848
; PRIOR FILING DATE: 2000-05-23/207,727
; PRIOR APPLICATION NUMBER: 60/207,727
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 60/230,335
; PRIOR FILING DATE: 2000-09-06
; PRIOR APPLICATION NUMBER: 60/230,347
; PRIOR FILING DATE: 2000-09-09
; PRIOR APPLICATION NUMBER: 60/242,578
```

```
; PRIOR FILING DATE: 2000-10-23
; PRIOR APPLICATION NUMBER: 60/253,625
; PRIOR FILING DATE: 2000-11-27
; PRIOR APPLICATION NUMBER: 60/257,931
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/267,636
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/269,308
; PRIOR FILING DATE: 2001-02-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 78614
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 45229
; LENGTH: 41
; TYPE: PRT
; ORGANISM: Acinetobacter baumannii
; US-10-282-122A-45229

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 41;
Pred. No. 1.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ACGV 4
Db 13 ACGV 16

RESULT 54
US-10-425-115-257966
; Sequence 257966, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 257966
; LENGTH: 41
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_166852C.1.pep
; US-10-425-115-257966

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 41;
Pred. No. 1.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ACGV 4
Db 26 ACGV 29

RESULT 55
US-10-773-446-115
; Sequence 115, Application US/10773446
; Publication No. US20050176662A1
; GENERAL INFORMATION:
; APPLICANT: INANA, GEORGE
; APPLICANT: McLAREN, MARGARET
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DETECTING AND TREATING RETINAL
; FILE REFERENCE: 39533-192229
; CURRENT APPLICATION NUMBER: US/10/773,446
; CURRENT FILING DATE: 2004-02-09
; NUMBER OF SEQ ID NOS: 131
; SOFTWARE: PatentIn version 3.2
```

```
; SEQ ID NO 115
; LENGTH: 41
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-773-446-115

Query Match
Best Local Similarity 100.0%; Score 19; DB 5; Length 41;
Pred. No. 1.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ACGV 4
Db 12 ACGV 15

RESULT 56
US-10-425-115-280416
; Sequence 280416, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 280416
; LENGTH: 43
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_18840C.1.pep
; US-10-425-115-280416

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 43;
Pred. No. 1.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ACGV 4
Db 31 ACGV 34

RESULT 57
US-10-425-115-256443
; Sequence 256443, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 256443
; LENGTH: 44
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_165468C.1.pcp
; US-10-425-115-256443

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 44;
Pred. No. 1.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```


Oy 1 AOGV 4
|||
Db 15 AOGV 18

RESULT 58

US-09-397-945-424
; Sequence 424, Application US/09397945
; Publication No. US20030065139A1
; GENERAL INFORMATION:
; APPLICANT: Human Genome Sciences, Inc. et al.
; TITLE OF INVENTION: 95 Human secreted proteins
; FILE REFERENCE: P2027P1
; CURRENT APPLICATION NUMBER: US/09/397,945
; PRIOR FILING DATE: 1999-09-17
; PRIOR APPLICATION NUMBER: PCT/US99/05804
; PRIOR FILING DATE: 1999-03-18
; PRIOR APPLICATION NUMBER: 60/078,566
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,576
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,573
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,574
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,579
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/080,314
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080,312
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/078,578
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,581
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,577
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,563
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/080,313
; PRIOR FILING DATE: 1998-04-01
; NUMBER OF SEQ ID NOS: 470
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 424
; LENGTH: 48
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-397-945-424

Query Match 100.0%; Score 19; DB 3; Length 48;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 AOGV 4
|||
Db 33 AOGV 36

RESULT 59

US-10-424-599-203996
; Sequence 203996, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; PRIOR FILING DATE: 2003-04-28

; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 203996
; LENGTH: 48
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_26235C.1.pdp
US-10-424-599-203996

Query Match 100.0%; Score 19; DB 4; Length 48;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 AOGV 4
|||
Db 12 AOGV 15

RESULT 60

US-10-424-599-216178
; Sequence 216178, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; PRIOR FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 216178
; LENGTH: 48
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_37238C.1.pdp
US-10-424-599-216178

Query Match 100.0%; Score 19; DB 4; Length 48;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 AOGV 4
|||
Db 10 AOGV 13

RESULT 61

US-10-653-595-424
; Sequence 424, Application US/10653595
; Publication No. US20040048304A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et. al.
; TITLE OF INVENTION: 95 Human secreted proteins
; FILE REFERENCE: P2027P1C1
; CURRENT APPLICATION NUMBER: US/10/653,595
; PRIOR FILING DATE: 2003-09-03
; PRIOR APPLICATION NUMBER: US 09/397945
; PRIOR FILING DATE: 1999-09-17
; PRIOR APPLICATION NUMBER: PCT/US99/05804
; PRIOR FILING DATE: 1999-03-18
; PRIOR APPLICATION NUMBER: 60/078,566
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,576
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,573
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,574
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,579

```

; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/080,314
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080,312
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/078,578
; PRIOR FILING DATE: 1998-03-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 470
; SOFTWARE: Patentn Ver. 2.0
; SEQ ID NO 424
; LENGTH: 48
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-653-595-424

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 48;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 33 ACGV 36

RESULT 62
US-10-425-115-339468
; Sequence 339468, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 339468
; LENGTH: 48
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_72766C.1.pcp
US-10-425-115-339468

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 48;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 6 ACGV 9

RESULT 63
US-10-029-386-27682
; Sequence 27682, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharon G.
; APPLICANT: Rank, David R.
; APPLICANT: Hantzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; FILE REFERENCE: AEOWCA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 27682
```

```

; LENGTH: 49
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AL139135.2
; OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 1.3
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.3
; OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.9
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 2.2
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 2.3
; OTHER INFORMATION: SWISSPROT HIT: P70213, EVALU 1.00e-07
US-10-029-386-27682

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 49;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 44 ACGV 47

RESULT 64
US-10-424-599-225119
; Sequence 225119, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 225119
; LENGTH: 49
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_45312C.1.pcp
US-10-424-599-225119

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 49;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 25 ACGV 28

RESULT 65
US-09-866-066-35
; Sequence 35, Application US/09866066
; Publication No. US2003013888A1
; GENERAL INFORMATION:
; APPLICANT: Benjamin, Christopher
; APPLICANT: Roberts, Steve
; APPLICANT: Ruble, Cara
; APPLICANT: Gotow, Lisa
; APPLICANT: Karnovsky, Alla
; TITLE OF INVENTION: Human Ion Channels
; FILE REFERENCE: 00229.US1
; CURRENT APPLICATION NUMBER: US/09/866,066
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: 60/207,152
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 60/207,257
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 60/207,119
```

;; PRIOR FILING DATE: 2000-05-26
;; NUMBER OF SEQ ID NOS: 42
;; SOFTWARE: Patentin version 3.0
;; SEQ ID NO 35
;; LENGTH: 51
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-09-866-066-35

Query Match
Best Local Similarity 100.0%; Score 19; DB 3; Length 51;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
Db 39 AOGV 42

RESULT 66
US-10-424-599-193989
; Sequence 193989, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J
; APPLICANT: Kovalic, David K
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 193989
; LENGTH: 51
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MKT3847_17199C.1.pep
US-10-424-599-193989

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 51;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
Db 13 AOGV 16

RESULT 67
US-10-969-677-35
; Sequence 35, Application US/10969677
; Publication No. US20050176098A1
; GENERAL INFORMATION:
; APPLICANT: Benjamin, Christopher
; APPLICANT: Roberts, Steve
; APPLICANT: Ruble, Cara
; APPLICANT: Gotow, Lisa
; APPLICANT: Karnovsky, Alla
; TITLE OF INVENTION: Human Ion Channels
; FILE REFERENCE: 00229_US1
; CURRENT APPLICATION NUMBER: US/10/969,677
; CURRENT FILING DATE: 2004-10-20
; PRIOR APPLICATION NUMBER: US/09/866,066
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/207,152
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 60/207,257
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 60/207,119
; PRIOR FILING DATE: 2000-05-26
; NUMBER OF SEQ ID NOS: 42

;; SOFTWARE: Patentin version 3.0
;; SEQ ID NO 35
;; LENGTH: 51
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-10-969-677-35

Query Match
Best Local Similarity 100.0%; Score 19; DB 5; Length 51;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
Db 39 AOGV 42

RESULT 68
US-10-425-115-314288
; Sequence 314288, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 314288
; LENGTH: 52
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MKT4577_49690C.1.pep
US-10-425-115-314288

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 52;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
Db 40 AOGV 43

RESULT 69
US-09-925-302-824
; Sequence 824, Application US/09925302
; Patent No. US20020044941A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
; FILE REFERENCE: PA104
; CURRENT APPLICATION NUMBER: US/09/925,302
; CURRENT FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: PCT/US00/05918
; PRIOR FILING DATE: 2000-03-08
; PRIOR APPLICATION NUMBER: 60/124,270
; PRIOR FILING DATE: 1999-03-12
; NUMBER OF SEQ ID NOS: 896
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 824
; LENGTH: 53
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (16)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE

```
; LOCATION: (46)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (47)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (52)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (53)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; US-09-925-302-824
```

```
Query Match          100.0%; Score 19; DB 3; Length 53;
Best Local Similarity 100.0%; Pred. No. 1.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 ACGV 4
        |||
Db      39 ACGV 42
```

```
RESULT 70
; US-09-925-302-824
; Sequence 824, Application US/09925302
; Publication No. US20030064072A9
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
; FILE REFERENCE: PA104
; CURRENT APPLICATION NUMBER: US/09/925,302
; CURRENT FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: PCT/US00/05918
; PRIOR FILING DATE: 2000-03-08
; PRIOR APPLICATION NUMBER: 60/124,270
; PRIOR FILING DATE: 1999-03-12
; NUMBER OF SEQ ID NOS: 896
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 824
; LENGTH: 53
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (16)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (46)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (47)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (52)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (53)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; US-09-925-302-824
```

```
Query Match          100.0%; Score 19; DB 3; Length 53;
Best Local Similarity 100.0%; Pred. No. 1.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 ACGV 4
        |||
Db      39 ACGV 42
```

```
RESULT 71
; US-10-016-768-3
; Sequence 3, Application US/10016768
; Publication No. US2002014243A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Baehrecke, Eric H.
; TITLE OF INVENTION: GENES REGULATING PROGRAMMED CELL DEATH
; FILE REFERENCE: 4115-131
; CURRENT APPLICATION NUMBER: US/10/016,768
; CURRENT FILING DATE: 2001-10-29
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 54
; TYPE: PRT
; ORGANISM: T. nigroviridis
; US-10-016-768-3
```

```
Query Match          100.0%; Score 19; DB 4; Length 54;
Best Local Similarity 100.0%; Pred. No. 1.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 ACGV 4
        |||
Db      36 ACGV 39
```

```
RESULT 72
; US-09-764-877-1474
; Sequence 1474, Application US/09764877
; Patent No. US20020147140A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PC005
; CURRENT APPLICATION NUMBER: US/09/764,877
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - refer to PALM or file wrapper
; NUMBER OF SEQ ID NOS: 4031
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1474
; LENGTH: 55
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-764-877-1474
```

```
Query Match          100.0%; Score 19; DB 3; Length 55;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 ACGV 4
        |||
Db      17 ACGV 20
```

```
RESULT 73
; US-10-242-515-1474
; Sequence 1474, Application US/10242515
; Publication No. US20040009488A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PC005C1
; CURRENT APPLICATION NUMBER: US/10/242,515
; CURRENT FILING DATE: 2002-09-13
; PRIOR APPLICATION NUMBER: 09/764,877
; PRIOR FILING DATE: 2001-01-17
; PRIOR APPLICATION NUMBER: 60/179,065
; PRIOR FILING DATE: 2000-01-31
; PRIOR APPLICATION NUMBER: 60/180,628
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: 60/214,886
; PRIOR FILING DATE: 2000-06-28
; PRIOR APPLICATION NUMBER: 60/217,487
; PRIOR FILING DATE: 2000-07-11
; PRIOR APPLICATION NUMBER: 60/225,758
; PRIOR FILING DATE: 2000-08-14
```

```
;; PRIOR APPLICATION NUMBER: 60/220,963
;; PRIOR FILING DATE: 2000-07-26
;; PRIOR APPLICATION NUMBER: 60/217,496
;; PRIOR FILING DATE: 2000-07-11
;; PRIOR APPLICATION NUMBER: 60/225,447
;; PRIOR FILING DATE: 2000-08-14
;; PRIOR APPLICATION NUMBER: 60/218,290
;; PRIOR FILING DATE: 2000-07-14
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 4031
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO 1474
;; LENGTH: 55
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-10-242-515-1474

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 55;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
Db 17 AOGV 20

RESULT 74
US-10-425-115-279298
;; Sequence 279298, Application US/10425115
;; Publication No. US20040214272A1
;; GENERAL INFORMATION:
;; APPLICANT: La Rosa, Thomas J.
;; APPLICANT: Kovacic, David K.
;; APPLICANT: Zhou, Yihua
;; APPLICANT: Cao, Yongwei
;; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
;; TITLE OF INVENTION: Plants
;; FILE REFERENCE: 38-21(53222)B
;; CURRENT APPLICATION NUMBER: US/10/425,115
;; CURRENT FILING DATE: 2003-04-28
;; NUMBER OF SEQ ID NOS: 369326
;; SEQ ID NO 279298
;; LENGTH: 55
;; TYPE: PRT
;; ORGANISM: Zea mays
;; FEATURE:
;; OTHER INFORMATION: Clone ID: MRT4577_18629C.1.pep
US-10-425-115-279298

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 55;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
Db 49 AOGV 52

RESULT 75
US-09-864-761-44380
;; Sequence 44380, Application US/09864761
;; Patent No. US20020048763A1
;; GENERAL INFORMATION:
;; APPLICANT: Penn, Sharon G.
;; APPLICANT: Rank, David R.
;; APPLICANT: Hanzel, David K.
;; APPLICANT: Chen, Wenheng
;; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
;; TITLE OF INVENTION: GENE EXPRESSION ANALYSIS BY MICROARRAY
;; FILE REFERENCE: Aecmica-X-1
;; CURRENT APPLICATION NUMBER: US/09/864,761
;; CURRENT FILING DATE: 2001-05-23
;; PRIOR APPLICATION NUMBER: US 60/180,312
```

```
;; PRIOR FILING DATE: 2000-02-04
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: US 09/632,366
;; PRIOR FILING DATE: 2000-08-03
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 09/608,408
;; PRIOR FILING DATE: 2000-06-30
;; PRIOR APPLICATION NUMBER: US 09/774,203
;; PRIOR FILING DATE: 2001-01-29
;; NUMBER OF SEQ ID NOS: 49117
;; SOFTWARE: Annonax Sequence Listing Engine vers. 1.1
;; SEQ ID NO 44380
;; LENGTH: 56
;; TYPE: PRT
;; ORGANISM: Homo sapiens
;; FEATURE:
;; OTHER INFORMATION: MAP TO AC004816.1
;; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.2
;; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 1.3
;; OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.2
;; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1.2
;; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.4
;; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.4
;; OTHER INFORMATION: EST HUMAN HIT: BE727589.1, EVALUATE 1.20e+00
;; OTHER INFORMATION: SWISSPROT HIT: P08325, EVALUATE 4.60e+00
US-09-864-761-44380

Query Match
Best Local Similarity 100.0%; Score 19; DB 3; Length 56;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
Db 6 AOGV 9

RESULT 76
US-10-116-255-32
;; Sequence 32, Application US/10116255
;; Publication No. US20030036646A1
;; GENERAL INFORMATION:
;; APPLICANT: Ni et al.
;; TITLE OF INVENTION: Uncoupling Protein Polynucleotides, Polypeptides, and
;; TITLE OF INVENTION: Antibodies
;; FILE REFERENCE: PT0099P1
;; CURRENT APPLICATION NUMBER: US/10/116,255
;; CURRENT FILING DATE: 2002-04-05
```

;; PRIOR APPLICATION NUMBER: 09/685,897
;; PRIOR FILING DATE: 2000-10-11
;; PRIOR APPLICATION NUMBER: PCT/US00/09534
;; PRIOR FILING DATE: 2000-04-06
;; PRIOR APPLICATION NUMBER: 60/128,701
;; PRIOR FILING DATE: 1999-04-09
;; PRIOR APPLICATION NUMBER: 60/142,821
;; PRIOR FILING DATE: 1999-07-08
;; PRIOR APPLICATION NUMBER: 60/149,448
;; PRIOR FILING DATE: 1999-08-18
;; PRIOR APPLICATION NUMBER: 60/164,751
;; PRIOR FILING DATE: 1999-11-12
;; NUMBER OF SEQ ID NOS: 66
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO 32
;; LENGTH: 56
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-10-116-255-32

Query Match 100.0%; Score 19; DB 4; Length 56;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
Db 39 AOGV 42

RESULT 77
US-10-264-049-3884
;; Sequence 3884, Application US/10264049
;; Publication No. US2004005579A1
;; GENERAL INFORMATION:
;; APPLICANT: Biree et al.
;; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;; FILE REFERENCE: PA133p1
;; CURRENT APPLICATION NUMBER: US/10/264,049
;; CURRENT FILING DATE: 2002-10-04
;; PRIOR APPLICATION NUMBER: PCT/US01/18569
;; PRIOR FILING DATE: 2001-06-07
;; PRIOR APPLICATION NUMBER: US 60/209,467
;; PRIOR FILING DATE: 2000-06-07
;; NUMBER OF SEQ ID NOS: 4360
;; SOFTWARE: PatentIn Ver. 3.1
;; SEQ ID NO 3884
;; LENGTH: 56
;; TYPE: PRT
;; ORGANISM: Homo sapiens
;; FEATURE:
;; NAME/KEY: MISC_FEATURE
;; LOCATION: (3)
;; OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
;; FEATURE:
;; NAME/KEY: MISC_FEATURE
;; LOCATION: (6)
;; OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
;; FEATURE:
;; NAME/KEY: MISC_FEATURE
;; LOCATION: (7)
;; OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
;; FEATURE:
;; NAME/KEY: MISC_FEATURE
;; LOCATION: (19)
;; OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
;; FEATURE:
;; NAME/KEY: MISC_FEATURE
;; LOCATION: (22)
;; OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
;; FEATURE:
;; NAME/KEY: MISC_FEATURE
;; LOCATION: (37)
;; OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids

;; FEATURE:
;; NAME/KEY: MISC_FEATURE
;; LOCATION: (43)
;; OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
;; FEATURE:
;; NAME/KEY: MISC_FEATURE
;; LOCATION: (54)
;; OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
US-10-264-049-3884

Query Match 100.0%; Score 19; DB 4; Length 56;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
Db 28 AOGV 31

RESULT 78

US-10-424-599-279039
;; Sequence 279039, Application US/10424599
;; Publication No. US20040031072A1
;; GENERAL INFORMATION:
;; APPLICANT: La Rosa Thomas J
;; APPLICANT: Zhou Yihua
;; APPLICANT: Cao Yongwei
;; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
;; FILE REFERENCE: 38-21(53223)B
;; CURRENT APPLICATION NUMBER: US/10/424,599
;; CURRENT FILING DATE: 2003-04-28
;; NUMBER OF SEQ ID NOS: 285684
;; SEQ ID NO 279039
;; LENGTH: 56
;; TYPE: PRT
;; ORGANISM: Glycine max
;; FEATURE:
;; OTHER INFORMATION: Clone ID: PAT_MRT3847_93996C.1.pep
US-10-424-599-279039

Query Match 100.0%; Score 19; DB 4; Length 56;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
Db 47 AOGV 50

RESULT 79

US-10-425-115-263648
;; Sequence 263648, Application US/10425115
;; Publication No. US20040214272A1
;; GENERAL INFORMATION:
;; APPLICANT: La Rosa, Thomas J.
;; APPLICANT: Kovallit, David K.
;; APPLICANT: Zhou, Yihua
;; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;; TITLE OF INVENTION: Plants
;; FILE REFERENCE: 38-21(53222)B
;; CURRENT APPLICATION NUMBER: US/10/425,115
;; CURRENT FILING DATE: 2003-04-28
;; NUMBER OF SEQ ID NOS: 369326
;; SEQ ID NO 263648
;; LENGTH: 56
;; TYPE: PRT
;; ORGANISM: Zea mays
;; FEATURE:
;; OTHER INFORMATION: Clone ID: MRT4577_172059C.1.pep
US-10-425-115-263648

Query Match 100.0%; Score 19; DB 4; Length 57;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 44 AOGV 47

RESULT 80

US-10-424-599-182978
; Sequence 182978, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated with
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 182978
; LENGTH: 57
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(57)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_136242C.1.pep
US-10-424-599-182978

Query Match 100.0%; Score 19; DB 4; Length 57;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 3 AOGV 6

RESULT 81

US-10-424-599-249716
; Sequence 249716, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated with
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 249716
; LENGTH: 57
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(57)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_67522C.1.pep
US-10-424-599-249716

Query Match 100.0%; Score 19; DB 4; Length 57;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 19 AOGV 22

RESULT 82

US-10-029-386-33617
; Sequence 33617, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharon G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; FILE REFERENCE: A60MICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 33617
; LENGTH: 58
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR7.1
; OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 0.47
; OTHER INFORMATION: SWISSPROT HIT: Q14168, EVALU8 7.00e-20
US-10-029-386-33617

Query Match 100.0%; Score 19; DB 4; Length 58;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 31 AOGV 34

RESULT 83

US-10-425-115-192059
; Sequence 192059, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 192059
; LENGTH: 58
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_106743C.1.pep
US-10-425-115-192059

Query Match 100.0%; Score 19; DB 4; Length 58;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 1 AOGV 4

```
RESULT 84
US-10-425-115-219711
; Sequence 219711, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT FILING DATE: 2003-04-28
; CURRENT APPLICATION NUMBER: US/10/425,115
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 219711
; LENGTH: 58
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_131965C.1.pep
US-10-425-115-219711

Query Match          100.0%; Score 19; DB 4; Length 58;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db       31 ACGV 34

RESULT 85
US-10-425-115-336290
; Sequence 336290, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT FILING DATE: 2003-04-28
; CURRENT APPLICATION NUMBER: US/10/425,115
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 336290
; LENGTH: 58
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(58)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_69805C.1.pep
US-10-425-115-336290

Query Match          100.0%; Score 19; DB 4; Length 58;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db       4 ACGV 7

RESULT 86
US-09-925-298-590
; Sequence 590, Application US/09925298
```

```
; Publication No. US20020039764A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
; FILE REFERENCE: PA103
; CURRENT APPLICATION NUMBER: US/09/925,298
; CURRENT FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: PCT/US00/05881
; PRIOR FILING DATE: 2000-03-08
; PRIOR APPLICATION NUMBER: 60/124,270
; PRIOR FILING DATE: 1999-03-12
; NUMBER OF SEQ ID NOS: 846
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 590
; LENGTH: 59
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-925-298-590

Query Match          100.0%; Score 19; DB 3; Length 59;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db       13 ACGV 16

RESULT 87
US-10-102-806-590
; Sequence 590, Application US/10102806
; Publication No. US20030054421A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
; FILE REFERENCE: PA103P1C1
; CURRENT APPLICATION NUMBER: US/10/102,806
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 09/925,298
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: PCT/US00/05881
; PRIOR FILING DATE: 2000-03-08
; PRIOR APPLICATION NUMBER: 60/124,270
; PRIOR FILING DATE: 1999-03-12
; NUMBER OF SEQ ID NOS: 846
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 590
; LENGTH: 59
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-102-806-590

Query Match          100.0%; Score 19; DB 4; Length 59;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db       13 ACGV 16

RESULT 88
US-10-029-386-28279
; Sequence 28279, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharon G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR GI
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
```



```
;; CURRENT FILING DATE: 2001-12-20
;; NUMBER OF SEQ ID NOS: 34288
;; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
;; SEQ ID NO 28279
;; LENGTH: 59
;; TYPE: PRT
;; ORGANISM: Homo sapiens
;; FEATURE:
;; OTHER INFORMATION: MAP TO CHR22_184.2.0
;; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.1
;; OTHER INFORMATION: EXPRESSED IN HEPA, SIGNAL = 0.61
;; OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.1
;; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.2
;; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.95
;; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 0.98
;; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.1
;; OTHER INFORMATION: SWISSPROT HIT: P13463, EVALU6 6.10e+00
US-10-029-386-28279

Query Match          100.0%; Score 19; DB 4; Length 59;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      1 AOGV 4
        ||||
Db      52 AOGV 55

RESULT 89
US-10-425-115-278273
;; Sequence 278273, Application US/10425115
;; Publication No. US20040214272A1
;; GENERAL INFORMATION:
;; APPLICANT: La Rosa, Thomas J.
;; APPLICANT: Kovalic, David K.
;; APPLICANT: Zhou, Yihua
;; APPLICANT: Cao, Yongwei
;; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;; TITLE OF INVENTION: Plants
;; FILE REFERENCE: 38-21(53222)B
;; CURRENT APPLICATION NUMBER: US/10/425,115
;; CURRENT FILING DATE: 2003-04-28
;; NUMBER OF SEQ ID NOS: 369326
;; SEQ ID NO 278273
;; LENGTH: 59
;; TYPE: PRT
;; ORGANISM: Zea mays
;; FEATURE:
;; OTHER INFORMATION: Clone ID: MRT4577_18535C.1.pep
US-10-425-115-278273

Query Match          100.0%; Score 19; DB 4; Length 59;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      1 AOGV 4
        ||||
Db      13 AOGV 16

RESULT 90
US-09-864-408A-2276
;; Sequence 2276, Application US/09864408A
;; Publication No. US20040009474A1
;; GENERAL INFORMATION:
;; APPLICANT: Leach, Martin D.
;; APPLICANT: Shinkets, Richard A.
;; TITLE OF INVENTION: No. US20040009474A1 Human Polynucleotides and Polypeptides Encc
;; FILE REFERENCE: 21402-012
;; CURRENT APPLICATION NUMBER: US/09/864,408A
;; CURRENT FILING DATE: 2001-05-24
;; PRIOR APPLICATION NUMBER: 60/206,690
;; PRIOR FILING DATE: 2000-05-24
```

```
;; NUMBER OF SEQ ID NOS: 9068
;; SOFTWARE: FASTSEQ for Windows Version 4.0
;; SEQ ID NO 2276
;; LENGTH: 60
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-09-864-408A-2276

Query Match          100.0%; Score 19; DB 3; Length 60;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      1 AOGV 4
        ||||
Db      20 AOGV 23

RESULT 91
US-10-424-599-198924
;; Sequence 198924, Application US/10424599
;; Publication No. US20040031072A1
;; GENERAL INFORMATION:
;; APPLICANT: La Rosa, Thomas J.
;; APPLICANT: Kovalic, David K.
;; APPLICANT: Zhou, Yihua
;; APPLICANT: Cao, Yongwei
;; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
;; FILE REFERENCE: 38-21(53223)B
;; CURRENT APPLICATION NUMBER: US/10/424,599
;; CURRENT FILING DATE: 2003-04-28
;; NUMBER OF SEQ ID NOS: 285684
;; SEQ ID NO 198924
;; LENGTH: 60
;; TYPE: PRT
;; ORGANISM: Glycine max
;; FEATURE:
;; OTHER INFORMATION: Clone ID: PAT_MRT3847_21653C.1.pep
US-10-424-599-198924

Query Match          100.0%; Score 19; DB 4; Length 60;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      1 AOGV 4
        ||||
Db      24 AOGV 27

RESULT 92
US-10-424-599-189118
;; Sequence 189118, Application US/10424599
;; Publication No. US20040031072A1
;; GENERAL INFORMATION:
;; APPLICANT: La Rosa, Thomas J.
;; APPLICANT: Kovalic, David K.
;; APPLICANT: Zhou, Yihua
;; APPLICANT: Cao, Yongwei
;; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
;; FILE REFERENCE: 38-21(53223)B
;; CURRENT APPLICATION NUMBER: US/10/424,599
;; CURRENT FILING DATE: 2003-04-28
;; NUMBER OF SEQ ID NOS: 285684
;; SEQ ID NO 189118
;; LENGTH: 62
;; TYPE: PRT
;; ORGANISM: Glycine max
;; FEATURE:
;; NAME/KEY: unsure
;; LOCATION: (1) ..(62)
;; OTHER INFORMATION: unsure at all Xaa locations
;; FEATURE:
```

OTHER INFORMATION: Clone ID: PAT_MRT3847_141789C.1.pep
US-10-424-599-189318

Query Match 100.0%; Score 19; DB 4; Length 62;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOCV 4
Db 39 AOCV 42

RESULT 93

US-10-424-599-189377
Sequence 189377, Application US/10424599
Publication No. US20040031072A1

GENERAL INFORMATION:

APPLICANT: La Rosa Thomas J

APPLICANT: Kovalic David K

APPLICANT: Zhou Yihua

APPLICANT: Cao Yongwei

TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With

TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement

FILE REFERENCE: 38-21(53223)B

CURRENT APPLICATION NUMBER: US/10/424,599

CURRENT FILING DATE: 2003-04-28

NUMBER OF SEQ ID NOS: 285684

SEQ ID NO 189377

LENGTH: 62

TYPE: PRT

ORGANISM: Glycine max

FEATURE:

OTHER INFORMATION: Clone ID: PAT_MRT3847_142023C.1.pep
US-10-424-599-189377

Query Match 100.0%; Score 19; DB 4; Length 62;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOCV 4
Db 18 AOCV 21

RESULT 94

US-10-425-114-71256

Sequence 71256, Application US/10425114
Publication No. US20040034888A1

GENERAL INFORMATION:

APPLICANT: Liu, Jingdong

APPLICANT: Zhou, Yihua

APPLICANT: Kovalic, David K.

APPLICANT: Screen, Steven E

APPLICANT: Tabaska, Jack E

APPLICANT: Cao, Yongwei

TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With

TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement

FILE REFERENCE: 38-21(5313)B

CURRENT APPLICATION NUMBER: US/10/425,114

CURRENT FILING DATE: 2003-04-28

NUMBER OF SEQ ID NOS: 73128

SEQ ID NO 71256

LENGTH: 62

TYPE: PRT

ORGANISM: Zea mays

FEATURE:

OTHER INFORMATION: Clone ID: LIB3067-051-FL1.pep
US-10-425-114-71256

Query Match 100.0%; Score 19; DB 4; Length 62;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOCV 4
Db 13 AOCV 16

RESULT 95

US-10-425-115-188418

Sequence 188418, Application US/10425115
Publication No. US20040214272A1

GENERAL INFORMATION:

APPLICANT: La Rosa, Thomas J.

APPLICANT: Kovalic, David K.

APPLICANT: Zhou, Yihua

APPLICANT: Cao, Yongwei

TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With

TITLE OF INVENTION: Plants

FILE REFERENCE: 38-21(53222)B

CURRENT APPLICATION NUMBER: US/10/425,115

CURRENT FILING DATE: 2003-04-28

NUMBER OF SEQ ID NOS: 369326

SEQ ID NO 188418

LENGTH: 62

TYPE: PRT

ORGANISM: Zea mays

FEATURE:

OTHER INFORMATION: Clone ID: MRT4577_103429C.1.pep
US-10-425-115-188418

Query Match 100.0%; Score 19; DB 4; Length 62;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOCV 4
Db 55 AOCV 58

RESULT 96

US-10-029-386-31780

Sequence 31780, Application US/10029386
Publication No. US20030194704A1

GENERAL INFORMATION:

APPLICANT: Penn, Sharon G.

APPLICANT: Rank, David R.

APPLICANT: Hanzel, David K.

TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR

TITLE OF INVENTION: EXPRESSION ANALYSIS TWO

FILE REFERENCE: A60MICA-X-2

CURRENT APPLICATION NUMBER: US/10/029,386

CURRENT FILING DATE: 2001-12-20

NUMBER OF SEQ ID NOS: 34288

SOFTWARE: Annotmax Sequence Listing Engine vers. 1.1

SEQ ID NO 31780

LENGTH: 63

TYPE: PRT

ORGANISM: Homo sapiens

FEATURE:

OTHER INFORMATION: MAP TO AF172277.1

OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.3

OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.1

OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1

OTHER INFORMATION: SWISSPROT HIT: Q01635, EVALU 1.00e-20

US-10-029-386-31780

Query Match 100.0%; Score 19; DB 4; Length 63;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOCV 4
Db 41 AOCV 44

```
RESULT 97
US-10-424-599-262885
; Sequence 262885, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 262885
; LENGTH: 63
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_79406C.1.pep
US-10-424-599-262885

Query Match          100.0%; Score 19; DB 4; Length 63;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db       34 ACGV 37

RESULT 98
US-10-424-599-270368
; Sequence 270368, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 270368
; LENGTH: 63
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_86160C.1.pep
US-10-424-599-270368

Query Match          100.0%; Score 19; DB 4; Length 63;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db       45 ACGV 48

RESULT 99
US-10-425-115-251637
; Sequence 251637, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
```

```
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 251637
; LENGTH: 63
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(63)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_161079C.1.pep
US-10-425-115-251637

Query Match          100.0%; Score 19; DB 4; Length 63;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db       58 ACGV 61

RESULT 100
US-10-450-763-56831
; Sequence 56831, Application US/10450763
; Publication No. US20050196754A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc
; TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
; FILE REFERENCE: 790CIP3/US
; CURRENT APPLICATION NUMBER: US/10/450,763
; CURRENT FILING DATE: 2003-06-11
; PRIOR APPLICATION NUMBER: PCT/US01/08631
; PRIOR FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/540,217
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: 09/649,167
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 60736
; SOFTWARE: Custom
; SEQ ID NO 56831
; LENGTH: 63
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (1)..(63)
; OTHER INFORMATION: Xaa = X or * as defined in Table 2
US-10-450-763-56831

Query Match          100.0%; Score 19; DB 5; Length 63;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db       34 ACGV 37

RESULT 101
US-10-424-599-177860
; Sequence 177860, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
```

```
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 177860
; LENGTH: 64
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_131623C.1.pep
; US-10-424-599-177860

Query Match      100.0%; Score 19; DB 4; Length 64;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db      18 ACGV 21

RESULT 102
US-10-425-115-197187
; Sequence 197187, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 197187
; LENGTH: 64
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_111417C.1.pep
; US-10-425-115-197187

Query Match      100.0%; Score 19; DB 4; Length 64;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db      38 ACGV 41

RESULT 103
US-10-425-115-219280
; Sequence 219280, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 219280
; LENGTH: 64
; TYPE: PRT
```

```
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_131575C.1.pep
; US-10-425-115-219280

Query Match      100.0%; Score 19; DB 4; Length 64;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db      25 ACGV 28

RESULT 104
US-10-437-963-106625
; Sequence 106625, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Wu, Wei
; APPLICANT: Cao, Yongwei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 106625
; LENGTH: 65
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_11051C.1.pep
; US-10-437-963-106625

Query Match      100.0%; Score 19; DB 4; Length 65;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db      48 ACGV 51

RESULT 105
US-10-425-115-240290
; Sequence 240290, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 240290
; LENGTH: 65
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_150727C.1.pep
; US-10-425-115-240290
```

Query Match 100.0%; Score 19; DB 4; Length 65;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 20 AOGV 23

RESULT 106
US-10-425-115-357026

; Sequence 357026, Application US/10425115
; Publication No. US2004021472A1

; GENERAL INFORMATION:

; APPLICANT: La Rosa, Thomas J.

; APPLICANT: Kovalic, David K.

; APPLICANT: Zhou, Yihua

; APPLICANT: Cao, Yongwei

; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With

; FILE REFERENCE: 38-21(5322)B

; CURRENT APPLICATION NUMBER: US/10/425,115

; CURRENT FILING DATE: 2003-04-28

; NUMBER OF SEQ ID NOS: 369326

; SEQ ID NO 357026

; LENGTH: 65

; TYPE: PRT

; ORGANISM: Zea mays

; FEATURE:

; OTHER INFORMATION: Clone ID: MRT4577_88777C.1.pdp

US-10-425-115-357026

Query Match 100.0%; Score 19; DB 4; Length 65;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 3 AOGV 6

RESULT 107

US-10-424-599-257517

; Sequence 257517, Application US/10424599

; Publication No. US20040031072A1

; GENERAL INFORMATION:

; APPLICANT: La Rosa, Thomas J.

; APPLICANT: Kovalic, David K.

; APPLICANT: Zhou, Yihua

; APPLICANT: Cao, Yongwei

; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With

; FILE REFERENCE: 38-21(5322)B

; CURRENT APPLICATION NUMBER: US/10/424,599

; CURRENT FILING DATE: 2003-04-28

; NUMBER OF SEQ ID NOS: 285684

; SEQ ID NO 257517

; LENGTH: 66

; TYPE: PRT

; ORGANISM: Glycine max

; FEATURE:

; OTHER INFORMATION: Clone ID: PAT_MRT3847_74561C.1.pdp

US-10-424-599-257517

Query Match 100.0%; Score 19; DB 4; Length 66;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 23 AOGV 26

RESULT 108

US-10-437-963-106620

; Sequence 106620, Application US/10437963

; Publication No. US20040123343A1

; GENERAL INFORMATION:

; APPLICANT: La Rosa, Thomas J.

; APPLICANT: Kovalic, David K.

; APPLICANT: Zhou, Yihua

; APPLICANT: Cao, Yongwei

; APPLICANT: Boukharov, Andrey A.

; APPLICANT: Barbazuk, Brad

; APPLICANT: Li, Ping

; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With

; FILE REFERENCE: 38-21(5322)B

; CURRENT APPLICATION NUMBER: US/10/437,963

; CURRENT FILING DATE: 2003-05-14

; NUMBER OF SEQ ID NOS: 204966

; SEQ ID NO 106620

; LENGTH: 67

; TYPE: PRT

; ORGANISM: Oryza sativa

; FEATURE:

; OTHER INFORMATION: Clone ID: PAT_MRT4530_11047C.1.pdp

US-10-437-963-106620

Query Match 100.0%; Score 19; DB 4; Length 67;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 25 AOGV 28

RESULT 109

US-10-437-963-158436

; Sequence 158436, Application US/10437963

; Publication No. US20040123343A1

; GENERAL INFORMATION:

; APPLICANT: La Rosa, Thomas J.

; APPLICANT: Kovalic, David K.

; APPLICANT: Zhou, Yihua

; APPLICANT: Cao, Yongwei

; APPLICANT: Boukharov, Andrey A.

; APPLICANT: Barbazuk, Brad

; APPLICANT: Li, Ping

; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With

; FILE REFERENCE: 38-21(5322)B

; CURRENT APPLICATION NUMBER: US/10/437,963

; CURRENT FILING DATE: 2003-05-14

; NUMBER OF SEQ ID NOS: 204966

; SEQ ID NO 158436

; LENGTH: 67

; TYPE: PRT

; ORGANISM: Oryza sativa

; FEATURE:

; OTHER INFORMATION: Clone ID: PAT_MRT4530_57911C.1.pdp

US-10-437-963-158436

Query Match 100.0%; Score 19; DB 4; Length 67;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 24 AOGV 27

RESULT 110

```
US-10-425-115-200989
; Sequence 200989, Application US/10425115
; Publication NO. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 200989
; LENGTH: 67
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(67)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_11488C.1.pep
US-10-425-115-200989

Query Match          100.0%; Score 19; DB 4; Length 67;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db       35 ACGV 38

RESULT 111
US-10-425-115-231718
; Sequence 231718, Application US/10425115
; Publication NO. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 231718
; LENGTH: 67
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_142922C.1.pep
US-10-425-115-231718

Query Match          100.0%; Score 19; DB 4; Length 67;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db       13 ACGV 16

RESULT 112
US-11-097-143-39966
; Sequence 39966, Application US/11097143
; Publication NO. US20050208558A1
; GENERAL INFORMATION:
; APPLICANT: Venter, J. Craig
```

```
; APPLICANT: et al.
; TITLE OF INVENTION: DETECTION KIT, SUCH AS NUCLEIC ACID
; TITLE OF INVENTION: ARRAYS, FOR DETECTING EXPRESSION OF 10,000 OR MORE
; TITLE OF INVENTION: DROSOPHILA GENES.
; FILE REFERENCE: CL000728
; CURRENT APPLICATION NUMBER: US/11/097,143
; CURRENT FILING DATE: 2005-04-04
; PRIOR APPLICATION NUMBER: 60/157,932
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: 60/160,191
; PRIOR FILING DATE: 1999-10-19
; PRIOR APPLICATION NUMBER: 60/161,932
; PRIOR FILING DATE: 1999-10-28
; PRIOR APPLICATION NUMBER: 60/164,769
; PRIOR FILING DATE: 1999-11-12
; PRIOR APPLICATION NUMBER: 60/173,383
; PRIOR FILING DATE: 1999-12-28
; PRIOR APPLICATION NUMBER: 60/175,693
; PRIOR FILING DATE: 2000-01-12
; PRIOR APPLICATION NUMBER: 60/184,931
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: 60/191,637
; PRIOR FILING DATE: 2000-03-23
; NUMBER OF SEQ ID NOS: 43008
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 39966
; LENGTH: 67
; TYPE: PRT
; ORGANISM: DROSOPHILA
US-11-097-143-39966

Query Match          100.0%; Score 19; DB 6; Length 67;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
Db       9 ACGV 12

RESULT 113
US-10-425-115-354448
; Sequence 354448, Application US/10425115
; Publication NO. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 354448
; LENGTH: 68
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(68)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_86428C.1.pep
US-10-425-115-354448

Query Match          100.0%; Score 19; DB 4; Length 68;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
        ||||
```

Db 39 AOV 42

RESULT 114
US-09-782-142-1
Sequence 1, Application US/09782142
Patent No. US20020001827A1
GENERAL INFORMATION:
APPLICANT: Bandman, Olga
Hawkins, Phillip R.
Murry, Lynn E.
Goli, Surya K.
TITLE OF INVENTION: NOVEL HUMAN CYTOKINES
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Drive
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASESEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/782,142
FILING DATE: 12-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/792,013
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Billings, Lucy J.
REGISTRATION NUMBER: 36,749
REFERENCE/DOCKET NUMBER: PF-0205 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-855-0555
TELEFAX: 415-845-4166
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 69 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
LIBRARY: SINTST01
CLONE: 1431384
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-782-142-1

Query Match 100.0%; Score 19; DB 3; Length 69;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOV 4
|||
Db 5 AOV 8

RESULT 115
US-10-300-257-1
Sequence 1, Application US/10300257
Publication No. US20030096371A1
GENERAL INFORMATION:
APPLICANT: Bandman, Olga
Hawkins, Phillip R.
Murry, Lynn E.
Goli, Surya K.
TITLE OF INVENTION: HUMAN CYTOKINES
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:

ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Drive
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASESEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/300,257
FILING DATE: 19-No. US20030096371A1-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: <Unknown>
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Billings, Lucy J.
REGISTRATION NUMBER: 36,749
REFERENCE/DOCKET NUMBER: PF-0205 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-855-0555
TELEFAX: 415-845-4166
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 69 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
LIBRARY: SINTST01
CLONE: 1431384
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-10-300-257-1

Query Match 100.0%; Score 19; DB 4; Length 69;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOV 4
|||
Db 5 AOV 8

RESULT 116
US-10-424-599-255403
Sequence 255403, Application US/10424599
Publication No. US20040031072A1
GENERAL INFORMATION:
APPLICANT: La Rosa Thomas J
APPLICANT: Kovalic David K
APPLICANT: Zhou Yihua
APPLICANT: Cao Yongwei
TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
FILE REFERENCE: 38-21(53223)B
CURRENT APPLICATION NUMBER: US/10/424,599
CURRENT FILING DATE: 2003-04-28
NUMBER OF SEQ ID NOS: 285684
SEQ ID NO 255403
LENGTH: 69
TYPE: PRT
ORGANISM: Glycine max
FEATURE:
OTHER INFORMATION: Clone ID: PAT_MRT3847_72650C.1.pep
US-10-424-599-255403

Query Match 100.0%; Score 19; DB 4; Length 69;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 21 ACGV 24

RESULT 117

US-10-437-963-191908
; Sequence 191908, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 191908
; LENGTH: 69
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(69)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_88183C.1.pep
US-10-437-963-191908

Query Match 100.0%; Score 19; DB 4; Length 69;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 23 ACGV 26

RESULT 118

US-10-767-701-34429
; Sequence 34429, Application US/10767701
; Publication No. US20040172684A1
; GENERAL INFORMATION:
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53535)B
; CURRENT APPLICATION NUMBER: US/10/767,701
; CURRENT FILING DATE: 2004-01-23
; NUMBER OF SEQ ID NOS: 63128
; SEQ ID NO 34429
; LENGTH: 69
; TYPE: PRT
; ORGANISM: Sorghum bicolor
; FEATURE:
; OTHER INFORMATION: Clone ID: SORBI-28MAY03-C48184_1.pep
US-10-767-701-34429

Query Match 100.0%; Score 19; DB 4; Length 69;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||

Db 59 ACGV 62

RESULT 119

US-10-425-115-324687
; Sequence 324687, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 324687
; LENGTH: 69
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_59186C.1.pep
US-10-425-115-324687

Query Match 100.0%; Score 19; DB 4; Length 69;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 29 ACGV 32

RESULT 120

US-10-424-599-242839
; Sequence 242839, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 242839
; LENGTH: 70
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_61312C.1.pep
US-10-424-599-242839

Query Match 100.0%; Score 19; DB 4; Length 70;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 10 ACGV 13

RESULT 121

US-10-437-963-134195
; Sequence 134195, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.

APPLICANT: Kovalic, David K.
APPLICANT: Zhou, Yinhua
APPLICANT: Cao, Yongwei
APPLICANT: Wu, Wei
APPLICANT: Boukharov, Andrey A.
APPLICANT: Barbazuk, Brad
APPLICANT: Li, Ping
TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
FILE REFERENCE: 38-21(53221)B
CURRENT FILING DATE: 2003-05-14
NUMBER OF SEQ ID NOS: 204966
SEQ ID NO 134195
LENGTH: 70
TYPE: PRT
ORGANISM: Oryza sativa
FEATURE:
OTHER INFORMATION: Clone ID: PAT_MRT4530_35993C.1.pap
US-10-437-963-134195

Query Match 100.0%; Score 19; DB 4; Length 70;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
DB 11 ACGV 14

RESULT 122
US-10-425-115-321591
Sequence 321591, Application US/10425115
Publication No. US20040214272A1
GENERAL INFORMATION:
APPLICANT: La Rosa, Thomas J.
APPLICANT: Kovalic, David K.
APPLICANT: Zhou, Yinhua
APPLICANT: Cao, Yongwei
TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
FILE REFERENCE: 38-21(53221)B
CURRENT FILING DATE: 2003-04-28
NUMBER OF SEQ ID NOS: 369326
SEQ ID NO 321591
LENGTH: 70
TYPE: PRT
ORGANISM: Zea mays
FEATURE:
OTHER INFORMATION: Clone ID: MRT4577_56356C.1.pap
US-10-425-115-321591

Query Match 100.0%; Score 19; DB 4; Length 70;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
DB 8 ACGV 11

RESULT 123
US-10-926-683-1548
Sequence 1548, Application US/10926683
Publication No. US20050106595A1
GENERAL INFORMATION:
APPLICANT: Dumas Mline Edwards, J.B.
APPLICANT: Duclert A.
APPLICANT: Giordano, J.Y.
TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
FILE REFERENCE: GENSET.025CPI
CURRENT APPLICATION NUMBER: US/10/926,683

CURRENT FILING DATE: 2004-08-25
PRIOR APPLICATION NUMBER: US/09/471,276
PRIOR FILING DATE: 1999-12-21
PRIOR APPLICATION NUMBER: 09/057,719
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 09/069,047
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: PCT/IB99/00712
PRIOR FILING DATE: 1999-04-09
NUMBER OF SEQ ID NOS: 1622
SOFTWARE: Patent.pm
SEQ ID NO 1548
LENGTH: 71
TYPE: PRT
ORGANISM: Homo sapiens
US-10-926-683-1548

Query Match 100.0%; Score 19; DB 5; Length 71;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
DB 59 ACGV 62

RESULT 124
US-10-131-406-6
Sequence 6, Application US/10131406
Publication No. US20030013104A1
GENERAL INFORMATION:
APPLICANT: LEVY, STUART B.
TITLE OF INVENTION: MULTIPLE ANTIBIOTIC RESISTANCE OPERON
ASSAYS
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: WOLF, GREENFIELD & SACKS, P.C.
STREET: 600 ATLANTIC AVENUE
CITY: BOSTON
STATE: MA
COUNTRY: USA
ZIP: 02210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/131,406
FILING DATE: 22-Apr-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/225,480
FILING DATE: <Unknown>
APPLICATION NUMBER: US 07/938,085
FILING DATE: 28-AUG-1992
ATTORNEY/AGENT INFORMATION:
NAME: GATES, EDWARD R.
REGISTRATION NUMBER: 31,616
REFERENCE/DOCKET NUMBER: T0359/7003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-720-3500
TELEFAX: 617-720-2441
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 72 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-10-131-406-6

Query Match 100.0%; Score 19; DB 4; Length 72;

Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
Db 17 AOCV 20

RESULT 125

US-10-424-599-182197
; Sequence 182197, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 182197
; LENGTH: 72
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_135537C.1.pep
US-10-424-599-182197

Query Match Best Local Similarity 100.0%; Score 19; DB 4; Length 72;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
Db 1 AOCV 4

RESULT 126

US-10-424-599-234373
; Sequence 234373, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 234373
; LENGTH: 72
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_53667C.1.pep
US-10-424-599-234373

Query Match Best Local Similarity 100.0%; Score 19; DB 4; Length 72;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
Db 52 AOCV 55

RESULT 127

US-10-425-115-202113
; Sequence 202113, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 202113
; LENGTH: 72
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_115914C.1.pep
US-10-425-115-202113

QY 1 AOCV 4
Db 8 AOCV 11

RESULT 128

US-10-425-115-348682
; Sequence 348682, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 348682
; LENGTH: 72
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_81163C.1.pep
US-10-425-115-348682

Query Match Best Local Similarity 100.0%; Score 19; DB 4; Length 72;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
Db 8 AOCV 11

RESULT 129

US-10-989-992-6
; Sequence 6, Application US/1098992
; Publication No. US20050136460A1
; GENERAL INFORMATION:
; APPLICANT: LEVY, STUART B.
; TITLE OF INVENTION: MULTIPLE ANTIBIOTIC RESISTANCE OPERON
; ASSAYS
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
US-10-989-992-6

Query Match Best Local Similarity 100.0%; Score 19; DB 4; Length 72;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
Db 40 AOCV 43

RESULT 129

US-10-989-992-6
; Sequence 6, Application US/1098992
; Publication No. US20050136460A1
; GENERAL INFORMATION:
; APPLICANT: LEVY, STUART B.
; TITLE OF INVENTION: MULTIPLE ANTIBIOTIC RESISTANCE OPERON
; ASSAYS
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
US-10-989-992-6

ADDRESSEE: WOLF, GREENFIELD & SACKS, P.C.
STREET: 600 ATLANTIC AVENUE
CITY: BOSTON
STATE: MA
COUNTRY: USA
ZIP: 02210
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/989,992
FILING DATE: 15-Nov-2004
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/10/131,406
FILING DATE: 22-Apr-2002
APPLICATION NUMBER: US/08/225,480
FILING DATE: <Unknown>
APPLICATION NUMBER: US 07/938,085
FILING DATE: 28-AUG-1992
ATTORNEY/AGENT INFORMATION:
NAME: GATES, EDWARD R.
REGISTRATION NUMBER: 31,616
REFERENCE/DOCKET NUMBER: T0359/7003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-720-3500
TELEFAX: 617-720-2441
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 72 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-10-989-992-6

Query Match 100.0%; Score 19; DB 5; Length 72;
Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 17 ACGV 20

RESULT 130
US-09-864-408A-2882
Sequence 2882, Application US/09864408A
Publication No. US20040009474A1
GENERAL INFORMATION:
APPLICANT: Shinkels, Richard A.
TITLE OF INVENTION: No. US20040009474A1 Human Polynucleotides and Polypeptides Encc
FILE REFERENCE: 21402-012
CURRENT APPLICATION NUMBER: US/09/864,408A
CURRENT FILING DATE: 2001-05-24
PRIOR APPLICATION NUMBER: 60/206,690
PRIOR FILING DATE: 2000-05-24
NUMBER OF SEQ ID NOS: 9068
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2882
LENGTH: 74
TYPE: PRT
ORGANISM: Homo sapiens
US-09-864-408A-2882

Query Match 100.0%; Score 19; DB 3; Length 74;
Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 1 ACGV 4

Db 48 ACGV 51

RESULT 131
US-10-424-599-178691
Sequence 178691, Application US/10424599
Publication No. US20040031072A1
GENERAL INFORMATION:
APPLICANT: La Rosa Thomas J
APPLICANT: Kovacic David K
APPLICANT: Zhou Yihua
APPLICANT: Cao Yongwei
TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated with
FILE REFERENCE: 38-21(53223)B
CURRENT APPLICATION NUMBER: US/10/424,599
CURRENT FILING DATE: 2003-04-28
NUMBER OF SEQ ID NOS: 285684
SEQ ID NO 178691
LENGTH: 74
TYPE: PRT
ORGANISM: Glycine max
FEATURES:
OTHER INFORMATION: Clone ID: PAT_MRT3847_132375C.1.pep
US-10-424-599-178691

Query Match 100.0%; Score 19; DB 4; Length 74;
Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 61 ACGV 64

RESULT 132
US-09-867-550-1124
Sequence 1124, Application US/09867550
Patent No. US20020082206A1
GENERAL INFORMATION:
APPLICANT: Leach, Martin D.
APPLICANT: Mehraban, Rued,
APPLICANT: Conley, Pamela
APPLICANT: Law, Debbie
APPLICANT: Topper, James
TITLE OF INVENTION: No. US20020082206A1 Polynucleotides from Atherogenic Cells and
FILE REFERENCE: 21402-013 (Cura-313)
CURRENT APPLICATION NUMBER: US/09/867,550
CURRENT FILING DATE: 2001-09-20
PRIOR APPLICATION NUMBER: USN 60/208,427
PRIOR FILING DATE: 2000-05-30
NUMBER OF SEQ ID NOS: 2125
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 1124
LENGTH: 75
TYPE: PRT
ORGANISM: Homo sapiens
US-09-867-550-1124

Query Match 100.0%; Score 19; DB 3; Length 75;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 4 ACGV 7

RESULT 133
US-10-424-599-154365
Sequence 154365, Application US/10424599

```
/ Publication No. US20040031072A1
/ GENERAL INFORMATION:
/ APPLICANT: La Rosa, Thomas J
/ APPLICANT: Kovacic David K
/ APPLICANT: Zhou, Yihua
/ APPLICANT: Cao, Yongwei
/ TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
/ TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
/ FILE REFERENCE: 38-21(53223)B
/ CURRENT APPLICATION NUMBER: US/10/424,599
/ CURRENT FILING DATE: 2003-04-28
/ NUMBER OF SEQ ID NOS: 285684
/ SEQ ID NO 154365
/ LENGTH: 75
/ TYPE: PRT
/ ORGANISM: Glycine max
/ FEATURE:
/ NAME/KEY: unsure
/ LOCATION: (1)..(75)
/ OTHER INFORMATION: unsure at all Xaa locations
/ OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 0.85
/ OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.75
/ OTHER INFORMATION: SWISSPROT HIT: P40182, EVALU 2.50e+00
US-10-424-599-154365
```

```
Query Match 100.0%; Score 19; DB 4; Length 75;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 AOCV 4
Db 7 AOCV 10
```

```
RESULT 134
US-10-437-963-147518
/ Sequence 147518, Application US/10437963
/ Publication No. US20040123343A1
/ GENERAL INFORMATION:
/ APPLICANT: La Rosa, Thomas J
/ APPLICANT: Kovacic, David K
/ APPLICANT: Zhou, Yihua
/ APPLICANT: Cao, Yongwei
/ APPLICANT: Wu, Wei
/ APPLICANT: Boukharov, Andrey A
/ APPLICANT: Barbazuk, Brad
/ APPLICANT: Li, Ping
/ TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
/ TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
/ FILE REFERENCE: 38-21(53221)B
/ CURRENT APPLICATION NUMBER: US/10/437,963
/ CURRENT FILING DATE: 2003-05-14
/ NUMBER OF SEQ ID NOS: 204966
/ SEQ ID NO 147518
/ LENGTH: 75
/ TYPE: PRT
/ ORGANISM: Oryza sativa
/ FEATURE:
/ NAME/KEY: unsure
/ LOCATION: (1)..(75)
/ OTHER INFORMATION: unsure at all Xaa locations
/ OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 0.94
/ OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 0.85
/ OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.75
/ OTHER INFORMATION: SWISSPROT HIT: P40182, EVALU 2.50e+00
US-10-437-963-147518
```

```
Query Match 100.0%; Score 19; DB 4; Length 75;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 AOCV 4
Db 64 AOCV 67
```

```
RESULT 135
US-10-425-115-222854
/ Sequence 222854, Application US/10425115
/ Publication No. US20040214272A1
```

```
/ GENERAL INFORMATION:
/ APPLICANT: La Rosa, Thomas J
/ APPLICANT: Kovacic, David K
/ APPLICANT: Zhou, Yihua
/ APPLICANT: Cao, Yongwei
/ TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
/ TITLE OF INVENTION: Plants
/ FILE REFERENCE: 38-21(53222)B
/ CURRENT APPLICATION NUMBER: US/10/425,115
/ CURRENT FILING DATE: 2003-04-28
/ NUMBER OF SEQ ID NOS: 369326
/ SEQ ID NO 222854
/ LENGTH: 75
/ TYPE: PRT
/ ORGANISM: Zea mays
/ FEATURE:
/ NAME/KEY: unsure
/ LOCATION: (1)..(75)
/ OTHER INFORMATION: unsure at all Xaa locations
/ OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 0.94
/ OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 0.85
/ OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.75
/ OTHER INFORMATION: SWISSPROT HIT: P40182, EVALU 2.50e+00
US-10-425-115-222854
```

```
Query Match 100.0%; Score 19; DB 4; Length 75;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 AOCV 4
Db 24 AOCV 27
```

```
RESULT 136
US-10-029-386-30198
/ Sequence 30198, Application US/10029386
/ Publication No. US20030194704A1
/ GENERAL INFORMATION:
/ APPLICANT: Penn, Sharon G
/ APPLICANT: Rank, David R
/ APPLICANT: Hanzel, David K
/ TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR GI
/ TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
/ FILE REFERENCE: ABOMICA-X-2
/ CURRENT APPLICATION NUMBER: US/10/029,386
/ CURRENT FILING DATE: 2001-12-20
/ NUMBER OF SEQ ID NOS: 34288
/ SOFTWARE: Annomax Sequence Listering Engine vers. 1.1
/ SEQ ID NO 30198
/ LENGTH: 76
/ TYPE: PRT
/ ORGANISM: Homo sapiens
/ FEATURE:
/ NAME/KEY: MAP TO CHR13.1
/ OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 0.9
/ OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1.1
/ OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 0.94
/ OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 0.85
/ OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.75
/ OTHER INFORMATION: SWISSPROT HIT: P40182, EVALU 2.50e+00
US-10-029-386-30198
```

```
Query Match 100.0%; Score 19; DB 4; Length 76;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 AOCV 4
Db 59 AOCV 62
```

```
RESULT 137
US-10-425-115-221278
```

; Sequence 221278, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 221278
; LENGTH: 76
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURES:
; NAME/KEY: unsure
; LOCATION: (1)..(76)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_133398C.1.pep
US-10-425-115-221278

Query Match 100.0%; Score 19; DB 4; Length 76;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOVV 4
 ||||
Db 38 AOVV 41

RESULT 139
US-10-425-115-292142
; Sequence 292142, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 292142
; LENGTH: 76
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURES:
; NAME/KEY: unsure
; LOCATION: (1)..(76)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_2951C.1.pep
US-10-425-115-292142

Query Match 100.0%; Score 19; DB 4; Length 76;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOVV 4
 ||||
Db 16 AOVV 19

RESULT 139
US-10-425-115-355384
; Sequence 355384, Application US/10425115

; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 355384
; LENGTH: 76
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURES:
; NAME/KEY: unsure
; LOCATION: (1)..(76)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_87277C.1.pep
US-10-425-115-355384

Query Match 100.0%; Score 19; DB 4; Length 76;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOVV 4
 ||||
Db 68 AOVV 71

RESULT 140
US-10-425-115-271573
; Sequence 271573, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 271573
; LENGTH: 77
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURES:
; NAME/KEY: unsure
; LOCATION: (1)..(76)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_179269C.1.pep
US-10-425-115-271573

Query Match 100.0%; Score 19; DB 4; Length 77;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOVV 4
 ||||
Db 32 AOVV 35

RESULT 141
US-10-425-115-289812
; Sequence 289812, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua

```
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(5322)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 289812
; LENGTH: 77
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(77)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_27398C.1.pep
; US-10-425-115-289812

Query Match          100.0%; Score 19; DB 4; Length 77;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 AOCV 4
        |||
Db      61 AOCV 64

RESULT 142
; US-10-425-115-319654
; Sequence 319654, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(5322)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 319654
; LENGTH: 77
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_54595C.1.pep
; US-10-425-115-319654

Query Match          100.0%; Score 19; DB 4; Length 77;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 AOCV 4
        |||
Db      6 AOCV 9

RESULT 143
; US-10-425-115-330336
; Sequence 330336, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(5322)B
; CURRENT APPLICATION NUMBER: US/10/425,115
```

```
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 330336
; LENGTH: 77
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_64366C.1.pep
; US-10-425-115-330336

Query Match          100.0%; Score 19; DB 4; Length 77;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 AOCV 4
        |||
Db      32 AOCV 35

RESULT 144
; US-10-425-115-243630
; Sequence 243630, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(5322)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 243630
; LENGTH: 78
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_153773C.1.pep
; US-10-425-115-243630

Query Match          100.0%; Score 19; DB 4; Length 78;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 AOCV 4
        |||
Db      66 AOCV 69

RESULT 145
; US-10-450-763-56828
; Sequence 56828, Application US/10450763
; Publication No. US20050196754A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc
; TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
; FILE REFERENCE: 790CIP3/US
; CURRENT APPLICATION NUMBER: US/10/450,763
; CURRENT FILING DATE: 2003-06-11
; PRIOR APPLICATION NUMBER: PCT/US01/08631
; PRIOR FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/540,217
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: 09/649,167
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 60736
; SOFTWARE: Custom
; SEQ ID NO 56828
; LENGTH: 78
; TYPE: PRT
; ORGANISM: Homo sapiens
```

```
FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(78)
; OTHER INFORMATION: Xaa = X or * as defined in Table 2
US-10-450-763-56828
```

```
Query Match
Best Local Similarity 100.0%; Score 19; DB 5; Length 78;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 AOGV 4
    |||
Db 55 AOGV 58
```

```
RESULT 146
US-10-437-963-195350
; Sequence 195350, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 195350
; LENGTH: 79
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_91307C.1.pep
US-10-437-963-195350
```

```
Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 79;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 AOGV 4
    |||
Db 50 AOGV 53
```

```
RESULT 147
US-10-425-115-264068
; Sequence 264068, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 264068
; LENGTH: 79
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_172445C.1.pep
US-10-425-115-264068
```

```
Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 79;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 AOGV 4
    |||
Db 22 AOGV 25
```

```
RESULT 148
US-10-424-599-277301
; Sequence 277301, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 277301
; LENGTH: 81
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_92426C.1.pep
US-10-424-599-277301
```

```
Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 81;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 AOGV 4
    |||
Db 56 AOGV 59
```

```
RESULT 149
US-10-437-963-137515
; Sequence 137515, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 137515
; LENGTH: 81
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_38992C.1.pep
US-10-437-963-137515
```

```
Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 81;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1 ACGV 4
|||
Db 18 ACGV 21

RESULT 150
US-10-425-115-263146
; Sequence 263146, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 263146
; LENGTH: 81
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_171600C.1.pep
US-10-425-115-263146

Query Match 100.0%; Score 19; DB 4; Length 81;
Best Local Similarity 100.0%; Pred. No. 2.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 53 ACGV 56

RESULT 151
US-10-425-115-306230
; Sequence 306230, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 306230
; LENGTH: 81
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_42347C.1.pep
US-10-425-115-306230

Query Match 100.0%; Score 19; DB 4; Length 81;
Best Local Similarity 100.0%; Pred. No. 2.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 4 ACGV 7

RESULT 152
US-10-424-599-163460
; Sequence 163460, Application US/10424599
; Publication No. US20040031072A1

; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 163460
; LENGTH: 82
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_118623C.1.pep
US-10-424-599-163460

Query Match 100.0%; Score 19; DB 4; Length 82;
Best Local Similarity 100.0%; Pred. No. 2.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 22 ACGV 25

RESULT 153
US-10-424-599-227097
; Sequence 227097, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 227097
; LENGTH: 82
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_47099C.1.pep
US-10-424-599-227097

Query Match 100.0%; Score 19; DB 4; Length 82;
Best Local Similarity 100.0%; Pred. No. 2.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 70 ACGV 73

RESULT 154
US-10-425-115-236419
; Sequence 236419, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115


```
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 236419
; LENGTH: 82
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_147196C.1.pcp
US-10-425-115-236419

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 82;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 30 ACGV 33

RESULT 155
US-10-424-599-270384
; Sequence 270384, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J
; APPLICANT: Kovalic, David K
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT FILING DATE: 2003-04-28
; CURRENT APPLICATION NUMBER: US/10/424,599
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 270384
; LENGTH: 83
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_86175C.1.pcp
US-10-424-599-270384

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 83;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 9 ACGV 12

RESULT 156
US-10-437-963-180416
; Sequence 180416, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53221)B
; CURRENT FILING DATE: 2003-05-14
; CURRENT APPLICATION NUMBER: US/10/437,963
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 180416
; LENGTH: 83
; TYPE: PRT
```

```
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_77786C.1.pcp
US-10-437-963-180416

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 83;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 4 ACGV 7

RESULT 157
US-10-425-115-205887
; Sequence 205887, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT FILING DATE: 2003-04-28
; CURRENT APPLICATION NUMBER: US/10/425,115
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 205887
; LENGTH: 83
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_119352C.1.pcp
US-10-425-115-205887

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 83;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 60 ACGV 63

RESULT 158
US-10-425-115-241912
; Sequence 241912, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT FILING DATE: 2003-04-28
; CURRENT APPLICATION NUMBER: US/10/425,115
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 241912
; LENGTH: 83
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(83)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_152202C.1.pcp
US-10-425-115-241912
```

Query Match 100.0%; Score 19; DB 4; Length 83;
Best Local Similarity 100.0%; Pred. No. 2.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
|||
Db 20 AOCV 23

RESULT 159
US-10-425-115-289244
; Sequence 289244, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; PRIOR FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 289244
; LENGTH: 83
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -20...-1
US-10-425-115-289244
; OTHER INFORMATION: Clone ID: MRT4577_26880C.1.pep

Query Match 100.0%; Score 19; DB 4; Length 83;
Best Local Similarity 100.0%; Pred. No. 2.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
|||
Db 50 AOCV 53

RESULT 160
US-09-731-872-330
; Sequence 330, Application US/09731872
; Patent No. US20020102604A1
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, Jean Baptiste
; APPLICANT: Bougueleret, Lydie
; APPLICANT: Jobert, Severin
; TITLE OF INVENTION: FULL-LENGTH HUMAN CDNAS ENCODING POTENTIALLY SECRETED PROTEINS
; FILE REFERENCE: 78.US3.REG
; CURRENT APPLICATION NUMBER: US/09/731,872
; CURRENT FILING DATE: 2000-12-07
; PRIOR APPLICATION NUMBER: US 60/169,629
; PRIOR FILING DATE: 1999-12-08
; PRIOR APPLICATION NUMBER: US 60/187,470
; PRIOR FILING DATE: 2000-03-06
; NUMBER OF SEQ ID NOS: 482
; SOFTWARE: Patent.pm
; SEQ ID NO 330
; LENGTH: 84
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -20...-1
US-09-731-872-330

Query Match 100.0%; Score 19; DB 3; Length 84;
Best Local Similarity 100.0%; Pred. No. 2.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4

Db 30 AOCV 33
|||

RESULT 161
US-09-876-997-330
; Sequence 330, Application US/09876997
; Publication No. US20030152921A1
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, Jean Baptiste
; APPLICANT: Bougueleret, Lydie
; APPLICANT: Jobert, Severin
; TITLE OF INVENTION: FULL-LENGTH HUMAN CDNAS ENCODING POTENTIALLY SECRETED PROTEINS
; FILE REFERENCE: 78.US4.CIP
; CURRENT APPLICATION NUMBER: US/09/876,997
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/731,872
; PRIOR FILING DATE: 2000-12-07
; PRIOR APPLICATION NUMBER: US 60/187,470
; PRIOR FILING DATE: 2000-03-06
; PRIOR APPLICATION NUMBER: US 60/169,629
; PRIOR FILING DATE: 1999-12-08
; NUMBER OF SEQ ID NOS: 482
; SOFTWARE: Patent.pm
; SEQ ID NO 330
; LENGTH: 84
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -20...-1
US-09-876-997-330

Query Match 100.0%; Score 19; DB 3; Length 84;
Best Local Similarity 100.0%; Pred. No. 2.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
|||
Db 30 AOCV 33

RESULT 162
US-10-425-115-364443
; Sequence 364443, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 364443
; LENGTH: 84
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -20...-1
US-10-425-115-364443
; OTHER INFORMATION: Clone ID: MRT4577_95540C.1.pep

Query Match 100.0%; Score 19; DB 4; Length 84;
Best Local Similarity 100.0%; Pred. No. 2.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
|||
Db 73 AOCV 76

```
RESULT 163
US-10-643-836-330
; Sequence 330, Application US/10643836
; Publication No. US2005096458A1
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, Jean Baptiste
; APPLICANT: Bougueleret, Lydie
; APPLICANT: Jobert, Severin
; TITLE OF INVENTION: FULL-LENGTH HUMAN CDNA5 ENCODING POTENTIALLY SECRETED PROTEINS
; FILE REFERENCE: 78. US3. REG
; CURRENT APPLICATION NUMBER: US/10/643,836
; PRIOR FILING DATE: 2003-08-19
; PRIOR APPLICATION NUMBER: US/09/731,872
; PRIOR FILING DATE: 2000-12-07
; PRIOR APPLICATION NUMBER: US 60/169,629
; PRIOR FILING DATE: 1999-12-08
; PRIOR APPLICATION NUMBER: US 60/187,470
; PRIOR FILING DATE: 2000-03-06
; NUMBER OF SEQ ID NOS: 482
; SOFTWARE: Patent.pm
; SEQ ID NO 330
; LENGTH: 84
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -20...-1
US-10-643-836-330

Query Match
Best Local Similarity 100.0%; Score 19; DB 5; Length 84;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1 AOGV 4
    ||||
Db 30 AOGV 33

RESULT 164
US-10-450-763-35681
; Sequence 35681, Application US/10450763
; Publication No. US20050196754A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc
; TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
; FILE REFERENCE: 790CIP3/US
; CURRENT APPLICATION NUMBER: US/10/450,763
; PRIOR FILING DATE: 2003-06-11
; PRIOR APPLICATION NUMBER: PCT/US01/08631
; PRIOR FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/540,217
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: 09/649,167
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 60736
; SOFTWARE: Custom
; SEQ ID NO 35681
; LENGTH: 84
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(84)
; OTHER INFORMATION: Xaa = X or * as defined in Table 2
US-10-450-763-35681

Query Match
Best Local Similarity 100.0%; Score 19; DB 5; Length 84;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1 AOGV 4
    ||||
Db 30 AOGV 33

RESULT 165
US-11-097-143-21975
; Sequence 21975, Application US/11097143
; Publication No. US20050208558A1
; GENERAL INFORMATION:
; APPLICANT: Venter, J. Craig
; APPLICANT: et al.
; TITLE OF INVENTION: DETECTION KIT, SUCH AS NUCLEIC ACID
; TITLE OF INVENTION: ARRAYS, FOR DETECTING EXPRESSION OF 10,000 OR MORE
; TITLE OF INVENTION: DROSOPHILA GENES.
; FILE REFERENCE: CLO00728
; CURRENT APPLICATION NUMBER: US/11/097,143
; PRIOR FILING DATE: 2005-04-04
; PRIOR APPLICATION NUMBER: 60/157,832
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: 60/160,191
; PRIOR FILING DATE: 1999-10-19
; PRIOR APPLICATION NUMBER: 60/161,932
; PRIOR FILING DATE: 1999-10-28
; PRIOR APPLICATION NUMBER: 60/164,769
; PRIOR FILING DATE: 1999-11-12
; PRIOR APPLICATION NUMBER: 60/173,383
; PRIOR FILING DATE: 1999-12-28
; PRIOR APPLICATION NUMBER: 60/175,693
; PRIOR FILING DATE: 2000-01-12
; PRIOR APPLICATION NUMBER: 60/184,831
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: 60/191,637
; PRIOR FILING DATE: 2000-03-23
; NUMBER OF SEQ ID NOS: 43008
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 21975
; LENGTH: 84
; TYPE: PRT
; ORGANISM: DROSOPHILA
US-11-097-143-21975

Query Match
Best Local Similarity 100.0%; Score 19; DB 6; Length 84;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1 AOGV 4
    ||||
Db 50 AOGV 53

RESULT 166
US-10-425-114-68442
; Sequence 68442, Application US/10425114
; Publication No. US20040034888A1
; GENERAL INFORMATION:
; APPLICANT: Liu, Jingdong
; APPLICANT: Zhou, Yihua
; APPLICANT: Kovalic, David K.
; APPLICANT: Screen, Steven E
; APPLICANT: Tabaska, Jack E
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53113)B
; CURRENT APPLICATION NUMBER: US/10/425,114
; PRIOR FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 73128
; SEQ ID NO 68442
; LENGTH: 85
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: LIB3136-058-H12_F11.pep
US-10-425-114-68442
```

Query Match 100.0%; Score 19; DB 4; Length 85;
Best Local Similarity 100.0%; Pred. No. 2.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
DB 8 ACGV 11

RESULT 167

US-10-363-616-365
; Sequence 365, Application US/10363616
; Publication No. US20040044181A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc
; TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
; FILE REFERENCE: 21272-113 (793)
; CURRENT APPLICATION NUMBER: US/10/363,616
; CURRENT FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: 09/654,935
; PRIOR FILING DATE: 2000-09-01
; NUMBER OF SEQ ID NOS: 490
; SEQ ID NO 365
; LENGTH: 85
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-363-616-365

Query Match 100.0%; Score 19; DB 4; Length 85;
Best Local Similarity 100.0%; Pred. No. 2.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
DB 44 ACGV 47

RESULT 168

US-10-335-977-8250
; Sequence 8250, Application US/10335977
; Publication No. US20040052799A1
; GENERAL INFORMATION:
; APPLICANT: DOUGLAS SMITH et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES
; RELATING TO HELICOBACTER PYLORI FOR
; DIAGNOSTICS AND THERAPEUTICS
; NUMBER OF SEQUENCES: 10031
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-ROM ISO9660
; OPERATING SYSTEM: Windows NT 4.0
; SOFTWARE: UNIX
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/335,977
; FILING DATE: 30-Dec-2002
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/993,002
; FILING DATE: 17-DEC-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Mandragouras, Amy E.
; REGISTRATION NUMBER: 36,207
; REFERENCE/DOCKET NUMBER: GTN-018
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214

; INFORMATION FOR SEQ ID NO: 8250:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 85 amino acids
; TYPE: amino acid
; TOPOLOGY: linear

; MOLECULAR TYPE: protein
; HYPOTHETICAL: YES
; ORIGINAL SOURCE:
; ORGANISM: Helicobacter pylori
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (B) LOCATION 1...85
; ; SEQUENCE DESCRIPTION: SEQ ID NO: 8250:
US-10-335-977-8250

Query Match 100.0%; Score 19; DB 4; Length 85;
Best Local Similarity 100.0%; Pred. No. 2.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
DB 23 ACGV 26

RESULT 169

US-10-425-115-368000
; Sequence 368000, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovacic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 368000
; LENGTH: 85
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_98789C.1.pep
US-10-425-115-368000

Query Match 100.0%; Score 19; DB 4; Length 85;
Best Local Similarity 100.0%; Pred. No. 2.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
DB 18 ACGV 21

RESULT 170

US-09-955-502-4
; Sequence 4, Application US/09955502
; Patent No. US20020072118A1
; GENERAL INFORMATION:
; APPLICANT: Downs, Diana M.
; APPLICANT: Gralnick, Jeff A.
; TITLE OF INVENTION: Method for Preventing Superoxide Damage to Cells and
; FILE REFERENCE: 960296.97559
; CURRENT APPLICATION NUMBER: US/09/955,502
; CURRENT FILING DATE: 2001-09-18
; PRIOR APPLICATION NUMBER: 60/234,588
; PRIOR FILING DATE: 2000-09-22
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4

LENGTH: 86
TYPE: PRT
ORGANISM: Bordetella bronchiseptica
US-09-955-502-4

Query Match
Best Local Similarity 100.0%; Score 19; DB 3; Length 86;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 82 AOGV 85

RESULT 171
US-09-864-408A-2696
Sequence 2696, Application US/09864408A
Publication No. US20040009474A1
GENERAL INFORMATION:

APPLICANT: Leach, Martin D.
APPLICANT: Shinkets, Richard A.
TITLE OF INVENTION: No. US20040009474A1 Human Polynucleotides and Polypeptides Encc
FILE REFERENCE: 21402-012
CURRENT APPLICATION NUMBER: US/09/864,408A
CURRENT FILING DATE: 2001-05-24
PRIOR APPLICATION NUMBER: 60/206,690
PRIOR FILING DATE: 2000-05-24
NUMBER OF SEQ ID NOS: 9068
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2696
LENGTH: 86
TYPE: PRT
ORGANISM: Homo sapiens
US-09-864-408A-2696

Query Match
Best Local Similarity 100.0%; Score 19; DB 3; Length 86;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 75 AOGV 78

RESULT 172
US-10-335-977-8249
Sequence 8249, Application US/10335977
Publication No. US20040052799A1

GENERAL INFORMATION:
APPLICANT: DOUGLAS SMITH et al
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES
RELATING TO HELICOBACTER PYLORI FOR
DIAGNOSTICS AND THERAPEUTICS
NUMBER OF SEQUENCES: 10031
CORRESPONDENCE ADDRESSES:

ADDRESSES: LAHIVE & COCKFIELD
STREET: 28 State Street
CITY: Boston
STATE: Massachusetts
COUNTRY: USA
ZIP: 02109-1875

COMPUTER READABLE FORM:
MEDIUM TYPE: CD-ROM ISO9660
COMPUTER: IBM PC Compatible
OPERATING SYSTEM: Windows NT 4.0
SOFTWARE: UNIX

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/335,977
FILING DATE: 30-Dec-2002
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/993,002
FILING DATE: 17-DEC-1997
ATTORNEY/AGENT INFORMATION:

NAME: Mandragourae, Amy E.
REGISTRATION NUMBER: 36,207
REFERENCE/DOCKET NUMBER: GTN-018
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617)227-7400
TELEFAX: (617)742-4214
INFORMATION FOR SEQ ID NO: 8249:

SEQUENCE CHARACTERISTICS:
LENGTH: 86 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
HYPOTHETICAL: YES

ORIGINAL SOURCE:
ORGANISM: Helicobacter pylori
FEATURES:
NAME/KEY: misc feature
LOCATION: (B) LOCATION 1...86

SEQUENCE DESCRIPTION: SEQ ID NO: 8249:
US-10-335-977-8249

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 86;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 24 AOGV 27

RESULT 173
US-10-799-514-13
Sequence 13, Application US/10799514
Publication No. US20040241178A1
GENERAL INFORMATION:

APPLICANT: Spertini, Francois
APPLICANT: Corthees, Blaise
TITLE OF INVENTION: Allergen Peptide Fragments and Use Thereof
FILE REFERENCE: 25720-502
CURRENT APPLICATION NUMBER: US/10/799,514
CURRENT FILING DATE: 2004-03-12
PRIOR APPLICATION NUMBER: 60/455,004
PRIOR FILING DATE: 2003-03-14
NUMBER OF SEQ ID NOS: 23
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 13
LENGTH: 86
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURES:

OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-799-514-13

Query Match
Best Local Similarity 100.0%; Score 19; DB 5; Length 86;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 44 AOGV 47

RESULT 174
US-10-424-599-283838
Sequence 283838, Application US/10424599
Publication No. US20040031072A1

GENERAL INFORMATION:
APPLICANT: La Rosa Thomas J
APPLICANT: Kovalic David K
APPLICANT: Zhou Yihua
APPLICANT: Cao Yongwei
TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With

;; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
;; FILE REFERENCE: 38-21(53223)B
;; CURRENT APPLICATION NUMBER: US/10/424,599
;; CURRENT FILING DATE: 2003-04-28
;; NUMBER OF SEQ ID NOS: 285684
;; SEQ ID NO 283838
;; LENGTH: 87
;; TYPE: PRT
;; ORGANISM: Glycine max
;; FEATURE:
;; NAME/KEY: unsure
;; LOCATION: (1)..(87)
;; OTHER INFORMATION: unsure at all Xaa locations
;; FEATURE:
;; OTHER INFORMATION: Clone ID: PAT_MRT3847_98329C.1.pep
US-10-424-599-283838

Query Match 100.0%; Score 19; DB 4; Length 87;
Best Local Similarity 100.0%; Pred. No. 3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 37 ACGV 40

RESULT 175
US-10-437-963-123960
;; Sequence 123960, Application US/10437963
;; Publication No. US20040123343A1
;; GENERAL INFORMATION:
;; APPLICANT: La Rosa, Thomas J.
;; APPLICANT: Kovalic, David K.
;; APPLICANT: Zhou, Yihua
;; APPLICANT: Cao, Yongwei
;; APPLICANT: Wu, Wei
;; APPLICANT: Boukharov, Andrey A.
;; APPLICANT: Barbazuk, Brad
;; APPLICANT: Li, Ping
;; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
;; FILE REFERENCE: 38-21(53221)B
;; CURRENT APPLICATION NUMBER: US/10/437,963
;; CURRENT FILING DATE: 2003-05-14
;; NUMBER OF SEQ ID NOS: 204966
;; SEQ ID NO 123960
;; LENGTH: 87
;; TYPE: PRT
;; ORGANISM: Oryza sativa
;; FEATURE:
;; NAME/KEY: unsure
;; LOCATION: (1)..(87)
;; OTHER INFORMATION: unsure at all Xaa locations
;; FEATURE:
;; OTHER INFORMATION: Clone ID: PAT_MRT4530_26744C.1.pep
US-10-437-963-123960

Query Match 100.0%; Score 19; DB 4; Length 87;
Best Local Similarity 100.0%; Pred. No. 3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 41 ACGV 44

RESULT 176
US-09-989-920-196
;; Sequence 196, Application US/09989920
;; Patent No. US20020172957A1
;; GENERAL INFORMATION:
;; APPLICANT: Macina, Roberto
;; APPLICANT: Recipon, Herre

;; APPLICANT: Chen, Sei-Yu
;; APPLICANT: Sun, Yongming
;; APPLICANT: Liu, Chenghua
;; TITLE OF INVENTION: Compositions and Methods Relating to Lung Specific Genes and Proce
;; FILE REFERENCE: DEX-0291
;; CURRENT APPLICATION NUMBER: US/09/989,920
;; CURRENT FILING DATE: 2001-11-21
;; PRIOR APPLICATION NUMBER: 60/252,500
;; PRIOR FILING DATE: 2000-11-22
;; NUMBER OF SEQ ID NOS: 284
;; SOFTWARE: PatentIn version 3.1
;; SEQ ID NO 196
;; LENGTH: 88
;; TYPE: PRT
;; ORGANISM: Homo sapien
US-09-989-920-196

Query Match 100.0%; Score 19; DB 3; Length 88;
Best Local Similarity 100.0%; Pred. No. 3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 69 ACGV 72

RESULT 177
US-10-437-963-148963
;; Sequence 148963, Application US/10437963
;; Publication No. US20040123343A1
;; GENERAL INFORMATION:
;; APPLICANT: La Rosa, Thomas J.
;; APPLICANT: Kovalic, David K.
;; APPLICANT: Zhou, Yihua
;; APPLICANT: Cao, Yongwei
;; APPLICANT: Wu, Wei
;; APPLICANT: Boukharov, Andrey A.
;; APPLICANT: Barbazuk, Brad
;; APPLICANT: Li, Ping
;; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
;; FILE REFERENCE: 38-21(53221)B
;; CURRENT APPLICATION NUMBER: US/10/437,963
;; CURRENT FILING DATE: 2003-05-14
;; NUMBER OF SEQ ID NOS: 204966
;; SEQ ID NO 148963
;; LENGTH: 88
;; TYPE: PRT
;; ORGANISM: Oryza sativa
;; FEATURE:
;; OTHER INFORMATION: Clone ID: PAT_MRT4530_49342C.1.pep
US-10-437-963-148963

Query Match 100.0%; Score 19; DB 4; Length 88;
Best Local Similarity 100.0%; Pred. No. 3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 23 ACGV 26

RESULT 178
US-10-425-115-199844
;; Sequence 199844, Application US/10425115
;; Publication No. US20040214272A1
;; GENERAL INFORMATION:
;; APPLICANT: La Rosa, Thomas J.
;; APPLICANT: Kovalic, David K.
;; APPLICANT: Zhou, Yihua
;; APPLICANT: Cao, Yongwei
;; APPLICANT: Boukharov, Andrey A.
;; APPLICANT: Barbazuk, Brad
;; APPLICANT: Li, Ping
;; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;; TITLE OF INVENTION: Plants

FILE REFERENCE: 38-21(53222)B
CURRENT APPLICATION NUMBER: US/10/425,115
CURRENT FILING DATE: 2003-04-28
NUMBER OF SEQ ID NOS: 369326
SEQ ID NO 199844
LENGTH: 88
TYPE: PRT
ORGANISM: Zea mays
FEATURE:
OTHER INFORMATION: Clone ID: MRT4577_11384C.1.pep
US-10-425-115-199844

Query Match 100.0%; Score 19; DB 4; Length 88;
Best Local Similarity 100.0%; Pred. No. 3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
Db 80 AOGV 83

RESULT 179
US-10-425-115-353524
Sequence 353524, Application US/10425115
Publication No. US20040214272A1
GENERAL INFORMATION:
APPLICANT: La Rosa, Thomas J.
APPLICANT: Kovalic, David K.
APPLICANT: Zhou, Yihua
APPLICANT: Cao, Yongwei
TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
TITLE OF INVENTION: Plants
FILE REFERENCE: 38-21(53222)B
CURRENT APPLICATION NUMBER: US/10/425,115
CURRENT FILING DATE: 2003-04-28
NUMBER OF SEQ ID NOS: 369326
SEQ ID NO 353524
LENGTH: 88
TYPE: PRT
ORGANISM: Zea mays
FEATURE:
OTHER INFORMATION: Clone ID: MRT4577_8558C.1.pep
US-10-425-115-353524

Query Match 100.0%; Score 19; DB 4; Length 88;
Best Local Similarity 100.0%; Pred. No. 3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
Db 65 AOGV 68

RESULT 180
US-10-424-599-173797
Sequence 173797, Application US/10424599
Publication No. US20040031072A1
GENERAL INFORMATION:
APPLICANT: La Rosa, Thomas J.
APPLICANT: Kovalic, David K.
APPLICANT: Zhou, Yihua
APPLICANT: Cao, Yongwei
TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated with
TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
FILE REFERENCE: 38-21(53223)B
CURRENT APPLICATION NUMBER: US/10/424,599
CURRENT FILING DATE: 2003-04-28
NUMBER OF SEQ ID NOS: 285684
SEQ ID NO 173797
LENGTH: 89
TYPE: PRT
ORGANISM: Glycine max
FEATURE:

OTHER INFORMATION: Clone ID: PAT_MRT3847_127958C.1.pep
US-10-424-599-173797

Query Match 100.0%; Score 19; DB 4; Length 89;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
Db 12 AOGV 15

RESULT 181
US-10-693-367-14
Sequence 14, Application US/10693367
Publication No. US20040091992A1
GENERAL INFORMATION:
APPLICANT: The Trustees of Columbia University
APPLICANT: Minden, Audrey
TITLE OF INVENTION: PAK4, A NOVEL GENE ENCODING A SERINE/THREONINE KINASE
FILE REFERENCE: 575/55311-A-PCT-US
CURRENT APPLICATION NUMBER: US/10/693,367
CURRENT FILING DATE: 2003-10-24
PRIOR APPLICATION NUMBER: US/09/718,032
PRIOR FILING DATE: 2000-11-21
PRIOR APPLICATION NUMBER: PCT/US99/11341
PRIOR FILING DATE: 1999-05-21
PRIOR APPLICATION NUMBER: 09/082,737
PRIOR FILING DATE: 1998-05-21
NUMBER OF SEQ ID NOS: 17
SOFTWARE: PatentIn version 3.1
SEQ ID NO 14
LENGTH: 89
TYPE: PRT
ORGANISM: mouse
US-10-693-367-14

Query Match 100.0%; Score 19; DB 4; Length 89;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
Db 78 AOGV 81

RESULT 182
US-10-425-115-232359
Sequence 232359, Application US/10425115
Publication No. US20040214272A1
GENERAL INFORMATION:
APPLICANT: La Rosa, Thomas J.
APPLICANT: Kovalic, David K.
APPLICANT: Zhou, Yihua
APPLICANT: Cao, Yongwei
TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
TITLE OF INVENTION: Plants
FILE REFERENCE: 38-21(53222)B
CURRENT APPLICATION NUMBER: US/10/425,115
CURRENT FILING DATE: 2003-04-28
NUMBER OF SEQ ID NOS: 369326
SEQ ID NO 232359
LENGTH: 89
TYPE: PRT
ORGANISM: Zea mays
FEATURE:
OTHER INFORMATION: Clone ID: MRT4577_143506C.1.pep
US-10-425-115-232359

Query Match 100.0%; Score 19; DB 4; Length 89;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
DB 31 ACGV 34

RESULT 183

US-10-425-115-221841
; Sequence 221841, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 221841
; LENGTH: 90
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(90)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_133910C.1.pcp
US-10-425-115-221841

Query Match 100.0%; Score 19; DB 4; Length 90;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
DB 27 ACGV 30

RESULT 184

US-10-424-599-282611
; Sequence 282611, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 282611
; LENGTH: 91
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PRT_MRT3847_97219C.1.pcp
US-10-424-599-282611

Query Match 100.0%; Score 19; DB 4; Length 91;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
DB 23 ACGV 26

RESULT 185

US-10-767-701-58893
; Sequence 58893, Application US/10767701
; Publication No. US20040172684A1
; GENERAL INFORMATION:
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof For Plant Improvement
; FILE REFERENCE: 38-21(53535)B
; CURRENT APPLICATION NUMBER: US/10/767,701
; CURRENT FILING DATE: 2004-01-29
; NUMBER OF SEQ ID NOS: 63128
; SEQ ID NO 58893
; LENGTH: 91
; TYPE: PRT
; ORGANISM: Sorghum bicolor
; FEATURE:
; OTHER INFORMATION: Clone ID: 6676508.pcp
US-10-767-701-58893

Query Match 100.0%; Score 19; DB 4; Length 91;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
DB 17 ACGV 20

RESULT 186

US-10-425-115-215363
; Sequence 215363, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 215363
; LENGTH: 91
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_128008C.1.pcp
US-10-425-115-215363

Query Match 100.0%; Score 19; DB 4; Length 91;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
DB 38 ACGV 41

RESULT 187

US-10-450-763-35010
; Sequence 35010, Application US/10450763
; Publication No. US20050196754A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc
; TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
; FILE REFERENCE: 790CIP3/US
; CURRENT APPLICATION NUMBER: US/10/450,763
; CURRENT FILING DATE: 2003-06-11


```

; PRIOR APPLICATION NUMBER: PCT/US01/06631
; PRIOR FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/540,217
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: 09/649,167
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 60736
; SOFTWARE: Custom
; SEQ ID NO 35010
; LENGTH: 91
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-450-763-35010

Query Match
Best Local Similarity 100.0%; Score 19; DB 5; Length 91;
Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
Db 24 AOGV 27

RESULT 188
US-10-424-599-152428
; Sequence 152428, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 152428
; LENGTH: 92
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_108666C.1.pep
US-10-424-599-152428

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 92;
Pred. No. 3.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
Db 58 AOGV 61

RESULT 189
US-10-425-115-255856
; Sequence 255856, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 255856
; LENGTH: 92
; TYPE: PRT

; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_164933C.1.pep
US-10-425-115-255856

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 92;
Pred. No. 3.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
Db 24 AOGV 27

RESULT 190
US-10-509-055-4
; Sequence 4, Application US/10509055
; Publication No. US20050227354A1
; GENERAL INFORMATION:
; APPLICANT: SAGAWA, Hiroaki et al.
; TITLE OF INVENTION: PROCESS FOR PRODUCING CYTOTOXIC LYMPHOCYTE
; FILE REFERENCE: 1422-0644PUS1
; CURRENT APPLICATION NUMBER: US/10/509,055
; CURRENT FILING DATE: 2004-09-24
; PRIOR APPLICATION NUMBER: PCT/JP03/03575
; PRIOR FILING DATE: 2003-03-25
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: Patent-In 3.3
; SEQ ID NO 4
; LENGTH: 92
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: partial region of fibronectin named III-12
US-10-509-055-4

Query Match
Best Local Similarity 100.0%; Score 19; DB 5; Length 92;
Pred. No. 3.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
Db 84 AOGV 87

RESULT 191
US-10-424-599-176284
; Sequence 176284, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 176284
; LENGTH: 93
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(93)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_130201C.1.pep
US-10-424-599-176284

Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 93;
Pred. No. 3.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Best Local Similarity 100.0%; Pred. No. 3.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOCV 4
Db 14 AOCV 17

RESULT 192
US-10-425-115-245408
; Sequence 245408, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovacic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 245408
; LENGTH: 93
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_155398C.1.pcp
US-10-425-115-245408

Query Match 100.0%; Score 19; DB 4; Length 93;
Best Local Similarity 100.0%; Pred. No. 3.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOCV 4
Db 37 AOCV 40

RESULT 193
US-10-425-115-280821
; Sequence 280821, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovacic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 280821
; LENGTH: 93
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_1920C.1.pcp
US-10-425-115-280821

Query Match 100.0%; Score 19; DB 4; Length 93;
Best Local Similarity 100.0%; Pred. No. 3.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOCV 4
Db 13 AOCV 16

RESULT 194

US-10-484-148-23
; Sequence 23, Application US/10484148
; Publication No. US20040248251A1
; GENERAL INFORMATION:
; APPLICANT: Lal, Preeti G.; HONCHELL, Cynthia D.;
; APPLICANT: FORSYTHE, Ian J.; CHAWLA, Narinder K.;
; APPLICANT: TANG, Y. Tom; BOROWSKI, Mark L.; BARROSO, Ines;
; APPLICANT: YUE, Henry; WARREN, Bridget A.;
; APPLICANT: THANGAVEILU, Kavitha; GIETZEN, Kimberly J.;
; APPLICANT: AZIMZAI, Yalda; LEE, Ernestine A.;
; APPLICANT: BAUGHN, Mariah R.; GORVAD, Ann E.;
; APPLICANT: DUGGAN, Brendan M.; TRAN, Bao;
; APPLICANT: LI, Joana X.; RICHARDSON, Thomas W.;
; APPLICANT: ELLIOTT, Vicki S.; ZEBARJADIAN, Yeganeh
; APPLICANT: TRAN, Yuen K.; YAO, Monique G.;
; APPLICANT: PETERSON, David P.; LUO, Wen
; APPLICANT: LEHR-MASON, Patricia M.
; TITLE OF INVENTION: RECEPTORS AND MEMBRANE ASSOCIATED PROTEINS
; FILE REFERENCE: PF-1082 USN
; CURRENT APPLICATION NUMBER: US/10/484,148
; CURRENT FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: PCT/US02/22833
; PRIOR FILING DATE: 2002-07-16
; PRIOR APPLICATION NUMBER: US 60/306,020
; PRIOR FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: US 60/308,179
; PRIOR FILING DATE: 2001-07-27
; PRIOR APPLICATION NUMBER: US 60/309,702
; PRIOR FILING DATE: 2001-08-02
; PRIOR APPLICATION NUMBER: US 60/311,476
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: US 60/311,718
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: US 60/311,551
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: US 60/314,798
; PRIOR FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: US 60/316,639
; PRIOR FILING DATE: 2001-08-31
; PRIOR APPLICATION NUMBER: US 60/317,996
; PRIOR FILING DATE: 2001-09-07
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PERL Program
; SEQ ID NO 23
; LENGTH: 93
; TYPE: PRT
; ORGANISM: Homo sapiens
; NAME/KEY: misc feature
; OTHER INFORMATION: Incyte ID No: 1985321CD1
US-10-484-148-23

Query Match 100.0%; Score 19; DB 5; Length 93;
Best Local Similarity 100.0%; Pred. No. 3.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOCV 4
Db 89 AOCV 92

RESULT 195
US-10-425-115-341122
; Sequence 341122, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovacic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B

```
;; CURRENT APPLICATION NUMBER: US/10/425,115
;; CURRENT FILING DATE: 2003-04-28
;; NUMBER OF SEQ ID NOS: 369326
;; SEQ ID NO 341122
;; LENGTH: 94
;; TYPE: PRT
;; ORGANISM: Zea mays
;; FEATURE:
;; OTHER INFORMATION: Clone ID: MRT4577_74271C.1.pep
US-10-425-115-341122
```

```
Query Match          100.0%; Score 19; DB 4; Length 94;
Best Local Similarity 100.0%; Pred. No. 3.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 AOGV 4
        |||
Db       45 AOGV 48
```

```
RESULT 196
US-10-156-761-11115
; Sequence 11115, Application US/10156761
; Publication No. US20030119018A1
; GENERAL INFORMATION:
; APPLICANT: OMIURA, SATOSHI
; APPLICANT: IKEDA, HARUO
; APPLICANT: ISHIKAWA, JUN
; APPLICANT: HORIKAWA, HIROSHI
; APPLICANT: SHIBA, TADAYOSHI
; APPLICANT: SAKAKI, YOSHIYUKI
; APPLICANT: HATTORI, NASHIRIRA
; TITLE OF INVENTION: NOVEL POLYNUCLEOTIDES
; FILE REFERENCE: 249-262
; CURRENT APPLICATION NUMBER: US/10/156,761
; CURRENT FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: JP 2001-204089
; PRIOR FILING DATE: 2001-05-30
; PRIOR APPLICATION NUMBER: JP 2001-272697
; PRIOR FILING DATE: 2001-08-02
; NUMBER OF SEQ ID NOS: 15109
; SEQ ID NO 11115
; LENGTH: 95
; TYPE: PRT
; ORGANISM: Streptomyces avermitilis
US-10-156-761-11115
```

```
Query Match          100.0%; Score 19; DB 4; Length 95;
Best Local Similarity 100.0%; Pred. No. 3.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 AOGV 4
        |||
Db       54 AOGV 57
```

```
RESULT 197
US-10-425-115-298069
; Sequence 298069, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 298069
; LENGTH: 95
```

```
;; TYPE: PRT
;; ORGANISM: Zea mays
;; FEATURE:
;; NAME/KEY: unsure
;; LOCATION: (1)..(95)
;; OTHER INFORMATION: unsure at all Xaa locations
;; FEATURE:
;; OTHER INFORMATION: Clone ID: MRT4577_34909C.1.pep
US-10-425-115-298069
```

```
Query Match          100.0%; Score 19; DB 4; Length 95;
Best Local Similarity 100.0%; Pred. No. 3.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 AOGV 4
        |||
Db       42 AOGV 45
```

```
RESULT 198
US-10-425-115-314568
; Sequence 314568, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 314568
; LENGTH: 95
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_49944C.1.pep
US-10-425-115-314568
```

```
Query Match          100.0%; Score 19; DB 4; Length 95;
Best Local Similarity 100.0%; Pred. No. 3.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 AOGV 4
        |||
Db       5 AOGV 8
```

```
RESULT 199
US-10-425-115-348114
; Sequence 348114, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 348114
; LENGTH: 95
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_80644C.1.pep
US-10-425-115-348114
```

Query Match 100.0%; Score 19; DB 4; Length 95;
Best Local Similarity 100.0%; Pred. No. 3.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||||
Db 52 ACGV 55

RESULT 200
US-10-424-599-220040
; Sequence 220040, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovallc David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 220040
; LENGTH: 96
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)-(96)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_40725C.1.pcp
US-10-424-599-220040

Query Match 100.0%; Score 19; DB 4; Length 96;
Best Local Similarity 100.0%; Pred. No. 3.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||||
Db 73 ACGV 76

RESULT 201
US-10-437-963-186534
; Sequence 186534, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovallc, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 186534
; LENGTH: 96
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_83325C.1.pcp
US-10-437-963-186534

Query Match 100.0%; Score 19; DB 4; Length 96;
Best Local Similarity 100.0%; Pred. No. 3.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||||
Db 77 ACGV 80

RESULT 202
US-10-767-701-48980
; Sequence 48980, Application US/10767701
; Publication No. US20040172684A1
; GENERAL INFORMATION:
; APPLICANT: Kovallc, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53535)B
; CURRENT APPLICATION NUMBER: US/10/767,701
; CURRENT FILING DATE: 2004-01-29
; NUMBER OF SEQ ID NOS: 63128
; SEQ ID NO 48980
; LENGTH: 96
; TYPE: PRT
; ORGANISM: Sorghum bicolor
; FEATURE:
; OTHER INFORMATION: Clone ID: LIB3476-024-P1-K1-G11.pcp
US-10-767-701-48980

Query Match 100.0%; Score 19; DB 4; Length 96;
Best Local Similarity 100.0%; Pred. No. 3.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||||
Db 18 ACGV 21

RESULT 203
US-10-425-115-220279
; Sequence 220279, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovallc, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 220279
; LENGTH: 96
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)-(96)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_13247C.1.pcp
US-10-425-115-220279

Query Match 100.0%; Score 19; DB 4; Length 96;
Best Local Similarity 100.0%; Pred. No. 3.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||||

Db 44 AOGV 47

RESULT 204
US-10-437-963-198150
; Sequence 198150, Application US/10437963
; Publication No. US2004012343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Mu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53221)B
; CURRENT FILING DATE: 2003-05-14
; CURRENT APPLICATION NUMBER: US/10/437,963
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 198150
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_93839C.1.pcp
US-10-437-963-198150

Query Match 100.0%; Score 19; DB 4; Length 97;
Best Local Similarity 100.0%; Pred. No. 3.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||
Db 89 AOGV 92

RESULT 205
US-10-425-115-358132
; Sequence 358132, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53222)B
; CURRENT FILING DATE: 2003-04-28
; CURRENT APPLICATION NUMBER: US/10/425,115
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 358132
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(97)
; OTHER INFORMATION: unsure at all Xaa locations
; OTHER INFORMATION: Clone ID: MRT4577_89784C.1.pcp
US-10-425-115-358132

Query Match 100.0%; Score 19; DB 4; Length 97;
Best Local Similarity 100.0%; Pred. No. 3.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||
Db 24 AOGV 27

RESULT 206
US-10-501-282-1482
; Sequence 1482, Application US/10501282
; Publication No. US20050203280A1
; GENERAL INFORMATION:
; APPLICANT: MCNICHAE, JOHN CALHOUN
; APPLICANT: ZAGORSKY, ROBERT JOHN
; APPLICANT: RUSSELL, DAVID PARRISH
; APPLICANT: FLETCHER, LEAH DIANE
; TITLE OF INVENTION: ALLOIOCCUS OTTIDIS OPEN READING FRAMES (ORFS) ENCODING
; FILE REFERENCE: AM100780 L2
; CURRENT APPLICATION NUMBER: US/10/501,282
; CURRENT FILING DATE: 2004-07-09
; PRIOR APPLICATION NUMBER: 60/333,777
; PRIOR FILING DATE: 2001-11-29
; PRIOR APPLICATION NUMBER: 60/426,742
; PRIOR FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: PCT/US02/36123
; PRIOR FILING DATE: 2002-11-25
; NUMBER OF SEQ ID NOS: 6653
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1482
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Alloiococcus otitidis
US-10-501-282-1482

Query Match 100.0%; Score 19; DB 5; Length 97;
Best Local Similarity 100.0%; Pred. No. 3.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||
Db 43 AOGV 46

RESULT 207
US-10-424-599-189929
; Sequence 189929, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT FILING DATE: 2003-04-28
; CURRENT APPLICATION NUMBER: US/10/424,599
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 189929
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_142524C.1.pcp
US-10-424-599-189929

Query Match 100.0%; Score 19; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||
Db 15 AOGV 18RESULT 208
US-10-424-599-194380

Sequence 194380, Application US/10424599
Publication No. US20040031072A1
GENERAL INFORMATION:
APPLICANT: La Rosa Thomas J
APPLICANT: Kovacic David K
APPLICANT: Zhou Yihua
APPLICANT: Cao Yongwei
TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
FILE REFERENCE: 38-21(53223)B
CURRENT APPLICATION NUMBER: US/10/424,599
CURRENT FILING DATE: 2003-04-28
NUMBER OF SEQ ID NOS: 285684
SEQ ID NO 194380
LENGTH: 98
TYPE: PRT
ORGANISM: Glycine max
FEATURE:
OTHER INFORMATION: Clone ID: PAT_MRT3847_17552C.1.pep
US-10-424-599-194380

Query Match 100.0%; Score 19; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
DB 60 ACGV 63

RESULT 209
US-10-617-320-5200
Sequence 5200, Application US/10617320
Publication No. US20050136404A1
GENERAL INFORMATION:
APPLICANT: Lynn A Doucette-Stamm and David Bush
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID
SEQUENCES RELATING TO STREPTOCOCCUS PNEUMONIAE FOR DIAGN
THERAPEUTICS
NUMBER OF SEQUENCES: 5206
CORRESPONDENCE ADDRESS:
ADDRESSEE: GENOME THERAPEUTICS CORPORATION
STREET: 100 Beaver Street
CITY: Waltham
STATE: Massachusetts
COUNTRY: USA
ZIP: 02354
COMPUTER READABLE FORM:
MEDIUM TYPE: CD-ROM ISO9660
COMPUTER: <Unknown>
OPERATING SYSTEM: <Unknown>
SOFTWARE: <Unknown>
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/617,320
FILING DATE: 10-Jul-2003
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/107,433
FILING DATE: 30-Jun-1998
APPLICATION NUMBER: 60/ 085131
FILING DATE: May 12, 1998
APPLICATION NUMBER: 60/051553
FILING DATE: July 2, 1997
ATTORNEY/AGENT INFORMATION:
NAME: Arinello, Pamela Deneke
REGISTRATION NUMBER: 40,489
REFERENCE/DOCKET NUMBER: GTC-011
TELECOMMUNICATION INFORMATION:
TELEPHONE: (781)893-5007
TELEFAX: (781)893-8277
INFORMATION FOR SEQ ID NO: 5200:
SEQUENCE CHARACTERISTICS:
LENGTH: 99 amino acids
TYPE: amino acid

TOPOLOGY: linear
MOLECULE TYPE: protein
HYPOTHETICAL: YES
ORIGINAL SOURCE:
ORGANISM: Streptococcus pneumoniae
FEATURE:
NAME/KEY: misc feature
LOCATION: (B) LOCATION 1...99
SEQUENCE DESCRIPTION: SEQ ID NO: 5200:
US-10-617-320-5200

Query Match 100.0%; Score 19; DB 5; Length 99;
Best Local Similarity 100.0%; Pred. No. 3.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
DB 85 ACGV 88

RESULT 210
US-10-080-170-56
Sequence 56, Application US/10080170
Publication No. US20030129601A1
GENERAL INFORMATION:
APPLICANT: COLE, S.T.
TITLE OF INVENTION: COMPARATIVE MYCOBACTERIAL GENOMICS AS A TOOL FOR
IDENTIFYING TARGETS FOR THE DIAGNOSIS, PROPHYLAXIS OR
TREATMENT OF MYCOBACTERIOSIS
FILE REFERENCE: 03495.0218
CURRENT APPLICATION NUMBER: US/10/080,170
CURRENT FILING DATE: 2002-06-10
PRIOR APPLICATION NUMBER: 60/270,123
PRIOR FILING DATE: 2001-02-22
NUMBER OF SEQ ID NOS: 652
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 56
LENGTH: 100
TYPE: PRT
ORGANISM: Mycobacterium leprae
US-10-080-170-56

Query Match 100.0%; Score 19; DB 4; Length 100;
Best Local Similarity 100.0%; Pred. No. 3.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
DB 68 ACGV 71

RESULT 211
US-10-080-170-56
Sequence 56, Application US/10080170
Publication No. US20040121322A9
GENERAL INFORMATION:
APPLICANT: COLE, S.T.
TITLE OF INVENTION: COMPARATIVE MYCOBACTERIAL GENOMICS AS A TOOL FOR
IDENTIFYING TARGETS FOR THE DIAGNOSIS, PROPHYLAXIS OR
TREATMENT OF MYCOBACTERIOSIS
FILE REFERENCE: 03495.0218
CURRENT APPLICATION NUMBER: US/10/080,170
CURRENT FILING DATE: 2002-06-10
PRIOR APPLICATION NUMBER: 60/270,123
PRIOR FILING DATE: 2001-02-22
NUMBER OF SEQ ID NOS: 652
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 56
LENGTH: 100
TYPE: PRT
ORGANISM: Mycobacterium leprae
US-10-080-170-56

Query Match 100.0%; Score 19; DB 4; Length 100;
Best Local Similarity 100.0%; Pred. No. 3.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
68 AOGV 71

Db

RESULT 212
US-10-468-356-56
; Sequence 56, Application US/10468356
; Publication No. US20040197896A1
; GENERAL INFORMATION:
; APPLICANT: COLE, STEWART
; TITLE OF INVENTION: COMPARATIVE MYCOBACTERIAL GENOMICS AS A TOOL FOR
; TITLE OF INVENTION: IDENTIFYING TARGETS FOR THE DIAGNOSIS, PROPHYLAXIS OR
; TITLE OF INVENTION: TREATMENT OF MYCOBACTERIOSES
; FILE REFERENCE: 05394.0019
; CURRENT APPLICATION NUMBER: US/10/468,356
; CURRENT FILING DATE: 2003-08-19
; PRIOR APPLICATION NUMBER: 10/080,170
; PRIOR FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/270,123
; PRIOR FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 655
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 56
; LENGTH: 100
; TYPE: PRT
; ORGANISM: Mycobacterium leprae
US-10-468-356-56

Query Match 100.0%; Score 19; DB 4; Length 100;
Best Local Similarity 100.0%; Pred. No. 3.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
68 AOGV 71

Db

RESULT 213
US-10-425-115-222178
; Sequence 222178, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 222178
; LENGTH: 100
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_134216C.1.pep
US-10-425-115-222178

Query Match 100.0%; Score 19; DB 4; Length 100;
Best Local Similarity 100.0%; Pred. No. 3.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
72 AOGV 75

Db

RESULT 214
US-10-425-115-289173
; Sequence 289173, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: Kovalic, Thomas J.
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 289173
; LENGTH: 100
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_26816C.1.pep
US-10-425-115-289173

Query Match 100.0%; Score 19; DB 4; Length 100;
Best Local Similarity 100.0%; Pred. No. 3.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
64 AOGV 67

Db

RESULT 215
US-09-864-408A-2992
; Sequence 2992, Application US/09864408A
; Publication No. US20040009474A1
; GENERAL INFORMATION:
; APPLICANT: Leach, Martin D.
; APPLICANT: Shinkets, Richard A.
; TITLE OF INVENTION: No. US20040009474A1 Human Polynucleotides and Polypeptides Enco
; FILE REFERENCE: 21402-012
; CURRENT APPLICATION NUMBER: US/09/864,408A
; CURRENT FILING DATE: 2001-05-24
; PRIOR APPLICATION NUMBER: 60/206,690
; PRIOR FILING DATE: 2000-05-24
; NUMBER OF SEQ ID NOS: 9068
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2992
; LENGTH: 101
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-864-408A-2992

Query Match 100.0%; Score 19; DB 3; Length 101;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
77 AOGV 80

Db

RESULT 216
US-10-437-963-121960
; Sequence 121960, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei

```
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; PRIOR FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 121960
; LENGTH: 101
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(101)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_24934C.1.pep
US-10-437-963-121960

Query Match          100.0%; Score 19; DB 4; Length 101;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4      ||||
DB      68 ACGV 71

RESULT 217
US-10-450-763-32365
; Sequence 32365, Application US/10450763
; Publication No. US20050196754A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc
; TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
; FILE REFERENCE: 790CIP3/US
; CURRENT APPLICATION NUMBER: US/10/450,763
; CURRENT FILING DATE: 2003-06-11
; PRIOR APPLICATION NUMBER: PCT/US01/08631
; PRIOR FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/540,217
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: 09/649,167
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 60736
; SOFTWARE: Custom
; SEQ ID NO 32365
; LENGTH: 101
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(101)
; OTHER INFORMATION: Xaa = X or * as defined in Table 2
US-10-450-763-32365

Query Match          100.0%; Score 19; DB 5; Length 101;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4      ||||
DB      46 ACGV 49

RESULT 218
US-10-450-763-54297
; Sequence 54297, Application US/10450763
; Publication No. US20050196754A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc
```

```
; TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
; FILE REFERENCE: 790CIP3/US
; CURRENT APPLICATION NUMBER: US/10/450,763
; CURRENT FILING DATE: 2003-06-11
; PRIOR APPLICATION NUMBER: PCT/US01/08631
; PRIOR FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/540,217
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: 09/649,167
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 60736
; SOFTWARE: Custom
; SEQ ID NO 54297
; LENGTH: 101
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(101)
; OTHER INFORMATION: Xaa = X or * as defined in Table 2
US-10-450-763-54297

Query Match          100.0%; Score 19; DB 5; Length 101;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4      ||||
DB      46 ACGV 49

RESULT 219
US-10-101-464A-699
; Sequence 699, Application US/10101464A
; Publication No. US20030046728A1
; GENERAL INFORMATION:
; APPLICANT: Strabala, Timothy
; APPLICANT: Nieuwenhuizen, Nicolaas
; APPLICANT: Higgins, Colleen M.
; TITLE OF INVENTION: Compositions Isolated from Plant Cells
; TITLE OF INVENTION: and Their Use in the Modification of Plant Cell Signaling
; FILE REFERENCE: 11000.1020c2
; CURRENT APPLICATION NUMBER: US/10/101,464A
; CURRENT FILING DATE: 2002-03-18
; PRIOR APPLICATION NUMBER: 09/704,302
; PRIOR FILING DATE: 2000-11-01
; PRIOR APPLICATION NUMBER: 09/228,986
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/162,866
; PRIOR FILING DATE: 1999-11-01
; PRIOR APPLICATION NUMBER: PCT/US00/00724
; PRIOR FILING DATE: 2000-01-11
; NUMBER OF SEQ ID NOS: 989
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 699
; LENGTH: 102
; TYPE: PRT
; ORGANISM: Pinus radiata
US-10-101-464A-699

Query Match          100.0%; Score 19; DB 4; Length 102;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4      ||||
DB      31 ACGV 34

RESULT 220
US-10-080-170-301
; Sequence 301, Application US/10080170
; Publication No. US20030129601A1
```



```

; GENERAL INFORMATION:
; APPLICANT: COLE, S.T.
; TITLE OF INVENTION: COMPARATIVE MYCOBACTERIAL GENOMICS AS A TOOL FOR
; TITLE OF INVENTION: IDENTIFYING TARGETS FOR THE DIAGNOSIS, PROPHYLAXIS OR
; FILE REFERENCE: 03495, 0218
; CURRENT APPLICATION NUMBER: US/10/080,170
; PRIOR FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: 60/270,123
; NUMBER OF SEQ ID NOS: 652
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 301
; LENGTH: 102
; TYPE: PRT
; ORGANISM: Mycobacterium leprae
US-10-080-170-301

Query Match          100.0%; Score 19; DB 4; Length 102;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 AQGV 4
        ||||
Db       66 AQGV 69

RESULT 221
US-10-424-599-159264
; Sequence 159264, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J
; APPLICANT: Kovalic, David K
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated with
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 159264
; LENGTH: 102
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(102)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_114836C.1.pep
US-10-424-599-159264

Query Match          100.0%; Score 19; DB 4; Length 102;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 AQGV 4
        ||||
Db       3 AQGV 6

RESULT 222
US-10-080-170-301
; Sequence 301, Application US/10080170
; Publication No. US20040121322A9
; GENERAL INFORMATION:
; APPLICANT: COLE, S.T.
; TITLE OF INVENTION: COMPARATIVE MYCOBACTERIAL GENOMICS AS A TOOL FOR
; TITLE OF INVENTION: IDENTIFYING TARGETS FOR THE DIAGNOSIS, PROPHYLAXIS OR
; TITLE OF INVENTION: TREATMENT OF MYCOBACTERIOSES
; FILE REFERENCE: 03495, 0218
```

```

; CURRENT APPLICATION NUMBER: US/10/080,170
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: 60/270,123
; PRIOR FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 652
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 301
; LENGTH: 102
; TYPE: PRT
; ORGANISM: Mycobacterium leprae
US-10-080-170-301

Query Match          100.0%; Score 19; DB 4; Length 102;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 AQGV 4
        ||||
Db       66 AQGV 69

RESULT 223
US-10-468-356-301
; Sequence 301, Application US/10468356
; Publication No. US20040197896A1
; GENERAL INFORMATION:
; APPLICANT: COLE, STEWART
; TITLE OF INVENTION: COMPARATIVE MYCOBACTERIAL GENOMICS AS A TOOL FOR
; TITLE OF INVENTION: IDENTIFYING TARGETS FOR THE DIAGNOSIS, PROPHYLAXIS OR
; FILE REFERENCE: 05394, 0019
; CURRENT APPLICATION NUMBER: US/10/468,356
; CURRENT FILING DATE: 2003-08-19
; PRIOR APPLICATION NUMBER: 10/080,170
; PRIOR FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/270,123
; PRIOR FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 655
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 301
; LENGTH: 102
; TYPE: PRT
; ORGANISM: Mycobacterium leprae
US-10-468-356-301

Query Match          100.0%; Score 19; DB 4; Length 102;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 AQGV 4
        ||||
Db       66 AQGV 69

RESULT 224
US-10-425-115-265628
; Sequence 265628, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 265628
; LENGTH: 102
; TYPE: PRT
; ORGANISM: Zea mays
```

```
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(102)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT457_173859C.1.pep
US-10-425-115-265628
```

```
Query Match          100.0%; Score 19; DB 4; Length 102;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 ACGV 4
      ||||
Db      84 ACGV 87
```

```
RESULT 225
US-10-864-252-699
; Sequence 699, Application US/10864252
; Publication No. US2005050583A1
; GENERAL INFORMATION:
; APPLICANT: Strabala, Timothy
; APPLICANT: Nieuwenhuizen, Nicolaas
; APPLICANT: Higgins, Colleen M.
; TITLE OF INVENTION: Compositions Isolated from Plant Cells
; TITLE OF INVENTION: and Their Use in the Modification of Plant Cell Signaling
; FILE REFERENCE: 11000.10203
; CURRENT APPLICATION NUMBER: US/10/864,252
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: 10/101,464
; PRIOR FILING DATE: 2002-03-18
; PRIOR APPLICATION NUMBER: 09/704,302
; PRIOR FILING DATE: 2000-11-01
; PRIOR APPLICATION NUMBER: 09/228,986
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/162,866
; PRIOR FILING DATE: 1999-11-01
; PRIOR APPLICATION NUMBER: PCT/US00/00724
; PRIOR FILING DATE: 2000-01-11
; NUMBER OF SEQ ID NOS: 989
; SOFTWARE: FASTSEQ for Windows Version 4.0
; SEQ ID NO 699
; LENGTH: 102
; TYPE: PRT
; ORGANISM: Pinus radiata
US-10-864-252-699
```

```
Query Match          100.0%; Score 19; DB 5; Length 102;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 ACGV 4
      ||||
Db      31 ACGV 34
```

```
RESULT 226
US-10-424-599-179799
; Sequence 179799, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J
; APPLICANT: Kovacic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 179799
```

```
; LENGTH: 103
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_133374C.1.pep
US-10-424-599-179799
```

```
Query Match          100.0%; Score 19; DB 4; Length 103;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 ACGV 4
      ||||
Db      73 ACGV 76
```

```
RESULT 227
US-10-424-599-261546
; Sequence 261546, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J
; APPLICANT: Kovacic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 261546
; LENGTH: 103
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(103)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_78199C.1.pep
US-10-424-599-261546
```

```
Query Match          100.0%; Score 19; DB 4; Length 103;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 ACGV 4
      ||||
Db      38 ACGV 41
```

```
RESULT 228
US-10-424-599-198118
; Sequence 198118, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J
; APPLICANT: Kovacic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 198118
; LENGTH: 104
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; NAME/KEY: unsure
```

```

; LOCATION: (1)..(104)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_20925C.1.pdp
US-10-424-599-198118
Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 104;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
   |||
   |||
Db 87 AOGV 90

RESULT 229
US-10-424-599-244826
; Sequence 244826, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J
; APPLICANT: Zhou, Yihua
; APPLICANT: Kovalic, David K
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated with
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 244826
; LENGTH: 104
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(104)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_63107C.1.pdp
US-10-424-599-244826
Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 104;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
   |||
   |||
Db 100 AOGV 103

RESULT 230
US-10-425-115-205212
; Sequence 205212, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J
; APPLICANT: Kovalic, David K
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 205212
; LENGTH: 104
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(104)
```

```

; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_118742C.1.pdp
US-10-425-115-205212
Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 104;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
   |||
   |||
Db 84 AOGV 87

RESULT 231
US-10-425-115-273311
; Sequence 273311, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J
; APPLICANT: Kovalic, David K
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 273311
; LENGTH: 104
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_180845C.1.pdp
US-10-425-115-273311
Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 104;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
   |||
   |||
Db 5 AOGV 8

RESULT 232
US-10-424-599-258231
; Sequence 258231, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J
; APPLICANT: Kovalic, David K
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated with
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 258231
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_75205C.1.pdp
US-10-424-599-258231
Query Match
Best Local Similarity 100.0%; Score 19; DB 4; Length 105;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1 ACGV 4
||||
Db 73 ACGV 76

RESULT 233

US-10-437-963-187330
; Sequence 187330, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Mu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 187330
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_84043C.1.pep
US-10-437-963-187330

Query Match 100.0%; Score 19; DB 4; Length 105;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ACGV 4
||||
Db 47 ACGV 50

RESULT 234

US-10-424-599-207947
; Sequence 207947, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 207947
; LENGTH: 106
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(106)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_29802C.1.pep
US-10-424-599-207947

Query Match 100.0%; Score 19; DB 4; Length 106;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ACGV 4

Db 78 ACGV 81

RESULT 235

US-10-437-963-124557
; Sequence 124557, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Mu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 124557
; LENGTH: 106
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_27284C.1.pep
US-10-437-963-124557

Query Match 100.0%; Score 19; DB 4; Length 106;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ACGV 4
||||
Db 14 ACGV 17

RESULT 236

US-10-425-115-197558
; Sequence 197558, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 197558
; LENGTH: 106
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_111756C.1.pep
US-10-425-115-197558

Query Match 100.0%; Score 19; DB 4; Length 106;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ACGV 4
||||
Db 102 ACGV 105

RESULT 237

```
US-10-425-115-354333
; Sequence 354333, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 354333
; LENGTH: 106
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(106)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_86323C.1.pap
US-10-425-115-354333

Query Match          100.0%; Score 19; DB 4; Length 106;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 AQGV 4
        ||||
Db      45 AQGV 48

RESULT 238
US-10-775-481A-55
; Sequence 55, Application US/10775481A
; Publication No. US20040258687A1
; GENERAL INFORMATION:
; APPLICANT: Waldman, Scott A.
; APPLICANT: Picari, Giovanni Mario
; APPLICANT: Park, Jason
; APPLICANT: Schulz, Stephanie
; APPLICANT: Wolfe, Henry R.
; APPLICANT: Lubbe, Wilhelm
; TITLE OF INVENTION: The Use of GCC Ligands
; FILE REFERENCE: 08321-0168 US1
; CURRENT APPLICATION NUMBER: US/10/775,481A
; CURRENT FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: US 60/446,730
; PRIOR FILING DATE: 2003-02-10
; NUMBER OF SEQ ID NOS: 56
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 55
; LENGTH: 106
; TYPE: PRT
; ORGANISM: Rattus norvegicus
US-10-775-481A-55

Query Match          100.0%; Score 19; DB 5; Length 106;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 AQGV 4
        ||||
Db      19 AQGV 22

RESULT 239
US-09-800-095A-104
; Sequence 104, Application US/09800095A
; Publication No. US20020086988A1

; GENERAL INFORMATION:
; APPLICANT: Conklin, Darrell C.
; APPLICANT: Presnell, Scott R.
; APPLICANT: Adler, David A.
; TITLE OF INVENTION: FULL LENGTH EXPRESS POLYNUCLEOTIDES AND THE POLYPEPTIDES THEY ENC
; FILE REFERENCE: 00-09
; CURRENT APPLICATION NUMBER: US/09/800,095A
; CURRENT FILING DATE: 2001-09-28
; PRIOR APPLICATION NUMBER: 60/187,221
; PRIOR FILING DATE: 2000-03-03
; NUMBER OF SEQ ID NOS: 123
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 104
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-800-095A-104

Query Match          100.0%; Score 19; DB 3; Length 107;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 AQGV 4
        ||||
Db      38 AQGV 41

RESULT 240
US-09-833-245-1848
; Sequence 1848, Application US/09833245
; Publication No. US20040010134A1
; GENERAL INFORMATION:
; APPLICANT: Human Genome Sciences, Inc.
; TITLE OF INVENTION: Albumin Fusion Proteins
; FILE REFERENCE: PFS46PCT
; CURRENT APPLICATION NUMBER: US/09/833,245
; CURRENT FILING DATE: 2001-04-12
; PRIOR APPLICATION NUMBER: 60/229,358
; PRIOR FILING DATE: 2000-04-12
; PRIOR APPLICATION NUMBER: 60/256,931
; PRIOR FILING DATE: 2000-12-21
; PRIOR APPLICATION NUMBER: 60/199,384
; PRIOR FILING DATE: 2000-04-25
; NUMBER OF SEQ ID NOS: 2267
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 1848
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-833-245-1848

Query Match          100.0%; Score 19; DB 3; Length 107;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 AQGV 4
        ||||
Db      73 AQGV 76

RESULT 241
US-10-424-599-16119
; Sequence 16119, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
```

;; CURRENT FILING DATE: 2003-04-28
;; NUMBER OF SEQ ID NOS: 285684
;; SEQ ID NO 16119
;; LENGTH: 107
;; TYPE: PRT
;; ORGANISM: Glycine max
;; FEATURE:
;; NAME/KEY: unsure
;; LOCATION: (1)..(107)
;; OTHER INFORMATION: unsure at all Xaa locations
;; FEATURE:
;; OTHER INFORMATION: Clone ID: PAT_MRT3847_116508C.1.pep
US-10-424-599-16119

Query Match 100.0%; Score 19; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
Db 7 AOGV 10

RESULT 242
US-10-424-599-177891
;; Sequence 177891, Application US/10424539
;; Publication No. US20040031072A1
;; GENERAL INFORMATION:
;; APPLICANT: La Rosa, Thomas J.
;; APPLICANT: Kovalic, David K.
;; APPLICANT: Zhou, Yihua
;; APPLICANT: Cao, Yongwei
;; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
;; FILE REFERENCE: 38-21(53223)B
;; CURRENT APPLICATION NUMBER: US/10/424,599
;; CURRENT FILING DATE: 2003-04-28
;; NUMBER OF SEQ ID NOS: 285684
;; SEQ ID NO 177891
;; LENGTH: 107
;; TYPE: PRT
;; ORGANISM: Glycine max
;; FEATURE:
;; NAME/KEY: unsure
;; LOCATION: (1)..(107)
;; OTHER INFORMATION: unsure at all Xaa locations
;; FEATURE:
;; OTHER INFORMATION: Clone ID: PAT_MRT3847_131651C.1.pep
US-10-424-599-177891

Query Match 100.0%; Score 19; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
Db 90 AOGV 93

RESULT 243
US-10-425-115-291289
;; Sequence 291289, Application US/10425115
;; Publication No. US20040214272A1
;; GENERAL INFORMATION:
;; APPLICANT: La Rosa, Thomas J.
;; APPLICANT: Kovalic, David K.
;; APPLICANT: Zhou, Yihua
;; APPLICANT: Cao, Yongwei
;; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;; TITLE OF INVENTION: Plants
;; FILE REFERENCE: 38-21(53222)B
;; CURRENT APPLICATION NUMBER: US/10/425,115
;; CURRENT FILING DATE: 2003-04-28

;; NUMBER OF SEQ ID NOS: 369326
;; SEQ ID NO 291289
;; LENGTH: 107
;; TYPE: PRT
;; ORGANISM: Zea mays
;; FEATURE:
;; NAME/KEY: unsure
;; LOCATION: (1)..(107)
;; OTHER INFORMATION: unsure at all Xaa locations
;; FEATURE:
;; OTHER INFORMATION: Clone ID: MRT4577_28742C.1.pep
US-10-425-115-291289

Query Match 100.0%; Score 19; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
Db 65 AOGV 68

RESULT 244
US-10-425-115-294264
;; Sequence 294264, Application US/10425115
;; Publication No. US20040214272A1
;; GENERAL INFORMATION:
;; APPLICANT: La Rosa, Thomas J.
;; APPLICANT: Kovalic, David K.
;; APPLICANT: Zhou, Yihua
;; APPLICANT: Cao, Yongwei
;; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;; TITLE OF INVENTION: Plants
;; FILE REFERENCE: 38-21(53222)B
;; CURRENT APPLICATION NUMBER: US/10/425,115
;; CURRENT FILING DATE: 2003-04-28
;; NUMBER OF SEQ ID NOS: 369326
;; SEQ ID NO 294264
;; LENGTH: 108
;; TYPE: PRT
;; ORGANISM: Zea mays
;; FEATURE:
;; OTHER INFORMATION: Clone ID: MRT4577_31455C.1.pep
US-10-425-115-294264

Query Match 100.0%; Score 19; DB 4; Length 108;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
Db 48 AOGV 51

RESULT 245
US-10-437-963-180999
;; Sequence 180999, Application US/10437963
;; Publication No. US20040123343A1
;; GENERAL INFORMATION:
;; APPLICANT: La Rosa, Thomas J.
;; APPLICANT: Kovalic, David K.
;; APPLICANT: Zhou, Yihua
;; APPLICANT: Cao, Yongwei
;; APPLICANT: Wu, Wei
;; APPLICANT: Boukharov, Andrey A.
;; APPLICANT: Barbazuk, Brad
;; APPLICANT: Li, Ping
;; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
;; FILE REFERENCE: 38-21(53221)B
;; CURRENT APPLICATION NUMBER: US/10/437,963
;; CURRENT FILING DATE: 2003-05-14
;; NUMBER OF SEQ ID NOS: 204966

```
; SEQ ID NO 180999
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(109)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_78315C.1.pep
US-10-437-963-180999
```

```
Query Match          100.0%; Score 19; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 AOGV 4
        ||||
Db       55 AOGV 58
```

```
RESULT 246
US-10-425-115-260668
; Sequence 260668, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 260668
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_169344C.1.pep
US-10-425-115-260668
```

```
Query Match          100.0%; Score 19; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 AOGV 4
        ||||
Db       58 AOGV 61
```

```
RESULT 247
US-10-425-115-280327
; Sequence 280327, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 280327
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
```

```
; NAME/KEY: unsure
; LOCATION: (1)..(109)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_18760C.1.pep
US-10-425-115-280327
```

```
Query Match          100.0%; Score 19; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 AOGV 4
        ||||
Db       44 AOGV 47
```

```
RESULT 248
US-10-425-115-361658
; Sequence 361658, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 361658
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_93009C.1.pep
US-10-425-115-361658
```

```
Query Match          100.0%; Score 19; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 AOGV 4
        ||||
Db       38 AOGV 41
```

```
RESULT 249
US-10-424-599-164976
; Sequence 164976, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated with
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 164976
; LENGTH: 110
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_119991C.1.pep
US-10-424-599-164976
```

```
Query Match          100.0%; Score 19; DB 4; Length 110;
Best Local Similarity 100.0%; Pred. No. 3.8e+03;
```

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ACGV 4
 ||||
 Db 26 ACGV 29

RESULT 250

US-10-425-115-352048
 ; Sequence 352048, Application US/10425115
 ; Publication No. US20040214272A1
 ; GENERAL INFORMATION:
 ; APPLICANT: La Rosa, Thomas J.
 ; APPLICANT: Kovalic, David K.
 ; APPLICANT: Zhou, Yihua
 ; APPLICANT: Cao, Yongwei
 ; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
 ; TITLE OF INVENTION: Plants
 ; FILE REFERENCE: 38-21(53222)B
 ; CURRENT APPLICATION NUMBER: US/10/425,115
 ; CURRENT FILING DATE: 2003-04-28
 ; NUMBER OF SEQ ID NOS: 369326
 ; SEQ ID NO 352048
 ; LENGTH: 110
 ; TYPE: PRT
 ; ORGANISM: Zea mays
 ; FEATURE:
 ; OTHER INFORMATION: Clone ID: MFT4577_84232C.1.pep
 ; US-10-425-115-352048

Query Match 100.0%; Score 19; DB 4; Length 110;

Best Local Similarity 100.0%; Pred. No. 3.8e+03; Mismatches 0; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
 ||||
 Db 23 ACGV 26

Search completed: February 21, 2006, 09:19:43
 Job time : 128 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM protein - protein search, using sw model

Run on: February 21, 2006, 08:56:13 ; Search time 33 Seconds
(without alignments)
10.021 Million cell updates/sec

Title: US-10-821-256-2
Perfect score: 19
Sequence: 1 AOGV 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues
Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:*
1: /cgn2_6/ptodata/1/1aa/5_COMB.pep:*
2: /cgn2_6/ptodata/1/1aa/6_COMB.pep:*
3: /cgn2_6/ptodata/1/1aa/H_COMB.pep:*
4: /cgn2_6/ptodata/1/1aa/PCTUS_COMB.pep:*
5: /cgn2_6/ptodata/1/1aa/RB_COMB.pep:*
6: /cgn2_6/ptodata/1/1aa/backfile1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	19	100.0	8	2	US-08-884-235-10
2	19	100.0	10	2	US-10-123-675-28
3	19	100.0	15	2	US-09-220-415-37
4	19	100.0	15	2	US-09-675-776-37
5	19	100.0	15	2	US-09-676-739-37
6	19	100.0	15	2	US-09-676-732-37
7	19	100.0	15	2	US-09-677-152-37
8	19	100.0	19	2	US-10-394-980-6
9	19	100.0	21	2	US-09-936-588-8
10	19	100.0	22	1	US-08-482-142-24
11	19	100.0	22	1	US-08-478-572-24
12	19	100.0	22	4	US-08-484-296-24
13	19	100.0	22	4	PCT-US95-04481-15
14	19	100.0	23	1	US-08-482-142-40
15	19	100.0	23	1	US-08-478-572-40
16	19	100.0	23	2	US-08-484-296-40
17	19	100.0	23	2	US-08-933-100B-3
18	19	100.0	24	1	US-08-141-324-22
19	19	100.0	24	1	US-08-541-902-22
20	19	100.0	25	1	US-08-482-142-38
21	19	100.0	25	1	US-08-478-572-38
22	19	100.0	25	2	US-08-484-296-38
23	19	100.0	25	2	US-09-596-120-9
24	19	100.0	26	1	US-07-879-685B-2
25	19	100.0	27	1	US-08-821-119-6
26	19	100.0	27	1	US-08-900-660A-6
27	19	100.0	29	1	US-08-482-142-39

28	19	100.0	29	1	US-08-478-572-39	Sequence 39, Appl
29	19	100.0	29	2	US-08-484-296-39	Sequence 39, Appl
30	19	100.0	34	1	US-07-700-526-7	Sequence 7, Appl
31	19	100.0	34	4	PCT-US92-03132-7	Sequence 7, Appl
32	19	100.0	37	1	US-08-164-151-14	Sequence 14, Appl
33	19	100.0	38	2	US-09-092-315-22	Sequence 22, Appl
34	19	100.0	38	2	US-09-733-524A-22	Sequence 22, Appl
35	19	100.0	38	2	US-10-189-977A-22	Sequence 22, Appl
36	19	100.0	40	2	US-08-096-044C-11	Sequence 11, Appl
37	19	100.0	40	2	US-09-252-991A-27289	Sequence 27289, A
38	19	100.0	62	2	US-09-489-039A-8531	Sequence 8531, A
39	19	100.0	62	2	US-09-248-796A-26843	Sequence 26843, A
40	19	100.0	65	2	US-09-489-039A-13242	Sequence 13242, A
41	19	100.0	65	2	US-09-513-999C-6489	Sequence 6489, Ap
42	19	100.0	69	2	US-08-792-013-1	Sequence 1, Appl
43	19	100.0	71	2	US-09-471-276-1548	Sequence 1548, Ap
44	19	100.0	72	1	US-08-225-480-6	Sequence 6, Appl
45	19	100.0	72	2	US-09-118-445-6	Sequence 6, Appl

ALIGNMENTS

RESULT 1
US-08-884-235-10
Sequence 10, Application US/08884235
Patent No. 6329573
GENERAL INFORMATION:
APPLICANT: Lightfoot, David A.
APPLICANT: Long, Lynn M.
TITLE OF INVENTION: PLANTS CONTAINING THE gdnA GENE AND
TITLE OF INVENTION: METHODS OF USE THEREOF
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Pillsbury Madison & Sutro, L.L.P.
STREET: 1100 New York Avenue, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: United States of America
ZIP: 20005-3918
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MS Word
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/884,235
FILING DATE: 27-JUN-1997
CLASSIFICATION: 800
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 residues
TYPE: amino acid
STRANDEDNESS: not relevant
TOPOLOGY: not relevant
MOLECULE TYPE: protein
US-08-884-235-10

Query Match 100.0%; Score 19; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
Db 4 AOGV 7

RESULT 2
US-10-122-675-28
Sequence 28, Application US/10122675
Patent No. 6927031
GENERAL INFORMATION:

APPLICANT: Anderson, David
APPLICANT: Li, Weigun
APPLICANT: Li, Henry
APPLICANT: Rigel Pharmaceuticals, Inc.
TITLE OF INVENTION: Methods for Identifying Polypeptide Factors Interacting
TITLE OF INVENTION: With RNA
FILE REFERENCE: 021044-002000US
CURRENT APPLICATION NUMBER: US/10/122,675
CURRENT FILING DATE: 2002-10-31
NUMBER OF SEQ ID NOS: 29
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 28
LENGTH: 10
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: inosine
OTHER INFORMATION: monophosphate dehydrogenase (IMPDH) peptide
US-10-122-675-28

Query Match 100.0%; Score 19; DB 2; Length 10;
Best Local Similarity 100.0%; Pred. No. 97;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
|||
DB 4 AOCV 7

RESULT 3
US-09-220-415-37
Sequence 37, Application US/09220415
Patent No. 6583109
GENERAL INFORMATION:
APPLICANT: Gallo, Robert C.
APPLICANT: Bryant, Joseph
APPLICANT: Lunardi-Iekandar, Yanto
TITLE OF INVENTION: Therapeutic Polypeptides from (-hCG and Derivatives
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: Intellectual Property/Technology Law
STREET: P.O. Box 14329
CITY: Research Triangle Park
STATE: NC
COUNTRY: USA
ZIP: 27709
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: Patentin
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/220,415
FILING DATE: 24-DEC-1998
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US97/11210
FILING DATE: 24-JUN-1998
APPLICATION NUMBER: PCT/US97/11209
FILING DATE: 24-JUN-1998
APPLICATION NUMBER: PCT/US97/11448
FILING DATE: 24-JUN-1998
APPLICATION NUMBER: PCT/US97/11202
FILING DATE: 24-JUN-1998
ATTORNEY/AGENT INFORMATION:
NAME: Steven J. Hultquist
REGISTRATION NUMBER: 28,021
REFERENCE/DOCKET NUMBER: 4115-116
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-419-9350
TELEFAX: 919-419-9354
INFORMATION FOR SEQ ID NO: 37:
SEQUENCE CHARACTERISTICS:

LENGTH: 15 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-220-415-37

Query Match 100.0%; Score 19; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
|||
DB 3 AOCV 6

RESULT 4
US-09-675-776-37
Sequence 37, Application US/09675776
Patent No. 6596688
GENERAL INFORMATION:
APPLICANT: Gallo, Robert C.
APPLICANT: Bryant, Joseph
APPLICANT: Lunardi-Iekandar, Yanto
TITLE OF INVENTION: METHOD FOR PROMOTING HEMATOPOIESIS
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: Intellectual Property/Technology Law
STREET: P.O. Box 14329
CITY: Research Triangle Park
STATE: NC
COUNTRY: USA
ZIP: 27709
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: Patentin
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/675,776
FILING DATE: 29-Sep-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/220,415
FILING DATE: 24-DEC-1998
APPLICATION NUMBER: PCT/US97/11210
FILING DATE: 24-JUN-1998
APPLICATION NUMBER: PCT/US97/11209
FILING DATE: 24-JUN-1998
APPLICATION NUMBER: PCT/US97/11448
FILING DATE: 24-JUN-1998
APPLICATION NUMBER: PCT/US97/11202
FILING DATE: 24-JUN-1998
ATTORNEY/AGENT INFORMATION:
NAME: Marianne Fulerer
REGISTRATION NUMBER: 39,983
REFERENCE/DOCKET NUMBER: 4115-116 DIV2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-419-9350
TELEFAX: 919-419-9354
INFORMATION FOR SEQ ID NO: 37:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 37:
US-09-675-776-37

Query Match 100.0%; Score 19; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOV 4
Db 3 AOV 6

RESULT 5

US-09-676-739-37

; Sequence 37, Application US/09676739

; Patent No. 6620416

; GENERAL INFORMATION:

APPLICANT: Gallo, Robert C.

Bryant, Joseph

Lunardi-Iskandar, Yanto

TITLE OF INVENTION: METHOD FOR TREATING HIV

NUMBER OF SEQUENCES: 37

CORRESPONDENCE ADDRESS:

ADDRESS: Intellectual Property/Technology Law

STREET: P.O. Box 14329

CITY: Research Triangle Park

STATE: NC

COUNTRY: USA

ZIP: 27709

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: PatentIn

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/676,739

FILING DATE: 29-Sep-2000

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 09/220,415

FILING DATE: 24-DEC-1998

APPLICATION NUMBER: PCT/US97/11210

FILING DATE: 24-JUN-1998

APPLICATION NUMBER: PCT/US97/11209

FILING DATE: 24-JUN-1998

APPLICATION NUMBER: PCT/US97/11448

FILING DATE: 24-JUN-1998

APPLICATION NUMBER: PCT/US97/11202

FILING DATE: 24-JUN-1998

ATTORNEY/AGENT INFORMATION:

NAME: Marianne Fullerer

REGISTRATION NUMBER: 39,983

REFERENCE/DOCKET NUMBER: 4115-116 DIV1

TELECOMMUNICATION INFORMATION:

TELEPHONE: 919-419-9350

TELEFAX: 919-419-9354

INFORMATION FOR SEQ ID NO: 37:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: protein

SEQUENCE DESCRIPTION: SEQ ID NO: 37:

US-09-676-739-37

Query Match 100.0%; Score 19; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOV 4
Db 3 AOV 6

RESULT 6

US-09-675-362-37

; Sequence 37, Application US/09675362

; Patent No. 6699834

GENERAL INFORMATION:
APPLICANT: Gallo, Robert C.

Bryant, Joseph

Lunardi-Iskandar, Yanto

TITLE OF INVENTION: METHOD FOR TREATING CANCER

NUMBER OF SEQUENCES: 37

CORRESPONDENCE ADDRESS:

ADDRESS: Intellectual Property/Technology Law

STREET: P.O. Box 14329

CITY: Research Triangle Park

STATE: NC

COUNTRY: USA

ZIP: 27709

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: PatentIn

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/675,362

FILING DATE: 29-Sep-2000

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 09/220,415

FILING DATE: 24-DEC-1998

APPLICATION NUMBER: PCT/US97/11210

FILING DATE: 24-JUN-1998

APPLICATION NUMBER: PCT/US97/11209

FILING DATE: 24-JUN-1998

APPLICATION NUMBER: PCT/US97/11448

FILING DATE: 24-JUN-1998

APPLICATION NUMBER: PCT/US97/11202

FILING DATE: 24-JUN-1998

ATTORNEY/AGENT INFORMATION:

NAME: Marianne Fullerer

REGISTRATION NUMBER: 39,983

REFERENCE/DOCKET NUMBER: 4115-116 DIV3

TELECOMMUNICATION INFORMATION:

TELEPHONE: 919-419-9354

TELEFAX: 919-419-9350

INFORMATION FOR SEQ ID NO: 37:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: protein

SEQUENCE DESCRIPTION: SEQ ID NO: 37:

US-09-675-362-37

Query Match 100.0%; Score 19; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOV 4
Db 3 AOV 6

RESULT 7

US-09-677-152-37

; Sequence 37, Application US/09677152

; Patent No. 6805882

; GENERAL INFORMATION:

APPLICANT: Gallo, Robert C.

Bryant, Joseph

Lunardi-Iskandar, Yanto

TITLE OF INVENTION: Therapeutic Fractions of Sources of hCG

NUMBER OF SEQUENCES: 37

CORRESPONDENCE ADDRESS:

ADDRESS: Intellectual Property/Technology Law

STREET: P.O. Box 14329

CITY: Research Triangle Park

```
/ STATE: NC
/ COUNTRY: USA
/ ZIP: 27709
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: DOS
/ SOFTWARE: Patentin
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/677,152
/ FILING DATE: 02-Oct-2000
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US97/11210
/ FILING DATE: 24-JUN-1998
/ APPLICATION NUMBER: PCT/US97/11209
/ FILING DATE: 24-JUN-1998
/ APPLICATION NUMBER: PCT/US97/11448
/ FILING DATE: 24-JUN-1998
/ APPLICATION NUMBER: PCT/US97/11202
/ FILING DATE: 24-JUN-1998
/ APPLICATION NUMBER: USSN 09/220,415
/ FILING DATE: <Unknown>
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Steven J. Hultquist
/ REGISTRATION NUMBER: 28,021
/ REFERENCE/DOCKET NUMBER: 4115-116
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 919-419-9350
/ TELEFAX: 919-419-9354
/ INFORMATION FOR SEQ ID NO: 37:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/ SEQUENCE DESCRIPTION: SEQ ID NO: 37:
US-09-677-152-37

Query Match      100.0%; Score 19; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
      ||||
Db      3 ACGV 6

RESULT 8
US-10-394-980-6
/ Sequence 6, Application US/10394980
/ Patent No. 6908740
/ GENERAL INFORMATION:
/ APPLICANT: Vandekerckhove, Joel
/ TITLE OF INVENTION: METHODS AND APPARATUS FOR GEL-FREE QUALITATIVE AND
/ FILE OF INVENTION: QUANTITATIVE PROTEOME ANALYSIS, AND USES THEREFOR
/ CURRENT APPLICATION NUMBER: US/10/394,980
/ CURRENT FILING DATE: 2003-03-21
/ PRIOR APPLICATION NUMBER: PCT/EP02/03368
/ PRIOR FILING DATE: 2002-03-22
/ PRIOR APPLICATION NUMBER: US60/278,171
/ PRIOR FILING DATE: 2001-03-22
/ PRIOR APPLICATION NUMBER: US60/318,749
/ PRIOR FILING DATE: 2001-09-12
/ PRIOR APPLICATION NUMBER: US60/323,999
/ PRIOR FILING DATE: 2001-09-20
/ NUMBER OF SEQ ID NOS: 473
/ SOFTWARE: Patentin version 3.1
/ SEQ ID NO 6
/ LENGTH: 19
```

```
/ TYPE: PRT
/ ORGANISM: Homo sapiens
/ FEATURE:
/ NAME/KEY: MISC FEATURE
/ OTHER INFORMATION: part of AMBP_HUMAN (P02760) alphae-1-microglobulin)
US-10-394-980-6

Query Match      100.0%; Score 19; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
      ||||
Db      3 ACGV 6

RESULT 9
US-09-936-588-8
/ Sequence 8, Application US/09936588
/ Patent No. 6858775
/ GENERAL INFORMATION:
/ APPLICANT: XU, Ming-Qun
/ APPLICANT: EVANS, Thomas C.
/ APPLICANT: PRADHAN, Sriharsha
/ APPLICANT: COMB, Donald G.
/ APPLICANT: PAULUS, Henry
/ APPLICANT: SUN, Luo
/ APPLICANT: CHEN, Lixin
/ APPLICANT: GHOSH, Inca
/ APPLICANT: NEW ENGLAND BIOLOGICALS, INC.
/ APPLICANT: BOSTON BIOMEDICAL RESEARCH INSTITUTE
/ TITLE OF INVENTION: METHOD FOR GENERATING SPLIT, NON-TRANSFERABLE GENES
/ FILE OF INVENTION: THAT ARE ABLE TO EXPRESS AN ACTIVE PROTEIN PRODUCT
/ CURRENT APPLICATION NUMBER: US/09/936,588
/ CURRENT FILING DATE: 2001-09-13
/ PRIOR APPLICATION NUMBER: 60/135,677
/ PRIOR FILING DATE: 1999-05-24
/ NUMBER OF SEQ ID NOS: 134
/ SOFTWARE: Patentin Ver. 2.0
/ SEQ ID NO 8
/ LENGTH: 21
/ TYPE: PRT
/ ORGANISM: Escherichia coli
US-09-936-588-8

Query Match      100.0%; Score 19; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ACGV 4
      ||||
Db      11 ACGV 14

RESULT 10
US-08-482-142-24
/ Sequence 24, Application US/08482142
/ Patent No. 5820862
/ GENERAL INFORMATION:
/ APPLICANT: Garman, Richard
/ APPLICANT: Greenstein, Julia
/ APPLICANT: Kuo, Mei-chang
/ APPLICANT: Rogers, Bruce
/ APPLICANT: Franzén, Henry
/ APPLICANT: Chen, Xian
/ APPLICANT: Evans, Sean
/ APPLICANT: Shaked, Ze'ev
/ TITLE OF INVENTION: T CELL EPITOPES OF THE MAJOR ALLERGENS
/ FILE OF INVENTION: FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
/ NUMBER OF SEQUENCES: 207
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: IMMUNOLOGIC PHARMACEUTICAL CORPORATION
```

STREET: 610 LINCOLN STREET
CITY: WALTHAM
STATE: MA
COUNTRY: USA
ZIP: 02154
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII TEXT
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,142
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/445,307
FILING DATE: 07 June 1995
ATTORNEY/AGENT INFORMATION:
NAME: CRAIG, ANNE I.
REGISTRATION NUMBER: 32,976
REFERENCE/DOCKET NUMBER: 017.6US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 466-6000
TELEFAX: (617) 466-6040
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: N-terminal
US-08-482-142-24

Query Match 100.0%; Score 19; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGGV 4
Db 11 AAGV 14

RESULT 11
US-08-478-572-24
Sequence 24, Application US/08478572
Patent No. 5968526
GENERAL INFORMATION:
APPLICANT: Garman, Richard
APPLICANT: Greenstein, Julia
APPLICANT: Kuo, Mei-chang
APPLICANT: Rogers, Bruce
APPLICANT: Franzen, Henry
APPLICANT: Chen, Xian
APPLICANT: Evans, Sean
APPLICANT: Shaked, Ze'ev
TITLE OF INVENTION: T CELL EPITOPES OF THE MAJOR ALLERGENS
TITLE OF INVENTION: FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
NUMBER OF SEQUENCES: 207
CORRESPONDENCE ADDRESSES:
ADDRESSEE: IMMUNOLOGIC PHARMACEUTICAL CORPORATION
STREET: 610 LINCOLN STREET
CITY: WALTHAM
STATE: MA
COUNTRY: USA
ZIP: 02154
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII TEXT
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/478,572
FILING DATE: 07-June-1995

CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/445,307
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: CRAIG, ANNE I.
REGISTRATION NUMBER: 32,976
REFERENCE/DOCKET NUMBER: 017.6US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 466-6000
TELEFAX: (617) 466-6040
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: N-terminal
US-08-478-572-24

Query Match 100.0%; Score 19; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGGV 4
Db 11 AAGV 14

RESULT 12
US-08-484-296-24
Sequence 24, Application US/08484296
Patent No. 6268491
GENERAL INFORMATION:
APPLICANT: Garman, Richard
APPLICANT: Greenstein, Julia
APPLICANT: Kuo, Mei-chang
APPLICANT: Rogers, Bruce
APPLICANT: Franzen, Henry
APPLICANT: Chen, Xian
APPLICANT: Evans, Sean
APPLICANT: Shaked, Ze'ev
TITLE OF INVENTION: T CELL EPITOPES OF THE MAJOR ALLERGENS
TITLE OF INVENTION: FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
NUMBER OF SEQUENCES: 207
CORRESPONDENCE ADDRESSES:
ADDRESSEE: IMMUNOLOGIC PHARMACEUTICAL CORPORATION
STREET: 610 LINCOLN STREET
CITY: WALTHAM
STATE: MA
COUNTRY: USA
ZIP: 02154
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII TEXT
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,296
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/445,307
FILING DATE: 07 June 1995
ATTORNEY/AGENT INFORMATION:
NAME: CRAIG, ANNE I.
REGISTRATION NUMBER: 32,976
REFERENCE/DOCKET NUMBER: 017.6US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 466-6000
TELEFAX: (617) 466-6040
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:

LENGTH: 22 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: N-terminal
US-08-484-296-24

Query Match 100.0%; Score 19; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 11 ACGV 14

RESULT 13
PCT-US95-04481-15

Sequence 15, Application PC/TUS9504481
GENERAL INFORMATION:

APPLICANT: Pharmaceutical Peptide Formulations For Treatment of Dust Mit

TITLE OF INVENTION: 54

NUMBER OF SEQUENCES: 54

COMPUTER READABLE FORM: FLOPPY disk

MEDIUM TYPE: FLOPPY disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent in Release #1.0, Version #1.30 (ERO)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US95/04481

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/227,772

FILING DATE: April 14, 1994

ATTORNEY/AGENT INFORMATION:

NAME: Vanstone, Darlene A.

REGISTRATION NUMBER: 35,279

REFERENCE/DOCKET NUMBER: 017.5 PCT

TELECOMMUNICATION INFORMATION:

TELEPHONE: (617) 466-6000

TELEFAX: (617) 466-6040

INFORMATION FOR SEQ ID NO: 15:

SEQUENCE CHARACTERISTICS:

LENGTH: 22 amino acids

TYPE: amino acid

STRANDEDNESS:

TOPOLOGY: linear

MOLECULE TYPE: peptide

FRAGMENT TYPE: internal

PCT-US95-04481-15

Query Match 100.0%; Score 19; DB 4; Length 22;

Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 11 ACGV 14

RESULT 14
US-08-482-142-40

Sequence 40, Application US/08482142
GENERAL INFORMATION:

APPLICANT: Garman, Richard

APPLICANT: Greenstein, Julia

APPLICANT: Kuo, Mei-chang

APPLICANT: Rogers, Bruce

APPLICANT: Franzen, Henry

APPLICANT: Chen, Xian

APPLICANT: Evans, Sean

APPLICANT: Shaked, Ze'ev
TITLE OF INVENTION: T CELL EPITOPES OF THE MAJOR ALLERGENS
FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
NUMBER OF SEQUENCES: 207
CORRESPONDENCE ADDRESS:
ADDRESS: IMMUNOLOGIC PHARMACEUTICAL CORPORATION
STREET: 610 LINCOLN STREET
CITY: WALTHAM
STATE: MA
COUNTRY: USA
ZIP: 02154

COMPUTER READABLE FORM: FLOPPY disk
MEDIUM TYPE: FLOPPY disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII TEXT

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,142
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/445,307
FILING DATE: 07 June 1995

ATTORNEY/AGENT INFORMATION:
NAME: CRAIG, ANNE I.

REGISTRATION NUMBER: 32,976

REFERENCE/DOCKET NUMBER: 017.6US

TELECOMMUNICATION INFORMATION:

TELEPHONE: (617) 466-6000

TELEFAX: (617) 466-6040

INFORMATION FOR SEQ ID NO: 40:

SEQUENCE CHARACTERISTICS:

LENGTH: 23 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

FRAGMENT TYPE: N-terminal

US-08-482-142-40

Query Match 100.0%; Score 19; DB 1; Length 23;

Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 8 ACGV 11

RESULT 15
US-08-478-572-40

Sequence 40, Application US/08478572
GENERAL INFORMATION:

APPLICANT: Garman, Richard

APPLICANT: Greenstein, Julia

APPLICANT: Kuo, Mei-chang

APPLICANT: Rogers, Bruce

APPLICANT: Franzen, Henry

APPLICANT: Chen, Xian

APPLICANT: Evans, Sean

APPLICANT: Shaked, Ze'ev

TITLE OF INVENTION: T CELL EPITOPES OF THE MAJOR ALLERGENS
FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
NUMBER OF SEQUENCES: 207
CORRESPONDENCE ADDRESS:
ADDRESS: IMMUNOLOGIC PHARMACEUTICAL CORPORATION
STREET: 610 LINCOLN STREET
CITY: WALTHAM
STATE: MA
COUNTRY: USA
ZIP: 02154
COMPUTER READABLE FORM: FLOPPY disk
MEDIUM TYPE: FLOPPY disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII TEXT
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/478,572
FILING DATE: 07-June-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/445,307
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: CRAIG, ANNE I.
REGISTRATION NUMBER: 32,976
REFERENCE/DOCKET NUMBER: 017.6US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 466-6000
TELEFAX: (617) 466-6040
INFORMATION FOR SEQ ID NO: 40:
SEQUENCE CHARACTERISTICS:
LENGTH: 23 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: N-terminal
US-08-478-572-40

Query Match 100.0%; Score 19; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGV 4
Db 8 AGV 11

RESULT 16
US-08-484-296-40
Sequence 40, Application US/08484296
Patent No. 6268491
GENERAL INFORMATION:
APPLICANT: Garman, Richard
APPLICANT: Greenstein, Julia
APPLICANT: Kuo, Mei-chang
APPLICANT: Rogers, Bruce
APPLICANT: Franzen, Henry
APPLICANT: Chen, Xian
APPLICANT: Evans, Sean
APPLICANT: Shaked, Ze'ev
TITLE OF INVENTION: T CELL EPITOPES OF THE MAJOR ALLERGENS
TITLE OF INVENTION: FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
NUMBER OF SEQUENCES: 207
CORRESPONDENCE ADDRESS:
ADDRESSEE: IMMUNOLOGIC PHARMACEUTICAL CORPORATION
STREET: 610 LINCOLN STREET
CITY: WALTHAM
STATE: MA
COUNTRY: USA
ZIP: 02154
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII TEXT
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,296
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/445,307
FILING DATE: 07 June 1995
ATTORNEY/AGENT INFORMATION:
NAME: CRAIG, ANNE I.
REGISTRATION NUMBER: 32,976

REFERENCE/DOCKET NUMBER: 017.6US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 466-6000
TELEFAX: (617) 466-6040
INFORMATION FOR SEQ ID NO: 40:
SEQUENCE CHARACTERISTICS:
LENGTH: 23 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: N-terminal
US-08-484-296-40

Query Match 100.0%; Score 19; DB 2; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGV 4
Db 8 AGV 11

RESULT 17
US-08-933-1008-3
Sequence 3, Application US/089331008
Patent No. 6274704
GENERAL INFORMATION:
APPLICANT: FUKAI, FUMIO
APPLICANT: KATAYAMA, TAKASHI
TITLE OF INVENTION: BIOLOGICALLY ACTIVE PEPTIDE AND CANCER
TITLE OF INVENTION: METASTASIS INHIBITOR
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: PILLSBURY, MADISON & SUTRO
STREET: 1100 NEW YORK AVENUE, N.W.
CITY: WASHINGTON
STATE: D.C.
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/933,100B
FILING DATE: 18-SEP-1997
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: PERRY, GLENN
REGISTRATION NUMBER: 28458
REFERENCE/DOCKET NUMBER: 7898/242094
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-861-3000
TELEFAX: 202-822-0944
TELEX: 6714627 CUSH
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 23 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
FEATURE:
OTHER INFORMATION: Sequence of a part (1669 - 1691) of Heparin binding site
Patent No. 6274704
US-08-933-1008-3

Query Match 100.0%; Score 19; DB 2; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGV 4

Db 15 AOCV 18

RESULT 18
US-08-141-324-22
Sequence 22, Application US/08141324
Patent No. 5475097

GENERAL INFORMATION:

APPLICANT: Travis, James

APPLICANT: Potempa, Jan S.

APPLICANT: Barr, Philip J.

APPLICANT: Pavloff, Nadine

APPLICANT: Pike, Robert N.

TITLE OF INVENTION: Lysine-specific Porphyromonas gingivalis

TITLE OF INVENTION: Protease

NUMBER OF SEQUENCES: 28

CORRESPONDENCE ADDRESS:

ADDRESSEE: Greenlee and Winner, P.C.

STREET: 5370 Manhattan Circle, Suite 201

CITY: Boulder

STATE: CO

COUNTRY: US

ZIP: 80303

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent in Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/141,324

FILING DATE: 21-OCT-1993

CLASSIFICATION: 424

ATTORNEY/AGENT INFORMATION:

NAME: Ferber, Donna M.

REGISTRATION NUMBER: 33,878

REFERENCE/DOCKET NUMBER: 44-93

TELECOMMUNICATION INFORMATION:

TELEPHONE: 303-499-8080

TELEFAX: 303-499-8089

INFORMATION FOR SEQ ID NO: 22:

SEQUENCE CHARACTERISTICS:

LENGTH: 24 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: protein

HYPOTHETICAL: NO

ANTI-SENSE: NO

FRAGMENT TYPE: Internal

US-08-141-324-22

QY 1 AOCV 4

Db 11 AOCV 14

Query Match 100.0%; Score 19; DB 1; Length 24;

Best Local Similarity 100.0%; Pred. No. 2.4e+02;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 19

US-08-541-902-22

Sequence 22, Application US/08541902

Patent No. 5707620

GENERAL INFORMATION:

APPLICANT: Travis, James

APPLICANT: Potempa, Jan S.

APPLICANT: Barr, Philip J.

APPLICANT: Pavloff, Nadine

APPLICANT: Pike, Robert N.

TITLE OF INVENTION: Lysine-specific Porphyromonas gingivalis

NUMBER OF SEQUENCES: 28
CORRESPONDENCE ADDRESS:
ADDRESSEE: Greenlee and Winner, P.C.
STREET: 5370 Manhattan Circle, Suite 201
CITY: Boulder

STATE: CO

COUNTRY: US

ZIP: 80303

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent in Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/541,902

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/141,324

FILING DATE: 21-OCT-1993

ATTORNEY/AGENT INFORMATION:

NAME: Ferber, Donna M.

REGISTRATION NUMBER: 33,878

REFERENCE/DOCKET NUMBER: 44-93

TELECOMMUNICATION INFORMATION:

TELEPHONE: 303-499-8080

TELEFAX: 303-499-8089

INFORMATION FOR SEQ ID NO: 22:

SEQUENCE CHARACTERISTICS:

LENGTH: 24 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: protein

HYPOTHETICAL: NO

ANTI-SENSE: NO

FRAGMENT TYPE: Internal

US-08-541-902-22

QY 1 AOCV 4

Db 11 AOCV 14

Query Match 100.0%; Score 19; DB 1; Length 24;

Best Local Similarity 100.0%; Pred. No. 2.4e+02;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 20

US-08-482-142-38

Sequence 38, Application US/08482142

Patent No. 5820862

GENERAL INFORMATION:

APPLICANT: Garman, Richard

APPLICANT: Greenstein, Julia

APPLICANT: Kuo, Wei-chang

APPLICANT: Rogers, Bruce

APPLICANT: Franzen, Henry

APPLICANT: Chen, Xian

APPLICANT: Evans, Sean

APPLICANT: Shaked, Ze'ev

TITLE OF INVENTION: T CELL EPITOPES OF THE MAJOR ALLERGENS

TITLE OF INVENTION: FROM DERMATOPHAGOIDES (HOUSE DUST MITE)

NUMBER OF SEQUENCES: 207

CORRESPONDENCE ADDRESS:

ADDRESSEE: IMMUNOLOGIC PHARMACEUTICAL CORPORATION

STREET: 610 LINCOLN STREET

CITY: WALTHAM

STATE: MA

COUNTRY: USA

ZIP: 02154

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII TEXT
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482.142
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/445.307
FILING DATE: 07 June 1995
ATTORNEY/AGENT INFORMATION:
NAME: CRAIG, ANNE I.
REGISTRATION NUMBER: 32.976
REFERENCE/DOCKET NUMBER: 017.6US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 466-6000
TELEFAX: (617) 466-6040
INFORMATION FOR SEQ ID NO: 38:
SEQUENCE CHARACTERISTICS:
LENGTH: 25 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: N-terminal
US-08-482-142-38

Query Match 100.0%; Score 19; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
DB 20 AOGV 23

RESULT 21
US-08-478-572-38
Sequence 38, Application US/08478572
Patent No. 5968526
GENERAL INFORMATION:
APPLICANT: Garman, Richard
APPLICANT: Greenstein, Julia
APPLICANT: Kuo, Mei-chang
APPLICANT: Rogers, Bruce
APPLICANT: Franzen, Henry
APPLICANT: Chen, Xian
APPLICANT: Evans, Sean
APPLICANT: Shaked, Ze'ev
TITLE OF INVENTION: T CELL EPITOPES OF THE MAJOR ALLERGENS
FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
NUMBER OF SEQUENCES: 207
CORRESPONDENCE ADDRESS:
ADDRESSEE: IMMUNOLOGIC PHARMACEUTICAL CORPORATION
STREET: 610 LINCOLN STREET
CITY: WALTHAM
STATE: MA
COUNTRY: USA
ZIP: 02154
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII TEXT
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/478.572
FILING DATE: 07-June-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/445.307
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: CRAIG, ANNE I.
REGISTRATION NUMBER: 32.976

REFERENCE/DOCKET NUMBER: 017.6US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 466-6000
TELEFAX: (617) 466-6040
INFORMATION FOR SEQ ID NO: 38:
SEQUENCE CHARACTERISTICS:
LENGTH: 25 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: N-terminal
US-08-478-572-38

Query Match 100.0%; Score 19; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
DB 20 AOGV 23

RESULT 22
US-08-484-296-38
Sequence 38, Application US/08484296
Patent No. 6268491
GENERAL INFORMATION:
APPLICANT: Garman, Richard
APPLICANT: Greenstein, Julia
APPLICANT: Kuo, Mei-chang
APPLICANT: Rogers, Bruce
APPLICANT: Franzen, Henry
APPLICANT: Chen, Xian
APPLICANT: Evans, Sean
APPLICANT: Shaked, Ze'ev
TITLE OF INVENTION: T CELL EPITOPES OF THE MAJOR ALLERGENS
FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
NUMBER OF SEQUENCES: 207
CORRESPONDENCE ADDRESS:
ADDRESSEE: IMMUNOLOGIC PHARMACEUTICAL CORPORATION
STREET: 610 LINCOLN STREET
CITY: WALTHAM
STATE: MA
COUNTRY: USA
ZIP: 02154
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII TEXT
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484.296
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/445.307
FILING DATE: 07 June 1995
ATTORNEY/AGENT INFORMATION:
NAME: CRAIG, ANNE I.
REGISTRATION NUMBER: 32.976
REFERENCE/DOCKET NUMBER: 017.6US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 466-6000
TELEFAX: (617) 466-6040
INFORMATION FOR SEQ ID NO: 38:
SEQUENCE CHARACTERISTICS:
LENGTH: 25 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: N-terminal
US-08-484-296-38

Query Match 100.0%; Score 19; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 20 ACGV 23

RESULT 23
US-09-596-120-9
; Sequence 9, Application US/09596120
; Patent No. 6517838
; GENERAL INFORMATION:
; APPLICANT: Hook, Magnus A.
; APPLICANT: Brown, Eric L.
; TITLE OF INVENTION: Decotin Binding Proteins Essential Peptides and Methods of Use
; FILE REFERENCE: 12740.0210.NPUS00 (TWAK:210)
; CURRENT APPLICATION NUMBER: US/09/596,120
; CURRENT FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 9
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligopeptide
US-09-596-120-9

Query Match 100.0%; Score 19; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 10 ACGV 13

RESULT 24
US-07-879-685B-2
; Sequence 2, Application US/07879685B
; Patent No. 5296383
; GENERAL INFORMATION:
; APPLICANT: DAIKIN INDUSTRIES, LTD.
; TITLE OF INVENTION: A human centromere antigen
; TITLE OF INVENTION: polypeptide
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Umeda Center Building, 4-12
; STREET: Nakazaki-nishi, 2-chome
; CITY: Kita-ku
; STATE: Osaka
; COUNTRY: Japan
; ZIP: 530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/879,685B
; FILING DATE: 19920507
; CLASSIFICATION: 436
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 3-102517
; FILING DATE: 08-May-1991
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: peptide

; FRAGMENT TYPE: internal fragment
; ORIGINAL SOURCE:
; ORGANISM: human
US-07-879-685B-2

Query Match 100.0%; Score 19; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 11 ACGV 14

RESULT 25
US-08-821-119-6
; Sequence 6, Application US/08821119
; Patent No. 5821104
; GENERAL INFORMATION:
; APPLICANT: Holm, Kaj Andre
; APPLICANT: Rasmussen, Grethe
; APPLICANT: Halkier, Torben
; APPLICANT: Lembeck, Jan
; TITLE OF INVENTION: tripeptidyl Aminopeptidase
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5821104o No. 5821104disk of No. 5821104th America, Inc.
; STREET: 405 Lexington Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10174
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/821,119
; FILING DATE: 19-MAR-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Lambiris, Elias J
; REGISTRATION NUMBER: 33,728
; REFERENCE/DOCKET NUMBER: 4107.204-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-878-9655
; TELEX:
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. 5821104e
US-08-821-119-6

Query Match 100.0%; Score 19; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 17 ACGV 20

RESULT 26
US-08-900-660A-6
; Sequence 6, Application US/08900660A
; Patent No. 5876947
; GENERAL INFORMATION:
; APPLICANT: Kudryk, Bohdan J

APPLICANT: Bini, Alessandra
APPLICANT: Zhang, Jian-zhong
TITLE OF INVENTION: MONOSPECIFIC ANTIBODY REACTIVE
TITLE OF INVENTION: WITH FIBRINOGEN AND
TITLE OF INVENTION: FIBRINOPEPTIDE B
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hoffmann & Baron, LLP
STREET: 350 Jericho Turnpike
CITY: Jericho
STATE: New York
COUNTRY: USA
ZIP: 11753
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/900,660A
FILING DATE: 25-JUL-1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Baron, Ronald J
REGISTRATION NUMBER: 29281
REFERENCE/DOCKET NUMBER: 454-15
TELECOMMUNICATION INFORMATION:
TELEPHONE: 516 822 3550
TELEFAX: 516 822 3582
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-900-660A-6

Query Match 100.0%; Score 19; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
Db 21 AOGV 24

RESULT 27
US-08-482-142-39
Sequence 39, Application US/08482142
Patent No. 5620862
GENERAL INFORMATION:
APPLICANT: Garman, Richard
APPLICANT: Greenstein, Julia
APPLICANT: Kuo, Mei-chang
APPLICANT: Rogers, Bruce
APPLICANT: Franzen, Henry
APPLICANT: Evans, Sean
APPLICANT: Shaked, Ze'ev
TITLE OF INVENTION: T CELL EPITOPES OF THE MAJOR ALLERGENS
TITLE OF INVENTION: FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
NUMBER OF SEQUENCES: 207
CORRESPONDENCE ADDRESS:
ADDRESSEE: IMMUNOLOGIC PHARMACEUTICAL CORPORATION
STREET: 610 LINCOLN STREET
CITY: WALTHAM
STATE: MA
COUNTRY: USA
ZIP: 02154
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: ASCII TEXT
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,142
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/445,307
FILING DATE: 07 June 1995
ATTORNEY/AGENT INFORMATION:
NAME: CRAIG, ANNE I.
REGISTRATION NUMBER: 32,976
REFERENCE/DOCKET NUMBER: 017.6US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 466-6000
TELEFAX: (617) 466-6040
INFORMATION FOR SEQ ID NO: 39:
SEQUENCE CHARACTERISTICS:
LENGTH: 29 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: N-terminal
US-08-482-142-39

Query Match 100.0%; Score 19; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
Db 8 AOGV 11

RESULT 28
US-08-478-572-39
Sequence 39, Application US/08478572
Patent No. 568526
GENERAL INFORMATION:
APPLICANT: Garman, Richard
APPLICANT: Greenstein, Julia
APPLICANT: Kuo, Mei-chang
APPLICANT: Rogers, Bruce
APPLICANT: Franzen, Henry
APPLICANT: Evans, Sean
APPLICANT: Shaked, Ze'ev
TITLE OF INVENTION: T CELL EPITOPES OF THE MAJOR ALLERGENS
TITLE OF INVENTION: FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
NUMBER OF SEQUENCES: 207
CORRESPONDENCE ADDRESS:
ADDRESSEE: IMMUNOLOGIC PHARMACEUTICAL CORPORATION
STREET: 610 LINCOLN STREET
CITY: WALTHAM
STATE: MA
COUNTRY: USA
ZIP: 02154
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII TEXT
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/478,572
FILING DATE: 07-June-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/445,307
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: CRAIG, ANNE I.
REGISTRATION NUMBER: 32,976
REFERENCE/DOCKET NUMBER: 017.6US
TELECOMMUNICATION INFORMATION:

TELEPHONE: (617) 466-6000
TELEFAX: (617) 466-6040
INFORMATION FOR SEQ ID NO: 39:
SEQUENCE CHARACTERISTICS:
LENGTH: 29 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: N-terminal
US-08-478-572-39

Query Match 100.0%; Score 19; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
DB 8 ACGV 11

RESULT 29
US-08-484-296-39
Sequence 39, Application US/08484296
Patent No. 6268491
GENERAL INFORMATION:
APPLICANT: Garman, Richard
APPLICANT: Greenstein, Julia
APPLICANT: Kuo, Mei-chang
APPLICANT: Rogers, Bruce
APPLICANT: Franzen, Henry
APPLICANT: Chen, Xian
APPLICANT: Evans, Sean
APPLICANT: Shaked, Zeev
TITLE OF INVENTION: T CELL EPITOPES OF THE MAJOR ALLERGENS
TITLE OF INVENTION: FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
NUMBER OF SEQUENCES: 207
CORRESPONDENCE ADDRESS:
ADDRESSEE: IMMUNOLOGIC PHARMACEUTICAL CORPORATION
STREET: 610 LINCOLN STREET
CITY: WALTHAM
STATE: MA
COUNTRY: USA
ZIP: 02154
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII TEXT
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,296
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/445,307
FILING DATE: 07 June 1995
ATTORNEY/AGENT INFORMATION:
NAME: CRAIG, ANNE I.
REGISTRATION NUMBER: 32,976
REFERENCE/DOCKET NUMBER: 017.6US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 466-6000
TELEFAX: (617) 466-6040
INFORMATION FOR SEQ ID NO: 39:
SEQUENCE CHARACTERISTICS:
LENGTH: 29 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: N-terminal
US-08-484-296-39

Query Match 100.0%; Score 19; DB 2; Length 29;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ACGV 4
|||
DB 8 ACGV 11

RESULT 30
US-07-700-526-7
Sequence 7, Application US/07700526
Patent No. 516133
GENERAL INFORMATION:
APPLICANT: Houston, L. L.
APPLICANT: Liu, David Y.
APPLICANT: Kaymakalan, Zehra
TITLE OF INVENTION: Method for Inhibiting Adhesion of White
TITLE OF INVENTION: Blood Cells to Endothelial Cells
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cetus Corporation
STREET: 1400 Fifty-Third Street
CITY: Emeryville
STATE: CA
COUNTRY: USA
ZIP: 94608
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/700,526
FILING DATE: 19910816
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: McGarrigle Jr., Philip L.
REGISTRATION NUMBER: 31,395
REFERENCE/DOCKET NUMBER: 2600.1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 420-3217
TELEFAX: (415) 658-5239
TELEX: 4992659
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 34 amino acids
TYPE: AMINO ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
US-07-700-526-7

Query Match 100.0%; Score 19; DB 1; Length 34;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
DB 18 ACGV 21

Search completed: February 21, 2006, 08:57:28
Job time : 34 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: February 21, 2006, 08:56:53 ; Search time 133 Seconds
(without alignments)
13.214 Million cell updates/sec

Title: US-10-821-256-2

Perfect score: 19

Sequence: 1 AQCIV 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 6981

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 100%

Maximum Match 100%

Listing first 500 summaries

Database :

1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*
9: geneseqp2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	ID	Description
1	19	100.0	4 7 ADC97878	ADC97878 Signalin
2	19	100.0	4 7 ADC97891	ADC97891 Signalin
3	19	100.0	4 7 ADC98118	ADC98118 Signalin
4	19	100.0	4 7 ADC97855	ADC97855 Signalin
5	19	100.0	4 7 ADC98185	ADC98185 Signalin
6	19	100.0	4 7 ADC98145	ADC98145 Signalin
7	19	100.0	4 7 ADC97811	ADC97811 Signalin
8	19	100.0	4 7 ADN01224	ADN01224 Human nuc
9	19	100.0	4 8 ADG86532	ADG86532 NF-kappaB
10	19	100.0	4 8 ADG86590	ADG86590 NF-kappaB
11	19	100.0	4 8 ADH29151	ADH29151 Necrosis
12	19	100.0	4 8 ADG73593	ADG73593 NF-kappaB
13	19	100.0	4 8 ADG86561	ADG86561 NF-kappaB
14	19	100.0	4 8 ADI20991	ADI20991 Human nuc
15	19	100.0	4 8 ADI16437	ADI16437 NF-kappaB
16	19	100.0	4 8 ADK42374	ADK42374 Antibacte
17	19	100.0	4 8 ADM48491	ADM48491 NF-kappaB
18	19	100.0	4 8 ADO15345	ADO15345 Nuclear f
19	19	100.0	4 8 ADT08600	ADT08600 Human cho
20	19	100.0	4 8 ADT08628	ADT08628 Human cho
21	19	100.0	4 8 ADT08656	ADT08656 Human cho
22	19	100.0	4 8 ADT79351	ADT79351 Nuclear f
23	19	100.0	4 8 ADT49387	ADT49387 Human cho
24	19	100.0	4 8 ADU46871	ADU46871 Gene regu

25	19	100.0	4 9 ADY03875	ADY03875 Peptide d
26	19	100.0	4 9 ADY82494	ADY82494 Porcine h
27	19	100.0	4 9 AEA27819	AEA27819 Gene-regu
28	19	100.0	9 6 ABU11098	ABU11098 House dus
29	19	100.0	10 4 ADZ50681	ADZ50681 Y. pestis
30	19	100.0	9 9 AAG85717	AAG85717 Saccharom
31	19	100.0	10 8 ADP94302	ADP94302 Human cel
32	19	100.0	12 4 AAB35370	AAB35370 Human bet
33	19	100.0	13 4 AAB00107	AAB00107 T. lanugi
34	19	100.0	14 2 AAR49859	AAR49859 Sequence
35	19	100.0	14 4 AAM98513	AAM98513 Human pep
36	19	100.0	15 2 AAM50068	AAM50068 Human cho
37	19	100.0	15 2 AAW47508	AAW47508 Human bet
38	19	100.0	15 2 AAN50103	AAN50103 Human cho
39	19	100.0	15 5 ABB04474	ABB04474 Human end
40	19	100.0	15 8 ADH52629	ADH52629 Human cho
41	19	100.0	15 8 ADH52592	ADH52592 Human cho
42	19	100.0	15 8 ADK39780	ADK39780 Human cho
43	19	100.0	15 8 ADT90972	ADT90972 Human bet
44	19	100.0	16 2 AAR51746	AAR51746 Der p I d
45	19	100.0	16 8 ADU87133	ADU87133 Peptide d
46	19	100.0	18 5 AAU70963	AAU70963 M. tuberc
47	19	100.0	18 5 AAU70974	AAU70974 M. tuberc
48	19	100.0	18 9 ADV55657	ADV55657 G protein
49	19	100.0	18 9 ADV54661	ADV54661 G protein
50	19	100.0	18 9 ADY64079	ADY64079 Human MCS
51	19	100.0	18 9 ADY64078	ADY64078 Human MCS
52	19	100.0	19 2 AAW92548	AAW92548 Beta-acti
53	19	100.0	19 2 AAW92549	AAW92549 Beta-acti
54	19	100.0	19 6 ABB74723	ABB74723 Proteome
55	19	100.0	19 7 ADP14799	ADP14799 SLF/sjogr
56	19	100.0	19 9 ADV55698	ADV55698 G protein
57	19	100.0	19 9 ADV54702	ADV54702 G protein
58	19	100.0	19 9 ADX56536	ADX56536 Cardiovas
59	19	100.0	20 7 ADC99563	ADC99563 Cancer-re
60	19	100.0	20 8 ADK15603	ADK15603 Human G25
61	19	100.0	20 8 ADT36531	ADT36531 RCC-absgoc
62	19	100.0	21 4 AAB57305	AAB57305 Antigenic
63	19	100.0	22 2 AAR63638	AAR63638 DPL-16(117
64	19	100.0	22 2 AAR77133	AAR77133 Dermatoch
65	19	100.0	22 2 AAW71926	AAW71926 Dermatoch
66	19	100.0	22 2 AAW50375	AAW50375 Dermatoch
67	19	100.0	22 4 AAU18978	AAU18978 T-cell ep
68	19	100.0	23 2 AAR36414	AAR36414 DPL-28.2(
69	19	100.0	23 2 AAR51762	AAR51762 Der p I d
70	19	100.0	23 2 AAW37822	AAW37822 Peptide d
71	19	100.0	23 2 AAW71937	AAW71937 Dermatoch
72	19	100.0	23 2 AAY50391	AAY50391 Dermatoch
73	19	100.0	23 2 AAY36513	AAY36513 Fragment
74	19	100.0	23 4 AAU18994	AAU18994 T-cell ep
75	19	100.0	23 6 ADA12069	ADA12069 Human nov
76	19	100.0	24 5 ABP46165	ABP46165 Human Bly
77	19	100.0	24 5 ABP46958	ABP46958 Human Bly
78	19	100.0	24 7 ADG96992	ADG96992 scFV VHCD
79	19	100.0	24 7 ADG97785	ADG97785 scFV VHCD
80	19	100.0	25 2 AAR36412	AAR36412 DPL-27.1(
81	19	100.0	25 2 AAR51760	AAR51760 Der p I d
82	19	100.0	25 2 AAW71935	AAW71935 Dermatoch
83	19	100.0	25 2 AAY50389	AAY50389 Dermatoch
84	19	100.0	25 4 AAU21152	AAU21152 Peptide #
85	19	100.0	25 4 AAU18992	AAU18992 T-cell ep
86	19	100.0	25 4 ABB43470	ABB43470 Peptide #
87	19	100.0	25 4 AAM77363	AAM77363 Peptide #
88	19	100.0	25 4 AAM77220	AAM77220 Human bon
89	19	100.0	25 4 AAM64402	AAM64402 Human liv
90	19	100.0	25 4 ABB58847	ABB58847 Human bra
91	19	100.0	25 7 ADC26857	ADC26857 B. burgdo
92	19	100.0	25 7 ADN59708	ADN59708 Thrombopo
93	19	100.0	25 8 ABO60121	ABO60121 Human gen
94	19	100.0	25 9 ADV54693	ADV54693 G protein
95	19	100.0	25 9 ADV55689	ADV55689 G protein
96	19	100.0	26 2 AAR30640	AAR30640 Epitope o
97	19	100.0	27 2 AAR35624	AAR35624 Tripeptid

98	19	100.0	27	2	AAW97423	AAW97423	Peptide o	171	19	100.0	65	3	AA602408	AA602408	Human sec
99	19	100.0	27	9	ADX56530	ADX56530	Cardiovas	172	19	100.0	65	3	AA607706	AA607706	Arabidops
100	19	100.0	29	2	AA836413	AA836413	DPI-28.1(173	19	100.0	65	3	AA626813	AA626813	Zea maye
101	19	100.0	29	2	AA851761	AA851761	Der p I d	174	19	100.0	65	7	AB066725	AB066725	Klebsiell
102	19	100.0	29	2	AAW71936	AAW71936	Dermatoph	175	19	100.0	66	3	AA607705	AA607705	Arabidops
103	19	100.0	29	2	AA550330	AA550330	Deratoph	176	19	100.0	66	4	AA682556	AA682556	Human imm
104	19	100.0	29	4	AAU18993	AAU18993	T-cell ep	177	19	100.0	66	4	AAU53135	AAU53135	Protiomb
105	19	100.0	29	7	ADD35439	ADD35439	Streptoco	178	19	100.0	66	6	ABM49654	ABM49654	Protiomb
106	19	100.0	30	2	AAW06643	AAW06643	Human DEC	179	19	100.0	67	4	ABM71058	ABM71058	Drosophi1
107	19	100.0	30	8	ADP45511	ADP45511	Human NTD	180	19	100.0	67	8	ADU04369	ADU04369	MHV prote
108	19	100.0	30	9	ADV85620	ADV85620	Human DEC	181	19	100.0	69	3	AA626016	AA626016	Zea maye
109	19	100.0	33	3	AA827936	AA827936	Human sec	182	19	100.0	69	4	AA601158	AA601158	Novel hum
110	19	100.0	35	9	ADY97195	ADY97195	Herpes b1	183	19	100.0	69	5	AAU076429	AAU076429	Novel hum
111	19	100.0	36	9	ADX56537	ADX56537	Cardiovas	184	19	100.0	69	6	ADA21106	ADA21106	Human sec
112	19	100.0	37	2	AA825974	AA825974	Peptide m	185	19	100.0	69	7	ADA67726	ADA67726	Novel hum
113	19	100.0	37	2	AAW21614	AAW21614	Antimicro	186	19	100.0	71	3	AA65387	AA65387	Human 5'
114	19	100.0	37	2	AA192803	AA192803	SYNthetic	187	19	100.0	71	4	AA663498	AA663498	Human gas
115	19	100.0	37	7	ADC73331	ADC73331	Bovine an	188	19	100.0	71	8	ADU72951	ADU72951	Non-signa
116	19	100.0	38	8	ABO59877	ABO59877	Human gen	189	19	100.0	71	9	ADZ73942	ADZ73942	Human inc
117	19	100.0	40	9	ADZ97828	ADZ97828	Human cor	190	19	100.0	72	2	AA858812	AA858812	E. coli m
118	19	100.0	41	6	ABU17305	ABU17305	Protein e	191	19	100.0	72	2	AAW71459	AAW71459	Protein e
119	19	100.0	41	6	ABE94393	ABE94393	Human AMD	192	19	100.0	72	4	AAU07749	AAU07749	House dus
120	19	100.0	45	4	AAW42224	AAW42224	Human EST	193	19	100.0	72	4	AAW87649	AAW87649	Human imm
121	19	100.0	45	5	AB890716	AB890716	Chlamydia	194	19	100.0	72	4	AAU43630	AAU43630	Protiomb
122	19	100.0	49	2	AA869856	AA869856	Fibronect	195	19	100.0	72	6	ABU09526	ABU09526	E. coli m
123	19	100.0	49	4	AB809222	AB809222	Mouse put	196	19	100.0	72	6	ABM40149	ABM40149	Protiomb
124	19	100.0	49	8	ADN11831	ADN11831	Fibronect	197	19	100.0	72	9	AEA32550	AEA32550	marc prot
125	19	100.0	49	8	ABO54048	ABO54048	Human gen	198	19	100.0	74	5	ABP04492	ABP04492	Human ORF
126	19	100.0	51	5	AAE18040	AAE18040	Human ion	199	19	100.0	74	5	ABP32468	ABP32468	Human ORF
127	19	100.0	51	8	ADN48261	ADN48261	Thermococ	200	19	100.0	75	5	ABP64192	ABP64192	Human ORF
128	19	100.0	52	4	AA863533	AA863533	Human imm	201	19	100.0	76	2	AAW72051	AAW72051	HSV-2 ect
129	19	100.0	53	3	AA858486	AA858486	Lung canc	202	19	100.0	76	8	ABO56564	ABO56564	Human gen
130	19	100.0	53	5	ABP00538	ABP00538	Human ORF	203	19	100.0	77	8	ADL05542	ADL05542	M. catarr
131	19	100.0	54	5	AAE24593	AAE24593	Fish E93	204	19	100.0	78	4	AAU59277	AAU59277	Protiomb
132	19	100.0	55	4	AB803527	AB803527	Human mus	205	19	100.0	78	4	ABG26469	ABG26469	Novel hum
133	19	100.0	55	6	ABU12821	ABU12821	Novel hum	206	19	100.0	78	6	ABM57196	ABM57196	Protiomb
134	19	100.0	56	2	AAJ28847	AAJ28847	Human mus	207	19	100.0	79	5	ABP01669	ABP01669	Human ORF
135	19	100.0	56	3	AA841885	AA841885	Granulin	208	19	100.0	80	3	AA619634	AA619634	Human sec
136	19	100.0	56	3	AA850390	AA850390	Human unc	209	19	100.0	80	8	ADH39815	ADH39815	Fara amin
137	19	100.0	56	4	AB840247	AB840247	Human pep	210	19	100.0	81	5	ABP10494	ABP10494	Human ORF
138	19	100.0	56	4	AAW33926	AAW33926	Peptide #	211	19	100.0	82	4	AAU52713	AAU52713	Protiomb
139	19	100.0	56	4	AAW73737	AAW73737	Human bon	212	19	100.0	82	6	ABM49232	ABM49232	Novel hum
140	19	100.0	56	4	AA661034	AA661034	Human bra	213	19	100.0	83	4	AAW87125	AAW87125	Human sec
141	19	100.0	56	4	ABG55482	ABG55482	Human liv	214	19	100.0	83	4	AAW87125	AAW87125	Human imm
142	19	100.0	56	5	ABG43619	ABG43619	Human pep	215	19	100.0	84	3	AA634308	AA634308	Arabidops
143	19	100.0	56	5	ABP42752	ABP42752	Human ova	216	19	100.0	84	4	AB865061	AB865061	Drosophi1
144	19	100.0	56	8	ADL27363	ADL27363	Amino aci	217	19	100.0	84	4	AAU61282	AAU61282	Protiomb
145	19	100.0	58	5	ABP07528	ABP07528	Human ORF	218	19	100.0	84	4	ABG05322	ABG05322	Novel hum
146	19	100.0	58	8	ABO59983	ABO59983	Human gen	219	19	100.0	84	4	ABG89210	ABG89210	Human sec
147	19	100.0	58	9	AEA79702	AEA79702	Cellulomo	220	19	100.0	84	6	ABM57801	ABM57801	Protiomb
148	19	100.0	58	9	AEA48196	AEA48196	Part of t	221	19	100.0	84	6	ABP76020	ABP76020	Human GEN
149	19	100.0	59	3	AA858882	AA858882	Breast an	222	19	100.0	84	6	ABP76176	ABP76176	Human GEN
150	19	100.0	59	4	AAU55984	AAU55984	Protiomb	223	19	100.0	85	3	AA627024	AA627024	Zea maye
151	19	100.0	59	5	ABP00743	ABP00743	Human ORF	224	19	100.0	85	3	AA632676	AA632676	Zea maye
152	19	100.0	59	6	ABM04473	ABM04473	Human end	225	19	100.0	85	3	AAU25324	AAU25324	Zea maye
153	19	100.0	59	6	ABM52503	ABM52503	Protiomb	226	19	100.0	85	4	AAU52346	AAU52346	Protiomb
154	19	100.0	59	8	ABO54645	ABO54645	Human gen	227	19	100.0	85	5	ABP62928	ABP62928	Human pol
155	19	100.0	60	4	AAU48005	AAU48005	Protiomb	228	19	100.0	85	6	ABM48865	ABM48865	Human pol
156	19	100.0	60	5	ABP32165	ABP32165	Human ORF	229	19	100.0	85	6	ADQ75906	ADQ75906	Lysine de
157	19	100.0	60	7	ABM44584	ABM44584	Protiomb	230	19	100.0	85	8	ADQ75905	ADQ75905	Lysine de
158	19	100.0	60	7	ABO78543	ABO78543	Pseudomon	231	19	100.0	85	8	ADY12627	ADY12627	Plant ful
159	19	100.0	61	4	AAU61564	AAU61564	Protiomb	232	19	100.0	85	9	AAU94141	AAU94141	M. xanthu
160	19	100.0	61	5	ABP04708	ABP04708	Human ORF	233	19	100.0	86	4	AAU47746	AAU47746	Protiomb
161	19	100.0	61	6	ABM58003	ABM58003	Protiomb	234	19	100.0	86	5	ABP78149	ABP78149	Amino aci
162	19	100.0	62	4	AAU64327	AAU64327	Protiomb	235	19	100.0	86	5	ABP32375	ABP32375	Human ORF
163	19	100.0	62	6	ABM60846	ABM60846	Protiomb	236	19	100.0	86	6	ABM44265	ABM44265	Human ORF
164	19	100.0	62	7	ABO62014	ABO62014	Klebsiell	237	19	100.0	86	8	ADR87224	ADR87224	Dust mite
165	19	100.0	62	8	ADY23472	ADY23472	Plant ful	238	19	100.0	87	4	AAU62248	AAU62248	Protiomb
166	19	100.0	63	3	AA626814	AA626814	Zea maye	239	19	100.0	87	6	ABM58767	ABM58767	Protiomb
167	19	100.0	63	4	AAW83149	AAW83149	Human imm	240	19	100.0	88	4	AAU54801	AAU54801	Protiomb
168	19	100.0	63	4	ABG26472	ABG26472	Novel hum	241	19	100.0	88	4	ABU60929	ABU60929	Lung spec
169	19	100.0	63	8	ABO58146	ABO58146	Human gen	242	19	100.0	88	6	ABM51320	ABM51320	Protiomb
170	19	100.0	64	5	ABP29155	ABP29155	Streptoco	243	19	100.0	89	2	AAW74147	AAW74147	Human pro

244	19	100.0	89	3	AAV59139	AAV59139	Mouse	ser	317	19	100.0	109	6	ABM41131	ABM41131	Proionib
245	19	100.0	89	8	ADP56448	ADP56448	Human	PRO	318	19	100.0	110	8	ADR08805	ADR08805	Human pro
246	19	100.0	91	4	AAU14672	AAU14672	Novel	bon	319	19	100.0	112	4	AAH83219	AAH83219	Human imm
247	19	100.0	91	4	ABG04651	ABG04651	Novel	hum	320	19	100.0	112	7	ADC32931	ADC32931	Human nov
248	19	100.0	91	5	ABP09720	ABP09720	Human ORF		321	19	100.0	113	4	AAU61907	AAU61907	Proionib
249	19	100.0	91	5	ABP11499	ABP11499	Human ORF		322	19	100.0	113	5	ABU05357	ABU05357	M. tuberc
250	19	100.0	92	6	ABP79711	ABP79711	N. gonorr		323	19	100.0	113	6	ABM58426	ABM58426	Proionib
251	19	100.0	92	7	ADCC01121	ADCC01121	Enterohae		324	19	100.0	114	4	ABG07701	ABG07701	Novel hum
252	19	100.0	92	7	ADPD49007	ADPD49007	Fibronect		325	19	100.0	114	8	ADQ65348	ADQ65348	Novel hum
253	19	100.0	92	9	ADV51055	ADV51055	Human car		326	19	100.0	115	4	ABE01694	ABE01694	Human gen
254	19	100.0	92	9	ADV51133	ADV51133	Human car		327	19	100.0	115	5	ABG63962	ABG63962	Human alb
255	19	100.0	92	9	ADW63881	ADW63881	Human fib		328	19	100.0	115	6	ADA57488	ADA57488	Human sec
256	19	100.0	92	9	ADY37467	ADY37467	Fibronect		329	19	100.0	115	6	ADA41366	ADA41366	Human sec
257	19	100.0	93	4	AAE017704	AAE017704	Arabidops		330	19	100.0	115	7	ABR48083	ABR48083	Human sec
258	19	100.0	93	4	AAU41229	AAU41229	Proionib		331	19	100.0	115	7	ADC74511	ADC74511	Human sec
259	19	100.0	93	4	ABP02475	ABP02475	Human ORF		332	19	100.0	115	8	ADL77227	ADL77227	Albumin f
260	19	100.0	93	5	ABM37748	ABM37748	Proionib		333	19	100.0	116	2	AAW75888	AAW75888	Peptide f
261	19	100.0	93	6	ABM37748	ABM37748	Proionib		334	19	100.0	116	3	AAV78867	AAV78867	Streptomy
262	19	100.0	93	7	ADC42863	ADC42863	REMAP pro		335	19	100.0	116	3	AAE26812	AAE26812	Zea maye
263	19	100.0	93	7	ADP59056	ADP59056	Human pol		336	19	100.0	116	6	ABP77495	ABP77495	N. gonorr
264	19	100.0	93	8	ADS98115	ADS98115	Protein f		337	19	100.0	116	7	ADM05847	ADM05847	Human pro
265	19	100.0	93	8	ADS98807	ADS98807	Protein f		338	19	100.0	117	9	ADX40189	ADX40189	HIV Rev p
266	19	100.0	94	3	AAE34307	AAE34307	Arabidops		339	19	100.0	117	3	AAE40639	AAE40639	Human ORF
267	19	100.0	95	3	AAE35252	AAE35252	Zea maye		340	19	100.0	118	3	AAE55453	AAE55453	Arabidops
268	19	100.0	95	4	AAE66608	AAE66608	Human imm		341	19	100.0	118	3	AAE59261	AAE59261	Arabidops
269	19	100.0	95	4	AAU49298	AAU49298	Proionib		342	19	100.0	118	7	ADC00756	ADC00756	Enterohae
270	19	100.0	95	6	ABM45817	ABM45817	Proionib		343	19	100.0	119	9	ABM97506	ABM97506	M. xanthu
271	19	100.0	96	6	ABM65132	ABM65132	Proionib		344	19	100.0	119	9	ABE42205	ABE42205	L. pneumo
272	19	100.0	97	5	ABP07548	ABP07548	Human ORF		345	19	100.0	120	3	AAE33216	AAE33216	Pilus rad
273	19	100.0	97	6	ADBO7542	ADBO7542	Alloiocec		346	19	100.0	120	3	AAE36014	AAE36014	Zea maye
274	19	100.0	98	4	ABM80621	ABM80621	Envirohme		347	19	100.0	120	4	AAU48433	AAU48433	Proionib
275	19	100.0	98	9	ABM80893	ABM80893	M. xanthu		348	19	100.0	120	5	ABP53947	ABP53947	Human ORF
276	19	100.0	99	3	AAE42065	AAE42065	Human ORF		349	19	100.0	120	6	ABM44952	ABM44952	Proionib
277	19	100.0	99	3	AAE34306	AAE34306	Arabidops		350	19	100.0	121	2	AAV72822	AAV72822	Human sec
278	19	100.0	99	8	ADR96565	ADR96565	Novel S.		351	19	100.0	121	3	AAE40960	AAE40960	Human ORF
279	19	100.0	99	9	AAE60435	AAE60435	Streptococ		352	19	100.0	121	5	ABP06047	ABP06047	Human ORF
280	19	100.0	100	3	AAE58682	AAE58682	Wheat N-a		353	19	100.0	121	6	ABO14316	ABO14316	Novel hum
281	19	100.0	100	5	ABU05405	ABU05405	M. tuberc		354	19	100.0	121	8	ADG78724	ADG78724	Human sec
282	19	100.0	101	4	AAU57656	AAU57656	Proionib		355	19	100.0	121	8	ADN61014	ADN61014	Human sec
283	19	100.0	101	4	ABG23938	ABG23938	Novel hum		356	19	100.0	121	9	ABE37743	ABE37743	L. pneumo
284	19	100.0	101	4	ABG02006	ABG02006	Novel hum		357	19	100.0	121	9	ABE41053	ABE41053	L. pneumo
285	19	100.0	101	5	ABP02607	ABP02607	Human ORF		358	19	100.0	122	4	AAO03181	AAO03181	Human pol
286	19	100.0	101	5	ABP32523	ABP32523	Human ORF		359	19	100.0	122	4	AAU28136	AAU28136	Novel hum
287	19	100.0	101	6	ABM54175	ABM54175	Proionib		360	19	100.0	122	7	ADU70355	ADU70355	Human hea
288	19	100.0	102	2	AAW44566	AAW44566	Serine pr		361	19	100.0	122	8	ADX68079	ADX68079	Plant ful
289	19	100.0	102	3	AAE25380	AAE25380	Pilus rad		362	19	100.0	123	4	AAU46796	AAU46796	Human sec
290	19	100.0	102	5	ABU05650	ABU05650	M. tuberc		363	19	100.0	123	4	AAU46796	AAU46796	Human sec
291	19	100.0	102	5	AAU70953	AAU70953	M. tuberc		364	19	100.0	123	6	AAE43315	AAE43315	Human pol
292	19	100.0	102	9	ABE26458	ABE26458	M. tuberc		365	19	100.0	124	2	AAV74516	AAV74516	Streptococ
293	19	100.0	103	5	AAE26458	AAE26458	M. tuberc		366	19	100.0	124	5	ABP28228	ABP28228	Streptococ
294	19	100.0	103	5	AAE26458	AAE26458	M. tuberc		367	19	100.0	124	7	ADP60375	ADP60375	Human con
295	19	100.0	104	4	AAE26458	AAE26458	M. tuberc		368	19	100.0	124	8	ADP60375	ADP60375	Human con
296	19	100.0	104	4	AAE26458	AAE26458	M. tuberc		369	19	100.0	124	8	ADP60375	ADP60375	Human con
297	19	100.0	105	3	AAE26458	AAE26458	M. tuberc		370	19	100.0	124	8	ADP60375	ADP60375	Human con
298	19	100.0	105	4	AAE26458	AAE26458	M. tuberc		371	19	100.0	125	3	AAE26458	AAE26458	M. tuberc
299	19	100.0	105	6	ABM60563	ABM60563	Proionib		372	19	100.0	125	3	AAE26458	AAE26458	M. tuberc
300	19	100.0	105	8	ADP09942	ADP09942	Human pro		373	19	100.0	125	3	AAE26458	AAE26458	M. tuberc
301	19	100.0	106	4	AAU23565	AAU23565	Novel hum		374	19	100.0	125	3	AAE26458	AAE26458	M. tuberc
302	19	100.0	106	5	ABP01625	ABP01625	Human ORF		375	19	100.0	126	5	ADK36711	ADK36711	Novel hum
303	19	100.0	106	5	ABP07850	ABP07850	Human ORF		376	19	100.0	126	6	ABU49557	ABU49557	Protein e
304	19	100.0	106	5	ABP10649	ABP10649	Human ORF		377	19	100.0	127	3	AAE38548	AAE38548	Arabidops
305	19	100.0	106	8	ADR45874	ADR45874	Amhno aci		378	19	100.0	127	3	AAE37202	AAE37202	Arabidops
306	19	100.0	107	3	AAE38549	AAE38549	Arabidops		379	19	100.0	127	4	AAE38549	AAE38549	Arabidops
307	19	100.0	107	3	AAE38549	AAE38549	Arabidops		380	19	100.0	127	4	AAE38549	AAE38549	Arabidops
308	19	100.0	107	4	AAU27665	AAU27665	Human pro		381	19	100.0	127	5	AAE38549	AAE38549	Arabidops
309	19	100.0	107	4	AAU43191	AAU43191	Proionib		382	19	100.0	127	5	AAE38549	AAE38549	Arabidops
310	19	100.0	107	4	AAE38549	AAE38549	Proionib		383	19	100.0	128	3	AAE38549	AAE38549	Arabidops
311	19	100.0	107	4	AAE38549	AAE38549	Proionib		384	19	100.0	128	8	ADK87918	ADK87918	Plant ful
312	19	100.0	107	5	ABG65099	ABG65099	Human nov		385	19	100.0	129	3	AAE38549	AAE38549	Arabidops
313	19	100.0	107	6	ABM39710	ABM39710	Proionib		386	19	100.0	129	6	ABU70484	ABU70484	Human adi
314	19	100.0	107	8	ADL78366	ADL78366	Albumin f		387	19	100.0	130	6	ABU33550	ABU33550	Protein e
315	19	100.0	108	5	ADK35938	ADK35938	Novel hum		388	19	100.0	130	9	ABE41937	ABE41937	L. pneumo
316	19	100.0	109	4	AAU4612	AAU4612	Proionib		389	19	100.0	131	3	AAE53560	AAE53560	Human 5'

390	19	100.0	131	3	AAg33895	AAg33895	Arabidops
391	19	100.0	131	8	ADr08724	ADr08724	Human pro
392	19	100.0	131	8	ADu72924	ADu72924	Non-sigma
393	19	100.0	131	9	ADz73915	ADz73915	Human inc
394	19	100.0	132	4	AAb95434	AAb95434	Human pro
395	19	100.0	132	8	ADr01297	ADr01297	Farnesyl
396	19	100.0	133	4	AAm15391	AAm15391	Peptide #
397	19	100.0	133	4	ABM34397	ABM34397	Peptide #
398	19	100.0	133	4	AAm7879	AAm7879	Peptide #
399	19	100.0	133	4	ABM29224	ABM29224	Peptide #
400	19	100.0	133	4	ABM19808	ABM19808	Peptide #
401	19	100.0	133	4	AAm67582	AAm67582	Human bon
402	19	100.0	133	4	AAm55187	AAm55187	Human bra
403	19	100.0	133	4	ABG49228	ABG49228	Human liv
404	19	100.0	133	4	AAm03153	AAm03153	Peptide #
405	19	100.0	133	4	AAg92797	AAg92797	C glucanl
406	19	100.0	133	5	ABG37173	ABG37173	Human pep
407	19	100.0	133	5	ADK36712	ADK36712	Novel hum
408	19	100.0	133	6	ABU00401	ABU00401	Human nov
409	19	100.0	133	9	ABM92218	ABM92218	M. xanthu
410	19	100.0	134	8	ADU16466	ADU16466	M. tuberc
411	19	100.0	135	2	AA136512	AA136512	Fragment
412	19	100.0	135	6	ADAl2068	ADAl2068	Human nov
413	19	100.0	135	9	ABE38714	ABE38714	L. pneumo
414	19	100.0	136	5	ABJ10959	ABJ10959	Yeast sel
415	19	100.0	136	8	ABU21645	ABU21645	Protein e
416	19	100.0	138	5	ABM92218	ABM92218	Maize per
417	19	100.0	138	5	ABM49093	ABM49093	Listeria
418	19	100.0	138	6	ABU32715	ABU32715	Protein e
419	19	100.0	139	6	AAg41059	AAg41059	Zea maye
420	19	100.0	139	7	ABO64152	ABO64152	Klebsiell
421	19	100.0	140	2	AAV36950	AAV36950	Protein i
422	19	100.0	140	4	ABM11054	ABM11054	Human lam
423	19	100.0	140	4	ABG21912	ABG21912	Novel hum
424	19	100.0	140	5	ABP02193	ABP02193	Human ORF
425	19	100.0	140	5	ABM77702	ABM77702	Amino aci
426	19	100.0	140	7	ADC01512	ADC01512	Enterohae
427	19	100.0	140	8	ADr05621	ADr05621	E coli TH
428	19	100.0	141	4	ABM67857	ABM67857	Drosophil
429	19	100.0	141	5	AAm49445	AAm49445	Lactobaci
430	19	100.0	141	6	ABU25143	ABU25143	Protein e
431	19	100.0	141	7	ADM05254	ADM05254	Human pro
432	19	100.0	141	8	ABO59733	ABO59733	Human gen
433	19	100.0	141	9	AEAT9768	AEAT9768	Xylanihac
434	19	100.0	141	9	AEA48261	AEA48261	ASP 69B4
435	19	100.0	142	2	AAW28048	AAW28048	Threonine
436	19	100.0	142	2	AAW28048	AAW28048	Human gen
437	19	100.0	142	8	ADK73317	ADK73317	Plant ful
438	19	100.0	142	9	ABM96670	ABM96670	M. xanthu
439	19	100.0	142	9	ABM96670	ABM96670	M. xanthu
440	19	100.0	143	2	AAV04782	AAV04782	Mycobacte
441	19	100.0	143	4	AAW25848	AAW25848	Human pro
442	19	100.0	143	6	ABU29973	ABU29973	Protein e
443	19	100.0	144	4	ABG18087	ABG18087	Novel hum
444	19	100.0	144	8	ADK73393	ADK73393	Plant ful
445	19	100.0	144	8	AEA43773	AEA43773	C. necato
446	19	100.0	145	4	AAU40398	AAU40398	Propionib
447	19	100.0	145	7	ABM36917	ABM36917	Propionib
448	19	100.0	145	7	ADP66822	ADP66822	Helicobac
449	19	100.0	145	8	ADP66824	ADP66824	Helicobac
450	19	100.0	145	8	ADK93828	ADK93828	Plant ful
451	19	100.0	146	4	ABG29413	ABG29413	Novel hum
452	19	100.0	146	5	ADG79448	ADG79448	Human sec
453	19	100.0	146	8	ADK73014	ADK73014	Plant ful
454	19	100.0	147	4	AAW86520	AAW86520	Human gen
455	19	100.0	147	4	AAW86520	AAW86520	Human gen
456	19	100.0	147	6	ABO53684	ABO53684	Novel hum
457	19	100.0	147	6	ADA36367	ADA36367	Actineto
458	19	100.0	148	3	AAW25824	AAW25824	Arabidops
459	19	100.0	148	3	AAW38547	AAW38547	Arabidops
460	19	100.0	148	3	AAW37201	AAW37201	Arabidops
461	19	100.0	148	4	AAW37201	AAW37201	C glucanl
462	19	100.0	148	7	ADB74343	ADB74343	Mycobacte

463	19	100.0	148	8	ADG23636	ADG23636	Bacterial
464	19	100.0	149	4	AAO12923	AAO12923	Human pol
465	19	100.0	150	2	AAU18444	AAU18444	Human sig
466	19	100.0	150	4	AAU54480	AAU54480	Propionib
467	19	100.0	150	6	ABM50999	ABM50999	Propionib
468	19	100.0	150	7	ADH34365	ADH34365	Vibrio ch
469	19	100.0	152	8	ADY23136	ADY23136	Plant ful
470	19	100.0	152	3	AAW57156	AAW57156	Human pro
471	19	100.0	152	4	ABG16639	ABG16639	Novel hum
472	19	100.0	153	2	AAW77754	AAW77754	Staphyloc
473	19	100.0	153	3	AAW77576	AAW77576	Human cyc
474	19	100.0	153	3	AAW41043	AAW41043	Human ORF
475	19	100.0	153	4	AAW38917	AAW38917	Human pol
476	19	100.0	153	4	ABG27650	ABG27650	Novel hum
477	19	100.0	153	4	AAU31783	AAU31783	Novel hum
478	19	100.0	153	5	ABP09251	ABP09251	Human ORF
479	19	100.0	153	5	AAW17872	AAW17872	Sequence
480	19	100.0	153	5	ABW49178	ABW49178	Listeria
481	19	100.0	153	6	ADU58176	ADU58176	Soybean s
482	19	100.0	153	6	ADU54840	ADU54840	Human pro
483	19	100.0	153	6	ABU08006	ABU08006	Guar meta
484	19	100.0	153	6	ABR47525	ABR47525	Breast ca
485	19	100.0	153	7	ADW61633	ADW61633	Rat Prote
486	19	100.0	153	7	ADG64497	ADG64497	Family A
487	19	100.0	153	8	ADN04998	ADN04998	Antipsoxi
488	19	100.0	153	8	ADQ67007	ADQ67007	Novel hum
489	19	100.0	153	8	ADP55493	ADP55493	Human PRO
490	19	100.0	153	8	ADP25213	ADP25213	PRO polyp
491	19	100.0	153	8	ADW60578	ADW60578	Plant pol
492	19	100.0	154	2	AAW20648	AAW20648	H. pylori
493	19	100.0	154	2	AAW30642	AAW30642	A. thalial
494	19	100.0	154	3	AAW44503	AAW44503	Plant vir
495	19	100.0	154	4	AAW33661	AAW33661	Human pro
496	19	100.0	154	6	ABU22969	ABU22969	Protein e
497	19	100.0	154	8	ADW09025	ADW09025	Human pro
498	19	100.0	154	9	AEA79750	AEA79750	Cellulomo
499	19	100.0	154	9	AEA48243	AEA48243	Homologou
500	19	100.0	155	2	AAW95496	AAW95496	M. leprae

ALIGNMENTS

RESULT 1	
ADC97878	ADC97878 standard; peptide; 4 AA.
XX	
AC	ADC97878;
XX	
DT	01-JAN-2004 (first entry)
XX	
DE	Signalling molecule gene regulatory peptide.
XX	
KW	gene expression modulation; signalling molecule;
KW	NF-kappaB/Rel protein inhibitor; antiinflammatory; antiarthritic;
KW	cerobroprotective; cardiant; antibacterial; immunosuppressive;
KW	dermatological; nephrotropic; NF-kappaB/Rel protein modulator;
KW	inflammatory disease; arthritis; ischaemia; cerebrovascular disease;
KW	ischaemic heart failure; anthrax; angiogenesis; autoimmune disease;
KW	systemic lupus erythematosus; ulcerative colitis; Addison's disease;
XX	Goodpasture's disease.
OS	Synthetic.
XX	
PN	WO2003029292-A2.
XX	
PD	10-APR-2003.
XX	
PF	04-OCT-2002; 2002W0-NL000639.
XX	
PR	04-OCT-2001; 2001EP-00203748.
XX	
PR	21-DEC-2001; 2001US-00028075.
XX	

PA (UTRO-) UNIV ROTTERDAM ERASMUS.
 XX Khan NA, Benner R;
 XX WPI; 2003-393380/37.
 DR
 XX
 XX
 PS Modulating gene expression in a cell, useful for treating acute or
 PT chronic inflammatory diseases (e.g. arthritis), ischemic events or
 PT autoimmune diseases, comprises providing the cell with a signaling
 PT molecule.
 XX
 XX Disclosure; Page 44; 217pp; English.
 XX
 CC The present invention describes a method for modulating gene expression
 CC in a cell comprising providing the cell with a signalling molecule
 CC comprising a peptide or its functional analogue. Also described: (1)
 CC identifying or obtaining a signalling molecule comprising a peptide or
 CC its functional derivative or analogue capable of modulating expression of
 CC a gene in a cell; (2) a signalling molecule useful in modulating
 CC expression of a gene in a cell and identifiable or obtainable by the
 CC method of (1); and (3) an inhibitor of nuclear factor (NF)-kappaB/Rel
 CC protein activation comprising a signalling molecule of (2). The
 CC signalling molecule has antiinflammatory, antiarthritic,
 CC cerebroprotective, cardiac, antibacterial, immunosuppressive,
 CC dermatological and nephrotropic activities, and can be used as a NF-
 CC kappaB/Rel protein modulator. The signalling molecule is useful for the
 CC production of a pharmaceutical composition for the modulation of gene
 CC expression by inhibiting NF-kappaB/Rel protein activation. The method is
 CC useful for modulating gene expression, and for treating acute or chronic
 CC inflammatory diseases (e.g. arthritis), ischaemic event including
 CC cerebrovascular disease and ischaemic heart failure, anthrax,
 CC angioneurosis, or autoimmune diseases (e.g. systemic lupus erythematosus,
 CC ulcerative colitis, Addison's disease or Goodpasture's disease). The
 CC present sequence represents a peptide used in the exemplification of the
 CC present invention.
 CC
 XX
 XX Sequence 4 AA;
 SQ
 Query Match 100.0%; Score 19; DB 7; Length 4;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AGGV 4
 ||||
 Db 1 AGGV 4
 RESULT 2
 ADC97891
 XX ADC97891 standard; peptide; 4 AA.
 XX
 AC ADC97891;
 XX
 XX
 XX 01-JAN-2004 (first entry)
 DE
 XX
 XX Signalling molecule gene regulatory peptide.
 XX
 XX gene expression modulation; signalling molecule;
 KW NF-kappaB/Rel protein inhibitor; antiinflammatory; antiarthritic;
 KW cerebroprotective; cardiac; antibacterial; immunosuppressive;
 KW dermatological; nephrotropic; NF-kappaB/Rel protein modulator;
 KW inflammatory diseases; arthritis; ischaemia; cerebrovascular disease;
 KW ischaemic heart failure; anthrax; angioneurosis; autoimmune disease;
 KW systemic lupus erythematosus; ulcerative colitis; Addison's disease;
 KW Goodpasture's disease.
 XX
 OS Synthetic.
 XX
 XX WO2003029292-A2.
 XX
 XX 10-APR-2003.
 PD
 XX 04-OCT-2002; 2002WO-NL000639.
 PP

XX	04-OCT-2001; 2001EP-00203748.
PR	21-DEC-2001; 2001US-00028075.
XX	
PA	(UWRO-) UNIV ROTTERDAM ERASMUS.
XX	
PI	Khan NA, Benner R;
XX	
DR	WP1; 2003-393380/37.
XX	
PT	Modulating gene expression in a cell, useful for treating acute or
PT	chronic inflammatory diseases (e.g. arthritis), ischemic events or
PT	autoimmune diseases, comprises providing the cell with a signaling
PT	molecule.
XX	
PS	Example; Page 69; 217pp; English.
XX	
CC	The present invention describes a method for modulating gene expression
CC	in a cell comprising providing the cell with a signalling molecule
CC	comprising a peptide or its functional analogue. Also described: (1)
CC	identifying or obtaining a signalling molecule comprising a peptide or
CC	its functional derivative or analogue capable of modulating expression of
CC	a gene in a cell; (2) a signalling molecule useful in modulating
CC	expression of a gene in a cell and identifiable or obtainable by the
CC	method of (1); and (3) an inhibitor of nuclear factor (NF)-kappaB/Rel
CC	protein activation comprising a signalling molecule of (2). The
CC	signalling molecule has antiinflammatory, antiarthritic,
CC	cerebroprotective, cardiac, antibacterial, immunosuppressive,
CC	dermatological and nephrotropic activities, and can be used as a NF-
CC	kappaB/Rel protein modulator. The signalling molecule is useful for the
CC	production of a pharmaceutical composition for the modulation of gene
CC	expression by inhibiting NF-kappaB/Rel protein activation. The method is
CC	useful for modulating gene expression, and for treating acute or chronic
CC	inflammatory diseases (e.g. arthritis), ischemic event including
CC	cerebrovascular disease and ischemic heart failure, anthrax,
CC	angiogenesis, or autoimmune diseases (e.g. systemic lupus erythematosus,
CC	ulcerative colitis, Addison's disease or Goodpasture's disease). The
CC	present sequence represents a peptide used in the exemplification of the
CC	present invention.
XX	
XX	Sequence 4 AA;
SQ	
	Query Match 100.0%; Score 19; DB 7; Length 4;
	Best Local Similarity 100.0%; Pred. No. 2e+06;
	Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	1 AGGV 4
DB	1 AGGV 4
RESULT 3	
ADC98118	
ID	ADC98118 standard; peptide; 4 AA.
XX	
AC	ADC98118;
XX	
DT	01-JAN-2004 (first entry)
XX	
DE	Signalling molecule gene regulatory peptide.
XX	
DE	gene expression modulation; signalling molecule;
KW	NF-kappaB/Rel protein inhibitor; antiinflammatory; antiarthritic;
KW	cerebroprotective; cardiac; antibacterial; immunosuppressive;
KW	dermatological; nephrotropic; NF-kappaB/Rel protein modulator;
KW	inflammatory disease; arthritis; ischaemia; cerebrovascular disease;
KW	ischemic heart failure; anthrax; angiogenesis; autoimmune disease;
KW	systemic lupus erythematosus; ulcerative colitis; Addison's disease;
KW	Goodpasture's disease.
XX	
XX	Synthetic.
DS	
XX	WO2003029292-A2.
PN	

XX 10-APR-2003.
PD
XX
PF 04-OCT-2002; 2002WO-NL000639.
XX
PR 04-OCT-2001; 2001EP-00203748.
XX
PR 21-DEC-2001; 2001US-00028075.
XX
PA (UYRO-) UNIV ROTTERDAM ERASMUS.
XX
PI Khan NA, Benner R;
XX
DR WPI; 2003-393380/37.
XX
PT Modulating gene expression in a cell, useful for treating acute or
XX chronic inflammatory diseases (e.g. arthritis), ischemic events or
XX autoimmune diseases, comprises providing the cell with a signaling
XX molecule.

XX Example; Page 98; 217pp; English.
PS
XX

The present invention describes a method for modulating gene expression in a cell comprising providing the cell with a signalling molecule comprising a peptide or its functional analogue. Also described: (1) identifying or obtaining a signalling molecule comprising a peptide or its functional derivative or analogue capable of modulating expression of a gene in a cell; (2) a signalling molecule useful in modulating expression of a gene in a cell and identifiable or obtainable by the method of (1); and (3) an inhibitor of nuclear factor (NF-kappaB/Rel protein activation comprising a signalling molecule of (2). The signalling molecule has anti-inflammatory, antiarthritic, cerebroprotective, cardiant, antibacterial, immunosuppressive, dermatological and nephrotropic activities, and can be used as a NF-kappaB/Rel protein modulator. The signalling molecule is useful for the production of a pharmaceutical composition for the modulation of gene expression by inhibiting NF-kappaB/Rel protein activation. The method is useful for modulating gene expression, and for treating acute or chronic inflammatory diseases (e.g. arthritis), ischaemic event including cerebrovascular disease and ischaemic heart failure, anthrax, angiogenesis, or autoimmune diseases (e.g. systemic lupus erythematosus, ulcerative colitis, Addison's disease or Goodpasture's disease). The present sequence represents a peptide used in the exemplification of the present invention.

SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 7; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||
1 AOGV 4

Db

RESULT 4
ADC97855
ID ADC97855 standard; peptide; 4 AA.

AC ADC97855;
XX
DT 01-JAN-2004 (first entry)
XX

Signalling molecule gene regulatory peptide.

gene expression modulation; signalling molecule;
NF-kappaB/Rel protein inhibitor; antiinflammatory; antiarthritic;
cerebroprotective; cardiant; antibacterial; immunosuppressive;
dermatological; nephrotropic; NF-kappaB/Rel protein modulator;
inflammatory disease; arthritis; ischaemia; cerebrovascular disease;
ischaemic heart failure; anthrax; angiogenesis; autoimmune disease;
systemic lupus erythematosus; ulcerative colitis; Addison's disease;
Goodpasture's disease.

OS Synthetic.
PN WO2003029292-A2.
XX
XX
PD 10-APR-2003.
XX
XX
PF 04-OCT-2002; 2002WO-NL000639.
PR 04-OCT-2001; 2001EP-00203748.
PR 21-DEC-2001; 2001US-00028075.
XX
XX
PA (UIRO-) UNIV ROTTERDAM ERASMUS.
XX
XX
PI Khan NA, Benner R;
XX
DR WPI, 2003-393380/37.
XX
PT Modulating gene expression in a cell, useful for treating acute or
PT chronic inflammatory diseases (e.g. arthritis), ischemic events or
PT autoimmune diseases, comprises providing the cell with a signalling
molecule.
XX
PS Disclosure; Page 40; 21pp; English.

The present invention describes a method for modulating gene expression in a cell comprising providing the cell with a signalling molecule comprising a peptide or its functional analogue. Also described: (1) identifying or obtaining a signalling molecule comprising a peptide or its functional derivative or analogue capable of modulating expression of a gene in a cell; (2) a signalling molecule useful in modulating expression of a gene in a cell and identifiable or obtainable by the method of (1); and (3) an inhibitor of nuclear factor (NF)-kappaB/Rel protein activation comprising a signalling molecule of (2). The signalling molecule has anti-inflammatory, antiarthritic, cerebroprotective, cardiant, antibacterial, immunosuppressive, dermatological and nephrotropic activities, and can be used as a NF-kappaB/Rel protein modulator. The signalling molecule is useful for the production of a pharmaceutical composition for the modulation of gene expression by inhibiting NF-kappaB/Rel protein activation. The method is useful for modulating gene expression, and for treating acute or chronic inflammatory diseases (e.g. arthritis), ischaemic event including cerebrovascular disease and ischaemic heart failure, anthrax, angioedema, or autoimmune diseases (e.g. systemic lupus erythematosus, ulcerative colitis, Addison's disease or Goodpasture's disease). The present sequence represents a peptide used in the exemplification of the present invention.

Sequence 4 AA;

	Query Match	100.0%;	Score 19;	DB 7;	Length 4;
	Best Local Similarity	100.0%;	Pred.	No. 2e+06;	
Matches	4;	Conservative	0;	Mismatches	0;
				Indels	0;
Gy	1 AAGV 4				
Db	1 AGGV 4				

RESULT 5
ADC98185
ID ADC98185 standard; peptide; 4 AA.
AC ADC98185;
XX
DT 01-JAN-2004 (first entry)
XX
DE Signalling molecule gene regulatory peptide.
XX
KW gene expression modulation; signalling molecule;
KW NF-kappaB/Rel protein inhibitor; antiinflammatory; antirheumatic;
KW cerebroprotective; cardiant; antibacterial; immunosuppressive;
KW dermatological; nephrotropic; NF-kappaB/Rel protein modulator;

KM inflammatory disease; arthritis; ischaemia; cerebrovascular disease;
 KM ischemic heart failure; anthrax; angiogenesis; autoimmune disease;
 KM systemic lupus erythematosus; ulcerative colitis; Addison's disease;
 KM Goodpasture's disease.
 OS Synthetic.
 KM WO2003029292-A2.
 PN 10-APR-2003.
 XX 10-APR-2003.
 XX 04-OCT-2002; 2002WO-NL000639.
 PF 04-OCT-2001; 2001EP-00203748.
 PR 21-DEC-2001; 2001US-00028075.
 XX (UYRO-) UNIV ROTTERDAM ERASMUS.
 PA Khan NA, Benner R;
 PI WPI; 2003-393380/37.
 XX
 XX Modulating gene expression in a cell, useful for treating acute or
 PT chronic inflammatory diseases (e.g. arthritis), ischemic events or
 PT autoimmune diseases, comprises providing the cell with a signaling
 PT molecule.

Example; Page 102; 217pp; English.

The present invention describes a method for modulating gene expression in a cell comprising providing the cell with a signalling molecule comprising a peptide or its functional analogue. Also described: (1) identifying or obtaining a signalling molecule comprising a peptide or its functional derivative or analogue capable of modulating expression of a gene in a cell; (2) a signalling molecule useful in modulating expression of a gene in a cell and identifiable or obtainable by the method of (1); and (3) an inhibitor of nuclear factor (NF)-kappaB/Rel protein activation comprising a signalling molecule of (2). The signalling molecule has antiinflammatory, antiarthritic, cerebroprotective, cardiant, antibacterial, immunosuppressive, dermatological and nephrotoxic activities, and can be used as a NF-kappaB/Rel protein modulator. The signalling molecule is useful for the production of a pharmaceutical composition for the modulation of gene expression by inhibiting NF-kappaB/Rel protein activation. The method is useful for modulating gene expression, and for treating acute or chronic inflammatory diseases (e.g. arthritis), ischemic event including cerebrovascular disease and ischemic heart failure, anthrax, angiogenesis, or autoimmune diseases (e.g. systemic lupus erythematosus, ulcerative colitis, Addison's disease or Goodpasture's disease). The present sequence represents a peptide used in the exemplification of the present invention.

Sequence 4 AA;

Query Match 100.0%; Score 19; DB 7; Length 4;
 Best Local Similarity 100.0%; Pred. No. 2e+06; 0; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0;

QY 1 ACGV 4
 ||||
 DB 1 ACGV 4

RESULT 6
 ADC98145
 ID ADC98145 standard; peptide; 4 AA.

AC ADC98145;

DT 01-JAN-2004 (first entry)

XX Signalling molecule gene regulatory peptide.

DE
 XX

KM gene expression modulation; signalling molecule;
 KM NF-kappaB/Rel protein inhibitor; antiinflammatory; antiarthritic;
 KM cerebroprotective; cardiant; antibacterial; immunosuppressive;
 KM dermatological; nephrotoxic; NF-kappaB/Rel protein modulator;
 KM inflammatory disease; arthritis; ischaemia; cerebrovascular disease;
 KM ischemic heart failure; anthrax; angiogenesis; autoimmune disease;
 KM systemic lupus erythematosus; ulcerative colitis; Addison's disease;
 KM Goodpasture's disease.
 OS Synthetic.
 KM WO2003029292-A2.
 PN 10-APR-2003.
 XX 10-APR-2003.
 XX 04-OCT-2002; 2002WO-NL000639.
 PF 04-OCT-2001; 2001EP-00203748.
 PR 21-DEC-2001; 2001US-00028075.
 XX (UYRO-) UNIV ROTTERDAM ERASMUS.
 PA Khan NA, Benner R;
 PI WPI; 2003-393380/37.
 XX
 XX Modulating gene expression in a cell, useful for treating acute or
 PT chronic inflammatory diseases (e.g. arthritis), ischemic events or
 PT autoimmune diseases, comprises providing the cell with a signaling
 PT molecule.

Example; Page 101; 217pp; English.

The present invention describes a method for modulating gene expression in a cell comprising providing the cell with a signalling molecule comprising a peptide or its functional analogue. Also described: (1) identifying or obtaining a signalling molecule comprising a peptide or its functional derivative or analogue capable of modulating expression of a gene in a cell; (2) a signalling molecule useful in modulating expression of a gene in a cell and identifiable or obtainable by the method of (1); and (3) an inhibitor of nuclear factor (NF)-kappaB/Rel protein activation comprising a signalling molecule of (2). The signalling molecule has antiinflammatory, antiarthritic, cerebroprotective, cardiant, antibacterial, immunosuppressive, dermatological and nephrotoxic activities, and can be used as a NF-kappaB/Rel protein modulator. The signalling molecule is useful for the production of a pharmaceutical composition for the modulation of gene expression by inhibiting NF-kappaB/Rel protein activation. The method is useful for modulating gene expression, and for treating acute or chronic inflammatory diseases (e.g. arthritis), ischemic event including cerebrovascular disease and ischemic heart failure, anthrax, angiogenesis, or autoimmune diseases (e.g. systemic lupus erythematosus, ulcerative colitis, Addison's disease or Goodpasture's disease). The present sequence represents a peptide used in the exemplification of the present invention.

Sequence 4 AA;

Query Match 100.0%; Score 19; DB 7; Length 4;
 Best Local Similarity 100.0%; Pred. No. 2e+06; 0; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0;

QY 1 ACGV 4
 ||||
 DB 1 ACGV 4

RESULT 7
 ADC97811
 ID ADC97811 standard; peptide; 4 AA.

AC ADC97811;

XX

DT 01-JAN-2004 (first entry)
 XX
 DE Signalling molecule gene regulatory peptide.
 XX
 KW gene expression modulation; signalling molecule;
 KW NF-kappaB/Rel protein inhibitor; antiinflammatory; antiarthritic;
 KW cerebroprotective; cardiant; antibacterial; immunosuppressive;
 KW dermatological; nephrotropic; NF-kappaB/Rel protein modulator;
 KW inflammatory disease; arthritis; ischemia; cerebrovascular disease;
 KW ischemic heart failure; anthrax; angio genesis; autoimmune disease;
 KW systemic lupus erythematosus; ulcerative colitis; Addison's disease;
 KW Goodpasture's disease.
 XX
 OS Synthetic.
 XX
 PN WO2003029292-A2.
 XX
 PD 10-APR-2003.
 XX
 PF 04-OCT-2002; 2002WO-NL000639.
 XX
 PR 04-OCT-2001; 2001EP-00203748.
 XX
 PR 21-DEC-2001; 2001US-00028075.
 XX
 PA (UYRO-) UNIV ROTTERDAM ERASMUS.
 XX
 PI Khan NA, Benner R;
 XX
 DR WPI; 2003-393380/37.
 XX
 PT Modulating gene expression in a cell, useful for treating acute or
 PT chronic inflammatory diseases (e.g. arthritis), ischemic events or
 PT autoimmune diseases, comprises providing the cell with a signaling
 PT molecule.
 XX
 PS Claim 18; Page 125; 217pp; English.
 XX
 CC The present invention describes a method for modulating gene expression
 CC in a cell comprising providing the cell with a signalling molecule
 CC comprising a peptide or its functional analogue. Also described: (1)
 CC identifying or obtaining a signalling molecule comprising a peptide or
 CC its functional derivative or analogue capable of modulating expression of
 CC a gene in a cell; (2) a signalling molecule useful in modulating
 CC expression of a gene in a cell and identifiable or obtainable by the
 CC method of (1); and (3) an inhibitor of nuclear factor (NF)-kappaB/Rel
 CC protein activation comprising a signalling molecule of (2). The
 CC signalling molecule has antiinflammatory, antiarthritic,
 CC cerebroprotective, cardiant, antibacterial, immunosuppressive,
 CC dermatological and nephrotropic activities, and can be used as a NF-
 CC kappaB/Rel protein modulator. The signalling molecule is useful for the
 CC production of a pharmaceutical composition for the modulation of gene
 CC expression by inhibiting NF-kappaB/Rel protein activation. The method is
 CC useful for modulating gene expression, and for treating acute or chronic
 CC inflammatory diseases (e.g. arthritis), ischemic event including
 CC cerebrovascular disease and ischemic heart failure, anthrax,
 CC angio genesis, or autoimmune diseases (e.g. systemic lupus erythematosus,
 CC ulcerative colitis, Addison's disease or Goodpasture's disease). The
 CC present sequence represents a peptide used in the exemplification of the
 CC present invention.
 CC
 XX
 SQ Sequence 4 AA;
 XX
 Query Match 100.0%; Score 19; DB 7; Length 4;
 Best Local Similarity 100.0%; Pred. No. 2e+06; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0;
 DB 1 AOGV 4
 1 AOGV 4
 DB 1 AOGV 4
 RESULT 8
 ADN01224

ID ADN01224 standard; peptide; 4 AA.
 XX
 AC ADN01224;
 XX
 DT 17-JUN-2004 (first entry)
 XX
 DE Human nuclear factor-kappaB modulating peptide NMPF-46.
 XX
 KW Human; nuclear factor-kappaB; NMPF; inflammatory condition;
 KW nitrogen oxide; anthrax; gene transcription factor;
 KW tumour necrosis factor alpha; TNF-alpha.
 XX
 OS Homo sapiens.
 XX
 PN US2003119720-A1.
 XX
 PD 26-JUN-2003.
 XX
 PF 21-DEC-2001; 2001US-00029206.
 XX
 PR 29-MAR-2001; 2001US-00821380.
 XX
 PA (KHAN/) KHAN N A.
 XX
 PA (BENN/) BENNER R.
 XX
 PI Khan NA, Benner R;
 XX
 DR WPI; 2003-810947/76.
 XX
 PT Treatment of an inflammatory condition, e.g. anthrax, comprises
 PT administering, to a subject, a molecule comprising an oligopeptide
 PT peptide or its functional analog.
 XX
 PS Claim 9; Page 16; 80pp; English.
 XX
 CC The invention relates to treating an inflammatory condition by
 CC administering to a subject a molecule comprising an oligopeptide peptide
 CC (termed NMPF) or its functional analogue capable of reducing production
 CC of nitrogen oxide by a cell. The peptides are derived from human proteins
 CC interacting with nuclear factor-kappaB. The method is for treating an
 CC acute inflammatory condition, e.g. anthrax. The inventive molecule
 CC reduces production of nitrogen oxide by a cell, and modulates
 CC translocation and/or activity of a gene transcription factor in the cell
 CC to allow modulation of tumour necrosis factor (TNF)-alpha production by
 CC the cell. The present sequence is an oligopeptide of the invention.
 CC
 XX
 SQ Sequence 4 AA;
 XX
 Query Match 100.0%; Score 19; DB 7; Length 4;
 Best Local Similarity 100.0%; Pred. No. 2e+06; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0;
 DB 1 AOGV 4
 1 AOGV 4
 DB 1 AOGV 4
 RESULT 9
 ADG86532
 ID ADG86532 standard; peptide; 4 AA.
 XX
 AC ADG86532;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE NF-kappaB gene-regulatory peptide #2.
 XX
 KW Ischaemic event; nuclear factor-kappaB; NF-kappaB;
 KW gene-regulatory peptide; down-regulation; thrombolytic agent;
 KW tissue plasminogen activity; stroke; myocardial infarction;
 KW pro-inflammatory cytokine; vasotropic; cerebroprotective; vasotropic;
 KW cardiant.
 XX

OS Unidentified.
XX
PN US2003220258-A1.
XX
PD 27-NOV-2003.
XX
PF 08-APR-2003; 2003US-00409642.
XX
PR 21-DEC-2001; 2001US-00028075.
XX
PA (BENN/) BENNER R.
XX
PA (KHAN/) KHAN N A.
XX
PI (JACO/) JACOBS B C J.
XX
PI Benner R, Khan NA, Jacobs BCJ;
XX
PI WPI; 2004-097355/10.
XX
PT Modulating ischemic event in subject involves providing the subject with
PT gene-regulatory peptide or its functional analogue.
XX
PS Example; SEQ ID NO 2; 17pp; English.
XX
CC The present invention relates to a method for modulating or treating
CC ischemic events in a subject. The method involves providing the subject
CC with a nuclear factor-kappaB (NF-kappaB) gene-regulatory peptide or its
CC functional analogue. The method comprises providing the subject with an
CC NF-kappaB down-regulating peptide or its functional analogue, and a
CC thrombolytic agent having tissue plasminogen activity. The method of the
CC invention is useful for modulating or treating ischemic events such as
CC stroke or myocardial infarction in a subject. The invention is capable of
CC modulating expression of gene encoding a pro-inflammatory cytokine. The
CC present sequence represents a NF-kappaB gene-regulatory peptide.
XX
SQ Sequence 4 AA;
XX
Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 ACGV 4
DB 1 ACGV 4
XX
RESULT 10
ADG86590
ID ADG86590 standard; peptide; 4 AA.
XX
AC ADG86590;
XX
DT 11-MAR-2004 (first entry)
XX
DE NF-kappaB gene-regulatory peptide #2.
XX
XX Iatrogenic event; nuclear factor-kappaB; NF-kappaB;
KW gene-regulatory peptide; down-regulation; cell destruction; cell lysis;
KW tissue; iatrogenic disease; pro-inflammatory cytokine response;
KW antiinflammatory.
XX
OS Unidentified.
XX
PN US2003220261-A1.
XX
PD 27-NOV-2003.
XX
PF 08-APR-2003; 2003US-00409671.
XX
PR 21-DEC-2001; 2001US-00028075.
XX
PA (KHAN/) KHAN N A.
XX
PA (BENN/) BENNER R.
XX

PI Khan NA, Benner R;
XX
DR WPI; 2004-107014/11.
XX
PT Modulating an iatrogenic event in a subject, useful for treating a
PT subject suffering from iatrogenic disease, comprises providing the
PT subject with a gene-regulatory peptide or its functional analogue.
XX
PS Example; SEQ ID NO 2; 16pp; English.
XX
CC The present invention relates to a method for modulating or treating an
CC iatrogenic event in a subject. The method involves providing the subject
CC with a nuclear factor-kappaB (NF-kappaB) gene-regulatory peptide or its
CC functional analogue. The method comprises providing the subject with an
CC NF-kappaB down-regulating peptide or its functional analogue. The
CC iatrogenic event involves destruction or lysis of a cell or tissue of the
CC subject or of a pathogen hosted by the subject. Modulating an iatrogenic
CC event is useful for treating subjects suffering from iatrogenic disease.
CC The gene-regulatory peptide, e.g. nuclear factor-kappa B down-regulating
CC peptide, is useful for producing a pharmaceutical composition for the
CC treatment of an additional pro-inflammatory cytokine response occurring
CC after an iatrogenic event in a subject. The present sequence represents a
CC NF-kappaB gene-regulatory peptide.
XX
SQ Sequence 4 AA;
XX
Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 ACGV 4
DB 1 ACGV 4
XX
RESULT 11
ADH29151
ID ADH29151 standard; peptide; 4 AA.
XX
AC ADH29151;
XX
DT 11-MAR-2004 (first entry)
XX
DE Necrosis factor kappa B (NFkB) down regulating peptide #2.
XX
XX immunosuppressant; gene therapy; NF-kappaB antagonist;
KW Rel protein-antagonist; transplant; gene-regulatory;
KW hypertonic pharmaceutical composition; NF-kappaB down-regulating peptide;
KW chronic rejection; necrosis factor kappa B down-regulating peptide;
KW immune response.
XX
OS Synthetic.
XX
PN US2003219425-A1.
XX
PD 27-NOV-2003.
XX
PF 08-APR-2003; 2003US-00409027.
XX
PR 21-DEC-2001; 2001US-00028075.
XX
PA (KHAN/) KHAN N A.
XX
PA (BENN/) BENNER R.
XX
PA (YZER/) YZERMAN J N M.
XX
PI Khan NA, Benner R, Yzermans JNM;
XX
PI WPI; 2004-089275/09.
XX
PT Modulation of transplant survival in recipient of transplant comprises
PT providing transplant with gene-regulatory peptide or functional analog.
XX
PS Example; SEQ ID NO 2; 18pp; English.
XX

XX The invention describes a method of modulating transplant survival in a
CC recipient of the transplant comprising providing the transplant with a
CC gene-regulatory peptide or its functional analogue. Also described is a
CC hyperoncic pharmaceutical composition comprising NF-kappaB down-
CC regulating peptide or its functional analogue. The invention prevents and
CC treats rejection, particularly chronic rejection, of a transplant by a
CC recipient of the transplant. This is the amino acid sequence of a
CC necrosis factor kappa B (NFkB) down-regulating peptide used to modify the
CC immune response and treat transplant rejection.
XX
SQ Sequence 4 AA;
QY
Db 1 ACGV 4
1 ACGV 4
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
RESULT 12
ADG73593
ID ADG73593 standard; peptide; 4 AA.
XX
AC ADG73593;
XX
XX 11-MAR-2004 (first entry)
XX
DE NF-kappaB gene-regulatory peptide #2.
XX
KM Immunosuppressive state; nuclear factor-kappaB; NF-kappaB;
KM gene-regulatory peptide; disseminated intravascular coagulation; trauma;
KM counter anti-inflammatory response syndrome; upregulation;
KM anti-inflammatory response; interleukin-10; IL-10;
KM pro-inflammatory response; tumour necrosis factor-alpha; TNF-alpha;
KM nitric oxide; interleukin-5; IL-5; interleukin-1beta; IL-1beta;
KM anticoagulation.
XX
OS Unidentified.
XX
XX US2003220257-A1.
XX
XX 27-NOV-2003.
XX
XX 08-APR-2003; 2003US-00409032.
XX
XX 21-DEC-2001; 2001US-00028075.
XX
XX (BENNER R. KHAN N A.
XX (KHAN N A.
XX
XX Benner R, Khan NA;
XX
XX WPI; 2004-069536/07.
XX
XX Modulating or treating immunosuppressive state in subject involves
XX providing the subject with a gene-regulatory peptide or its functional
XX analogue.
XX
XX Example; SEQ ID NO 2; 14pp; English.
XX
XX The present invention relates to a method for modulating or treating
XX immunosuppressive states in a subject. The method involves providing the
XX subject with a nuclear factor-kappaB (NF-kappaB) gene-regulatory peptide
XX or its functional analogue. Also disclosed is a pharmaceutical
XX composition comprising an NF-kappaB up-regulating peptide or its
XX functional analogue, and an agent directed against disseminated
XX intravascular coagulation. The method of the invention is useful for
XX modulating or treating immunosuppressive state in a subject that has
XX experienced trauma or is at risk of suffering a counter anti-inflammatory
XX response syndrome. The invention allows the upregulation of anti-

CC inflammatory responses such as interleukin-10 (IL-10), and the
CC downregulation of pro-inflammatory responses such as those mediated by
CC tumour necrosis factor-alpha (TNF-alpha), nitric oxide, IL-5, and IL-
CC 1beta. The present sequence represents a NF-kappaB gene-regulatory
CC peptide.
XX
SQ Sequence 4 AA;
QY
Db 1 ACGV 4
1 ACGV 4
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
RESULT 13
ADG86561
ID ADG86561 standard; peptide; 4 AA.
XX
AC ADG86561;
XX
XX 11-MAR-2004 (first entry)
XX
DE NF-kappaB gene-regulatory peptide #2.
XX
KM Nuclear factor-kappaB; NF-kappaB; gene-regulatory peptide;
KM conjunctivitis; dry eye; immunosuppression; down-regulation;
KM inflammatory pathway; NF-kappaB/Rel family; ophthalmological;
KM immunosuppressive.
XX
OS Unidentified.
XX
XX US2003220260-A1.
XX
XX 27-NOV-2003.
XX
XX 08-APR-2003; 2003US-00409659.
XX
XX 21-DEC-2001; 2001US-00028075.
XX
XX (KHAN N A.
XX (BENNER R. KHAN N A.
XX
XX Khan NA, Benner R;
XX
XX WPI; 2004-097357/10.
XX
XX Pharmaceutical composition for topical application used to treat
XX conjunctivitis and to modulate immunosuppression, comprises gene-
XX regulatory peptide or its functional analogue.
XX
XX Example; SEQ ID NO 2; 20pp; English.
XX
XX The present invention relates to a method for modulating or treating a
XX variety of diseases in a subject. The method involves providing the
XX subject with a nuclear factor-kappaB (NF-kappaB) gene-regulatory peptide
XX or its functional analogue. The method of the invention is useful for
XX modulating NF-kappaB. The method may be used to treated conjunctivitis
XX for the treatment of dry eyes. It is also used to modulate
XX immunosuppression. The invention is capable of down-regulating
XX inflammatory pathways. It is also capable of modulating the transcription
XX of genes that are under the control of NF-kappaB/Rel family of factors.
XX The present sequence represents a NF-kappaB gene-regulatory peptide.
XX
SQ Sequence 4 AA;
QY
Db 1 ACGV 4
1 ACGV 4
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 AOCV 4

RESULT 14

ID ADI20991 standard; peptide; 4 AA.

AC ADI20991;

DT 22-APR-2004 (first entry)

DE Human nuclear factor kappa B (NFkappaB) gene regulatory peptide #2.

KM Human; nuclear factor kappa B; NFkappaB; gene regulatory peptide; hCG;

KM human chorionic gonadotropin; inflammatory cytokine;

KM neurological disorder; schizophrenia; manic depression; bipolar disorder;

KM multiple sclerosis; post-partum psychosis; autism;

KM chronic fatigue syndrome; fibromyalgia; Alzheimer's disease;

KM mood disorder; stress; transcription factor; Rel protein;

KM cell-mediated immunity; IL-10; tumour necrosis factor; nitric oxide;

KM IL-5; IL-6; IL-1beta.

OS Homo sapiens.

PN US2003220259-A1.

PD 27-NOV-2003.

PF 08-APR-2003; 2003US-00409654.

PR 21-DEC-2001; 2001US-00028075.

PA (BENN/) BENNER R.

PA (KHAN/) KHAN N A.

PA (WENS/) WENSVOORT G.

PI Benner R, Khan NA, Wensvoort G;

PI WPI; 2004-097356/10.

PT Modulating neurological disorder in a subject involves providing the

PT subject with a gene-regulatory peptide or its functional analogue.

PS Example; Page 5; 11pp; English.

XX The invention relates to modulating a neurological disorder in a subject

XX involves providing the subject with a gene-regulatory peptide or its

XX functional analogue (e.g. those derived from human chorionic

XX gonadotropin, produced during pregnancy and thought to regulate pro-

XX inflammatory cytokine production via regulation of NF-kappaB (nuclear

XX factor kappa B). The gene regulatory peptide or its functional analogue

XX down-regulates translocation and/or activity, of a gene transcription

XX factor (comprising NF-kappaB/Rel protein). The invention is used for

XX modulating a neurological disorder (such as in a subject that presents

XX clinical signs of autism, e.g. schizophrenia, manic depression and other

XX bipolar disorders, multiple sclerosis, postpartum psychosis, autism,

XX chronic fatigue syndrome, fibromyalgia, Alzheimer's, mood disorders, and

XX certain form of stress. The invention reduces the frequency and limits

XX the lasting effects of psychological manifestations of neuroimmune

XX disease. It counters the involvement of cell-mediated immunity in the

XX etiology of neurologic disease. It allows up-regulating anti-inflammatory

XX responses such as IL-10, and downregulating pro-inflammatory responses

XX such as mediated by tumour necrosis factor (TNF)-alpha, nitric oxide, IL-

XX 5, IL-6 and IL-1beta. The present sequence is a gene regulating peptide

XX of the invention.

XX Sequence 4 AA;

XX Query Match 100.0%; Score 19; DB 8; Length 4;

XX Best Local Similarity 100.0%; Pred. No. 2e+06;

XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOCV 4

RESULT 15

ID ADI16437 standard; peptide; 4 AA.

AC ADI16437;

DT 22-APR-2004 (first entry)

DE NF-kappaB down-regulating peptide, SEQ ID NO 2.

KM burn injury; gene-regulatory; NF-kappaB down-regulating peptide;

KM disseminated intravascular coagulation; bacteriostatic; silver;

KM hypocoag; burn.

OS Undefined.

PN US2003224995-A1.

PD 04-DEC-2003.

PF 08-APR-2003; 2003US-00409694.

PR 21-DEC-2001; 2001US-00028075.

PA (KHAN/) KHAN N A.

PA (WENS/) WENSVOORT G.

PA (BENN/) BENNER R.

PI Khan NA, Wensvoort G, Benner R;

PI WPI; 2004-033998/03.

PT Modulating burn injury in subject, comprises providing gene-regulatory

PT peptide or its analog to subject.

PS Example; SEQ ID NO 2; 17pp; English.

XX The invention relates to a novel method for modulating burn injury in a

XX subject. The method involves providing a gene-regulatory peptide or its

XX analogue to the subject. The invention further relates to: a

XX pharmaceutical composition comprising an NF-kappaB down-regulating

XX peptide or its functional analogue, and an agent directed against

XX disseminated intravascular coagulation, or a bacteriostatic compound

XX comprising silver; a hypotonic pharmaceutical composition comprising an

XX NF-kappaB down-regulating peptide or its functional analogue; and a

XX method for treating a subject suffering from a burn, involving providing

XX the subject with a sufficient amount of a gene-regulatory peptide to down

XX -regulate translocation and/or activity of NF-kappaB/Rel protein and

XX further providing an agent having activated protein C activity and

XX directed against disseminated intravascular coagulation. This sequence

XX represents an NF-kappaB down-regulating peptide to be used in a

XX pharmaceutical composition of the invention.

XX Sequence 4 AA;

XX Query Match 100.0%; Score 19; DB 8; Length 4;

XX Best Local Similarity 100.0%; Pred. No. 2e+06;

XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX OY 1 AOCV 4

XX Db 1 AOCV 4

XX RESULT 16

XX ADK42374

XX ID ADK42374 standard; peptide; 4 AA.

AC ADK42374;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Antibacterial peptide from pHP #135.
 XX
 KW pig; heparin binding protein; HBP; neutrophil elastase; antibacterial;
 KW cytokine IL-6; monocyte; bacterial infection; sepsis; septic shock;
 KW disseminated intravascular coagulation; meningococcal meningitis;
 KW pneumococcal pneumonia; inflammatory response; cell apoptosis;
 KW suppressed immune system; cancer; autoimmune diseases; trauma.
 XX
 OS Sus scrofa.
 XX
 PN WO2004016653-A2.
 XX
 PD 26-FEB-2004.
 XX
 PF 14-AUG-2003; 2003WO-DK000542.
 XX
 PR 15-AUG-2002; 2002DK-00001212.
 XX 19-AUG-2002; 2002US-0404155P.
 PR 27-JUN-2003; 2003DK-00000987.
 XX
 PA (LEUK-) LEUKETOCH AS.
 XX
 PI Djurup R, Flodgaard HJ, Norris K;
 XX WPI; 2004-257185/24.
 DR
 XX
 PT New peptides of heparin-binding protein and/or human neutrophil elastase
 PT for manufacturing a medicament for the treatment of e.g. bacterial
 PT infections, disseminated intravascular coagulation, cancer or autoimmune
 PT diseases.
 PT
 PS Claim 52; SEQ ID NO 356; 21pp; English.
 XX
 CC The invention relates to an antibacterial peptide conforming to the
 CC generic peptide sequence appearing as ADK42632, the motif being derived
 CC from analysis of the protein sequences of human heparin binding protein,
 CC hHBP, pig pHP and human neutrophil elastase (hNLE). Also included are a
 CC process for producing the new peptide (comprising providing an expression
 CC vector containing a DNA sequence encoding one or more of the above-
 CC mentioned amino acid sequences, transforming host cells with the above-
 CC mentioned amino acid sequences, transforming host cells with the vector,
 CC and a pharmaceutical composition comprising the new peptide. The peptide
 CC is capable of inhibiting or stimulating the secretion of cytokine IL-6
 CC from monocytes. The peptides are useful in manufacturing a medicament for
 CC the treatment of Gram-negative or Gram-positive bacterial infection, such
 CC as sepsis, severe sepsis, septic shock, disseminated intravascular
 CC coagulation, meningococcal meningitis or pneumococcal pneumonia. These
 CC may also be used in manufacturing a medicament for the stimulation or
 CC inhibition of inflammatory response, for the prevention of cell
 CC apoptosis, or for the treatment of individuals having suppressed immune
 CC system, cancer, autoimmune diseases and/or trauma. The present sequence
 CC represents an antibacterial peptide of the invention derived from pig
 CC HBP.
 XX
 SQ Sequence 4 AA;
 XX
 Query Match 100.0%; Score 19; DB 8; Length 4;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 17
 ADM48491
 ID ADM48491 standard; peptide; 4 AA.
 XX

AC ADM48491;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE NF-kappaB down-regulating peptide #2.
 XX
 KW Multiple sclerosis; MS; gene-regulatory peptide; NF-kappaB.
 XX
 OS Unidentified.
 XX
 PN US2003215434-A1.
 XX
 PD 20-NOV-2003.
 XX
 PF 08-APR-2003; 2003US-00409630.
 XX
 PR 21-DEC-2001; 2001US-00028075.
 XX
 PA (KHAN/) KHAN N A.
 XX (BENNN/) BENNER R.
 XX
 PI Khan NA, Benner R;
 XX WPI; 2004-080670/08.
 DR
 XX
 PT Modulation of relapsing/remitting disease in subject suffering from
 PT multiple sclerosis, by providing the subject with gene-regulatory peptide
 PT or its functional analogues.
 PT
 PS Example; Page 4; 11pp; English.
 XX
 CC The invention relates to a method for modulating relapsing/remitting
 CC disease in subject suffering from multiple sclerosis (MS), by providing
 CC the subject with gene-regulatory peptide or its functional analogues. The
 CC gene-regulatory peptide or its functional analogue has NF-kappaB down-
 CC regulating activity in LPS (sic) stimulated RAW264.7 cells. The method is
 CC useful for modulating relapsing/remitting disease in subject suffering
 CC from multiple sclerosis. The present sequence is a NF-kappaB down-
 CC regulating peptide. This sequence is used to illustrate the method of the
 CC invention.
 CC
 XX
 SQ Sequence 4 AA;
 XX
 Query Match 100.0%; Score 19; DB 8; Length 4;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 18
 ADO15345
 ID ADO15345 standard; peptide; 4 AA.
 XX
 AC ADO15345;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Nuclear factor-kappaB down-regulating peptide #2.
 XX
 KW Inflammatory condition; counter-inflammatory condition;
 KW gene-regulatory peptide; pro-inflammatory cytokine;
 KW tumour necrosis factor-alpha; interferon-gamma; interleukin-1beta;
 KW interleukin-6; counter-inflammatory cytokine; interleukin-4;
 KW interleukin-10; HLA-DR expression; circulating monocyte;
 KW arachidonic acid metabolite; plasma prostaglandin.
 XX
 OS Unidentified.
 XX
 PN US2004013661-A1.
 XX

PD 22-JAN-2004.
 XX 08-APR-2003; 2003US-00409657.
 XX 21-DEC-2001; 2001US-00028075.
 PR (WENS/) WENSVOORT G.
 PA (KHAN/) KHAN N A.
 PA (BENR/) BENNER R.
 XX Wensvoort G, Khan NA, Benner R;
 PI WPI; 2004-108189/11.
 DR
 XX
 XX
 PT Treating subject suffering from inflammatory and/or counter-inflammatory
 PT condition, by determining disease stage using diagnostic process,
 PT providing gene-regulatory peptide to subject depending on disease stage.
 XX
 PS Example; Page 6; 14pp; English.
 XX
 XX The invention relates to treating a subject suffering from inflammatory
 CC and/or counter-inflammatory condition, involves determining subject's
 CC inflammatory disease stage using diagnostic process, and providing
 CC subject with gene-regulatory peptide or its functional analogue depending
 CC on the outcome of determination of disease stage. The diagnostic process
 CC includes determining the level of a pro-inflammatory cytokine in a sample
 CC taken from a patient (where the pro-inflammatory cytokine is chosen from
 CC tumour necrosis factor-alpha, interferon-gamma, interleukin-1beta,
 CC interleukin-6, and its combination), determining the level of a counter-
 CC inflammatory cytokine (e.g., interleukin-4 or interleukin-10),
 CC determining HLA-DR expression on circulating monocytes, determining
 CC arachidonic acid metabolite levels and determining plasma prostaglandin
 CC levels (a ratio between prostaglandins 1 and 2) in the subject. The gene-
 CC regulatory peptide or its functional analogue down-regulates (for an
 CC inflammatory condition) or up-regulates (for a counter-inflammatory
 CC condition) translocation activity, or translocation and activity of pro-
 CC inflammatory cytokine gene expression mediated by a gene transcripction
 CC factor (NF-kappaB/Rel protein). The method is useful for treating subject
 CC suffering from inflammatory and/or counter-inflammatory condition. The
 CC present sequence is a NF-kappaB/Rel down-regulating peptide.
 XX
 XX Sequence 4 AA;
 SQ
 Query Match 100.0%; Score 19; DB 8; Length 4;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ACGV 4
 Db 1 ACGV 4
 Db
 RESULT 19
 ADT08600 standard; peptide; 4 AA.
 XX
 AC ADT08600;
 XX
 DT 30-DEC-2004 (first entry)
 XX
 DE Human chorionic gonadotropin related peptide #2.
 XX
 XX Antiinflammatory; Nuclear factor kappa B; NF-kappaB; human;
 KM chorionic gonadotropin; hCG.
 XX
 OS Homo sapiens.
 XX
 PN EP146611-A1.
 XX
 PD 13-OCT-2004.
 XX
 PF 08-APR-2003; 2003EP-00076022.
 XX
 PF

PR 08-APR-2003; 2003EP-00076022.
 XX
 XX (BIOT-) BIOTEMPT BV.
 PA
 XX
 DR WPI; 2004-749906/74.
 XX
 XX
 PT Modulating an iatrogenic event comprises providing the subject with a
 PT gene-regulatory peptide or its functional analogue, particularly an
 PT inhibitor of NF-kappaB/Rel translocation or activity.
 XX
 PS Example; Page 9; 16pp; English.
 XX
 XX The present invention relates to a method for modulating an iatrogenic
 CC event (i.e. an adverse event that results from medical treatment) in a
 CC subject. The method comprises providing the subject with a gene-
 CC regulatory peptide or its functional analogue, where the peptide or
 CC analogue inhibits the translocation and/or activity of a gene
 CC transcripction factor such as Nuclear Factor (NF)-kappaB/ Rel protein or
 CC AP-1 protein. The iatrogenic event comprises destruction or lysis of a
 CC cell or tissue of the subject or of a pathogen hosted by the subject. The
 CC lysis is due to treatment of the subject with a pharmaceutical
 CC composition selected from antigens, vaccines, antibodies, anticoagulants,
 CC antibiotics, antitoxins, antibacterial agents, antiparasitic agents,
 CC antiprotzoic agents, antifungal agents, antiviral agents, cytolytic
 CC agents, cytostatic agents and thrombolytic agents. The lysis may be due
 CC to treatment of the subject with a virus comprising a lytic phase. The
 CC present sequence is one such gene-regulatory peptide used in the method
 CC of the invention which is derived from human chorionic gonadotropin
 CC (hCG). This peptide is a NF-kappaB down regulating peptide.
 XX
 XX Sequence 4 AA;
 SQ
 Query Match 100.0%; Score 19; DB 8; Length 4;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ACGV 4
 Db 1 ACGV 4
 Db
 RESULT 20
 ADT08628 standard; peptide; 4 AA.
 XX
 AC ADT08628;
 XX
 DT 30-DEC-2004 (first entry)
 XX
 DE Human chorionic gonadotropin related peptide #2.
 XX
 XX Antiinflammatory; Antibacterial; Immunosuppressive; Immunostimulant;
 KM Immunomodulator; inflammatory disorder; Nuclear Factor kappaB; NF-kappaB;
 KM human; chorionic gonadotropin; hCG.
 XX
 OS Homo sapiens.
 XX
 PN EP146612-A1.
 XX
 PD 13-OCT-2004.
 XX
 DE 08-APR-2003; 2003EP-00076023.
 XX
 PF 08-APR-2003; 2003EP-00076023.
 XX
 PA (BIOT-) BIOTEMPT BV.
 XX
 DR WPI; 2004-711295/70.
 XX
 PT Treating a subject suffering from an inflammatory or counter-inflammatory
 PT condition comprises subjecting the subject to a diagnostic process and
 PT administering an appropriate gene-regulatory peptide based on the
 PT results.

XX Example; Page 10; 20pp; English.

CC The present invention relates to a method for treating a subject
 CC suspected to suffer from an inflammatory and/or a counter-inflammatory
 CC condition. The method comprises subjecting the subject to a diagnostic
 CC process aimed at determining inflammatory disease stage and providing the
 CC subject with a gene-regulatory peptide or its functional analogue
 CC depending on the results of the diagnostic process. The diagnostic
 CC process includes determining the level of a pro-inflammatory cytokine,
 CC which is preferably selected from tumor necrosis factor-alpha, interferon
 CC -gamma, interleukin-1-beta and interleukin-6. The diagnostic process
 CC includes determining the level of a counter-inflammatory cytokine
 CC selected from interleukin-4 and interleukin-10. The diagnostic process
 CC preferably includes determining HLA-DR expression on circulating
 CC monocytes of the subject. The diagnostic process preferably includes
 CC determining arachidonic acid metabolite levels. The process preferably
 CC includes determining plasma prostaglandin levels, specifically
 CC determining a ratio between prostaglandins 1 and 2 (PGE1 and PGE2). The
 CC method comprises providing the subject with a gene-regulatory peptide or
 CC its functional analogue based on the determination of disease stage as an
 CC essentially inflammatory condition, where the gene-regulatory peptide
 CC down-regulates translocation and/or activity of pro-inflammatory cytokine
 CC gene expression mediated by a gene transcription factor. The
 CC transcription factor preferably comprises an Nuclear Factor (NF) -
 CC kappaB/Rel protein and the translocation and/or activity of the protein
 CC is inhibited. The peptide is preferably selected from peptides having NF-
 CC kappaB down-regulating activity in lipopolysaccharide (LPS) stimulated or
 CC unstimulated RAW264.7 cells. Inflammatory conditions that may be treated
 CC include systemic inflammatory response syndrome (SIRS) and sepsis.
 CC Counter-inflammatory conditions that may be treated include
 CC immunosuppression associated with major trauma. The present sequence is
 CC one such gene-regulatory peptide used in the method of the invention
 CC which is derived from human chorionic gonadotropin (hCG). This peptide is
 CC a NF-kappaB down regulating peptide.

XX Sequence 4 AA;

Query Match 100.0%; Score 19; DB 8; Length 4;
 Best Local Similarity 100.0%; Pred. No. 2e+06; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
 ||||
 Db 1 ACGV 4

RESULT 21

ADT08656
 ID ADT08656 standard; peptide; 4 AA.

XX ADT08656;

AC 30-DEC-2004 (first entry)

XX Human chorionic gonadotropin related peptide #2.

XX Antinflammatory; Antidiabetic; Neuroprotective; Immunosuppressive;
 KW Dermatological; Antirheumatic; Antiallergic; Antiallergic;
 KW Antiaesthetic; Antiparasitic; Virucide; Antibacterial;
 KW Nuclear Factor kappaB; NF-kappaB; inflammatory disorder; human;
 KW chorionic gonadotropin; hCG.

OS Homo sapiens.

XX EPI466613-A1.

PD 13-OCT-2004.

XX 08-APR-2003; 2003EP-00076030.

PF 08-APR-2003; 2003EP-00076030.

PR 08-APR-2003; 2003EP-00076030.

PA (BIOT-) BIOTEMPT BV.

XX WPI; 2004-711296/70.

DR Pharmaceutical composition useful for treating e.g. diabetes, multiple

PT sclerosis comprises gene-regulatory peptide.

XX Example; Page 6; 29pp; English.

CC The present invention relates to novel pharmaceutical compositions
 CC comprising a gene-regulatory peptide, its functional analog and diluent.
 CC The gene-regulatory peptide modulates (preferably inhibits) translocation
 CC and gene transcription factor e.g. Nuclear Factor (NF)-kappaB/Rel
 CC protein; regulates expression of gene encoding an inflammatory mediator
 CC containing cytokine selected from TNF-alpha, TGF-beta, interferon gamma,
 CC IL-1beta, IL-4, IL-5, IL-6, IL-10, IL-12, IL-23 and IL-40. The
 CC compositions are useful for treating disease such as inflammatory disease
 CC such as chronic inflammation e.g. diabetes, multiple sclerosis, chronic
 CC transplant rejection, acute inflammation e.g. septic or anaphylactic
 CC shock, acute or hyper acute transplant rejection; autoimmune disease e.g.
 CC systemic lupus erythematosus or rheumatoid arthritis; allergy e.g. asthma
 CC or parasitic disease; overly strong immune response directed against an
 CC infectious agent e.g. virus or bacterium, systemically. The present
 CC sequence is one such gene-regulatory peptide used in the method of the
 CC invention which is derived from human chorionic gonadotropin (hCG).

XX Sequence 4 AA;

Query Match 100.0%; Score 19; DB 8; Length 4;
 Best Local Similarity 100.0%; Pred. No. 2e+06; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
 ||||
 Db 1 ACGV 4

RESULT 22

ADT79351
 ID ADT79351 standard; peptide; 4 AA.

XX ADT79351;

AC 30-DEC-2004 (first entry)

XX Nuclear factor (NF)-kappaB up-regulating peptide #1.

XX Gene-regulatory peptide; chronic inflammatory disease; diabetes;
 KW multiple sclerosis; acute inflammation; septic shock; anaphylactic shock;
 KW transplant rejection; autoimmune disease; systemic lupus erythematosus;
 KW rheumatoid arthritis; allergic reaction; asthma; parasitic disease;
 KW immune response; antinflammatory; antidiabetic; neuroprotective;
 KW immunosuppressive; antibacterial; antiallergic; dermatological;
 KW antiarthritis; antirheumatic; antiaesthetic; antiparasitic;
 KW nuclear factor-kappaB; NF-kappaB.

OS Synthetic.

XX US2004202645-A1.

PD 14-OCT-2004.

PF 08-APR-2003; 2003US-00409668.

PR 08-APR-2003; 2003US-00409668.

XX (KHAN/) KHAN N A.

PA (BENNER/) BENNER R.

PI Khan NA, Benner R;

DR WPI; 2004-727977/71.

PT Composition, useful to treat e.g. acute/chronic inflammation, autoimmune
PT disease and an allergic reaction, comprises a gene-regulatory peptide or
PT its functional analogue together with a diluent.
XX
PS Disclosure; SEQ ID NO 2; 28pp; English.
XX
CC The invention relates to a pharmaceutical composition comprising a gene-
CC regulatory peptide or its functional analogue together with a diluent.
CC The pharmaceutical composition is useful to systemically treat chronic
CC inflammatory disease (diabetes, multiple sclerosis or chronic transplant
CC rejection); acute inflammation (septic or anaphylactic shock or acute and
CC hyper acute transplant rejection); autoimmune disease (systemic lupus
CC erythematosus or rheumatoid arthritis); allergic reaction (asthma or
CC parasitic disease); and/or overly strong immune response directed against
CC an infectious agent (bacteria or virus) infecting the subject. The
CC present sequence is a nuclear factor (NF)-kappaB gene-regulatory peptide.
XX
SQ Sequence 4 AA;
XX
Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06; Mismatches 0; Gaps 0;
Matches 4; Conservative 0; Indels 0; Gaps 0;
QY 1 ACGV 4
Db 1 ACGV 4
XX
RESULT 23
ADT49387
ID ADT49387 standard; peptide: 4 AA.
XX
AC ADT49387;
XX
DT 13-JAN-2005 (first entry)
XX
DE Human chorionic gonadotropin derived peptide, NMPP-46.
XX
XX Immunomodulator; human chorionic gonadotropin; hCG; sepsis; shock;
XX septic shock; gene regulation; bone disease; osteoporosis; inflammation;
XX tissue damage; multiple organ failure; diabetes; insulinitis; glucosuria;
XX immune-mediated disorder; wasting syndrome; NMPP-46.
XX
OS Homo sapiens.
XX
XX US2004208885-A1.
XX
XX 21-OCT-2004.
XX
PD 07-JAN-2004; 2004US-00753510.
XX
PF 03-MAR-2001; 2001MO-NL000259.
XX
PR 21-DEC-2001; 2001US-00028075.
XX
PR 30-SEP-2002; 2002US-00262522.
XX
PR 10-APR-2003; 2002MO-NL000639.
XX
PA (KHAN/) KHAN N A.
XX
PA (BENN/) BENNER R.
XX
PI Khan NA, Benner R;
XX
XX WPI; 2004-747166/73.
XX
XX Composition useful for treating e.g. a bone disease such as osteoporosis,
XX or sepsis, comprises a purified or isolated peptide that modulates
XX production of nitric oxide by a cell.
XX
XX Claim 11; SEQ ID NO 2, 50pp; English.
XX
XX The present invention relates to compounds exhibiting immunomodulatory
XX activity as determined by measuring the compounds ability to modulate
XX production of NO by a cell. In particular, the compounds include
XX oligopeptides derived from human chorionic gonadotropin (hCG), and with

CC the antigenic binding activity of hCG. The peptides comprise a small
CC amino acid segment of a larger sequence, defined in the specification, or
CC a derivative of the segment having one or more conservative
CC substitutions, and exhibiting an immunoregulatory activity. The
CC oligopeptides are useful in the treatment of sepsis, shock, septic shock,
CC tissue damage, multiple organ failure, diabetes, glucosuria, insulinitis,
CC immune-mediated disorder, wasting syndrome and have gene regulation
CC activities. The invention provides a method for the treatment of bone
CC disease such as osteoporosis, useful in post menopausal women that no
CC longer have a natural source of hCG and its breakdown products.
CC Immunomodulatory effects of the oligopeptides have been observed in T-cell
CC assays showing the inhibition of pathological Th1 immune responses.
CC suppression of inflammation cytokines (MIP), increase in antiinflammatory
CC cytokines (IL-10, TGF-beta) and immunomodulatory effects on antigen-
CC presenting cells, monocytes and macrophages. The present sequence is an
CC amino acid portion of a longer sequence derived from hCG, and is named as
XX NMPP-46 in the specification.
XX
SQ Sequence 4 AA;
XX
Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06; Mismatches 0; Gaps 0;
Matches 4; Conservative 0; Indels 0; Gaps 0;
QY 1 ACGV 4
Db 1 ACGV 4
XX
RESULT 24
ADU46871
ID ADU46871 standard; peptide: 4 AA.
XX
XX ADU46871;
XX
XX 27-JAN-2005 (first entry)
XX
XX Gene regulatory peptide for treatment of immune-related disorder.
XX
XX Gene regulation; human chorionic gonadotropin; antiinflammatory;
XX antidiabetic; neuroprotective; immunosuppressive; dermatological;
XX antirheumatic; antiarthritic; antiallergic; antiasthmatic; antiparasitic;
XX gynecological; nuclear factor kappa B.
XX
XX Synthetic.
XX
XX WO2004093897-A1.
XX
XX 04-NOV-2004.
XX
XX 08-APR-2004; 2004MO-EP003747.
XX
XX 08-APR-2003; 2003EP-00076021.
XX
XX 08-APR-2003; 2003EP-00076022.
XX
XX 08-APR-2003; 2003EP-00076023.
XX
XX 08-APR-2003; 2003EP-00076024.
XX
XX 08-APR-2003; 2003EP-00076025.
XX
XX 08-APR-2003; 2003EP-00076026.
XX
XX 08-APR-2003; 2003EP-00076027.
XX
XX 08-APR-2003; 2003EP-00076028.
XX
XX 08-APR-2003; 2003EP-00076029.
XX
XX 08-APR-2003; 2003EP-00076030.
XX
XX 30-APR-2003; 2003US-00409671.
XX
XX 30-APR-2003; 2003CN-00131227.
XX
XX (BIOT-) BIOTEMPT BV.
XX
XX Khan NA, Benner R, Wensvoort G;
XX
XX WPI; 2004-784832/77.
XX
XX A pharmaceutical composition for mucosal or oral treatment of immune-
XX mediated disorders (e.g. allergy, transplant disorders or inflammatory

PT diseases) comprises an amount of a gene-regulatory peptide and a
XX pharmaceutical diluent.
PS Example; SEQ ID NO 2; 95pp; English.
XX
CC The present sequence is that of a nuclear factor kappa B (NFkB)
CC regulating peptide that is an example of gene regulatory peptides of the
CC invention. The invention provides the treatment of a disease by mucosal,
CC preferably oral, administration of a pharmaceutical composition
CC comprising a gene regulatory peptide obtained or derived from human
CC chorionic gonadotropin (hCG) in order to generate systemic modulation of
CC the expression of a gene. Such peptides are present naturally in pregnant
CC women and are derived from proteolytic breakdown of placental
CC gonadotropins such as hCG produced during pregnancy. However, synthetic
CC variants and modifications of these peptides having equivalent activity
CC can be synthesised and tested for activity using e.g. NOD mice.
CC Pharmaceutical compositions comprising gene regulatory peptides of the
CC invention can be used to treat an inflammatory disease such as: a disease
CC comprising chronic inflammation, such as diabetes, multiple sclerosis or
CC chronic transplant rejection; acute inflammation such as septic or
CC anaphylactic shock or acute or hyper-acute transplant rejection; an
CC autoimmune disease such as systemic lupus erythematosus or rheumatoid
CC arthritis; an allergy such as asthma or parasitic disease; or an overly
CC strong immune response directed against an infectious agent (all
CC claimed). The gene regulatory peptides modulate the translocation and/or
CC activity of a gene transcription factor, especially they inhibit NFkB/Rel
CC protein or regulate expression of an inflammatory mediator such as a
CC cytokine. The present peptide is a NFkB down-regulating peptide, and was
CC shown to modulate the translocation of NFkB into the nucleus of RAW264.7
CC macrophages. It can be produced by solid-phase synthesis. The peptide is
CC preferred for oral administration, and is preferred for use in the
CC treatment of a neurological disorder, a relapsing/remitting disease such
CC as multiple sclerosis, diabetes, or a menopause, post-menopausal or
CC osteoporosis condition, and can be added to transplant preservation fluid
CC or transplant perfusion fluid. It is the most preferred peptide for oral
CC treatment of reperfusion injury.
XX
SQ Sequence 4 AA;
XX
Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ACGV 4
|||
Db 1 ACGV 4
XX
RESULT 25
ADY03875
ID ADY03875 standard; peptide; 4 AA.
XX
AC ADY03875;
XX
DT 05-MAY-2005 (first entry)
XX
DE Peptide database creation method peptide #2.
XX
XX peptide library; peptide mapping; gonadotropin; tumor necrosis factor;
XX interleukin; interferon.
XX
OS Synthetic.
XX
PN US2005037430-A1.
XX
PD 17-FEB-2005.
XX
PF 08-APR-2004; 2004US-00821240.
XX
PR 29-MAR-2000; 2000EP-00201139.
PR 03-MAR-2001; 2001WO-NL000259.
PR 04-OCT-2001; 2001EP-00203748.
PR 21-DEC-2001; 2001US-00028075.

PR 30-SEP-2002; 2002US-00262522.
PR 10-APR-2003; 2002WO-NL000639.
PR 07-JAN-2004; 2004US-00753510.
XX
XX (BIOT-) BIOTEMPT BV.
XX
XX Khan NA, Benner R;
XX
DR WPI; 2005-172262/18.
XX
XX
PT Creating a peptide database, involves screening peptides to determine
PT activity of peptide, analyzing physical, chemical, or biological property
PT of peptides, recording properties of all peptides in peptide database.
XX
PS Disclosure; SEQ ID NO 2; 95pp; English.
XX
XX The invention relates to a method of creating (M1) a peptide database, by
XX providing a first source of peptides, screening a peptide to determine
XX the activity of the peptide, analyzing the results, characterizing a
XX physical, chemical, or biological property of the peptide, recording in
XX a peptide database the characteristics of all peptides, recording in the
XX peptide database results of analysis of the peptides, thus generating a
XX database or part of a database of peptides. (M1) is useful for creating a
XX peptide database. The peptides are related to gonadotropin, especially
XX human chorionic gonadotropin. Analyzing the peptides comprises analyzing
XX an anti-shock effect, analyzing TNF-alpha, analyzing effect of peptide on
XX angiogenesis, analyzing a condition associated with a dysfunctional LDL
XX receptor or analyzing the effect of the peptide on at least one
XX inflammatory mediator chosen from IL-1-alpha, IL-1-beta, IL-6, TNF-alpha,
XX LIF, IFN-gamma, OSM, CNP, GM-CSF, IL-11, IL-12, IL-17, IL-18 and IL-8.
XX The peptides are related to beta-catenin, C-reactive protein, matrix
XX metalloproteinase-2 or Bruton's tyrosine kinase. (M1) is useful for
XX assaying several peptides by ex vivo, in vivo, and animal assays, thus
XX allowing for rational design of molecular mixtures that better alleviate
XX the symptoms of certain diseases. This sequence corresponds to a peptide
XX of the invention.
XX
SQ Sequence 4 AA;
XX
Query Match 100.0%; Score 19; DB 9; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ACGV 4
|||
Db 1 ACGV 4
XX
RESULT 26
ADY82494
ID ADY82494 standard; peptide; 4 AA.
XX
AC ADY82494;
XX
DT 16-JUN-2005 (first entry)
XX
DE Forcine heparin binding protein (HBP) antigenic peptide, SEQ ID 356.
XX
XX Antibacterial; Antiinflammatory; Inflammation; Cytostatic; Vulnerary;
XX Anticoagulant; Heparin binding agent antagonist; Bacterial infection;
XX infection; cancer; cytostatic; neoplasm; trauma; injury;
XX autoimmune disease; immunosuppressive; immune disorder;
XX bacterial meningitis; meningitis; neuroprotective; neurological disease;
XX heparin binding protein; HBP; monoclonal antibody; antibody production;
XX antigen; disseminated intravascular coagulation; hematological disease.
XX
OS Sus sp.
XX
PN WO2005028512-A1.
XX
PD 31-MAR-2005.
XX
PF 17-SEP-2004; 2004WO-DK000634.

PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002MO-GB001534.
 XX
 PR 06-APR-2001; 2001GB-00008752.
 XX
 PA (ISIS-) ISIS INNOVATION LTD.
 XX
 PI Ogg G, Seneviratne S;
 XX
 DR WPI; 2003-058499/05.
 XX
 PT New peptide fragments of the Der p1 antigen of the house dust mite
 PT Dermatophagoides pteronyssinus contain a human CD8+ T cell epitope and
 PT are useful to treat and prevent allergy to the major house dust mite
 PT allergen.
 XX
 PS Disclosure; Page 31; 47pp; English.
 XX
 CC The present invention relates to house dust mite (Dermatophagoides
 CC pteronyssinus) Der p1 antigen peptides containing human CD8 cell
 CC epitopes. The peptides of the invention are useful in the treatment of
 CC human or animal patients, particularly to raise an immune response to the
 CC Der p1 antigen. They are useful in the treatment and prevention of
 CC allergies to the major house dust mite antigen, and to monitor disease
 CC activity in atopic patients. ABU1078-ABU1146 represent house dust mite
 CC Der p1 antigen peptides containing CD8+ T-cell epitopes
 XX
 SQ Sequence 9 AA;

Query Match 100.0%; Score 19; DB 6; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
 ||||
 Db 4 ACGV 7

RESULT 29
 ADZ50681
 ID ADZ50681 standard; peptide; 9 AA.
 XX
 AC ADZ50681;
 XX
 DT 14-JUL-2005 (first entry)
 XX
 DE Y. pestis cytotoxic T-cell epitope SEQ ID 749.
 XX
 KW Yersinia pestis infection; antibacterial; infection; epitope; T-cell;
 KW vaccine; biological warfare.
 XX
 OS Yersinia pestis.
 XX
 PN WO2005037855-A2.
 XX
 PD 28-APR-2005.
 XX
 PF 15-OCT-2004; 2004MO-US033883.
 XX
 PR 17-OCT-2003; 2003US-0511653P.
 XX
 PA (PECO-) PECOS LABS INC.
 XX
 PI Lund O, Lundegaard C, Nielsen M, Morning P, Deans RJ, Buus S;
 PI Brunak S;
 XX
 DR WPI; 2005-315677/32.
 XX
 PT New cytotoxic Yersinia pestis T-cell epitope comprising 10 amino acids,
 PT useful as a vaccine or diagnostic tool and for inducing immune response
 PT in a subject.
 XX

PS Claim 1; SEQ ID NO 749; 235pp; English.
 XX
 CC The invention relates to a cytotoxic Yersinia pestis T-cell epitope.
 CC selected from any of the 1000 sequences of 9 amino acids appearing as
 CC ADZ49933-ADZ50932. Also included are predicting peptides that are
 CC epitopes or can be used as diagnostic tools (comprising predicting which
 CC peptides bind to a MHC molecule (not defined) with high affinity using a
 CC neural network with at least one of the following features: some or all
 CC of the inputs to the neural networks are generated using a hidden Markov
 CC model; or some or all of the inputs are encoded by an amino acid
 CC substitution matrix; different from an identity matrix and a vaccine or
 CC diagnostic tool using a limited number such as at least 1, 2, 3, 4, 5, 8,
 CC 16, 32, 64, 128, 256, 512 of the peptides of ADZ49933-ADZ50932. In
 CC predicting peptides, the prediction of the neural network is combined
 CC with prediction or measurement of one of the following: proteasomal
 CC cleavage sites; MHC binding; presence of sequence or related sequence(s)
 CC in patent databases; TAP binding; gene or protein expression level;
 CC function of the protein; localization of the protein; and similarity to
 CC self proteins. The epitope is useful as a vaccine or diagnostic tool, and
 CC for inducing immune response in a subject (said immunity to Yersinia
 CC pestis infection, the causative agent of plague). The present sequence is
 CC a cytotoxic Yersinia pestis T-cell epitope of the invention.
 XX
 SQ Sequence 9 AA;

Query Match 100.0%; Score 19; DB 9; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
 ||||
 Db 4 ACGV 7

RESULT 30
 AAG85717
 ID AAG85717 standard; peptide; 10 AA.
 XX
 AC AAG85717;
 XX
 DT 11-SEP-2001 (first entry)
 XX
 DE Saccharomyces cerevisiae peptide, SEQ ID NO: 666.
 XX
 KW Saccharomyces cerevisiae; complementary peptide; peptide identification;
 KW drug discovery; drug design.
 XX
 OS Saccharomyces cerevisiae.
 XX
 PN WO200142276-A1.
 XX
 PD 14-JUN-2001.
 XX
 PF 13-DEC-2000; 2000MO-GB004773.
 XX
 PR 13-DEC-1999; 99GB-00029471.
 XX
 PA (PROT-) PROTEOM LTD.
 XX
 PI Roberts GW, Heal JR;
 PI
 XX
 DR WPI; 2001-367863/38.
 XX
 PT Identifying complementary peptides by analysis of protein and nucleotide
 PT sequence databases, useful in drug design.
 XX
 PS Example 3; Page 121; 488pp; English.
 XX
 CC The invention relates to the identification of complementary peptides by
 CC analysis of protein and nucleotide sequence databases from higher
 CC eukaryotic genomes, excluding human and plants. The specific
 CC complementary peptides interact with their relevant target proteins
 CC encoded in the eukaryote genome. The peptides may be used as reagents and

CC drugs for drug discovery and as lead ligands for drug design and
CC development. The present sequence is a complementary peptide from
CC Saccharomyces cerevisiae
XX

SQ Sequence 10 AA;

Query Match 100.0%; Score 19; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 3 ACGV 6

RESULT 31

ADP94302
ID ADF94302 standard; peptide; 10 AA.

XX
AC ADF94302;

XX 26-FEB-2004 (first entry)

XX Human cell protein fragment #27.

XX affinity-labelled RNA; drug discovery; HCV infection; biotin labelled;
KM human.

XX Homo sapiens.

XX US2003194712-A1.

XX 16-OCT-2003.

XX 12-APR-2002; 2002US-00122675.

XX 12-APR-2002; 2002US-00122675.

XX (RIGE-) RIGEL PHARM INC.

XX Lu H, Li W, Anderson D;

XX WPI; 2004-010212/01.

PT Screening for polypeptides that bind to an RNA, useful for treating
PT hepatitis C virus infection, comprises incubating an affinity-labeled RNA
PT with a cellular extract, isolating the RNA and identifying polypeptides
PT bound to the RNA.

PS Example 2; Page 11; 14pp; English.

CC The invention relates to a method of screening for polypeptides that bind
CC to an RNA comprising incubating an affinity-labelled RNA with a
CC cytoplasmic extract, where the RNA is linked to an affinity-labelled
CC oligonucleotide, isolating the affinity-labelled RNA, and identifying
CC polypeptides bound to the affinity-labelled RNA. The method is useful in
CC identifying polypeptide factors interacting with RNA. The polypeptide may
CC be used for drug discovery and in preventing or treating diseases, e.g.
CC HCV infection. The present sequence represents the amino acid sequence of
CC a cell protein fragment extracted by a biotinylated hepatitis C virus
CC IRES.

XX Sequence 10 AA;

Query Match 100.0%; Score 19; DB 8; Length 10;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 4 ACGV 7

RESULT 32

AAB35370
ID AAB35370 standard; peptide; 12 AA.

XX AAB35370;

XX 08-MAY-2001 (first entry)

XX Alpha2beta1 integrin binding peptide #35.

XX Alpha2beta1 integrin; angiogenesis; cell proliferation; cancer;
KM diabetic retinopathy; restenosis; atherosclerosis; rheumatoid arthritis;
KM macular degeneration; psoriasis; cell adhesion; cell motility.

XX Synthetic.

XX WO200105812-A2.

XX 25-JAN-2001.

XX 12-JUL-2000; 2000WO-US018986.

XX 15-JUL-1999; 99US-0144549P.

XX (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX Roberts DD, Krutzsch HC;

XX WPI; 2001-182656/18.

XX New peptides that bind to or are recognized by alpha3-beta1 integrins,
PT useful for inhibiting cell adhesion to extracellular matrix, cell
PT motility and proliferation and for treating rheumatoid arthritis and
PT cancer.

PS Claim 4; Page 34; 84pp; English.

CC The present invention provides a number of peptides which bind to
CC alpha3beta1 integrins. They are useful in the modulation of cell adhesion
CC and motility, and in the treatment of cancer, diabetic retinopathy,
CC rheumatoid arthritis, macular degeneration, atherosclerosis, psoriasis
CC and restenosis. The present sequence is an example of one of the peptides
CC of the invention

XX Sequence 12 AA;

Query Match 100.0%; Score 19; DB 4; Length 12;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 1 ACGV 4

RESULT 33

ABM00107
ID ABM00107 standard; peptide; 13 AA.

XX ABM00107;

XX 02-APR-2003 (first entry)

XX T. lanuginosus lipase antibody binding peptide sequence 24.

XX allergen; protein coordinate data; vaccine; antiallergic; immunogenicity;
KM detergent; personal care composition; cosmetic.

XX Unidentified.

XX WO200183559-A2.

XX 08-NOV-2001.

```

XX 30-APR-2001; 2001WO-DK000293.
XX
XX
XX 28-APR-2000; 2000DK-00000707.
XX
XX 10-MAY-2000; 2000US-0203345P.
XX
XX 28-FEB-2001; 2001DK-00000327.
XX
XX 21-MAR-2001; 2001US-0277817P.
XX
XX (NOVO ) NOVOZYMES AS.
XX
XX
XX Roggen EL, Ernst S, Svendsen A, Frits EP, Von Der Osten C;
XX
XX WPI; 2001-626552/72.
XX
XX
XX Selecting protein variants having modified immunogenicity, used to
XX produce vaccines, detergents and personal care compositions, involves
XX localizing epitope sequences on the three-dimensional structure of a
XX protein.
XX
XX Example 1; Page 146; 513pp; English.
XX
XX
XX The invention relates to selecting a protein variant having modified
XX immunogenicity, compared to a parent protein, comprising using the
XX antibody binding sequence to localise epitope sequences on the three
XX dimensional structure of the parent protein and defining an epitope area
XX including amino acids within 5 Angstrom of the epitope amino acids. The
XX method is useful for identifying structural epitopes on the 3-dimensional
XX surface of commercial and environmental allergens. Compositions
XX containing the protein variants are used as vaccines, detergents and
XX personal care compositions, e.g. Shampoo, balsam, hair conditioners, hair
XX waving compositions, hair dyeing compositions, hair tonic, hair liquid,
XX hair cream, hair rinse, hair spray, chewing gum, skin cream, sunscreen,
XX shaving foam, cream soap, skin milk or foundation. The present sequence
XX is that of an antibody binding peptide sequence related to the invention
XX
XX
XX Sequence 13 AA;
SQ
Query Match 100.0%; Score 19; DB 4; Length 13;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AOCV 4
Db 6 AOCV 9
RESULT 34
AAR49859
ID AAR49859 standard; peptide; 14 AA.
XX
XX AAR49859;
AC
XX
XX 25-MAR-2003 (revised)
XX 12-SEP-1994 (first entry)
XX
XX Sequence of tryptic digest peptide of bovine glial growth factor III (GGF
XX III).
XX
XX Glial growth factor; GGF III; mitogen; Schwann cell.
XX
XX Bos taurus.
XX
XX WO9404560-A1.
XX
XX 03-MAR-1994.
XX
XX 13-AUG-1993; 93WO-GB001721.
XX
XX 14-AUG-1992; 92GB-00017316.
XX
XX (LUDW-) LUDWIG INST CANCER RES.
XX
XX Goodearl ADJ, Stroobant P, Waterfield MD;

```

```

XX
XX WPI; 1994-083104/10.
XX
XX
XX New polypeptide factor and peptide(s) from bovine pituitary - having
XX mitogenic activity in stimulating division of Schwann cells, used for
XX therapy, prophylaxis, diagnosis of neuro-degenerative disease, glial cell
XX tumours, etc.
XX
XX Claim 32; Page 31; 44pp; English.
XX
XX
XX A novel polypeptide was purified from bovine pituitaries. It has
XX mitogenic activity stimulating the division of Schwann cells, and
XX exhibits a mol. wt. of 43-35kD when carrying native glycosylation. It was
XX digested with trypsin and lysylendopeptidase to obtain novel peptides
XX AAR49858-R49866 and AAR49867-R49871 respectively. When peptides AAR49862-
XX R49866 were sequenced to completion it was found that none of these
XX sequences is apparently related to GGF-I or GGF-II peptide sequences. A
XX polypeptide contg. any of the sequences in AAR49858- AAR49871 is claimed,
XX as is DNA encoding each of the peptides. (Updated on 25-MAR-2003 to
XX correct PN field.)
XX
XX
XX Sequence 14 AA;
SQ
Query Match 100.0%; Score 19; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AOCV 4
Db 4 AOCV 7
RESULT 35
AAR98513
ID AAR98513 standard; peptide; 14 AA.
XX
XX AAR98513;
AC
XX
XX 24-JUN-2002 (first entry)
XX
XX Human peptide #1788 encoded by a SNP oligonucleotide.
XX
XX
XX Immunosuppressive; immunostimulatory; antiinflammatory; cytostatic;
XX neuroprotective; antimicrobial; gene therapy; vaccine; amylase; cancer;
XX amyloid protein; angiotensin; apoptosis related protein; cadherin;
XX cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor;
XX complement related protein; cytochrome; kinesin; cytokine; interferon;
XX interleukin; G-protein coupled receptor; thioesterase; inflammation;
XX multifactorial disease; autoimmune disease; infection;
XX nervous system disease.
XX
XX Homo sapiens.
XX
XX WO200147944-A2.
XX
XX 05-JUL-2001.
XX
XX 28-DEC-2000; 2000WO-US035498.
XX
XX 28-DEC-1999; 99US-0173419P.
XX
XX 27-DEC-2000; 2000US-00173419.
XX
XX (CURA-) CURAGEN CORP.
XX
XX Shinketsu RA, Leach M;
XX
XX WPI; 2001-465210/50.
XX
XX Polymorphic nucleic acids encoding e.g. amylases, cyclins, polymerases,
XX oncogenes and histones, useful for diagnosing and treating, e.g. cancer,
XX autoimmune diseases and infections.
XX
XX Disclosure; Page 4060; 4143pp; English.
XX
XX

```


XX The present invention relates to oligonucleotides (see AAL26793-AAL34659)
CC encoding polymorphic variants of proteins related to amyloses, amyloid
CC proteins, angiotensin, apoptosis related proteins, cadherin, cyclin,
CC polymerase, oncogenes, histones, kinases, colony stimulating factors,
CC complement related proteins, cytochromes, kinesin, cytokines,
CC interferons, interleukins, G-protein coupled receptors and thioesterases.
CC The present sequence is a peptide encoded by one such oligonucleotide.
CC The oligonucleotide and the peptides encoded by them may be used in the
CC prevention, diagnosis and treatment of diseases associated with
CC inappropriate expression of the proteins listed above. Disorders that may
CC be prevented, diagnosed and/or treated include multifactorial diseases
CC with a genetic component, such as autoimmune diseases (e.g. rheumatoid
CC arthritis, multiple sclerosis, diabetes, systemic lupus erythematosus
CC and Grave's disease), inflammation, cancer (e.g. cancers of the bladder,
CC brain, breast, colon and kidney, leukaemia), diseases of the nervous
CC system and an infection of pathogenic organisms
XX
SQ Sequence 14 AA;

Query Match 100.0%; Score 19; DB 4; Length 14;
Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
DB 3 ACGV 6

RESULT 36
AAM50068
ID AAM50068 standard; peptide; 15 AA.
XX
AC AAM50068;
XX
DT 26-JUN-1998 (first entry)
XX
DE Human chorionic gonadotropin beta-chain scrambled fragment.
XX
KM Beta-chain; human; chorionic gonadotropin; beta-hCG; inhibition;
KM human immunodeficiency virus; HIV; infection; replication;
KM Kaposi's sarcoma; haematopoiesis.
XX
OS Synthetic.
XX
PN MO9749373-A2.
XX
PD 31-DEC-1997.
XX
PF 24-JUN-1997; 97WO-US011202.
XX
PR 24-JUN-1996; 96US-00669681.
PR 09-SEP-1996; 96US-00709948.
XX
PA (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.
XX
PI Gallo RC, Bryant J, Lunardi-Iekandar Y;
XX
DR WPI; 1998-076887/07.
XX
XX Human chorionic gonadotropin peptide derivatives - are active in
PT inhibiting, e.g. HIV infection or replication, Kaposi's Sarcoma or have
PT pro-haematopoietic activity.
XX
XX
PS Example; Page 112; 174pp; English.
XX
CC The present sequence is a peptide derivative of the beta-chain of human
CC chorionic gonadotropin (beta-hCG). The peptide is active in inhibiting,
CC e.g. HIV infection or replication or Kaposi's sarcoma, or has pro-
CC haematopoietic activity
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 19; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
DB 3 ACGV 6

RESULT 37
AAM47508
ID AAM47508 standard; protein; 15 AA.
XX
AC AAM47508;
XX
DT 23-SEP-1998 (first entry)
XX
DE Human beta-hCG scrambled protein fragment #2.
XX
KM Beta-human chorionic gonadotropin; beta-hCG; hematopoietic cell; HIV;
KM treatment; proliferation; human immunodeficiency virus; diethylphide;
KM idiopathic thrombocytopenia purpura; anaemia; neutropenia; tumour;
KM chemotherapy; radiation; autoimmune disease; genetic disorder.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN MO9749418-A1.
XX
PD 31-DEC-1997.
XX
PE 24-JUN-1997; 97WO-US011209.
XX
PR 24-JUN-1996; 96US-00669654.
PR 09-SEP-1996; 96US-00709924.
XX
XX
PA (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.
XX
PI Gallo RC, Bryant J, Lunardi-Iekandar Y;
XX
DR WPI; 1998-076906/07.
XX
XX Treating or preventing disease by increasing production of haematopoietic
PT cells - using human chorionic gonadotropin or its fragments or
PT derivatives, in vivo or in vitro, e.g. in cases of HIV infection, anaemia
PT etc.
XX
PS Disclosure; Page 101; 162pp; English.
XX
XX AAM47474-M47508 represent fragments of the beta subunit of human
CC chorionic gonadotropin which is used in a method for the treatment or
CC prevention of disease, by increasing production of at least one type of
CC hematopoietic cell. A method is also described in which non-terminally
CC differentiated haematopoietic cells are treated in vitro to increase
CC proliferation then returned to the patient. The method is specified for
CC treating human immunodeficiency virus (HIV) infection, idiopathic
CC thrombocytopenia purpura, anaemia or neutropenia, or subjects who have
CC undergone chemotherapy or radiation treatment. More generally it can be
CC used to treat a wide range of conditions involving haematopoietic
CC failure, (non-) haematopoietic tumours, autoimmune disease and genetic
CC disorders (using a transformed haematopoietic cell). The in vitro method
CC can also be used to expand haematopoietic cells for subsequent
CC therapeutic use
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 19; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
DB 3 ACGV 6

```

RESULT 38
AAMS0103
ID AAMS0103 standard; peptide; 15 AA.
XX
AC AAMS0103;
XX
DT 26-JUN-1998 (first entry)
XX
DE Human chorionic gonadotropin beta-chain scrambled fragment.
XX
KM Beta-chain; human; chorionic gonadotropin; beta-hCG; treatment;
XX prevention; wasting syndrome; viral infection; cancer;
XX chronic cardiovascular disease; chemotherapy; radiation therapy.
XX
OS Homo sapiens.
XX
PN WO9749721-A1.
XX
PD 31-DEC-1997.
XX
PF 24-JUN-1997; 97WO-US011448.
XX
PR 24-JUN-1996; 96US-00669675.
XX
PR 09-SEP-1996; 96US-00709933.
XX
PA (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.
XX
PI Gallo RC, Bryant J, Lunardi-Iskandar Y;
XX
DR WPI, 1998-077106/07.
XX
PT Treating or preventing wasting syndrome - by administration of human
XX chorionic gonadotropin, beta-hCG, peptides or derivatives of these.
XX
PS Example; Page 80; 126pp; English.
XX
CC The present sequence is a peptide derivative of the beta-chain of human
XX chorionic gonadotropin (beta-hCG). The peptide can be used to treat or
XX prevent a wasting syndrome associated with viral infection, e.g. human
XX immunodeficiency syndrome virus infection, cancer, chronic cardiovascular
XX disease, chemotherapy or radiation therapy
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 19; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOSV 4
DB 3 AOSV 6

RESULT 39
ABB04474
ID ABB04474 standard; peptide; 15 AA.
XX
AC ABB04474;
XX
DT 15-MAR-2002 (first entry)
XX
DE Human endoprotease 6 N-terminal peptide.
XX
KM Human; endoprotease 6; cancer; haemopathy; HIV infection; gene therapy.
XX
OS Homo sapiens.
XX
PN CN1315558-A.
XX
PD 03-OCT-2001.
XX

```

```

PF 24-MAR-2000; 2000CN-00115125.
XX
PR 24-MAR-2000; 2000CN-00115125.
XX
PA (BODE-) BODE GENE DEV CO LTD SHANGHAI.
XX
PI Mao Y, Xie Y;
XX
DR WPI, 2002-056348/08.
XX
PT New human endoprotease 6 and encoding polynucleotide, useful for treating
XX cancer, hemopathy and human immunodeficiency virus.
XX
PS Example 5; Page 18 (Disclosure); 32pp; Chinese.
XX
CC The present invention provides the protein and coding sequences of human
XX endoprotease 6. The sequences can be used in the treatment of cancer,
XX haemopathy and HIV infection. The present sequence is the N-terminus of
XX the protein of the invention
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 19; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOSV 4
DB 6 AOSV 9

RESULT 40
ADH52629
ID ADH52629 standard; peptide; 15 AA.
XX
AC ADH52629;
XX
DT 25-MAR-2004 (first entry)
XX
DE Human chorionic gonadotropin beta-chain (beta-hCG) scrambled A2 peptide.
XX
KM beta-chain; human chorionic gonadotropin; beta-hCG; cytostatic;
XX anti-HIV; HIV-viral load; HIV infection; cancer; scrambled A2.
XX
OS Synthetic.
XX
OS Homo sapiens.
XX
PN US6583109-B1.
XX
PD 24-JUN-2003.
XX
PF 24-DEC-1998; 98US-00220415.
XX
PR 24-JUN-1997; 97WO-US011202.
XX
PR 24-JUN-1997; 97WO-US011209.
XX
PR 24-JUN-1997; 97WO-US011210.
XX
PR 24-JUN-1997; 97WO-US011448.
XX
PA (GALLI/) GALLO R C.
XX (BRYA/) BRYANT J.
XX (LUNA/) LUNARDI-ISKANDAR Y.
XX
PI Gallo RC, Bryant J, Lunardi-Iskandar Y;
XX
DR WPI, 2004-118040/12.
XX
PT New isolated beta hCG protein or peptide, useful for preventing
XX progression of HIV infection.
XX
PS Example; SEQ ID NO 37; 118pp; English.
XX
CC The invention relates to a novel isolated protein or peptide comprising a
XX fragment of the beta-chain of human chorionic gonadotropin (beta-hCG)
XX

```

CC having at least one conservative substitution relative to the beta-hCG
CC sequence and exhibiting a therapeutic effect such as reducing HIV viral
CC load. The peptide of the invention demonstrates cytostatic and anti-HIV
CC activities and may be useful for reducing HIV-viral load, preventing the
CC progression of HIV infection, reducing cancer cells and preventing the
CC progression of cancer. The current sequence is that of the human beta-hCG
CC peptide of the invention.

XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 19; DB 8; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||
Db 3 AOGV 6

RESULT 41

ADHS2592
ID ADHS2592 standard; peptide; 15 AA.

AC ADHS2592;

DT 25-MAR-2004 (first entry)

DE Human chorionic gonadotropin beta-chain (beta-hCG) scrambled A2 peptide.

XX haemopoiesis; haemopoietic cell; beta chain;
KW human chorionic gonadotropin; beta-hCG; antianaemic; cytostatic;
KW haemostatic; anti-HIV; immunosuppressive; anabolic; anaemia; blood;
KW neoplastic; chemotherapy; radiation; bone marrow transplant; tumour;
KW HIV infection; autoimmune disorder; wasting syndrome; human;
KW scrambled A2.

XX
OS Synthetic.

OS Homo sapiens.

PN US6596688-B1.

PD 22-JUL-2003.

PF 29-SEP-2000; 2000US-00675776.

PR 24-JUN-1997; 97WO-US011202.

PR 24-JUN-1997; 97WO-US011209.

PR 24-JUN-1997; 97WO-US011210.

PR 24-JUN-1997; 97WO-US011448.

PR 24-DEC-1998; 98US-00220415.

PA (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.

PI Gallo RC, Bryant J, Lunardi-Iskandar Y;

DR WPI; 2004-068173/07.

PT Promoting hematopoiesis comprises contacting hematopoietic cells with an
PT amount of the beta chain of human chorionic gonadotropin.

PS Example; SEQ ID NO 37; 118bp; English.

XX The invention relates to a novel method for promoting haemopoiesis
CC comprising contacting haemopoietic cells with an amount of an isolated
CC beta chain of human chorionic gonadotropin (beta-hCG) protein or peptide.

CC The method of the invention has antianaemic, cytostatic, haemostatic,
CC anti-HIV, immunosuppressive and anabolic applications and may be useful
CC for treating, preventing or delaying the onset of a disease or disorder
CC associated with one or more haemopoietic cell deficiencies such as
CC anaemia, a disease resulting from a failure or dysfunction of normal
CC blood cell production and/or maturation or a neoplastic disease of a
CC haemopoietic organ. The protein or peptide may be used to promote
CC haemopoiesis following chemotherapy, exposure to radiation, bone marrow

CC transplant or a treatment comprising infusion of genetically modified
CC haemopoietic stem cells, as well as to effect a bone marrow rescue
CC procedure following otherwise lethal chemotherapy or irradiation of a
CC malignant tumour. Furthermore, the protein may be used to prevent or
CC treat HIV infection, autoimmune disorders or wasting syndrome. The
CC current sequence is that of the human chorionic gonadotropin beta-chain
CC (beta-hCG) scrambled A2 peptide of the invention.

XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 19; DB 8; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||
Db 3 AOGV 6

RESULT 42

ADK39780
ID ADK39780 standard; peptide; 15 AA.

AC ADK39780;

DT 20-MAY-2004 (first entry)

DE Human chorionic gonadotropin beta chain-derived peptide #35.

XX human; Cytostatic; Anti-HIV; Virocide; Immunosuppressive; Gene-Therapy;
KW cancer; beta-human chorionic gonadotropin; hCG; hyperplasia; metaplasia;
KW dysplasia; hyperproliferative malignant stem cell disorder; leukaemia;
KW sarcoma; carcinoma; human immunodeficiency virus; HIV;
KW autoimmune disorder; wasting syndrome.

XX
OS Homo sapiens.

PN US6699834-B1.

PD 02-MAR-2004.

PF 29-SEP-2000; 2000US-00675362.

PR 24-JUN-1997; 97WO-US011202.

PR 24-JUN-1997; 97WO-US011209.

PR 24-JUN-1997; 97WO-US011210.

PR 24-JUN-1997; 97WO-US011448.

PR 24-DEC-1998; 98US-00220415.

PA (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.

PI Gallo RC, Bryant J, Lunardi-Iskandar Y;

DR WPI; 2004-200901/19.

PT Treating and inhibiting the growth of cancer, HIV infections and wasting
PT syndrome in a subject by administering a protein or peptide having at
PT least one segment of the beta-human chorionic gonadotropin.

PS Disclosure; SEQ ID NO 37; 118bp; English.

XX The invention relates to a method of treating and inhibiting the growth
CC of cancer in a subject, comprising administering a protein or peptide
CC comprising at least one segment consisting of 5-50 amino acid segment of
CC the sequence of beta-human chorionic gonadotropin (hCG), where the
CC protein or peptide exhibits an anti-cancer effect. The protein or peptide
CC is administered in conjunction with another cancer therapy, and is
CC administered to treat a pre-malignant condition, wherein the pre-
CC malignant condition comprises non-neoplastic cell growth selected from
CC the group consisting of hyperplasia, metaplasia and dysplasia. The
CC methods and compositions of the present invention are useful for treating
CC and/or preventing cancer, wherein the cancer is a gestational
CC trophoblastic tumour, a testicular germ cell tumour, a bladder cancer, a

CC pancreatic cancer, a cervical cancer, lung cancer, liver cancer, ovarian
 CC cancer, colon or stomach cancer, a virally induced cancer, neuroblastoma,
 CC breast cancer, prostate cancer or renal cancer, or is a leukaemia
 CC hyperproliferative malignant stem cell disorder, or is a leukaemia
 CC selected from the group consisting of acute lymphocytic leukaemia, acute
 CC myelocytic leukaemia, myeloblastic, promyelocytic, myelomonocytic,
 CC monocytic, erythroleukaemia, chronic myelocytic (granulocytic) leukaemia,
 CC and chronic lymphocytic leukaemia, or is selected from the group
 CC consisting of sarcomas and carcinomas, fibrosarcoma, myosarcoma,
 CC liposarcoma, chondrosarcoma, osteogenic sarcoma, chorioma, angiosarcoma,
 CC endothelioma, lymphangiosarcoma, lymphangioblastoma, leiomyosarcoma,
 CC synovialoma, mesothelioma, Ewing's tumour, leiomyosarcoma,
 CC rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer,
 CC ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell
 CC carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland
 CC carcinoma, papillary carcinoma, papillary adenocarcinomas,
 CC cytoductocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal
 CC cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma,
 CC embryonal carcinoma, Wilms' tumour, cervical cancer, uterine cancer,
 CC testicular tumour, lung carcinoma, small cell lung carcinoma, bladder
 CC carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma,
 CC craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic
 CC neuroma, oligodendroglioma, meningioma, melanoma and retinoblastoma,
 CC and/or Kaposi's sarcoma. They can also be used in preventing and/or
 CC treating human immunodeficiency virus (HIV) infection, autoimmune
 CC disorders and wasting syndrome. The present sequence represents the amino
 CC acid sequence of a peptide derived from beta-human chorionic gonadotropin
 CC (hCG), used in the method of the invention.

SO Sequence 15 AA;

Query Match 100.0%; Score 19; DB 8; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.9e+02;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
 ||||
 DB 3 AOGV 6

RESULT 43

ADT90972
 ID ADT90972 standard; peptide; 15 AA.

XX ADT90972;

XX 30-DEC-2004 (first entry)

DE Human beta-hCG (human chorionic gonadotropin) scrambled peptide #2.

XX Human chorionic gonadotropin; hCG; AIDS;
 KW acquired immune deficiency syndrome; ARC; AIDS-related complex;
 KW aplastic anaemia; pancytopenia; thrombocytopaenia;
 KW Blackfan-Diamond syndrome; haematopoietic disorder;

KW acute lymphocytic leukaemia; chronic lymphocytic leukaemia;
 KW Waldenstrom's macroglobulinaemia; Hodgkin's lymphoma;
 KW non-Hodgkin's lymphoma; immunosuppression; malignant tumour;
 KW solid tumour; cancer; retinoblastoma; glioblastoma; rhabdomyosarcoma;
 KW Ewing's sarcoma; Kaposi's sarcoma; KS; autoimmune disorders;

KW rheumatoid arthritis; chronic hepatitis; multiple sclerosis;
 KW systemic lupus erythematosus; SLE; genetic disorder; Fanconi's syndrome;
 KW Bloom's syndrome; Chwastmann-Diamond syndrome; Lesch-Nyhan syndrome;
 KW severe combined immunodeficiency disease; SCID; Gaucher's disease;

KW Kostmann's syndrome; osteoporosis; myelocleorosis;
 KW Chediak-Higashi syndrome; mucopolysaccharidoses; mucopolidosis;
 KW infectious disease; bacterial infection; brucellosis; listeriosis;
 KW leprosy; tuberculosis; parasitic infection; malaria; leishmaniasis;
 KW fungal infection; gene therapy; anti-HIV; antimicrobial; cytostatic;
 KW antanaemic; human; mutant; mutein.

XX Homo sapiens.
 OS Synthetic.

XX US6805682-B1.

XX 19-OCT-2004.

XX 02-OCT-2000; 2000US-00677152.

XX 24-JUN-1997; 97WO-US011202.

XX 24-JUN-1997; 97WO-US011209.

XX 24-JUN-1997; 97WO-US011210.

XX 24-JUN-1997; 97WO-US011448.

XX 24-DEC-1998; 98US-00220415.

XX (UNMA-) UNIV MARYLAND BIOTECHNOLOGY INST.

XX Gallo RC, Bryant J, Lunardi-Iskandar Y;

XX WPI; 2004-735330/72.

XX Therapeutic composition, useful to treat e.g. HIV infection and cancer,

XX comprises at least one fraction separated from a urine sample comprising

XX at least one fraction of naturally occurring human chorionic

XX gonadotropin.

XX Example; SEQ ID NO 37; 117bp; English.

XX The present invention relates to fractions of sources and/or preparations
 CC of human chorionic gonadotropin (hCG) such as fractions of human early
 CC pregnancy urine, which fractions have anti-HIV (human immunodeficiency
 CC virus) activity. The invention is useful to treat and prevent the
 CC progression of HIV infection to AIDS (acquired immune deficiency
 CC syndrome) and ARC (AIDS-related complex). The invention is also useful
 CC for treating diseases by promoting haematopoiesis. The diseases or
 CC disorders treated by increasing the production of haematopoietic cells
 CC includes diseases resulting from a failure or dysfunction of normal blood
 CC cell production and maturation such as aplastic anaemia, pancytopenia,
 CC thrombocytopaenia, Blackfan-Diamond syndrome etc., haematopoietic
 CC disorders such as acute and chronic lymphocytic (lymphoblastic)

CC leukaemia, Waldenstrom's macroglobulinaemia, Hodgkin's lymphoma, non-
 CC Hodgkin's lymphoma etc., immunosuppression in patients with malignant and
 CC solid tumours such as cancer, retinoblastoma, glioblastoma,
 CC rhabdomyosarcoma, Ewing's sarcoma, Kaposi's sarcoma (KS) etc., autoimmune
 CC disorders such as rheumatoid arthritis, chronic hepatitis, multiple
 CC sclerosis, systemic lupus erythematosus (SLE), etc., genetic (congenital)

CC disorders such as Fanconi's syndrome, Bloom's syndrome, Chwastmann-
 CC Diamond syndrome, Lesch-Nyhan syndrome, severe combined immunodeficiency
 CC disease (SCID), Gaucher's disease, Kostmann's syndrome etc., diseases
 CC such as osteoporosis, myelocleorosis, Chediak-Higashi syndrome,
 CC mucopolysaccharidoses, mucopolidosis etc. and other infectious diseases

CC including bacterial infections such as brucellosis, listeriosis, leprosy,
 CC tuberculosis etc., parasitic infections such as malaria, leishmaniasis
 CC etc. and fungal infections. The invention is also useful in gene therapy.

CC The present sequence is human beta-hCG (human chorionic gonadotropin)
 CC scrambled peptide. This beta-hCG peptide is also termed as scrambled A2.

XX Sequence 15 AA;

Query Match 100.0%; Score 19; DB 8; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.9e+02;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
 ||||
 DB 3 AOGV 6

RESULT 44

ADT51746
 ID ADT51746 standard; procein; 16 AA.

XX ADT51746;

XX 01-FEB-1995 (first entry)

RESULT 46

AAU70963 standard; peptide: 18 AA.

AAU70963;

25-FEB-2002 (first entry)

M. tuberculosis Rv0285 protein immunogenic peptide P6.

Tuberculosis; Tuberculostatic; antibacterial; vaccine; Rv0284; Rv0285;

Rv0455C; Rv0569; Rv1195; Rv1386; Rv3878; Rv3879; MT3106.1;

ORF13a; Rv0284c; Mycobacterium bovis; Mycobacterium africanum;

BCG vaccine; immunogenic peptide.

Mycobacterium tuberculosis.

W0200179274-A2.

25-OCT-2001.

19-APR-2001; 2001WO-DK000276.

19-APR-2000; 2000DK-0000666.

21-FEB-2001; 2001DK-0000283.

(STAT-) STATENS SERUM INST.

Agger EM, Andersen P, Okkels LMW, Weidlingh K;

WPI; 2002-061970/08.

Example 3; Page 39; 111pp; English.

The invention relates to a substantially pure polypeptide comprising an

amino acid sequence selected from Rv0284, Rv0285, Rv0455C, Rv0569,

Rv1195, Rv1386, Rv3477, Rv3878, Rv3879C or MT3106.1 (also disclosed are

ORF13a and Rv0284c), or their immunogenic portion, nucleic acids

encoding them and an amino acid sequence analogue having at least 70%

sequence identity to the polypeptide and is immunogenic. The protein is

useful in preparing a pharmaceutical composition for diagnosing

tuberculosis and in preparing a vaccine against tuberculosis caused by

virulent mycobacteria. The vaccine or immunogenic/ pharmaceutical

composition can be used prophylactically in a subject already infected with a

virulent mycobacterium, or therapeutically in a subject already infected

with a virulent mycobacterium. The protein is useful for preventing,

treating and detecting infections caused by species of tuberculosis

complex (M. tuberculosis, M. bovis, M. africanum). The nucleic acids may

be used for effecting in vivo expression of the antigen, and in

diagnostic assays for detecting the presence of pathogenic organisms in a

sample. The vaccine is an improvement of the living BCG vaccine presently

available, where one or more copies of the DNA sequence encoding one or

more polypeptide has been incorporated into the genome of the

microorganism to allow the microorganism to express and secrete the

polypeptide. Incorporation of more than one copy of a nucleotide sequence

enhances the immune response. The present sequence represents an

immunogenic peptide derived from an M. tuberculosis protein of the

invention

Sequence 18 AA;

SQ

Query Match 100.0%; Score 19; DB 5; Length 18;

Best Local Similarity 100.0%; Pred. No. 7.2e+02;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 AAGV 4

6 AAGV 9

DB

RESULT 47

AAU70974 standard; peptide: 18 AA.

AAU70974;

25-FEB-2002 (first entry)

M. tuberculosis Rv1386 protein immunogenic peptide P7.

Tuberculosis; Tuberculostatic; antibacterial; vaccine; Rv0284; Rv0285;

Rv0455C; Rv0569; Rv1195; Rv1386; Rv3477; Rv3878; Rv3879; MT3106.1;

ORF13a; Rv0284c; Mycobacterium bovis; Mycobacterium africanum;

BCG vaccine; immunogenic peptide.

Mycobacterium tuberculosis.

W0200179274-A2.

25-OCT-2001.

19-APR-2001; 2001WO-DK000276.

19-APR-2000; 2000DK-0000666.

21-FEB-2001; 2001DK-0000283.

(STAT-) STATENS SERUM INST.

Agger EM, Andersen P, Okkels LMW, Weidlingh K;

WPI; 2002-061970/08.

Example 3; Page 40; 111pp; English.

The invention relates to a substantially pure polypeptide comprising an

amino acid sequence selected from Rv0284, Rv0285, Rv0455C, Rv0569,

Rv1195, Rv1386, Rv3477, Rv3878, Rv3879C or MT3106.1 (also disclosed are

ORF13a and Rv0284c), or their immunogenic portion, nucleic acids

encoding them and an amino acid sequence analogue having at least 70%

sequence identity to the polypeptide and is immunogenic. The protein is

useful in preparing a pharmaceutical composition for diagnosing

tuberculosis and in preparing a vaccine against tuberculosis caused by

virulent mycobacteria. The vaccine or immunogenic/ pharmaceutical

composition can be used prophylactically in a subject already infected with a

virulent mycobacterium, or therapeutically in a subject already infected

with a virulent mycobacterium. The protein is useful for preventing,

treating and detecting infections caused by species of tuberculosis

complex (M. tuberculosis, M. bovis, M. africanum). The nucleic acids may

be used for effecting in vivo expression of the antigen, and in

diagnostic assays for detecting the presence of pathogenic organisms in a

sample. The vaccine is an improvement of the living BCG vaccine presently

available, where one or more copies of the DNA sequence encoding one or

more polypeptide has been incorporated into the genome of the

microorganism to allow the microorganism to express and secrete the

polypeptide. Incorporation of more than one copy of a nucleotide sequence

enhances the immune response. The present sequence represents an

immunogenic peptide derived from an M. tuberculosis protein of the

invention

Sequence 18 AA;

SQ

Query Match 100.0%; Score 19; DB 5; Length 18;

Best Local Similarity 100.0%; Pred. No. 7.2e+02;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 AAGV 4

6 AAGV 9

DB

RESULT 48

ADV55657
ID ADV55657 standard; peptide; 18 AA.
XX
AC ADV55657;
XX
DT 10-MAR-2005 (first entry)
XX
DE G protein coupled receptor peptide SEQ ID NO 3155.
XX
KW diagnosis; cancer; obesity; diabetes; asthma; inflammation; depression;
KM food; feedstuff; cosmetics; agriculture; animal breeding; GPCK.
XX
OS Unidentified.
XX
PN WO2004111636-A2.
XX
PD 23-DEC-2004.
XX
PF 17-JUN-2004; 2004WO-EP051158.
XX
PR 17-JUN-2003; 2003BP-00101775.
PR 17-JUN-2003; 2003US-0479061P.
XX
PA (VIBV-) VIB VZW.
PA (UYGE-) UNIV GENT.
XX
PI Kas K, Vandekerckhove J, Krols L;
XX
DR WPI; 2005-057893/06.
XX
PT Identifying a peptide combo which corresponds with a family of proteins,
PT useful for diagnosing a variety of diseases, drug development or in
PT agriculture, comprises generating peptides by applying a digest on the
PT family of protein.
XX
PS Example; SEQ ID NO 3155; 265pp; English.
XX
SS The invention relates to a method of identifying a peptide combo which
CC corresponds with a family of proteins where each of the members of the
CC peptide combo is derived from a unique protein from the family. The
CC peptide combo is useful for quantifying specific known splice variants of
CC one or more particular proteins in a sample, for diagnosing complex
CC genetic diseases such as cancer, obesity, diabetes, asthma and
CC inflammation, neuropsychiatric disorders such as depression, for
CC quantifying one to several hundreds of protein disease markers
CC simultaneously leading to a more accurate diagnostic sub-classification,
CC for determining the extent of protein modification in a particular sample
CC of proteins, for tissue-typing analysis, for prenatal testing to detect
CC the presence of a congenital disease or for quantitating protein levels
CC diagnostic of a chromosomal abnormality, for diagnosing immune diseases
CC or neurological diseases, as biomarkers preclinical drug development,
CC development of improved animal models, biomarkers related with
CC toxicology, clinical drug development, guidance marketed drugs,
CC prognostic or diagnostic disease markers, drug target validation and
CC selection, monitoring protein splicing, drug lead profiling, pathway
CC analysis, answering basic disease biology questions, and in the fields of
CC food and feed, cosmetics, agriculture and animal breeding. The present
CC sequence represents a peptide from a G-protein coupled receptor peptide
CC combo.
XX
SQ Sequence 18 AA;

Query Match 100.0%; Score 19; DB 9; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.2e+02; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0;

QY 1 AGV 4
|||
DB 5 AGV 8

RESULT 49

ADV54661
ID ADV54661 standard; peptide; 18 AA.
XX
AC ADV54661;
XX
DT 10-MAR-2005 (first entry)
XX
DE G protein coupled receptor peptide SEQ ID NO 2158.
XX
KW diagnosis; cancer; obesity; diabetes; asthma; inflammation; depression;
KM food; feedstuff; cosmetics; agriculture; animal breeding; GPCK.
XX
OS Unidentified.
XX
PN WO2004111636-A2.
XX
PD 23-DEC-2004.
XX
PF 17-JUN-2004; 2004WO-EP051158.
XX
PR 17-JUN-2003; 2003BP-00101775.
PR 17-JUN-2003; 2003US-0479061P.
XX
PA (VIBV-) VIB VZW.
PA (UYGE-) UNIV GENT.
XX
PI Kas K, Vandekerckhove J, Krols L;
XX
DR WPI; 2005-057893/06.
XX
PT Identifying a peptide combo which corresponds with a family of proteins,
PT useful for diagnosing a variety of diseases, drug development or in
PT agriculture, comprises generating peptides by applying a digest on the
PT family of protein.
XX
PS Example; SEQ ID NO 2158; 265pp; English.
XX
SS The invention relates to a method of identifying a peptide combo which
CC corresponds with a family of proteins where each of the members of the
CC peptide combo is derived from a unique protein from the family. The
CC peptide combo is useful for quantifying specific known splice variants of
CC one or more particular proteins in a sample, for diagnosing complex
CC genetic diseases such as cancer, obesity, diabetes, asthma and
CC inflammation, neuropsychiatric disorders such as depression, for
CC quantifying one to several hundreds of protein disease markers
CC simultaneously leading to a more accurate diagnostic sub-classification,
CC for determining the extent of protein modification in a particular sample
CC of proteins, for tissue-typing analysis, for prenatal testing to detect
CC the presence of a congenital disease or for quantitating protein levels
CC diagnostic of a chromosomal abnormality, for diagnosing immune diseases
CC or neurological diseases, as biomarkers preclinical drug development,
CC development of improved animal models, biomarkers related with
CC toxicology, clinical drug development, guidance marketed drugs,
CC prognostic or diagnostic disease markers, drug target validation and
CC selection, monitoring protein splicing, drug lead profiling, pathway
CC analysis, answering basic disease biology questions, and in the fields of
CC food and feed, cosmetics, agriculture and animal breeding. The present
CC sequence represents a peptide from a G-protein coupled receptor peptide
CC combo.
XX
SQ Sequence 18 AA;

Query Match 100.0%; Score 19; DB 9; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.2e+02; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0;

QY 1 AGV 4
|||
DB 5 AGV 8


```

RESULT 50
ADY64078
ID ADY64078 standard; peptide; 18 AA.
XX
AC ADY64078;
XX
DT 02-JUN-2005 (first entry)
XX
DE Human MCSP epitope peptide #239.
XX
KM melanoma-associated chondroitin sulfate proteoglycan; cytotoxin;
KM melanoma; cytosstatic; neoplasm; cancer; diagnosis; antibody therapy.
XX
OS Homo sapiens.
XX
PN US2005063967-A1.
XX
PD 24-MAR-2005.
XX
PF 24-SEP-2004; 2004US-00949846.
XX
PR 21-JAN-2003; 2003US-00348231.
PR 19-DEC-2003; 2003US-00743451.
PR 20-JAN-2004; 2004US-00762129.
PR 26-MAR-2004; 2004US-00810744.
XX
PA (ARIU-) ARIUS RES INC.
PI Young DSF, Hahn SR, Findlay HP, Ferry AL;
XX
XX WPI; 2005-241247/25.
XX
PT Mediating cytotoxicity of human tumor cell expressing melanoma-associated
PT chondroitin sulfate proteoglycan (MCSP) on the cell surface comprises
PT contacting with an isolated MCSP binding monoclonal antibody or its
PT antigen binding fragment.
XX
XX Example 4; Page 15; 47pp; English.
XX
XX The invention relates to a novel method for mediating cytotoxicity of a
XX human tumor cell using cancerous disease modifying antibodies (CDMAB),
XX especially cells expressing a melanoma-associated chondroitin sulfate
XX proteoglycan (MCSP) antigenic moiety on the cell surface. The method
XX involves contacting the cell with an isolated monoclonal antibody
XX (deposited with the ATCC as PTA-5643) or its antigen binding fragment
XX that binds to the expressed MCSP antigenic moiety, where cell
XX cytotoxicity occurs as a result of the binding. A CDMAB used in a method
XX of the invention has cytostatic activity. The method is useful for
XX mediating cytotoxicity of a human tumor cell and especially useful for
XX treating a patient suffering from a cancerous disease. The sequences
XX shown in (ADY63841-ADY64097) represent peptide fragments of MCSP, used to
XX create an overlapping peptide array in order to carry out antibody
XX epitope mapping experiments.
XX
SQ Sequence 18 AA;
XX
Query Match 100.0%; Score 19; DB 9; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.2e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 AOGV 4
DB 6 AOGV 9
XX
RESULT 51
ADY64078
ID ADY64078 standard; peptide; 18 AA.
XX
AC ADY64078;
XX
DT 02-JUN-2005 (first entry)
XX

```

```

DE Human MCSP epitope peptide #238.
XX
XX melanoma-associated chondroitin sulfate proteoglycan; cytotoxin;
KM melanoma; cytosstatic; neoplasm; cancer; diagnosis; antibody therapy.
XX
OS Homo sapiens.
XX
PN US2005063967-A1.
XX
PD 24-MAR-2005.
XX
PF 24-SEP-2004; 2004US-00949846.
XX
PR 21-JAN-2003; 2003US-00348231.
PR 19-DEC-2003; 2003US-00743451.
PR 20-JAN-2004; 2004US-00762129.
PR 26-MAR-2004; 2004US-00810744.
XX
PA (ARIU-) ARIUS RES INC.
PI Young DSF, Hahn SE, Findlay HP, Ferry AL;
XX
XX WPI; 2005-241247/25.
XX
PT Mediating cytotoxicity of human tumor cell expressing melanoma-associated
PT chondroitin sulfate proteoglycan (MCSP) on the cell surface comprises
PT contacting with an isolated MCSP binding monoclonal antibody or its
PT antigen binding fragment.
XX
XX Example 4; Page 15; 47pp; English.
XX
XX The invention relates to a novel method for mediating cytotoxicity of a
XX human tumor cell using cancerous disease modifying antibodies (CDMAB),
XX especially cells expressing a melanoma-associated chondroitin sulfate
XX proteoglycan (MCSP) antigenic moiety on the cell surface. The method
XX involves contacting the cell with an isolated monoclonal antibody
XX (deposited with the ATCC as PTA-5643) or its antigen binding fragment
XX that binds to the expressed MCSP antigenic moiety, where cell
XX cytotoxicity occurs as a result of the binding. A CDMAB used in a method
XX of the invention has cytostatic activity. The method is useful for
XX mediating cytotoxicity of a human tumor cell and especially useful for
XX treating a patient suffering from a cancerous disease. The sequences
XX shown in (ADY63841-ADY64097) represent peptide fragments of MCSP, used to
XX create an overlapping peptide array in order to carry out antibody
XX epitope mapping experiments.
XX
SQ Sequence 18 AA;
XX
Query Match 100.0%; Score 19; DB 9; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.2e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 AOGV 4
DB 15 AOGV 18
XX
RESULT 52
AAW92548
ID AAW92548 standard; peptide; 19 AA.
XX
AC AAW92548;
XX
DT 26-APR-1999 (first entry)
XX
DE Beta-actin array biotinylated peptide substrate #6.
XX
KM Peptide substrate; CCT; eukaryotic type II chaperonin complex; cyclin;
KM binding agent; substrate-binding site; SBS; substrate folding; actin;
KM tubulin; treatment; cancer; anticancer drug; viral infection; screening;
KM reduced toxicity.
XX
XX Synthetic.
XX

```


XX Key Location/Qualifiers
PH Modified-site 1 /note= "Ser modified by biotin"
PT
FT
XX WO9853322-A1.
XX
XX 26-NOV-1998.
XX PD
XX 22-MAY-1998; 98WO-GB001485.
XX PF
XX 23-MAY-1997; 97GB-00010762.
XX PR
XX (CANC-) INST CANCER RES ROYAL CANCER HOSPITAL.
XX PA
XX Willison K, Hynes G, Liou AK;
XX PI
XX WPI, 1999-070162/06.
XX DR
XX Identifying specific binding agents for substrate binding site in CCT
PT chaperonin complex - also new peptide binding agents and their mimetics,
PT and peptides containing a specific CCT binding site, used for treating
PT cancer.
XX
XX PS Disclosure; Fig 11; 97pp; English.
XX
XX This invention describes a method which uses the CCT (eukaryotic type II
CC chaperonin) complex or part of it, for identifying a binding agent that
CC can occupy a substrate-binding site (SBS) on the CCT complex. By binding
CC to the CCT complex, the binding agents block an SBS so that biological
CC activity of the CCT complex is affected, particularly its ability to fold
CC substrates such as actin, tubulin and cyclin. The binding agents are
CC useful for treatment of cancer, particularly when used in combination
CC with an anticancer drug, or viral infections. Nucleic acid fragments are
CC used to screen for agents, e.g. binding agents that modulate interaction
CC between the CCT complex and a protein that is to be folded. The binding
CC agents may target cells that are actively synthesizing tubulin etc.
CC (unlike known microtubule-stabilising agents that affect all cells), so
CC should have reduced toxicity for normal cells. AAW92543-W92549 are
CC peptide substrates used in the method of the invention
CC
XX
SQ Sequence 19 AA;
Query Match 100.0%; Score 19; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.6e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AOGV 4
Db 9 AOGV 12
RESULT 53
AAW92549
ID AAW92549 standard; peptide; 19 AA.
XX
XX AAW92549;
AC
XX
DT 26-APR-1999 (first entry)
XX
XX Beta-actin array biotinylated peptide substrate #7.
XX
XX Peptide substrate; CCT; eukaryotic type II chaperonin complex; cyclin;
KW binding agent; substrate-binding site; SBS; substrate folding; actin;
KW tubulin; treatment; cancer; anticancer drug; viral infection; screening;
KW reduced toxicity.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
PH Modified-site 1 /note= "Ser modified by biotin"
FT
FT
XX

PN WO9853322-A1.
XX
XX 26-NOV-1998.
XX PD
XX 22-MAY-1998; 98WO-GB001485.
XX PF
XX 23-MAY-1997; 97GB-00010762.
XX PR
XX (CANC-) INST CANCER RES ROYAL CANCER HOSPITAL.
XX PA
XX Willison K, Hynes G, Liou AK;
XX PI
XX WPI, 1999-070162/06.
XX DR
XX Identifying specific binding agents for substrate binding site in CCT
PT chaperonin complex - also new peptide binding agents and their mimetics,
PT and peptides containing a specific CCT binding site, used for treating
PT cancer.
XX
XX PS Disclosure; Fig 11; 97pp; English.
XX
XX This invention describes a method which uses the CCT (eukaryotic type II
CC chaperonin) complex or part of it, for identifying a binding agent that
CC can occupy a substrate-binding site (SBS) on the CCT complex. By binding
CC to the CCT complex, the binding agents block an SBS so that biological
CC activity of the CCT complex is affected, particularly its ability to fold
CC substrates such as actin, tubulin and cyclin. The binding agents are
CC useful for treatment of cancer, particularly when used in combination
CC with an anticancer drug, or viral infections. Nucleic acid fragments are
CC used to screen for agents, e.g. binding agents that modulate interaction
CC between the CCT complex and a protein that is to be folded. The binding
CC agents may target cells that are actively synthesizing tubulin etc.
CC (unlike known microtubule-stabilising agents that affect all cells), so
CC should have reduced toxicity for normal cells. AAW92543-W92549 are
CC peptide substrates used in the method of the invention
CC
XX
SQ Sequence 19 AA;
Query Match 100.0%; Score 19; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.6e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AOGV 4
Db 9 AOGV 12
RESULT 54
ABP74723
ID ABP74723 standard; peptide; 19 AA.
XX
XX ABP74723;
AC
XX
DT 03-FEB-2003 (first entry)
XX
XX Proteome analysis related peptide #8.
XX
XX Proteome analysis; isolation; determination; diagnostic assay; detection;
KW protein marker; identification; metastatic; invasive cancer;
KW differential expression; signalling pathway; chromatography.
KW
XX Homo sapiens.
OS
XX Synthetic.
OS
XX
XX 03-OCT-2002.
XX PD
XX 22-MAR-2002; 2002WO-EP003368.
XX PF
XX 22-MAR-2001; 2001US-0278171P.
XX PR 12-SEP-2001; 2001US-0318749P.
XX PR 20-SEP-2001; 2001US-0323999P.
XX

```

XX PA (VLA-) VLAAMS INTERUNIVERSITAIR INST BIOTECHNOG.
XX PT Vandekerckhove J, Gevaert K;
XX DR WPI; 2003-067379/06.
XX PT Method for isolation of peptides from complex mixture of peptides
XX PT involves specific chemical and/or enzymatic alteration of at least one
XX PT type of peptide.
XX PS Example 19; Page 138; 193pp; English.
XX CC The present invention describes a method (M1) for the isolation of a
XX CC subset of peptides from a protein peptide mixture (P1). M1 involves: (a)
XX CC separating the protein peptide mixture into fractions of peptides via
XX CC chromatography; (b) chemically, or enzymatically, or chemically and
XX CC enzymatically, altering at least one amino acid of at least one of the
XX CC peptides in each fraction, thereby generating a subset of altered
XX CC peptides; and (c) isolating the altered (flagged) peptides out of each
XX CC fraction via chromatography, where the chromatography of steps (a) and
XX CC (c) is performed with the same type of chromatography. M1 can be used for
XX CC the isolation and determination of peptides from protein peptide
XX CC mixtures. M1 can also be used in diagnostic assays for detection of the
XX CC presence, the absence or a variation in expression level of at least one
XX CC protein marker or a specific set of proteins indicative of a disease
XX CC state. M1 can be used for identifying target proteins present in
XX CC metastatic and invasive cancers, in differential expression of proteins
XX CC in transgenic mice, identification of proteins that are upregulated or
XX CC down regulated in disease tissues, in identification of intracellular
XX CC changes in cells with physiological changes such as metabolic shift, in
XX CC the identification of biomarkers in cancers and in the identification of
XX CC signalling pathways. The method is gel-free methodology for qualitative
XX CC and quantitative proteome analysis without the need for multidimensional
XX CC chromatography and without the use of affinity tags. ABP74714 to ABP75190
XX CC represent peptide sequences used in the exemplification of the present
XX CC invention
XX SQ Sequence 19 AA;
XX
XX Query Match 100.0%; Score 19; DB 6; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 7.6e+02;
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 ACGV 4
XX ||||
XX Db 3 ACGV 6
XX
XX RESULT 55
XX ADP14799
XX ID ADP14799 standard; peptide; 19 AA.
XX
XX ADF14799;
XX
XX 12-FEB-2004 (first entry)
XX
XX SLE/sjogren syndrome autoantigen-derived peptide - SEQ ID 294.
XX
XX plant; deamidation; tissue transglutaminase; TTG; celiac disease; CD;
XX KM gluten intolerance; autoimmune; rheumatoid arthritis; multiple sclerosis;
XX KM systemic lupus erythematosus; sjogren syndrome; diabetes;
XX KM immunosuppressive; antirheumatic; antiarthritic; antidiabetic;
XX KM dermatological; antiinflammatory.
XX
XX Unidentified.
XX OS
XX PN EP1332760-A1.
XX
XX 06-AUG-2003.
XX
XX 04-FEB-2002; 2002EP-00075456.
XX

```

```

PR 04-FEB-2002; 2002EP-00075456.
XX
XX PA (ZIEK-) ACAD ZIEKENHUIS LEIDEN.
XX PT WPI; 2003-647889/62.
XX DR
XX PT New gluten peptides or epitopes prone to deamidation by tissue
XX PT transglutaminase, useful for treating celiac disease or an autoimmune
XX PT disease, rheumatoid arthritis, multiple sclerosis, systemic lupus
XX PT erythematosus, or diabetes.
XX
XX PS Claim 3; SEQ ID NO 294; 143pp; English.
XX
XX CC The invention relates to a novel peptide or epitope which is prone to
XX CC deamidation by tissue transglutaminase (TTG) and is a causative factor of
XX CC celiac disease (CD, gluten intolerance) or an autoimmune disease such as
XX CC rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus,
XX CC sjogren syndrome or diabetes. The peptide of the invention demonstrates
XX CC immunosuppressive, antirheumatic, antiarthritic, antidiabetic,
XX CC dermatological and antiinflammatory activities whilst pharmaceutical
XX CC compositions comprising the peptides or epitopes may be useful for the
XX CC treatment of a celiac disease or an autoimmune disease such as rheumatoid
XX CC arthritis, multiple sclerosis, systemic lupus erythematosus, sjogren
XX CC syndrome or diabetes. Gluten-derived peptides may be useful in the
XX CC preparation of therapeutic agents capable of eliminating a subset of
XX CC cells, particularly gluten-sensitive or auto-antigen sensitive T cells.
XX CC The current sequence is that of the systemic lupus erythematosus
XX CC (SLE)/sjogren syndrome autoantigen-derived peptide of the invention.
XX SQ Sequence 19 AA;
XX
XX Query Match 100.0%; Score 19; DB 7; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 7.6e+02;
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 ACGV 4
XX ||||
XX Db 9 ACGV 12
XX
XX RESULT 56
XX ADV55698
XX ID ADV55698 standard; peptide; 19 AA.
XX
XX ADV55698;
XX
XX 10-MAR-2005 (first entry)
XX
XX G protein coupled receptor peptide SEQ ID NO 3197.
XX
XX diagnosis; cancer; obesity; diabetes; asthma; inflammation; depression;
XX KM food; feedstuff; cosmetics; agriculture; animal breeding; GPCR.
XX
XX Unidentified.
XX OS
XX PN WO2004111636-A2.
XX
XX 23-DEC-2004.
XX
XX 17-JUN-2004; 2004WO-EP051158.
XX PF
XX 17-JUN-2003; 2003EP-00101775.
XX PR
XX 17-JUN-2003; 2003US-0479061P.
XX
XX (VIBV-) VIB VZW.
XX PA (UYGE-) UNIV GENT.
XX
XX Kae K, Vandekerckhove J, Krols L;
XX WPI; 2005-057893/06.
XX
XX Identifying a peptide combo which corresponds with a family of proteins,
XX PT useful for diagnosing a variety of diseases, drug development or in
XX

```

```

PT  agriculture, comprises generating peptides by applying a digest on the
PT  family of protein.
PS  Example; SEQ ID NO 3197; 265pp; English.
XX
XX  The invention relates to a method of identifying a peptide combo which
CC  corresponds with a family of proteins where each of the members of the
CC  peptide combo is derived from a unique protein from the family. The
CC  peptide combo is useful for quantifying specific known splice variants of
CC  one or more particular proteins in a sample, for diagnosing complex
CC  genetic diseases such as cancer, obesity, diabetes, asthma and
CC  inflammation, neuropsychiatric disorders such as depression, for
CC  quantifying one to several hundreds of protein disease markers
CC  simultaneously leading to a more accurate diagnostic sub-classification,
CC  for determining the extent of protein modification in a particular sample
CC  of proteins, for tissue-typing analysis, for prenatal testing to detect
CC  the presence of a congenital disease or for quantitating protein levels
CC  diagnostic of a chromosomal abnormality, for diagnosing immune diseases
CC  or neurological diseases, as biomarkers preclinical drug development,
CC  development of improved animal models, biomarkers related with
CC  toxicology, clinical drug development, guidance marketed drugs,
CC  prognostic or diagnostic disease markers, drug target validation and
CC  selection, monitoring protein splicing, drug lead profiling, pathway
CC  analysis, answering basic disease biology questions, and in the fields of
CC  food and feed, cosmetics, agriculture and animal breeding. The present
CC  sequence represents a peptide from a G-protein coupled receptor peptide
CC  combo.
XX
XX  Sequence 19 AA;
SQ
XX
XX  Query Match          100.0%; Score 19; DB 9; Length 19;
XX  Best Local Similarity 100.0%; Pred. No. 7.6e+02;
XX  Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY  1 A QGV 4
XX  ||||
XX  6 A QGV 9
Db
XX
XX  RESULT 57
XX  ADV54702
XX  ADV54702 standard; peptide; 19 AA.
XX
XX  ADV54702;
XX
XX  10-MAR-2005 (first entry)
XX
XX  G protein coupled receptor peptide SEQ ID NO 2199.
XX
XX  diagnosis; cancer; obesity; diabetes; asthma; inflammation; depression;
XX  food; feedstuff; cosmetics; agriculture; animal breeding; GPCR.
XX
XX  Unidentified.
XX
XX  WO2004111636-A2.
XX
XX  23-DEC-2004.
XX
XX  17-JUN-2004; 2004WO-EP051158.
XX
XX  17-JUN-2003; 2003EP-00101775.
XX  17-JUN-2003; 2003US-0479061P.
XX
XX  (VIBV-) VIB VZM.
XX  (UYGB-) UNIV GENT.
XX
XX  Kae K, Vandeckerckhove J, Krols L;
XX
XX  WPI; 2005-057893/06.
XX
XX  Identifying a peptide combo which corresponds with a family of proteins,
PT  useful for diagnosing a variety of diseases, drug development or in
PT  agriculture, comprises generating peptides by applying a digest on the

```

```

PT  family of protein.
XX
XX  Example; SEQ ID NO 2199; 265pp; English.
XX
XX  The invention relates to a method of identifying a peptide combo which
CC  corresponds with a family of proteins where each of the members of the
CC  peptide combo is derived from a unique protein from the family. The
CC  peptide combo is useful for quantifying specific known splice variants of
CC  one or more particular proteins in a sample, for diagnosing complex
CC  genetic diseases such as cancer, obesity, diabetes, asthma and
CC  inflammation, neuropsychiatric disorders such as depression, for
CC  quantifying one to several hundreds of protein disease markers
CC  simultaneously leading to a more accurate diagnostic sub-classification,
CC  for determining the extent of protein modification in a particular sample
CC  of proteins, for tissue-typing analysis, for prenatal testing to detect
CC  the presence of a congenital disease or for quantitating protein levels
CC  diagnostic of a chromosomal abnormality, for diagnosing immune diseases
CC  or neurological diseases, as biomarkers preclinical drug development,
CC  development of improved animal models, biomarkers related with
CC  toxicology, clinical drug development, guidance marketed drugs,
CC  prognostic or diagnostic disease markers, drug target validation and
CC  selection, monitoring protein splicing, drug lead profiling, pathway
CC  analysis, answering basic disease biology questions, and in the fields of
CC  food and feed, cosmetics, agriculture and animal breeding. The present
CC  sequence represents a peptide from a G-protein coupled receptor peptide
CC  combo.
XX
XX  Sequence 19 AA;
SQ
XX
XX  Query Match          100.0%; Score 19; DB 9; Length 19;
XX  Best Local Similarity 100.0%; Pred. No. 7.6e+02;
XX  Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY  1 A QGV 4
XX  ||||
XX  6 A QGV 9
Db
XX
XX  RESULT 58
XX  ADX56536
XX  ID ADX56536 standard; peptide; 19 AA.
XX
XX  ADX56536;
XX
XX  05-MAY-2005 (first entry)
XX
XX  Cardiovascular disorder plasma protein tryptic fragment SEQ ID NO 353.
XX
XX  coronary artery disease; primary biliary cirrhosis; gallstones;
XX  celiac disease; irritable bowel syndrome; diabetes; scleroderma; nausea;
XX  emesis; constipation; diarrhea; cardiovascular disease; immune disorder;
XX  endocrine disease; gastrointestinal disease; metabolic disorder;
XX  dermatological disease; musculoskeletal disease; Carfant; Vasotropic;
XX  Hepatotropic; Litholytic; Immunosuppressive; Gastrointestinal-den.;
XX  Antiinflammatory; Antidiabetic; Dermatological; Antiemetic; Laxative;
XX  Antidiarrhetic; diagnosis.
XX
XX  Homo sapiens.
XX
XX  WO2005015206-A2.
XX
XX  17-FEB-2005.
XX
XX  06-AUG-2004; 2004WO-EP008860.
XX
XX  08-AUG-2003; 2003US-0493599P.
XX  08-AUG-2003; 2003US-0493836P.
XX  08-AUG-2003; 2003US-0493867P.
XX  08-AUG-2003; 2003US-0493985P.
XX
XX  (XENO-) XENOVA LTD.
XX  (NOVS ) NOVARTIS AG.
XX  (NOVS ) NOVARTIS PHARMA GMBH.
XX

```

XX Argoud-Puy G, Bederr N, Bougueleret L, Cusin I, Mahe B;
PI Nimejnd A, Reftas S, Rose K, Saudrais C, Scherer A, Papoian R;
XX WPI; 2005-195824/20.
DR
PT Screening and/or diagnosing cardiovascular disorder in subject involves
PT detecting and/or quantifying level of polypeptide in biological sample
PT from subject and comparing with control sample.
XX
PS Claim 1; SEQ ID NO 353; 349pp; English.
XX
CC The invention relates to a method of screening and/or diagnosing a
CC cardiovascular disorder (CD) in a subject which comprises detecting
CC and/or quantifying the level of a polypeptide in a biological sample from
CC the subject and comparing the level to that of control sample. The method
CC is useful for screening, diagnosing and treating coronary artery disease,
CC biliary cirrhosis, gallstones, celiac disease, irritable bowel syndrome,
CC diabetes, scleroderma, nausea, vomiting, constipation and diarrhea. The
CC method is rapid and efficient. The present sequence represents a
CC cardiovascular disorder plasma protein tryptic fragment.
CC
SQ Sequence 19 AA;
XX
QY Query Match 100.0%; Score 19; DB 9; Length 19;
Db Best Local Similarity 100.0%; Pred. No. 7.6e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 AOGV 4
3 AOGV 6
XX
RESULT 59
ADK99563
ID ADC99563 standard; peptide; 20 AA.
XX
AC ADC99563;
XX
DT 01-JAN-2004 (first entry)
XX
DE Cancer-related VEGF-R1/Flt1-binder peptide - SEQ ID 401.
XX
KM Cytostatic; cancer; gene therapy; DGI-2; DGI-5; DGI-7; DGI-9; Hras;
KM Ieptin; VEGF; vascular endothelial growth factor receptor; VEGF-R1;
KM VEGF-R2; VEGF-R3; Flt1; FMS-related tyrosine kinase 1; Flk1; KDR;
KM kinase insert domain protein receptor; EGFR; epidermal growth factor;
KM FGFR1; fibroblast growth factor; Tie-1.
XX
OS Unidentified.
XX
PN WO2003035839-A2.
XX
PD 01-MAY-2003.
XX
PF 24-OCT-2002; 2002WO-US034021.
XX
PR 24-OCT-2001; 2001US-0345471P.
XX
PA (DGI-B-) DGI BIOTECHNOLOGIES INC.
XX
PI Piliula RC, Brissette R, Spruyt M, Dedova O, Blume A;
PI Prendergast J, Goldstein N;
XX
DR WPI; 2003-457332/43.
XX
PT Selecting target and target binder pairs for preparing a composition for
PT treating cancer by mixing in a reaction vessel phage expressing
PT biological targets and phage expressing target binders.
XX
PS Claim 26; SEQ ID NO 401; 172pp; English.
XX
CC The invention relates to a novel method of selecting target and target

CC binder pairs comprising mixing in a reaction vessel phage expressing
CC biological targets and phage expressing target binders, each having
CC distinguishable selection markers and selecting target and target binder
CC pairs based on the selection markers. The molecules of the invention
CC demonstrate cytostatic activity whilst the method may be useful for
CC selecting target and target binder pairs for preparing a composition for
CC treating cancer. Furthermore, the method may be utilised during gene
CC therapy procedures. The current sequence is that of the cancer-related
CC VEGF-R1/Flt1 (vascular endothelial growth factor-receptor 1/FMS-related
CC tyrosine kinase 1)-binder peptide of the invention.
XX
SQ Sequence 20 AA;
XX
QY Query Match 100.0%; Score 19; DB 7; Length 20;
Db Best Local Similarity 100.0%; Pred. No. 8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 AOGV 4
6 AOGV 9
XX
RESULT 60
ADK15603
ID ADK15603 standard; peptide; 20 AA.
XX
AC ADK15603;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human G250 tumour antigen derived peptide #13.
XX
KM Human; G250 tumour antigen; immunogenic peptide; CD4+; CD8+;
KM T-cell immune response; renal cell carcinoma; RCC; cancer; kidney;
KM prostate; head; neck; gastrointestinal tract; colon; stomach; bladder;
KM cyostatic; immunostimulant.
XX
OS Homo sapiens.
XX
PN US2004053391-A1.
XX
PD 18-MAR-2004.
XX
PF 11-SEP-2002; 2002US-00241814.
XX
PR 11-SEP-2002; 2002US-00241814.
XX
PA (UTNI-) UNIV NIEMEGEN.
XX
PI Vissers JLM, De Vries IJM, Oosterwijk E, Figdor CG, Adema GJ;
XX
DR WPI; 2004-247730/23.
XX
PT New renal cell carcinoma-antigen G250-derived peptide, useful as vaccine
PT for treating or preventing cancer, e.g. renal cell carcinoma, cancer of
PT the kidney, prostate, head, neck, bladder or gastrointestinal tract, e.g.
PT colon or stomach.
XX
PS Example; SEQ ID NO 13; 17pp; English.
XX
CC The present invention relates to human G250 tumour antigen derived
CC immunogenic peptides capable of eliciting CD4+ and CD8+ T-cell immune
CC response. The immunogenic peptides can elicit an immune response against
CC cells that express the G250 antigen, such as those found in renal cell
CC carcinoma (RCC). The immunogenic peptides and/or the nucleotide sequences
CC that encode them are useful for the manufacture of a composition for
CC treating or preventing cancer, e.g. renal cell carcinoma or a cancer of
CC the kidney, prostate, head, neck, gastrointestinal tract or any of its
CC part, e.g. colon or stomach or bladder. The peptides are also useful for
CC the preparation of a composition for treating or preventing a tumour that
CC expresses the G250 antigen. The immunogenic peptides are also useful in
CC eliciting an immune response in a human or animal against a tumour. The
CC present sequence represents a human G250 tumour antigen derived peptide.

XX Sequence 20 AA;
SQ Query Match 100.0%; Score 19; DB 8; Length 20;
Best Local Similarity 100.0%; Pred. No. 8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
DB 1 AOGV 4

RESULT 61
ADT36531
ID ADT36531 standard; peptide; 20 AA.
XX
XX ADT36531;
XX
DT 02-DEC-2004 (first entry)
XX
DE RCC-associated antigen G250-derived peptide (residues 337-356), SEQ:13.
XX
XX Human; renal cell carcinoma-associated antigen G250;
KM RCC-associated antigen G250; tumour-associated antigen MN/CA IX; cancer;
KM kidney; prostate; head, neck; gastrointestinal tract;
KM renal cell carcinoma; colon; stomach; bladder; CD4+ T cell response;
KM CD4+ T cell response; cytostatic; vaccine; gene therapy; immunotherapy;
KM HLA class II binding; MHC class II binding; human leukocyte antigen;
KM major histocompatibility complex.
XX
XX Homo sapiens.
XX
XX AU2002300986-A1.
XX
XX 01-APR-2004.
XX
XX 12-SEP-2002; 2002AU-00300986.
XX
XX 12-SEP-2002; 2002AU-00300986.
XX
XX (UYN1-) UNIV NIJMEGEN.
XX
XX Adema GJ, Fijdor CG, Oosterwijk E, De Vries JM, Vissers JLM;
XX WPI; 2004-662544/65.
XX
XX New renal cell carcinoma-antigen G250-derived peptide other than human
PT G250 protein, useful for preventing or treating cancer such as renal cell
PT carcinoma or cancer of kidney, prostate, colon, stomach or bladder.
PT
XX Example; SEQ ID NO 13; 40pp; English.

XX The invention relates to a peptide derived from human renal cell
CC carcinoma (RCC)-associated antigen G250 comprising the sequence shown in
CC ADT36533 or a sequence having at most 3 amino acid replacements with
CC respect to it. The peptide of the invention is not the human G250 protein
CC (ADT36534, also known as tumour-associated antigen MN/CA IX), and
CC preferably comprises the sequence shown in ADT36533 or a sequence with 1-
CC 4 amino acid substitutions compared to ADT36533. The invention also
CC relates to compositions comprising a peptide of the invention or an
CC antigen presenting cell loaded with a peptide of the invention; a gene
CC therapy agent comprising a nucleotide sequence encoding a peptide of the
CC invention; and the use of the gene therapy agent for treating cancer. The
CC peptides, compositions and gene therapy agents are useful in the
CC treatment and prevention of cancers such as those of the kidney,
CC prostate, bladder, head, neck, gastrointestinal tract (or part thereof).
CC They are especially useful for treating or preventing renal cell
CC carcinoma, colon cancer, stomach cancer, bladder cancer or a cancer which
CC expresses the G250 protein or a sequence at least 95% identical to it.
CC Because the peptides of the invention are able to elicit CD4+ and CD8+ T-
CC cell responses against cells expressing the G250 antigen, they can be
CC used in immunotherapy for the treatment of cancers. The peptides may also
CC be used as vaccines for the prevention of cancer, and in immunological.

CC diagnostic and/or analytical applications. Sequences ADT36519-ADT36532
CC represent RCC-associated antigen G250-derived peptides predicted to bind
CC to HLA (human leukocyte antigen) class II molecules which were tested for
CC their ability to induce a CD4+ (helper) T cell response in the example of
CC the invention. The position given on page 23 for this peptide in the full
CC -length G250 protein differs by one amino acid to its position in
CC ADT36534.

XX
XX Sequence 20 AA;
SQ Query Match 100.0%; Score 19; DB 8; Length 20;
Best Local Similarity 100.0%; Pred. No. 8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
DB 1 AOGV 4

RESULT 62
AAB57305
ID AAB57305 standard; peptide; 21 AA.
XX
XX AAB57305;
XX
XX 09-MAR-2001 (first entry)
XX
XX Antigenic peptide from acetolactate synthase N-terminal.
XX
XX Protein expression; genetic engineering; horizontal transfer.
XX
XX Escherichia coli.
XX
XX WO200071701-A1.
XX
XX 30-NOV-2000.
XX
XX 23-MAY-2000; 2000WO-US014122.
XX
XX 24-MAY-1999; 99US-0135677P.
XX
XX (NEME) NEW ENGLAND BIOLABS INC.
XX (BOST-) BOSTON BIOMEDICAL RES INST.
XX
XX Xu M, Evans TC, Pradhan S, Comb DG, Paulus H, Sun L, Chen L;
XX PI Ghosh I;
XX WPI; 2001-032033/04.
XX
XX Reconstituting a target protein in a predetermined location in an
PT organism useful for creating transgenic crops comprises splitting DNA
PT coding for the target protein into fragments and separating and
PT expressing the fragments in the organism.

XX Example 1; Page 54; 177pp; English.

XX The present invention relates to reconstituting a target protein in a
CC predetermined location within an organism, involving splitting DNA coding
CC for the target protein into at least two fragments, separating and
CC expressing the DNA fragments within the organism and reconstituting the
CC target protein. This may be used for genetic engineering of crops. This
CC type of transgene allows efficient protein expression but does not
CC require a gene coupling approach and has a significantly lower chance of
CC spread by horizontal gene transfer than current methods

XX
XX Sequence 21 AA;
SQ Query Match 100.0%; Score 19; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 8.4e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
DB 1 AOGV 4

Db 11 AGV 14

RESULT 63
AAR36398 standard; peptide; 22 AA.
XX
XX AAR36398;
AC
XX
XX 25-MAR-2003 (revised)
DT 12-AUG-1993 (first entry)
XX
XX DPI-16 (170-191) a Dermatophagoides protein allergen.
DE
XX
XX T cell epitope; house dust mite; allergy; soluble; Der PI.
KM
XX
XX Synthetic.
OS
XX WO9308279-A1.
PN
XX 29-APR-1993.
PD
XX
XX 15-OCT-1992; 92WO-US008637.
PF
XX
XX 16-OCT-1991; 91US-00777859.
PR 08-MAY-1992; 92US-00881396.
XX
XX (IMMU-) IMMUNOLOGIC PHARM CORP.
PA
XX Garman RD, Greenstein JL, Kuo MC, Rogers BL;
PI WPI; 1993-152472/18.
DR
XX
XX Isolated peptide(s) of dermatophagoides protein allergens - for diagnosis
PT and treatment of sensitivity to house dust mite.
XX
XX
XX Claim 10; Fig 3; 176pp; English.
PS
XX
XX The peptide is one of a series of overlapping peptides synthesised by
CC standard techniques to cover the whole Dermatophagoides pteronyssinus Der
CC PI sequence. The T cell epitopes of the protein were mapped by detection
CC of the peptide's ability to stimulate T cell activity. The peptides may
CC be used for diagnosis and treatment of sensitivity to house dust mite
CC allergens. When administered to house dust mite sensitive individuals,
CC the peptides are capable of modifying the allergic response to the
CC allergens. The peptides may be modified for e.g. increasing solubility,
CC enhancing therapeutic or preventive efficacy or stability. See also
CC AAR34686-700 and AAR36398-490. (Updated on 25-MAR-2003 to correct PN
CC field.)
CC
XX
SQ Sequence 22 AA;
Query Match 100.0%; Score 19; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 8.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGV 4
|||
Db 11 AGV 14

RESULT 64
AAR77133 standard; peptide; 22 AA.
ID AAR77133;
XX
XX AAR77133;
AC
XX
XX 25-MAR-2003 (revised)
DT 31-MAY-1996 (first entry)
XX
XX Dermatophagoides pteronyssinus group I peptide DPI-16 (170-191).
DE
XX
XX House dust mite; DerPI; DerPII; DerPII; allergen; allergy;
KM

KM overlapping peptide; screening.
XX
XX Dermatophagoides pteronyssinus.
OS
XX WO9528424-A1.
FN
XX 26-OCT-1995.
PD
XX
XX 12-APR-1995; 95WO-US004481.
PF
XX 14-APR-1994; 94US-00227772.
PR
XX
XX (IMMU-) IMMUNOLOGIC PHARM CORP.
PA
XX
XX Chen X, Evans S, Shaked Z, Franzen HM, Kuo M;
PI WPI; 1995-373765/48.
DR
XX
XX Compans. contg. house mite allergen-derived peptide(s), some of which are
PT new - are used to treat allergy, and are stable, soluble and able to
PT induce T cell non-responsiveness.
XX
XX Disclosure; Fig 2; 61pp; English.
PS
XX
XX Claimed therapeutic compositions contain at least one of the peptides DPI
CC -21.2 and DPI-22.2 and also at least one of the new peptides DPI-23.31,
CC DPI-26.6, DPII-20.9, DPII-22.14 and DPII-25.15. The compositions are
CC useful for treating sensitivity to house dust mite allergens. The
CC peptides were identified by screening overlapping peptides derived from
CC D.pteronyssinus and D.farinae group I and II allergens for T-cell
CC reactivity in sensitised individuals. The present sequence is that of
CC overlapping peptide DPI-16 (170-191). (Updated on 25-MAR-2003 to correct
CC PR field.)
CC
XX
SQ Sequence 22 AA;
Query Match 100.0%; Score 19; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 8.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGV 4
|||
Db 11 AGV 14

RESULT 65
AAW71926 standard; peptide; 22 AA.
ID AAW71926;
XX
XX AAW71926;
AC
XX 27-AUG-2003 (revised)
DT 25-MAR-2003 (revised)
DT 16-DEC-1998 (first entry)
XX
XX Dermatophagoides Der p I protein peptide DPI-16.
DE
XX
XX genus Dermatophagoides; major protein allergen; T cell epitope; Der p I;
KM Der p II; Der f I; Der f II; house dust mite allergy.
XX
XX Dermatophagoides.
OS
XX
XX US5820862-A.
FN
XX
XX 13-OCT-1998.
PD
XX
XX 07-JUN-1995; 95US-00482142.
PF
XX 14-APR-1993; 93WO-US003471.
PR 14-APR-1994; 94US-00227772.
PR 19-MAY-1995; 95US-00445307.
XX
XX (IMMU-) IMMUNOLOGIC PHARM CORP.
PA

XX Franzen HM, Kuo M, Evans S, Garman RD, Greenstein JL, Chen X;
PI Shaked Z, Rogers BL,
XX WPI; 1998-567590/48.
XX Dermacophagoides allergen peptides - useful for treating house dust mite
PT allergy.
XX
PS Disclosure; Col 89-91; 155pp; English.
XX
CC The present invention describes peptides for treating sensitivity to
CC house dust mite allergens from the genus Dermatophagoides. Peptides
CC within the scope of the invention comprise at least one T cell epitope,
CC or preferably at least two T cell epitopes of a protein allergen selected
CC from the allergens Der p I, Der p II, Der f I, or Der f II. The invention
CC also describes modified peptides having similar or enhanced therapeutic
CC properties as the corresponding, naturally occurring allergen, but having
CC reduced side effects. AAW71912 to AAW72000, and AAW72257 to AAW72330
CC represent peptides from the present invention. (Updated on 25-MAR-2003 to
CC correct PR field.) (Updated on 27-AUG-2003 to correct OS field.)
XX
SQ Sequence 22 AA;

Query Match 100.0%; Score 19; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 8.9e+02; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0;

QY 1 AOGV 4
Db 11 AOGV 14

RESULT 66
AAV50375
ID AAV50375 standard; peptide; 22 AA.
XX
AC AAV50375;
XX
DT 25-JAN-2000 (first entry)
XX
DE Dermatophagoides sp major protein allergen DP I-16.
XX
KM Allergen; house dust mite; detection; sensitivity; T cell epitope;
KM screening; allergic disorder; asthma; rhinitis; ectopic dermatitis;
KM Der f I; Der p I; Der p II; Der f II.
XX
OS Dermatophagoides sp.
XX
PN US5968526-A.
XX
PD 19-OCT-1999.
XX
PF 07-JUN-1995; 95US-00478572.
XX
PR 14-APR-1994; 94US-00227772.
PR 12-APR-1995; 95WO-US004481.
PR 19-MAY-1995; 95US-00445307.
XX
PA (IMMU-) IMMUNOLOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Rogers BL, Franzen HM, Shaked Z;
PI Chen X, Evans S, Kuo M;
XX
XX WPI; 1999-590385/50.
XX
PT Screening individuals for allergic reactions to T cell epitopes of major
PT allergens from house dust mites.
XX
PS Claim 10; Col 91-92; 158pp; English.
XX
CC This invention describes a novel method (I) for detecting whether an
CC individual is sensitive to Dermatophagoides (house dust mites). The

CC method involves detecting sensitivity to house dust mites in patients,
CC comprising combining a blood sample from the individual with 1 or more
CC isolated T cell epitopes of the protein allergens I and II (DP I) and
CC (DP II) from Dermatophagoides (house dust mites). 32 T cell epitopes
CC with varying, defined amino acids sequences (given in the specification)
CC may be used in (I). The sample and allergens are combined under
CC conditions appropriate for the binding of blood components with the
CC polypeptides. The extent of binding is then indicative of the sensitivity
CC of the patient to house dust mites. (I) may be used to screen individuals
CC for sensitivity to Dermatophagoides (house dust mites). The house dust
CC mite is a major cause of a variety of allergic disorders such as asthma,
CC rhinitis and eczopic dermatitis. AAV50360-Y50542 and AAV50546-Y50555
CC represent house dust mite allergen peptide fragments derived from Der p
CC I, Der f II, Der f I and Der f II
XX
SQ Sequence 22 AA;

Query Match 100.0%; Score 19; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 8.9e+02; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0;

QY 1 AOGV 4
Db 11 AOGV 14

RESULT 67
AAU18978
ID AAU18978 standard; peptide; 22 AA.
XX
AC AAU18978;
XX
DT 04-DEC-2001 (first entry)
XX
DE T-cell epitope containing peptide DPI-16.
XX
KM House dust mite; allergenic peptide; Der p I; Der p II; Der f I;
KM Der f II; antiallergenic; immunostimulant; house dust mite allergy;
KM T-cell epitope.
XX
OS Dermatophagoides pteronyssinus.
XX
PN US6268491-B1.
XX
PD 31-JUL-2001.
XX
PF 07-JUN-1995; 95US-00484296.
XX
PR 16-OCT-1991; 91US-00777859.
PR 08-MAY-1992; 92US-00881396.
PR 14-APR-1993; 93WO-US003471.
PR 14-APR-1994; 94US-00227772.
PR 19-MAY-1995; 95US-00445307.
XX
PA (IMMU-) IMMUNOLOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Kuo M, Rogers BL, Franzen HM, Chen X;
PI Evans S, Shaked Z;
XX
XX WPI; 2001-549074/61.
XX
PT Peptides comprising T cell groups of the major allergens from
PT Dermatophagoides (house dust mites), useful for treating house dust mite
PT allergy in humans, and for diagnosing sensitivity to house dust mite
PT protein allergens.
XX
PS Example 3; Fig 3; 158pp; English.
XX
CC The invention relates to an isolated peptide of the major protein
CC allergens of the genus Dermatophagoides, which comprises at least one T
CC cell group of a protein allergen from Der p (DP) I, DP II, Der f (DF) I
CC or DF II. The isolated peptide comprises at least two regions, each
CC region comprising at least one T cell group of a protein allergen of the

CC Genus Dermatophagoides. The regions are derived from the same or
 CC different protein allergens of the genus Dermatophagoides. The peptides
 CC are useful for treating house dust mite allergy in humans. The peptides
 CC are also useful for detecting or diagnosing sensitivity to house dust
 CC mite protein allergens. The present peptides have similar or enhanced
 CC therapeutic properties as the naturally-occurring allergen, but have
 CC reduced side effects, and increased solubility and stability. The present
 CC sequence represents an allergenic T-cell epitope containing peptide
 CC derived from the Dermatophagoides allergenic proteins

XX Sequence 22 AA;

Query Match 100.0%; Score 19; DB 4; Length 23;

Best Local Similarity 100.0%; Pred. No. 8.9e+02; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0;

Qy 1 AOGV 4
 ||||
 Db 11 AOGV 14

RESULT 68

AAR36414

ID AAR36414 standard; peptide; 23 AA.

XX AAR36414;

XX 25-MAR-2003 (revised)

DT 12-AUG-1993 (first entry)

XX DRI-28.2(173-195) a Dermatophagoides protein allergen.

XX T cell epitope; house dust mite; allergy; soluble; Der PI.

XX Synthetic.

XX WO9308279-A1.

XX 29-APR-1993.

XX 15-OCT-1992; 92WO-US008637.

XX 16-OCT-1991; 91US-00777859.

PR 08-MAY-1992; 92US-00861396.

XX (IMMU-) IMMUNOLOGIC PHARM CORP.

PI Garman RD, Greenstein JL, Kuo MC, Rogers BL;

XX WPI; 1993-152472/18.

PT Isolated peptide(s) of dermatophagoides protein allergens - for diagnosis
 and treatment of sensitivity to house dust mite.

XX Claim 10; Fig 3; 176pp; English.

XX The peptide is one of a series of overlapping peptides synthesised by
 CC standard techniques to cover the whole Dermatophagoides pteronyssinus Der
 CC PI sequence. The T cell epitopes of the protein were mapped by detection
 CC of the peptide's ability to stimulate T cell activity. The peptides may
 CC be used for diagnosis and treatment of sensitivity to house dust mite
 CC allergens. When administered to house dust mite sensitive individuals,
 CC the peptides are capable of modifying the allergic response to the
 CC allergens. The peptides may be modified for e.g. increasing solubility,
 CC enhancing therapeutic or preventive efficacy or stability. See also
 CC AAR34686-700 and AAR36398-490. (Updated on 25-MAR-2003 to correct PN
 CC field.)

XX Sequence 23 AA;

Query Match 100.0%; Score 19; DB 2; Length 23;

Best Local Similarity 100.0%; Pred. No. 9.3e+02; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0;

Qy 1 AOGV 4
 ||||
 Db 8 AOGV 11

RESULT 69

AAR51762

ID AAR51762 standard; protein; 23 AA.

XX AAR51762;

DT 01-FEB-1995 (first entry)

XX Der p I derived peptide, DP I-28.2(173-195).

XX Group I; protein allergen; house dust mite; D. pteronyssinus; Der p I;
 KW homology; D. farinae; Der f I; group II; Der p II; Der f II; T-cell;
 KW epitopes; fusion peptides; antigenic fragments; substitution; deletion;
 KW addition; chemical synthesis; chemical cleavage; recombinant techniques;
 KW allergic response; immunoglobulin E; IgE; immunotherapy; anaphylaxis;
 KW IgE-mediated responses; anaphylaxis; lymphokine secretion profile; modify;
 KW T cell subpopulations; unresponsive; immune response; tolerance.

XX Dermatophagoides pteronyssinus.

XX ZA9302677-A.

XX 26-JAN-1994.

XX 16-APR-1993; 93ZA-00002677.

XX 16-APR-1993; 93ZA-00002677.

XX (IMMU-) IMMUNOLOGIC PHARM CORP.

PI Garman RD, Greenstein JL, Kuo M, Rogers BL;

XX WPI; 1994-126807/15.

PT Isolated and/or modified peptides comprising T-cell epitopes - of major
 protein allergens of genus Dermatophagoides, used to treat or diagnose
 sensitivity to house dust mites.

XX Claim 28; Page 67; 154pp; English.

XX The sequences given in AAR51731-841 represent T-cell epitopes derived
 CC from the group I and II protein allergens from the house dust mite D.
 CC farinae and D. pteronyssinus, Der f I, Der f II, Der p I and Der p II
 CC respectively. The Der f II protein has a high homology having an
 CC identity of 88% with an identity of 81% between the two group I proteins
 CC (see also AAR51727-30). Fusion peptides may be produced which comprise at
 CC least two or these antigenic fragments. Each region of these fusion
 CC peptides may be derived from the same, or different, mite allergens. The
 CC antigenic fragments may be altered by substitution, deletion or addition
 CC to enhance their antigenicity. These peptides may be produced by chemical
 CC synthesis, chemical cleavage of the protein allergen or by recombinant
 CC techniques. These peptides, or the fusion peptides, when administered to
 CC a house dust mite sensitive individual, are capable of modifying the
 CC allergic response of the individual to the allergen. The peptides do not
 CC bind to immunoglobulin E (IgE), or bind IgE to a lesser extent than the
 CC full length protein allergen. This reduces the major complications of
 CC standard immunotherapy, which are IgE-mediated responses such as
 CC anaphylaxis. Exposure of mite allergic patients to these peptides may
 CC tolerate or avert an appropriate T cell subpopulations such that they
 CC become unresponsive to mite allergens and do not participate in mounting
 CC an immune response upon exposure. Administration of the peptides may also
 CC modify the lymphokine secretion profile as compared with exposure to the
 CC naturally occurring mite protein allergen

XX Sequence 23 AA;

Query Match 100.0%; Score 19; DB 2; Length 23;

Best Local Similarity 100.0%; Pred. No. 9.3e+02; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0;

OY 1 AOGV 4
1111
Db 8 AOGV 11

RESULT 70

AAW37822
ID AAW37822 standard; peptide; 23 AA.

XX AAW37822;

XX 14-AUG-1998 (first entry)

DE Peptide derived from the heparin binding site of plasma fibrinonec tin.

XX Cell adhesion activity; heparin binding site; human;

KW plasma fibrinonec tin; inhibition; cancer metastasis.

XX Synthetic.

OS Homo sapiens.

XX EP837074-A2.

XX 22-APR-1998.

XX 18-SEP-1997; 97EP-00116293.

XX 19-SEP-1996; 96JP-00248247.

XX (HISM) HISAMITSU PHARM CO LTD.

PI Fukai F, Katayama T;

XX WPI; 1998-219072/20.

XX Peptide(s) that inhibit cell adhesion - comprising fragments of heparin-

XX binding site of fibrinonec tin.

XX Example 1; Page 9; 21pp; English.

XX Synthetic peptides AAW37820-24 and AAW56673-80 have cell adhesion

CC inhibition activity. All the peptides were modified with maleimide-

CC activated Keyhole Limpet Haemocyanine in order to improve their

CC solubility. The peptides are derived from a part of the heparin binding

CC site of human plasma fibrinonec tin, the present sequence being derived

CC from residues 1669 to 1691. Peptide AAW56680 has the strongest cell

CC adhesion inhibition activity. The peptides are used for inhibiting cancer

CC metastasis

XX Sequence 23 AA;

XX

XX

XX

XX

XX

XX

XX

DE Dermatophagoides Der p I protein peptide DPI-28.2.

XX genus Dermatophagoides; major protein allergen; T cell epitope; Der p I;

KW Der p II; Der f I; Der f II; house dust mite allergy.

XX Dermatophagoides.

XX US5820862-A.

XX 13-OCT-1998.

XX 07-JUN-1995; 95US-00482142.

XX 14-APR-1993; 93WO-US003471.

XX 14-APR-1994; 94US-00227772.

XX 19-MAY-1995; 95US-00445307.

XX (IMMU-) IMMULOGIC PHARM CORP.

XX Franzen EM, Kuo M, Evans S, Garman RD, Greenstein JL, Chen X;

XX Shaked Z, Rogers BL;

XX WPI; 1998-567590/48.

XX Dermatophagoides allergen peptides - useful for treating house dust mite

XX allergy.

XX Discloure; Col 97-99; 155pp; English.

XX The present invention describes peptides for treating sensitivity to

CC house dust mite allergens from the genus Dermatophagoides. Peptides

CC within the scope of the invention comprise at least one T cell epitope,

CC or preferably at least two T cell epitopes of a protein allergen selected

CC from the allergens Der p I, Der p II, Der f I, or Der f II. The invention

CC also describes modified peptides having similar or enhanced therapeutic

CC properties as the corresponding, naturally occurring allergen, but having

CC reduced side effects. AAW71912 to AAW72000, and AAW72257 to AAW72330

CC represent peptides from the present invention. (Updated on 25-MAR-2003 to

CC correct PR field.) (Updated on 27-AUG-2003 to correct OS field.)

XX Sequence 23 AA;

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

DE Dermatophagoides Der p I protein peptide DPI-28.2.

XX genus Dermatophagoides; major protein allergen; T cell epitope; Der p I;

KW Der p II; Der f I; Der f II; house dust mite allergy.

XX Dermatophagoides.

XX US5820862-A.

XX 13-OCT-1998.

XX 07-JUN-1995; 95US-00482142.

XX 14-APR-1993; 93WO-US003471.

XX 14-APR-1994; 94US-00227772.

XX 19-MAY-1995; 95US-00445307.

XX (IMMU-) IMMULOGIC PHARM CORP.

XX Franzen EM, Kuo M, Evans S, Garman RD, Greenstein JL, Chen X;

XX Shaked Z, Rogers BL;

XX WPI; 1998-567590/48.

XX Dermatophagoides allergen peptides - useful for treating house dust mite

XX allergy.

XX Discloure; Col 97-99; 155pp; English.

XX The present invention describes peptides for treating sensitivity to

CC house dust mite allergens from the genus Dermatophagoides. Peptides

CC within the scope of the invention comprise at least one T cell epitope,

CC or preferably at least two T cell epitopes of a protein allergen selected

CC from the allergens Der p I, Der p II, Der f I, or Der f II. The invention

CC also describes modified peptides having similar or enhanced therapeutic

CC properties as the corresponding, naturally occurring allergen, but having

CC reduced side effects. AAW71912 to AAW72000, and AAW72257 to AAW72330

CC represent peptides from the present invention. (Updated on 25-MAR-2003 to

CC correct PR field.) (Updated on 27-AUG-2003 to correct OS field.)

XX Sequence 23 AA;

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

PR 14-APR-1994; 94US-0022772.
 PR 12-APR-1995; 95MO-US004481.
 PR 19-MAY-1995; 95US-00445307.
 XX
 PA (IMMU-) IMMUNOLOGIC PHARM CORP.
 PI Garman RD, Greenstein JL, Rogers BL, Franzen HM, Shaked Z;
 PI Chen X, Evans S, Kuo M;
 XX WPI; 1999-590385/50.
 DR
 XX
 PT Screening individuals for allergic reactions to T cell epitopes of major
 PT allergens from house dust mites.
 XX
 PS Claim 1e'; Column 99-100; 158pp; English.
 XX
 CC This invention describes a novel method (I) for detecting whether an
 CC individual is sensitive to Dermatophagoides (house dust mites). The
 CC method involves detecting sensitivity to house dust mites in patients,
 CC comprising combining a blood sample from the individual with 1 or more
 CC isolated T cell epitopes of the protein allergens I and II (DP I) and
 CC (DP II) from Dermatophagoides (house dust mites). 32 T cell epitopes
 CC with varying defined amino acids sequences (given in the specification)
 CC may be used in (I). The sample and allergens are combined under
 CC conditions appropriate for the binding of blood components with the
 CC polypeptides. The extent of binding is then indicative of the sensitivity
 CC of the patient to house dust mites. (I) may be used to screen individuals
 CC for sensitivity to Dermatophagoides (house dust mites). The house dust
 CC mite is a major cause of a variety of allergic disorders such as asthma,
 CC rhinitis and eczopic dermatitis. AAY50360-Y50542 and AAY50546-Y50555
 CC represent house dust mite allergen peptide fragments derived from Der p
 CC I, Der f II, Der f I and Der f II
 XX
 SQ Sequence 23 AA;
 Query Match 100.0%; Score 19; DB 2; Length 23;
 Best Local Similarity 100.0%; Pred. No. 9.3e+02; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AAGV 4
 ||||
 Db 8 AAGV 11
 RESULT 73
 AAY36513
 ID AAY36513 standard; protein; 23 AA.
 XX
 AC AAY36513;
 XX
 DT 17-SEP-1999 (first entry)
 XX
 DE Fragment of human secreted protein encoded by gene 32.
 XX
 KM Human; secreted protein; cancer; tumour; developmental abnormality;
 KM foetal deficiency; blood disorder; immune system disorder; inflammation;
 KM autoimmune disease; allergy; Alzheimer's disease; cognitive disorder;
 KM schizophrēnia; arthritis; asthma; psoriasis; sepsis; skin disorder;
 KM atherosclerosis; diabetes; cardiovascular disorder; kidney disorder;
 KM digestive disorder; endocrine disorder; infection; AIDS.
 XX
 OS Homo sapiens.
 XX
 PN W09931117-A1.
 XX
 PD 24-JUN-1999.
 XX
 PF 17-DEC-1998; 98MO-US027059.
 XX
 PR 18-DEC-1997; 97US-0068006P.
 PR 18-DEC-1997; 97US-0068007P.
 PR 18-DEC-1997; 97US-0068008P.
 PR 18-DEC-1997; 97US-0068053P.

PR 18-DEC-1997; 97US-0068054P.
 PR 18-DEC-1997; 97US-0068057P.
 PR 18-DEC-1997; 97US-0068064P.
 PR 18-DEC-1997; 97US-0070923P.
 PR 18-DEC-1997; 97US-0068169P.
 PR 19-DEC-1997; 97US-0068365P.
 PR 19-DEC-1997; 97US-0068367P.
 PR 19-DEC-1997; 97US-0068368P.
 PR 19-DEC-1997; 97US-0068369P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Moore PA, Ruben SM, Carter KC, Shi Y, Rosen CA, Soppet DR;
 PI Kyaw H, Wei Y, Florence K, Duan RD, Florence C, Greene JM, Feng P;
 PI Ferrie AM, Yu G, Janat F, Ni J;
 XX WPI; 1999-418749/35.
 DR
 XX
 PT New isolated human genes encoding secreted polypeptides.
 PT
 PS Disclosure; Page 470; 537pp; English.
 XX
 CC AAY97916 to AAY98029 represent 110 isolated human secreted protein genes.
 CC AAY36224 to AAY36727 represent the secreted proteins encoded by the 110
 CC human genes. The genes and their corresponding secreted polypeptides are
 CC useful for preventing, treating or ameliorating medical conditions, e.g.
 CC by protein or gene therapy. Also pathological conditions can be diagnosed
 CC by determining the amount of the new polypeptides in a sample or by
 CC determining the presence of mutations in the new genes. Specific uses are
 CC described for each of the 110 genes, based on which tissues they are most
 CC highly expressed in, and include developing products for the diagnosis or
 CC treatment of cancer, tumours, developmental abnormalities and foetal
 CC deficiencies, blood disorders, diseases of the immune system, autoimmune
 CC diseases, inflammation, allergies, Alzheimer's and cognitive disorders,
 CC schizophrēnia, arthritis, asthma, psoriasis, sepsis, skin disorders,
 CC atherosclerosis, diabetes, cardiovascular disorders, kidney disorders,
 CC digestive/endocrine disorders, infections and AIDS. The polypeptides are
 CC also useful for identifying their binding partners. The sequences given
 CC in AAY97907 to AAY97915 and AAY36223 are used in the exemplification of
 CC the present invention
 XX
 SQ Sequence 23 AA;
 Query Match 100.0%; Score 19; DB 2; Length 23;
 Best Local Similarity 100.0%; Pred. No. 9.3e+02; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AAGV 4
 ||||
 Db 3 AAGV 6
 RESULT 74
 AAU18994
 ID AAU18994 standard; peptide; 23 AA.
 XX
 AC AAU18994;
 XX
 DT 04-DEC-2001 (first entry)
 XX
 DE T-cell epitope containing peptide DPI-28.2.
 XX
 KM House dust mite; allergenic peptide; Der p I; Der p II; Der f I;
 KM Der f II; antiallergenic; immunostimulant; house dust mite allergy;
 KM T-cell epitope.
 XX
 OS Dermatophagoides pteronyssinus.
 XX
 PN US6260491-B1.
 XX
 PD 31-JUN-2001.
 XX
 PF 07-JUN-1995; 95US-00484296.

XX 16-OCT-1991; 91US-00777859.
PR 08-MAY-1992; 92US-00881396.
PR 14-APR-1993; 93MO-US003471.
PR 14-APR-1994; 94US-00227772.
PR 19-MAY-1995; 95US-00445307.
XX (IMMU-) IMMUNOLOGIC PHARM CORP.
XX Garman RD, Greenstein JL, Kuo M, Rogers BL, Franzen HM, Chen X;
PI Evans S, Shaked Z;
XX WPI, 2001-549074/61.
XX Peptides comprising T cell groups of the major allergens from
PT Dermatophagoides (house dust mites), useful for treating house dust mite
PT allergy in humans, and for diagnosing sensitivity to house dust mite
PT protein allergens.
XX Claim 1; Fig 3; 158pp; English.
XX The invention relates to an isolated peptide of the major protein
CC allergens of the genus Dermatophagoides, which comprises at least one T
CC cell group of a protein allergen from Der p (DP) I, DP II, Der f (DF) I
CC or DF II. The isolated peptide comprises at least two regions, each
CC region comprising at least one T cell group of a protein allergen of the
CC genus Dermatophagoides. The regions are derived from the same or
CC different protein allergens of the genus Dermatophagoides. The peptides
CC are useful for treating house dust mite allergy in humans. The peptides
CC are also useful for detecting or diagnosing sensitivity to house dust
CC mite protein allergens. The present peptides have similar or enhanced
CC therapeutic properties as the naturally-occurring allergen, but have
CC reduced side effects, and increased solubility and stability. The present
CC sequence represents an allergenic T-cell epitope containing peptide
CC derived from the Dermatophagoides allergenic proteins
XX
SQ Sequence 23 AA;
Query Match 100.0%; Score 19; DB 4; Length 23;
Best Local Similarity 100.0%; Pred. No. 9.3e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ACGV 4
DB 8 ACGV 11
RESULT 75
ADA12069
ID ADA12069 standard; protein; 23 AA.
XX
XX ADA12069;
XX
XX 06-NOV-2003 (first entry)
XX
XX Human novel secreted protein associated polypeptide #339.
XX
XX cancer; inflammation; immune disorder; neurological disorder;
KW blood clotting disorder; food additive; food preservative;
KW storage capability; fat content; nutritional component; human;
KW secreted protein.
XX
XX Homo sapiens.
XX
XX OS
XX US2003055236-A1.
XX
XX 20-MAR-2003.
XX
XX 14-MAR-2002; 2002US-00097065.
XX
XX 18-DEC-1997; 97US-0068006P.
PR 18-DEC-1997; 97US-0068007P.
PR 18-DEC-1997; 97US-0068008P.

PR 18-DEC-1997; 97US-0068053P.
PR 18-DEC-1997; 97US-0068054P.
PR 18-DEC-1997; 97US-0068057P.
PR 18-DEC-1997; 97US-0068064P.
PR 18-DEC-1997; 97US-0070923P.
PR 19-DEC-1997; 97US-0068169P.
PR 19-DEC-1997; 97US-0068365P.
PR 19-DEC-1997; 97US-0068367P.
PR 19-DEC-1997; 97US-0068368P.
PR 19-DEC-1997; 97US-0068369P.
PR 17-DEC-1998; 98MO-US027059.
XX 17-JUN-1999; 99US-00334595.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Moore PA, Ruben SM, Carter KC, Shi Y, Rosen CA, Soppet DR;
PI Kyaw H, Wei Y, Florence KA, Duan DR, Florence C, Greene JM, Feng P;
PI Ferrie AM, Yu G, Janat F, NI J;
XX WPI, 2003-567105/53.
XX
XX New secreted HKABT24 nucleic acid molecules and polypeptides, useful for
PT preventing, treating, or ameliorating a medical condition, such as
PT cancer, inflammation, immune disorders, neurological and blood clotting
PT disorders.
XX
XX Disclosure; Page 58; 118pp; English.
XX
XX The invention relates to an isolated HKABT24 nucleic acid molecule. The
CC polypeptides, nucleic acid and antibodies are useful for diagnosing a
CC pathological condition or a susceptibility to a pathological condition,
CC for preventing, treating, or ameliorating a medical condition, such as
CC cancer, inflammation and other immune disorders, neurological and blood
CC clotting disorders. The nucleic acids are also useful for chromosome
CC identification, radiation hybrid mapping or long-range restriction
CC mapping. The polypeptides and antibodies are useful for providing
CC immunological probes for differential identification of the tissues
CC immunohistochemistry assays. The polypeptide, polynucleotide, agonist or
CC antagonist may also be used as a food additive or preservative to
CC increase or decrease storage capabilities, fat content or other
CC nutritional components. The present sequence represents the amino acid
CC sequence of a novel human secreted protein associated polypeptide. Note:
CC The sequence data for this patent did not form part of the printed
CC specification but was obtained in electronic format directly from USPTO
CC at segdata.uspto.gov.uk/sequence.html?DocID=20030055236.
XX
SQ Sequence 23 AA;
Query Match 100.0%; Score 19; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 9.3e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ACGV 4
DB 3 ACGV 6
RESULT 76
ABP46165
ID ABP46165 standard; peptide; 24 AA.
XX
XX ABP46165;
XX
XX 19-AUG-2002 (first entry)
XX
XX Human Blys binding scFv VH CDR3 SEQ ID 2176.
XX
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antineoplastic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.

XX	Homo sapiens.
OS	
PN	WO200202641-A1.
PD	10-JAN-2002.
XX	
PE	15-JUN-2001; 2001WO-US019110.
XX	
PR	16-JUN-2000; 2000US-0212210P.
PR	17-OCT-2000; 2000US-0240816P.
PR	16-MAR-2001; 2001US-0276248P.
PR	21-MAR-2001; 2001US-0277379P.
PR	25-MAY-2001; 2001US-02993499P.
XX	
PA	(HUMA-) HUMAN GENOME SCT INC.
PA	(CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX	
PI	Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX	
XX	WPI; 2002-114799/15.
XX	
PT	Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
PT	diagnosis and treatment of cancers and immune disorders.
XX	
PS	Claim 2; Page 2945; 3148pp; English.
XX	
CC	This invention describes novel antibodies that immunospecifically bind to
CC	B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC	tumour necrosis factor (TNF) super family and induces B cell
CC	proliferation and differentiation. The antibodies of the invention have
CC	cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC	antirheumatic and antiAIDS activity and can be used in vaccines to
CC	inhibit the expression and activity of Blys. The antibodies bind to Blys in
CC	and so may be used to detect and quantitate the presence of Blys in
CC	biological samples and may be used in this way to diagnose disease
CC	associated with aberrant expression of Blys. They may also be
CC	administered to treat diseases associated with aberrant Blys expression
CC	and actively such as cancer, immune, and autoimmune disorders and
CC	diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC	immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC	acquired immunodeficiency syndrome (AIDS)). ABR43990-ABP47228 represent
CC	the antibodies and fragments of the antibodies described in the method of
CC	the invention
XX	
SQ	Sequence 24 AA;
XX	
QY	1 AAGV 4
Db	17 AAGV 20
XX	
Query Match	100.0%; Score 19; DB 5; Length 24;
Best Local Similarity	100.0%; Pred. No. 9.7e+02;
Matches 4; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
XX	
RESULT 77	
ID	ABP46958
ABP46958	standard; peptide; 24 AA.
XX	
AC	ABP46958;
XX	
DT	19-AUG-2002 (first entry)
XX	
DE	Human Blys binding scFv VH CDR3 SEQ ID 2969.
XX	
KW	Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW	tumour necrosis factor; B cell proliferation; B cell differentiation;
KW	immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW	antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW	systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW	common variable immunodeficiency; acquired immunodeficiency syndrome.

OS	Homo sapiens.
XX	
XX	WO200202641-A1.
XX	
PD	10-JAN-2002.
XX	
XX	
PF	15-JUN-2001; 2001WO-US019110.
XX	
XX	
PR	16-JUN-2000; 2000US-0232210P.
PR	17-OCT-2000; 2000US-0240816P.
PR	16-MAR-2001; 2001US-0276248P.
PR	21-MAR-2001; 2001US-0277379P.
PR	25-MAY-2001; 2001US-0293499P.
XX	
PA	(HUMA-) HUMAN GENOME SCI INC.
PA	(CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX	
PI	Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D,
XX	
XX	WPI, 2002-114799/15.
DR	
XX	
PT	Antibodies against B lymphocyte Stimulating polypeptides, useful for the
PT	diagnosis and treatment of cancers and immune disorders.
XX	
XX	
PS	Claim 2; Page 3088-3089; 3148pp; English.
XX	
CC	This invention describes novel antibodies that immunospecifically bind to
CC	B lymphocyte Stimulator (BLyS) polypeptides. BLyS is a member of the
CC	tumour necrosis factor (TNF) super family and induces B cell
CC	proliferation and differentiation. The antibodies of the invention have
CC	cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC	antirheumatic and antiAIDS activity and can be used in vaccines to
CC	inhibit the expression and activity of BLyS. The antibodies bind to BLyS
CC	and so may be used to detect and quantitate the presence of BLyS in
CC	biological samples and may be used in this way to diagnose disease
CC	associated with aberrant expression of BLyS. They may also be
CC	administered to treat diseases associated with aberrant BLyS expression
CC	and actively such as cancer, immune, and autoimmune disorders and
CC	diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis, and
CC	immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC	acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC	the antibodies and fragments of the antibodies described in the method of
CC	the invention
XX	
XX	
SO	Sequence 24 AA;
Query Match	100.0%; Score 19; DB 5; Length 24;
Best Local Similarity	100.0%; Pred. No. 9.7e+02;
Matches 4; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	1 AAGV 4
DB	17 AAGV 20
RESULT 78	
ADG696992	
ID	ADG696992 standard; peptide; 24 AA.
XX	
XX	
AC	ADG696992;
XX	
XX	
DT	11-MAR-2004 (first entry)
XX	
XX	
DE	scfv VHCDR3 peptide that immunospecifically binds BLyS Segid 2176.
XX	
XX	
KW	antibody; B lymphocyte stimulator; BLyS; tumour necrosis factor;
KW	B cell proliferation; differentiation; scFv; myaesthesia gravis;
KW	multiple sclerosis; ashma; rheumatoid arthritis; AIDS; leukaemia;
KW	carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
KW	antiinflammatory; antiallergic; antiallergic; cytostatic.
OS	Unidentified.
XX	

```

PN WO2003055979-A2.
XX
XX 10-JUL-2003.
XX
XX 14-NOV-2002; 2002WO-US036496.
XX
XX 16-NOV-2001; 2001US-0331469P.
XX
XX 19-DEC-2001; 2001US-0340817P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX
XX WPI; 2003-505530/47.
XX
XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
XX (Blys), useful for detecting and treating diseases or disorders e.g.
XX rheumatoid arthritis, asthma and leukemia.
XX
XX Example 1; SEQ ID NO 2176; 394pp; English.
XX
XX This invention relates to novel antibodies that immunospecifically bind
XX to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
XX chromosome 13q34 and encodes a protein that is a member of the tumour
XX necrosis factor superfamily and induces both in vivo and in vitro B cell
XX proliferation and differentiation. Specifically, it refers to single
XX chain antibody molecules (scFvs) derived, preferably, from the variable
XX heavy CDR3 region that immunospecifically bind to a polypeptide, or
XX fragment thereof, of either human, murine, rat or monkey Blys. The
XX present invention refers to the use of such antibodies in various methods
XX for the detection, diagnosis and prognosis of diseases related to the
XX aberrant expression or inappropriate function of Blys or its receptor. As
XX such, these compositions are useful for identifying immune disorders
XX including myasthenia gravis and multiple sclerosis, inflammatory
XX disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
XX as AIDS and proliferative disorders including leukaemia, carcinoma and
XX lymphoma. Accordingly, they can be described as exhibiting various
XX activities such as antineumatic, antiarthritic, neuroprotective,
XX antiinflammatory, antiaesthetic, antiallergic and cystostatic. This
XX peptide sequence is a single chain antibody variable heavy CDR3 peptide
XX that immunospecifically binds Blys of the invention.
XX
SQ Sequence 24 AA;
Query Match 100.0%; Score 19; DB 7; Length 24;
Best Local Similarity 100.0%; Pred. No. 9.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 AOGV 4
Db 17 AOGV 20

```

```

RESULT 79
ADG97785
ID ADG97785 standard; peptide; 24 AA.
XX
XX ADG97785;
XX
XX 11-MAR-2004 (first entry)
XX
XX scFv VHCDR3 peptide that immunospecifically binds Blys SegID 2969.
XX
XX antibody; B lymphocyte stimulator; Blys; tumour necrosis factor;
XX B cell proliferation; differentiation; scFv; myasthenia gravis;
XX multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
XX carcinoma; lymphoma; antineumatic; antiallergic; neuroprotective;
XX antiinflammatory; antiaesthetic; antiallergic; cystostatic.
XX
XX Unidentified.
XX
XX OS
XX
XX WO2003055979-A2.
XX
XX

```

```

PD 10-JUL-2003.
XX
XX 14-NOV-2002; 2002WO-US036496.
XX
XX 16-NOV-2001; 2001US-0331469P.
XX
XX 19-DEC-2001; 2001US-0340817P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX
XX WPI; 2003-505530/47.
XX
XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
XX (Blys), useful for detecting and treating diseases or disorders e.g.
XX rheumatoid arthritis, asthma and leukemia.
XX
XX Example 1; SEQ ID NO 2969; 394pp; English.
XX
XX This invention relates to novel antibodies that immunospecifically bind
XX to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
XX chromosome 13q34 and encodes a protein that is a member of the tumour
XX necrosis factor superfamily and induces both in vivo and in vitro B cell
XX proliferation and differentiation. Specifically, it refers to single
XX chain antibody molecules (scFvs) derived, preferably, from the variable
XX heavy CDR3 region that immunospecifically bind to a polypeptide, or
XX fragment thereof, of either human, murine, rat or monkey Blys. The
XX present invention refers to the use of such antibodies in various methods
XX for the detection, diagnosis and prognosis of diseases related to the
XX aberrant expression or inappropriate function of Blys or its receptor. As
XX such, these compositions are useful for identifying immune disorders
XX including myasthenia gravis and multiple sclerosis, inflammatory
XX disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
XX as AIDS and proliferative disorders including leukaemia, carcinoma and
XX lymphoma. Accordingly, they can be described as exhibiting various
XX activities such as antineumatic, antiarthritic, neuroprotective,
XX antiinflammatory, antiaesthetic, antiallergic and cystostatic. This
XX peptide sequence is a single chain antibody variable heavy CDR3 peptide
XX that immunospecifically binds Blys of the invention.
XX
SQ Sequence 24 AA;
Query Match 100.0%; Score 19; DB 7; Length 24;
Best Local Similarity 100.0%; Pred. No. 9.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 AOGV 4
Db 17 AOGV 20

```

```

RESULT 80
AAR36412
ID AAR36412 standard; peptide; 25 AA.
XX
XX AAR36412;
XX
XX 25-MAR-2003 (revised)
XX
XX 12-AUG-1993 (first entry)
XX
XX DPT-27.1(161-185) a Dermatophagoides protein allergen.
XX
XX T cell epitope; house dust mite; allergy; soluble; Der p1.
XX
XX Synthetic.
XX
XX WO9308279-A1.
XX
XX 29-APR-1993.
XX
XX 15-OCT-1992; 92WO-US008637.
XX
XX 16-OCT-1991; 91US-00777859.
XX
XX

```

PR 08-MAY-1992; 92US-00881396.
XX
XX (IMMU-) IMMUNOLOGIC PHARM CORP.
XX
XX Garman RD, Greenstein JL, Kuo MC, Rogers BL;
XX WPI; 1993-152472/18.
XX
XX Isolated peptide(s) of dermatophagoides protein allergens - for diagnosis
PT and treatment of sensitivity to house dust mite.
XX
XX Claim 10; Fig 3; 176pp; English.
XX
XX The peptide is one of a series of overlapping peptides synthesised by
CC standard techniques to cover the whole Dermatophagoides pteronyssinus Der
CC pI sequence. The T cell epitopes of the protein were mapped by detection
CC of the peptide's ability to stimulate T cell activity. The peptides may
CC be used for diagnosis and treatment of sensitivity to house dust mite
CC allergens. When administered to house dust mite sensitive individuals,
CC the peptides are capable of modifying the allergic response to the
CC allergens. The peptides may be modified for e.g. increasing solubility,
CC enhancing therapeutic or preventive efficacy or stability. See also
CC AAR34686-700 and AAR36398-490. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 19; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 20 ACGV 23
|||
|||

RESULT 81
AAR51760
ID AAR51760 standard; protein; 25 AA.
XX
AC AAR51760;
XX
DT 01-FEB-1995 (first entry)
XX
DE Der p I derived peptide. DP I-27.1(161-185).
XX
XX Group I; protein allergen; house dust mite; D. pteronyssinus; Der p I;
KW homology; D. farinae; Der f I; group II; Der p II; Der f II; T-cell;
KW epitopes; fusion peptides; antigenic fragments; substitution; deletion;
KW addition; chemical synthesis; chemical cleavage; recombinant techniques;
KW allergic response; immunoglobulin E; IgE; immunotherapy; anaphylaxis;
KW IgE-mediated responses; anergise; lymphokine secretion profile; modify;
KW T cell subpopulations; unresponsive; immune response; tolerance.
XX
OS Dermatophagoides pteronyssinus.
XX
PN ZA9302677-A.
XX
PD 26-JAN-1994.
XX
PF 16-APR-1993; 93ZA-00002677.
XX
PR 16-APR-1993; 93ZA-00002677.
XX
XX (IMMU-) IMMUNOLOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Kuo M, Rogers BL;
XX WPI; 1994-126807/15.
XX
XX Isolated and/or modified peptides comprising T-cell epitopes - of major
PT protein allergens of genus Dermatophagoides, used to treat or diagnose
PT sensitivity to house dust mites.

XX
PS Claim 28; Page 66; 154pp; English.
XX
XX The sequences given in AAR51731-841 represent T-cell epitopes derived
CC from the group I and II protein allergens from the house dust mite D.
CC farinae and D. pteronyssinus, Der f I, Der f II, Der p I and Der p II
CC respectively. The Der f II proteinSC shows high homology having an
CC identity of 88% with an identity of 81% between the two group I proteins
CC (see also AAR51727-30). Fusion peptides may be produced which comprise at
CC least two or these antigenic fragments. Each region of these fusion
CC peptides may be derived from the same, or different, mite allergens. The
CC antigenic fragments may be altered by substitution, deletion or addition
CC to enhance their antigenicity. These peptides may be produced by chemical
CC synthesis, chemical cleavage of the fusion peptides, when administered to
CC a house dust mite sensitive individual, are capable of modifying the
CC allergic response of the individual to the allergen. The peptides do not
CC bind to immunoglobulin E (IgE), or bind IgE to a lesser extent than the
CC full length protein allergen. This reduces the major complications of
CC standard immunotherapy, which are IgE-mediated responses such as
CC anaphylaxis. Exposure of mite allergic patients to these peptides may
CC tolerate or anergise appropriate T cell subpopulations such that they
CC become unresponsive to mite allergens and do not participate in mounting
CC an immune response upon exposure. Administration of the peptides may also
CC modify the lymphokine secretion profile as compared with exposure to the
CC naturally occurring mite protein allergen
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 19; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 20 ACGV 23
|||
|||

RESULT 82
AAW71935
ID AAW71935 standard; peptide; 25 AA.
XX
AC AAW71935;
XX
DT 27-AUG-2003 (revised)
DT 25-MAR-2003 (revised)
DT 16-DEC-1998 (first entry)
XX
DE Dermatophagoides Der p I protein peptide DPI-27.1.
XX
XX genus Dermatophagoides; major protein allergen; T cell epitope; Der p I;
KW Der p II; Der f I; Der f II; house dust mite allergy.
XX
OS Dermatophagoides.
XX
PN US5820862-A.
XX
PD 13-OCT-1998.
XX
PF 07-JUN-1995; 95US-00482142.
XX
PR 14-APR-1993; 93WO-US003471.
PR 14-APR-1994; 94US-00227772.
PR 19-MAY-1995; 95US-00445307.
XX
XX (IMMU-) IMMUNOLOGIC PHARM CORP.
XX
XX Franzen HM, Kuo M, Evans S, Garman RD, Greenstein JL, Chen X;
PI Shaked Z, Rogers BL;
XX WPI; 1998-567590/48.
XX
XX Dermatophagoides allergen peptides - useful for treating house dust mite

PT allergy.
XX
XX Disclousure; Col 97-98; 155pp; English.
XX
CC The present invention describes peptides for treating sensitivity to
CC house dust mite allergens from the genus Dermatophagoides. Peptides
CC within the scope of the invention comprise at least one T cell epitope,
CC or preferably at least two T cell epitopes of a protein allergen selected
CC from the allergens Der p I, Der p II, Der f I, or Der f II. The invention
CC also describes modified peptides having similar or enhanced therapeutic
CC properties as the corresponding, naturally occurring allergen, but having
CC reduced side effects. AAM71912 to AAM72000, and AAM72257 to AAM72330
CC represent peptides from the present invention. (Updated on 25-MAR-2003 to
CC correct PR field.) (Updated on 27-AUG-2003 to correct OS field.)
XX
SQ Sequence 25 AA;
XX
Query Match 100.0%; Score 19; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AOGV 4
DB 20 AOGV 23
XX
RESULT 83
AAY50389
ID AAY50389 standard; peptide; 25 AA.
XX
XX AAY50389;
XX
DT 25-JAN-2000 (first entry)
XX
XX Dermatophagoides sp major protein allergen DP I-27.1.
XX
XX Allergen; house dust mite; detection; sensitivity; T cell epitope;
XX screening; allergic disorder; asthma; rhinitis; eczopic dermatitis;
XX Der f I; Der p I; Der p II; Der f II.
XX
XX Dermatophagoides sp.
XX
XX US5968526-A.
XX
XX 19-OCT-1999.
XX
XX 07-JUN-1995; 95US-00478572.
XX
XX 14-APR-1994; 94US-00237772.
XX 12-APR-1995; 95MO-US004481.
XX 19-MAY-1995; 95US-00445307.
XX
XX (IMMU-) IMMUNOLOGIC PHARM CORP.
XX
XX Garman RD, Greenstein JL, Rogers BL, Franzen HM, Shaked Z;
XX Chen X, Evans S, Kuo M;
XX
XX WPI; 1999-590385/50.
XX
XX Screening individuals for allergic reactions to T cell epitopes of major
XX allergens from house dust mites.
XX
XX Claim 1c; Column 99-100; 158pp; English.
XX
XX This invention describes a novel method (I) for detecting whether an
XX individual is sensitive to Dermatophagoides (house dust mites). The
XX method involves detecting sensitivity to house dust mites in patients,
XX comprising combining a blood sample from the individual with I or more
XX isolated T cell epitopes of the protein allergens I and II (DP I) and
XX (DP II) from Dermatophagoides (house dust mites). 32 T cell epitopes
XX with varying, defined amino acids sequences (given in the specification)
XX may be used in (I). The sample and allergens are combined under
XX conditions appropriate for the binding of blood components with the

CC polypeptides. The extent of binding is then indicative of the sensitivity
CC of the patient to house dust mites. (I) may be used to screen individuals
CC for sensitivity to Dermatophagoides (house dust mites). The house dust
CC mite is a major cause of a variety of allergic disorders such as asthma,
CC rhinitis and eczopic dermatitis. AAY50360-Y50542 and AAY50546-Y50555
CC represent house dust mite allergen peptide fragments derived from Der p
CC I, Der f II, Der f I and Der f II
XX
SQ Sequence 25 AA;
XX
Query Match 100.0%; Score 19; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AOGV 4
DB 20 AOGV 23
XX
RESULT 84
AAM21152
ID AAM21152 standard; protein; 25 AA.
XX
XX AAM21152;
XX
DT 12-OCT-2001 (first entry)
XX
XX Peptide #7586 encoded by probe for measuring cervical gene expression.
XX
XX Probe; human; microarray; gene expression; cervical epithelial cell;
XX cervical cancer.
XX
XX Homo sapiens.
XX
XX WO200157278-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000670.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-488901/53.
XX
XX Claim 27; SEQ ID NO 25978; 487pp; English.
XX
XX The present invention relates to human single exon nucleic acid probes
XX (SENP; see AAI10068-AA128459). The present sequence is a peptide encoded
XX by one such probe. The SENPs are derived from human HeLa cells. The SENPs
XX can be used to produce a single exon microarray, which can be used for
XX measuring human gene expression in a sample derived from human cervical
XX epithelial cells. By measuring gene expression, the probes are therefore
XX useful in grading and/or staging of diseases of the cervix, notably
XX cervical cancer. Note: The sequence data for this patent did not form
XX part of the printed specification, but was obtained in electronic format
XX directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 25 AA;
XX
Query Match 100.0%; Score 19; DB 4; Length 25;

Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||||
Db 16 AOGV 19

RESULT 85

AAU18992
ID AAU18992 standard; peptide; 25 AA.

AC AAU18992;

DT 04-DEC-2001 (first entry)

DE T-cell epitope containing peptide DPI-27.1.

KM House dust mite; allergenic peptide; Der p I; Der p II; Der f I;
KW Der f II; antiallergenic; immunostimulant; house dust mite allergy;
KM T-cell epitope.

OS Dermacophagoides pteronyssinus.

PN US6268491-B1.

FD 31-JUL-2001.

XX 07-JUN-1995; 95US-00484296.

XX 16-OCT-1991; 91US-00777859.

PR 08-MAY-1992; 92US-00881396.

PR 14-APR-1993; 93MO-US003471.

PR 14-APR-1994; 94US-00227772.

PR 19-MAY-1995; 95US-00445307.

XX (IMMU-) IMMUNOLOGIC PHARM CORP.

XX Garman RD, Greenstein JL, Kuo M, Rogers BL, Franzen HM, Chen X;
PI Evans S, Shaked Z;

XX WPI; 2001-549074/61.

PT Peptides comprising T cell groups of the major allergens from
PT Dermatophagoides (house dust mites), useful for treating house dust mite
PT allergy in humans, and for diagnosing sensitivity to house dust mite
PT protein allergens.

XX Claim 1; Fig 3; 158pp; English.

XX The invention relates to an isolated peptide of the major protein
CC allergens of the genus Dermatophagoides, which comprises at least one T
CC cell group of a protein allergen from Der p (DP) I, DP II, Der f (DF) I
CC or DF II. The isolated peptide comprises at least two regions, each
CC region comprising at least one T cell group of a protein allergen of the
CC genus Dermatophagoides. The regions are derived from the same or
CC different protein allergens of the genus Dermatophagoides. The peptides
CC are useful for treating house dust mite allergy in humans. The peptides
CC are also useful for detecting or diagnosing sensitivity to house dust
CC mite protein allergens. The present peptides have similar or enhanced
CC therapeutic properties as the naturally-occurring allergen, but have
CC reduced side effects, and increased solubility and stability. The present
CC sequence represents an allergenic T-cell epitope containing peptide
CC derived from the Dermatophagoides allergenic proteins

XX Sequence 25 AA;

SO Query Match 100.0%; Score 19; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||||

Db 16 AOGV 19

RESULT 86

AAU18992
ID AAU18992 standard; peptide; 25 AA.

AC AAU18992;

DT 04-FEB-2002 (first entry)

DE Peptide #10976 encoded by human foetal liver single exon probe.
KW Human; foetal liver; gene expression; single exon nucleic acid probe.
XX Homo sapiens.

OS MO200157277-A2.

PN 09-AUG-2001.

XX 30-JAN-2001; 2001WO-US000669.

XX 04-FEB-2000; 2000US-0180312P.

PR 26-MAY-2000; 2000US-0207456P.

PR 30-JUN-2000; 2000US-00608408.

PR 03-AUG-2000; 2000US-00632366.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

XX (MOLE-) MOLECULAR DYNAMICS INC.

XX Penn SG, Hanzel DK, Chen W, Rank DR;

XX WPI; 2001-483447/52.

XX Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human fetal liver.

XX Claim 27; SEQ ID NO 36105; 639pp + Sequence Listing; English.

XX The invention relates to a single exon nucleic acid probe for measuring
CC human gene expression in a sample derived from human foetal liver. The
CC single exon nucleic acid probes may be used for predicting, measuring and
CC displaying gene expression in samples derived from human fetal liver. The
CC present sequence is a peptide encoded by a single exon nucleic acid probe
CC of the invention. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 25 AA;

SO Query Match 100.0%; Score 19; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||||

Db 16 AOGV 19

RESULT 87

AAU18992
ID AAU18992 standard; protein; 25 AA.

AC AAU18992;

DT 17-OCT-2001 (first entry)

DE Peptide #11400 encoded by probe for measuring placental gene expression.
KW Probe; microarray; human; placenta; antenatal diagnosis;


```

KW genetic disorder.
XX
XX Homo sapiens.
XX
XX WO200157272-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 30-JUN-2000; 2000US-00608408.
XX
XX 03-AUG-2000; 2000US-00632366.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-488897/53.
XX
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human placenta.
XX
XX Claim 27; SEQ ID NO 37632; 654bp; English.
XX
XX The present invention relates to single exon nucleic acid probes (SENP;
XX see AA131315-AA157546). The present sequence is a peptide encoded by one
XX such probe. The probes are useful for producing a microarray for
XX predicting, measuring and displaying gene expression in samples derived
XX from human placenta. The probes are useful for antenatal diagnosis of
XX human genetic disorders
XX
XX Sequence 25 AA;
XX
XX Query Match 100.0%; Score 19; DB 4; Length 25;
XX Best Local Similarity 100.0%; Pred. No. 1e+03;
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 ACGV 4
XX ||||
XX 16 ACGV 19
XX
XX Db
XX
XX RESULT 88
XX AAM77220
XX ID AAM77220 standard; protein; 25 AA.
XX
XX AAM77220;
XX
XX 06-NOV-2001 (first entry)
XX
XX Human bone marrow expressed probe encoded protein SEQ ID NO: 37526.
XX
XX Human; bone marrow expressed exon; gene expression analysis; probe;
XX microarray; cancer; leukaemia; lymphoma; myeloma.
XX
XX Homo sapiens.
XX
XX WO200157276-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 30-JUN-2000; 2000US-00608408.
XX
XX 03-AUG-2000; 2000US-00632366.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000US-0234687P.
XX

```

```

PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-488900/53.
XX
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human bone marrow.
XX
XX Example 4; SEQ ID NO 37526; 658bp + Sequence Listing; English.
XX
XX The present invention provides a number of single exon nucleic acid
XX probes which are derived from genomic sequences expressed in the human
XX bone marrow. They can be used to measure gene expression in bone marrow
XX samples, which may enable the improved diagnosis and treatment of cancers
XX such as lymphoma, leukaemia and myeloma. The present sequence is a
XX protein encoded by one of the probes of the invention
XX
XX Sequence 25 AA;
XX
XX Query Match 100.0%; Score 19; DB 4; Length 25;
XX Best Local Similarity 100.0%; Pred. No. 1e+03;
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 ACGV 4
XX ||||
XX 16 ACGV 19
XX
XX Db
XX
XX RESULT 89
XX AAM64402
XX ID AAM64402 standard; protein; 25 AA.
XX
XX AAM64402;
XX
XX 05-NOV-2001 (first entry)
XX
XX Human brain expressed single exon probe encoded protein SEQ ID NO: 36507.
XX
XX Human; brain expressed exon; gene expression analysis; probe; microarray;
XX Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer.
XX
XX Homo sapiens.
XX
XX WO200157275-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 30-JUN-2000; 2000US-00608408.
XX
XX 03-AUG-2000; 2000US-00632366.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-483446/52.
XX
XX Single exon nucleic acid probes for analyzing gene expression in human
XX brains.
XX
XX Example 4; SEQ ID NO 36507; 650bp + Sequence Listing; English.
XX
XX The present invention provides a number of single exon nucleic acid
XX

```

CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is a protein encoded by one of
CC the probes of the invention
XX

XX Sequence 25 AA;

Query Match 100.0%; Score 19; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGV 4
16 AGV 19

RESULT 90

ABG58847 standard; peptide; 25 AA.

XX AC ABG58847;
XX 25-FEB-2003 (first entry)

XX DE Human liver peptide, SEQ ID NO 37495.

XX KM Human, liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
XX hypercholesterolaemia; coronary heart disease.

XX OS Homo sapiens.

XX WO200157273-A2.

XX PD 09-AUG-2001.

XX PF 30-JAN-2001; 2001WO-US000664.

XX PR 04-FEB-2000; 2000US-0180312P.

XX PR 26-MAY-2000; 2000US-0207456P.

XX PR 30-JUN-2000; 2000US-00608408.

XX PR 03-AUG-2000; 2000US-00632366.

XX PR 21-SEP-2000; 2000US-0234687P.

XX PR 27-SEP-2000; 2000US-0236359P.

XX PR 04-OCT-2000; 2000GB-00024263.

XX PA (MOLE-) MOLECULAR DYNAMICS INC.

XX PI Penn SG, Hanzel DK, Chen W, Rank DR;

XX DR WPI; 2001-488898/53.

XX PT Human genome-derived single exon nucleic acid probes useful for analyzing

XX PT gene expression in human adult liver.

XX PS Claim 27, SEQ ID NO 37495; 658pp; English.

XX CC The invention relates to a single exon nucleic acid probe (SENP) (I) for

XX CC measuring human gene expression in a sample derived from human adult

XX CC liver, comprising one of 13109 defined nucleotide sequences given in the

XX CC specification (or complements/ fragments). The probe hybridises at high

XX CC stringency to a nucleic acid molecule expressed in the human adult liver.

XX CC (I) may be used for predicting, measuring and displaying gene expression

XX CC in samples derived from human adult liver. The genes identified may be

XX CC involved in genetic liver diseases such as cirrhosis,

XX CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is

XX CC associated with coronary heart disease. ABG47348-ABG5930 represent human

XX CC liver single exon encoded peptides of the invention. Note: The sequence

XX CC information for this patent does not appear in the printed specification

XX CC but was obtained in electronic format directly from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 25 AA;

Query Match 100.0%; Score 19; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGV 4
16 AGV 19

RESULT 91
ADC26857 standard; peptide; 25 AA.

XX ID ADC26857;
XX 18-DEC-2003 (first entry)

XX DT B. burgdorferi decorin binding protein A (Dbpa) synthetic peptide P8.

XX DE Decorin binding protein A; Dbpa; immune response; bacterial infection;

XX KM decorin adhesion; colonisation; spirochete; adhesion; collagen fibre;

XX KM decorin; dermatan sulphate proteoglycan; Dbpa; lipoprotein; vaccine;

XX KM delayed type hypersensitivity; DTH; Lyme disease; LD;

XX KM multisystemic disorder; Lyme arthritis; antibacterial.

XX OS Borrelia burgdorferi.

XX PN US6517838-B1.

XX PD 11-FEB-2003.

XX PF 16-JUN-2000; 2000US-00596120.

XX PR 16-JUN-2000; 2000US-00596120.

XX PA (TEXA) UNIV TEXAS A & M SYSTEM.

XX PI Hoegok MA, Brown EL;

XX DR WPI; 2003-634321/60.

XX PT Generating immune response against Borrelia bacteria, for treating Lyme

XX PT disease, by administering decorin binding protein A-derived peptide or a

XX PT combination of decorin binding protein A-derived peptides to mammal.

XX PS Example 1; Fig 1; 33pp; English.

XX CC The invention discloses a method for generating an immune response

XX CC against Borrelia bacteria infection which involves administering a

XX CC decorin binding protein A (Dbpa)-derived peptide or a combination of two

XX CC or more Dbpa-derived peptides, where the peptides span critical binding

XX CC regions required for Dbpa/decorin adhesion. Colonisation of the

XX CC spirochetes occurs by adhesion of B. burgdorferi to collagen fibres,

XX CC particularly to decorin, a dermatan sulphate proteoglycan. Dbpa and B are

XX CC expressed at the surface of the spirochetes as lipoproteins and act as

XX CC adhesins, binding to the decorin. Also disclosed are antisera and

XX CC antibodies generated against the decorin binding proteins, vaccines

XX CC comprising decorin binding peptides, antisera and antibodies raised

XX CC against the decorin binding proteins, diagnostic kits comprising the

XX CC decorin binding peptides, or antibodies or antisera raised against them,

XX CC pharmaceutical compositions comprising the decorin binding peptides, or

XX CC antibodies or antisera raised against them, inhibiting decorin binding

XX CC protein from binding decorin in a blood sample by contacting the blood

XX CC sample with Dbpa-derived peptide fragment, identifying a candidate

XX CC substance that alters the binding of Dbpa-derived protein fragment or

XX CC related peptide to decorin, a modulator of Dbpa-derived protein or

XX CC peptide fragment binding to decorin, modulating Dbpa-derived protein or

XX CC peptide fragment binding to decorin, identifying a candidate Dbpa-derived

XX CC peptide fragment with improved decorin binding and use of decorin binding

XX CC peptides, or antibodies or antisera raised against them for the

XX CC treatment, prevention and diagnosis of Borrelia burgdorferi infections

CC and for coating medical devices or polymeric biomaterials in vitro and in
 CC vivo. The peptides are administered by topical, oral, anal, vaginal,
 CC intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or
 CC intradermal route. The method is useful (e.g. as a vaccine) for
 CC generating an immune response against *Borrelia* bacteria or preventing
 CC *Borrelia* infection in a mammal and as a delayed type hypersensitivity
 CC (DTH) response inducer. Preferably, the method is useful for treating
 CC Lyme disease (LD), which can lead to multisystemic disorders that may
 CC affect the joints (Lyme arthritis), skin, heart and central nervous
 CC system. The sequence presented is a peptide which was synthesised as part
 CC of a series of peptides spanning the full length of the *B. burgdorferi*
 CC DbpA protein.
 CC
 SQ Sequence 25 AA;
 Query Match 100.0%; Score 19; DB 7; Length 25;
 Best Local Similarity 100.0%; Pred. No. 1e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ACGV 4
 Db 10 ACGV 13
 RESULT 92
 ADNS9708 100.0%; Score 19; DB 7; Length 25;
 ID ADNS9708 standard; peptide; 25 AA.
 AC ADNS9708;
 XX
 DT 01-JUL-2004 (first entry)
 DE Thrombopoietin mimetic peptide TMP12, seq id 57.
 DE
 XX
 KW Haemostatic; antihaemic; immunosuppressive; platelet;
 KW transmembrane signaling; mpl receptor; thrombopoietin mimetic peptide;
 KW TMP; c-mpl receptor; platelet precursor; megakaryocyte;
 KW thrombocytopenia; aplastic anaemia; autoimmune thrombocytopenia;
 KW autoimmune haemolytic anaemia; Hughes' syndrome;
 KW lupoid thrombocytopenia.
 KW
 XX
 OS Homo sapiens.
 XX
 PN WO2003031589-A2.
 PD 17-APR-2003.
 XX
 PD 17-APR-2003.
 XX
 PE 11-OCT-2002; 2002WO-US032552.
 XX
 PR 11-OCT-2001; 2001US-0328666P.
 PR 10-OCT-2002; 2002US-00269806.
 XX
 PA (AMGE-) AMGEN INC.
 XX
 PI Min H, Sitney KC, Hartley C;
 XX
 DR WPI; 2003-403101/38.
 DR N-PSDB; ADNS9707.
 XX
 PT Novel thrombopoietin mimetic peptides which bind to mpl receptor, and
 PT which stimulate the production of platelets and/or the production of
 PT platelet precursors, useful for treating thrombocytopenia.
 PT
 XX
 PS Disclosure; SEQ ID NO 57; 126pp; English.
 XX
 CC The invention relates to a thrombopoietin mimetic peptide (TMP) (I) that
 CC binds to the c-mpl (mpl) receptor, and which stimulates the production of
 CC platelets and/or the production of platelet precursors, is new. Further
 CC disclosed is a composition of matter (II) that binds to an mpl receptor,
 CC and a pharmaceutical composition comprising (II) and a carrier. The
 CC pharmaceutical composition of the invention is useful for treating
 CC thrombocytopenia in an animal, and for increasing megakaryocytes or
 CC platelets in a patient. The TMP of the invention is useful for treating

CC conditions involving a megakaryocyte and/or platelet deficiency, e.g.
 CC disease conditions involving thrombocytopenia such as aplastic anaemia,
 CC autoimmune thrombocytopenia, drug induced immune thrombocytopenia,
 CC autoimmune haemolytic anaemia, Hughes' syndrome and lupoid
 CC thrombocytopenia. The TMP of the invention is also useful for
 CC maintaining the viability or storage life of platelets and/or
 CC megakaryocytes and its derived cells. The compounds demonstrate an
 CC improved ability to bind to and/or trigger transmembrane signal through,
 CC i.e. activating, the mpl receptor the compounds have superior
 CC thrombopoietic activity, i.e. the ability to stimulate, in vivo and in
 CC vitro, the production of platelets and/or megakaryopoietic activity,
 CC i.e. the ability to stimulate, in vivo and in vitro, the production of
 CC platelet precursors. Further, certain of the compounds also exhibit
 CC superior therapeutic properties, such as improved plasma half-life,
 CC biological activity and in vivo circulation time. The current sequence
 CC represents a TMP fragment.
 CC
 SQ Sequence 25 AA;
 Query Match 100.0%; Score 19; DB 7; Length 25;
 Best Local Similarity 100.0%; Pred. No. 1e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ACGV 4
 Db 1 ACGV 4
 RESULT 93
 ABO60121 100.0%; Score 19; DB 7; Length 25;
 ID ABO60121 standard; protein; 25 AA.
 AC ABO60121;
 XX
 DT 29-JUL-2004 (first entry)
 DE Human genome derived single exon protein #6355.
 DE
 XX
 KW Human; gene expression; single exon probe; microarray;
 KW alternative splicing event; genomic alteration.
 KW
 XX
 OS Homo sapiens.
 XX
 PN US2003194704-A1.
 PD 16-OCT-2003.
 XX
 PD 16-OCT-2003.
 XX
 PE 03-APR-2002; 2002US-00029386.
 XX
 PR 03-APR-2002; 2002US-00029386.
 XX
 PA (PENN/) PENN S G.
 PA (RANK/) RANK D R.
 PA (HANZ/) HANZEL D K.
 XX
 PI Penn SG, Rank DR, Hanzel DK;
 XX
 DR WPI; 2004-119264/12.
 DR
 XX
 PT New human genome-derived single exon nucleic acid probes useful for human
 PT gene expression analysis, for identifying or characterizing alternative
 PT splicing events, for assessing genomic alterations or as tools for
 PT surveying tissues.
 PT
 XX
 PS Claim 45; SEQ ID NO 33755; 80pp; English.
 XX
 CC The invention relates to a nucleic acid probe for measuring human gene
 CC expression, comprising any of the 27,400 fully defined nucleotide
 CC sequences in the specification, or their complements or fragments, and
 CC encoding at least 8 amino acids of any of the 6888 amino acid sequences
 CC fully defined in the specification. The probe is a single exon probe that
 CC hybridises under high stringency conditions to a nucleic acid molecule
 CC expressed in human cells or tissues. Also included are a spatially-

CC addressable set of single exon nucleic acid probes for measuring human
CC gene expression (comprising a plurality of single exon nucleic acid
CC probes cited above, where each of the plurality of probes is separately
CC and addressably isolatable or amplifiable from the plurality), a single
CC exon microarray for measuring human gene expression, a method of
CC measuring human gene expression, a vector comprising the single exon
CC probe cited above, an ORF-encoded peptide comprising at least 8
CC contiguous amino acids of any of the above-mentioned amino acid
CC sequences (optionally with conservative amino acid substitutions), an
CC isolated antibody that binds specifically to a peptide cited above,
CC methods of selling and/or licensing single exon probes or microarrays to
CC a customer desiring to measure gene expression, a method of providing
CC human gene expression data by subscription, and a computer-readable
CC storage medium which contains a database having a plurality of records
CC (each record including data on the expression of a single exon probe
CC cited above. The probe, methods and apparatus are useful in gene
CC expression analysis. The probes may be used as tools for surveying
CC tissues to detect the presence of expressed messages that contain their
CC specific exon, or in constructing genome-derived single exon microarrays.
CC In addition, the probes are used in identifying and characterizing
CC alternative splicing events, in detecting and characterizing gross
CC alterations in the genomic locus that includes their exon, in assessing
CC smaller genomic alterations, in priming the synthesis of nucleic acids,
CC or in expressing the ORF-encoded peptide. The present sequence is a human
CC single exon probe protein of the invention. Note: The sequence data for
CC this patent did not form part of the invention. Note: The sequence data for
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?docID=20030194704
CC
XX

Sequence 25 AA;

Query Match 100.0%; Score 19; DB 8; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGGV 4
|||
Db 1 AGGV 4

RESULT 94
ADV54693

ID ADV54693 standard; peptide; 25 AA.

XX
AC ADV54693;

XX
DT 10-MAR-2005 (first entry)

XX
DE G protein coupled receptor peptide SEQ ID NO 2190.

XX
KW diagnosis; cancer; obesity; diabetes; asthma; inflammation; depression;
KW food; feedstuff; cosmetics; agriculture; animal breeding; GPCR.

XX
OS Unidentified.

XX
PN WO2004111636-A2.

XX
PD 23-DEC-2004.

XX
PF 17-JUN-2004; 2004WO-EP051158.

XX
PR 17-JUN-2003; 2003BP-00101775.

XX
PR 17-JUN-2003; 2003US-0479061P.

XX
PA (VIBV-) VIB VZW.

XX
PA (UYGE-) UNIV GENT.

XX
PI Kae K, Vandekerckhove J, Krols L;

XX
DR WPI; 2005-057893/06.

XX
PT Identifying a peptide combo which corresponds with a family of proteins,
PT useful for diagnosing a variety of diseases, drug development or in

PT agriculture, comprises generating peptides by applying a digest on the
PT family of protein.

XX
PS Example; SEQ ID NO 2190; 265pp; English.

XX
CC The invention relates to a method of identifying a peptide combo which
CC corresponds with a family of proteins where each of the members of the
CC peptide combo is derived from a unique protein from the family. The
CC peptide combo is useful for quantifying specific known splice variants of
CC one or more particular proteins in a sample, for diagnosing complex
CC genetic diseases such as cancer, obesity, diabetes, asthma and
CC inflammation, neuropsychiatric disorders such as depression, for
CC quantifying one to several hundreds of protein disease markers
CC simultaneously leading to a more accurate diagnostic sub-classification,
CC for determining the extent of protein modification in a particular sample
CC of proteins, for tissue-typing analysis, for prenatal testing to detect
CC the presence of a congenital disease or for quantitating protein levels
CC diagnostic of a chromosomal abnormality, for diagnosing immune diseases
CC or neurological diseases, as biomarkers preclinical drug development,
CC development of improved animal models, biomarkers related with
CC toxicology, clinical drug development, guidance marketed drugs,
CC prognostic or diagnostic disease markers, drug target validation and
CC selection, monitoring protein splicing, drug lead profiling, pathway
CC analysis, answering basic disease biology questions, and in the fields of
CC food and feed, cosmetics, agriculture and animal breeding. The present
CC sequence represents a peptide from a G-protein coupled receptor peptide
CC combo.
XX
XX

Sequence 25 AA;

Query Match 100.0%; Score 19; DB 9; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGGV 4
|||
Db 5 AGGV 8

RESULT 95
ADV55689

ID ADV55689 standard; peptide; 25 AA.

XX
AC ADV55689;

XX
DT 10-MAR-2005 (first entry)

XX
DE G protein coupled receptor peptide SEQ ID NO 3188.

XX
KW diagnosis; cancer; obesity; diabetes; asthma; inflammation; depression;
KW food; feedstuff; cosmetics; agriculture; animal breeding; GPCR.

XX
OS Unidentified.

XX
PN WO2004111636-A2.

XX
PD 23-DEC-2004.

XX
PF 17-JUN-2004; 2004WO-EP051158.

XX
PR 17-JUN-2003; 2003BP-00101775.

XX
PR 17-JUN-2003; 2003US-0479061P.

XX
PA (VIBV-) VIB VZW.

XX
PA (UYGE-) UNIV GENT.

XX
PI Kae K, Vandekerckhove J, Krols L;

XX
DR WPI; 2005-057893/06.

XX
PT Identifying a peptide combo which corresponds with a family of proteins,
PT useful for diagnosing a variety of diseases, drug development or in
PT agriculture, comprises generating peptides by applying a digest on the

PT family of protein.
XX
PS Example: SEQ ID NO 3188, 265pp, English.
XX
CC The invention relates to a method of identifying a peptide combo which
CC corresponds with a family of proteins where each of the members of the
CC peptide combo is derived from a unique protein from the family. The
CC peptide combo is useful for quantifying specific known splice variants of
CC one or more particular proteins in a sample, for diagnosing complex
CC genetic diseases such as cancer, obesity, diabetes, asthma and
CC inflammation, neuropsychiatric disorders such as depression, for
CC quantifying one to several hundreds of protein disease markers
CC simultaneously leading to a more accurate diagnostic sub-classification,
CC for determining the extent of protein modification in a particular sample
CC of proteins, for tissue-typing, analysis, for prenatal testing to detect
CC the presence of a congenital disease or for quantitating protein levels
CC diagnostic of a chromosomal abnormality, for diagnosing immune diseases
CC or neurological diseases, as biomarkers preclinical drug development,
CC development of improved animal models, biomarkers related with
CC toxicology, clinical drug development, guidance marketed drugs,
CC prognostic or diagnostic disease markers, drug target validation and
CC selection, monitoring protein splicing, drug lead profiling, pathway
CC analysis, answering basic disease biology questions, and in the fields of
CC food and feed, cosmetics, agriculture and animal breeding. The present
CC sequence represents a peptide from a G-protein coupled receptor peptide
CC combo.
XX
SQ Sequence 25 AA;
XX
Query Match 100.0%; Score 19; DB 9; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AQGV 4
DB 5 AQGV 8
XX
RESULT 96
AAR30640
ID AAR30640 standard; peptide; 26 AA.
XX
AC AAR30640;
XX
DT 06-MAY-1993 (first entry)
XX
DE Epitope of human CENP-B.
XX
KM Centromere protein; antibodies; polypeptide.
XX
OS Homo sapiens.
XX
PN JP04334398-A.
XX
PD 20-NOV-1992.
XX
PF 08-MAY-1991; 91JP-00102517.
XX
PR 08-MAY-1991; 91JP-00102517.
XX
RA (DAIK) DAIKIN KOGYO KK.
XX
DR WPI; 1993-005542/01.
XX
PT Human centromere antigen polypeptide - for detection of human antibodies
PT and identification of disease.
XX
PS Claim 1; Page 2; 15pp; Japanese.
XX
CC The polypeptide constitutes an epitope of the human centromere protein B
CC (CENP-B) and can be produced by standard recombinant DNA techniques. The
CC polypeptide can be used to detect anti-human centromere antibodies. The
CC type of diseases of a patient having the antibody can be exactly

CC classified using the polypeptide. See also AAR30639-41
XX
SQ Sequence 26 AA;
XX
Query Match 100.0%; Score 19; DB 2; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AQGV 4
DB 11 AQGV 14
XX
RESULT 97
AAR95624
ID AAR95624 standard; peptide; 27 AA.
XX
AC AAR95624;
XX
DT 18-DEC-1996 (first entry)
XX
DE Tripeptidyl aminopeptidase fragment #3.
XX
KM Tripeptidyl aminopeptidase; tripeptide cleavage; enzyme deactivation;
KM enzyme; increased stability; microbially produced human enzyme; TPAP;
KM aspergillus.
XX
OS Aspergillus niger.
XX
PN WO9614404-A1.
XX
PD 17-MAY-1996.
XX
PF 08-NOV-1995; 95WO-DK000446.
XX
PR 08-NOV-1994; 94DK-00001288.
XX
PR 22-DEC-1994; 94DK-00001470.
XX
PA (NOVO) NOVO-NORDISK AS.
XX
PI Holm KA, Rasmussen G, Halkier T, Lehmbeck J;
XX
DR WPI; 1996-251755/25.
XX
PT New isolated fungal tripeptidyl amino:peptidase enzymes - and related
PT DNA, used for cleavage of proteins or for developing prods. which can
PT provide protein prods. with increased stability.
XX
PS Claim 2; Page 43; 58pp; English.
XX
CC AAR95622-R95627 represent partial sequences of the Aspergillus niger
CC tripeptidyl aminopeptidase (TPAP). TPAP is capable of non-specifically
CC cleaving tripeptides from the unsubstituted N-terminus of protein
CC products. The enzyme can also be used for the cleavage of proteins, such
CC as for the deactivation of enzymes after they have exerted a desired
CC effect. By altering this sequence a host cell with reduced (or
CC eliminated) TPAP production can be produced. This alteration comprises
CC random (or site-directed) mutagenesis of part of the essential DNA
CC sequence (such as the promoter sequence) encoding TPAP (see AAR7801-
CC T27803 for partial sequences). Alternatively inhibition may occur through
CC hybridisation of a complementary sequence to reduce (or eliminate)
CC translation of the protein. Products free from TPAP can be produced by
CC fermentation of a TPAP-producing cell to a combined pH and temperature
CC treatment to reduce the TPAP activity. The product of interest can then
CC be isolated from the broth. This method can therefore be used to produce
CC products with reduced TPAP activity, such as enzyme preparations with
CC increased stability. This is particularly useful in the stability of
CC microbially produced products, such as human enzymes
XX
SQ Sequence 27 AA;
XX
Query Match 100.0%; Score 19; DB 2; Length 27;
Best Local Similarity 100.0%; Pred. No. 1.1e+03;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
| | | |
Db 17 ACGV 20

RESULT 98
AAW97423
ID AAW97423 standard; peptide; 27 AA.
XX
AC AAW97423;
XX
DT 20-MAY-1999 (first entry)
XX
DE Peptide of the specification.
XX
KM Epitope; fibrinogen; fibrinopeptide B; monospecific antibody;
KM thrombotic status; thrombogenesis; atherogenesis.
XX
OS Undifferentiated.
XX
PN WO9905176-A1.
XX
PD 04-FEB-1999.
XX
PF 22-JUL-1998; 98WO-US015059.
XX
PR 25-JUL-1997; 97US-00900660.
XX
PA (NYBL-) NEW YORK BLOOD CENT INC.
XX
PI Kudryk BJ, Redman CM, Zhang J;
XX
DR WPI; 1999-142856/12.
XX
PT New fibrinogen-specific antibodies - can bind fibrinopeptide B, used for
PT detection, purification and diagnosing thrombogenesis or atherogenesis.
XX
PS Disclosure; Page 60; 64pp; English.
XX
XX The specification describes an epitope derived from fibrinogen or a
CC fibrinopeptide, and a monospecific antibody that binds specifically with
CC that epitope. The antibodies can be used for detecting and measuring
CC enzyme-mediated digestion of fibrinogen. They can be used for the precise
CC and accurate detection of fibrinopeptide B and des-Arg FPB resulting in
CC an objective measure of the thrombotic status of the patient. They can be
CC used for diagnosing the presence or probability of thrombogenesis or
CC atherogenesis in a subject. They can also be used for purifying
CC fibrinogen or fibrinopeptide. The present sequence appears in the
CC specification
XX
SQ Sequence 27 AA;

Query Match 100.0%; Score 19; DB 2; Length 27;
Best Local Similarity 100.0%; Pred. No. 1.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
| | | |
Db 21 ACGV 24

RESULT 99
ADX56530
ID ADX56530 standard; peptide; 27 AA.
XX
AC ADX56530;
XX
DT 05-MAY-2005 (first entry)
XX
DE Cardiovascular disorder plasma protein cryptic fragment SEQ ID NO 347.
XX

KM coronary artery disease; primary biliary cirrhosis; gallstones;
KM celiac disease; irritable bowel syndrome; diabetes; scleroderma; nausea;
KM emesis; constipation; diarrhea; cardiovascular disease; immune disorder;
KM endocrine disease; gastrointestinal disease; metabolic disorder;
KM dermatological disease; musculoskeletal disease; Cardiant; Vascotropic;
KM Hepatotropic; Litholytic; Immunosuppressive; Gastrointestinal-gen.;
KM Antiinflammatory; Antidiabetic; Dermatological; Antileptic; Laxative;
KM Antidiarrhetic; diagnosis.
XX
XX Homo sapiens.
OS
XX WO2005015206-A2.
XX
XX 17-FEB-2005.
XX
PD 17-FEB-2005.
XX
PF 06-AUG-2004; 2004WO-EP008860.
XX
PR 08-AUG-2003; 2003US-0493599P.
PR 08-AUG-2003; 2003US-0493836P.
PR 08-AUG-2003; 2003US-0493867P.
PR 08-AUG-2003; 2003US-0493985P.
XX
XX (XENO-) XENOVA LTD.
PA (NOVS) NOVARTIS AG.
PA (NOVS) NOVARTIS PHARMA GMBH.
XX
PI Argoud-Puy G, Bederr N, Bougueleret L, Cusin I, Mahe E;
PI Niknejad A, Reflaas S, Rose K, Saudrats C, Scherer A, Papotian R;
XX
XX WPI; 2005-195824/20.
XX
PT Screening and/or diagnosing cardiovascular disorder in subject involves
PT detecting and/or quantifying level of polypeptide in biological sample
PT from subject and comparing with control sample.
XX
PS Claim 1; SEQ ID NO 347; 349pp; English.
XX
XX The invention relates to a method of screening and/or diagnosing a
CC cardiovascular disorder (CD) in a subject which comprises detecting a
CC and/or quantifying the level of a polypeptide in a biological sample from
CC the subject and comparing the level to that of control sample. The method
CC is useful for screening, diagnosing and treating coronary artery disease,
CC biliary cirrhosis, gallstones, celiac disease, irritable bowel syndrome,
CC diabetes, scleroderma, nausea, vomiting, constipation and diarrhea. The
CC method is rapid and efficient. The present sequence represents a
CC cardiovascular disorder plasma protein cryptic fragment.
XX
SQ Sequence 27 AA;

Query Match 100.0%; Score 19; DB 9; Length 27;
Best Local Similarity 100.0%; Pred. No. 1.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
| | | |
Db 11 ACGV 14

RESULT 100
AAR36413
ID AAR36413 standard; peptide; 29 AA.
XX
AC AAR36413;
XX
DT 25-MAR-2003 (revised)
DT 12-AUG-1993 (first entry)
XX
DE DPI-28.1(173-201) a Dermacophagoides protein allergen.
XX
XX T cell epitope; house dust mite; allergy; soluble; Der PI.
XX
XX Synthetic.
XX

PN WO9308279-A1.
 XX 29-APR-1993.
 XX 15-OCT-1992; 92WO-US008637.
 PF 16-OCT-1991; 91US-0077859.
 PR 08-MAY-1992; 92US-00881396.
 XX (IMMU-) IMMUNOLOGIC PHARM CORP.
 PA Garman RD, Greenstein JL, Kuo MC, Rogers BL;
 PI WPI; 1993-152472/18.
 DR WPI; 1993-152472/18.
 XX Isolated peptide(s) of dermatophagoides protein allergens - for diagnosis
 PT and treatment of sensitivity to house dust mite.
 PS Claim 10; Fig 3; 176pp; English.
 XX The peptide is one of a series of overlapping peptides synthesised by
 CC standard techniques to cover the whole Dermatophagoides pteronyssinus Der
 CC PI sequence. The T cell epitopes of the protein were mapped by detection
 CC of the peptide's ability to stimulate T cell activity. The peptides may
 CC be used for diagnosis and treatment of sensitivity to house dust mite
 CC allergens. When administered to house dust mite sensitive individuals,
 CC the peptides are capable of modifying the allergic response to the
 CC allergens. The peptides may be modified for e.g. increasing solubility,
 CC enhancing therapeutic or preventive efficacy or stability. See also
 CC AAR34666-700 and AAR36398-490. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 CC Sequence 29 AA;
 SQ
 Query Match 100.0%; Score 19; DB 2; Length 29;
 Best Local Similarity 100.0%; Pred. No. 1.2e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AOGV 4
 ||||
 Db 8 AOGV 11
 RESULT 101
 AAR51761
 ID AAR51761 standard; protein; 29 AA.
 AC AAR51761;
 XX 01-FEB-1995 (first entry)
 DT Der p I derived peptide, DP I-28.1(173-201).
 DE Der p I
 XX Group I; protein allergen; house dust mite; D. pteronyssinus; Der p I;
 KW homology; D. farinae; Der f I; group II; Der p II; Der f II; T-cell;
 KW epitopes; fusion peptides; antigenic fragments; substitution; deletion;
 KW addition; chemical synthesis; chemical cleavage; recombinant techniques;
 KW allergic response; immunoglobulin E; IgE; immunotherapy; anaphylaxis;
 KW IgE-mediated responses; anergise; lymphokine secretion profile; modify;
 KW T cell subpopulations; unresponsive; immune response; tolerance.
 XX Dermatophagoides pteronyssinus.
 OS Dermatophagoides pteronyssinus.
 XX ZA9302677-A.
 PN ZA9302677-A.
 XX 26-JAN-1994.
 PD 26-JAN-1994.
 XX 16-APR-1993; 93ZA-00002677.
 PF 16-APR-1993; 93ZA-00002677.
 PR 16-APR-1993; 93ZA-00002677.
 XX (IMMU-) IMMUNOLOGIC PHARM CORP.
 PA

PI Garman RD, Greenstein JL, Kuo M, Rogers BL;
 XX WPI; 1994-126807/15.
 DR WPI; 1994-126807/15.
 XX Isolated and/or modified peptides comprising T-cell epitopes - of major
 PT protein allergens of genus Dermatophagoides, used to treat or diagnose
 PT sensitivity to house dust mites.
 XX Claim 10; Page 66; 154pp; English.
 PS The sequences given in AAR51731-841 represent T-cell epitopes derived
 CC from the group I and II protein allergens from the house dust mite D.
 CC farinae and D. pteronyssinus, Der f I, Der f II, Der p I and Der p II
 CC respectively. The Der f II proteinCC shows high homology having an
 CC identity of 88%, with an identity of 81% between the two group I proteins
 CC (see also AAR51727-30). Fusion peptides may be produced which comprise at
 CC least two or these antigenic fragments. Each region of these fusion
 CC peptides may be derived from the same, or different, mite allergens. The
 CC antigenic fragments may be altered by substitution, deletion or addition
 CC to enhance their antigenicity. These peptides may be produced by chemical
 CC synthesis, chemical cleavage of the protein allergen or by recombinant
 CC techniques. These peptides, or the fusion peptides, when administered to
 CC a house dust mite sensitive individual, are capable of modifying the
 CC allergic response of the individual to the allergen. The peptides do not
 CC bind to immunoglobulin E (IgE), or bind IgE to a lesser extent than the
 CC full length protein allergen. This reduces the major complications of
 CC standard immunotherapy, which are IgE-mediated responses such as
 CC anaphylaxis. Exposure of mite allergic patients to these peptides may
 CC tolerate or anergise appropriate T cell subpopulations such that they
 CC become unresponsive to mite allergens and do not participate in mounting
 CC an immune response upon exposure. Administration of the peptides may also
 CC modify the lymphokine secretion profile as compared with exposure to the
 CC naturally occurring mite protein allergen
 CC Sequence 29 AA;
 SQ
 Query Match 100.0%; Score 19; DB 2; Length 29;
 Best Local Similarity 100.0%; Pred. No. 1.2e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AOGV 4
 ||||
 Db 8 AOGV 11
 RESULT 102
 AAW71936
 ID AAW71936 standard; peptide; 29 AA.
 AC AAW71936;
 XX 27-AUG-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 16-DEC-1998 (first entry)
 DE Dermatophagoides Der p I protein peptide DPI-28.1.
 XX genus Dermatophagoides; major protein allergen; T cell epitope; Der p I;
 KW Der p II; Der f I; Der f II; house dust mite allergy.
 KW Dermatophagoides.
 OS Dermatophagoides.
 XX US5820862-A.
 PN US5820862-A.
 XX 13-OCT-1998.
 PD 13-OCT-1998.
 XX 07-JUN-1995; 95US-00482142.
 PF 07-JUN-1995; 95US-00482142.
 PR 14-APR-1993; 93WO-US003471.
 PR 14-APR-1994; 94US-00227772.
 PR 19-MAY-1995; 95US-00445307.
 XX (IMMU-) IMMUNOLOGIC PHARM CORP.
 PA

XX Franzen HM, Kuo M, Evans S, Garman RD, Greenstein JL, Chen X;
PI Shaked Z, Rogers BL;
XX WPI; 1998-567590/48.
XX Dermatophagoides allergen peptides - useful for treating house dust mite
PT allergy.
XX
XX Disclosure; Col 97-98; 155pp; English.
XX The present invention describes peptides for treating sensitivity to
CC house dust mite allergens from the genus Dermatophagoides. Peptides
CC within the scope of the invention comprise at least one T cell epitope,
CC or preferably at least two T cell epitopes of a protein allergen selected
CC from the allergens Der p I, Der p II, Der f I, or Der f II. The invention
CC also describes modified peptides having similar or enhanced therapeutic
CC properties as the corresponding, naturally occurring allergen, but having
CC reduced side effects. AAM71912 to AAM72000, and AAM72257 to AAM72330
CC represent peptides from the present invention. (Updated on 25-MAR-2003 to
CC correct PR field.) (Updated on 27-AUG-2003 to correct OS field.)
XX
XX Sequence 29 AA;
SQ
Query Match 100.0%; Score 19; DB 2; Length 29;
Best Local Similarity 100.0%; Pred. No. 1.2e+03; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0;
QY 1 AGV 4
Db 8 AGV 11
RESULT 103
AAV50390
ID AAV50390 standard; peptide; 29 AA.
XX
AC AAV50390;
XX
DT 25-JAN-2000 (first entry)
XX
DE Dermatophagoides sp major protein allergen DP I-28.1.
XX
KW Allergen; house dust mite; detection; sensitivity; T cell epitope;
KW screening; allergic disorder; asthma; rhinitis; eczopic dermatitis;
KW Der f I; Der p I; Der p II; Der f II.
XX
OS Dermatophagoides sp.
XX
PN US5968526-A.
XX
PD 19-OCT-1999.
XX
PE 07-JUN-1995; 95US-00478572.
XX
PR 14-APR-1994; 94US-00227772.
PR 12-APR-1995; 95WO-US004481.
PR 19-MAY-1995; 95US-00445307.
XX
PA (IMMU-) IMMUNOLOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Rogers BL, Franzen HM, Shaked Z;
PI Chen X, Evans S, Kuo M;
XX
DR WPI; 1999-590385/50.
XX
PT Screening individuals for allergic reactions to T cell epitopes of major
PT allergens from house dust mites.
XX
PS Claim id', Column 99-100; 158pp; English.
XX
CC This invention describes a novel method (I) for detecting whether an
CC individual is sensitive to Dermatophagoides (house dust mites). The

CC method involves detecting sensitivity to house dust mites in patients,
CC comprising combining a blood sample from the individual with I or more
CC isolated T cell epitopes of the protein allergens I and II (DP I) and
CC (DP II) from Dermatophagoides (house dust mites). 32 T cell epitopes
CC with varying, defined amino acid sequences (given in the specification)
CC may be used in (I). The sample and allergens are combined under
CC conditions appropriate for the binding of blood components with the
CC polypeptides. The extent of binding is then indicative of the sensitivity
CC of the patient to house dust mites. (I) may be used to screen individuals
CC for sensitivity to Dermatophagoides (house dust mites). The house dust
CC mite is a major cause of a variety of allergic disorders such as asthma,
CC rhinitis and eczopic dermatitis. AAV50360-Y50542 and AAV50546-Y50555
CC represent house dust mite allergen peptide fragments derived from Der p
CC I, Der f II, Der f I and Der f II
XX
XX Sequence 29 AA;
SQ
Query Match 100.0%; Score 19; DB 2; Length 29;
Best Local Similarity 100.0%; Pred. No. 1.2e+03; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0;
QY 1 AGV 4
Db 8 AGV 11
RESULT 104
AAU18993
ID AAU18993 standard; peptide; 29 AA.
XX
AC AAU18993;
XX
DT 04-DEC-2001 (first entry)
XX
DE T-cell epitope containing peptide DPI-28.1.
XX
KW House dust mite; allergenic peptide; Der p I; Der p II; Der f I;
KW Der f II; antiallergenic; immunostimulant; house dust mite allergy;
KW T-cell epitope.
XX
OS Dermatophagoides pteronyssinus.
XX
PN US6268491-B1.
XX
PD 31-JUL-2001.
XX
PE 07-JUN-1995; 95US-00484296.
XX
PR 16-OCT-1991; 91US-00777859.
PR 08-MAY-1992; 92US-00881396.
PR 14-APR-1993; 93WO-US003471.
PR 14-APR-1994; 94US-00227772.
PR 19-MAY-1995; 95US-00445307.
XX
PA (IMMU-) IMMUNOLOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Kuo M, Rogers BL, Franzen HM, Chen X;
PI Evans S, Shaked Z;
XX
DR WPI; 2001-549074/61.
XX
PT Peptides comprising T cell groups of the major allergens from
PT Dermatophagoides (house dust mites), useful for treating house dust mite
PT allergy in humans, and for diagnosing sensitivity to house dust mite
PT protein allergens.
XX
PS Claim 2; Fig 3; 158pp; English.
XX
CC The invention relates to an isolated peptide of the major protein
CC allergens of the genus Dermatophagoides, which comprises at least one T
CC cell group of a protein allergen from Der p (DP) I, DP II, Der f (DP) I
CC or DP II. The isolated peptide comprises at least two regions, each
CC region comprising at least one T cell group of a protein allergen of the

CC genus Dermatophagoides. The regions are derived from the same or
 CC different protein allergens of the genus Dermatophagoides. The peptides
 CC are useful for treating house dust mite allergy in humans. The peptides
 CC are also useful for detecting or diagnosing sensitivity to house dust
 CC mite protein allergens. The present peptides have similar or enhanced
 CC therapeutic properties as the naturally-occurring allergen, but have
 CC reduced side effects, and increased solubility and stability. The present
 CC sequence represents an allergenic T-cell epitope containing peptide
 CC derived from the Dermatophagoides allergenic proteins

CC SQ Sequence 29 AA;

Query Match 100.0%; Score 19; DB 4; Length 29;
 Best Local Similarity 100.0%; Pred. No. 1.2e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
 ||||
 8 AOGV 11

RESULT 105

ADD35439 standard; peptide; 29 AA.

AC ADD35439;

DT 15-JAN-2004 (first entry)

DE Streptococcus pneumoniae aroA peptide #2.

KW crystallised recombinant protein; metabolism; Staphylococcus aureus;

KW Streptococcus pneumoniae; Helicobacter pylori; Escherichia coli;

KW Pseudomonas aeruginosa; vaccine.

OS Streptococcus pneumoniae.

PN WO2003044185-A2.

PD 30-MAY-2003.

PP 21-NOV-2002; 2002WO-CA001768.

PR 21-NOV-2001; 2001US-0332160P.

PR 27-NOV-2001; 2001US-0333661P.

PR 18-DEC-2001; 2001US-0333665P.

PR 19-DEC-2001; 2001US-0341954P.

PR 19-DEC-2001; 2001US-0342003P.

PR 20-DEC-2001; 2001US-0342542P.

PR 21-DEC-2001; 2001US-0344252P.

PR 28-DEC-2001; 2001US-0343570P.

PR 28-DEC-2001; 2001US-0343606P.

PR 28-DEC-2001; 2001US-0343679P.

PA (AFPI-) AFFINUM PHARM INC.

PI Edwards A, Dharamsi A, Vedadi M, Alam MZ, Awrey D, Beattie B;

PI Canadlen V, Domagala M, Houston S, Mansoury K, Necakov S, Nethery K;

PI Ng I, Pinder B, Sheldrick B, Vallee F, Wrexel O;

XX WPI; 2003-513596/48.

XX New crystallized recombinant polypeptides from Staphylococcus aureus,

PT Streptococcus pneumoniae, Helicobacter pylori or Pseudomonas aeruginosa

PT involved in general metabolism, useful as drug targets for pathogenic

PT bacteria.

XX Disclousure; SEQ ID NO 38; 277pp; English.

XX The invention comprises a crystallised recombinant protein that is

CC involved in general metabolism, the recombinant protein may be from

CC Staphylococcus aureus, Streptococcus pneumoniae, Helicobacter pylori,

CC Escherichia coli or Pseudomonas aeruginosa. The crystallised recombinant
 CC protein of the invention is useful in the prevention (vaccine) or
 CC treatment of a disease or disorder caused by S. pneumoniae, H. pylori, E.
 CC coli or P. aeruginosa. The present amino acid sequence was used in the
 CC exemplification of the invention.

CC SQ Sequence 29 AA;

Query Match 100.0%; Score 19; DB 7; Length 29;
 Best Local Similarity 100.0%; Pred. No. 1.2e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
 ||||
 21 AOGV 24

RESULT 106

AAW00643 standard; peptide; 30 AA.

AC AAW00643;

DT 19-NOV-1996 (first entry)

DE Human DEC-205 C-terminal peptide (aa1714-1743).

KW Dendritic and epithelial cell 205 kDa; DEC-205; receptor; C-type lectin;

KW antigen presentation; immune stimulation; vaccine; immune suppression.

OS Homo sapiens.

PN WO9623882-A1.

PD 08-AUG-1996.

PP 31-JAN-1996; 96WO-US001383.

PR 31-JAN-1995; 95US-00381528.

PA (UYRQ) UNIV ROCKEFELLER.

PI Steinman RM, Nussenzweig MC, Swiggard WJ, Jiang W;

PI WPI; 1996-371431/37.

PT Ligands for integral membrane protein DEC - useful in comps. to target

PT molecules to partic. areas of the body, e.g. for immune modulation, and

PT to induce immune suppression.

XX Claim 8; Page 118; 152pp; English.

XX A peptide sequence (AAW00643) comprises the C-terminal portion (amino

XX acids 1714-1743) of human DEC-205 (see also AAW00644), an integral

XX membrane protein expressed by dendritic cells. DEC-205 is useful for

XX screening for ligands useful in comps. to target molecules to partic.

XX areas of the body, e.g. for immune stimulation (i.e., vaccination) or

XX immune suppression

XX SQ Sequence 30 AA;

Query Match 100.0%; Score 19; DB 2; Length 30;
 Best Local Similarity 100.0%; Pred. No. 1.2e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
 ||||
 15 AOGV 18

RESULT 107

ADP45511 standard; peptide; 30 AA.

XX ADF45511;
AC 26-FEB-2004 (first entry)
XX
XX Human NUDE1 exon 9b related amino acid sequence.
XX
XX DISC1 partner; DISC1; ATP4; KIAA1167; KIAA0380; AKAP450; NUDE1;
XX neuroleptic; gene therapy; schizophrenia; psychotic disorder;
XX mood disorder; human.
XX
XX Homo sapiens.
XX
XX W02003102587-A1.
XX
XX 11-DEC-2003.
XX
XX 02-JUN-2003; 2003WO-GB002396.
XX
XX 01-JUN-2002; 2002GB-00012856.
XX
XX (UYED-) UNIV EDINBURGH.
XX
XX Millar K, Porteous DJ, Muir WJ, Blackwood D;
XX WPI; 2004-053510/05.
XX
XX Screening for a candidate agent, useful in treating, ameliorating or
XX preventing schizophrenia, psychotic or mood disorder, comprises forming a
XX mixture comprising the candidate agent, a DISC1 partner polypeptide and
XX DISC1 polypeptide.
XX
XX Disclosure; Page 6; 88pp; English.
XX
XX The present invention describes a method of screening for a candidate
XX agent (I) which modulates an interaction between a DISC1 partner
XX polypeptide and DISC1 polypeptide, which comprises forming a mixture
XX comprising the candidate agent, a DISC1 partner polypeptide selected from
XX ATR4, KIAA1167, KIAA0380, AKAP450 or NUDE1 or their splice variants,
XX mutant, fragments or orthologues and DISC1 polypeptide. (I) has
XX neuroleptic activity, and can be used in gene therapy. The method is
XX useful for screening a candidate agent, which modulates an interaction
XX between a DISC1 partner polypeptide and DISC1 polypeptide. Mutant forms
XX of ATR4, KIAA1167, KIAA0380, AKAP450 or NUDE1 are useful for identify
XX agents which substantially restore a wild-type functional activity of a
XX native or mutated DISC1 polypeptide or a mutated form of ATR4, KIAA1167,
XX KIAA0380, AKAP450 or NUDE1. A polynucleotide sequence encoding ATP4,
XX KIAA1167, KIAA0380, AKAP450 or NUDE1 or its fragment, derivative, mutant
XX or orthologue or sequences complementary to the polynucleotide sequences
XX is useful in determining a loss of expression of any one of the DISC1
XX partner. The polynucleotide and polypeptides are useful in the
XX manufacture of a medicament for the treatment of schizophrenia, other
XX psychotic disorders and mood disorders. The present sequence is used in
XX the exemplification of the present invention.
XX
XX Sequence 30 AA;
SQ
Query Match 100.0%; Score 19; DB 8; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AAGV 4
| | | |
| | | |
Db 22 AAGV 25

RESULT 108
ADV85620
ID ADV85620 standard; peptide; 30 AA.
XX
XX ADV85620;
AC
XX 10-MAR-2005 (first entry)
DT

XX Human DEC-205 C-terminal sequence, SEQ ID 1.
DE
XX Cytostratic; Virucide; Antibacterial; Antiparasitic; Vaccine;
XX endocytic receptor; dendritic cell; infection; cancer; DEC-205.
XX
XX Homo sapiens.
XX
XX US2004258688-A1.
XX
XX 23-DEC-2004.
XX
XX 12-MAR-2004; 2004US-00800023.
XX
XX 31-JAN-1995; 95US-00381528.
XX 31-JAN-1996; 96WO-US001383.
XX 05-JUN-2000; 2000US-00586704.
XX 09-AUG-2001; 2001US-00925284.
XX
XX (HAWI/) HAWIGER D.
XX (NUSS/) NUSSENZWEIG M.
XX (STEI/) STEINMAN R M.
XX (BONI/) BONIFAZ L.
XX
XX Hawiger D, Nussenzweig M, Steinman RM, Bonifaz L;
XX WPI; 2005-078933/09.
XX
XX Promoting antigen presentation comprises targeting antigen to dendritic
XX cells using an anti-DEC-205 antibody.
XX
XX Disclosure; SEQ ID NO 1; 116pp; English.
XX
XX The present invention relates to a method (M) for promoting highly
XX efficient antigen presentation in a mammal, by targeting a preselected
XX antigen to an endocytic receptor on an antigen-presenting cell, e.g. a
XX dendritic cell. An example of a dendritic cell is the cell endocytic
XX receptor DEC-205. The method comprises exposing dendritic cells from the
XX mammal to either: a conjugate comprising a preselected antigen covalently
XX bound to an antibody to DEC-205; or a recombinant anti-DEC-205 antibody
XX genetically engineered to contain at least one preselected antigen on at
XX least one preselected site on the antibody molecule; and promoting
XX maturation of the dendritic cells. The sequence encoding an anti-DEC-205
XX antibody (fragment) is preferably selected from ADV85632 and ADV85633,
XX which encode the heavy or light chain variable region of an anti-DEC-205
XX antibody. The antigen is targeted to antigen presenting cells through the
XX inclusion of the anti-DEC-205 antibody, making antigen presentation
XX highly efficient. The immunity induced is robust and long lasting, even
XX from a single dose at low concentration. The method of the invention is
XX useful for immunizing a mammal to prevent or treat a disease such as a
XX viral, bacterial or other infection or cancer. The immunization
XX preferably results in induction of long term T cell, B cell or mucosal
XX immunity. The present sequence is a C-terminal fragment of the human DEC-
XX 205 protein, corresponding to residues 174-1743 of the sequence given in
XX ADV85625.
XX
XX Sequence 30 AA;
SQ
Query Match 100.0%; Score 19; DB 9; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AAGV 4
| | | |
| | | |
Db 15 AAGV 18

RESULT 109
AAB27936
ID AAB27936 standard; peptide; 33 AA.
XX
XX AAB27936;
AC
XX

DT		02-PEB-2001	(first entry)
XX			
DE		Human secreted protein SEQ ID NO: 90.	
XX			
KW	Cycostatic; immunosuppressive; nootropic; neuroprotective; antiviral;		
KW	antiallergic; hepatotropic; antidiabetic; antiinflammatory; antitumor;		
KW	vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;		
KW	cardiac; gene therapy; cancer; immune disorder cardiovascular disorder;		
KW	neurological disease; infection; human; secreted protein.		
XX			
OS	Homo sapiens.		
PX			
PN	WO200055171-A1.		
PD			
PP	21-SEP-2000.		
PF	09-MAR-2000; 2000MO-US006043.		
PR	12-MAR-1999; 99US-0124146P.		
PR	23-NOV-1999; 99US-0167061P.		
PA	(HUMA-) HUMAN GENOME SCI INC.		
PI	Rosen CA, Ruden SM, Komatsoulis G;		
DR	WPI; 2000-638174/61.		
DR	N-PsDB; AAC59078.		
PT	Isolated nucleic acid molecule encoding a human secreted protein is used		
PS	in preventing, treating or ameliorating a medical condition.		
PS	Claim 11; Page 376; 438pp; English.		
CC	Sequences AAB27907-B27956 represent the amino acid sequences of 50 human		
CC	secreted proteins encoded by the genes AAC59049-CS098. The genes and		
CC	proteins are useful for preventing, ameliorating or treating medical		
CC	conditions, e.g. by protein or gene therapy. The genes are isolated from		
CC	a range of human tissues disclosed in the specification. The nucleic		
CC	acids, proteins, antibodies and (anti)agonists are useful in the		
CC	diagnosis, treatment and prevention of: (a) cancer, e.g. breast and		
CC	ovarian cancer, and other cancers of the adrenal gland, bone, bone		
CC	marrow, breast, gastrointestinal tract, liver, lung, or urogenital; (b)		
CC	immune disorders e.g. Addison's disease, allergies, autoimmune haemolytic		
CC	anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,		
CC	multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)		
CC	cardiovascular disorders such as myocardial ischaemias; (d) wound healing		
CC	; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)		
CC	infectious diseases such as viral, bacterial, fungal and parasitic		
CC	infections		
SQ	Sequence 33 AA;		
	Query Match	100.0%; Score 19; DB 3; Length 33;	
	Best Local Similarity	100.0%; Pred. No. 1.4e+03;	
	Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
OY	1 AOGV 4		
DG	25 AOGV 28		
	RESULT 110		
ID	ADY97195		
XX	ADY97195 standard; peptide; 35 AA.		
XX			
AC	ADY97195;		
DT	16-JUN-2005 (first entry)		
DE	Herpes simplex virus type 2 (HSV-2) HLA-binding epitope peptide RSI-3.		
XX			
KW	antigen; anti-HSV; virucide; HSV-1 infection; HSV-2 infection;		
KW	immunotherapy; vaccine.		

XX		Human herpesvirus 2.
OS		
XX		
PN		WO2005028496-A2.
XX		
XX		
PD		31-MAR-2005.
XX		
PF		13-SEP-2004; 2004WO-US029908.
XX		
PR		12-SEP-2003; 2003US-0503148P.
XX		
PA		(ANTI-) ANTIGENICS INC.
XX		
PI		Truneh A, Levey DL, Mo X, Lecclair KP, Kashi RS, Liu C;
DR		WPI, 2005-262770/27.
XX		
PT		New composition comprising different antigenic peptides, each comprising
PT		one or more HLA-binding epitopes of a different herpesvirus peptide,
PT		useful for treating or preventing infection, e.g. herpes simplex virus 1
or 2 infection.		
PS		Disclosure: SEQ ID NO 53; 114pp; English.
XX		
CC		The invention relates to a novel composition comprising different
CC		antigenic peptides, whereby each peptide comprises one or more HLA-
CC		binding epitopes of a different herpesvirus peptide selected from among
CC		herpesvirus peptides differing in amino acid sequence, the amino acid
CC		sequence of each herpesvirus peptide selected from SEQ ID Nos. 1-49,
CC		given in the specification. The Herpesviruses include the Herpes simplex
CC		viruses which, in turn, include two closely-related variants designated
CC		types 1 (HSV-1) and 2 (HSV-2). HSV-1 and HSV-2 are associated in some
CC		individuals with frequent and/or painful recurrences that manifest
CC		themselves as cold sores and genital herpes, respectively. Although
CC		continuous administration of antiviral drugs, such as acyclovir,
CC		ameliorates the severity of HSV infection and reduces the frequency and
CC		duration of associated episodes, such treatment does not tackle the
CC		establishment of latency or indeed the state of the latent virus. There
CC		currently exists no effective vaccine for the prevention or treatment of
CC		HSV-1 or HSV-2. The composition of the invention demonstrates anti-HSV
CC		and virucide activities and may be useful for treating or preventing
CC		infection, preferably a recurrent infection by HSV-1 or HSV-2, possibly
CC		via immunotherapy. The current sequence is that of a HSV-2 HLA-binding
CC		epitope peptide of the invention.
XX		
XX		
SQ		Sequence 35 AA;
Query Match	100.0%;	Score 19; DB 9; Length 35;
Best Local Similarity	100.0%;	Pred. No. 1.4e+03;
Matches	4; Conservative	0; Mismatches
		0; Indels
		0; Gaps
		0;
QY		
	1 AGCV	4
Dd		
	10 AGGV	13
RESULT 111		
ID	ADXS6537	standard; peptide; 36 AA.
XX		
AC	ADXS6537;	
XX		
DT		
05-MAY-2005		(first entry)
DE		
XX		Cardiovascular disorder plasma protein tryptic fragment SEQ ID NO 354.
XX		
KM		coronary artery disease; primary biliary cirrhosis; gallstones;
KM		celiac disease; irritable bowel syndrome; diabetes; scleroderma; nausea;
KM		emesis; constipation; diarrhea; cardiovascular disease; immune disorder;
KM		endocrine disease; gastrointestinal disease; metabolic disorder;
KM		dermatological disease; musculoskeletal disease; Cardiac; Vasotropic;
KM		Hepatotropic; Litholytic; Immunosuppressive; Gastrointestinal-Gen.;
KM		Antinflammatory; Antidiabetic; Dermatological; Antilemetic; Laxative;
KM		Antineoplastic; Anticancerous;

```

KM Antidiarrhetic; diagnosis.
XX
OS Homo sapiens.
XX
PN W02005015206-A2.
XX
PD 17-FEB-2005.
XX
PF 06-AUG-2004; 2004WO-EP008660.
XX
PR 08-AUG-2003; 2003US-0493599P.
PR 08-AUG-2003; 2003US-0493836P.
PR 08-AUG-2003; 2003US-0493867P.
XX 08-AUG-2003; 2003US-0493985P.
XX
PA (XENO-) XENOVA LTD.
PA (NOVS ) NOVARTIS AG.
PA (NOVS ) NOVARTIS PHARMA GMBH.
XX
PI Argoud-Puy G, Bederr N, Bougueleret L, Cusin I, Mahe E;
PI Miknejad A, Reffaas S, Rose K, Saudralis C, Scherer A, Papoian R;
XX WPI; 2005-195824/20.
DR
XX Screening and/or diagnosing cardiovascular disorder in subject involves
PT detecting and/or quantifying level of polypeptide in biological sample
PT from subject and comparing with control sample.
XX
PS Claim 1; SEQ ID NO 354; 349pp; English.
XX
CC The invention relates to a method of screening and/or diagnosing a
CC cardiovascular disorder (CD) in a subject which comprises detecting
CC and/or quantifying the level of a polypeptide in a biological sample from
CC the subject and comparing the level to that of control sample. The method
CC is useful for screening, diagnosing and treating coronary artery disease,
CC biliary cirrhosis, gallstones, celiac disease, irritable bowel syndrome,
CC diabetes, scleroderma, nausea, vomiting, constipation and diarrhea. The
CC method is rapid and efficient. The present sequence represents a
CC cardiovascular disorder plasma protein tryptic fragment.
XX
SQ Sequence 36 AA;
XX
QY Query Match 100.0%; Score 19; DB 9; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ACGV 4
Db 3 ACGV 6

```

```

PR 01-FEB-1991; 91US-00649784.
XX
XX (DOONG ) IST DONEGANI SPA GUIDO.
PA (ENIE ) ENICHEM SPA.
XX
XX Mapelli C, Dugas De Robertis C, Stahl GF, Bascomb NF;
PI Swerdloff MD, Williams JJ, Everett NP;
XX WPI; 1992-260816/32.
DR
XX Reverse antimicrobial peptide(s) and oligopeptide(s) - useful for
PT protecting plants from pathogens and for determining phytotoxicity.
PT
XX Disclosure; Fig 1; 79pp; English.
XX
CC The sequences given in AAR25963-83 are a collection of natural and
CC reverse peptides which are active against at least one microbial pathogen
CC and, preferably, at least one plant pathogen. It has been found that
CC acceptable activity and acceptable levels of protection against at least
CC one microbial pathogen and at least one microbial plant pathogen may be
CC obtained by reversing the sequence of amino acids contained within
CC naturally occurring antimicrobial peptides while maintaining the
CC directionality of the peptide bonds. These peptides possess relatively
CC low phytotoxicity and/or low susceptibility to proteolytic degradation.
CC The oligopeptides may be used as dimers composed of two peptide units
CC with or without an intervening bridge. The simplest structure taken by
CC these dimers is the "head-to-tail" configuration. This comprises at least
CC one first peptide monomer and at least one second peptide monomer. Each
CC peptide monomer has an N- and C-terminus, both of which are capable of
CC forming peptide bonds. In the head-to-tail configuration the C-terminal
CC amino acid of the first monomer peptide is directly bound to the N-
CC terminus of the second monomer peptide, by a peptide bond, without an
CC intervening bridging group. In other peptide dimers bridging groups may
CC be used and may be as few as one amino acid but may be as large as 100
CC amino acids in length and form omega loops or other secondary structures.
CC (Updated on 25-MAR-2003 to correct PN field.) (Updated on 25-MAR-2003 to
CC correct PA field.)
XX
SQ Sequence 37 AA;
XX
QY Query Match 100.0%; Score 19; DB 2; Length 37;
Best Local Similarity 100.0%; Pred. No. 1.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ACGV 4
Db 6 ACGV 9

```

XX (ENIE) ENICHEM SPA.
 PA Mapeili C, Dugae De Robertis C, Stahl GF, Bascomb NF;
 PI Swerdloff MD, Williams JI, Everett NP;
 XX WPI; 1999-304793/26.
 DR
 XX New oligopeptides containing at least two antimicrobial peptides, useful
 PT for protecting plants against microbial pathogens.
 PS Claim 26; Fig 1; 67pp; English.
 XX
 CC The invention relates to antimicrobial peptides including reverse
 CC antimicrobial peptides, antimicrobial oligopeptides and other
 CC antimicrobial compositions such as cecropin P1. The antimicrobial
 CC oligopeptides are active against at least one microbial pathogen, and
 CC comprise at least one of a first and one of a second peptide monomer,
 CC interconnected directly through a peptide bond via the N and C terminals,
 CC or indirectly through a disulfide bond or via bridges. At least one of
 CC the first and second monomers confers activity. Oligopeptides connected
 CC by bridges do not have the structure of Magainin Pre-pro protein. The
 CC antimicrobial peptides are used for providing protection to plants
 CC against plant pathogens, thus enhancing crop yields. The peptides are
 CC also useful for treatment of human or animal disease, as an additive to
 CC foods for preservation, or as a preservative in cosmetics and
 CC pharmaceuticals. Unlike prior art antimicrobial peptides Magainins 1 and
 CC 2, the new antimicrobial peptides don't have undesirable properties, are
 CC not subject to extensive proteolytic degradation, are not phytotoxic to
 CC the cell, and have a broader range of activity. The present sequence
 CC represents an antimicrobial oligopeptide. (Updated on 20-MAR-2003 to
 CC correct PF field.) (Updated on 20-MAR-2003 to correct PR field.)
 XX SQ Sequence 37 AA;
 QY
 Db 1 AOGV 4
 6 AOGV 9
 Query Match 100.0%; Score 19; DB 2; Length 37;
 Best Local Similarity 100.0%; Pred. No. 1.5e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 114
 ID AAY92803 standard; peptide; 37 AA.
 AC AAY92803;
 XX 29-AUG-2000 (first entry)
 DT
 XX
 DE Synthetic antimicrobial peptide, reverse cecropin A amide (Rev2).
 XX Magainin; antimicrobial; transgenic plant; protease degradation; Rev4;
 KM indolicidin; protein production; reverse peptide.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 37 /note= "amidated"
 FT
 XX W0200026344-A1.
 XX 11-MAY-2000.
 PD
 XX 29-OCT-1999; 99WO-US025561.
 PF
 XX 30-OCT-1998; 98US-0106373P.
 PR 02-NOV-1998; 98US-0106537P.
 XX (INTE-) INTERLINK BIOTECHNOLOGIES LLC.
 PA

PA (KENT) UNIV KENTUCKY RES FOUND.
 XX Everett NP, Li Q, Lawrence C, Davies MH;
 PI WPI; 2000-365597/31.
 DR
 XX Polypeptides for reducing proteolytic degradation of proteins
 PT administered to, or produced by a plant comprise indolicidin or its
 PT functional equivalents.
 XX
 PS Example 7; Page 34; 50pp; English.
 XX
 CC Indolicidin is a potent antimicrobial tridecapeptide, originally purified
 CC from cytoplasmic granules of bovine neutrophils. Reverse peptide, Rev4 of
 CC indolicidin (see AAY92794) was found to have increased stability against
 CC plant protease degradation. The ranking of peptide stabilities against
 CC proteases present in plant extracellular fluid was shown to be Rev4
 CC (AAY92796) > Rev6 (AAY92801) > Rev3 (AAY92802) > Rev2 > Rev8 (AAY92804).
 CC Expression of antimicrobial peptides in transgenic plants suffers a major
 CC limitation in that the foreign peptides are susceptible to rapid
 CC degradation by proteases. The invention concerns reducing the extent of
 CC protease degradation of a protein applied to, or produced by a plant by
 CC administering indolicidin, Rev4 or a functional equivalent to the plant.
 CC Transgenic plants expressing indolicidin and Rev4 are useful for
 CC production of the antimicrobial peptides. Compositions containing
 CC indolicidin and Rev4 are also useful for production of agronomically
 CC important proteins in plants
 XX SQ Sequence 37 AA;
 QY
 Db 1 AOGV 4
 6 AOGV 9
 Query Match 100.0%; Score 19; DB 3; Length 37;
 Best Local Similarity 100.0%; Pred. No. 1.5e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 115
 ID ADC73331 standard; peptide; 37 AA.
 AC ADC73331;
 XX 01-JAN-2004 (first entry)
 DT
 XX
 DE Bovine antibacterial peptide Indolicidin, reverse peptide Rev2.
 XX Antibacterial peptide; antibacterial; protease resistance; Rev4;
 KM indolicidin; plant disease; Rev2.
 XX
 OS Synthetic.
 XX
 FH US2003131383-A1.
 FN 10-JUL-2003.
 PD
 XX 23-SEP-2002; 2002US-00252773.
 PF
 XX 30-OCT-1998; 98US-0106373P.
 PR 02-NOV-1998; 98US-0106573P.
 PR 29-OCT-1999; 99US-00431546.
 XX (INTE-) INTERLINK BIOTECHNOLOGIES LLC.
 PA Everett NP, Li Q, Lawrence C, Davies MH;
 PI WPI; 2003-829607/77.
 DR
 XX New Rev4 peptide having enhanced stability to protease degradation,
 PT useful for controlling plant diseases and protecting other peptides from
 PT degradation by proteases of plant, fungal, viral, bacterial, insect or

PT other origin.
XX
PS Example 7; SEQ ID NO 11; 21pp; English.
XX
CC The invention relates to a peptide comprising an amino acid sequence,
CC designated as Rev4 (ADC7324), or its functional equivalent. Rev4 is a
CC reverse peptide analogue of bovine indolicidin. Also included is a
CC composition for use in protecting a peptide, polypeptide or protein from
CC protease degradation comprising Rev4 or its functional equivalent and a
CC carrier. The peptides and compositions of the present invention are
CC useful for the control of plant diseases and protecting other peptides
CC from degradation by proteases of plant, fungal, viral, bacterial, insect
CC or other origin. The present sequence is an indolicidin reverse peptide
CC Rev2.
XX
SQ Sequence 37 AA;
Query Match 100.0%; Score 19; DB 7; Length 37;
Best Local Similarity 100.0%; Pred. No. 1.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGGV 4
|||
6 AGGV 9
Db
RESULT 116
ABO59877
ID ABO59877 standard; protein; 38 AA.
XX
AC ABO59877;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human genome derived single exon protein #6111.
XX
KM Human; gene expression; single exon probe; microarray;
KM alternative splicing event; genomic alteration.
XX
OS Homo sapiens.
XX
PN US2003194704-A1.
XX
PD 16-OCT-2003.
XX
PF 03-APR-2002; 2002US-00029386.
XX
PR 03-APR-2002; 2002US-00029386.
XX
PA (PENN/) PENN S G.
PA (RANK/) RANK D R.
PA (HANK/) HANZEL D K.
XX
PI Penn SG, Rank DR, Hanzel DK;
XX
DR WPI; 2004-119264/12.
XX
PT New human genome-derived single exon nucleic acid probes useful for human
PT gene expression analysis, for identifying or characterizing alternative
PT splicing events, for assessing genomic alterations or as tools for
PT surveying tissues.
XX
PS Claim 45; SEQ ID NO 33511; 80pp; English.
XX
CC The invention relates to a nucleic acid probe for measuring human gene
CC expression, comprising any of the 27,400 fully defined nucleotide
CC sequences in the specification, or their complements or fragments, and
CC encoding at least 8 amino acids of any of the 688 amino acid sequences
CC fully defined in the specification. The probe is a single exon probe that
CC hybridizes under high stringency conditions to a nucleic acid molecule
CC expressed in human cells or tissues. Also included are a spatially-
CC addressable set of single exon nucleic acid probes for measuring human
CC gene expression (comprising a plurality of single exon nucleic acid

CC probes cited above, where each of the plurality of probes is separately
CC and addressably isolatable or amplifiable from the plurality), a single
CC exon microarray for measuring human gene expression, a method of
CC measuring human gene expression, a vector comprising the single exon
CC probe cited above, an ORF-encoded peptide comprising at least 8
CC contiguous amino acids of any of the above-mentioned amino acid
CC sequences (optionally with conservative amino acid substitutions), an
CC isolated antibody that binds specifically to a peptide cited above,
CC a method of selling and/or licensing single exon probes or microarrays to
CC a customer desiring to measure gene expression, a method of providing
CC human gene expression data by subscription, and a computer-readable
CC storage medium which contains a database having a plurality of records
CC (each record including data on the expression of a single exon probe
CC cited above. The probe, methods and apparatus are useful in gene
CC expression analysis. The probes may be used as tools for surveying
CC tissues to detect the presence of expressed messages that contain their
CC specific exon, or in constructing genome-derived single exon microarrays.
CC In addition, the probes are used in identifying and characterizing
CC alternative splicing events, in detecting and characterizing gross
CC alterations in the genomic locus that includes their exon, in assessing
CC smaller genomic alterations, in printing the synthesis of nucleic acids,
CC or in expressing the ORF-encoded peptide. The present sequence is a human
CC single exon probe protein of the invention. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?docid=20030194704
XX
SQ Sequence 38 AA;
Query Match 100.0%; Score 19; DB 8; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGGV 4
|||
24 AGGV 27
Db
RESULT 117
AD297828
ID AD297828 standard; protein; 40 AA.
XX
AC AD297828;
XX
DT 14-JUL-2005 (first entry)
XX
DE Human coronavirus 229E protease (amino acid residues 121-160).
XX
KM severe acute respiratory syndrome; SARS coronavirus infection;
KM respiratory disease; protease; infection; virucide; respiratory-gen.
XX
OS Human coronavirus 229E.
XX
PN WO2005041904-A2.
XX
PD 12-MAY-2005.
XX
PF 01-NOV-2004; 2004WO-US038391.
XX
PR 31-OCT-2003; 2003US-0516008P.
XX
PA (FULC-) FULCRUM PHARM INC.
XX
PI Freire E, Ottenbrite R, Xiao Y, Velazquez-Campoy A, Leavitt S;
PI Bacha U, Barrila J;
XX
DR WPI; 2005-356029/36.
XX
PT New boron-containing compounds are coronavirus protease inhibitors useful
PT to treat infection caused by coronavirus (severe acute respiratory
PT syndrome-associated coronavirus).
XX
PS Disclosure; SEQ ID NO 18; 418pp; English.

XX The invention relates to boron-containing compounds that are inhibitors
CC of severe acute respiratory syndrome (SARS) coronavirus protease. The
CC boron-containing compounds, e.g. boric acid or boronic acids of formulae
CC (1-4), are fully defined in the specification. Also described are: a
CC method for inhibiting coronavirus protease comprising contacting the
CC coronavirus protease with a boron-containing compound, and a method for
CC detecting coronavirus in a test sample comprising contacting the sample
CC with a boron-containing compound. The SARS coronavirus protease has one
CC or more serine or threonine residues at or near its active site.
CC Administration of a boron-containing compound of the invention is by
CC oral, rectal, sub-lingual, mucosal, nasal, ophthalmic, subcutaneous,
CC intramuscular, intravenous, transdermal, spinal, intrathecal, intra-
CC articular, intra-arterial, sub-arachnoid, bronchial, lymphatic, or
CC intraneurilic methods. The invention specifically discloses 403 boron-
CC containing compounds. The boron-containing compounds are useful for
CC treating infection caused by SARS coronavirus. This sequence represents a
CC region (amino acid residues 121-160) of a coronavirus protease that shows
CC homology with the same region of other coronavirus proteases.

XX Sequence 40 AA;

Query Match 100.0%; Score 19; DB 9; Length 40;

Best Local Similarity 100.0%; Pred. No. 1.7e+03; Mismatches 0; Indels 0; Gaps 0;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGGV 4
|||
3 AGGV 6

Db

RESULT 118

ABU17305
ID ABU17305 standard; protein; 41 AA.

XX ABU17305;

XX 19-JUN-2003 (first entry)

XX Protein encoded by Prokaryotic essential gene #2832.

XX Antisense; prokaryotic essential gene; cell proliferation; drug design.

XX Acinetobacter baumannii.

XX WO200271183-A2.

XX 03-OCT-2002.

XX 21-MAR-2002; 2002WO-US009107.

XX 21-MAR-2001; 2001US-00815242.

XX 06-SEP-2001; 2001US-00948993.

XX 25-OCT-2001; 2001US-0342923P.

XX 08-FEB-2002; 2002US-00072851.

XX 06-MAR-2002; 2002US-0362699P.

XX (ELIT-) ELITRA PHARM INC.

XX Wang L, Zamudio C, Malone C, Haselbeck R, Ohlsen KL, Zyskind JW;

XX Wall D, Trawick JD, Carr GJ, Yamamoto R, Forayth RA, Xu HH;

XX WPI; 2003-029926/02.

XX N-PSDB; ACA21175.

XX New antisense nucleic acids, useful for identifying proteins or screening

XX PT for homologous nucleic acids required for cellular proliferation to

XX isolate candidate molecules for rational drug discovery programs.

XX Claim 25; SEQ ID NO 45229; 1766pp; English.

XX The invention relates to an isolated nucleic acid comprising any one of

XX the 6213 antisense sequences given in the specification where expression

CC of the nucleic acid inhibits proliferation of a cell. Also included are:
CC (1) a vector comprising a promoter operably linked to the nucleic acid
CC encoding a polypeptide whose expression is inhibited by the antisense
CC nucleic acid; (2) a host cell containing the vector; (3) an isolated
CC polypeptide or its fragment whose expression is inhibited by the
CC antisense nucleic acid; (4) an antibody capable of specifically binding
CC the polypeptide; (5) producing the polypeptide; (6) inhibiting cellular
CC proliferation or the activity of a gene in an operon required for
CC proliferation; (7) identifying a compound that influences the activity of
CC the gene product or that has an activity against a biological pathway
CC required for proliferation, or that inhibits cellular proliferation; (8)
CC identifying a gene required for cellular proliferation or the biological
CC pathway in which a proliferation-required gene or its gene product lies
CC or a gene on which the test compound that inhibits proliferation of an
CC organism acts; (9) manufacturing an antibiotic; (10) profiling a
CC compound's activity; (11) a culture comprising strains in which the gene
CC product is overexpressed or underexpressed; (12) determining the extent
CC to which each of the strains is present in a culture or collection of
CC strains; or (13) identifying the target of a compound that inhibits the
CC proliferation of an organism. The antisense nucleic acids are useful for
CC identifying proteins or screening for homologous nucleic acids required
CC for cellular proliferation to isolate candidate molecules for rational
CC drug discovery programs, or for screening homologous nucleic acids
CC required for proliferation in cells other than *S. aureus*, *S. typhimurium*,
CC *K. pneumoniae* or *P. aeruginosa*. The present sequence is encoded by one of
CC the target prokaryotic essential genes. Note: The sequence data for this
CC patent did not form part of the printed specification, but was obtained
CC in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 41 AA;

Query Match 100.0%; Score 19; DB 6; Length 41;

Best Local Similarity 100.0%; Pred. No. 1.7e+03; Mismatches 0; Indels 0; Gaps 0;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGGV 4
|||
13 AGGV 16

Db

RESULT 119

AEB94393
ID AEB94393 standard; protein; 41 AA.

XX AEB94393;

XX 20-OCT-2005 (first entry)

XX Human AMPD-3 protein, SEQ ID NO: 115.

XX AMPD-related gene modulator; phagocytosis-related gene modulator;

XX age related macular degeneration; ophthalmological; ocular disease;

XX phagocytosis; therapeutic; animal disease model; screening; AMPD-3.

XX Homo sapiens.

XX Key

XX Misc-difference 1/Note= "Encoded by ACC"

XX US2005176662-A1.

XX 11-AUG-2005.

XX 09-FEB-2004; 2004US-00773446.

XX 09-FEB-2004; 2004US-00773446.

XX (UTMI-) UNIV MIAMI.

XX Inana G, McLaren M;

DR WPI; 2005-541777/55.
DR N-PSDB; AEB94295.
XX
PT Method for delaying/reversing a retinal or choroidal degenerative disease
PT or condition in a subject comprises contacting a retinal or choroidal
PT cell with an agent that modulates the expression/activity of a
PT phagocytosis-related gene.
XX
PS Disclosure; SEQ ID NO 115; 142pp; English.
XX
CC The present invention relates to multiple genes related to age-related
CC macular degeneration (AMD) and/or phagocytosis by retinal pigment
CC epithelial (RPE) cells of the eye. The methods and compositions of the
CC invention includes detecting and treating AMD and other retinal
CC degenerative conditions based on these phagocytosis-related and/or AMD-
CC related genes. The invention is useful for delaying/reversing/creating a
CC retinal or choroidal degenerative disease or condition such as age-
CC related macular degeneration (AMD) in a subject who is suffering from AMD
CC or at risk of developing AMD. The invention also provides animal models
CC useful for testing therapeutic compounds and treatment protocols for AMD
CC and gene arrays including polymorphic variants of phagocytosis-related
CC and/or AMD-related genes, useful in genetic screening of nucleic acid
CC samples from subjects to obtain profiles of polymorphic variant
CC sequences in a plurality of genes associated with AMD. The present
CC sequence is human AMDP-3 (also designated as AMD-related phagogene; AMDP
CC gene) protein.
XX
SQ Sequence 41 AA;
XX
Query Match 100.0%; Score 19; DB 9; Length 41;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGGV 4
|||
Db 12 AGGV 15
XX
RESULT 120
AAM24224
ID AAM24224 standard; protein; 45 AA.
XX
AC AAM24224;
XX
DT 12-OCT-2001 (first entry)
XX
DE Human EST encoded protein SEQ ID NO: 1749.
XX
KM Human; sheep; pig; cow; fruit fly; yeast; hamster; macaque; horse;
KM tomato; monkey; dog; sea urchin; expressed sequence tag; EST;
KM diagnostics; forensic test; gene mapping; genetic disorder; biodiversity;
KM gene therapy; nutrition.
XX
OS Homo sapiens.
XX
PN WO200154477-A2.
XX
PD 02-AUG-2001.
XX
PF 25-JAN-2001; 2001WO-US002687.
XX
PR 25-JAN-2000; 2000US-00491404.
PR 17-JUL-2000; 2000US-00617746.
PR 03-AUG-2000; 2000US-00631451.
PR 15-SEP-2000; 2000US-00663870.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Zhou P, Qian XB, Wang Z, Chen R, Aundi V;
PI Cao Y, Drmanac RA, Zhang J, Werhman T;
XX
XX WPI; 2001-476164/51.
DR N-PSDB; AAH98883.

XX
PT Isolated polypeptide for treatment of diseases, diagnostics, raising
PT antibodies and research use.
XX
PS Claim 20; Page 1154; 1275pp; English.
XX
CC The present invention provides the protein and coding sequences of novel
CC proteins from a variety of organisms, including human, dog, cat, horse,
CC cow, pig, hamster, monkey, macaque, yeast, bacteria, fruit fly, sea
CC urchin and tomato. These were derived from expressed sequence tags (ESTs)
CC from the organism of interest. They can be used in diagnostics,
CC forensics, gene mapping, identification of mutations, to assess
CC biodiversity and for nutritional purposes. The present sequence is a
CC protein of the invention
XX
SQ Sequence 45 AA;
XX
Query Match 100.0%; Score 19; DB 4; Length 45;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGGV 4
|||
Db 40 AGGV 43
XX
RESULT 121
ABB90716
ID ABB90716 standard; peptide; 45 AA.
XX
AC ABB90716;
XX
DT 29-AUG-2003 (revised)
DT 29-JUL-2002 (first entry)
XX
DE Chlamydia pneumoniae cp7107 protein homology region.
XX
KM Chlamydia pneumoniae; antigen; immunogen; vaccine; diagnosis;
KM human respiratory disease; cardiovascular disease; atherosclerosis;
KM coronary artery disease; carotid artery stenosis; myocardial infarction;
KM cerebrovascular disease; aortic aneurysm; claudication; stroke;
KM strain CWL029.
XX
OS Chlamydia pneumoniae.
XX
PN WO200202606-A2.
XX
PD 10-JAN-2002.
XX
PF 03-JUL-2001; 2001WO-IB001445.
XX
PR 03-JUL-2000; 2000GB-00016363.
PR 11-JUL-2000; 2000GB-00017047.
PR 21-JUL-2000; 2000GB-00017983.
PR 07-AUG-2000; 2000GB-00019368.
PR 18-AUG-2000; 2000GB-00020440.
PR 14-SEP-2000; 2000GB-00022583.
PR 10-NOV-2000; 2000GB-00027549.
PR 22-DEC-2000; 2000GB-00031706.
XX
PA (CHIR-) CHIRON SPA.
XX
PI Ratti G, Grandi G;
XX
DR WPI; 2002-154726/20.
XX
PT Novel Chlamydia pneumoniae protein useful in the manufacture of a
PT medicament for treatment or prevention of infection due to Chlamydia,
PT preferably Chlamydia pneumoniae, and for diagnostic purposes.
XX
PS Disclosure; Fig 191; 364pp; English.
XX
CC Sequences ABB90526-ABB90715 represent novel proteins from Chlamydia

CC pneumoniæ (strain CMU029), and ABL91184-ABL91373 represent DNA encoding
CC them. The proteins are predicted to be immunogenic and may therefore be
CC useful in vaccine production and for diagnostic purposes. Chlamydia
CC pneumoniae is a common cause of respiratory disease in humans, and is
CC also involved in the development of cardiovascular diseases such as
CC atherosclerosis, coronary artery disease, carotid artery stenosis,
CC myocardial infarction, cerebrovascular disease, aortic aneurysm,
CC claudication and stroke. The proteins and nucleic acids of the invention
CC may be used in vaccines and pharmaceutical compositions for the
CC prevention or treatment of chlamydial infections, particularly Chlamydia
CC pneumoniae infections. The proteins may also be used in the detection of
CC Chlamydia pneumoniae, and the nucleic acids may be used in PCR, branched
CC DNA probe assay or blotting techniques for determining Chlamydia
CC pneumoniae gene expression. Sequences ABB90716-ABB90720 represent regions
CC of Chlamydia pneumoniae proteins of the invention which share some
CC sequence homology. (Updated on 29-AUG-2003 to standardise OS field)
CC
SQ Sequence 45 AA;

Query Match 100.0%; Score 19; DB 5; Length 45;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGGV 4
|||
Db 37 AGGV 40

RESULT 122
AAR69856
ID AAR69856 standard; peptide; 49 AA.
AC AAR69856;
XX
DT 25-MAR-2003 (revised)
DT 18-MAR-1995 (first entry)
XX
DE Fibronectin peptide.
KW Rheumatoid arthritis; diagnosis; therapy; fibronectin; streptokinase.
XX
OS Synthetic.
FH Key Location/Qualifiers
FT Peptide 1..49
FT /note= "amino acids 1741-1790 of fibronectin"
FT Misc-difference 27..32
FT /note= "SEQ ID NO.1"
XX
PN WO9417411-A1.
XX
PD 04-AUG-1994.
XX
PF 27-JAN-1994; 94WO-US001077.
XX
PR 27-JAN-1993; 93US-00009471.
XX
PA (UTDU-) UNIV DUKE.
PA (TRIN-) TRINITY LAB INC.
XX
PI Pizzo SV, Gonzalez-Gronow M, Clinton BA,
XX WPL. 1994-264260/32.
DR
XX
PT Diagnosis and treatment of rheumatoid arthritis - using a predictive
PT factor peptide corresp. to a region common to fibronectin and
PT streptokinase.
XX
PS Disclosure; Page 55; 83pp; English.

The peptide corresponds to amino acids 1741-1790 of fibronectin, and regions of sequence similarity with AAR57728 (streptokinase peptide) are shown in Fig.1. A common peptide region is highlighted, and this peptide

CC	is used in the diagnosis of the onset/presence of rheumatoid arthritis,
CC	for monitoring the progress of therapy, or for therapy. (Updated on 25-
CC	MAR-2003 to correct PN field.)
XX	
SO	Sequence 49 AA;
QY	1 AOCV 4
Db	32 AOGV 35
RESULT 123	
ABB09222	
ID	ABB09222 standard; peptide: 49 AA.
XX	
AC	ABB09222;
XX	
DT	08-JUL-2002 (first entry)
DE	
XX	Mouse putative transmembrane anchor sequence SEQ ID NO:16.
XX	
KM	GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytosolic;
KM	glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;
KM	glial cell line derived neurotrophic factor; osteopetrotic; tumour;
KM	neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
KM	medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
KM	neuronal disorder; aberrant axonal sprouting.
XX	
OS	Mus musculus.
FN	
XX	WO200162795-A1.
PD	
XX	30-AUG-2001.
PX	
PF	14-NOV-2000; 2000WO-FI000994.
XX	
FR	21-FEB-2000; 2000FI-0000394.
PA	(LICE-) LICENTIA LTD.
PI	Aitakainen M, Saarna M, Poterjiev D, Landahl M, Timmusk T;
PI	Rossel J;
XX	
DR	WPI; 2001-596722/67.
PT	
PT	New nucleic acid sequence for manufacturing polypeptides for treating
PT	endocrine cancers comprises a cDNA encoding a splicing isoform of
PS	mammalian growth factor receptor (GFR) alpha4.
XX	
PS	Disclosure; Page 127; 143pp; English.
XX	
CC	The present invention describes an isolated and purified cDNA sequence
CC	encoding a splicing isoform of a mammalian growth factor receptor
CC	(GFR) alpha4, or its fragments. GFRalpha4 sequences have cytostatic,
CC	osteopetrotic, neuroprotective and anticonvulsant activities. GFRalpha4 is
CC	a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived
CC	neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4
CC	polynucleotide sequence can be used for recording GFRalpha4 mediated
CC	signalling in neurons or endocrine cells such as thyroid calcitonin-
CC	producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
CC	cells from the pituitary intermediate lobe. GFRalpha4 protein and
CC	polynucleotide sequences can be are used for manufacturing polypeptides
CC	useful for diagnosing and/or treating tumours in parathyroid gland cells,
CC	adrenal chromaffin cells, cells of pituitary intermediate lobe,
CC	neoplasia, endocrine tumours, medullary thyroid carcinoma and
CC	pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
CC	preventing neuronal death or aberrant axonal sprouting. The present
CC	sequence represents the mouse putative transmembrane anchor sequence,
CC	which can be used in the identification and isolation of nucleotide
CC	

CC sequences encoding GFRalpha4 proteins in the present invention
 XX
 SQ Sequence 49 AA;
 Query Match 100.0%; Score 19; DB 4; Length 49;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 ACGV 4
 21 ACGV 24
 Db
 RESULT 124
 ID ADN11831 standard; peptide; 49 AA.
 AC ADN11831;
 XX
 XX 17-JUN-2004 (first entry)
 DT
 XX Fibronection fragment.
 DE
 XX mannose-6-phosphate/insulin-like growth factor-2 receptor; CD222;
 KM fibrinolysis; cell adhesion; cell migration;
 KM transforming growth factor beta; TGFb; activation; apoptosis;
 KM arteriosclerosis; restenosis; autoimmunity; inflammation; cancer;
 KM streptokinase; plasminogen activation; vasotropic; cytostatic;
 KM immunosuppressive; antiinflammatory.
 XX
 OS Undefined.
 XX
 PN WO2004013177-A1.
 XX
 PD 12-FEB-2004.
 XX
 PF 05-AUG-2003; 2003WO-AT000224.
 XX
 PR 06-AUG-2002; 2002AT-00001193.
 XX
 PA (STOC/) STOCKINGER H.
 PI Stockinger H, Binder B, Lekea V, Godar S, Breuss J;
 XX
 XX WPI; 2004-157103/15.
 DR
 XX
 PT Use of mannose-6-phosphate/insulin-like growth factor-2 receptor (CD222)
 PT as regulator of urokinase plasminogen activator functions, useful for
 PT treating arteriosclerosis, restenosis, autoimmunity, inflammation and
 PT cancer.
 PS
 PS Disclosure, Fig 4; 35pp; German.
 XX
 XX This invention describes a novel mannose-6-phosphate/insulin-like growth
 CC factor-2 receptor (CD222) and its fragments or derivatives, as regulator
 CC of fibrinolysis, cell adhesion or migration, transforming growth factor
 CC beta (TGFb) activation and apoptosis, specifically arteriosclerosis,
 CC restenosis, autoimmunity, inflammation and cancer. The N-terminal region
 CC of CD222 (which is similar to streptokinase) is the active component, and
 CC can be used in the form of a peptide or other derivative. CD222 regulates
 CC plasminogen activation, cell adhesion and migration. TGFb activation and
 CC apoptosis mediated through the urokinase-type plasminogen activator (uPA)
 CC receptor (CD87). The products of the invention have antiarteriosclerotic,
 CC vasotropic, cytostatic, immunosuppressive and antiinflammatory activity.
 CC
 XX
 SQ Sequence 49 AA;
 Query Match 100.0%; Score 19; DB 8; Length 49;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 ACGV 4
 1111

Db 39 ACGV 42
 RESULT 125
 AB054048
 ID AB054048 standard; protein; 49 AA.
 XX
 AC AB054048;
 XX
 XX 29-JUL-2004 (first entry)
 DT
 XX Human genome derived single exon protein #282.
 DE
 XX Human; gene expression; single exon probe; microarray;
 KM alternative splicing event; genomic alteration.
 KM
 XX Homo sapiens.
 OS
 XX US2003194704-A1.
 PN
 XX 16-OCT-2003.
 PD
 XX 03-APR-2002; 2002US-00029386.
 PF
 XX 03-APR-2002; 2002US-00029386.
 PR
 XX (PENN/) PENN S G.
 PA (RANK/) RANK D R.
 PA (HANZ/) HANZEL D K.
 XX
 PI Penn SG, Rank DR, Hanzel DK;
 XX
 XX WPI; 2004-119264/12.
 DR
 XX
 PT New human genome-derived single exon nucleic acid probes useful for human
 PT gene expression analysis, for identifying or characterizing alternative
 PT splicing events, for assessing genomic alterations or as tools for
 PT surveying tissues.
 PT
 PS Claim 45; SEQ ID NO 27682; 80pp; English.
 XX
 XX The invention relates to a nucleic acid probe for measuring human gene
 CC expression, comprising any of the 27,400 fully defined nucleotide
 CC sequences in the specification, or their complements or fragments, and
 CC encoding at least 8 amino acids of any of the 6888 amino acid sequences
 CC fully defined in the specification. The probe is a single exon probe that
 CC hybridises under high stringency conditions to a nucleic acid molecule
 CC expressed in human cells or tissues. Also included are a spatially-
 CC addressable set of single exon nucleic acid probes for measuring human
 CC gene expression (comprising a plurality of single exon nucleic acid
 CC probes cited above, where each of the plurality of probes is separately
 CC and addressably isolatable or amplifiable from the plurality), a single
 CC exon microarray for measuring human gene expression, a method of
 CC measuring human gene expression, a vector comprising the single exon
 CC probe cited above, an ORF-encoded peptide comprising at least 8
 CC contiguous amino acids of any of the above-mentioned amino acid
 CC sequences (optionally with conservative amino acid substitutions), an
 CC isolated antibody that binds specifically to a peptide cited above,
 CC methods of selling and/or licensing single exon probes or microarrays to
 CC a customer desiring to measure gene expression, a method of providing
 CC human gene expression data by subcription, and a computer-readable
 CC storage medium which contains a database having a plurality of records
 CC (each record including data on the expression of a single exon probe
 CC cited above. The probe, methods and apparatus are useful in gene
 CC expression analysis. The probes may be used as tools for surveying
 CC tissues to detect the presence of expressed messages that contain their
 CC specific exon, or in constructing genome-derived single exon microarrays.
 CC In addition, the probes are used in identifying and characterising
 CC alternative splicing events, in detecting and characterising gross
 CC alterations in the genomic locus that includes their exon, in assessing
 CC smaller genomic alterations, in priming the synthesis of nucleic acids,
 CC or in expressing the ORF-encoded peptide. The present sequence is a human
 CC single exon probe protein of the invention. Note: The sequence data for

CC this patent did not form part of the printed specification, but was
 CC obtained in electronic format directly from USPTO at
 CC seqdata.uspto.gov/sequence.html?docID=20030194704

XX Sequence 49 AA;

Query Match 100.0%; Score 19; DB 8; Length 49;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
 ||||
 Db 44 AOGV 47

RESULT 126
 ID AAE18040 standard; protein; 51 AA.

XX AAE18040;
 XX 07-MAY-2002 (first entry)
 XX
 DE Human ion channel, ion-172.

XX Human, ion channel; neurological disorder; psychiatric disorder;
 XX schizophrenia; attention deficit hyperactivity disorder; depression;
 XX proliferation disease; migraine; ischaemia; neurodegenerative disease;
 XX macular degeneration; Alzheimer's disease; congestive heart failure;
 XX glaucoma; Parkinson's disease; cardiovascular disease; arrhythmia;
 XX high blood pressure; xeroderma; metabolic disease; neuroprotective;
 XX obesity; hormonal disorder; polycystic ovarian syndrome; gene therapy;
 XX alopecia; anxiety; stroke; neuroleptic; nootropic; cancer; diabetes.

XX Homo sapiens.

XX Key Location/Qualifiers
 FT Misc-difference 28..29
 FT /note="Encoded by AGCTGAGC of the inverse complementary
 FT strand of SEQ.ID.NO.16 (AAD28740)"

XX WO200192303-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016967.

XX 26-MAY-2000; 2000US-0207119P.

XX 26-MAY-2000; 2000US-0207152P.

XX 26-MAY-2000; 2000US-0207257P.

XX (PHAA) PHARMACIA & UPJOHN CO.

XX Benjamin CW, Roberds SL, Karnovsky AM, Ruble CL, Gotow LF;

XX WPI; 2002-147617/19.

XX N-PSDB; AAD28740.

XX

PS Claim 31; Page 78; 126pp; English.

CC The invention relates to ion channel polypeptides designated as ion-x
 CC (where x is 157-175) and their corresponding nucleic acids. The ion-x
 CC sequences and their modulators are useful for the treatment of human
 CC diseases and conditions such as neurological or psychiatric disorders.
 CC These compounds are useful for treating schizophrenia, attention deficit
 CC hyperactivity disorder, depression, anxiety, stroke, migraine, ischaemia
 CC or neurodegenerative disease (e.g. macular degeneration, Alzheimer's
 CC disease, glaucoma, or Parkinson's disease). The compounds that modulate

CC ion channels can be used for treating of cardiovascular diseases (e.g.
 CC congestive heart failure, arrhythmia, high blood pressure or xeroderma),
 CC metabolic diseases and disorders (e.g. diabetes or obesity), hormonal
 CC disorders (e.g. polycystic ovarian syndrome or alopecia) and
 CC proliferation diseases and cancers. The ion channels are also useful as
 CC targets for discovering ligands or drugs to treat many diverse disorders
 CC and defects. The ion-x sequences and their modulators may also be used in
 CC diagnostic assays for such diseases or conditions. Ion-x nucleic acids
 CC are used in gene therapy. The present amino acid sequence is human ion
 CC channel designated as ion-172

SQ Sequence 51 AA;

Query Match 100.0%; Score 19; DB 5; Length 51;
 Best Local Similarity 100.0%; Pred. No. 2.1e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
 ||||
 Db 39 AOGV 42

RESULT 127
 ID ADN48261 standard; protein; 51 AA.

XX ADN48261;
 XX 01-JUL-2004 (first entry)
 XX

DE Thermococcus kodakarensis KOD1 protein sequence SeqID2139.

XX gene disruption; gene targeting; marker gene; transformation;
 XX homologous recombination; hyperthermostable archaeobacterium; KOD1;
 XX gene structure; gene function; enzyme activity; medicine;
 XX forensic science; food; drug inspection; molecular biology; immunology.

XX Thermococcus kodakarensis.

XX WO2004022736-A1.

XX 18-MAR-2004.

XX 29-AUG-2003; 2003WO-IB003597.

XX 30-AUG-2002; 2002JP-00319011.

XX (NISC-) JAPAN SCI & TECHNOLOGY CORP.

XX Imanaka T, Atomi H;

XX WPI; 2004-257583/24.

XX

PT Method for disrupting targeted gene in genome of organism particularly

PT thermococcal bacterium and with genome chips for analysis, applicable in

PT studying gene structure and functions.

XX

PS Claim 9; SEQ ID NO 2139; 598pp; Japanese.

CC This invention relates to a novel method for targeting disruption of an
 CC arbitrary gene in a genome of an organism which comprises providing the
 CC whole sequential data of the genome of such organism, selecting at least
 CC 1 arbitrary region in the sequence, providing a vector that contains a
 CC sequence homologous with the selected region and a marker gene,
 CC transformation, and homologous recombination. The genome is preferably
 CC the genome of a hyperthermostable archaeobacterium, particularly
 CC Thermococcus kodakarensis KOD1. The method is for targeting the
 CC disruption of a gene in the genome of an organism, which is applicable in
 CC studying gene structure and functions as well as enzyme activities of
 CC encoded proteins and useful in medicine, forensic science, food or drug
 CC inspection, molecular biology and immunology. With this method, the
 CC disruption of a gene at an arbitrary position in a genome can be achieved
 CC efficiently and reliably. The present sequence is that of a protein

CC encoded by the genome of *Thermococcus kodakarensis* which was derived
CC using the method of the invention. Note: The sequence data for this
CC patent did not form part of the printed specification, but was obtained
CC in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 51 AA;

Query Match 100.0%; Score 19; DB 8; Length 51;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGGV 4
|||
Db 2 AGGV 5

RESULT 128
AAM6353
ID AAM86353 standard; protein; 52 AA.
XX
AC AAM86353;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen SEQ ID NO:13946.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytosolic; gene therapy; vaccine; metastasis.
XX
OS Homo sapiens.
XX
PN WC000157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001354.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0215135P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 11-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225477P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 18-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.

PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 06-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236337P.
PR 29-SEP-2000; 2000US-0236357P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241821P.
PR 20-OCT-2000; 2000US-0241822P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.

PR 17-NOV-2000; 2000US-0249211P.
 PR 17-NOV-2000; 2000US-0249212P.
 PR 17-NOV-2000; 2000US-0249213P.
 PR 17-NOV-2000; 2000US-0249214P.
 PR 17-NOV-2000; 2000US-0249215P.
 PR 17-NOV-2000; 2000US-0249216P.
 PR 17-NOV-2000; 2000US-0249217P.
 PR 17-NOV-2000; 2000US-0249218P.
 PR 17-NOV-2000; 2000US-0249219P.
 PR 17-NOV-2000; 2000US-0249220P.
 PR 17-NOV-2000; 2000US-0249221P.
 PR 17-NOV-2000; 2000US-0249222P.
 PR 17-NOV-2000; 2000US-0249223P.
 PR 17-NOV-2000; 2000US-0249224P.
 PR 17-NOV-2000; 2000US-0249225P.
 PR 17-NOV-2000; 2000US-0249226P.
 PR 17-NOV-2000; 2000US-0249227P.
 PR 17-NOV-2000; 2000US-0249228P.
 PR 17-NOV-2000; 2000US-0249229P.
 PR 17-NOV-2000; 2000US-0249230P.
 PR 17-NOV-2000; 2000US-0250160P.
 PR 01-DEC-2000; 2000US-0250391P.
 PR 05-DEC-2000; 2000US-0251030P.
 PR 05-DEC-2000; 2000US-0251988P.
 PR 05-DEC-2000; 2000US-0255719P.
 PR 06-DEC-2000; 2000US-0251479P.
 PR 08-DEC-2000; 2000US-0251856P.
 PR 08-DEC-2000; 2000US-0251858P.
 PR 08-DEC-2000; 2000US-0251859P.
 PR 08-DEC-2000; 2000US-0251989P.
 PR 08-DEC-2000; 2000US-0251990P.
 PR 11-DEC-2000; 2000US-0254097P.
 PR 05-JAN-2001; 2001US-0259678P.
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Rosen CA, Barash SC, Ruben SM;
 XX
 DR WPI; 2001-483426/52.
 DR N-PSDB; AAK59134.
 XX
 PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
 PT useful for preventing, diagnosing and/or treating cancers and metastasis.
 XX
 PS Claim 11; SEQ ID NO 13946; 30717bp + Sequence Listing; English.
 XX
 CC AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)
 CC amino acid sequences given in AAK62170 to AAK61921. (I) have cytostatic
 CC activity, and can be used in gene therapy and vaccine production. (I)
 CC proteins and polynucleotides may be used in the prevention, diagnosis and
 CC treatment of diseases associated with inappropriate (I) expression. For
 CC example, they may be used to treat disorders associated with decreased
 CC expression by rectifying mutations or deletions in a patient's genome
 CC that affect the activity of (I) by expressing inactive proteins or to
 CC supplement the patient's own production of (I). Additionally, (I)
 CC polynucleotides may be used to produce the secreted (I), by inserting the
 CC nucleic acids into a host cell and culturing the cell to express the
 CC protein. (I) proteins and polynucleotides may be used to prevent,
 CC diagnose and treat immune/hematopoietic-related diseases, especially
 CC cancers and cancer metastases of hematopoietic-derived cells. AAK64703
 CC to AAK87694 represent human immune/hematopoietic antigen genomic
 CC sequences from the present invention. AAK54942 to AAK54950 and AAK62169
 CC represent sequences used in the exemplification of the present invention
 XX
 SQ Sequence 52 AA;
 Query Match 100.0%; Score 19; DB 4; Length 52;
 Best Local Similarity 100.0%; Pred. No. 2.2e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AOGV 4
 DB 27 AOGV 30
 RESULT 129
 AAB58486
 ID AAB58486 standard; protein; 53 AA.

XX
 AC AAB58486;
 XX
 DT 14-MAR-2001 (first entry)
 XX
 DE Lung cancer associated polypeptide sequence SEQ ID 824.
 XX
 KM Human, lung cancer associated protein; neuroprotective; cytoskeletal;
 KM cardioactive; immunomodulatory; muscular active; vulnary;
 KM gastrointestinal; nephrotropic; antiinfective; gynecological;
 KM antibacterial; diagnosis; neural disorder; immune disorder; reproductive;
 KM proliferative disorder; wound healing; infectious disease.
 XX
 OS Homo sapiens.
 XX
 PN WO20055180-A2.
 XX
 PD 21-SEP-2000.
 XX
 PF 08-MAR-2000; 2000WO-US005918.
 XX
 PR 12-MAR-1999; 99US-0124270P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (ROSE/) ROSEN C A.
 XX
 PI Ruben SM;
 XX
 DR WPI; 2000-587514/55.
 DR N-PSDB; AAF18362.
 XX
 PT Lung cancer associated gene sequences, referred to as lung cancer
 PT antigens, useful for treatment, prevention, and diagnosis of disorders
 PT such as lung cancer.
 XX
 PS Claim 11; Page 1366; 1425bp; English.
 XX
 CC Polynucleotide sequences AAF17982 - AAF18424 encode human lung cancer
 CC associated proteins represented in AAB58106 - AAB58548. Lung cancer
 CC associated proteins and polynucleotide sequences, their agonists, and
 CC antagonists may have neuroprotective; cytoskeletal; cardioactive;
 CC immunomodulatory; muscular active general; vulnary; gastrointestinal
 CC general; nephrotropic; antiinfective; gynecological; or antibacterial
 CC activity. The invention also includes antibodies specific for the protein
 CC or polynucleotide sequences. The lung cancer associated polynucleotide
 CC sequences may be used for detection of lung cancer, chromosome
 CC identification, as chromosome markers, and for numerous other diagnostic
 CC or research purposes. The proteins may be used to treat disorders such as
 CC neural, immune, muscular, reproductive, gastrointestinal, pulmonary,
 CC cardiovascular, renal, and proliferative disorders. The proteins may also
 CC be used in the treatment of wounds and infectious diseases.
 CC Polynucleotide sequences AAF18425 - AAF18433 and peptide AAB58549 are
 CC used in the course of the invention for the identification and
 CC characterisation of the polynucleotide and protein sequences
 XX
 SQ Sequence 53 AA;
 Query Match 100.0%; Score 19; DB 3; Length 53;
 Best Local Similarity 100.0%; Pred. No. 2.2e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AOGV 4
 DB 39 AOGV 42
 RESULT 130
 AABP00538
 ID AABP00538 standard; protein; 53 AA.
 XX
 AC AABP00538;
 XX
 DT 24-JUN-2002 (first entry)

XX Human ORFX protein sequence SEQ ID NO:1058.
 DE
 XX
 XX Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
 KM hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
 KM degenerative disorder; osteoarthritis; neurodegenerative disorder;
 KM cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
 KM hyperextension; hypothyroidism; cholesterol ester storage disease;
 KM immune deficiency; immune disorder; infectious disease;
 KM autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
 KM myasthenia gravis.
 XX Homo sapiens.
 OS
 XX W0200192523-A2.
 PN
 XX 06-DEC-2001.
 PD
 XX 29-MAY-2001; 2001WO-US010836.
 PF
 XX 30-MAY-2000; 2000US-0206132P.
 PR 29-AUG-2000; 2000US-0228716P.
 XX
 XX (CURA-) CURAGEN CORP.
 PA
 XX Shinkets RA, Leach MD;
 PI WPI; 2002-106308/14.
 DR N-PSDB; ABN16290.
 XX
 XX Novel human polypeptides and polynucleotides useful for diagnosing,
 PT preventing and treating cardiovascular disease, neurodegenerative,
 PT hyperproliferative disorders and autoimmune disorders.
 XX
 PS Disclosure; SEQ ID NO 1058; 1037bp; English.
 XX
 XX The present invention describes substantially purified human proteins
 CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
 CC in the specification). ABN15762 to ABN27252 encode the human ORFX
 CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
 CC treating or preventing a pathology associated with an ORFX-associated
 CC disorder in humans, and in the manufacture of a medicament for treating a
 CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
 CC sequences can be used in gene therapy. ORFX sequences can be used in the
 CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
 CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
 CC osteoarthritis, neurodegenerative disorders, disorders related to organ
 CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
 CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
 CC storage disease, various immune deficiencies and disorders, infectious
 CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
 CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
 CC disease and autoimmune inflammatory eye disease. ORFX proteins are also
 CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
 CC bone degenerative disorders, or periodontal disease, and for gut
 CC protection or regeneration and treatment of lung or liver fibrosis,
 CC reperfusion injury in various tissues and conditions resulting from
 CC systemic cytokine damage. N.B. The sequence data for this patent did not
 CC form part of the printed specification, but was obtained in electronic
 CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
 CC
 XX
 SQ Sequence 53 AA;
 Query Match 100.0%; Score 19; DB 5; Length 53;
 Best Local Similarity 100.0%; Pred. No. 2.2e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AGGV 4
 ||||
 Db 8 AGGV 11
 RESULT 131

AAE24593
 ID AAE24593 standard; protein; 54 AA.
 XX
 AC AAE24593;
 DT 04-OCT-2002 (first entry)
 XX
 DE Fish E93 programmed cell death modulating protein conserved domain.
 XX
 KM Fish; cancer; programmed cell death modulating protein; adenocarcinoma;
 KM cellular apoptosis; leukaemia; acquired immunodeficiency syndrome; AIDS;
 KM neurodegenerative disease; Alzheimer's disease; retinitis pigmentosa;
 KM Parkinson's disease; myelodysplastic syndrome; cerebellar degeneration;
 KM aplastic anaemia; ischaemic injury; myocardial infarction; stroke;
 KM reperfusion injury; toxin-induced disease; genetic immunodeficiency;
 KM vaccine; gene therapy; lymphoma; cytostatic; melanoma; neuroprotective;
 KM myeloma; nootropic; vasotropic; immunostimulant; cerebroprotective;
 KM cardiant; E93 protein.
 XX
 OS Tetraodon nigroviridis.
 XX
 XX W0200234882-A2.
 PN
 XX 02-MAY-2002.
 PD
 XX 29-OCT-2001; 2001WO-US048053.
 PF
 XX 27-OCT-2000; 2000US-0243865P.
 PR
 XX (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.
 PA
 XX Baehrecke EH;
 PI WPI; 2002-479717/51.
 DR
 XX
 XX Novel programmed cell death modulating proteins, useful for treating or
 PT preventing disorders associated with abnormal cell proliferation and
 PT apoptosis such as cancer, stroke, Parkinson's disease, myocardial
 PT infarction.
 XX
 PS Claim 1; Fig 1; 88bp; English.
 XX
 XX The present invention relates to novel programmed cell death modulating
 CC proteins and polynucleotides encoding such proteins. Sequences of the
 CC invention are useful to screen potential cellular apoptosis inhibiting
 CC compounds to determine their use as therapeutic agents for treatment of
 CC diseases associated with increased programmed cell death. They are also
 CC useful for treating or preventing disorders associated with decrease in
 CC apoptosis. Programmed cell death modulating sequences are useful for
 CC treating or preventing cancer e.g. adenocarcinoma, leukemia, lymphoma,
 CC melanoma, myeloma. Inhibition of the activity of the sequences of the
 CC invention are useful for treating disorders associated with increase in
 CC cell death or apoptosis such as acquired immunodeficiency syndrome
 CC (AIDS), neurodegenerative diseases (e.g., Alzheimer's disease, retinitis
 CC pigmentosa, Parkinson's disease and cerebellar degeneration), ischaemic
 CC injuries (e.g., myocardial infarction, stroke, reperfusion injury),
 CC myelodysplastic syndromes (e.g., aplastic anaemia), toxin-induced
 CC diseases and other infectious or genetic immunodeficiencies. Sequences of
 CC the invention are used as vaccines and in gene therapy. The present
 CC sequence is fish E93 programmed cell death modulating protein conserved
 CC domain
 CC
 XX
 SQ Sequence 54 AA;
 Query Match 100.0%; Score 19; DB 5; Length 54;
 Best Local Similarity 100.0%; Pred. No. 2.3e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AGGV 4
 ||||
 Db 36 AGGV 39

RESULT 132
ID ABB03527 standard; protein; 55 AA.
XX ABB03527;
XX
DT 08-JAN-2002 (first entry)
XX
DE Human musculoskeletal system related polypeptide SEQ ID NO 1474.
XX
KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW vulnery; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiac; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein;
KW musculoskeletal system.
XX
OS Homo sapiens.
XX
PN WO20015367-A1.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001338.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 30-JUN-2000; 2000US-0214886P.
PR 07-JUL-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226682P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.

PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236328P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239933P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246529P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246529P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249246P.
PR 17-NOV-2000; 2000US-0249255P.
PR 17-NOV-2000; 2000US-0249257P.

Query Match	100.0%	Score 19	DB 4	Length 55
Best Local Similarity	100.0%	Pred. No. 2.3e+03		
Matches 4	Conservative	0	Mismatches 0	Indels 0
				Gaps 0
1 AAGV 4				
17 AAGV 20				
Sequence 55 AA				
FTP: wipo.int/pub/published_pcc_sequences				
Sequence 55 AA				
17-NOV-2000; 2000US-0249299P.				
17-NOV-2000; 2000US-0249300P.				
PR 01-DEC-2000; 2000US-0250160P.				
PR 01-DEC-2000; 2000US-0250391P.				
PR 05-DEC-2000; 2000US-0251030P.				
PR 05-DEC-2000; 2000US-0251988P.				
PR 05-DEC-2000; 2000US-0256719P.				
PR 06-DEC-2000; 2000US-0251479P.				
PR 08-DEC-2000; 2000US-0251856P.				
PR 08-DEC-2000; 2000US-0251868P.				
PR 08-DEC-2000; 2000US-0251869P.				
PR 08-DEC-2000; 2000US-0251989P.				
PR 08-DEC-2000; 2000US-0251990P.				
PR 11-DEC-2000; 2000US-0254097P.				
PR 05-JAN-2001; 2001US-0259678P.				
(HUMA-) HUMAN GENOME SCI INC.				
Rosen CA, Barash SC, Ruben SM;				
WPI; 2001-451937/48.				
N-PSDB; AAL35109.				
Isolated polypeptide for treating, preventing and/or prognosing				
PT disorders related to the musculoskeletal system including musculoskeletal				
PT cancers and also for testing and detection e.g. diagnosis.				
Claim 11; SEQ ID NO 1474; 781bp + Sequence Listing; English.				
The invention relates to novel genes (AAL34669-AAL37666) and proteins				
(AAB03087-AB04109) associated with the musculoskeletal system useful for				
preventing, treating or ameliorating medical conditions e.g. by protein				
or gene therapy. The genes are isolated from a range of human tissues				
disclosed in the specification. The nucleic acids, proteins, antibodies				
and (ant)agonists are useful in the diagnosis, treatment and prevention				
of: (a) cancer, e.g. breast and ovarian cancer and other cancers of the				
adrenal gland, bone, bone marrow, breast, gastrointestinal tract, liver,				
lung, or urogenital; (b) immune disorders e.g. Addison's disease,				
allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis,				
diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid				
arthritis and ulcerative colitis; (c) cardiovascular disorders such as				
myocardial ischaemia; (d) wound healing; (e) neurological diseases e.g.				
cerebral anoxia and epilepsy; and (f) infectious diseases such as viral,				
bacterial, fungal and parasitic infections. Note: The sequence data for				
this patent did not form part of the printed specification, but was				
obtained in electronic format directly from WIPO at				
ftp.wipo.int/pub/published_pcc_sequences				
Sequence 55 AA				
100.0%				
Score 19				
DB 4				
Length 55				
Pred. No. 2.3e+03				
Mismatches 0				
Indels 0				
Gaps 0				
1 AAGV 4				
17 AAGV 20				
Sequence 55 AA				
FTP: wipo.int/pub/published_pcc_sequences				
Sequence 55 AA				
17-NOV-2000; 2000US-0249299P.				
17-NOV-2000; 2000US-0249300P.				
PR 01-DEC-2000; 2000US-0250160P.				
PR 01-DEC-2000; 2000US-0250391P.				
PR 05-DEC-2000; 2000US-0251030P.				
PR 05-DEC-2000; 2000US-0251988P.				
PR 05-DEC-2000; 2000US-0256719P.				
PR 06-DEC-2000; 2000US-0251479P.				
PR 08-DEC-2000; 2000US-0251856P.				
PR 08-DEC-2000; 2000US-0251868P.				
PR 08-DEC-2000; 2000US-0251869P.				
PR 08-DEC-2000; 2000US-0251989P.				
PR 08-DEC-2000; 2000US-0251990P.				
PR 11-DEC-2000; 2000US-0254097P.				
PR 05-JAN-2001; 2001US-0259678P.				
(HUMA-) HUMAN GENOME SCI INC.				
Rosen CA, Barash SC, Ruben SM;				
W				

KW	Alzheimer's disease; Parkinson's disease; AIDS-related complex;
KW	endothelial growth; bone regeneration; peridontal regeneration;
KW	endothelial growth; bone graft; skin aging; keratinocyte growth; hair loss;
KW	endothelial growth; cell proliferation; cell growth; organ transplant;
KW	endothelial growth; body height; weight; hair colour; eye colour; skin;
KW	percentage of adipose tissue; pigmentation; cosmetic surgery; metabolism;
KW	biocytin; cardiac rhythm; depression; tendency for violence; pain;
KW	reproductive capability; hormone level; endocrine level; appetite;
KW	lipid; memory; stress; storage capability; fat content; lipid content;
KW	protein content; carbohydrate content; vitamin content; cofactor content;
KW	nutritional component.
OS	Homo sapiens.
XX	
XX	US2002147140-A1.
XX	
PD	10-OCT-2002.
XX	
PF	17-JAN-2001; 2001US-00764877.
XX	
PR	31-JAN-2000; 2000US-0179065P.
PR	04-FEB-2000; 2000US-0180628P.
PR	28-JUN-2000; 2000US-0214886P.
PR	07-JUL-2000; 2000US-0216647P.
PR	07-JUL-2000; 2000US-0216880P.
PR	11-JUL-2000; 2000US-0217487P.
PR	11-JUL-2000; 2000US-0217496P.
PR	14-JUL-2000; 2000US-0218290P.
PR	26-JUL-2000; 2000US-0220963P.
PR	26-JUL-2000; 2000US-0220964P.
PR	14-AUG-2000; 2000US-0224518P.
PR	14-AUG-2000; 2000US-0224519P.
PR	14-AUG-2000; 2000US-0225267P.
PR	14-AUG-2000; 2000US-0225268P.
PR	14-AUG-2000; 2000US-0225270P.
PR	14-AUG-2000; 2000US-0225447P.
PR	14-AUG-2000; 2000US-0225757P.
PR	14-AUG-2000; 2000US-0225758P.
PR	22-AUG-2000; 2000US-0226688P.
PR	30-AUG-2000; 2000US-0228924P.
PR	01-SEP-2000; 2000US-0229287P.
PR	01-SEP-2000; 2000US-0229343P.
PR	01-SEP-2000; 2000US-0229344P.
PR	05-SEP-2000; 2000US-0229509P.
PR	05-SEP-2000; 2000US-0229513P.
PR	08-SEP-2000; 2000US-0231413P.
PR	21-SEP-2000; 2000US-0234423P.
PR	21-SEP-2000; 2000US-0234474P.
PR	25-SEP-2000; 2000US-0234997P.
PR	27-SEP-2000; 2000US-0235834P.
PR	29-SEP-2000; 2000US-0236327P.
PR	29-SEP-2000; 2000US-0236367P.
PR	29-SEP-2000; 2000US-0236368P.
PR	29-SEP-2000; 2000US-0236370P.
PR	02-OCT-2000; 2000US-0236802P.
PR	02-OCT-2000; 2000US-0237037P.
PR	02-OCT-2000; 2000US-0237038P.
PR	02-OCT-2000; 2000US-0237039P.
PR	02-OCT-2000; 2000US-0237040P.
PR	13-OCT-2000; 2000US-0239935P.
PR	20-OCT-2000; 2000US-0240960P.
PR	20-OCT-2000; 2000US-0241785P.
PR	20-OCT-2000; 2000US-0241809P.
PR	01-NOV-2000; 2000US-0244617P.
PR	17-NOV-2000; 2000US-0249299P.
PR	08-DEC-2000; 2000US-0251856P.
PR	08-DEC-2000; 2000US-0251868P.
PR	08-DEC-2000; 2000US-0251869P.
XX	
PA	(ROSE/) ROSEN C A.
PA	(RUBE/) RUBEN S M.

PA (BARA/) BARASH S C.
 XX Rosen CA, Ruben SM, Barash SC;
 XX WPI: 2003-128199/12.
 DR N-PSDB; ABX58097.
 XX
 PT Isolated nucleic acid molecules encoding musculoskeletal system
 associated polypeptides, useful for detecting disorders, e.g. cancer.
 XX
 PS Claim 11; SEQ ID NO 1474; 321pp; English.
 XX
 CC The invention describes an isolated nucleic acid molecule comprising a
 sequence encoding musculoskeletal system associated polypeptides useful
 for detecting disorders, e.g., cancer or cancer metastases, in animals or
 humans. The nucleic acid: stimulates re-vascularization of ischemic
 tissues associated with conditions such as thrombosis, arteriosclerosis,
 CC and other cardiovascular conditions; treats wounds due to injuries,
 burns, post-operative tissue repair, and ulcers; stimulates angiogenesis
 and limb regeneration; stimulates neuronal growth; can treat and prevent
 neuronal damage occurring in certain disorders or neurodegenerative
 CC conditions, such as, Alzheimer's disease, Parkinson's disease, and AIDS-
 related complex; stimulates chondrocyte growth, thus they can be used to
 CC enhance bone and periodontal regeneration and aid in tissue transports or
 CC bone grafts; prevents skin aging due to sunburn by stimulating
 CC keratinocyte growth; prevents hair loss, since FGF family members
 CC activate hair-forming cells and promotes melanocyte growth; stimulates
 CC growth and differentiation of hematopoietic cells and bone marrow cells
 CC when used in combination with other cytokines; maintains organs before
 CC transplantation or for supporting cell culture of primary tissues;
 CC induces tissue of mesodermal origin to differentiate in early embryos;
 CC increases or decreases the differentiation or proliferation of embryonic
 CC stem cells, besides, hematopoietic lineage; modulates mammalian
 CC characteristics, such as, body height, weight, hair colour, eye colour,
 CC skin, percentage of adipose tissue, pigmentation, size, and shape (e.g.,
 CC cosmetic surgery); modulates mammalian metabolism; changes mammal's metal
 CC state or physical state by influencing biohythms, cardiac rhythms,
 CC depression, tendency for violence, tolerance for pain, reproductive
 CC capabilities, hormonal or endocrine levels, appetite, libido, memory, or
 CC stress; increases or decreases storage capabilities, fat content, lipid,
 CC protein, carbohydrate, vitamins, minerals, cofactors or other nutritional
 CC components. This is the amino acid sequence of a novel human
 CC musculoskeletal system antigen. Note: The sequence data for this patent
 CC did not form part of the printed specification, but was obtained in
 CC electronic format directly from the US patent office at
 CC ftp.segdata.uspto.gov/sequence.html?DocID=20020147140
 XX
 CC
 SQ Sequence 55 AA;
 Query Match 100.0%; Score 19; DB 6; Length 55;
 Best Local Similarity 100.0%; Pred. No. 2.3e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AGGV 4
 ||||
 Db 17 AGGV 20

RESULT 134
 ADJ28847
 ID ADJ28847 standard; protein; 55 AA.
 XX
 AC ADJ28847;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human musculoskeletal system-associated protein - SEQ ID 1474.
 XX
 KM musculoskeletal system; cytoskeletal; osteopathic; cancer; osteoporosis;
 KM gene therapy; vaccine; human.
 XX
 OS Homo sapiens.
 XX

PN US2004009488-A1.
 XX
 PD 15-JAN-2004.
 XX
 PF 13-SEP-2002; 2002US-00242515.
 XX
 PP 31-JAN-2000; 2000US-0179065P.
 PR 04-FEB-2000; 2000US-0180628P.
 PR 24-FEB-2000; 2000US-0184664P.
 PR 02-MAR-2000; 2000US-0186350P.
 PR 16-MAR-2000; 2000US-0189874P.
 PR 17-MAR-2000; 2000US-0190076P.
 PR 18-APR-2000; 2000US-0198123P.
 PR 19-MAY-2000; 2000US-0205515P.
 PR 07-JUN-2000; 2000US-0209467P.
 PR 28-JUN-2000; 2000US-0214886P.
 PR 30-JUN-2000; 2000US-0215135P.
 PR 07-JUL-2000; 2000US-0216647P.
 PR 07-JUL-2000; 2000US-0216880P.
 PR 11-JUL-2000; 2000US-0217487P.
 PR 11-JUL-2000; 2000US-0217496P.
 PR 14-JUL-2000; 2000US-0218290P.
 PR 26-JUL-2000; 2000US-0220963P.
 PR 26-JUL-2000; 2000US-0220964P.
 PR 14-AUG-2000; 2000US-0224518P.
 PR 14-AUG-2000; 2000US-0224519P.
 PR 14-AUG-2000; 2000US-0225213P.
 PR 14-AUG-2000; 2000US-0225214P.
 PR 14-AUG-2000; 2000US-0225266P.
 PR 14-AUG-2000; 2000US-0225267P.
 PR 14-AUG-2000; 2000US-0225268P.
 PR 14-AUG-2000; 2000US-0225270P.
 PR 14-AUG-2000; 2000US-0225447P.
 PR 14-AUG-2000; 2000US-0225757P.
 PR 14-AUG-2000; 2000US-0225758P.
 PR 14-AUG-2000; 2000US-0225759P.
 PR 18-AUG-2000; 2000US-0226279P.
 PR 22-AUG-2000; 2000US-0226681P.
 PR 22-AUG-2000; 2000US-0226868P.
 PR 22-AUG-2000; 2000US-0227182P.
 PR 23-AUG-2000; 2000US-0227009P.
 PR 30-AUG-2000; 2000US-0228924P.
 PR 01-SEP-2000; 2000US-0229287P.
 PR 01-SEP-2000; 2000US-0229343P.
 PR 01-SEP-2000; 2000US-0229344P.
 PR 01-SEP-2000; 2000US-0229345P.
 PR 05-SEP-2000; 2000US-0229509P.
 PR 05-SEP-2000; 2000US-0229513P.
 PR 06-SEP-2000; 2000US-0230437P.
 PR 06-SEP-2000; 2000US-0230438P.
 PR 08-SEP-2000; 2000US-0231242P.
 PR 08-SEP-2000; 2000US-0231243P.
 PR 08-SEP-2000; 2000US-0231244P.
 PR 08-SEP-2000; 2000US-0231413P.
 PR 08-SEP-2000; 2000US-0231414P.
 PR 08-SEP-2000; 2000US-0232080P.
 PR 08-SEP-2000; 2000US-0232081P.
 PR 12-SEP-2000; 2000US-0231968P.
 PR 14-SEP-2000; 2000US-0232397P.
 PR 14-SEP-2000; 2000US-0232388P.
 PR 14-SEP-2000; 2000US-0232397P.
 PR 14-SEP-2000; 2000US-0232399P.
 PR 14-SEP-2000; 2000US-0232400P.
 PR 14-SEP-2000; 2000US-0232401P.
 PR 14-SEP-2000; 2000US-0233063P.
 PR 14-SEP-2000; 2000US-0233064P.
 PR 14-SEP-2000; 2000US-0233065P.
 PR 21-SEP-2000; 2000US-0234223P.
 PR 21-SEP-2000; 2000US-0234274P.
 PR 25-SEP-2000; 2000US-0234997P.
 PR 25-SEP-2000; 2000US-0234998P.
 PR 26-SEP-2000; 2000US-0235484P.
 PR 27-SEP-2000; 2000US-0235834P.
 PR 27-SEP-2000; 2000US-0235836P.

PR	29-SEP-2000	2000US-0236327
PR	29-SEP-2000	2000US-0236367
PR	29-SEP-2000	2000US-0236368P
PR	29-SEP-2000	2000US-0236369P
PR	29-SEP-2000	2000US-0236370P
PR	02-OCT-2000	2000US-0236802P
PR	02-OCT-2000	2000US-0237037P
PR	02-OCT-2000	2000US-0237038P
PR	02-OCT-2000	2000US-0237039P
PR	02-OCT-2000	2000US-0237040P
PR	13-OCT-2000	2000US-0239935P
PR	13-OCT-2000	2000US-0239937P
PR	20-OCT-2000	2000US-0241187P
PR	20-OCT-2000	2000US-0241608P
PR	20-OCT-2000	2000US-0241609P
PR	20-OCT-2000	2000US-0241866P
PR	01-NOV-2000	2000US-0244617P
PR	01-NOV-2000	2000US-0246474P
PR	08-NOV-2000	2000US-0246475P
PR	08-NOV-2000	2000US-0246476P
PR	08-NOV-2000	2000US-0246477P
PR	08-NOV-2000	2000US-0246478P
PR	08-NOV-2000	2000US-0246533P
PR	08-NOV-2000	2000US-0246534P
PR	08-NOV-2000	2000US-0246552P
PR	08-NOV-2000	2000US-0246557P
PR	08-NOV-2000	2000US-0246528P
PR	08-NOV-2000	2000US-0246532P
PR	08-NOV-2000	2000US-0246609P
PR	08-NOV-2000	2000US-0246610P
PR	08-NOV-2000	2000US-0246611P
PR	08-NOV-2000	2000US-0246613P
PR	17-NOV-2000	2000US-0249207P
PR	17-NOV-2000	2000US-0249208P
PR	17-NOV-2000	2000US-0249209P
PR	17-NOV-2000	2000US-0249210P
PR	17-NOV-2000	2000US-0249211P
PR	17-NOV-2000	2000US-0249212P
PR	17-NOV-2000	2000US-0249213P
PR	17-NOV-2000	2000US-0249214P
PR	17-NOV-2000	2000US-0249215P
PR	17-NOV-2000	2000US-0249216P
PR	17-NOV-2000	2000US-0249217P
PR	17-NOV-2000	2000US-0249218P
PR	17-NOV-2000	2000US-0249244P
PR	17-NOV-2000	2000US-0249245P
PR	17-NOV-2000	2000US-0249264P
PR	17-NOV-2000	2000US-0249265P
PR	17-NOV-2000	2000US-0249287P
PR	17-NOV-2000	2000US-0249289P
PR	17-NOV-2000	2000US-0249300P
PR	01-DEC-2000	2000US-0250316P
PR	01-DEC-2000	2000US-0250319P
PR	05-DEC-2000	2000US-0251030P
PR	05-DEC-2000	2000US-0251198P
PR	05-DEC-2000	2000US-0256171P
PR	06-DEC-2000	2000US-0251479P
PR	06-DEC-2000	2000US-0251856P
PR	08-DEC-2000	2000US-0251868P
PR	08-DEC-2000	2000US-0251869P
PR	08-DEC-2000	2000US-0251969P
PR	08-DEC-2000	2000US-0251957P
PR	11-DEC-2000	2000US-0254093P
PR	05-JAN-2001	2001US-0256478P
PR	17-JAN-2001	2001US-00764877
XX		
XX		
XX	(HUMA-) HUMAN GENOME SCI INC.	

PI	Rosen CA, Ruben SM, Barash SC;
XX	
DR	WPI; 2004-090458/09.
XX	N-PSDB; ADJ27824.
XX	
PT	New nucleic acid molecule, useful for preparing a medicament for preventing, treating or ameliorating a medical condition e.g., cancer of musculoskeletal tissues or osteoporosis.
XX	
PS	Claim 11; SEQ ID NO 1474; 289PP; English.
XX	
CC	The invention relates to a novel isolated musculoskeletal system-associated nucleic acid molecule. The nucleic acid of the invention demonstrates cytostatic and osteopathic activities and may be useful for preparing a medicament for preventing, treating or ameliorating a medical condition such as cancer of the musculoskeletal tissues or osteoporosis, possibly via gene therapy or vaccine production. The current sequence is that of the human musculoskeletal system-associated polypeptide of the invention. The current sequence is not shown within the specification per se but is available on the USPTO web-site
CC	http://seqdata.uspto.gov/Sequence.html?DocID=20040009488.
XX	
SQ	Sequence 55 AA;
	Query Match 100.0%; Score 19; DB 8; Length 55;
	Best Local Similarity 100.0%; Pred. No. 2.3e+03; Mismatches 0; Gaps 0
	Matches 4; Conservative 0; Indels 0; Gaps 0
OY	1 AAGV 4
Db	17 AAGV 20
	RESULT 135
	AA#41885
ID	AA#41885 standard; peptide; 56 AA.
XX	
AC	AA#41885;
XX	
DT	25-MAR-2003 (revised)
DT	22-APR-1994 (first entry)
XX	
DE	Granulin E.
XX	
KM	Granulin; keratinocytes; wound healing; inhibition; peptide; granulocytes; leucocytes.
XX	
OS	Homo sapiens.
XX	
PN	WO9315195-A1.
XX	
PD	05-AUG-1993.
XX	
PF	28-FEB-1992; 92WO-CA000089.
XX	
PR	03-FEB-1992; 92US-00829233.
XX	
PA	(SOLO/) SOLOMON S.
XX	
PI	Solomon S;
XX	
DR	WPI; 1993-320328/40.
XX	
PT	New cysteine rich granulin peptide(s) from leucocyte(s) - are keratinocyte inhibitors useful topically for wound healing.
XX	
PS	Claim 8; Page 33; 53PP; English.
CC	The granulin inhibits keratinocytes and is useful in formulations for promoting the healing of wounds. This peptide was designated granulin E. (Updated on 25-MAR-2003 to correct PN field.)
XX	
SQ	Sequence 56 AA;

Query Match 100.0%; Score 19; DB 2; Length 56;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
DB 30 AOGV 33

RESULT 136
AAB50390
ID AAB50390 standard; protein; 56 AA.

AC AAB50390;
XX
DT 12-MAR-2001 (first entry)
XX
DE Human uncoupling protein #13.

XX Human; uncoupling protein; immunosuppressive; antiarthritic;
XX antirheumatic; antiproliferative; cardiac; vasotropic;
XX cerebroprotective; neuroprotective; antibacterial; optalmological;
XX gastrointestinal; nephrotropic; gynaecological; vulnary; thrombolytic;
XX gene therapy; cancer; wound; infectious disease; thrombosis; arthritis;
XX infertility.

XX Homo sapiens.
OS
PN WO200061614-A2.
XX
PD 19-OCT-2000.
XX
PP 06-APR-2000; 2000WO-US009534.
XX
PR 09-APR-1999; 99US-0128701P.
PR 08-JUN-1999; 99US-0142821P.
PR 18-AUG-1999; 99US-0149448P.
PR 12-NOV-1999; 99US-0164751P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Ni J, Komatsoulis G, Rosen CA, Soppet DR;
XX
DR WPI; 2000-656322/63.
DR N-PSDB; AAC90464.
XX
PT Uncoupling proteins and nucleic acid sequences encoding them, useful for
PT detecting, preventing and creating proliferative, neurological, immune
PT system, cardiovascular and gastrointestinal disorders.
XX
PS Claim 11; Page 330; 343pp; English.
XX
CC The present sequence is a human uncoupling protein. The nucleotide
CC sequences encoding the uncoupling proteins may be used for the detection
CC of various disorders such as cancer, for chromosome identification, as
CC chromosome markers and for numerous other diagnostic or research
CC purposes. The uncoupling protein encoded by the nucleotide sequences may
CC be used to treat disorders such as neural, immune, muscular, renal and
CC reproductive, gastrointestinal, pulmonary, cardiovascular, renal and
CC proliferative disorders, wounds, infectious diseases, thrombosis,
CC arthritis, and infertility
CC
XX Sequence 56 AA;
XX

Query Match 100.0%; Score 19; DB 3; Length 56;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
DB 39 AOGV 42

RESULT 137
ABB40247
ID ABB40247 standard; peptide; 56 AA.

XX
AC ABB40247;
XX
DT 04-FEB-2002 (first entry)
XX
DE Peptide #7753 encoded by human foetal liver single exon probe.
XX
XX Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS Homo sapiens.
XX
PN WO200157277-A2.
XX
PD 09-AUG-2001.
XX
PP 30-JAN-2001; 2001WO-US000669.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483447/52.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human fetal liver.
XX
PS Claim 27; SEQ ID NO 32882; 639pp + Sequence Listing; English.
XX
CC The invention relates to a single exon nucleic acid probe for measuring
CC human gene expression in a sample derived from human foetal liver. The
CC single exon nucleic acid probes may be used for predicting, measuring and
CC displaying gene expression in samples derived from human fetal liver. The
CC present sequence is a peptide encoded by a single exon nucleic acid probe
CC of the invention. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 56 AA;
XX

Query Match 100.0%; Score 19; DB 4; Length 56;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
DB 6 AOGV 9

RESULT 138
AAM33926
ID AAM33926 standard; protein; 56 AA.

XX
AC AAM33926;
XX
DT 17-OCT-2001 (first entry)
XX
DE Peptide #7963 encoded by probe for measuring placental gene expression.
XX
XX Probe; microarray; human; placenta; antenatal diagnosis;
XX genetic disorder.
XX

```

OS Homo sapiens.
XX
XX MO200157272-A2.
XX
XX 09-AUG-2001.
XX
XX PF 30-JAN-2001, 2001WO-US000663.
XX
XX PR 04-FEB-2000, 2000US-0180312P.
XX PR 26-MAY-2000, 2000US-0207456P.
XX PR 30-JUN-2000, 2000US-00608408.
XX PR 03-AUG-2000, 2000US-00632366.
XX PR 21-SEP-2000, 2000US-0234687P.
XX PR 27-SEP-2000, 2000US-0236359P.
XX PR 04-OCT-2000, 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX PA Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-488897/53.
XX
XX DR Human genome-derived single exon nucleic acid probes useful for analyzing
XX PT gene expression in human placenta.
XX
XX PS Claim 27; SEQ ID NO 34195; 654bp; English.
XX
XX The present invention relates to single exon nucleic acid probes (SENP:
XX see A113115-A157546). The present sequence is a peptide encoded by one
XX such probe. The probes are useful for producing a microarray for
XX predicting, measuring and displaying gene expression in samples derived
XX from human placenta. The probes are useful for antenatal diagnosis of
XX human genetic disorders
XX
XX SQ Sequence 56 AA;
XX
XX Query Match 100.0%; Score 19; DB 4; Length 56;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+03;
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 AOGV 4
XX ||||
XX 6 AOGV 9
XX
XX DB
XX
XX RESULT 139
XX ID AAM73737 standard; protein; 56 AA.
XX
XX AAM73737;
XX
XX 06-NOV-2001 (first entry)
XX
XX Human bone marrow expressed probe encoded protein SEQ ID NO: 34043.
XX
XX Human; bone marrow expressed exon; gene expression analysis; probe;
XX microarray; cancer; leukemia; lymphoma; myeloma.
XX
XX Homo sapiens.
XX
XX WO200157276-A2.
XX
XX PN
XX
XX 09-AUG-2001.
XX
XX PF 30-JAN-2001, 2001WO-US000668.
XX
XX PR 04-FEB-2000, 2000US-0180312P.
XX PR 26-MAY-2000, 2000US-0207456P.
XX PR 30-JUN-2000, 2000US-00608408.
XX PR 03-AUG-2000, 2000US-00632366.
XX PR 21-SEP-2000, 2000US-0234687P.
XX PR 27-SEP-2000, 2000US-0236359P.
XX PR 04-OCT-2000, 2000GB-00024263.
XX

```

XX	PA	(MOLE-) MOLECULAR DYNAMICS INC.
XX	PI	Penn SG, Hanzel DK, Chen W, Rank DR;
XX	DR	WPI; 2001-486900/53.
XX	PT	Human genome-derived single exon nucleic acid probes useful for analyzing
XX	PS	gene expression in human bone marrow.
XX	XX	Example 4; SEQ ID NO 34043; 658bp + Sequence Listing; English.
CC	CC	The present invention provides a number of single exon nucleic acid
CC	CC	probes which are derived from genomic sequences expressed in the human
CC	CC	bone marrow. They can be used to measure gene expression in bone marrow
CC	CC	samples, which may enable the improved diagnosis and treatment of cancers
CC	CC	such as lymphoma, leukaemia and myeloma. The present sequence is a
CC	CC	protein encoded by one of the probes of the invention
XX	XX	
XX	XX	Sequence 56 AA;
XX	XX	
XX	XX	Query Match 100.0%; Score 19; DB 4; Length 56;
XX	XX	Best Local Similarity 100.0%; Pred. No. 2,3e+03;
XX	XX	Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX	XX	
XX	XX	1 AAGV 4
XX	XX	
XX	XX	6 AAGV 9
XX	XX	
XX	XX	RESULT 140
XX	XX	AAM61034
XX	XX	ID AAM61034 standard; protein; 56 AA.
XX	XX	AC AAM61034;
XX	XX	DT 05-NOV-2001 (first entry)
XX	XX	
XX	XX	Human brain expressed single exon probe encoded protein SEQ ID NO: 33139.
XX	XX	
XX	XX	Human; brain expressed exon; gene expression analysis; probe; microarray;
XX	XX	Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer.
XX	XX	
XX	XX	Homo sapiens.
XX	XX	
XX	XX	WO200157275-A2.
XX	XX	
XX	XX	09-AUG-2001.
XX	XX	
XX	XX	30-JAN-2001; 2001WO-US000667.
XX	XX	
XX	XX	04-FEB-2000; 2000US-0180312P.
XX	XX	26-MAY-2000; 2000US-0207456P.
XX	XX	30-JUN-2000; 2000US-00608408.
XX	XX	PR 03-AUG-2000; 2000US-00632366.
XX	XX	PR 21-SEP-2000; 2000US-0234687P.
XX	XX	PR 27-SEP-2000; 2000US-0236359P.
XX	XX	PR 04-OCT-2000; 2000GB-00024263.
XX	XX	
XX	XX	(MOLE-) MOLECULAR DYNAMICS INC.
XX	XX	
XX	XX	Penn SG, Hanzel DK, Chen W, Rank DR;
XX	XX	WPI; 2001-483446/52.
XX	XX	
XX	XX	Single exon nucleic acid probes for analyzing gene expression in human
XX	XX	brains.
XX	XX	
XX	XX	Example 4; SEQ ID NO 33139; 650pp + Sequence Listing; English.
XX	XX	
XX	XX	The present invention provides a number of single exon nucleic acid
XX	XX	probes which are derived from genomic sequences expressed in the human
XX	XX	brain. They can be used to measure gene expression in brain cell samples,
XX	XX	

CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is a protein encoded by one of
CC the probes of the invention

XX Sequence 56 AA;

Query Match 100.0%; Score 19; DB 4; Length 56;
Best Local Similarity 100.0%; Pred. No. 2.3e+03; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0;

Qy 1 AAGV 4
|||
6 AAGV 9

RESULT 141
ABG55482
ID ABG55482 standard; peptide; 56 AA.

XX ABG55482;

XX 25-FEB-2003 (first entry)

DE Human liver peptide, SEQ ID NO 34130.

XX Human, liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW hypercholesterolaemia; coronary heart disease.

XX Homo sapiens.

XX WO200157273-A2.

XX 09-AUG-2001.

XX 30-JAN-2001; 2001WO-US000664.

XX 04-FEB-2000; 2000US-0180312P.

XX 26-MAY-2000; 2000US-0207456P.

XX 30-JUN-2000; 2000US-00608408.

XX 03-AUG-2000; 2000US-00632366.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX (MOLE-) MOLECULAR DYNAMICS INC.

XX Penn SG, Hanzel DK, Chen W, Rank DR;

XX WPI; 2001-488898/53.

XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human adult liver.

XX Claim 27; SEQ ID NO 34130; 658bp; English.

XX The invention relates to a single exon nucleic acid probe (SENP) (1) for
XX measuring human gene expression in a sample derived from human adult
XX liver, comprising one of 13109 defined nucleotide sequences given in the
XX specification (or complements/ fragments). The probe hybridises at high
XX stringency to a nucleic acid molecule expressed in the human adult liver.
XX (1) may be used for predicting, measuring and displaying gene expression
XX in samples derived from human adult liver. The genes identified may be
XX involved in genetic liver diseases such as cirrhosis,

XX hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
XX associated with coronary heart disease. ABG47348-ABG59930 represent human
XX liver single exon encoded peptides of the invention. Note: The sequence
XX information for this patent does not appear in the printed specification
XX but was obtained in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 56 AA;

Query Match 100.0%; Score 19; DB 4; Length 56;
Best Local Similarity 100.0%; Pred. No. 2.3e+03; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0;

Qy 1 AAGV 4
|||
6 AAGV 9

RESULT 142
ABG43619
ID ABG43619 standard; peptide; 56 AA.

XX ABG43619;

XX 19-AUG-2002 (first entry)

DE Human peptide encoded by genome-derived single exon probe SEQ ID 33284.

XX Human, single exon probe; asthma; lung cancer; COPD; ILD;

XX chronic obstructive pulmonary disease; interstitial lung disease;

XX familial idiopathic pulmonary fibrosis; neurofibromatosis;

XX tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;

XX Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;

XX pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;

XX primary ciliary dyskinesia; pulmonary hypertension;

XX hyaline membrane disease.

XX Homo sapiens.

XX WO200186003-A2.

XX 15-NOV-2001.

XX 30-JAN-2001; 2001WO-US000665.

XX 04-FEB-2000; 2000US-0180312P.

XX 26-MAY-2000; 2000US-0207456P.

XX 30-JUN-2000; 2000US-00608408.

XX 03-AUG-2000; 2000US-00632366.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX (MOLE-) MOLECULAR DYNAMICS INC.

XX Penn SG, Hanzel DK, Chen W, Rank DR;

XX WPI; 2002-114183/15.

XX Spatially-addressable set of single exon nucleic acid probes, used to
XX measure gene expression in human lung samples.

XX Claim 27; SEQ ID NO 33284; 634bp; English.

XX The invention relates to a spatially-addressable set of single exon
XX nucleic acid probes for measuring gene expression in a sample derived
XX from human lung comprising single exon nucleic acid probes having one of
XX 12614 nucleic acid sequences mentioned in the specification, or their
XX complements or the 12387 open reading frames derived from the 12614
XX probes. Also included are a microarray comprising the novel set of probes
XX; the novel set of probes which hybridise at high stringency to a nucleic
XX acid expressed in the human lung; measuring gene expression in a sample
XX collected from human lung, comprising (a) contacting the array with a
XX collection of detectably labeled nucleic acids derived from human lung
XX mRNA, and (b) measuring the label detectably bound to each probe of the
XX array; identifying exons in a eukaryotic genome, comprising (a)
XX algorithmically predicting at least one exon from genomic sequences of
XX the eukaryote; and (b) detecting specific hybridisation of detectably
XX labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
XX having a fragment identical to the predicted exon, the probe is included
XX in the above mentioned microarray; assigning exons to a single gene,

CC	comprising (a) identifying exons from genomic sequence by the method
CC	above and (b) measuring the expression of each of the exons in several
CC	tissues and/or cell types using hybridization to a single exon
CC	microarrays having a probe with the exon, where a common pattern of
CC	expression of the exons in the tissues and/or cell types indicates that
CC	the exons should be assigned to a single gene; a peptide comprising one
CC	of 1201 sequences, mentioned in the specification, or encoded by the
CC	probes/open reading frames (ORF). The probes are used for gene expression
CC	analysis, and for identifying exons in a gene, particularly using human
CC	lung derived mRNA and for the study of lung diseases such as asthma, lung
CC	cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC	disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC	rubrous scleriosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC	Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC	histiocytosis, lymphangioleiomyomatosis, pulmonary alveolar proteinosis,
CC	Karageneger syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC	dyskinesia, pulmonary hypertension and hyaline membrane disease. The
CC	present sequence is a peptide/protein encoded by a single exon probe of
CC	the invention. Note: The sequence data for this patent did not form part
CC	of the printed specification, but was obtained in electronic format
CC	directly from WIPo at ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 56 AA;
OY	
D8	
OY	1 AOGV 4 6 AOGV 9
DB	
RESULT 143	
ID	ABP42752 standard; protein; 56 AA.
AC	ABP42752
XX	ABP42752;
DT	22-AUG-2002 (first entry)
DE	Human ovarian antigen HOVEN86, SEQ ID NO:3884.
XX	
KW	Human; ovarian antigen; ovary; ovarian; breast; cancer; tumour; ovarian cancer; breast cancer; tumour; reproductive system disorder; infertility; pregnancy disorder; anovulation; polycystic ovary syndrome; PCOS; ovarian cyst; dysmenorrhoea; endocrine disorder; infection; inflammatory condition; immune disorder; blood disorder; cardiovascular disorder; respiratory disorder; neurological disorder; gastrointestinal disorder; urinary system disorder; drug screening; gene therapy; chromosome mapping; forensic analysis; antibody preparation; cytostatic; immunomodulatory; neuroprotective; antiinflammatory; gynaecological; reproductive.
XX	
OS	Homo sapiens.
XX	
PN	WO200200677-A1.
PD	03-JAN-2002.
XX	
FJ	07-JUN-2001; 2001WO-US018559.
XX	
PR	07-JUN-2000; 2000US-0209467P.
XX	
PA	(HUMA-) HUMAN GENOME SCT INC.
XI	Birse CE, Rosen CA;
XX	
XX	WPi; 2002-147878/19.
DR	N-PSDB; ABQ55829.
XX	
PT	Isolated nucleic acid molecules encoding novel ovarian polypeptides, useful in the prevention, treatment and diagnosis of cancer (e.g. ovarian

PT	cancer), immune disorders, cardiovascular disorders and neurological diseases.
PS	Claim 11; SEQ ID NO 3864; 2922pp; English.
PX	The invention relates to 2175 novel human ovarian antigens (ABP41054-ABP43228) and to cDNAs encoding them (ABQ54131-ABQ56105), and also encompasses polypeptides 90% identical and polynucleotides 95% identical to the sequences of the invention. The invention additionally relates to recombinant vectors and host cells comprising human ovarian antigen polynucleotides, antibodies against human ovarian antigens, and the use of ovarian antigen polynucleotides and polypeptides in diagnosing, treating, prognostic or preventing various ovary and/or breast-related disorders. Such conditions include ovarian cancer and breast cancer, and metastatic tumours of ovarian or breast origin, reproductive system disorders (e.g., infertility, disorders of pregnancy, anovulation, polycystic ovary syndrome, ovarian cysts, and dysmenorrhoea), endocrine disorders, infections (e.g., chlamydia, HIV, toxoplasmosis, and toxic shock syndrome), inflammatory conditions (e.g., mastitis, oophoritis and vaginitis), immune disorders (e.g., congenital and acquired immunodeficiencies, autoimmune oophoritis, systemic lupus erythematosus), blood-related disorders (e.g., anaemia), cardiovascular disorders, respiratory disorders, neurological disorders, gastrointestinal disorders and urinary system disorders. Ovarian antigen polypeptides and polynucleotides may also be used in screening for compounds which modulate ovarian antigen expression or activity. The polynucleotides may further be used for gene therapy, chromosome mapping, in the identification of individuals and in forensic analysis, and the polypeptides may be used as food additives or to prepare antibodies useful in disease diagnosis, drug targeting and phenotyping. The present sequence represents a human ovarian antigen of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
SQ	Sequence 56 AA;
Query Match	100.0%; Score 19; DB 5; Length 56;
Best Local Similarity	100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative	0; Mismatches 0; Gaps 0;
1 ACGV 4	
Db 28 AGGV 31	
RESULT 144	
ADL27363	ID ADL27363 standard; peptide; 56 AA.
XX AC	ADL27363;
XX DT	03-JUN-2004 (first entry)
DE	Amino acid sequence of the DEC-205 transmembrane cytoplasmic domain.
XX	
XX	allergen; endoplasmic reticulum; LAMP-1;
KW	Lysosome-Associated Membrane Protein 1; tissue plasminogen activator;
KM	LAMP-II; Lysosome-Associated Membrane Protein 2; DEC-205; P-selectin;
KM	Tyrosinase; GLUT4; glucose transporter; endothelin; Nef protein; lysosome;
KM	Blo t5; Blo 11; Der p1; Der p2; Der p3; Der f1; Der f2; Der f3;
XX	T helper cell epitope; allergic reaction; asthma; rhinitis.
OS	Homo sapiens.
PN	WO2004019978-A1.
PD	11-MAR-2004.
PF	29-AUG-2003; 2003WO-SG000205.
PR	29-AUG-2002; 2002US-0406659P.

PA (US1-) UNIV SINGAPORE NAT.
 XX
 XX Chua KY, Liew LN;
 PI
 DR WPI; 2004-239125/22.
 XX
 PT New recombinant nucleic acid comprising a gene encoding a first signal
 PT peptide operably linked to a gene encoding an allergen, useful for the
 PT manufacture of a medicament for treating or preventing an allergic
 PT reaction, e.g., asthma.
 XX
 PS Disclosure; Page 67; 79pp; English.
 XX
 CC The specification describes a recombinant nucleic acid comprising a gene
 CC encoding a first signal peptide operably linked to a gene encoding an
 CC allergen, where the first signal peptide mediates the translocation of
 CC the allergen into the endoplasmic reticulum. The first signal peptide is
 CC the N-terminal signal peptide of LAMP-1 (Lysosome-Associated Membrane
 CC Protein 1), human tissue plasminogen activator, LAMP-II (Lysosome-
 CC Associated Membrane Protein 2), DEC-205, P-selectin, tyrosinase, GLUT4
 CC (glucose transporter), endotubulin or Nef protein or its equivalent. The
 CC nucleic acid further comprises an operably linked gene encoding a second
 CC signal peptide where the second signal peptide targets the allergen to an
 CC endosome or lysosome. The second signal peptide is the C-terminal
 CC lysosome or endosome targeting sequence of LAMP-1, human tissue
 CC plasminogen activator, LAMP-II, DEC-205, P-selectin, tyrosinase, GLUT4,
 CC endotubulin or Nef protein or its equivalent. The nucleic acid encodes the
 CC allergen B10 t5, B10 i1, Der p1 or Der p2, Der p3, Der f1, Der f2, Der
 CC f3, a T helper cell epitope or its antigenic fragment containing one or
 CC more T helper cell epitope or its functional equivalent. The recombinant
 CC nucleic acid is useful for the manufacture of a medicament for treating
 CC or preventing an allergic reaction, e.g. asthma or rhinitis. The present
 CC sequence represents a peptide, which is used to construct nucleic acids
 CC of the invention.
 XX
 SO Sequence 56 AA;
 Query Match 100.0%; Score 19; DB 8; Length 56;
 Best Local Similarity 100.0%; Pred. No. 2.3e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AOGV 4
 DB 41 AOGV 44
 RESULT 145
 ABP07528
 ID ABP07528 standard; protein; 58 AA.
 XX
 AC ABP07528;
 XX
 DT 24-JUN-2002 (first entry)
 XX
 DE Human ORFX protein sequence SEQ ID NO:15038.
 XX
 KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
 KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
 KW degenerative disorder; osteoarthritis; neurodegenerative disorder;
 KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
 KW hypertension; hypothyroidism; cholesterol ester storage disease;
 KW immune deficiency; immune disorder; infectious disease;
 KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
 KW myasthenia gravis.
 XX
 OS Homo sapiens.
 XX
 PN MO200192523-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 29-MAY-2001; 2001WO-US010836.
 XX

PR 30-MAY-2000; 2000US-0206132P.
 PR 29-AUG-2000; 2000US-0228716P.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 PI Shinkets RA, Leach MD;
 XX
 DR WPI; 2002-106308/14.
 DR N-PSDB; ABN23280.
 XX
 PT Novel human polypeptides and polynucleotides useful for diagnosing,
 PT preventing and treating cardiovascular disease, neurodegenerative,
 PT hyperproliferative disorders and autoimmune disorders.
 XX
 PS Disclosure; SEQ ID NO 15038; 1037p; English.
 XX
 CC The present invention describes substantially purified human proteins
 CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
 CC in the specification). ABN15762 to ABN27252 encode the human ORFX
 CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
 CC treating or preventing a pathology associated with an ORFX-associated
 CC disorder in humans, and in the manufacture of a medicament for treating a
 CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
 CC sequences can be used in gene therapy. ORFX sequences can be used in the
 CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
 CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
 CC osteoarthritis, neurodegenerative disorders, disorders related to organ
 CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
 CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
 CC storage disease, various immune deficiencies and disorders, infectious
 CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
 CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
 CC disease and autoimmune inflammatory eye disease. ORFX proteins are also
 CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
 CC bone degenerative disorders, or periodontal disease, and for gut
 CC protection or regeneration and treatment of lung or liver fibrosis,
 CC reperfusion injury in various tissues and conditions resulting from
 CC systemic cytokine damage. N.B. The sequence data for this patent did not
 CC form part of the printed specification, but was obtained in electronic
 CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX
 SO Sequence 58 AA;
 Query Match 100.0%; Score 19; DB 5; Length 58;
 Best Local Similarity 100.0%; Pred. No. 2.4e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AOGV 4
 DB 35 AOGV 38
 RESULT 146
 AB059983
 ID AB059983 standard; protein; 58 AA.
 XX
 AC AB059983;
 XX
 DT 29-JUN-2004 (first entry)
 XX
 DE Human genome derived single exon protein #6217.
 XX
 KW Human; gene expression; single exon probe; microarray;
 KW alternative splicing event; genomic alteration.
 XX
 OS Homo sapiens.
 XX
 PN US2003194704-A1.
 XX
 PD 16-OCT-2003.
 XX
 PF 03-APR-2002; 2002US-00029386.
 XX

PR 03-APR-2002; 2002US-00029386.
 XX (PENN/) PENN S G.
 PA (RANK/) RANK D R.
 PA (HANZ/) HANZEL D K.
 XX Penn SG, Rank DR, Hanzel DK;
 XX WPI; 2004-119264/12.
 DR
 XX
 XX
 PT New human genome-derived single exon nucleic acid probes useful for human
 PT gene expression analysis, for identifying or characterizing alternative
 PT splicing events, for assessing genomic alterations or as tools for
 PT surveying tissues.
 XX
 PS Claim 45; SEQ ID NO 35617; 80bp; English.
 XX
 XX The invention relates to a nucleic acid probe for measuring human gene
 CC expression, comprising any of the 27,400 fully defined nucleotide
 CC sequences in the specification, or their complements or fragments, and
 CC encoding at least 8 amino acids of any of the 6888 amino acid sequences
 CC fully defined in the specification. The probe is a single exon probe that
 CC hybridizes under high stringency conditions to a nucleic acid molecule
 CC expressed in human cells or tissues. Also included are a spatially-
 CC addressable set of single exon nucleic acid probes for measuring human
 CC gene expression (comprising a plurality of single exon nucleic acid
 CC probes cited above, where each of the plurality of probes is separately
 CC and addressably isolatable or amplifiable from the plurality), a single
 CC exon microarray for measuring human gene expression, a method of
 CC measuring human gene expression, a vector comprising the single exon
 CC probe cited above, an ORF-encoded peptide comprising at least 8
 CC contiguous amino acids of any of the above-mentioned amino acid
 CC sequences (optionally with conservative amino acid substitutions), an
 CC isolated antibody that binds specifically to a peptide cited above,
 CC methods of selling and/or licensing single exon probes or microarrays to
 CC a customer desiring to measure gene expression, a method of providing
 CC human gene expression data by subscription, and a computer-readable
 CC storage medium which contains a database having a plurality of records
 CC (each record including data on the expression of a single exon probe
 CC cited above. The probe, methods and apparatus are useful in gene
 CC expression analysis. The probes may be used as tools for surveying
 CC tissues to detect the presence of expressed messages that contain their
 CC specific exon, or in constructing genome-derived single exon microarrays.
 CC In addition, the probes are used in identifying and characterizing
 CC alternative splicing events, in detecting and characterizing gross
 CC alterations in the genomic locus that includes their exon, in assessing
 CC smaller genomic alterations, in priming the synthesis of nucleic acids,
 CC or in expressing the ORF-encoded peptide. The present sequence is a human
 CC single exon probe protein of the invention. Note: The sequence data for
 CC this patent did not form part of the printed specification, but was
 CC obtained in electronic format directly from USPTO at
 CC seqdata.uspto.gov/sequence.html?docID=20030194704
 CC
 XX
 SQ Sequence 58 AA;
 QY
 Db 1 AGGV 4
 31 AGGV 34
 Query Match 100.0%; Score 19; DB 8; Length 58;
 Best Local Similarity 100.0%; Pred. No. 2.4e+03; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 RESULT 147
 AEA79702
 ID AEA79702 standard; protein; 58 AA.
 XX
 AC AEA79702;
 XX
 XX 11-AUG-2005 (first entry)
 DT
 XX Cellulomonas sp. isolate 69B4 serine protease fragment SEQ ID NO 12.

XX
 KM serine protease; cellulomonadin; feedstuff; textile; leather;
 KM protein engineering; enzyme engineering.
 XX
 OS Cellulomonas sp.
 XX W02005052146-A2.
 XX
 XX
 XX 09-JUN-2005.
 XX
 XX
 PF 19-NOV-2004; 2004MO-US039066.
 XX
 XX 19-NOV-2003; 2003US-0523609P.
 XX
 PA (GEMV) GENENCOR INT INC.
 PA (PROC) PROCTER & GAMBLE CO.
 XX
 PI Jones BE, Kolman M, Leeftang C, Oh H, Poulou AJ, Sadlowski ES,
 PI Shaw A, Van Der Kleij WA, Van Marrewijk L;
 XX WPI; 2005-425197/43.
 DR N-PSDB; AEA79703.
 DR
 XX
 XX Example 4; SEQ ID NO 12; 356bp; English.
 PS
 XX This invention describes a novel serine protease (cellulomonadin)
 CC obtained from a member of the Micrococcineae e.g. Cellulomonas 69B4,
 CC Oerskovia, Cellulomicrobium, Xylaniobacterium or Promicromonospora,
 CC useful in preparing cleaning compositions, animal feed compositions or
 CC textile or leather processing compositions. The invention also describes
 CC novel stable variant serine protease having at least one improved
 CC property as compared to wild-type protease e.g. altered substrate
 CC specificity, altered pI, improved activity and better performance in at
 CC least one property consisting of keratin hydrolysis, thermostability,
 CC casein activity, IAS stability or cleaning, as compared to wild-type
 CC Cellulomonas 69B4 protease. The invention also describes 1) a novel
 CC composition comprising an isolated serine protease having immunological
 CC cross-reactivity; 2) polynucleotides encoding the variant serine
 CC proteases; 3) an expression vector comprising a polynucleotide sequence
 CC encoding the protease variant; 4) a host cell comprising or transformed
 CC with the expression vector; 5) a method of producing an enzyme having
 CC protease activity; 6) a probe for detecting a nucleic acid sequence
 CC encoding an enzyme having proteolytic activity and obtained from a member
 CC of the Micrococcineae; 7) a liquid cleaning composition comprising at
 CC least one serine protease obtained from a member of the Micrococcineae or
 CC a proteolytic acid stable enzyme combined with additional enzymes or
 CC enzyme derivatives consisting of proteases, amylases, lipases,
 CC mannanases, pectinases, cellulases, oxidoreductases, hemicellulases or
 CC cellulases or stabilizing agent e.g. Borax, glycerol or competitive
 CC inhibitors; 8) a method of cleaning using the composition and 9) the
 CC manufacture of an animal feed comprising the serine protease. This
 CC sequence represents a fragment of the Cellulomonas sp. isolate 69B4
 CC serine protease. The polynucleotide encoding this fragment is used to
 CC design primers AEA79700 and AEA79701.
 CC
 XX
 SQ Sequence 58 AA;
 QY
 Db 1 AGGV 4
 47 AGGV 50
 Query Match 100.0%; Score 19; DB 9; Length 58;
 Best Local Similarity 100.0%; Pred. No. 2.4e+03; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 RESULT 148
 AEA48196
 ID AEA48196 standard; protein; 58 AA.


```

XX AC AEA48196;
XX DT 11-AUG-2005 (first entry)
XX DE Part of the serine protease derived from Cellulomonas, SEQ ID NO: 12.
XX KW serine protease; hydrolysis; animal feed; detergent; textile; leather;
XX enzyme.
XX OS Cellulomonas.
XX PN WO2005052161-A2.
XX PD 09-JUN-2005.
XX PP 19-NOV-2004; 2004WO-US039006.
XX PR 19-NOV-2003; 2003US-0523609P.
XX PA (GENENCOR ) GENENCOR INT INC.
XX PI Jones BE, Kolkman M, Leeftang C, Foulse AJ, Shaw A,
XX PI Van Der Kleij WA, Van Marrewijk L,
XX DR WPI; 2005-425198/43.
XX PS New serine protease (isolated from a member of the Micrococciaceae) useful
XX PT in e.g. cleaning composition and animal feed composition.
XX Example 4; SEQ ID NO 12; 333pp; English.
XX CC The present invention relates to new isolated variant serine protease as
XX CC given in SEQ ID NO:8 (1), obtained from a member of the Micrococciaceae.
XX CC Also claimed are compositions comprising an isolated serine protease
XX CC having immunological cross-reactivity with the serine proteases obtained
XX CC from a member of the Micrococciaceae and particularly the protease
XX CC obtained from Cellulomonas 69B4. The variant has improved stability as
XX CC compared to wild-type Cellulomonas 69B4 protease. The protease is
XX CC obtained from Cellulomonas, Oerskovia, Cellulosimicrobium,
XX CC Xylanbacterium or Promicromonospora (preferably Cellulomonas 69B4). The
XX CC variant serine protease comprises at least one substitution corresponding
XX CC to the amino acid positions in SEQ ID NO: 8, and where the variant
XX CC protease has better performance in at least one property of keratin
XX CC hydrolysis, thermostability, casein activity, LAS stability or cleaning,
XX CC as compared to wild-type Cellulomonas 69B4 protease. The invention deals
XX CC with serine proteases, genetic material encoding the proteases,
XX CC proteolytic proteins obtained from Micrococciaceae spp; variant proteins
XX CC developed from them, vectors comprising the DNA encoding the protease,
XX CC host cells transformed with the vector DNA and enzymes produced by the
XX CC host cells. (1) is useful in cleaning compositions and animal feed
XX CC compositions, and is useful in laundry and dish detergents. It is useful
XX CC in textile and leather processing compositions. The isolated
XX CC polynucleotide of (1) provides the capability of isolating further
XX CC polynucleotides, which encode proteins having serine protease activity.
XX CC The enzyme compositions have comparable or improved wash performance, as
XX CC compared to presently used subtilisin proteases. The present sequence is
XX CC part of the serine protease derived from Cellulomonas, SEQ ID NO: 12.
XX SO Sequence 58 AA;

```

Query Match 100.0%; Score 19; DB 9; Length 58;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AAGV 4
| | | |
Db 47 AAGV 50

```

XX AC AAB58882;
XX DT 27-MAR-2001 (first entry)
XX DE Breast and ovarian cancer associated antigen protein sequence SEQ ID 590.
XX KW Human; breast cancer; ovarian cancer; cytostatic; immunosuppressive;
XX KW neutropenic; neuroprotective; antiviral; antiallergic; hepatotropic;
XX KW antidiabetic; antineoplastic; antitumor; antileukemic; anticonvulsant;
XX KW antibacterial; antifungal; antiparasitic; cardiant; immune disorder;
XX KW Addison's disease; allergy; autoimmune haemolytic anaemia;
XX KW autoimmune thyroiditis; diabetes mellitus; Crohn's disease;
XX KW multiple sclerosis; rheumatoid arthritis; ulcerative colitis;
XX KW cardiovascular disorder; wound healing; neurological disease.
XX OS Homo sapiens.
XX PN WO200055173-A1.
XX PD 21-SEP-2000.
XX PP 08-MAR-2000; 2000WO-US005881.
XX PR 12-MAR-1999; 99US-0124270P.
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX PI Rosen CA, Ruben SM;
XX PI N-PSDB; AAF21785.
XX DR WPI; 2000-611515/58.
XX DR N-PSDB; AAF21785.
XX PS New human breast and ovarian cancer associated gene sequences and the
XX PT polypeptides encoded by these genes, useful in the prevention, treatment
XX PT and diagnosis of cancer, immune disorders, cardiovascular disorders and
XX PT neurological diseases.
XX CC Claim 11; Page 1027; 1299pp; English.
XX CC Sequences AAF21614 - AAF22031 represent DNA sequences encoding human
XX CC proteins AAB58711 - AAB59128. The DNA and protein sequences are
XX CC associated with breast and ovarian cancer. Included in the invention are
XX CC sequences AAF22032 - AAF22040 and AAB59129 which are used in the
XX CC isolation and characterisation of the DNA and protein sequences of the
XX CC invention. The breast and ovarian cancer associated DNA, protein, agonist
XX CC or antagonist sequences exhibit cytostatic; immunosuppressive; neutropenic;
XX CC neuroprotective; antiviral; antiallergic; hepatotropic; antidiabetic;
XX CC antineoplastic; antitumor; antileukemic; anticonvulsant; antibacterial;
XX CC antifungal; antiparasitic and cardiant activity. The polynucleotide and
XX CC protein sequences are used in the diagnosis of cancer, particularly
XX CC breast and ovarian cancer. The nucleic acid sequences, proteins, agonists
XX CC and agonists may also be used in the diagnosis, prevention and treatment
XX CC of immune disorders e.g. Addison's disease, allergies, autoimmune
XX CC haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's
XX CC disease, multiple sclerosis, rheumatoid arthritis and ulcerative colitis;
XX CC cardiovascular disorders such as myocardial ischaemias; wound healing;
XX CC neurological diseases such as cerebral anoxia and epilepsy; and
XX CC infectious diseases
XX SO Sequence 59 AA;

```

Query Match 100.0%; Score 19; DB 3; Length 59;
Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AAGV 4
| | | |
Db 13 AAGV 16

RESULT 149
AAB58882
ID AAB58882 standard; protein, 59 AA.

RESULT 150
AAB58882
ID AAB58882 standard; protein, 59 AA.

ID AAU55984 standard; protein; 59 AA.
XX
AC AAU55984;
XX
DT 27-FEB-2002 (first entry)
XX
DE Propionibacterium acnes immunogenic protein #16880.
XX
KW SAPHO syndrome; synovitis; acne; pustulosis; hypertois; osteomyelitis;
KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW dermatological; osteopathic; neuroprotectant.
XX
OS Propionibacterium acnes.
XX
PN M0200181581-A2.
XX
PD 01-NOV-2001.
XX
PF 20-APR-2001; 2001WO-US012865.
XX
PR 21-APR-2000; 2000US-0199047P.
PR 02-JUN-2000; 2000US-020841P.
PR 07-JUL-2000; 2000US-0216747P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Sheikh YM, Persing DH, Mitcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
DR N-PSDB; AAS59573.
XX
WIPI: 2001-616774/71.
XX
PT Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris.
XX
PS Example 1; SEQ ID NO 17179; 1069pp; English.
XX
CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 59 AA;
XX
Query Match 100.0%; Score 19; DB 4; Length 59;
Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

ID ABP00743 standard; protein; 59 AA.
XX
AC ABP00743;
XX
DT 24-JUN-2002 (first entry)
XX
DE Human ORFX protein sequence SEQ ID NO:1468.
XX
KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
KW degenerative disorder; osteoarthritis; neurodegenerative disorder;
KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
KW hypertension; hypothyroidism; cholesterol ester storage disease;
KW immune deficiency; immune disorder; infectious disease;
KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
KW myasthenia gravis.
XX
OS Homo sapiens.
XX
PN M0200192523-A2.
XX
PD 06-DEC-2001.
XX
PF 29-MAY-2001; 2001WO-US010836.
XX
PR 30-MAY-2000; 2000US-0206132P.
PR 29-AUG-2000; 2000US-0228716P.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shinkets RA, Leach MD;
PI N-PSDB; ABN16495.
XX
WIPI: 2002-106308/14.
XX
DR N-PSDB; ABN16495.
XX
PT Novel human polypeptides and polynucleotides useful for diagnosing,
PT preventing and treating cardiovascular disease, neurodegenerative,
PT hyperproliferative disorders and autoimmune disorders.
XX
PS Disclosure; SEQ ID NO 1468; 1037pp; English.
XX
XX The present invention describes substantially purified human proteins
XX (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
XX in the specification). ABN15762 to ABN27252 encode the human ORFX
XX proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
XX treating or preventing a pathology associated with an ORFX-associated
XX disorder in humans, and in the manufacture of a medicament for treating a
XX syndrome associated with ORFX-associated disorder. ORFX polynucleotide
XX sequences can be used in gene therapy. ORFX sequences can be used in the
XX treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
XX psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
XX osteoarthritis, neurodegenerative disorders, disorders related to organ
XX transplantation, cardiovascular diseases, diabetes mellitus, systemic
XX lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
XX storage disease, various immune deficiencies and disorders, infectious
XX diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
XX arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
XX disease and autoimmune inflammatory eye disease. ORFX proteins are also
XX useful for creating burns, incisions, ulcers, for treating osteoporosis,
XX bone degenerative disorders, or periodontal disease, and for gut
XX protection or regeneration and treatment of lung or liver fibrosis,
XX reperfusion injury in various tissues and conditions resulting from
XX systemic cytokine damage. N.B. The sequence data for this patent did not
XX form part of the printed specification, but was obtained in electronic
XX format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 59 AA;
XX
Query Match 100.0%; Score 19; DB 5; Length 59;
Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

US2003194704-A1.

16-OCT-2003.

03-APR-2002; 2002US-00029386.

03-APR-2002; 2002US-00029386.

(PENNY/) PENN S G.
(RANK/) RANK D R.
(HANZ/) HANZEL D K.

Penn SG, Rank DR, Hanzel DK;
WPI; 2004-119264/12.

New human genome-derived single exon nucleic acid probes useful for human gene expression analysis, for identifying or characterizing alternative splicing events, for assessing genomic alterations or as tools for surveying tissues.

Claim 45; SEQ ID NO 28279; 80bp; English.

The invention relates to a nucleic acid probe for measuring human gene expression, comprising any of the 27,400 fully defined nucleotide sequences in the specification, or their complements or fragments, and encoding at least 8 amino acids of any of the 688 amino acid sequences fully defined in the specification. The probe is a single exon probe that hybridizes under high stringency conditions to a nucleic acid molecule expressed in human cells or tissues. Also included are a spatially-addressable set of single exon nucleic acid probes for measuring human gene expression (comprising a plurality of single exon nucleic acid probes cited above, where each of the plurality of probes is separately and addressably isolatable or amplifiable from the plurality), a single exon microarray for measuring human gene expression, a method of measuring human gene expression, a vector comprising the single exon probe cited above, an ORF-encoded peptide comprising at least 8 contiguous amino acids of any of the above-mentioned amino acid sequences (optionally with conservative amino acid substitutions), an isolated antibody that binds specifically to a peptide cited above, a method of selling and/or licensing single exon probes or microarrays to a customer desiring to measure gene expression, a method of providing human gene expression data by subscription, and a computer-readable storage medium which contains a database having a plurality of records (each record including data on the expression of a single exon probe cited above. The probe, method and apparatus are useful in gene expression analysis. The probes may be used as tools for surveying tissues to detect the presence of expressed messages that contain their specific exon, or in constructing genome-derived single exon microarrays. In addition, the probes are used in identifying and characterizing alternative splicing events, in detecting and characterizing gross alterations in the genomic locus that includes their exon. In assessing smaller genomic alterations, in priming the synthesis of nucleic acids, or in expressing the ORF-encoded peptide. The present sequence is a human single exon probe protein of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from USPRO at seqdata.uspto.gov/sequence.html?DocID=20030194704

Sequence 59 AA:

Query Match 100.0%; Score 19; DB 8; Length 59;
Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0

1 AGGV 4
|||
52 AGGV 55

RESULT 155
AAU48065
ID AAU48065 standard; protein; 60 AA

Query Match	100.0%	Score 19	DB 4	Length 60
Best Local Similarity	100.0%	Pred. No. 2.5e+03		
Matches 4	Conservative 0	Mismatches 0	Indels 0	Gaps 0

QY 1 AGGV 4
 ||||
 DB 57 AAGV 60

RESUUT 156
 ABP32165
 ID ABP32165 standard; protein; 60 AA.

XX ABP32165;
 AC 08-JUL-2002 (first entry)
 XX
 DE Human ORF1138 protein, SEQ ID NO:2276.
 XX
 KM Human: ORF: open reading frame; ORFX: drug screening; diagnosis;
 KM disease monitoring; cytokine; cell proliferation; cell differentiation;
 KM immune modulation; haematopoiesis regulation; tissue growth;
 KM angiogenesis; activin; inhibin; chemotactic; chemokine; haemostatic;
 KM thrombolytic; tumour inhibition; bodily characteristics; fertility;
 KM behaviour; cancer; proliferative disorder; neurological disorder;
 KM cardiovascular disease; immune system disorder; organ transplantation;
 KM tissue growth disorder; tissue regeneration disorder; diabetes mellitus;
 KM hypothyroidism; cholesterol ester storage disease; infection; vulnery;
 KM vasotrophic; antipsoriatic; antidiabetic; cystostatic; nootropic;
 KM neuroprotective; antiatherosclerotic; anticoagulant; thrombolytic;
 KM cardiast; hypotensive; antithyroid; antiinflammatory; immunomodulator;
 KM dermatological; analgesic; virucide; antibacterial; fungicide.
 XX
 OS Homo sapiens.
 XX
 XX MO200190366-A2.
 XX
 XX 29-NOV-2001.
 XX
 XX 24-MAY-2001; 2001WO-US017076.
 XX
 XX 24-MAY-2000; 2000US-0206690P.
 XX
 XX (CURA-) CURAGEN CORP.
 XX
 XX Leach MD, Shimkets RA;
 XX
 XX WPI: 2002-106200/14.
 XX
 XX N-PSDB; ABN76191.
 DR
 XX
 XX Novel human polypeptides and polynucleotides useful for diagnosing,
 PT preventing and treating cardiovascular disease, neurodegenerative,
 PT hyperproliferative disorders and disorders related to organ
 PT transplantation.
 XX
 XX Claim 10; Page 832; 2508pp; English.
 PS
 XX Sequences ABP31028-ABP35561 represent 4534 novel human proteins
 CC designated ORF (open reading frame) 1-4534, and sequences ABN75054-
 CC ABN79587 represent CDNA encoding them. The invention also encompasses
 CC polypeptides at least 80% identical to the ORF1-ORF4534 (collectively
 CC referred to as ORFX) proteins, polynucleotides at least 85% identical to
 CC the ORFX nucleic acid sequences, vectors and host cells comprising ORFX
 CC polynucleotides, the recombinant production of ORFX proteins, antibodies
 CC specific for ORFX proteins, methods of detecting ORFX polynucleotides and
 CC polypeptides, methods of screening for modulators of ORFX expression or
 CC activity, and methods of screening individuals for a predisposition to an
 CC ORFX-associated disorder. The ORFX proteins of the invention have a wide
 CC range of biological activities, such as cytokine, cell proliferation,
 CC cell differentiation, immune modulation, haematopoiesis regulation,
 CC tissue growth, angiogenesis, activin or inhibin activity, chemotactic/
 CC chemokine activity, haemostatic activity, thrombolytic activity,
 CC receptor/ligand, antiinflammatory activity, tumour inhibition activity,
 CC and antiinfective activity, and may also be involved in the determination
 CC of bodily characteristics, fertility and behaviour. ORFX proteins,
 CC nucleic acids and antibodies may be used in the treatment of cancers,
 CC other proliferative disorders such as psoriasis and benign tumours,
 CC neurological disorders such as epilepsy and Alzheimer's disease,
 CC cardiovascular diseases, immune system disorders, disorders related to
 CC organ transplantation, disorders of tissue growth and regeneration,
 CC diseases such as diabetes mellitus, hypothyroidism, and cholesterol ester
 CC storage disease, and infectious diseases caused by viral, bacterial,
 CC fungal and other pathogens. ORFX nucleic acids may also be used as a
 CC source of primers and probes, in the detection of ORFX genomic sequences
 CC or transcripts, in the identification and cloning of homologous

CC sequences, in genetic diagnosis, and in forensic biology. The ORFX
 CC nucleic acids may additionally be used to produce transgenic animals
 CC which may be useful for studying the function and/or activity of ORFX
 CC protein, and in drug screening. The ORFX proteins may also be used as
 CC immunogens to generate specific antibodies, which are useful in the
 CC diagnosis, treatment and monitoring of ORFX-associated diseases
 XX
 XX SQ Sequence 60 AA;
 Query Match 100.0%; Score 19; DB 5; Length 60;
 Best Local Similarity 100.0%; Pred. No. 2.5e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ACGV 4
 Db 20 ACGV 23
 RESULT 157
 ABM44584
 ID ABM44584 standard; protein, 60 AA.
 AC
 XX ABM44584;
 XX
 XX 20-OCT-2003 (first entry)
 XX
 DE Propionibacterium acnes predicted ORF-encoded polypeptide #9260.
 XX
 KM Acne vulgaris; antieborrheic; dermatological; antibacterial;
 KM immunostimulant; immune response; vaccine.
 XX
 OS Propionibacterium acnes.
 XX
 XX WO2003033515-A1.
 XX
 XX 24-APR-2003.
 XX
 XX 11-OCT-2002; 2002WO-US032727.
 XX
 XX 15-OCT-2001; 2001US-00978825.
 XX
 XX (CORI-) CORIXA CORP.
 XX
 XX Mitcham JL, Skeiky YAW, Persing DH, Bhatia A, Maisonneuve JL,
 PI Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D,
 PI Barth B, Vallieve-Douglase J;
 XX
 XX WPI: 2003-381789/36.
 DR
 XX N-PSDB; ACF64470.
 XX
 XX New Propionibacterium acnes polypeptides and polynucleotides encoding the
 PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
 PT or for stimulating an immune response specific for a P. acnes protein.
 XX
 XX Example 1; SEQ ID NO 9260; 1481pp; English.
 PS
 XX The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
 CC encoding a Propionibacterium acnes protein. The invention also relates to
 CC polypeptides encoded by the polynucleotide (ABM35624-ABM64536) and to
 CC immunogenic fragments of P. acnes polypeptides. The invention
 CC additionally encompasses expression vectors and host cells comprising a
 CC polynucleotide of the invention; antibodies against polypeptides of the
 CC invention; fusion proteins comprising a polypeptide of the invention; a
 CC method for stimulating an immune response specific for a P. acnes
 CC polypeptide and an isolated T cell population comprising T cells prepared
 CC via this method; a vaccine composition (comprising P. acnes polypeptides,
 CC polynucleotides, antibodies, fusion proteins, T cell populations, or
 CC antigen-presenting cells that express the polypeptide); a method and kit
 CC for detecting or determining the presence or absence of P. acnes in a
 CC patient; and a method for inhibiting the development of P. acnes in a
 CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
 CC proteins, T cell populations or antigen-presenting cells that express the
 CC polypeptides are useful for diagnosing, preventing or treating acne

CC vulgaris, or for stimulating an immune response specific for a P. acnes
CC protein. The polynucleotides can also be used as probes or primers for
CC nucleic acid hybridisation. The vaccine composition is useful for the
CC stimulation of an immune response against P. acnes, or for treating acne,
CC and the kit is useful for performing a diagnostic assay. The present
CC sequence represents a polypeptide predicted to be encoded by an ORF (open
CC reading frame) contained within the P. acnes polynucleotides of the
CC invention. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 60 AA;

Query Match 100.0%; Score 19; DB 6; Length 60;
Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 57 ACGV 60

RESULT 158

ABO78543
ID ABO78543 standard; protein; 60 AA.

AC ABO78543;

DT 29-JUL-2004 (first entry)

XX Pseudomonas aeruginosa polypeptide #10718.

KW Bacterial infection; Pseudomonas aeruginosa infection; antibacterial.

OS Pseudomonas aeruginosa.

PN US6551795-B1.

PD 22-APR-2003.

PF 18-FEB-1999; 99US-00252991.

PR 18-FEB-1998; 98US-0074788P.

PR 27-JUL-1998; 98US-0094190P.

XX (GENO-) GENOME THERAPEUTICS CORP.

PI Rubenfield MJ, Nolling J, Deloughery C, Bush D;

DR WPI; 2003-615309/58.

DR N-PSDB; ABD12114.

PT Novel isolated nucleic acid encoding Pseudomonas aeruginosa polypeptide,
XX useful as molecular targets for diagnostics, prophylaxis and treatment of
XX pathological conditions resulting from bacterial infection.

XX Dislosure; SEQ ID NO 27289; 455BP; English.

XX The invention relates to Pseudomonas aeruginosa polypeptides and the
XX polynucleotides encoding them. The sequences are useful in diagnosis and
XX therapy of pathological conditions, as molecular targets for diagnostics,
XX prophylaxis and treatment of pathological conditions resulting from a
XX bacterial infection, for evaluating a compound, such as a polypeptide,
XX for the ability to bind a P. aeruginosa nucleic acid, as components of
XX effective antibacterial targets, as targets for antibacterial drugs,
XX including anti-P. aeruginosa drugs, as templates for recombinant
XX production of P. aeruginosa-derived peptides or polypeptides, as target
XX components for diagnosis and/or treatment of P. aeruginosa-caused
XX infection, and in detection of P. aeruginosa sequences or other sequences
XX of Pseudomonas species using biochip technology. Sequences ABO67826-
XX ABO8496 represent P. aeruginosa polypeptides of the invention. Note: The
XX sequence data for this patent did not form part of the printed
XX specification but was obtained in electronic format from USPTO at

CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 60 AA;

Query Match 100.0%; Score 19; DB 7; Length 60;
Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 24 ACGV 27

RESULT 159

AAU61564
ID AAU61564 standard; protein; 61 AA.

AC AAU61564;

DT 27-FEB-2002 (first entry)

DE Propionibacterium acnes immunogenic protein #22460.

XX SAPHO syndrome; synovitis; acne; pustulosis; hyperostosis; osteomyelitis;

KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;

KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;

XX dermatological; osteopathic; neuroprotectant.

OS Propionibacterium acnes.

PN W0200181581-A2.

PD 01-NOV-2001.

PF 20-APR-2001; 2001WO-US012865.

PR 21-APR-2000; 2000US-0199047P.

PR 02-JUN-2000; 2000US-0208641P.

PR 07-JUL-2000; 2000US-0216747P.

XX (CORI-) CORIXA CORP.

PA SKEIKY YAM, Persing DH, Mitcham JL, Wang SS, Bhatia A;

PI L'maisonmeuve J, Zhang Y, Jen S, Carter D;

DR WPI; 2001-616774/71.

DR N-PSDB; AAS59618.

XX Example 1; SEQ ID NO 22759; 1069BP; English.

XX Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
XX polypeptides. The proteins and their associated DNA sequences are used in
XX the treatment, prevention and diagnosis of medical conditions caused by
XX P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
XX pustulosis, hyperostosis and osteomyelitis), uveitis and endophthalmitis.
XX P. acnes is also involved in infections of bone, joints and the central
XX nervous system, however it is particularly involved in the inflammatory
XX lesions associated with acne vulgaris. A method for detecting the
XX presence or absence of P. acnes in a patient comprises contacting a
XX sample with a binding agent that binds to the proteins of the invention
XX and determining the amount of bound protein in the sample. The
XX polypeptides may be used as antigens in the production of antibodies
XX specific for P. acnes proteins. These antibodies can be used to
XX downregulate expression and activity of P. acnes polypeptides and
XX therefore treat P. acnes infections. The antibodies may also be used as
XX diagnostic agents for determining P. acnes presence, for example, by
XX enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
XX this patent did not form part of the printed specification, but was
XX obtained in electronic format directly from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 61 AA;
 SQ Query Match 100.0%; Score 19; DB 4; Length 61;
 Best Local Similarity 100.0%; Pred. No. 2.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 ACGV 4
 ||||
 Db 35 ACGV 38

RESULT 160
 ABP04708
 ID ABP04708 standard; protein; 61 AA.
 XX
 AC ABP04708;
 XX
 DT 25-JUN-2002 (first entry)
 XX
 DE Human ORFX protein sequence SEQ ID NO:9398.
 XX
 KM Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
 KM hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
 KM degenerative disorder; osteoarthritis; neurodegenerative disorder;
 KM cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
 KM hyperension; hypothyroidism; cholesterol ester storage disease;
 KM immune deficiency; immune disorder; infectious disease;
 KM autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
 KM myasthenia gravis.
 KM
 OS Homo sapiens.
 XX
 PN WO200192523-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 29-MAY-2001; 2001WO-US010836.
 XX
 PR 30-MAY-2000; 2000US-0206132P.
 PR 29-AUG-2000; 2000US-0228716P.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 PI Shimkets RA, Leach MD;
 XX
 DR WPI; 2002-106308/14.
 DR N-PSDB; ABN20460.
 XX
 PS Disclosure; SEQ ID NO 9398; 1037pp; English.
 XX
 CC The present invention describes substantially purified human proteins
 CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
 CC in the specification). ABN15762 to ABN27252 encode the human ORFX
 CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
 CC treating or preventing a pathology associated with an ORFX-associated
 CC disorder in humans, and in the manufacture of a medicament for treating a
 CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
 CC sequences can be used in gene therapy. ORFX sequences can be used in the
 CC treatment of cancer. Hyperproliferative disorders, cirrhosis of liver,
 CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
 CC osteoarthritis, neurodegenerative disorders, disorders related to organ
 CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
 CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
 CC storage disease, various immune deficiencies and disorders, infectious
 CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
 CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
 CC disease and autoimmune inflammatory eye disease. ORFX proteins are also

CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
 CC bone degenerative disorders, or periodontal disease, and for gut
 CC protection or regeneration and treatment of lung or liver fibrosis,
 CC reperfusion injury in various tissues and conditions resulting from
 CC systemic cytokine damage. N.B. The sequence data for this patent did not
 CC form part of the printed specification, but was obtained in electronic
 CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 61 AA;
 Query Match 100.0%; Score 19; DB 5; Length 61;
 Best Local Similarity 100.0%; Pred. No. 2.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 ACGV 4
 ||||
 Db 54 ACGV 57

RESULT 161
 ABMS8083
 ID ABMS8083 standard; protein; 61 AA.
 XX
 AC ABMS8083;
 XX
 DT 20-OCT-2003 (first entry)
 XX
 DE Propionibacterium acnes predicted ORF-encoded polypeptide #22759.
 XX
 KM Acne vulgaris; antiborbotic; dermatological; antibacterial;
 KM immunostimulant; immune response; vaccine.
 KM
 OS Propionibacterium acnes.
 XX
 PN WO2003033515-A1.
 XX
 PD 24-APR-2003.
 XX
 PF 11-OCT-2002; 2002WO-US032727.
 XX
 PR 15-OCT-2001; 2001US-00978825.
 XX
 PA (CORI-) CORIXA CORP.
 XX
 PI Mitcham JL, Skeiky YAW, Persing DH, Bhalaria A, Maisonneuve JL;
 PI Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
 PI Barth B, Valiieve-Douglas J;
 XX
 DR WPI; 2003-381789/36.
 DR N-PSDB; ACF64547.
 XX
 PS Example 1; SEQ ID NO 22759; 1481pp; English.
 XX
 CC The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
 CC encoding a Propionibacterium acnes protein. The invention also relates to
 CC polypeptides encoded by the polynucleotides (ABM5624-ABM64536) and to
 CC immunogenic fragments of P. acnes polypeptides. The invention
 CC additionally encompasses expression vectors and host cells comprising a
 CC polynucleotide of the invention; antibodies against polypeptides of the
 CC invention; fusion proteins comprising a polypeptide of the invention; a
 CC method for stimulating an immune response specific for a P. acnes
 CC polypeptide and an isolated T cell population comprising T cells prepared
 CC via this method; and a vaccine composition (comprising P. acnes polypeptides,
 CC polynucleotides, antibodies, fusion proteins, T cell populations, or
 CC antigen-presenting cells that express the polypeptide); a method and kit
 CC for detecting or determining the presence or absence of P. acnes in a
 CC patient; and a method for inhibiting the development of P. acnes in a
 CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
 CC proteins, T cell populations or antigen-presenting cells that express the

CC polypeptides are useful for diagnosing, preventing or treating acne
 CC vulgaris, or for stimulating an immune response specific for a P. acnes
 CC protein. The polynucleotides can also be used as probes or primers for
 CC nucleic acid hybridisation. The vaccine composition is useful for the
 CC stimulation of an immune response against P. acnes, or for treating acne,
 CC and the kit is useful for performing a diagnostic assay. The present
 CC sequence represents a polypeptide predicted to be encoded by an ORF (open
 CC reading frame) contained within the P. acnes polynucleotides of the
 CC invention. Note: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 61 AA;

Query Match 100.0%; Score 19; DB 6; Length 61;
 Best Local Similarity 100.0%; Pred. No. 2.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
 ||||
 Db 35 ACGV 38

RESULT 162

AAU64327
 ID AAU64327 standard; protein; 62 AA.

AC AAU64327;

DT 27-FEB-2002 (first entry)

DE Propionibacterium acnes immunogenic protein #25223.

XX SAPHO syndrome; synovitis; acne, pustulosis; hypertosis; osteomyelitis;
 KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
 KM inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
 KM dermatological; osteopathic; neuroprotectant.

XX Propionibacterium acnes.

XX WO200181581-A2.

XX 01-NOV-2001.

XX 20-APR-2001; 2001WO-US012865.

XX 21-APR-2000; 2000US-0199047P.

XX 02-JUN-2000; 2000US-0208841P.

XX 07-JUL-2000; 2000US-0216747P.

XX (CORI-) CORIXA CORP.

XX Skeiky YAM, Persing DH, Mitcham JL, Wang SS, Bhatia A;
 PI L.maisonneuve J, Zhang Y, Jen S, Carter D;
 DR N-PSDB; AAS59641.

XX WPI; 2001-616774/71.

PT Propionibacterium acnes polypeptides and nucleic acids useful for
 PT vaccinating against and diagnosing infections, especially useful for
 PT treating acne vulgaris.

XX Example 1; SEQ ID NO 25522; 1069pp; English.

CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
 CC polypeptides. The proteins and their associated DNA sequences are used in
 CC the treatment, prevention and diagnosis of medical conditions caused by
 CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
 CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
 CC P. acnes is also involved in infections of bone, joints and the central
 CC nervous system, however it is particularly involved in the inflammatory
 CC lesions associated with acne vulgaris. A method for detecting the
 CC presence or absence of P. acnes in a patient comprises contacting a

CC sample with a binding agent that binds to the proteins of the invention
 CC and determining the amount of bound protein in the sample. The
 CC polypeptides may be used as antigens in the production of antibodies
 CC specific for P. acnes proteins. These antibodies can be used to
 CC downregulate expression and activity of P. acnes polypeptides and
 CC therefore treat P. acnes infections. The antibodies may also be used as
 CC diagnostic agents for determining P. acnes presence, for example, by
 CC enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
 CC this patent did not form part of the printed specification, but was
 CC obtained in electronic format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 62 AA;

Query Match 100.0%; Score 19; DB 4; Length 62;
 Best Local Similarity 100.0%; Pred. No. 2.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
 ||||
 Db 17 ACGV 20

RESULT 163

ABM60846
 ID ABM60846 standard; protein; 62 AA.

AC ABM60846;

DT 20-OCT-2003 (first entry)

DE Propionibacterium acnes predicted ORF-encoded polypeptide #25522.

XX Acne vulgaris; antiseborrheic; dermatological; antibacterial;
 KW immunostimulant; immune response; vaccine.

XX Propionibacterium acnes.

XX WO2003033515-A1.

XX 24-APR-2003.

XX 11-OCT-2002; 2002WO-US032727.

XX 15-OCT-2001; 2001US-00978825.

XX (CORI-) CORIXA CORP.

XX Mitcham JL, Skeiky YAM, Persing DH, Bhatia A, Maisonneuve JL;
 PI Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
 PI Barch B, Valliave-Douglas J;
 XX WPI; 2003-381789/36.

DR N-PSDB; ACF64570.

PT New Propionibacterium acnes polypeptides and polynucleotides encoding the
 PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
 PT or for stimulating an immune response specific for a P. acnes protein.

XX Example 1; SEQ ID NO 25522; 1481pp; English.

CC The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
 CC encoding a Propionibacterium acnes protein. The invention also relates to
 CC polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
 CC immunogenic fragments of P. acnes polypeptides. The invention
 CC additionally encompasses expression vectors and host cells comprising a
 CC polynucleotide of the invention; antibodies against polypeptides of the
 CC invention; fusion proteins comprising a polypeptide of the invention; a
 CC method for stimulating an immune response specific for a P. acnes
 CC polypeptide and an isolated T cell population comprising T cells prepared
 CC via this method; a vaccine composition (comprising P. acnes polypeptides,
 CC polynucleotides, antibodies, fusion proteins, T cell populations, or
 CC antigen-presenting cells that express the polypeptide); a method and kit

CC for detecting or determining the presence or absence of *P. acnes* in a
CC patient; and a method for inhibiting the development of *P. acnes* in a
CC patient. The *P. acnes* polypeptides, polynucleotides, antibodies, fusion
CC proteins, T cell populations or antigen-presenting cells that express the
CC polypeptides are useful for diagnosing, preventing or treating *acne*
CC vulgaris, or for stimulating an immune response specific for a *P. acnes*
CC protein. The polynucleotides can also be used as probes or primers for
CC nucleic acid hybridisation. The vaccine composition is useful for the
CC stimulation of an immune response against *P. acnes*, or for treating *acne*,
CC and the kit is useful for performing a diagnostic assay. The present
CC sequence represents a polypeptide predicted to be encoded by an ORF (open
CC reading frame) contained within the *P. acnes* polynucleotides of the
CC invention. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at [ftp.wipo.int/pub/published_pct_sequences](http://wipo.int/pub/published_pct_sequences)

XX SQ Sequence 62 AA;

Query Match 100.0%; Score 19; DB 6; Length 62;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 AOGV 4
17 AOGV 20
Db

RESULT 164

ABO62014
ID ABO62014 standard; protein; 62 AA.

XX AC ABO62014;

XX DT 29-JUL-2004 (first entry)

XX DE Klebsiella pneumoniae polypeptide segid 8531.

XX KM Recombinant expression vector; transcription regulatory element;

XX KM Klebsiella pneumoniae protein; antibacterial; Vaccine.

XX OS Klebsiella pneumoniae.

XX PN US6610836-B1.

XX PD 26-AUG-2003.

XX PF 27-JAN-2000; 2000US-00489039.

XX PR 29-JAN-1999; 99US-0117747P.

XX PA (GENO-) GENOME THERAPEUTICS CORP.

XX PI Breton GL, Osborne M;

XX WPI; 2003-895346/82.

XX DR N-PSDB; ACR95565.

PT New nucleic acid encoding a Klebsiella pneumoniae polypeptide, useful for
PT preparing a vaccine composition against Klebsiella pneumoniae.

XX PS Disclosure; SEQ ID NO 8531; 932P; English.

XX The invention describes a new isolated nucleic acid encoding a Klebsiella
CC pneumoniae polypeptide. Also described are: a recombinant expression
CC vector comprising the nucleic acid, operably linked to a transcription
CC regulatory element; and a cell comprising the recombinant expression
CC vector. The nucleic acid is useful for preparing a vaccine composition
CC against Klebsiella pneumoniae. This is the amino acid sequence of a
CC Klebsiella pneumoniae polypeptide of the invention

XX SQ Sequence 62 AA;

Query Match 100.0%; Score 19; DB 7; Length 62;

Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
11 AOGV 14
Db

RESULT 165

ADY23472
ID ADY23472 standard; protein; 62 AA.

XX AC ADY23472;

XX DT 21-APR-2005 (first entry)

XX DE Plant full length insert polypeptide segid 71256.

KM plant protectant; plant growth regulator; gene therapy; plant;
KM recombinant DNA construct; physical array; plant breeding marker;

KM cold tolerance; heat tolerance; drought tolerance; herbicide tolerance;
KM extreme osmotic condition; pathogen tolerance; pest tolerance;

KM growth rate; cell cycle pathway; disease resistance;

KM galactomannan production; lignin production; plant growth regulator;

KM yield; plant growth; plant development; seed oil; protein yield;

KM protein content.

XX Unidentified.

XX US2004034888-A1.

XX PD 19-FEB-2004.

XX PF 28-APR-2003; 2003US-00425114.

XX PR 06-MAY-1999; 99US-00304517.

XX RR 05-NOV-2001; 2001US-00985678.

XX PA (LIU/J) LIU J.

XX PA (ZHOU/) ZHOU Y.

XX PA (KOVA/) KOVALIC D K.

XX PA (SCRE/) SCREEN S E.

XX PA (TABAS/) TABASKA J E.

XX PA (CAOY/) CAO Y.

PI Liu J, Zhou Y, Kovalic DK, Screen SE, Tabaska JE, Cao Y;
PI WPI; 2004-180133/17.

PT New recombinant DNA construct, useful for improving plant tolerance to
PT cold, heat, drought, herbicides, extreme osmotic conditions, pathogens or
PT pests, for conferring increased resistance to plant disease, or for
PT improving yield.

XX Claim 1; SEQ ID NO 71256; 15pp; English.

XX The invention describes a recombinant DNA construct comprising a
CC polynucleotide consisting of a sequence encoding an amino acid sequence
CC available in electronic form from the US patent office at
CC [ftp.seqdata.uspto.gov/sequence.html?docid:2004034888](http://seqdata.uspto.gov/sequence.html?docid:2004034888). The polynucleotide
CC of the invention are also useful in physical arrays of molecules and as
CC plant breeding markers. The recombinant DNA construct is useful for
CC improving plant tolerance to cold, heat, drought, herbicides, extreme
CC osmotic conditions, pathogens or pests, for manipulating growth rate in
CC plant cells by modification of the cell cycle pathway, for conferring
CC increased resistance to plant disease, for producing galactomannan,
CC lignin or plant growth regulators, for increasing the rate of homologous
CC recombination in plants, for improving yield by modification of
CC photosynthesis or carbohydrate, nitrogen or phosphorus use and/or uptake
CC or by providing improved plant growth and development under at least one
CC stress condition or for modifying seed oil or protein yield and/or
CC content. This is the amino acid sequence of a plant full length insert
CC polypeptide that can be used in the recombinant DNA construct of the

CC Invention.
XX Sequence 62 AA:
SQ
Query Match 100.0%; Score 19; DB 8; Length 62;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ACQV 4
Db 13 ACQV 16
RESULT 166
AAG26814
ID AAG26814 standard; protein: 63 AA.
XX
AC AAG26814;
XX
DT 17-OCT-2000 (first entry)
XX
DE Zea mays protein fragment SEQ ID NO: 31409.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
hybridisation assay; genetic mapping; gene expression control; promoter;
termination sequence; corn.
XX
OS Zea mays subsp. mays.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.
XX
XX 25-FEB-1999; 99US-0121825P.
PR 09-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131448P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135114P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136382P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.

PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142524P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0145088P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.

```
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149723P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158023P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0158293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161931P.
PR 29-OCT-1999; 99US-0162142P.
```

```
Query Match 100.0%; Score 19; DB 3; Length 63;
Best Local Similarity 100.0%; Pred. No. 2,7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 ACGV 4
DB 53 ACGV 56

RESULT 167
ID AAM83149 standard; protein, 63 AA.
XX
AC AAM83149;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen SEQ ID NO:10742.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
XX cytosolic; gene therapy; vaccine; metastasis.
XX
OS Homo sapiens.
XX
PN W0200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001354.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226888P.
PR 23-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227182P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
```

PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 25-SEP-2000; 2000US-0234999P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 13-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249254P.

PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX PI Rosen CA, Barash SC, Ruben SM;
XX
XX WPI; 2001-483426/52.
XX
XX DR N-PSDB; AAK55930.
XX
XX PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
XX useful for preventing, diagnosing and/or treating cancers and metastasis.
XX
XX PS Claim 11; SEQ ID NO 10742; 3071pp + Sequence Listing; English.
XX
XX CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
XX amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
XX activity, and can be used in gene therapy and vaccine production. (I)
XX proteins and polynucleotides may be used in the prevention, diagnosis and
XX treatment of diseases associated with inappropriate (I) expression. For
XX example, they may be used to treat disorders associated with decreased
XX expression by rectifying mutations or deletions in a patient's genome
XX that affect the activity of (I) by expressing inactive proteins or to
XX supplement the patients own production of (I). Additionally, (I)
XX polynucleotides may be used to produce the secreted (I), by inserting the
XX nucleic acids into a host cell and culturing the cell to express the
XX protein. (I) proteins and polynucleotides may be used to prevent,
XX diagnose and treat immune/haematopoietic-related diseases, especially
XX cancers and cancer metastases of haematopoietic-derived cells. AAK64703
XX to AAK87694 represent human immune/haematopoietic antigen genomic
XX sequences from the present invention. AAK54942 to AAK54950 and AAM82169
XX represent sequences used in the exemplification of the present invention
XX
SQ Sequence 63 AA;
Query Match 100.0%; Score 19; DB 4; Length 63;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AAGV 4
Db 8 AAGV 11
RESULT 168
ABG26472
ID ABG26472 standard; protein; 63 AA.
XX
XX AC ABG26472;
XX
XX DT 18-FEB-2002 (first entry)
XX
XX DE Novel human diagnostic protein #26463.
XX
XX KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
XX food supplement; medical imaging; diagnostic; genetic disorder.
XX
XX OS Homo sapiens.

XX	WO200175067-A2.
XX	
PD	11-OCT-2001.
XX	
PF	30-MAR-2001; 2001WO-US0008631.
XX	
PR	31-MAR-2000; 2000US-00540217.
XX	
PR	23-AUG-2000; 2000US-00649167.
XX	
PA	(HYSE-) HYSEQ INC.
XX	
PI	Dmanac RT, Liu C, Tang YT;
XX	
DR	WPI, 2001-639362/73.
XX	
DR	N-PsDB; AAS90659.
XX	
PT	New isolated polynucleotide and encoded polypeptides, useful in
PT	diagnostics, forensics, gene mapping, identification of mutations
PT	responsible for genetic disorders or other traits and to assess
PT	biodiversity.
XX	
PS	Claim 20; SEQ ID NO 56831; 103pp; English.
XX	
CC	The invention relates to isolated polynucleotide (I) and polypeptide (II)
CC	sequences. (I) is useful as hybridisation probes, polymerase chain
CC	reaction (PCR) primers, oligomers, and for chromosome and gene mapping,
CC	and in recombinant production of (II). The polynucleotides are also used
CC	in diagnostic as expressed sequence tags for identifying expressed
CC	genes. (II) is useful in gene therapy techniques to restore normal
CC	activity of (II) or to treat disease states involving (II). (II) is
CC	useful for generating antibodies against it, detecting or quantitating a
CC	polypeptide in tissue, as molecular weight markers and as a food
CC	supplement. (II) and its binding partners are useful in medical imaging
CC	of sites expressing (II). (I) and (II) are useful for treating disorders
CC	involving aberrant protein expression or biological activity. The
CC	polypeptide and polynucleotide sequences have applications in
CC	diagnostics, forensics, gene mapping, identification of mutations
CC	responsible for genetic disorders or other traits to assess biodiversity
CC	and to produce other types of data and products dependent on DNA and
CC	amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic
CC	amino acid sequences of the invention. Note: The sequence data for this
CC	patent did not appear in the printed specification, but was obtained in
CC	electronic format directly from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SO	Sequence 63 AA:
XX	
Query Match	100.0%; Score 19; DB 4; Length 63;
Best Local Similarity	100.0%; Pred. No. 2.7e+03;
Matches	4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	1 AGGV 4
Db	34 AAGV 37
XX	
RESULT 169	
ABO58146	
ID	ABO58146 standard; protein; 63 AA.
XX	
AC	ABO58146;
XX	
DT	29-JUL-2004 (first entry)
XX	
XX	
DE	Human genome derived single exon protein #4380.
XX	
KW	Human; gene expression; single exon probe; microarray;
XX	alternative splicing event; genomic alteration.
OS	Homo sapiens.
XX	
UN	US2003194704-A1.

16-OCT-2003.
03-APR-2002; 2002US-00029386.
03-APR-2002; 2002US-00029386.
(PENN/) PENN S G.
(RANK/) RANK D R.
(HANZ/) HANZEL D K.
Penn SG, Rank DR, Hanzel DK;
WPI; 2004-119264/12.
New human genome-derived single exon nucleic acid probes useful for human gene expression analysis, for identifying or characterizing alternative splicing events, for assessing genomic alterations or as tools for surveying tissues.
Claim 45; SEQ ID NO 31780; 80pp; English.
The invention relates to a nucleic acid probe for measuring human gene expression, comprising any of the 27,400 fully defined nucleotide sequences in the specification, or their complements or fragments, and encoding at least 8 amino acids of any of the 688 amino acid sequences fully defined in the specification. The probe is a single exon probe that hybridises under high stringency conditions to a nucleic acid molecule expressed in human cells or tissues. Also included are a spatially-addressable set of single exon nucleic acid probes for measuring human gene expression (comprising a plurality of single exon nucleic acid probes cited above, where each of the plurality of probes is separately and addressably isolatable or amplifiable from the plurality), a single exon microarray for measuring human gene expression, a method of measuring human gene expression, a vector comprising the single exon probe cited above, an ORF-encoded peptide comprising at least 8 contiguous amino acids of any of the above-mentioned amino acid sequences (optionally with conservative amino acid substitutions), an isolated antibody that binds specifically to a peptide cited above, a method of selling and/or licensing single exon probes or microarrays to a customer desiring to measure gene expression, a method of providing human gene expression data by subcription, and a computer-readable storage medium which contains a database having a plurality of records (each record including data on the expression of a single exon probe cited above. The probe, methods and apparatus are useful in gene expression analysis. The probes may be used as tools for surveying tissues to detect the presence of expressed messages that contain their specific exon, or in constructing genome-derived single exon microarrays. In addition, the probes are used in identifying and characterising alternative splicing events, in detecting and characterising gross alterations in the genomic locus that includes their exon, in assessing smaller genomic alterations, in priming the synthesis of nucleic acids, or in expressing the ORF-encoded peptide. The present sequence is a human single exon probe protein of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from USPTO at seqdata.uspto.gov/sequence.html?docID=20030194704
Sequence 63 AA;
Query Match 100.0%; Score 19; DB 8; Length 63;
Best Local Similarity 100.0%; Pred. No. 2,7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0.
1 AAGV 4
||||
41 AAGV 44
RESULT 170
ID ABB29155 standard; protein; 64 AA.
XX

AC ABP29155;
 XX 02-JUL-2002 (first entry)
 XX Streptococcus polypeptide SEQ ID NO 7486.
 DE Streptococcus polypeptide SEQ ID NO 7486.
 XX Streptococcus; GAS; GBS; group B streptococcus; Streptococcus agalactiae;
 KM group A streptococcus; Streptococcus pyogenes; antibacterial;
 KM antiinflammatory; infection; vaccine; meningitis; gene therapy.
 OS Streptococcus pyogenes.
 PN MO200234771-A2.
 XX 02-MAY-2002.
 XX 29-OCT-2001; 2001WO-GB004789.
 XX 27-OCT-2000; 2000GB-00026333.
 PR 24-NOV-2000; 2000GB-00028727.
 PR 07-MAR-2001; 2001GB-00005640.
 XX (CHIR-) CHIRON SPA.
 PA (GENO-) INST GENOMIC RRS.
 XX Telford J, Masignani V, Margarit Y Rosi, Grandi G, Fraser C,
 PI Tettein H;
 DR WPI; 2002-352536/38.
 DR N-PSDB; ABN69786.
 XX New Streptococcus protein for the treatment or prevention of infection or
 PT disease caused by Streptococcus bacteria, such as meningitis, and for
 PT detecting a compound that binds to the protein.
 XX Claim 1; Page 3892; 4525pp; English.
 XX The invention relates to a protein (ABP25413-ABP30895) from group B
 CC streptococcus/GBS (Streptococcus agalactiae) or group A streptococcus/GAS
 CC (Streptococcus pyogenes), comprising one of 5483 sequences (S1), given in
 CC the specification. The proteins have antibacterial and antiinflammatory
 CC activity. (1), nucleic acids encoding (1), ABN66044-ABN71526 and
 CC antibodies that bind (1) are used in the manufacture of medicaments for
 CC the treatment or prevention of infection or disease caused by
 CC Streptococcus bacteria, particularly S. agalactiae and S. pyogenes.
 CC Nucleic acids encoding (1) are used to detect Streptococcus in a
 CC biological sample. (1) is used to determine whether a compound binds to
 CC (1). A composition comprising (1) or a nucleic acid encoding (1), may be
 CC used as a vaccine or diagnostic composition. The disease caused by
 CC Streptococcus that is prevented or treated may be meningitis. Nucleic
 CC acid encoding (1) may be used to recombinantly produce (1), and may be
 CC used in gene therapy. Antibodies to (1) are used for affinity
 CC chromatography, immunoassays, and distinguishing/identifying
 CC Streptococcus proteins
 XX
 SQ Sequence 64 AA;
 Query Match 100.0%; Score 19; DB 5; Length 64;
 Best Local Similarity 100.0%; Pred. NO. 2.7e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AAGV 4
 ||||
 DB 30 AAGV 33
 RESULT 171
 ID AAG02408 standard; proteinn; 65 AA.
 XX AAG02408;
 AC
 XX
 DT 06-OCT-2000 (first entry)

XX Human secreted protein, SEQ ID NO: 6489.
 DE Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
 XX gene therapy; chromosome mapping.
 KM Homo sapiens.
 OS Homo sapiens.
 XX EP1033401-A2.
 PN 06-SEP-2000.
 PD 21-FEB-2000; 2000EP-00200610.
 PF 26-FEB-1999; 99US-0122487P.
 PR (GEST) GENSET.
 XX Dumas Milne Edwards J, Duclert A, Giordano J;
 PI WPI; 2000-500381/45.
 DR N-PSDB; AAC02414.
 XX New nucleic acid that is a 5' expressed sequence tag (5' EST) for
 PT obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
 PT diagnostic, forensic, gene therapy and chromosome mapping procedures.
 XX Claim 13; SEQ ID NO 6489; 71pp + Sequence Listing; English.
 PS The present sequence is a polypeptide encoded by one of a large number of
 CC 5' ESTs derived from mRNAs encoding secreted proteins. The 5' ESTs were
 CC prepared from total human RNAs or polyA+ RNAs derived from 30 different
 CC tissues. EST sequences usually correspond mainly to the 3' untranslated
 CC region (UTR) of the mRNA because they are often obtained from oligo-dT
 CC primed cDNA libraries. Such ESTs are not well suited for isolating cDNA
 CC sequences derived from the 5' ends of mRNAs and even in those cases where
 CC longer cDNA sequences have been obtained, the full 5' UTR is rarely
 CC included. 5' ESTs are derived from mRNAs with intact 5' ends and can
 CC therefore be used to obtain full length cDNAs and genomic DNAs. 5' ESTs
 CC are also used in diagnostic, forensic, gene therapy and chromosome
 CC mapping procedures. They are used to obtain upstream regulatory sequences
 CC and to design expression and secretion vectors
 XX
 SQ Sequence 65 AA;
 Query Match 100.0%; Score 19; DB 3; Length 65;
 Best Local Similarity 100.0%; Pred. NO. 2.7e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AAGV 4
 ||||
 DB 48 AAGV 51
 RESULT 172
 ID AAG07706 standard; proteinn; 65 AA.
 XX AAG07706;
 AC
 XX
 DT 17-OCT-2000 (first entry)
 XX Arabidopsis thaliana protein fragment SEQ ID NO: 4960.
 DE Protein identification; signal transduction pathway; metabolic pathway;
 KM hybridisation assay; genetic mapping; gene expression control; promoter;
 KM termination sequence.
 XX Arabidopsis thaliana.
 OS
 XX
 XX
 PN EP1033405-A2.
 XX
 DT 06-SEP-2000.

XX 25-FEB-2000; 2000EP-00301439.
PF
XX 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130072P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 28-APR-1999; 99US-0130891P.
PR 30-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 07-MAY-1999; 99US-0132487P.
PR 11-MAY-1999; 99US-0132863P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-01343221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 17-JUN-1999; 99US-0139453P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.

PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149930P.
PR 23-AUG-1999; 99US-0150565P.
PR 25-AUG-1999; 99US-0150884P.
PR 26-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.

PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159283P.
PR 13-OCT-1999; 99US-0159284P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 16-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 26-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161922P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match Best Local Similarity 100.0%; Score 19; DB 3; Length 65;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 ACGV 4
Db 62 ACGV 65

RESULT 173

AG26813
ID AAG26813 standard; protein; 65 AA.

AC AAG26813;

DT 17-OCT-2000 (first entry)

XX Zea mays protein fragment SEQ ID NO: 31408.

XX Protein identification; signal transduction pathway; metabolic pathway;
KM hybridisation assay; genetic mapping; gene expression control; promoter;
XX termination sequence; corn.

OS Zea mays subsp. mays.

PN EPI033405-A2.

PD 06-SEP-2000.

PF 25-FEB-2000; 2000EP-00301439.

XX 25-FEB-1999; 99US-0121825P.

PR 05-MAR-1999; 99US-0123180P.

PR 09-MAR-1999; 99US-0123548P.

PR 23-MAR-1999; 99US-0125788P.

PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135133P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136332P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 17-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.

PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144336P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149358P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157573P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.

PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160742P.
PR 21-OCT-1999; 99US-0160758P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 100.0%; Score 19; DB 3; Length 65;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1 ACGV 4
Db 55 ACGV 58

RESULT 174
AB066725
ID AB066725 standard; protein; 65 AA.
XX
AC AB066725;
XX
DT 29-JUL-2004 (first entry)
XX
DE Klebsiella pneumoniae polypeptide seqid 13242.
XX
KW Recombinant expression vector; transcription regulatory element;
KW Klebsiella pneumoniae protein; antibacterial; Vaccine.
XX
OS Klebsiella pneumoniae.
XX
PN US6610836-B1.
PD 26-AUG-2003.
XX
PP 27-JAN-2000; 2000US-00489039.
XX
PR 29-JAN-1999; 99US-0117747P.
PA (GENO-) GENOME THERAPEUTICS CORP.
XX
PI Breton GL, Osborne M;
XX
XX WPI; 2003-895346/82.
DR N-PSDB; ABD00296.
XX
PT New nucleic acid encoding a Klebsiella pneumoniae polypeptide, useful for
PT preparing a vaccine composition against Klebsiella pneumoniae.
XX

PS Disclosure; SEQ ID NO 13242; 932pp; English.
XX
CC The invention describes a new isolated nucleic acid encoding a Klebsiella
CC pneumoniae polypeptide. Also described are: a recombinant expression
CC vector comprising the nucleic acid, operably linked to a transcription
CC regulatory element; and a cell comprising the recombinant expression
CC vector. The nucleic acid is useful for preparing a vaccine composition
CC against Klebsiella pneumoniae. This is the amino acid sequence of a
XX Klebsiella pneumoniae polypeptide of the invention
SQ Sequence 65 AA;

Query Match 100.0%; Score 19; DB 7; Length 65;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AAGV 4
Db 22 AAGV 25

RESULT 175
AAG07705
ID AAG07705 standard; protein; 66 AA.
XX AAG07705;
AC
XX 17-OCT-2000 (first entry)
DT
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 4959.
XX
XX Protein identification; signal transduction pathway; metabolic pathway;
KM hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
PN EP1033405-A2.
PD
XX 06-SEP-2000.
PF
XX 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.

PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136382P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 17-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139482P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140823P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142380P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145122P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-01455913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.

PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146388P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149425P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154033P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 26-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157865P.
PR 06-OCT-1999; 99US-0158029P.
PR 07-OCT-1999; 99US-0158232P.
PR 08-OCT-1999; 99US-0158369P.
PR 12-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.

PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161922P.
PR 28-OCT-1999; 99US-0161923P.
PR 29-OCT-1999; 99US-0162142P.
Query Match 100.0%; Score 19; DB 3; Length 66;
Best Local Similarity 100.0%; Pred. No. 2.8e+03; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 Aqv 4
Db 63 Aqv 66
RESULT 176
AAM82556
ID AAM82556 standard; protein; 66 AA.
XX
AC AAM82556;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen SEQ ID NO:10149.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytosolic; gene therapy; vaccine; metastasis.
OS Homo sapiens.
XX
PN W0200157182-A2.
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001354.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 11-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226686P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.

PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230457P.
PR 06-SEP-2000; 2000US-0230458P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 25-SEP-2000; 2000US-0234999P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.

PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249219P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249246P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249287P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250319P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251889P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Barash SC, Ruben SM,
XX
XX WPI; 2001-483426/52.
XX N-PSDB; AAK5337.
DR
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and metastasis.
XX
XX Claim 11; SEQ ID NO 10149; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytotoxic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patient's own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting the
CC nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/hematopoietic-related diseases, especially
CC cancers and cancer metastases of hematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/hematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention
XX
SQ Sequence 66 AA:
Query Match 100.0%; Score 19; DB 4; Length 66;
Best Local Similarity 100.0%; Pred. No. 2.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ACGV 4
Db 52 ACGV 55
RESULT 177
AAU53135
ID AAU53135 standard; protein; 66 AA.
XX
AC AAU53135;
XX

DT 27-FEB-2002 (first entry)
 XX Propionibacterium acnes immunogenic protein #14031.
 XX
 XX SAPHO syndrome; synovitis; acne; pustulosis; hyperostosis; osteomyelitis;
 KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
 KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
 KW dermatological; osteopathic; neuroprotectant.
 XX
 XX Propionibacterium acnes.
 OS
 XX MO200181581-A2.
 PN
 XX 01-NOV-2001.
 PD
 XX 20-APR-2001; 2001WO-US012865.
 XX
 XX 21-APR-2000; 2000US-0199047P.
 PR 02-JUN-2000; 2000US-0208841P.
 PR 07-JUL-2000; 2000US-0216747P.
 XX
 XX (CORI-) CORIXA CORP.
 PA
 PI Skeiky YAM, Persing DH, Mitcham JL, Wang SS, Bhatia A;
 PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
 DR WPI; 2001-616774/71.
 DR N-PSDB; AAS59558.
 XX
 XX Propionibacterium acnes polypeptides and nucleic acids useful for
 PT vaccinating against and diagnosing infections, especially useful for
 PT treating acne vulgaris.
 PT
 XX Example 1; SEQ ID NO 14330; 1069pp; English.
 PS
 XX Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
 CC polypeptides. The proteins and their associated DNA sequences are used in
 CC the treatment, prevention and diagnosis of medical conditions caused by
 CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
 CC pustulosis, hyperostosis and osteomyelitis), uveitis and endophthalmitis.
 CC P. acnes is also involved in infections of bone, joints and the central
 CC nervous system, however it is particularly involved in the inflammatory
 CC lesions associated with acne vulgaris. A method for detecting the
 CC presence or absence of P. acnes in a patient comprises contacting a
 CC sample with a binding agent that binds to the proteins of the invention
 CC and determining the amount of bound protein in the sample. The
 CC polypeptides may be used as antigens in the production of antibodies
 CC specific for P. acnes proteins. These antibodies can be used to
 CC downregulate expression and activity of P. acnes polypeptides and
 CC therefore treat P. acnes infections. The antibodies may also be used as
 CC diagnostic agents for determining P. acnes presence, for example, by
 CC enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
 CC this patent did not form part of the printed specification, but was
 CC obtained in electronic format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX
 XX Sequence 66 AA;
 SQ
 XX Query Match 100.0%; Score 19; DB 4; Length 66;
 XX Best Local Similarity 100.0%; Pred. No. 2.8e+03;
 XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DT 20-OCT-2003 (first entry)
 XX Propionibacterium acnes predicted ORF-encoded polypeptide #14330.
 XX
 XX Acne vulgaris; antieborrheic; dermatological; antibacterial;
 KW immunostimulant; immune response; vaccine.
 KW
 XX Propionibacterium acnes.
 OS
 XX MO2003033515-A1.
 PN
 XX 24-APR-2003.
 PD
 XX 11-OCT-2002; 2002WO-US032727.
 XX
 XX 15-OCT-2001; 2001US-00978825.
 XX
 XX (CORI-) CORIXA CORP.
 PA
 PI Mitcham JL, Skeiky YAM, Persing DH, Bhatia A, Maisonneuve JL;
 PI Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
 PI Barth B, Vallieve-Douglas J;
 DR WPI; 2003-381789/36.
 DR N-PSDB; ACF64487.
 XX
 XX New Propionibacterium acnes polypeptides and polynucleotides encoding the
 PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
 PT or for stimulating an immune response specific for a P. acnes protein.
 PT
 XX Example 1; SEQ ID NO 14330; 1481pp; English.
 PS
 XX The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
 CC encoding a Propionibacterium acnes protein. The invention also relates to
 CC polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
 CC immunogenic fragments of P. acnes polypeptides. The invention
 CC additionally encompasses expression vectors and host cells comprising a
 CC polynucleotide of the invention; antibodies against polypeptides of the
 CC invention; fusion proteins comprising a polypeptide of the invention; a
 CC method for stimulating an immune response specific for a P. acnes
 CC polypeptide and an isolated T cell population comprising T cells prepared
 CC via this method; a vaccine composition (comprising P. acnes polypeptides,
 CC polynucleotides, antibodies, fusion proteins, T cell populations, or
 CC antigen-presenting cells that express the polypeptide); a method and kit
 CC for detecting or determining the presence or absence of P. acnes in a
 CC patient; and a method for inhibiting the development of P. acnes in a
 CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
 CC proteins, T cell populations or antigen-presenting cells that express the
 CC polypeptides are useful for diagnosing, preventing or treating acne
 CC vulgaris, or for stimulating an immune response specific for a P. acnes
 CC protein. The polynucleotides can also be used as probes or primers for
 CC nucleic acid hybridisation. The vaccine composition is useful for the
 CC stimulation of an immune response against P. acnes, or for treating acne,
 CC and the kit is useful for performing a diagnostic assay. The present
 CC sequence represents a polypeptide predicted to be encoded by an ORF (open
 CC reading frame) contained within the P. acnes polynucleotides of the
 CC invention. Note: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
 CC
 XX
 XX Sequence 66 AA;
 SQ
 XX Query Match 100.0%; Score 19; DB 6; Length 66;
 XX Best Local Similarity 100.0%; Pred. No. 2.8e+03;
 XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 178
 ABM49654
 ID ABM49654 standard; protein; 66 AA.
 XX
 XX ABM49654;
 AC
 XX

RESULT 179
 ABB71058

ID	ABB71058	standard; protein; 67 AA.
XX		
AC	ABB71058;	
XX		
DT	26-MAR-2002	(first entry)
XX		
DE	Drosophila melanogaster polypeptide SEQ ID NO 39966.	
XX		
KW	Drosophila; developmental biology; cell signalling; insecticide;	
KM	pharmaceutical.	
XX		
OS	Drosophila melanogaster.	
XX		
PN	WO200171042-A2.	
XX		
PD	27-SEP-2001.	
XX		
PF	23-MAR-2001; 2001WO-US009231.	
XX		
PR	23-MAR-2000; 2000US-0191637P.	
XX		
PR	11-JUL-2000; 2000US-00614150.	
XX		
PA	(PEKE) PE CORP NY.	
XX		
PI	Venter JC, Adams M, Li PWD, Myers EW,	
XX		
DR	WPI; 2001-656860/75.	
XX		
DR	N-PSDB; ABL15161.	
XX		
PT	New isolated nucleic acid detection reagent for detecting 1000 or more	
PT	genes from Drosophila and for elucidating cell signaling and cell-cell	
PT	interactions.	
XX		
PS	Disclosure; SEQ ID NO 39966; 21pp + Sequence Listing; English.	
XX		
CC	The invention relates to an isolated nucleic acid detection reagent	
CC	capable of detecting 1000 or more genes from Drosophila. The invention is	
CC	useful in developmental biology and in elucidating cell signaling and	
CC	cell-cell interactions in higher eukaryotes for the development of	
CC	insecticides, therapeutics and pharmaceutical drugs. The invention	
CC	discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA	
CC	sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-	
CC	ABB72072). The sequence data for this patent did not form part of the	
CC	printed specification, but was obtained in electronic format directly	
CC	from WIPO at ftp.wipo.int/pub/published_pct_sequences	
XX		
SQ	Sequence 67 AA;	
	Query Match	100.0%; Score 19; DB 4; Length 67;
	Best local similarity	100.0%; Pred. NO. 2.8e+03;
	Matches	4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	1 ACGV 4	
Db	9 ACGV 12	
RESULT 180		
ADU04369		
ID	ADU04369	standard; protein; 67 AA.
XX		
AC	ADU04369;	
XX		
DT	13-JAN-2005	(first entry)
XX		
DE	MHV protein with homology to SARS coronavirus ORF1A.	
XX		
KW	viral infection; virucide; autoimmune disease;	
KM	lymphoproliferative disorder; vaccine; gene therapy.	
XX		
OS	Murine hepatitis virus.	
XX		
PN	WO2004090544-A2.	

XX	PD	21-OCT-2004.
XX	PF	13-APR-2004; 2004WO-CA000544.
XX	PR	09-APR-2003; 2003US-0461137P.
XX	PR	30-SEP-2003; 2003US-0506779P.
XX	PA	(CABL-) CANADIAN BLOOD SERVICES.
XX	PI	Hu Y, Brown E;
XX	DR	WPI; 2004-766498/75.
XX	PT	Characterizing a viral infection in a host, for developing treatment for
XX	PT	severe acute respiratory syndrome-coronavirus (SARS-CoV), by determining
XX	PT	homology profile of a viral-based sequence element with an endogenous
XX	PT	host element.
XX	PS	Claim 8, Fig 20A, 166pp; English.
XX	XX	The invention relates to a novel method for characterising a viral
XX	CC	infection in a host. The method comprises identifying at least one viral-
XX	CC	based sequence element in a biological sample obtained from the host,
XX	CC	determining a homology profile of the viral-based sequence element with
XX	CC	at least one endogenous host element and characterising the viral
XX	CC	infection based on the homology profile, where the homology profile is
XX	CC	indicative of a viral behaviour of the viral infection in the host. The
XX	CC	method of the invention demonstrates virucide applications and may be
XX	CC	useful for preparing a medicament for detecting and/or treating a viral
XX	CC	infection or related condition, such as an autoimmune disease e.g. type
XX	CC	II cryoglobulinaemia, or lymphoproliferative disorder. The viral
XX	CC	infection may be due to HCV (Hepatitis C virus), HIV or a member of a
XX	CC	Retroviridae, Flaviviridae, Herpesviridae, Papillomaviridae or
XX	CC	Coronaviridae virus family. Treatment of the infection may utilise
XX	CC	vaccine or gene therapy. The target compound of the invention may be
XX	CC	useful for detecting the presence of a virus in a biological sample or
XX	CC	for manufacturing a medicament for treating SARS coronavirus (SARS-CoV)
XX	CC	and/or Human T-lymphotropic virus 1 (HTLV-1) infection. The methods are
XX	CC	further useful for developing treatment regimes to target genotype-
XX	CC	specific viral variants. The current sequence is that of the MIV protein
XX	CC	of the invention within homology to SARS coronavirus ORF1A.
XX	XX	
XX	XX	Sequence 67 AA;
XX	XX	
XX	XX	Query Match 100.0%; Score 19; DB 8; Length 67;
XX	XX	Best Local Similarity 100.0%; Pred. No. 2,8e+03;
XX	XX	Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX	XX	
XX	QY	1 AAGV 4
XX	XX	
XX	DB	38 AAGV 41
XX	XX	
XX	XX	RESULT 181
XX	XX	AAG26016
XX	XX	AA26016 standard; protein; 69 AA.
XX	XX	AA26016;
XX	XX	
XX	XX	17-OCT-2000 (first entry)
XX	XX	
XX	XX	Zea mays protein fragment SEQ ID NO: 30312.
XX	XX	
XX	XX	Protein identification; signal transduction pathway; metabolic pathway;
XX	XX	hybridisation assay; genetic mapping; gene expression control; promoter;
XX	XX	termination sequence; corn.
XX	XX	
XX	XX	Zea mays subsp. mays.
XX	XX	EP1033405-A2.
XX	XX	
XX	XX	06-SEP-2000.

XX 25-FEB-2000; 2000EP-00301439.
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 28-APR-1999; 99US-0130891P.
PR 30-APR-1999; 99US-0131449P.
PR 04-MAY-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 07-MAY-1999; 99US-0132487P.
PR 11-MAY-1999; 99US-0132863P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 17-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140605P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.

PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 21-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 23-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 03-AUG-1999; 99US-0146389P.
PR 04-AUG-1999; 99US-0147203P.
PR 04-AUG-1999; 99US-0147204P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.

PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match Best Local Similarity 100.0%; Score 19; DB 3; Length 69;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
DB 55 AOCV 58

RESULT 182

AAE01158
ID AAE01158 standard; protein; 69 AA.

AC AAE01158;

DT 17-JUL-2001 (first entry)

DE Novel human cytokine 1 (NHC-1) protein.

KM Novel human cytokine, NHC, cytototoxic, antiinflammatory, neuroprotective;
KM immunosuppressive; gene therapy; cancer; infection; autoimmune disease;
KM trauma; cystic fibrosis; leukaemia; asthma; neurodegenerative disease;
KM allograft rejection; Alzheimer's disease; Parkinson's disease; pregnancy.

OS Homo sapiens.

XX Homo sapiens.

XX US6204021-B1.

PD 20-MAR-2001.

PF 31-JAN-1997; 97US-00792013.

XX 31-JAN-1997; 97US-00792013.

XX (INCY-) INCYTE GENOMICS INC.

XX Bandman O, Hawkins PR, Murry LE, Goli SK;
PI WPI, 2001-289513/30.
XX N-PSDB; AAD05034.
DR
XX
PT New NHC-2 polynucleotides and polypeptides useful for diagnosing,
PT preventing, or treating cancers, inflammation, allograft rejection,
PT neurodegenerative diseases, and conditions affecting pregnancy, growth
PT and development.

XX Example 6; Fig 1; 30pp; English.

XX The present protein sequence is novel human cytokine 1 (NHC-1). NHC-1
CC cDNA was first identified in Incyte clone 141384 from an ileum library
CC of a patient with irritable bowel syndrome (SIBRS01). The present
CC invention relates to novel human cytokines, NHC-1 and NHC-2 collectively
CC known as NHC. The antagonists or inhibitors NHC are useful for
CC diagnosing, preventing, or treating cancers, inflammations (caused by
CC viral, bacterial, fungal, helminthic or protozoal infection), trauma,
CC autoimmune diseases (e.g. Cystic fibrosis, leukaemia, asthma), allograft
CC rejection, neurodegenerative diseases (e.g. Alzheimer's disease,
CC Parkinson's disease), and conditions affecting pregnancy, growth and
CC development. NHC polynucleotides are used in recombinant DNA molecules to
CC direct expression of NHC in host cells, in the diagnosis of conditions or
CC diseases associated with NHC expression, in detecting altered NHC
CC expression and in assays that detect the activation or induction of
CC various cancers. They are also used to generate hybridisation probes for
CC mapping naturally occurring genomic sequence, to detect differences in
CC gene sequences between normal, carrier or affected individuals, for
CC screening libraries of compounds in various drug screening techniques,
CC and in molecular biology. NHC sequences are also used in gene therapy

SQ Sequence 69 AA;

Query Match Best Local Similarity 100.0%; Score 19; DB 4; Length 69;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOCV 4
DB 5 AOCV 8

RESULT 183

AAU76429
ID AAU76429 standard; protein; 69 AA.

AC AAU76429;

DT 21-MAY-2002 (first entry)

DE Novel human cytokine-1 (NHC-1).

XX Human; cytokine; NHC-1; cancer; inflammation; viral infection;
KM bacterial infection; fungal infection; helminthic infection;
KM protozoal infection; trauma; autoimmune disease; haemolytic anaemia;
KM arteriosclerosis; asthma; biliary cirrhosis; cystic fibrosis; diabetes;
KM glomerulonephritis; hyperthyroidism; pulmonary fibrosis;
KM systemic lupus erythematosus; myasthenia gravis; osteoporosis;
KM pancreatitis; Sjogren's syndrome; scleroderma; allograft rejection;
KM neurodegenerative disease; Alzheimer's disease; transplantation;
KM amyotrophic lateral sclerosis; Huntington's disease; Parkinson's disease;
KM epilepsy; Down's syndrome; pregnancy; growth; development;
KM cell proliferation; Bone marrow cell; tissue regeneration.

OS Homo sapiens.

XX US2002001827-A1.

PD 03-JAN-2002.

XX 12-FEB-2001; 2001US-00782142.

XX 31-JAN-1997; 97US-00792013.
 XX (INCY-) INCYTE PHARM INC.
 XX Bandman O, Hawkins PR, Murry LE, Goli SK;
 XX WPI, 2002-163701/21.
 DR N-PSDB; ABK15586, ABK15588.
 XX New human cytokines and encoding polynucleotides, useful for treating,
 PT diagnosing or preventing cancers, inflammation, allograft rejection,
 PT neurodegenerative diseases and conditions affecting growth.
 XX
 PS Claim 1; Fig 1; 34pp; English.
 XX
 XX The invention describes a novel human cytokine, designated NHC (I). (I)
 CC is useful for screening a compound for effectiveness as an agonist or
 CC antagonist and preparing a polyclonal antibody or monoclonal antibody,
 CC useful in a diagnostic test for a condition or a disease associated with
 CC the expression of NHC in a biological sample, by combining the sample
 CC with Ab and detecting the Ab-NHC complex. The sample. The polypeptide and
 CC polynucleotide are useful from diagnosing, treating and preventing
 CC cancers, inflammation (e.g. viral, bacterial, fungal, helminthic or
 CC protozoal infection, trauma, autoimmune diseases such as haemolytic
 CC anaemia, arteriosclerosis, asthma, biliary cirrhosis, cystic fibrosis,
 CC diabetes, glomerulonephritis, myasthenia gravis, osteoporosis,
 CC pancreaticitis, Sjogren's syndrome and scleroderma), allograft rejection,
 CC neurodegenerative diseases (e.g. Alzheimer's disease, amyotrophic lateral
 CC sclerosis, Huntington's disease, Parkinson's disease, epilepsy and Down's
 CC syndrome), and conditions affecting pregnancy, growth and development.
 CC (I) is also useful for stimulating cell proliferation, and thus in ex
 CC vivo therapies involving bone marrow cells, and for regenerating tissues
 CC or organs for transplantation such as kidney, liver, pancreas and spleen.
 CC (I) is also useful in drug screening techniques. This is the amino acid
 CC sequence of novel human cytokine-1 (NHC-1), described in the method of
 CC the invention
 XX
 XX Sequence 69 AA;
 XX
 XX
 XX Query Match 100.0%; Score 19; DB 5; Length 69;
 XX Best Local Similarity 100.0%; Pred. No. 2.9e+03;
 XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 A QGV 4
 ||||
 Db 5 A QGV 8
 RESULT 184
 ADA21106
 ID ADA21106 standard; protein; 69 AA.
 XX
 AC ADA21106;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human secreted protein SECP-11 SEQ ID NO:11.
 XX
 XX human, secreted protein, SECP, anti-HIV, antiallergic, antiinflammatory;
 KM antianaemic; antiparkinsonian; nootropic; anticonvulsant;
 KM antiarteriosclerotic; antiasthmatic; immunosuppressive; antithyroid;
 KM cyostatic; hepatotropic; dermatological; antidiabetic; nephrotropic;
 KM antigout; thymomelic; neuroprotective; osteopathic; antiarthritic;
 KM antiparasitic; antihelminthic; antiparasitic; uropathic;
 KM ophthalmological; antineumatic; haemostatic; antibacterial; virucide;
 KM protozoacide; fungicide; gene therapy; cell proliferative disorder;
 KM arteriosclerosis; atherosclerosis; cirrhosis; hepatitis;
 KM paroxysmal nocturnal haemoglobinuria; polycythaemia vera; psoriasis;
 KM primary thrombocytopaenia; cancer; developmental disorder;
 KM renal tubular acidosis; anaemia; mental retardation;
 KM neurological disorder; Alzheimer's disease; Parkinson's disease;

KM epilepsy; autoimmune disorder; inflammatory disorder; AIDS; allergy;
 KM asthma; autoimmune thyroiditis; contact dermatitis; Crohn's disease;
 KM diabetes mellitus; glomerulonephritis; Goodpasture's syndrome; gout;
 KM Graves' disease; Hashimoto's thyroiditis; irritable bowel syndrome;
 KM multiple sclerosis; osteoarthritis; osteoporosis; pancreatitis;
 KM Reiter's syndrome; rheumatoid arthritis; Sjogren's syndrome; uveitis;
 KM infection.
 XX
 OS Homo sapiens.
 XX
 PN WO2003068943-A2.
 XX
 PD 21-AUG-2003.
 XX
 XX 13-FEB-2003; 2003WO-US004712.
 PF
 XX
 XX 13-FEB-2002; 2002US-0357002P.
 PR 06-MAR-2002; 2002US-0362439P.
 PR 19-MAR-2002; 2002US-0366041P.
 XX
 PA (INCY-) INCYTE GENOMICS INC.
 XX
 PI Lehr-Mason PM, Kabie AE, Elliott VS, Marguis JP, Baughn MR;
 PI Hafalia NK, Tran UK, Jin P, Tang YT, Zebartadian Y, Swarnaker A;
 PI Peterson DP, Fu GK, Yue H, Jackson AA, Jiang X, Hawkins PR, Lai PG,
 PI Khare R, Lee S, Lee SY, Richardson TW, Chang H;
 XX WPI, 2003-689669/65.
 DR N-PSDB; ADA21157.
 XX
 XX New human secreted proteins and polynucleotides, useful for diagnosing,
 PT treating or preventing autoimmune or inflammatory disorders (e.g. AIDS,
 PT allergy, asthma or anaemia), multiple sclerosis, osteoporosis, cancer or
 PT hepatitis.
 XX
 PS Claim 1; Page 225; 295pp; English.
 XX
 XX The present sequence represents a human secreted protein (I) designated
 CC SECP-11. (I) have anti-HIV, antiallergic, antiinflammatory, antianaemic,
 CC antiparkinsonian, nootropic, anticonvulsant, antiarteriosclerotic,
 CC antiasthmatic, immunosuppressive, antithyroid, cyostatic, hepatotropic,
 CC dermatological, antidiabetic, nephrotropic, antigout, thymomelic,
 CC neuroprotective, osteopathic, uropathic, ophthalmological,
 CC antihelminthic, antiparasitic, antibacterial, virucide, protozoacide and
 CC antineumatic, haemostatic, antibacterial, uropathic, ophthalmological,
 CC fungicide activities, and can be used in gene therapy. The human secreted
 CC proteins (SECP), polynucleotides, agonists and antagonists of the present
 CC invention are useful for diagnosing, treating or preventing disorders
 CC associated with aberrant expression of SECP, particularly cell
 CC proliferative disorders (e.g. arteriosclerosis, atherosclerosis,
 CC cirrhosis, hepatitis, paroxysmal nocturnal haemoglobinuria, polycythaemia
 CC vera, psoriasis, primary thrombocytopaenia or cancer), developmental
 CC disorders (e.g. renal tubular acidosis, anaemia or mental retardation),
 CC neurological disorders (e.g. Alzheimer's disease, Parkinson's disease or
 CC epilepsy), autoimmune/inflammatory disorders (e.g. AIDS, allergies,
 CC asthma, autoimmune thyroiditis, contact dermatitis, Crohn's disease,
 CC diabetes mellitus, glomerulonephritis, Goodpasture's syndrome, gout,
 CC Graves' disease, Hashimoto's thyroiditis, irritable bowel syndrome,
 CC multiple sclerosis, osteoarthritis, osteoporosis, pancreatitis, Reiter's
 CC syndrome, rheumatoid arthritis, Sjogren's syndrome, uveitis), or viral,
 CC bacterial, fungal, parasitic, protozoan or helminthic infections. The
 CC SECP and polynucleotides are also useful in assessing the effects of
 CC exogenous compounds on the expression of nucleic acids secreted proteins.
 CC The polynucleotides encoding SECP are useful for creating transgenic
 CC animals to model human disease.
 XX
 XX Sequence 69 AA;
 XX
 XX Query Match 100.0%; Score 19; DB 6; Length 69;
 XX Best Local Similarity 100.0%; Pred. No. 2.9e+03;
 XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGGV 4
 Db 19 AGGV 22

RESULT 185
 ID ADA67726 standard; protein; 69 AA.
 ADA67726

AC ADA67726;

DT 20-NOV-2003 (first entry)

DE Novel human cytokine 1, NHC-1.

XX human; cytokine; neurodegenerative disorder; Parkinson's disease;
 KW Alzheimer's disease; allograft rejection; inflammation; infection; viral;
 KW bacterial; fungal; protozoal; autoimmune disease; diabetes;
 KW hemolytic anaemia; arteriosclerosis; asthma; cystic fibrosis;
 KW myasthenia gravis; allergy; osteoporosis; Grave's disease; cancer;
 KW leukaemia; cervical cancer; breast cancer; pregnancy; growth;
 KW development.

OS Homo sapiens.

PN US2003096371-A1.

PD 22-MAY-2003.

PF 19-NOV-2002; 2002US-00300257.

PR 31-JAN-1997; 97US-00792013.

PR 12-FEB-2001; 2001US-00782142.

PA (INCY-) INCYTE GENOMICS INC.

PI Bandman O, Hawkins PR, Murry LB, Goli SK;

XX WPI; 2003-658246/62.

DR N-PSDB; ADA67730.

XX New human cytokines, NHC-1 and NHC-2, and encoding polynucleotides,
 PT useful for diagnosing, preventing, and treating diseases with abnormal
 PT expression or activity of NHC, such as cancer, inflammatory and
 PT neurodegenerative diseases.

PS Claim 1; Fig 1; 35pp; English.

XX The invention relates to an isolated novel human cytokine polypeptide.
 CC The polypeptide or its fragments, and the polynucleotide encoding the
 CC polypeptide are useful in diagnosing, preventing, and treating disorders
 CC associated with an abnormal expression or activity of NHC, such as
 CC neurodegenerative disorders (e.g., Parkinson's disease, Alzheimer's
 CC disease), allograft rejection, inflammation caused by viral, bacterial,
 CC fungal or protozoal infection, autoimmune diseases (e.g., diabetes,
 CC hemolytic anaemia, arteriosclerosis, asthma, cystic fibrosis, myasthenia
 CC gravis, allergies, osteoporosis and Grave's disease), cancers (e.g.
 CC leukaemia, cervical or breast cancer) and conditions affecting
 CC pregnancy, growth and development. The polynucleotides can be used to
 CC create humanised animals or transgenic animals to model human disease.
 CC The present sequence represents the amino acid sequence of novel human
 CC cytokine 1, NHC-1.

XX Sequence 69 AA;

Query Match 100.0%; Score 19; DB 7; Length 69;

Best Local Similarity 100.0%; Pred. No. 2.9e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGGV 4
 Db 5 AGGV 8

RESULT 186
 ID AAY65387 standard; protein; 71 AA.
 AAY65387

AC AAY65387;

DT 01-FEB-2000 (first entry)

DE Human 5' EST related polypeptide SEQ ID NO:1548.

XX Human; 5' EST; expressed sequence tag; secreted protein; diagnosis;
 KW gene therapy; chromosome mapping; upstream regulatory sequence; forensic;
 KW location; development; protein synthesis; stability; regulation;
 KW identification.

OS Homo sapiens.

PN WO9953051-A2.

PD 21-OCT-1999.

PF 09-APR-1999; 99WO-IB000712.

PR 09-APR-1998; 98US-00057719.

PR 28-APR-1998; 98US-00069047.

PA (GEST) GENSET.

PI Dumas Milne Edwards J, Duclet A, Giordano J;

XX WPI; 2000-038446/03.

DR N-PSDB; AAZ43001.

XX Novel secreted protein 5' expressed sequence tag sequences used in
 PT diagnostic, forensic, gene therapy, and chromosome mapping procedures.
 PS Claim 3; Page 816; 837pp; English.

XX AA242265 to AA243075 represent novel 5' expressed sequence tag (EST)
 CC sequences, corresponding to human secreted proteins. AAY64651 to AAY65438
 CC represent the EST-related proteins corresponding to AA242265 to AA243052.
 CC The 5' ESTs can be used for producing secreted human gene products. They
 CC can be used to identify and isolate 5' untranslated regions (UTRs) and
 CC upstream regulatory regions which control the location, development
 CC stage, rate, and quantity of protein synthesis, as well as stability of
 CC mRNA. The ESTs are also useful as probes for chromosome mapping, and to
 CC obtain full length cDNA clones. The ESTs can also be used in forensic
 CC procedures to identify individuals, or in diagnostic procedures to
 CC identify individuals having genetic diseases resulting from abnormal gene
 CC expression. The products may also be used in gene therapy protocols. The
 CC nucleic acids encoding signal peptides can be used for directing
 CC extracellular secretion of a polypeptide or the insertion of a cell. The
 CC polypeptide into a membrane, or importing a polypeptide into a cell. The
 CC proteins encoded by the EST sequences may be useful in treating a variety
 CC of human conditions. Secreted proteins have therapeutic value, and the
 CC identification of new secreted proteins is valuable. AA242249 to AA242264
 CC and AAY64644 to AAY64650 represent sequences used in the exemplification
 CC of the present invention

XX Sequence 71 AA;

Query Match 100.0%; Score 19; DB 3; Length 71;

Best Local Similarity 100.0%; Pred. No. 3e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGGV 4
 Db 59 AGGV 62

RESULT 187
 AAB63498

ID AAB63498 standard; protein; 71 AA.
XX AAB63498;
AC
XX
XX 26-MAR-2001 (first entry)
DT
XX
DE Human gastric cancer associated antigen protein sequence SEQ ID NO:860.
XX
XX Human; breast cancer; gastric cancer; prostate cancer; diagnosis;
XX cancer associated antigen; cytostatic; cancer vaccine.
XX
XX Homo sapiens.
OS
XX MO200073801-A2.
PN
XX 07-DEC-2000.
PD
XX
XX 26-MAY-2000; 2000MO-US014749.
PF
XX
XX 28-MAY-1999; 99US-0136526P.
PR
XX 10-SEP-1999; 99US-0153454P.
PR
XX (LUDM-) LUDMIG INST CANCER RES.
PA
XX
PI Obata Y;
XX
XX WPI; 2001-025274/03.
DR
XX
XX Nucleic acids encoding breast, gastric and prostate cancer associated
PT antigen precursors, useful for diagnosing and treating a condition
PT characterized by expression of an abnormal amount of a protein, e.g.
PT cancer.
XX
XX Example 1; Page 589; 729pp; English.
PS
XX AAF22422 to AAF22626, AAF22627 to AAF22773 and AAF22774 to AAF23014
XX represent nucleotide sequences encoding human breast, gastric and
CC prostate cancer associated antigen precursors (CAAP) respectively.
CC AAB63332 to AAB63467, AAB63468 to AAB63721 and AAB63722 to AAB63970
CC represent human breast, gastric and prostate CAAP protein sequence
CC respectively. CAAPs have cytostatic activity and can be used in the
CC production of cancer vaccines. The human CAAP proteins, peptides, nucleic
CC acids or anti-CAAP antibodies are useful for diagnosing and treating a
CC condition characterized by expression of an abnormal amount of a protein,
CC e.g. cancer
XX
XX Sequence 71 AA;
SQ
XX
XX Query Match 100.0%; Score 19; DB 4; Length 71;
Best Local Similarity 100.0%; Pred. No. 3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 ACGV 4
Db 20 ACGV 23
|||||
RESULTS 188
ADU72951
ID ADU72951 standard; protein; 71 AA.
XX
XX ADU72951;
AC
XX
XX 10-FEB-2005 (first entry)
DT
XX
XX Non-signal peptide-containing polypeptide fragment, SEQ ID NO:1548.
DE
XX
XX Protein secretion; recombinant protein; diagnosis; mapping; forensic;
KM gene therapy.
XX
XX Homo sapiens.
OS
XX
XX US6822072-B1.
PN

XX 23-NOV-2004.
PD
XX
XX 21-DEC-1999; 99US-00471276.
PF
XX
XX 09-APR-1998; 98US-00057719.
PR
XX 28-APR-1998; 98US-00069047.
PR
XX 09-APR-1999; 99MO-1B000712.
XX
XX (GEST) GENSET SA.
XX
XX Edwards JDM, Duclert A, Giordano J;
PI
XX WPI; 2004-812112/80.
DR
XX N-PSDB; ADU72163.
DR
XX
XX New expressed sequence tags and encoded human proteins useful for
PT diagnosing, preventing or treating diseases such as autoimmune disorders,
PT inflammation, wounds or infections, or in forensic or chromosome mapping
PT procedures.
XX
XX Example 15; SEQ ID NO 1548; 72pp; English.
PS
XX
XX The invention relates to an isolated or purified signal peptide
CC consisting of residues 1-16 of ADU72234 (signal peptide given separately
CC as ADU73026) which directs the extracellular secretion of a polypeptide
CC to which it is operably linked. The invention also relates to a method of
CC producing the signal peptide. The invention further discloses: isolated,
CC purified or enriched 5' expressed sequence tags (ESTs), many of which
CC encode all or a part of a secretory signal peptide; polypeptides encoded
CC by these ESTs (EST-related polypeptides); antibodies which recognize the
CC EST-related polypeptides; vectors and host cells comprising EST-related
CC nucleic acids of the invention; an array of ESTs; methods involving the
CC use of signal peptides of the invention to target polypeptides; and
CC methods involving the use of ESTs of the invention, for example, in
CC identifying a promoter in genomic DNA. The EST-encoded signal peptides of
CC the invention are useful for directing the secretion or import of a
CC recombinant polypeptide via the generation of protein fusions comprising
CC such signal peptides. The ESTs, EST-related polypeptides and methods of
CC the invention can be used for forensic procedures, chromosome mapping,
CC diagnostics, and therapeutic procedures, including gene therapy.
CC Sequences ADU72920-ADU72956 represent incomplete polypeptides apparently
CC lacking a signal peptide which are encoded by the 5' ESTs shown in
CC ADU72132-ADU72168. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from the US patent office at
CC seqdata.uspto.gov/sequence.html?docid=US6822072.
XX
XX Sequence 71 AA;
SQ
XX
XX Query Match 100.0%; Score 19; DB 8; Length 71;
Best Local Similarity 100.0%; Pred. No. 3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 ACGV 4
Db 59 ACGV 62
|||||
RESULTS 189
ADU73942
ID ADU73942 standard; protein; 71 AA.
XX
XX ADU73942;
AC
XX
XX 28-JUL-2005 (first entry)
DT
XX
XX Human incomplete polypeptide not including a signal peptide.
DE
XX
XX expressed sequence tag; EST; expression; protein secretion; diagnostic;
KM forensic; gene therapy; haplotype mapping.
XX
XX Homo sapiens.
OS

XX US2005106595-A1.
PN
XX
PD 19-MAY-2005.
XX
PF 25-AUG-2004; 2004US-00926683.
XX
PR 09-APR-1998; 98US-00057719.
PR 28-APR-1998; 98US-00069047.
PR 09-APR-1999; 99WO-18000712.
PR 21-DEC-1999; 99US-00471276.
PA (GEST) GENSET SA.
XX
PI Dumas MEJ, Duclert A, Giordano J;
XX WPI; 2005-384300/39.
DR N-PSDB; AD273154.
XX
XX New purified nucleic acid expressing secreted proteins useful in
PT forensic, gene therapy, and chromosome mapping procedures, and diagnosing
PT or treating cancer, atherosclerosis and autoimmune diseases, diabetes,
PT asthma and infections.
XX
PS Claim 1; SEQ ID NO 1548; 79pp; English.
XX
XX The invention relates to a novel purified nucleic acid (I) comprising any
CC of (AD272418-AD273205) or (AD273994-AD274016) and their complements; at
CC least 15 consecutive nucleotides of (I) and their complements; or any of
CC 788 nucleotide sequences encoding fully defined sequences of 16-255 amino
CC acids (AD272206-AD273993). The invention discloses 5' EST's derived from
CC mRNAs encoding secreted proteins. The 5' EST's may be used to obtain
CC cDNAs and genomic DNAs corresponding to the 5' ESTs. The methods and
CC compositions of the present invention are useful for expressing secreted
CC proteins or its portions (claimed) or to obtain antibodies capable of
CC specifically binding to the secreted proteins, and in diagnostic,
CC forensic, gene therapy, and chromosome mapping procedures, and for
CC designing expression vectors and secretion vectors. The present sequence
CC is used in the exemplification of the invention. Note: The sequence data
CC for this patent is not represented in the printed specification but is
CC based on sequence information supplied in electronic format from the
CC USPTO web site seqdata.uspto.gov/sequence.html; Document ID: 20050106595.
XX
SQ Sequence 71 AA:
Query Match 100.0%; Score 19; DB 9; Length 71;
Best Local Similarity 100.0%; Pred. No. 3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ACGV 4
Db 59 ACGV 62
RESULT 190
AARS5812
ID AARS5812 standard; protein; 72 AA.
XX
AC AARS5812;
XX
DT 16-OCT-2003 (revised)
DT 25-MAR-2003 (revised)
DT 14-OCT-1994 (first entry)
XX
XX E. coli multiple antibiotic resistance (Mar) enhancer.
XX
XX Cloned Mar operon; Mar regulatory region; MarO; MarA; MarR; MarB;
XX lacZ marker locus; Increased antibiotic sensitivity; Repression of Mar;
XX Multiple antibiotic resistance operon; Enhancer.
XX Escherichia coli; (K12).
XX
PN MO9405810-A1.

XX 17-MAR-1994.
PD
XX
PF 27-AUG-1993; 93WO-US008115.
XX
PR 28-AUG-1992; 92US-00938085.
XX
PA (TUFT) TUFTS COLLEGE.
XX
PI Levy SB;
XX WPI; 1994-101214/12.
DR N-PSDB; AAQ58707.
XX
XX Predicting antibiotic effectiveness of compositions - by cloning
PT fragments of the Mar operon, and antimicrobial compositions contg. these
PT fragments Multiple antibiotic resistance operon.
XX
PS Disclosure; Page 31-32; 55pp; English.
XX
XX This is an enhancer protein encoded by a wild-type multiple antibiotic
CC resistance (Mar) operon cloned from E.coli. It is operably linked to the
CC Mar repressor and activator. This is useful to test antibiotic
CC effectiveness, and can be used to enhance the effectiveness of known
CC antimicrobials or render ineffective antimicrobials effective. (Updated
CC on 25-MAR-2003 to correct PN field.) (Updated on 16-OCT-2003 to
CC standardise OS field)
XX
SQ Sequence 72 AA:
Query Match 100.0%; Score 19; DB 2; Length 72;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ACGV 4
Db 17 ACGV 20
RESULT 191
AAW71459
ID AAW71459 standard; protein; 72 AA.
XX
AC AAW71459;
XX
DT 25-MAR-2003 (revised)
DT 07-DEC-1998 (first entry)
XX
DE Protein encoded by ORF 72.
XX
XX Multiple antibiotic resistance operon; mar; antisense;
XX bacterial resistance; antibiotic; mar enhancer; marB.
XX
XX Escherichia coli.
XX
PN USS817793-A.
XX
PD 06-OCT-1998.
XX
PF 08-APR-1994; 94US-00225480.
XX
PR 28-AUG-1992; 92US-00938085.
XX
PA (TUFT) TUFTS COLLEGE.
XX
PI Levy SB;
XX
XX WPI; 1998-556472/47.
DR N-PSDB; AAV60383.
XX
XX DNA encoding activator of multiple antibiotic resistance operon - and
PT anti-sense molecule for lowering antibiotic resistance of bacteria.
XX

PS Disclosure; Col 35-36; 22pp; English.
XX
CC The present sequence represents the protein encoded by open reading frame
CC (ORF) 72 of an Escherichia coli multiple antibiotic resistance (mar)
CC operon. ORF 72 encodes the mar enhancer, which is necessary for
CC expression of the full mar phenotype. Antisense molecules directed
CC against the mar operon can be used to lower the resistance of bacteria to
CC antibiotics. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ Sequence 72 AA;
SQ
Query Match 100.0%; Score 19; DB 2; Length 72;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
GY 1 AGV 4
Db 17 AGV 20
RESULT 192
AAU07749
ID AAU07749 standard; protein; 72 AA.
XX
AC AAU07749;
XX
DT 04-DEC-2001 (first entry)
XX
DE House dust mite allergenic protein Der p I variant e.
XX
KM House dust mite; allergenic protein; Der p I; Der p II; Der f I;
KM Der f II; antiallergenic; immunostimulant; house dust mite allergy;
KM T-cell epitope; polymorphic variant.
XX
OS Dermatophagoides pteronyssinus.
XX
FH Key Location/Qualifiers
FT Misc-difference 1 /note= "The protein is deletion variant where residues 1-
FT 150 of the wild-type mature Der p I have been deleted"
XX
PN US6268491-B1.
XX
PD 31-JUL-2001.
XX
PF 07-JUN-1995; 95US-00484296.
XX
PR 16-OCT-1991; 91US-00777859.
PR 08-MAY-1992; 92US-00881396.
PR 14-APR-1993; 93WO-US003471.
PR 14-APR-1994; 94US-00227772.
PR 19-MAY-1995; 95US-00445307.
XX
PA (IMMU-) IMMUNOLOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Kuo M, Rogers BL, Franzen HM, Chen X;
PI Evans S, Shaked Z;
XX
DR WPI; 2001-549074/61.
XX
PT Peptides comprising T cell groups of the major allergens from
PT Dermatophagoides (house dust mites), useful for treating house dust mite
PT allergy in humans, and for diagnosing sensitivity to house dust mite
PT protein allergens.
XX
PS Disclosure; Fig 22; 158pp; English.
XX
CC The invention relates to an isolated peptide of the major protein
CC allergens of the genus Dermatophagoides, which comprises at least one T
CC cell group of a protein allergen from Der p (DP) I, DP II, Der f (DF) I
CC or DF II. The isolated peptide comprises at least two regions, each
CC region comprising at least one T cell group of a protein allergen of the
CC genus Dermatophagoides. The regions are derived from the same or

CC different protein allergens of the genus Dermatophagoides. The peptides
CC are useful for treating house dust mite allergy in humans. The peptides
CC are also useful for detecting or diagnosing sensitivity to house dust
CC mite protein allergens. The present peptides have similar or enhanced
CC therapeutic properties as the naturally-occurring allergen, but have
CC reduced side effects, and increased solubility and stability. The present
CC sequence represents an allergenic protein from Dermatophagoides from
CC which the T-cell epitope containing peptides are derived, a polymorphic
CC variant of Der p I. Note: The present sequence is not shown in the
CC specification but is derived from the Der p I sequence shown in figure 22
XX
SQ Sequence 72 AA;
SQ
Query Match 100.0%; Score 19; DB 4; Length 72;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
GY 1 AGV 4
Db 30 AGV 33
RESULT 193
AAM87649
ID AAM87649 standard; protein; 72 AA.
XX
AC AAM87649;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen SEQ ID NO:15242.
XX
KM Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KM cytostatic; gene therapy; vaccine; metastasis.
XX
OS Homo sapiens.
XX
FN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001354.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 14-JUL-2000; 2000US-0217496P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.

PR	22-AUG-2000	2000US-0226279F
PR	22-AUG-2000	2000US-0226611P
PR	22-AUG-2000	2000US-0226688P
PR	23-AUG-2000	2000US-0227182P
PR	23-AUG-2000	2000US-0227009P
PR	30-AUG-2000	2000US-0228924P
PR	01-SEP-2000	2000US-0229287P
PR	01-SEP-2000	2000US-0229343P
PR	01-SEP-2000	2000US-0229344P
PR	01-SEP-2000	2000US-0229345P
PR	05-SEP-2000	2000US-0229509P
PR	05-SEP-2000	2000US-0229513P
PR	06-SEP-2000	2000US-0230437P
PR	06-SEP-2000	2000US-0230438P
PR	08-SEP-2000	2000US-0231242P
PR	08-SEP-2000	2000US-0231243P
PR	08-SEP-2000	2000US-0231244P
PR	08-SEP-2000	2000US-0231413P
PR	08-SEP-2000	2000US-0231414P
PR	08-SEP-2000	2000US-0232080P
PR	08-SEP-2000	2000US-0232081P
PR	12-SEP-2000	2000US-0231968P
PR	14-SEP-2000	2000US-0232397P
PR	14-SEP-2000	2000US-0232398P
PR	14-SEP-2000	2000US-0232399P
PR	14-SEP-2000	2000US-0232400P
PR	14-SEP-2000	2000US-0232401P
PR	14-SEP-2000	2000US-0233063P
PR	14-SEP-2000	2000US-0233064P
PR	14-SEP-2000	2000US-0233065P
PR	21-SEP-2000	2000US-02334223P
PR	21-SEP-2000	2000US-0234274P
PR	25-SEP-2000	2000US-0234997P
PR	25-SEP-2000	2000US-0234998P
PR	26-SEP-2000	2000US-0235844P
PR	27-SEP-2000	2000US-0235846P
PR	29-SEP-2000	2000US-0236327P
PR	29-SEP-2000	2000US-0236327P
PR	29-SEP-2000	2000US-0236368P
PR	29-SEP-2000	2000US-0236369P
PR	29-SEP-2000	2000US-0236370P
PR	02-OCT-2000	2000US-0237037P
PR	02-OCT-2000	2000US-0237038P
PR	02-OCT-2000	2000US-0237039P
PR	02-OCT-2000	2000US-0237040P
PR	13-OCT-2000	2000US-0239935P
PR	13-OCT-2000	2000US-0239937P
PR	20-OCT-2000	2000US-0240960P
PR	20-OCT-2000	2000US-0241221P
PR	20-OCT-2000	2000US-0241785P
PR	20-OCT-2000	2000US-0241786P
PR	20-OCT-2000	2000US-0241787P
PR	20-OCT-2000	2000US-0241808P
PR	20-OCT-2000	2000US-0241809P
PR	20-OCT-2000	2000US-0241826P
PR	01-NOV-2000	2000US-0244517P
PR	08-NOV-2000	2000US-0246474P
PR	08-NOV-2000	2000US-0246475P
PR	08-NOV-2000	2000US-0246476P
PR	08-NOV-2000	2000US-0246477P
PR	08-NOV-2000	2000US-0246478P
PR	08-NOV-2000	2000US-0246523P
PR	08-NOV-2000	2000US-0246524P
PR	08-NOV-2000	2000US-0246525P
PR	08-NOV-2000	2000US-0246526P
PR	08-NOV-2000	2000US-0246527P
PR	08-NOV-2000	2000US-0246528P
PR	08-NOV-2000	2000US-0246532P
PR	08-NOV-2000	2000US-0246609P
PR	08-NOV-2000	2000US-0246610P
PR	08-NOV-2000	2000US-0246611P

PR	08-NOV-2000;	2000US-0246613P.
PR	17-NOV-2000;	2000US-0249207P.
PR	17-NOV-2000;	2000US-0249208P.
PR	17-NOV-2000;	2000US-0249209P.
PR	17-NOV-2000;	2000US-0249210P.
PR	17-NOV-2000;	2000US-0249211P.
PR	17-NOV-2000;	2000US-0249212P.
PR	17-NOV-2000;	2000US-0249213P.
PR	17-NOV-2000;	2000US-0249214P.
PR	17-NOV-2000;	2000US-0249215P.
PR	17-NOV-2000;	2000US-0249216P.
PR	17-NOV-2000;	2000US-0249217P.
PR	17-NOV-2000;	2000US-0249218P.
PR	17-NOV-2000;	2000US-0249219P.
PR	17-NOV-2000;	2000US-0249220P.
PR	01-DEC-2000;	2000US-0250160P.
PR	01-DEC-2000;	2000US-0250391P.
PR	05-DEC-2000;	2000US-0251030P.
PR	05-DEC-2000;	2000US-0251988P.
PR	05-DEC-2000;	2000US-0256779P.
PR	06-DEC-2000;	2000US-0251471P.
PR	08-DEC-2000;	2000US-0251856P.
PR	08-DEC-2000;	2000US-0251869P.
PR	08-DEC-2000;	2000US-0251869P.
PR	08-DEC-2000;	2000US-0251989P.
PR	08-DEC-2000;	2000US-0251990P.
PR	11-DEC-2000;	2000US-0254097P.
PR	05-JAN-2001;	2001US-0259678P.
XX		
PA	(HMDA-) HUMAN GENOME SCI INC.	
PI	Rosen CA,	Ruben SM;
XX		
DR	WPI; 2001-483426/52.	
DR	N-PsDB; AAK60430.	
XX		
PT	Nucleic acids encoding human immune/hematopoietic antigen polypeptides.	
XX	useful for preventing, diagnosing and/or treating cancers and metastasis.	
PS	Claim 11; SEQ ID NO 15242; 3071pp + Sequence listing; English.	
XX		
CC	AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)	
CC	amino acid sequences given in AAM82170 to AAM91921. (I) have cytotoxic	
CC	activity, and can be used in gene therapy and vaccine production. (I)	
CC	proteins and polynucleotides may be used in the prevention, diagnosis and	
CC	treatment of diseases associated with inappropriate (I) expression. For	
CC	example, they may be used to treat disorders associated with decreased	
CC	expression by rectifying mutations or deletions in a patient's genome	
CC	that affect the activity of (I) by expressing inactive proteins or to	
CC	supplement the patients own production of (I). Additionally, (I)	
CC	polynucleotides may be used to produce the secreted (I), by inserting the	
CC	nucleic acids into a host cell and culturing the cell to express the	
CC	protein. (I) proteins and polynucleotides may be used to prevent,	
CC	diagnose and treat immune/hematopoietic-related diseases, especially	
CC	cancers and cancer metastases of hematopoietic-derived cells. AAK64703	
CC	to AAK67694 represent human immune/hematopoietic antigen genomic	
CC	sequences from the present invention. AAK54942 to AAK54950 and AAM62169	
CC	represent sequences used in the exemplification of the present invention	
XX		
SEQ	Sequence 72 AA;	
Query Match	100.0%; Score 19; DB 4; Length 72;	
Best Local Similarity	100.0%; Pred. No. 3.le+03;	
Matches	4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 AGGV 4	
DB	7 AGGV 10	

RESULT 194
AAU43630
ID AAU43630 standard; protein; 72 AA.
XX
AC AAU43630;
XX
DT 27-FEB-2002 (first entry)
XX
DE Propionibacterium acnes immunogenic protein #4526.
XX
KM SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KM uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KM inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KM dermatological; osteopathic; neuroprotectant.
XX
OS Propionibacterium acnes.
XX
PN W0200181581-A2.
XX
PD 01-NOV-2001.
XX
PF 20-APR-2001; 2001WO-US012865.
XX
PR 21-APR-2000; 2000US-0199047P.
PR 02-JUN-2000; 2000US-0208841P.
PR 07-JUL-2000; 2000US-0216747P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Skeiky YAM, Persing DH, Mitcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Yen S, Carter D;
XX
DR WPI: 2001-616774/71.
DR N-PSDB; AAS59521.
XX
PT Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris.
XX
PS Example 1; SEQ ID NO 4825; 1069pp; English.
XX
CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 72 AA;
XX
Query Match 100.0%; Score 19; DB 4; Length 72;
Best Local Similarity 100.0%; Pred. NO. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 AGGV 4
DB 51 AGGV 54

RESULT 195
ABU09526
ID ABU09526 standard; protein; 72 AA.
XX
AC ABU09526;
XX
DT 30-JUN-2003 (first entry)
XX
DE E. coli multiple antibiotic resistance operon protein MarB.
XX
KM Multiple antibiotic resistance; Mar; operon; infection; MarB; MarA;
KM ORF157; ORF266; ORF64; antimicrobial.
XX
OS Escherichia coli.
XX
PN US2003013104-A1.
XX
PD 16-JAN-2003.
XX
PF 22-APR-2002; 2002US-00131406.
XX
PR 28-AUG-1992; 92US-00938085.
PR 08-APR-1994; 94US-00225480.
PR 17-JUL-1998; 98US-00118445.
XX
PA (TUFT) UNIV TUFTS.
XX
PI Levy SB;
XX
DR WPI: 2003-401595/38.
DR N-PSDB; ABX95686.
XX
PT Identifying bacterial loci which affect resistance to antibiotic
PT compositions, by binding an activator of bacterial antibiotic resistance
PT operon to bacterial DNA, and assaying for sites on DNA to which activator
PT binds.
XX
PS Claim 84; Page 19; 26pp; English.
XX
CC The invention relates to identifying bacterial loci which affect
CC resistance to antibiotic compositions, involves allowing an activator of
CC a bacterial multiple antibiotic resistance (mar) operon to bind to a
CC bacterial DNA molecule, and assaying for sites on the DNA to which the
CC activator binds. The method alternatively involves introducing within the
CC bacteria an operable nucleotide sequence encoding at least a functional
CC fragment of an activator of a bacterial multiple antibiotic resistance
CC operon, where the fragment of the activator is capable of substantially
CC increasing the expression of a bacterial mar phenotype, and assaying for
CC changes in the levels of expression of the loci within the bacteria.
CC Substitively, the method involves subjecting bacteria to a first set of
CC conditions such that the bacteria express or do not express a mar
CC phenotype, introducing within the bacteria a nucleotide sequence
CC including a marker locus and free of a regulatory region operably joined
CC to the marker locus, permitting the sequence to integrate within a
CC chromosome or at random sites within a chromosome of the bacteria,
CC assaying for expression of the marker locus, subjecting a subset of the
CC bacteria which express or do not express the marker locus to a second set
CC of conditions such that the subset of bacteria do not express or express
CC the phenotype, assaying for bacteria in the subset of bacteria which do
CC not express or express the marker locus under the second set of
CC conditions, and determining the site of integration of the marker locus
CC in the subset of bacteria which express the marker locus under the first
CC set of conditions and which express or do not express the marker locus
CC under the second set of conditions. The method is useful for identifying
CC bacterial loci which affect resistance to antibiotic compositions. An
CC antibiotic composition is useful for inhibiting the growth of bacteria
CC (e.g. a bacteria causing an infection), by exposing the bacteria to a
CC composition including an amount of an antibiotic composition and an
CC amount of substance which substantially decreases the expression of a mar
CC phenotype by the bacteria. The substance is a nucleotide sequence
CC comprising at least a functional fragment of a repressor locus of a

CC bacterial mar operon operably joined to a regulatory region such that the
 CC expression of the repressor locus is substantially dependent upon the
 CC regulatory region and the sequence is free from operable sequences
 CC encoding an activator of a bacterial mar operon. The substance is a
 CC nucleotide sequence having substantial homology to at least a fragment of
 CC an activator locus of a bacterial multiple resistance operon and is an
 CC inhibitor of the activity of an activator of a bacterial mar operon. The
 CC E. coli mar operon encodes the MarR, MarB, MarA, ORF157, ORF266 and ORF64
 CC proteins. The present sequence is the MarB protein

XX Sequence 72 AA;

Query Match 100.0%; Score 19; DB 6; Length 72;

Best Local Similarity 100.0%; Pred. No. 3.1e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGGV 4
 Db 17 AGGV 20

RESULT 196

ABM40149
 ID ABM40149 standard; protein; 72 AA.

XX ABM40149;

XX 20-OCT-2003 (first entry)

XX Propionibacterium acnes predicted ORF-encoded polypeptide #4825.

XX Acne vulgaris; antiseborrheic; dermatological; antibacterial;

XX immunostimulant; immune response; vaccine.

XX Propionibacterium acnes.

XX WO2003033515-A1.

XX 24-APR-2003.

XX 11-OCT-2002; 2002WO-US032727.

XX 15-OCT-2001; 2001US-00978825.

XX (CORI-) CORIXA CORP.

XX Mitcham JL, Skeiky YAM, Persing DH, Bhadia A, Maisonneuve JL;
 PI Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
 PI Barth B, Valliave-Douglas J;

XX WPI; 2003-381789/36.

XX N-PSDB; ACF64450.

XX New Propionibacterium acnes polypeptides and polynucleotides encoding the
 PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
 PT or for stimulating an immune response specific for a P. acnes protein.

XX Example 1; SEQ ID NO 4825; 1481bp; English.

XX The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
 CC encoding a Propionibacterium acnes protein. The invention also relates to
 CC polypeptides encoded by the polynucleotides (ABM55624-ABM64536) and to
 CC immunogenic fragments of P. acnes polypeptides. The invention

CC additionally encompasses expression vectors and host cells comprising a
 CC polynucleotide of the invention; antibodies against polypeptides of the
 CC invention; fusion proteins comprising a polypeptide of the invention; a
 CC method for stimulating an immune response specific for a P. acnes

CC polypeptide and an isolated T cell population comprising T cells prepared
 CC via this method; a vaccine composition (comprising P. acnes polypeptides,
 CC polynucleotides, antibodies, fusion proteins, T cell populations, or

CC antigen-presenting cells that express the polypeptide); a method and kit
 CC for detecting or determining the presence or absence of P. acnes in a
 CC patient; and a method for inhibiting the development of P. acnes in a

CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
 CC proteins, T cell populations or antigen-presenting cells that express the
 CC polypeptides are useful for diagnosing, preventing or treating acne
 CC vulgaris, or for stimulating an immune response specific for a P. acnes
 CC protein. The polynucleotides can also be used as probes or primers for
 CC nucleic acid hybridisation. The vaccine composition is useful for the
 CC stimulation of an immune response against P. acnes, or for treating acne,
 CC and the kit is useful for performing a diagnostic assay. The present
 CC sequence represents a polypeptide predicted to be encoded by an ORF (open
 CC reading frame) contained within the P. acnes polynucleotides of the
 CC invention. Note: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 72 AA;

Query Match 100.0%; Score 19; DB 6; Length 72;
 Best Local Similarity 100.0%; Pred. No. 3.1e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGGV 4
 Db 51 AGGV 54

RESULT 197

AEA32550
 ID AEA32550 standard; protein; 72 AA.

XX AEA32550;

XX 25-AUG-2005 (first entry)

XX marc protein, SEQ ID 5.

XX Multidrug-resistance; antibiotic-resistance; operon.

XX Escherichia coli.

XX US2005136460-A1.

XX 23-JUN-2005.

XX 15-NOV-2004; 2004US-00989992.

XX 28-AUG-1992; 92US-00938085.

XX 08-APR-1994; 94US-00225480.

XX 17-JUL-1998; 98US-00118445.

XX 22-APR-2002; 2002US-00131406.

XX (LEVY/) LEVY S B.

XX Levy SB;

XX WPI; 2005-457506/46.

XX N-PSDB; AEA32545.

XX Method for predicting antibiotic effectiveness of a composition comprises
 PT exposing a bacteria to the composition and assaying the effect of the
 PT exposure on the expression of a genetic locus.

XX Disclosure; SEQ ID NO 6; 23pp; English.

XX The present invention relates to a method for predicting the antibiotic
 CC effectiveness of a composition (A). The method comprises exposing a
 CC bacteria to (A) and assaying the effect of the exposure on the expression
 CC of a genetic locus, where the expression is regulated in part and

CC indirectly by at least a functional fragment of a regulatory region of a
 CC bacterial multiple antibiotic resistance (mar) operon within the
 CC bacteria. The present sequence is a protein encoded by the wild-type mar

CC operon of E. coli which was used to illustrate the invention.

XX Sequence 72 AA;

Query Match 100.0%; Score 19; DB 9; Length 72;
 Best Local Similarity 100.0%; Pred. No. 3.1e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
 ||||
 Db 17 AOGV 20

RESULT 198
 ABP04492
 ID ABP04492 standard; protein; 74 AA.
 XX
 AC ABP04492;
 XX
 DT 24-JUN-2002 (first entry)
 XX
 DE Human ORFX protein sequence SEQ ID NO:8966.
 XX
 KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
 KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
 KW degenerative disorder; osteoarthritis; neurodegenerative disorder;
 KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
 KW hypertension; hypothyroidism; cholesterol ester storage disease;
 KW immune deficiency; immune disorder; infectious disease;
 KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
 KW myasthenia gravis.
 XX
 OS Homo sapiens.
 PN WO200192523-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 29-MAY-2001; 2001WO-US010836.
 XX
 PR 30-MAY-2000; 2000US-0206132P.
 PR 29-AUG-2000; 2000US-0228716P.
 XX
 PA (CURA-) CURAGEN CORP.
 PI Shimkete RA, Leach MD;
 DR WPI; 2002-106308/14.
 DR N-PSDB; ABN20244.
 XX
 PT Novel human polypeptides and polynucleotides useful for diagnosing,
 PT preventing and treating cardiovascular disease, neurodegenerative,
 PT hyperproliferative disorders and autoimmune disorders.
 XX
 PS Disclosure; SEQ ID NO 8966; 1037pp; English.
 XX
 CC The present invention describes substantially purified human proteins
 CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
 CC in the specification)). ABN15762 to ABN27252 encode the human ORFX
 CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
 CC treating or preventing a pathology associated with an ORFX-associated
 CC disorder in humans, and in the manufacture of a medicament for treating a
 CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
 CC sequences can be used in gene therapy. ORFX sequences can be used in the
 CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
 CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
 CC osteoarthritis, neurodegenerative disorders, disorders related to organ
 CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
 CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
 CC storage disease, various immune deficiencies and disorders, infectious
 CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
 CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
 CC disease and autoimmune inflammatory eye disease. ORFX proteins are also
 CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
 CC bone degenerative disorders, or periodontal disease, and for gut
 CC protection or regeneration and treatment of lung or liver fibrosis.

CC reperfusion injury in various tissues and conditions resulting from
 CC systemic cytokine damage. N.B. The sequence data for this patent did not
 CC form part of the printed specification, but was obtained in electronic
 CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX

Sequence 74 AA;
 SQ

Query Match 100.0%; Score 19; DB 5; Length 74;
 Best Local Similarity 100.0%; Pred. No. 3.1e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
 ||||
 Db 48 AOGV 51

RESULT 199
 ABP32468
 ID ABP32468 standard; protein; 74 AA.
 XX
 AC ABP32468;
 XX
 DT 08-JUL-2002 (first entry)
 XX
 DE Human ORF1441 protein, SEQ ID NO:2882.
 XX
 KW Human; ORF; open reading frame; ORFX; drug screening; diagnosis;
 KW disease monitoring; cytokine; cell proliferation; cell differentiation;
 KW immune modulation; haematopoiesis regulation; tissue growth;
 KW angiogenesis; activin; inhibin; chemotactic; chemokinetic; haemostatic;
 KW thrombolytic; tumour inhibition; bodily characteristics; fertility;
 KW behaviour; cancer; proliferative disorder; neurological disorder;
 KW cardiovascular disease; immune system disorder; organ transplantation;
 KW tissue growth disorder; tissue regeneration disorder; diabetes mellitus;
 KW hypothyroidism; cholesterol ester storage disease; infection; vulnery;
 KW vasoprotective; antipsoriatic; antidiabetic; cytostatic; nocotropic;
 KW neuroprotective; antiatherosclerotic; anticoagulant; thrombolytic;
 KW cardiac; hypotensive; antithyroid; antiinflammatory; immunomodulator;
 KW dermatological; analgesic; virucide; antibacterial; fungicide.
 XX
 OS Homo sapiens.
 PN WO200190366-A2.
 XX
 PD 29-NOV-2001.
 XX
 PF 24-MAY-2001; 2001WO-US017076.
 XX
 PR 24-MAY-2000; 2000US-0206690P.
 XX
 PA (CURA-) CURAGEN CORP.
 PI Leach MD, Shimkete RA;
 DR WPI; 2002-106200/14.
 DR N-PSDB; ABN76494.
 XX
 PT Novel human polypeptides and polynucleotides useful for diagnosing,
 PT preventing and treating cardiovascular disease, neurodegenerative,
 PT hyperproliferative disorders and disorders related to organ
 PT transplantation.
 XX
 PS Claim 10; Page 980; 2508pp; English.
 XX
 CC Sequences ABP31028-ABP35561 represent 4534 novel human proteins
 CC designated ORF (open reading frame) 1-4534, and sequences ABN75054-
 CC ABN79587 represent cDNAs encoding them. The invention also encompasses
 CC polypeptides at least 80% identical to the ORF1-ORF4534 (collectively
 CC referred to as ORFX) proteins, polynucleotides at least 85% identical to
 CC the ORFX nucleic acid sequences, vectors and host cells comprising ORFX
 CC polynucleotides, the recombinant production of ORFX proteins, antibodies
 CC specific for ORFX proteins, methods of detecting ORFX polynucleotides and
 CC polypeptides, methods of screening for modulators of ORFX expression or

CC activity, and methods of screening individuals for a predisposition to an
 CC ORFX-associated disorder. The ORFX proteins of the invention have a wide
 CC range of biological activities, such as cytokine, cell proliferation,
 CC cell differentiation, immune modulation, haematopoietic regulation,
 CC tissue growth, angiogenesis, activin or inhibin activity, chemotactic/
 CC chemokinetic activity, haemostatic activity, thrombolytic activity,
 CC receptor/ligand, antiinflammatory activity, tumour inhibition activity,
 CC and anti-infective activity, and may also be involved in the determination
 CC of bodily characteristics, fertility and behaviour. ORFX proteins,
 CC nucleic acids and antibodies may be used in the treatment of cancers,
 CC other proliferative disorders such as psoriasis and benign tumours,
 CC neurological disorders such as epilepsy and Alzheimer's disease,
 CC cardiovascular diseases, immune system disorders, disorders related to
 CC organ transplantation, disorders of tissue growth and regeneration,
 CC diseases such as diabetes mellitus, hypothyroidism, and cholesterol ester
 CC storage disease, and infectious diseases caused by viral, bacterial,
 CC fungal and other pathogens. ORFX nucleic acids may also be used as a
 CC source of primers and probes, in the detection of ORFX genomic sequences
 CC or transcripts, in the identification and cloning of homologous
 CC sequences, in genetic diagnosis, and in forensic biology. The ORFX
 CC nucleic acids may additionally be used to produce transgenic animals
 CC which may be useful for studying the function and/or activity of ORFX
 CC protein, and in drug screening. The ORFX proteins may also be used as
 CC immunogens to generate specific antibodies, which are useful in the
 CC diagnosis, treatment and monitoring of ORFX-associated diseases

CC Sequence 74 AA;

Query Match 100.0%; Score 19; DB 5; Length 74;
 Best Local Similarity 100.0%; Pred. No. 3.1e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
 |||||
 Db 48 ACGV 51

RESULT 200
 ABP64192

ID ABP64192 standard; protein; 75 AA.

XX ABP64192;

XX 04-NOV-2002 (first entry)

XX Human ORF562.

XX Cytostatic; Cardiant; Anti-allergic; Immunosuppressive; Vulnery;

KM Antiinflammatory; gene therapy; human; ORFX; atherogenic; platelet;

KM human umbilical vein endothelial cell; HUVEC; atherosclerotic plaque;

KM cancer; cardiovascular disease; allergy; autoimmune disease;

KM wound healing; blood coagulation disorder; inflammatory disorder.

OS Homo sapiens.

XX US2002082206-A1.

XX 27-JUN-2002.

XX 30-MAY-2001; 2001US-00867550.

XX 30-MAY-2000; 2000US-0208427P.

XX (LEAC/) LEACH M D.

XX (MEHR/) MEHRABAN F.

XX (CONL/) CONLEY P B.

XX (TOPP/) TOPPER J N.

XX (LAWD/) LAW D.

XX Leach MD, Mehraban F, Conley PB, Topper JN, Law D;

XX WPI; 2002-626554/67.

XX N-PSDB; ABQ98755.

XX New polypeptide designated ORFX are present in human atherogenic cells
 PT and are useful to prevent and treat ORFX-associated disorders including
 PT cancer, allergy, wound healing or autoimmune, cardiovascular or
 PT inflammatory disease.

PS Claim 10; SEQ ID NO 1124; 78pp; English.

CC The present invention relates to novel human ORFX polypeptides and their
 CC coding sequences (ABP63631-ABP64681 and ABQ98194-ABQ99267). The sequences
 CC were discovered in human atherogenic cells, in particular in platelets
 CC and human umbilical vein endothelial cells (HUVEC) and are expressed in
 CC many other tissues as well. Atherogenic cells are cells which have the
 CC potential to develop atherosclerotic plaques. The ORFX polypeptides and
 CC nucleic acids are useful for treating or preventing a pathological
 CC condition associated with an ORFX-associated disorder, e.g. cancer,
 CC cardiovascular disease, allergy, autoimmune disease, wound healing, blood
 CC coagulation disorders or inflammatory disorders. Note: The sequence data
 CC for this patent did not form part of the printed specification, but was
 CC obtained in electronic format directly from the USPO web site at
 CC seqdata.uspo.gov/sequence.html?docid=2020082206

CC Sequence 75 AA;

Query Match 100.0%; Score 19; DB 5; Length 75;
 Best Local Similarity 100.0%; Pred. No. 3.2e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
 |||||
 Db 4 ACGV 7

RESULT 201
 AAW72051

ID AAW72051 standard; protein; 76 AA.

XX AAW72051;

XX 07-DEC-1998 (first entry)

XX HSV-2 strain SB5 Contig ID 38 ORF#1 protein.

KM HSV-2 strain SB5; immunological response induction; therapy;

KM antiviral identification; viral protein inhibitor.

XX Herpes simplex virus 2.

XX WO9820016-A1.

XX 14-MAY-1998.

XX 31-OCT-1997; 97WO-US020016.

XX 04-NOV-1996; 96US-0030279P.

XX 09-JUN-1997; 97US-0049018P.

XX (SMIK) SMITHKLINE BEECHAM CORP.

XX Besser KM, Chan JY, Dabrowski-Amara1 CE, Delvecchio AM, Dillon SB;

XX Leary JM;

XX WPI; 1998-286847/25.

XX N-PSDB; AAV62136.

XX Herpes simplex virus type-2 sequences - useful in, e.g. prevention and

XX treatment of infection or inducing immunological response in mammal.

XX Claim 10; Page 59; 748pp; English.

XX This sequence represents a Herpes simplex virus type-2 (HSV-2) protein

XX sequence of the invention. This sequence was isolated from a HSV-2 strain

XX SB5 (deposited as ATCC VR-2546) DNA fragment designated Contig ID 38.

CC Based on homology, this sequence is a minor capsid protein I2. The
CC proteins can be used for the treatment or prevention of disease, to
CC induce an immunological response in a mammal or to identify inhibitors,
CC activators or novel antivirals. Antagonists of the proteins can be used
CC to inhibit a viral polypeptide. The DNA sequence or a vector containing
CC it can also be used to induce an immunological response in a mammal
XX
SQ Sequence 76 AA;
Query Match 100.0%; Score 19; DB 2; Length 76;
Best Local Similarity 100.0%; Pred. No. 3.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 AGV 4
Db 6 AGV 9
RESULT 202
ABO56564
ID ABO56564 standard; protein; 76 AA.
XX
AC ABO56564;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human genome derived single exon protein #2798.
XX
KM Human; gene expression; single exon probe; microarray;
XX alternative splicing event; genomic alteration.
XX
OS Homo sapiens.
XX
PN US2003194704-A1.
XX
PD 16-OCT-2003.
XX
PF 03-APR-2002; 2002US-00029386.
XX
PR 03-APR-2002; 2002US-00029386.
XX
PA (PENN/) PENN S G.
XX (RANK/) RANK D R.
XX (HANZ/) HANZEL D K.
XX
PI Penn SG, Rank DR, Hanzel DK;
XX
DR WPI; 2004-119264/12.
XX
PT New human genome-derived single exon nucleic acid probes useful for human
PT gene expression analysis, for identifying or characterizing alternative
PT splicing events, for assessing genomic alterations or as tools for
PT surveying tissues.
XX
PS Claim 45; SEQ ID NO 30198; 80pp; English.
XX
XX The invention relates to a nucleic acid probe for measuring human gene
XX expression, comprising any of the 27,400 fully defined nucleotide
XX sequences in the specification, or their complements or fragments, and
XX encoding at least 8 amino acids of any of the 6888 amino acid sequences
XX fully defined in the specification. The probe is a single exon probe that
XX hybridises under high stringency conditions to a nucleic acid molecule
XX expressed in human cells or tissues. Also included are a spatially-
XX addressable set of single exon nucleic acid probes for measuring human
XX gene expression (comprising a plurality of single exon nucleic acid
XX probes cited above, where each of the plurality of probes is separately
XX and addressably isolatable or amplifiable from the plurality), a single
XX exon microarray for measuring human gene expression, a method of
XX measuring human gene expression, a vector comprising the single exon
XX probe cited above, an ORF-encoded peptide comprising at least 8
XX contiguous amino acids of any of the above-mentioned amino acid
XX sequences (optionally with conservative amino acid substitutions), an
XX isolated antibody that binds specifically to a peptide cited above,

CC methods of selling and/or licensing single exon probes or microarrays to
CC a customer desiring to measure gene expression, a method of providing
CC human gene expression data by subscription, and a computer-readable
CC storage medium which contains a database having a plurality of records
CC (each record including data on the expression of a single exon probe
CC cited above. The probe, methods and apparatus are useful in gene
CC expression analysis. The probes may be used as tools for surveying
CC tissues to detect the presence of expressed messages that contain their
CC specific exon, or in constructing genome-derived single exon microarrays.
CC In addition, the probes are used in identifying and characterising
CC alternative splicing events, in detecting and characterising gross
CC alterations in the genomic locus that includes their exon, in assessing
CC smaller genomic alterations, in priming the synthesis of nucleic acids,
CC or in expressing the ORF-encoded peptide. The present sequence is a human
CC single exon probe protein of the invention. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?docID=20030194704
XX
SQ Sequence 76 AA;
Query Match 100.0%; Score 19; DB 8; Length 76;
Best Local Similarity 100.0%; Pred. No. 3.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 AGV 4
Db 59 AGV 62
RESULT 203
ADL05542
ID ADL05542 standard; protein; 77 AA.
XX
AC ADL05542;
XX
DT 06-MAY-2004 (first entry)
XX
DE M. catarrhalis protein #1308.
XX
KM Moraxella catarrhalis; infection.
XX
OS Moraxella catarrhalis.
XX
PN US6673910-B1.
XX
PD 06-JAN-2004.
XX
PF 04-APR-2000; 2000US-00540236.
XX
PR 08-APR-1999; 99US-0128416P.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
XX
PI Breton GL;
XX
DR WPI; 2004-178127/17.
DR N-PSDB; ADL03622.
XX
PT New nucleic acid encoding a Moraxella catarrhalis polypeptide, useful for
PT preparing a composition for diagnosing, preventing or treating infection
PT caused by Moraxella catarrhalis.
XX
PS Disclosure; SEQ ID NO 3228; 429pp; English.
XX
XX The invention relates to an isolated nucleic acid encoding an Moraxella
XX catarrhalis polypeptide. The nucleic acid is useful for preparing a
XX composition for diagnosing, preventing or treating infection caused by
XX Moraxella catarrhalis. The present sequence represents the amino acid
XX sequence of a M. catarrhalis protein.
XX
SQ Sequence 77 AA;

Query Match 100.0%; Score 19; DB 8; Length 77;
 Best Local Similarity 100.0%; Pred. No. 3.3e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 ACGV 4
 ||||
 DB 47 ACGV 50

RESULT 204

AAU59277
 ID AAU59277 standard; protein; 78 AA.

XX AAU59277;

XX 27-FEB-2002 (first entry)

XX Propionibacterium acnes immunogenic protein #20173.

XX SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
 KM uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
 KM inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
 KM dermatological; osteopathic; neuroprotectant.

XX Propionibacterium acnes.

XX MO200181581-A2.

XX 01-NOV-2001.

XX 20-APR-2001; 2001MO-US012865.

XX 21-APR-2000; 2000US-0199047P.

XX 02-JUN-2000; 2000US-0208841P.

XX 07-JUL-2000; 2000US-0216747P.

XX (CORI-) CORIXA CORP.

XX Sheily YW, Persing DH, Mitcham JL, Wang SS, Bharia A;
 PI L'atsomeuve J, Zhang Y, Jen S, Carter D;

XX WPI; 2001-616774/71.

XX N-PSDB; AAS59601.

XX Propionibacterium acnes polypeptides and nucleic acids useful for
 PT vaccinating against and diagnosing infections, especially useful for
 PT treating acne vulgaris.

XX Example 1; SEQ ID NO 20472; 1069pp; English.

XX Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
 CC polypeptides. The proteins and their associated DNA sequences are used in
 CC the treatment, prevention and diagnosis of medical conditions caused by
 CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
 CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
 CC P. acnes is also involved in infections of bone, joints and the central
 CC nervous system, however it is particularly involved in the inflammatory
 CC lesions associated with acne vulgaris. A method for detecting the
 CC presence or absence of P. acnes in a patient comprises contacting a
 CC sample with a binding agent that binds to the proteins of the invention
 CC and determining the amount of bound protein in the sample. The
 CC polypeptides may be used as antigens in the production of antibodies
 CC specific for P. acnes proteins. These antibodies can be used to
 CC downregulate expression and activity of P. acnes polypeptides and
 CC therefore treat P. acnes infections. The antibodies may also be used as
 CC diagnostic agents for determining P. acnes presence, for example, by
 CC enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
 CC this patent did not form part of the printed specification, but was
 CC obtained in electronic format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 78 AA;

Query Match 100.0%; Score 19; DB 4; Length 78;
 Best Local Similarity 100.0%; Pred. No. 3.3e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 ACGV 4
 ||||
 DB 11 ACGV 14

RESULT 205

ABG26469
 ID ABG26469 standard; protein; 78 AA.

XX ABG26469;

XX 18-FEB-2002 (first entry)

XX Novel human diagnostic protein #26460.

XX Human; chromosome mapping; gene mapping; gene therapy; forensic;
 KM food supplement; medical imaging; diagnostic; genetic disorder.

XX Homo sapiens.

XX MO200175067-A2.

XX 11-OCT-2001.

XX 30-MAR-2001; 2001MO-US008631.

XX 31-MAR-2000; 2000US-00540217.

XX 23-AUG-2000; 2000US-00649167.

XX (HYSE-) HYSEQ INC.

XX Dermanac RT, Liu C, Tang YT;

XX WPI; 2001-639362/73.

XX N-PSDB; AAS90656.

XX New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity.

XX Claim 20; SEQ ID NO 56828; 103pp; English.

XX The invention relates to isolated polynucleotide (I) and polypeptide (II)
 CC sequences. (I) is useful as hybridisation probes, polymerase chain
 CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,
 CC and in recombinant production of (II). The polynucleotides are also used
 CC in diagnostics as expressed sequence tags for identifying expressed
 CC genes. (I) is useful in gene therapy techniques to restore normal
 CC activity of (II) or to treat disease states involving (II). (II) is
 CC useful for generating antibodies against it, detecting or quantitating a
 CC polypeptide in tissue, as molecular weight markers and as a food
 CC supplement. (II) and its binding partners are useful in medical imaging
 CC of sites expressing (II). (I) and (II) are useful for treating disorders
 CC involving aberrant protein expression or biological activity. The
 CC polypeptides and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic
 CC amino acid sequences of the invention. Note: The sequence data for this
 CC patent did not appear in the printed specification, but was obtained in
 CC electronic format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 78 AA;

XX Query Match 100.0%; Score 19; DB 4; Length 78;
 XX Best Local Similarity 100.0%; Pred. No. 3.3e+03;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
 ||||
 Db 55 AOGV 58

RESULT 206

ABM55796
 ID ABM55796 standard; protein; 78 AA.

AC ABM55796;

DT 20-OCT-2003 (first entry)

DE Propionibacterium acnes predicted ORF-encoded polypeptide #20472.

KW Acne vulgaris; antiseborrheic; dermatological; antibacterial;

KW immunostimulant; immune response; vaccine.

OS Propionibacterium acnes.

PN WO2003033515-A1.

PD 24-APR-2003.

PF 11-OCT-2002; 2002WO-US032727.

PR 15-OCT-2001; 2001US-00978825.

PA (CORI-) CORIXA CORP.

PI Mitcham JT, Skeiky YAW, Persing DH, Bhatia A, Maisonneuve JL;

P1 Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;

P1 Barth B, Valliave-Douglas J;

DR WPI: 2003-381789/36.

DR N-PSDB; ACF64530.

PT New Propionibacterium acnes polypeptides and polynucleotides encoding the
 PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
 PT or for stimulating an immune response specific for a P. acnes protein.

PS Example 1; SEQ ID NO 20472; 1481bp; English.

CC The invention relates to an isolated polynucleotide (ACF6435-ACF64733)
 CC encoding a Propionibacterium acnes protein. The invention also relates to
 CC polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
 CC immunogenic fragments of P. acnes polypeptides. The invention
 CC additionally encompasses expression vectors and host cells comprising a
 CC polynucleotide of the invention; antibodies against polypeptides of the
 CC invention; fusion proteins comprising a polypeptide of the invention; a
 CC method for stimulating an immune response specific for a P. acnes
 CC polypeptide and an isolated T cell population comprising T cells prepared
 CC via this method; a vaccine composition (comprising P. acnes polypeptides,
 CC polynucleotides, antibodies, fusion proteins, T cell populations, or
 CC antigen-presenting cells that express the polypeptide); a method and kit
 CC for detecting or determining the presence or absence of P. acnes in a
 CC patient; and a method for inhibiting the development of P. acnes in a
 CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
 CC polypeptides, T cell populations or antigen-presenting cells that express the
 CC polypeptides are useful for diagnosing, preventing or treating acne
 CC vulgaris, or for stimulating an immune response specific for a P. acnes
 CC protein. The polynucleotides can also be used as probes or primers for
 CC nucleic acid hybridisation. The vaccine composition is useful for the
 CC stimulation of an immune response against P. acnes, or for treating acne,
 CC and the kit is useful for performing a diagnostic assay. The present
 CC sequence represents a polypeptide predicted to be encoded by an ORF (open
 CC reading frame) contained within the P. acnes polynucleotides of the
 CC invention. Note: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pcf_sequences

SEQ Sequence 78 AA;

Query Match 100.0%; Score 19; DB 6; Length 78;
 Best Local Similarity 100.0%; Pred. No. 3.3e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AOGV 4
 ||||
 Db 11 AOGV 14

RESULT 207

ABP01669
 ID ABP01669 standard; protein; 79 AA.

AC ABP01669;

DT 24-JUN-2002 (first entry)

DE Human ORFX protein sequence SEQ ID NO:3320.

KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;

KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;

KW degenerative disorder; osteoarthritis; neurodegenerative disorder;

KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;

KW hypertension; hypothyroidism; cholesterol ester storage disease;

KW immune deficiency; immune disorder; infectious disease;

KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;

KW myasthenia gravis.

OS Homo sapiens.

PN WO200192523-A2.

PD 06-DEC-2001.

PF 29-MAY-2001; 2001WO-US010836.

PR 30-MAY-2000; 2000US-0206132P.

PR 29-AUG-2000; 2000US-0228716P.

PA (CURA-) CURAGEN CORP.

PI Shinkets RA, Leach MD;

DR WPI: 2002-106308/14.

DR N-PSDB; ABN17421.

PT Novel human polypeptides and polynucleotides useful for diagnosing,
 PT preventing and treating cardiovascular disease, neurodegenerative,
 PT hyperproliferative disorders and autoimmune disorders.

PS Disclosure; SEQ ID NO 3320; 1037bp; English.

CC The present invention describes substantially purified human proteins
 CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
 CC in the specification)). ABN15762 to ABN27252 encode the human ORFX
 CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
 CC treating or preventing a pathology associated with an ORFX-associated
 CC disorder in humans, and in the manufacture of a medicament for treating a
 CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
 CC sequences can be used in gene therapy. ORFX sequences can be used in the
 CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
 CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
 CC osteoarthritis, neurodegenerative disorders, disorders related to organ
 CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
 CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
 CC storage disease, various immune deficiencies and disorders, infectious
 CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
 CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
 CC disease and autoimmune inflammatory eye disease. ORFX proteins are also
 CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
 CC bone degenerative disorders, or periodontal disease, and for gut

CC protection or regeneration and treatment of lung or liver fibrosis;
CC reperfusion injury in various tissues and conditions resulting from
CC systemic cytokine damage. N.B. The sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 79 AA;

Query Match 100.0%; Score 19; DB 5; Length 79;
Best Local Similarity 100.0%; Pred. No. 3.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 AOGV 4
|||
Db 54 AOGV 57

RESULT 208
AAG19634
ID AAG19634 standard; protein: 80 AA.

AC AAG19634;
XX
DT 17-OCT-2000 (first entry)
XX

DE Arabidopsis thaliana protein fragment SEQ ID NO: 21509.

XX Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KM termination sequence.

XX Arabidopsis thaliana.

PN EPI033405-A2.

PD 06-SEP-2000.

XX
PF 25-FEB-2000; 2000EP-00301439.

XX 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123160P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 22-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 28-APR-1999; 99US-0130891P.
PR 30-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 07-MAY-1999; 99US-0132487P.
PR 11-MAY-1999; 99US-0132863P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.

PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 14-JUN-1999; 99US-0138847P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140833P.
PR 29-JUN-1999; 99US-0140911P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142970P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.

```

PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-01471999;
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149903P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157533P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 14-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159589P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161929P.
PR 28-OCT-1999; 99US-0161932P.
PR 29-OCT-1999; 99US-0161933P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 100.0%; Score 19; DB 3; Length 80;
Best Local Similarity 100.0%; Pred. No. 3.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
   ||||
Db 60 AOGV 63

RESULT 209
ADH39815
ID ADH39815 standard; protein; 80 AA.
XX
XX ADH39815;
AC
XX
XX 11-MAR-2004 (first entry)
DT
XX
XX FarA amino acid sequence.
DE
XX actinomyces-originated plasmid; linear plasmid; pSLA2-L;
KW Streptomyces rochei; secondary metabolite; antibiotic; vitamin;
KW lankamycin; mithramycin-like substance; carotenoid; lankacidin.
XX
XX Unidentified.
OS
XX WO2004001039-A1.
PN
XX
XX 31-DEC-2003.
PD
XX
XX 19-JUN-2003; 2003WO-JP007767.
PP
XX
XX 20-JUN-2002; 2002JP-00179345.
PR
XX
XX (NISC-) JAPAN SCI & TECHNOLOGY CORP.
PA
XX
XX Kinashi H;
PI
XX
XX WPI; 2004-082503/08.
DR
XX
XX Actinomyces-originated plasmids for producing secondary metabolites e.g.
PT antibiotics and vitamins like lankamycins, lankacidins, mithramycin-like
PT substances and carotenoids.
PI
XX
XX Disclosure; Fig 6A; 499pp; Japanese.
PS
XX
XX The present invention describes an actinomyces-originated plasmid is a
CC linear plasmid (pSLA2-L) originating in Streptomyces rochei, which has a
CC base sequence capable of providing any of the protein sequences of SEQ ID
CC NO.1 to 143 (ADH39670 to ADH39812), or one based on these sequences but
CC with some amino acids deleted, substituted or added and capable of
CC producing a secondary metabolite. Also described is a process for
CC producing a secondary metabolite by using the plasmid. The plasmid can be
CC used for producing secondary metabolites e.g. antibiotics and vitamins
CC like lankamycins, mithramycin-like substances, carotenoids and
CC lankacidins. Such secondary metabolites are produced selectively and
CC efficiently. The present sequence represents an amino acid sequence given
CC in the exemplification of the present invention.
XX
XX Sequence 80 AA;
SQ

Query Match 100.0%; Score 19; DB 8; Length 80;
Best Local Similarity 100.0%; Pred. No. 3.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
   ||||
Db 57 AOGV 60

RESULT 210
ABP10494
ID ABP10494 standard; protein; 81 AA.

```


XX ABP10494;
AC
XX
XX 24-JUN-2002 (first entry)
XX
XX Human ORFX protein sequence SEQ ID NO:20970.
XX
XX
XX Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
XX hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
XX degenerative disorder; osteoarthritis; neurodegenerative disorder;
XX cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
XX hyperextension; hypochyroidism; cholesterol ester storage disease;
XX immune deficiency; immune disorder; infectious disease;
XX autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
XX myasthenia gravis.
XX Homo sapiens.
XX
XX WO200192523-A2.
XX
XX 06-DEC-2001.
XX
XX 29-MAY-2001; 2001WO-US010836.
XX
XX 30-MAY-2000; 2000US-0206132P.
XX 29-AUG-2000; 2000US-0228716P.
XX
XX (CURA-) CURAGEN CORP.
XX
XX Shinkets RA, Leach MD;
XX
XX WPI; 2002-106308/14.
XX N-PSDB; ABN26246.
XX
XX Novel human polypeptides and polynucleotides useful for diagnosing,
XX preventing and treating cardiovascular disease, neurodegenerative,
XX hyperproliferative disorders and autoimmune disorders.
XX
XX
XX Disclosure; SEQ ID NO 20970; 1037bp; English.
XX
XX
XX The present invention describes substantially purified human proteins
XX (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
XX in the specification). ABN15762 to ABN27252 encode the human ORFX
XX protein given in ABP00010 to ABP11500. ORFX proteins are useful for
XX treating or preventing a pathology associated with an ORFX-associated
XX disorder in humans, and in the manufacture of a medicament for treating a
XX syndrome associated with ORFX-associated disorder. ORFX polynucleotide
XX sequences can be used in gene therapy. ORFX sequences can be used in the
XX treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
XX psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
XX osteoarthritis, neurodegenerative disorders, disorders related to organ
XX transplantation, cardiovascular diseases, diabetes mellitus, systemic
XX lupus erythematosus, hyperextension, hypochyroidism, cholesterol ester
XX storage disease, various immune deficiencies and disorders, infectious
XX diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
XX arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
XX disease and autoimmune inflammatory eye disease. ORFX proteins are also
XX useful for treating burns, incisions, ulcers, for treating osteoporosis,
XX bone degenerative disorders, or periodontal disease, and for gut
XX protection or regeneration and treatment of lung or liver fibrosis,
XX reperfusion injury in various tissues and conditions resulting from
XX systemic cytokine damage. N.B. The sequence data for this patent did not
XX form part of the printed specification, but was obtained in electronic
XX format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 81 AA;
SQ

Query Match 100.0%; Score 19; DB 5; Length 81;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 AAGV 4
|||||

DB 48 AAGV 51
RESULT 211
AAU52713
ID AAU52713 standard; protein; 82 AA.
XX
XX
XX AAU52713;
AC
XX
XX 27-FEB-2002 (first entry)
XX
XX
XX Propionibacterium acnes immunogenic protein #13609.
XX
XX
XX SAPHO syndrome; synovitis; acne; pustulosis; hyperostosis; osteomyelitis;
XX uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
XX inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
XX dermatological; osteopathic; neuroprotectant.
XX
XX
XX Propionibacterium acnes.
XX
XX
XX WO200181581-A2.
XX
XX
XX 01-NOV-2001.
XX
XX
XX 20-APR-2001; 2001WO-US012865.
XX
XX
XX 21-APR-2000; 2000US-0199047P.
XX 02-JUN-2000; 2000US-0208841P.
XX 07-JUL-2000; 2000US-0216747P.
XX
XX (CORI-) CORIXA CORP.
XX
XX
XX Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;
XX L'maisonneuve J, Zhang Y, Jen S, Carter D;
XX
XX WPI; 2001-616774/71.
XX N-PSDB; AAS59557.
XX
XX
XX Propionibacterium acnes polypeptides and nucleic acids useful for
XX vaccinating against and diagnosing infections, especially useful for
XX treating acne vulgaris.
XX
XX
XX Example 1; SEQ ID NO 13908; 1069bp; English.
XX
XX
XX Sequences AAU52713-AM68017 represent Propionibacterium acnes immunogenic
XX polypeptides. The proteins and their associated DNA sequences are used in
XX the treatment, prevention and diagnosis of medical conditions caused by
XX P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
XX pustulosis, hyperostosis and osteomyelitis), uveitis and endophthalmitis.
XX P. acnes is also involved in infections of bone, joints and the central
XX nervous system, however it is particularly involved in the inflammatory
XX lesions associated with acne vulgaris. A method for detecting the
XX presence or absence of P. acnes in a patient comprises contacting a
XX sample with a binding agent that binds to the proteins of the invention
XX and determining the amount of bound protein in the sample. The
XX polypeptides may be used as antigens in the production of antibodies
XX specific for P. acnes proteins. These antibodies can be used to
XX downregulate expression and activity of P. acnes polypeptides and
XX therefore treat P. acnes infections. The antibodies may also be used as
XX diagnostic agents for determining P. acnes presence, for example, by
XX enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
XX this patent did not form part of the printed specification, but was
XX obtained in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 82 AA;
SQ

Query Match 100.0%; Score 19; DB 4; Length 82;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 AAGV 4
|||||

Db 66 ACGV 69

RESULT 212

ABM49232
ID ABM49232 standard; protein; 82 AA.

XX ABM49232;

AC 20-OCT-2003 (first entry)

XX Propionibacterium acnes predicted ORF-encoded polypeptide #13908.

XX Acne vulgaris; antiseborrheic; dermatological; antibacterial;

XX Immunostimulant; immune response; vaccine.

XX Propionibacterium acnes.

XX WO200303515-A1.

XX 24-APR-2003.

XX 11-OCT-2002; 2002WO-US032727.

XX 15-OCT-2001; 2001US-00978825.

XX (CORI-) CORIXA CORP.

XX Mitcham JL, Skeiky YAW, Persing DH, Bhactia A, Maisonneuve JL;

XX Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;

XX Barth B, Vallieve-Douglase J;

XX WPI; 2003-381789/36.

XX N-PSDB; ACF64486.

XX Example 1; SEQ ID NO 13908; 1481bp; English.

XX The invention relates to an isolated polynucleotide (ACF64435-ACF64733) encoding a Propionibacterium acnes protein. The invention also relates to CC polypeptides encoded by the polynucleotides (ABM3624-ABM64536) and to CC immunogenic fragments of P. acnes polypeptides. The invention CC additionally encompasses expression vectors and host cells comprising a CC polynucleotide of the invention; antibodies against polypeptides of the CC invention; fusion proteins comprising a polypeptide of the invention; a CC method for stimulating an immune response specific for a P. acnes CC polypeptide and an isolated T cell population comprising T cells prepared CC via this method; a vaccine composition (comprising P. acnes polypeptides, CC polynucleotides, antibodies, fusion proteins, T cell populations, or CC antigen-presenting cells that express the polypeptide); a method and kit CC for detecting or determining the presence or absence of P. acnes in a CC patient; and a method for inhibiting the development of P. acnes in a CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion CC proteins, T cell populations or antigen-presenting cells that express the CC polypeptides are useful for diagnosing, preventing or treating acne CC vulgaris, or for stimulating an immune response specific for a P. acnes CC protein. The polynucleotides can also be used as probes or primers for CC nucleic acid hybridization. The vaccine composition is useful for the CC stimulation of an immune response against P. acnes, or for treating acne, CC and the kit is useful for performing a diagnostic assay. The present CC sequence represents a polypeptide predicted to be encoded by an ORF (open CC reading frame) contained within the P. acnes polynucleotides of the CC invention. Note: The sequence data for this patent did not form part of CC the printed specification, but was obtained in electronic format directly CC from WIPO at ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 82 AA;

Query March 100.0%; Score 19; DB 6; Length 82;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 66 ACGV 69

RESULT 213

AAG02108
ID AAG02108 standard; protein; 83 AA.

XX AAG02108;

XX 06-OCT-2000 (first entry)

XX Human secreted protein, SEQ ID NO: 6189.

XX Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;

XX gene therapy; chromosome mapping.

XX Homo sapiens.

XX EP1033401-A2.

XX 06-SEP-2000.

XX 21-FEB-2000; 2000EP-0020610.

XX 26-FEB-1999; 99US-0122487P.

XX (GEST) GENSET.

XX Dumas Milne Edwards J, Duclert A, Giordano J;

XX WPI; 2000-500381/45.

XX N-PSDB; AAC02114.

XX New nucleic acid that is a 5' expressed sequence tag (5' EST) for CC obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for CC diagnostic, forensic, gene therapy and chromosome mapping procedures.

XX Claim 13; SEQ ID NO 6189; 71bp + Sequence Listing; English.
XX The present sequence is a polypeptide encoded by one of a large number of CC 5' ESTs derived from mRNAs encoding secreted proteins. The 5' ESTs were CC prepared from total human RNAs or polyA+ RNAs derived from 30 different CC tissues. EST sequences usually correspond mainly to the 3' untranslated CC region (UTR) of the mRNA because they are often obtained from oligo-dT CC primed cDNA libraries. Such ESTs are not well suited for isolating cDNA CC sequences derived from the 5' ends of mRNAs and even in those cases where CC longer cDNA sequences have been obtained, the full 5' UTR is rarely CC included. 5' ESTs are derived from mRNAs with intact 5' ends and can CC therefore be used to obtain full length cDNAs and genomic DNAs. 5' ESTs CC are also used in diagnostic, forensic, gene therapy and chromosome CC mapping procedures. They are used to obtain upstream regulatory sequences CC and to design expression and secretion vectors

SQ Sequence 83 AA;

Query March 100.0%; Score 19; DB 3; Length 83;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
Db 75 ACGV 78

RESULT 214

AAM87125
ID AAM87125 standard; protein; 83 AA.

XX AAM87125;

XX 07-NOV-2001 (first entry)
XX
DT Human immune/haematopoietic antigen SEQ ID NO:14718.
XX
DE Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis.
XX
OS Homo sapiens.
XX
PN W0200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001KO-US001354.
XX
XX 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226686P.
PR 23-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227189P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229350P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232387P.
PR 14-SEP-2000; 2000US-0232388P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.

PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241212P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.

PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Rosen CA, Barash SC, Ruben SM;
XX WPI: 2001-483426/52.
DR N-PSDB; AAK53906.
XX Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and metastasis.
XX Claim 11; SEQ ID NO 14718; 3071pp + Sequence Listing; English.
XX AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)
CC amino acid sequences given in AAM62170 to AAM91921. (I) have cytoskeletal
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting the
CC nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/hematopoietic-related diseases, especially
CC cancers and cancer metastases of hematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/hematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM62169
CC represent sequences used in the exemplification of the present invention
XX
XX SQ Sequence 83 AA;
Query Match 100.0%; Score 19; DB 4; Length 83;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGGV 4
|||
38 AGGV 41
Db
RESULT 215
AAG34308
ID AAG34308 standard; protein; 84 AA.
XX
XX AAG34308;
XX
XX 18-OCT-2000 (first entry)
XX
XX Arabidopsis thaliana protein fragment SEQ ID NO: 41721.
XX
XX Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
XX termination sequence.
XX Arabidopsis thaliana.
XX OS
XX EP1033405-A2.
XX PN
XX 06-SEP-2000.
XX PD
XX 25-FEB-2000; 2000EP-00301439.
XX PF
XX 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.

PR 23-MAR-1999; 99US-0125798P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 28-APR-1999; 99US-0130891P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 05-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.

```

PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145132P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 26-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147312P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.

```

```

PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159339P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 26-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161922P.
PR 28-OCT-1999; 99US-0161933P.
PR 29-OCT-1999; 99US-0162142P.

```

```

Query Match 100.0%; Score 19; DB 3; Length 84;
Best Local Similarity 100.0%; Pred.No.3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AOCV 4
Db 21 AOCV 24

```

```

RESULT 216
ABB65061
ID ABB65061 standard; protein; 84 AA.
XX
AC ABB65061;
XX
DT 26-MAR-2002 (first entry)
XX
DE Drosophila melanogaster polypeptide SEQ ID NO 21975.
XX
KM Drosophila; developmental biology; cell signalling; insecticide;
pharmaceutical.
XX
OS Drosophila melanogaster.
XX
PN K02001.71042-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001MO-US009231.
PR 23-MAR-2000; 2000US-0191637P.
PR 11-JUL-2000; 2000US-00614150.
XX
PA (PEKE ) PE CORP NY.
XX
PI Venter JC, Adams M, Li PWD, Myers EW;
WPI; 2001-656860/75.
DR N-PSDB; ABL09164.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more

```

PT genes from *Drosophila* and for elucidating cell signaling and cell-cell interactions.

XX PS Disclosure, SEQ ID NO 21975, 21pp + Sequence Listing, English.

XX CC The invention relates to an isolated nucleic acid detection reagent capable of detecting 1000 or more genes from *Drosophila*. The invention is useful in developmental biology and in elucidating cell signalling and cell-cell interactions in higher eukaryotes for the development of insecticides, therapeutics and pharmaceutical drugs. The invention discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA sequences (ABL01840-ABL16175) and the encoded proteins (ABBS7737-ABB72072). The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 84 AA;

Query Match 100.0%; Score 19; DB 4; Length 84;
Best Local Similarity 100.0%; Pred. No. 3.6e+03; Mismatches 0; Gaps 0;
Matches 4; Conservative 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 50 ACGV 53

RESULT 217
AAU61282
ID AAU61282 standard; protein; 84 AA.

XX AC AAU61282;

XX DT 27-FEB-2002 (first entry)

XX DE Propionibacterium acnes immunogenic protein #22178.

XX KW SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis; uveitis; endophthalmitis; bone; joint; central nervous system; ELISA; inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay; dermatological; osteophtic; neuroprotectant.

XX OS Propionibacterium acnes.

XX PN WO200181581-A2.

XX PD 01-NOV-2001.

XX PF 20-APR-2001; 2001WO-US012865.

XX PR 21-APR-2000; 2000US-0199047P.
02-JUN-2000; 2000US-0208841P.
07-JUL-2000; 2000US-0216747P.

XX PA (CORI-) CORIXA CORP.

XX PI Skeiky YAM, Persing DH, Mitcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
XX WPI, 2001-616774/71.
XX DR N-PSDB; AAS59615.

XX PT Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris.

XX PS Example 1; SEQ ID NO 22477; 1069pp; English.

XX CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic polypeptides. The proteins and their associated DNA sequences are used in the treatment, prevention and diagnosis of medical conditions caused by *P. acnes*. The disorders include SAPHO syndrome (synovitis, acne, pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.

CC P. acnes is also involved in infections of bone, joints and the central nervous system, however it is particularly involved in the inflammatory lesions associated with acne vulgaris. A method for detecting the presence or absence of *P. acnes* in a patient comprises contacting a sample with a binding agent that binds to the proteins of the invention and determining the amount of bound protein in the sample. The polypeptides may be used as antigens in the production of antibodies specific for *P. acnes* proteins. These antibodies can be used to downregulate expression and activity of *P. acnes* polypeptides and therefore treat *P. acnes* infections. The antibodies may also be used as diagnostic agents for determining *P. acnes* presence, for example, by enzyme linked immunosorbent assay (ELISA). Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 84 AA;

Query Match 100.0%; Score 19; DB 4; Length 84;
Best Local Similarity 100.0%; Pred. No. 3.6e+03; Mismatches 0; Gaps 0;
Matches 4; Conservative 0; Indels 0; Gaps 0;

QY 1 ACGV 4
|||
Db 65 ACGV 68

RESULT 218
ABG05322
ID ABG05322 standard; protein; 84 AA.

XX AC ABG05322;

XX DT 13-FEB-2002 (first entry)

XX DE Novel human diagnostic protein #5313.

XX KW Human; chromosome mapping; gene mapping; gene therapy; forensic; food supplement; medical imaging; diagnostic; genetic disorder.

XX OS Homo sapiens.

XX PN WO200175067-A2.

XX PD 11-OCT-2001.

XX PF 30-MAR-2001; 2001WO-US008631.

XX PR 31-MAR-2000; 2000US-00540217.
23-AUG-2000; 2000US-00649167.

XX PA (HYSE-) HYSEQ INC.

XX PI Drmanac RT, Liu C, Tang YT;
XX WPI, 2001-639362/73.
XX DR N-PSDB; AAS69509.

XX PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity.

XX PS Claim 20; SEQ ID NO 35681; 103pp; English.

XX CC The invention relates to isolated polynucleotide (I) and polypeptide (II) sequences. (I) is useful as hybridisation probes, polymerase chain reaction (PCR) primers, oligomers, and for chromosome and gene mapping, and in recombinant production of (II). The polynucleotides are also used in diagnostics as expressed sequence tags for identifying expressed genes. (I) is useful in gene therapy techniques to restore normal activity of (II) or to treat disease states involving (II). (II) is useful for generating antibodies against it, detecting or quantitating a

CC polypeptide in tissue, as molecular weight markers and as a food
 CC supplement. (II) and its binding partners are useful in medical imaging
 CC of sites expressing (II). (I) and (II) are useful for treating disorders
 CC involving aberrant protein expression or biological activity. The
 CC polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. ABG0010-ABG30377 represent novel human diagnostic
 CC amino acid sequences of the invention. Note: The sequence data for this
 CC patent did not appear in the printed Specification, but was obtained in
 CC electronic format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 84 AA;

Query Match 100.0%; Score 19; DB 4; Length 84;
 Best Local Similarity 100.0%; Pred. No. 3.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
 ||||
 DB 39 ACGV 42

RESULT 219

ABG89210
 ID AAG89210 standard; protein; 84 AA.

XX AAG89210;

XX 11-SEP-2001 (first entry)

XX Human secreted protein, SEQ ID NO: 330.

XX Human secreted protein; gene therapy; vaccine; treatment; diagnosis;

XX GENSET.

XX Homo sapiens.

XX WO200142451-A2.

XX 14-JUN-2001.

XX 07-DEC-2000; 2000WO-1B001938.

XX 08-DEC-1999; 99US-0169629P.

XX 06-MAR-2000; 2000US-0187470P.

XX (GENSET) GENSET.

XX Dumas Milne Edwards J, Bougueleret L, Jobert S;

XX WPI; 2001-367870/38.

XX N-PSTB; AAH4813.

XX Full length GENSET human nucleic acids encoding potentially secreted
 PT proteins, useful in gene therapy and vaccination against a variety of
 PT diseases, and for diagnosis of those diseases.
 PS Claim 21, Page 848; 921pp; English.

XX The invention relates to full length GENSET human nucleic acids encoding
 CC potentially secreted proteins. The nucleic acids and the polypeptides
 CC they encode may be used in the prevention, treatment and diagnosis of
 CC diseases associated with inappropriate GENSET gene expression. For
 CC example, they be used to treat disorders associated with decreased GENSET
 CC gene expression by rectifying mutations or deletions in a patient's
 CC genome that affect the activity of GENSET or by supplementing the
 CC patient's own production of GENSET polypeptides. Conversely, antisense
 CC nucleic acid molecules may be administered to down regulate GENSET
 CC expression by binding with the cells' own genes and preventing their
 CC expression. The sense and antisense nucleic acids may also be used as DNA

CC probes in diagnostic assays to detect and quantitate the presence of
 CC similar nucleic acid sequences in samples, and hence to determine which
 CC patients may be in need of restorative therapy. The GENSET polypeptides
 CC may be used as antigens in the production of antibodies and in assays to
 CC identify modulators (agonists and antagonists) of GENSET polypeptide
 CC expression and activity. The present sequence is a GENSET polypeptide of
 CC the invention

XX Sequence 84 AA;

Query Match 100.0%; Score 19; DB 4; Length 84;
 Best Local Similarity 100.0%; Pred. No. 3.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ACGV 4
 ||||
 DB 30 ACGV 33

RESULT 220

ABM57801
 ID ABM57801 standard; protein; 84 AA.

XX ABM57801;

XX 20-OCT-2003 (first entry)

XX Propionibacterium acnes predicted ORF-encoded polypeptide #22477.

XX Acne vulgaris; antiseborrheic; dermatological; antibacterial;

XX immunostimulant; immune response; vaccine.

XX Propionibacterium acnes.

XX WO2003033515-A1.

XX 24-APR-2003.

XX 11-OCT-2002; 2002WO-US032727.

XX 15-OCT-2001; 2001US-00978825.

XX (CORI-) CORIXA CORP.

XX Mitcham JL, Skeiky YAW, Persing DH, Bhatia A, Maisonneuve JL;

XX Zhang Y, Wang S, Jen S, Lodes WJ, Benson DR, Jones R, Carter D;

XX Barth B, Valliave-Douglas J;

XX WPI; 2003-381769/36.

XX N-PSTB; ACF64544.

XX New Propionibacterium acnes polypeptides and polynucleotides encoding the
 PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
 PT or for stimulating an immune response specific for a P. acnes protein.
 PS Example 1; SEQ ID NO 22477; 1481pp; English.

XX The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
 CC encoding a Propionibacterium acnes protein. The invention also relates to
 CC polypeptides encoded by the polynucleotides (ABM5624-ABM64536) and to
 CC immunogenic fragments of P. acnes polypeptides. The invention
 CC additionally encompasses expression vectors and host cells comprising a
 CC polynucleotide of the invention; antibodies against polypeptides of the
 CC invention; fusion proteins comprising a polypeptide of the invention; a
 CC method for stimulating an immune response specific for a P. acnes
 CC polypeptide and an isolated T cell population comprising T cells prepared
 CC via this method; a vaccine composition (comprising P. acnes polypeptides,
 CC polynucleotides, antibodies, fusion proteins, T cell populations, or
 CC antigen-presenting cells that express the polypeptide); a method and kit
 CC for detecting or determining the presence or absence of P. acnes in a
 CC patient; and a method for inhibiting the development of P. acnes in a
 CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
 CC proteins, T cell populations or antigen-presenting cells that express the

CC polypeptides are useful for diagnosing, preventing or treating acne
CC vulgaris, or for stimulating an immune response specific for a P. acnes
CC protein. The polynucleotides can also be used as probes or primers for
CC nucleic acid hybridisation. The vaccine composition is useful for the
CC stimulation of an immune response against P. acnes, or for treating acne,
CC and the kit is useful for performing a diagnostic assay. The present
CC sequence represents a polypeptide predicted to be encoded by an ORF (open
CC reading frame) contained within the P. acnes polynucleotides of the
CC invention. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
CC
XX

SQ Sequence 84 AA;

Query Match 100.0%; Score 19; DB 6; Length 84;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 AOGV 4
|||
Db 65 AOGV 68

RESULT 221

ID ABP76020 standard; protein; 84 AA.

AC ABP76020;

DT 21-FEB-2003 (first entry)

DE Human GENSET protein SEQ ID 227.

XX Cytostatic; antiinflammatory; nootropic; neuroprotective; cardiant;
KM gastrointestinal; gene therapy; GENSET; heavy metal toxicity; cancer;
KM inflammatory disease; immune disorder; neuromuscular; toxicity;
KM central nervous system; cardiovascular; gastrointestinal.

XX Homo sapiens.

XX WO200283898-A1.

XX 24-OCT-2002.

XX 18-APR-2001; 2001WO-IB000914.

XX 18-APR-2001; 2001WO-IB000914.

XX (GENSET) GENSET.

XX Bejanin S, Tanaka H, Dumas Milne Edwards J, Jobert S, Giordano J;
XX WPI; 2003-075548/07.

XX New GENSET polynucleotides and polypeptides, useful for treating heavy
PT metal toxicity, cancer, inflammatory diseases, immune disorders, and the
PT neuromuscular, CNS, cardiovascular or gastrointestinal effects of the
PT toxicity.

PS Claim 14; Page 426-427; 735pp; English.

CC The present invention relates to novel GENSET polynucleotides (AB236404-
CC AB236911) encoding polypeptides (ABP75963-ABP76368). The polynucleotides
CC and polypeptides are useful in screening and diagnostic assays for
CC abnormal GENSET expression and/or biological activity. They are also
CC useful for screening of compounds for treating or preventing GENSET-
CC related disorders, such as heavy metal toxicity, cancer, inflammatory
CC diseases, immune disorders, and the neuromuscular, central nervous system
CC (CNS), cardiovascular or gastrointestinal effects of the toxicity

SQ Sequence 84 AA;

Query Match 100.0%; Score 19; DB 6; Length 84;

Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 AOGV 4
|||
Db 30 AOGV 33

RESULT 222

ID ABP76176 standard; protein; 84 AA.

AC ABP76176;

DT 21-FEB-2003 (first entry)

DE Human GENSET protein SEQ ID 502.

XX Cytostatic; antiinflammatory; nootropic; neuroprotective; cardiant;
KM gastrointestinal; gene therapy; GENSET; heavy metal toxicity; cancer;
KM inflammatory disease; immune disorder; neuromuscular; toxicity;
KM central nervous system; cardiovascular; gastrointestinal.

XX Homo sapiens.

XX WO200283898-A1.

XX 24-OCT-2002.

XX 18-APR-2001; 2001WO-IB000914.

XX 18-APR-2001; 2001WO-IB000914.

XX (GENSET) GENSET.

XX Bejanin S, Tanaka H, Dumas Milne Edwards J, Jobert S, Giordano J;
XX WPI; 2003-075548/07.

XX New GENSET polynucleotides and polypeptides, useful for treating heavy
PT metal toxicity, cancer, inflammatory diseases, immune disorders, and the
PT neuromuscular, CNS, cardiovascular or gastrointestinal effects of the
PT toxicity.

PS Claim 14; Page 553; 735pp; English.

CC The present invention relates to novel GENSET polynucleotides (AB236404-
CC AB236911) encoding polypeptides (ABP75963-ABP76368). The polynucleotides
CC and polypeptides are useful in screening and diagnostic assays for
CC abnormal GENSET expression and/or biological activity. They are also
CC useful for screening of compounds for treating or preventing GENSET-
CC related disorders, such as heavy metal toxicity, cancer, inflammatory
CC diseases, immune disorders, and the neuromuscular, central nervous system
CC (CNS), cardiovascular or gastrointestinal effects of the toxicity

SQ Sequence 84 AA;

Query Match 100.0%; Score 19; DB 6; Length 84;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 AOGV 4
|||
Db 30 AOGV 33

RESULT 223

ID AAG27024 standard; protein; 85 AA.

AC AAG27024;

DT 17-OCT-2000 (first entry)

XX Zea mays protein fragment SEQ ID NO: 31702.
DE
XX Protein identification; signal transduction pathway; metabolic pathway;
KM hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence; corn.
XX
OS Zea mays subsp. mays.
XX
PN EP1033405-A2.
PD
XX 06-SEP-2000.
XX
XX 25-FEB-2000; 2000EP-00301439.
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123160P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125768P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 07-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 21-MAY-1999; 99US-0135629P.
PR 24-MAY-1999; 99US-0136021P.
PR 25-MAY-1999; 99US-0136392P.
PR 27-MAY-1999; 99US-0136782P.
PR 28-MAY-1999; 99US-0137222P.
PR 01-JUN-1999; 99US-0137528P.
PR 03-JUN-1999; 99US-0137502P.
PR 04-JUN-1999; 99US-0137724P.
PR 07-JUN-1999; 99US-0138094P.
PR 08-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139457P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140658P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142380P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144335P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 20-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145092P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147436P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148317P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148655P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.

PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158023P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161922P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 100.0%; Score 19; DB 3; Length 85;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGGV 4
|||
74 AGGV 77

RESULT 224

AGG32676
ID AGG32676 standard; protein; 85 AA.

XX AGG32676;

DT 17-OCT-2000 (first entry)

DE Zea mays protein fragment SEQ ID NO: 39466.

XX Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence; corn.

XX

OS Zea mays subsp. mays.

XX EP1033405-A2.

XX 06-SEP-2000.

PD 25-FEB-2000; 2000EP-00301439.

XX 25-FEB-1999; 99US-0121825P.

XX 05-MAR-1999; 99US-0123180P.

PR 09-MAR-1999; 99US-0123548P.

PR 23-MAR-1999; 99US-0125788P.

PR 25-MAR-1999; 99US-0126264P.

PR 29-MAR-1999; 99US-0126785P.

PR 01-APR-1999; 99US-0127462P.

PR 06-APR-1999; 99US-0128234P.

PR 08-APR-1999; 99US-0128714P.

PR 16-APR-1999; 99US-0129845P.

PR 19-APR-1999; 99US-0130077P.

PR 21-APR-1999; 99US-0130449P.

PR 23-APR-1999; 99US-0130510P.

PR 28-APR-1999; 99US-0130891P.

PR 30-APR-1999; 99US-0132048P.

PR 04-MAY-1999; 99US-0132407P.

PR 05-MAY-1999; 99US-0132484P.

PR 06-MAY-1999; 99US-0132486P.

PR 07-MAY-1999; 99US-0132487P.

PR 11-MAY-1999; 99US-0132863P.

PR 14-MAY-1999; 99US-0134218P.

PR 14-MAY-1999; 99US-0134219P.

PR 14-MAY-1999; 99US-0134370P.

PR 18-MAY-1999; 99US-0134768P.

PR 19-MAY-1999; 99US-0134941P.

PR 20-MAY-1999; 99US-0135124P.

PR 21-MAY-1999; 99US-0135353P.

PR 24-MAY-1999; 99US-0135629P.

PR 25-MAY-1999; 99US-0136021P.

PR 27-MAY-1999; 99US-0136392P.

PR 28-MAY-1999; 99US-0136782P.

PR 01-JUN-1999; 99US-0137222P.

PR 03-JUN-1999; 99US-0137528P.

PR 04-JUN-1999; 99US-0137502P.

PR 07-JUN-1999; 99US-0137724P.

PR 08-JUN-1999; 99US-0138094P.

PR 10-JUN-1999; 99US-0138540P.

PR 10-JUN-1999; 99US-0138847P.

PR 14-JUN-1999; 99US-0139119P.

PR 16-JUN-1999; 99US-0139452P.

PR 16-JUN-1999; 99US-0139453P.

PR 17-JUN-1999; 99US-0139452P.

PR 18-JUN-1999; 99US-0139454P.

PR 18-JUN-1999; 99US-0139455P.

PR 18-JUN-1999; 99US-0139456P.

PR 18-JUN-1999; 99US-0139457P.

PR 18-JUN-1999; 99US-0139458P.

PR 18-JUN-1999; 99US-0139459P.

PR 18-JUN-1999; 99US-0139461P.

PR 18-JUN-1999; 99US-0139462P.

PR 18-JUN-1999; 99US-0139463P.

PR 18-JUN-1999; 99US-0139750P.

PR 18-JUN-1999; 99US-0139763P.

PR 21-JUN-1999; 99US-0139817P.

PR 22-JUN-1999; 99US-0139899P.

PR 23-JUN-1999; 99US-0140353P.

PR 23-JUN-1999; 99US-0140354P.

PR 24-JUN-1999; 99US-0140635P.

PR 28-JUN-1999; 99US-0140823P.

PR 29-JUN-1999; 99US-0140991P.

PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 28-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147250P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.

PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156569P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159339P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159311P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161982P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 100.0%; Score 19; DB 3; Length 85;
Best Local Similarity 100.0%; Pred. No. 3.6e+03; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0;

QY 1 AAGV 4
||||
DB 74 AAGV 77

RESULT 225
AAG25324
ID AAG25324 standard; protein; 85 AA.
XX
AC AAG25324;
XX
DT 17-OCT-2000 (first entry)
XX
DE Zea mays protein fragment SEQ ID NO: 29341.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence; corn.
XX
OS Zea mays subsp. mays.
XX
PN BP1033405-A2.
XX
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.

XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123546P.
PR 23-MAR-1999; 99US-0125786P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137529P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142056P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.

PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 19-JUL-1999; 99US-0144336P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147993P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149358P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.

PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161930P.
PR 28-OCT-1999; 99US-0161932P.
PR 28-OCT-1999; 99US-0161933P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 100.0%; Score 19; DB 3; Length 85;
Best Local Similarity 100.0%; Pred. No. 3.6e+03; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0;

QY 1 ACGV 4
Db 74 ACGV 77

RESULT 226

AAU52346
ID AAU52346 standard; protein; 85 AA.

AC AAU52346;

DT 27-FEB-2002 (first entry)

DE Propionibacterium acnes immunogenic protein #13242.

XX SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW dermatological; osteopathic; neuroprotectant.

OS Propionibacterium acnes.

PN WO200181581-A2.

PD 01-NOV-2001.

PF 20-APR-2001; 2001WO-US012865.

PR 21-APR-2000; 2000US-0199047P.

PR 02-JUN-2000; 2000US-0208841P.

PR 07-JUL-2000; 2000US-0216747P.

PA (CORI-) CORIXA CORP.

XX Skeiky YAM, Persing DH, Metcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
XX WPI; 2001-616774/71.
DR N-PSDB; AAS59554.
XX Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris.

PS Example 1; SEQ ID NO 13541; 1069pp; English.

CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 85 AA;

Query Match 100.0%; Score 19; DB 4; Length 85;
Best Local Similarity 100.0%; Pred. No. 3.6e+03; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0;

QY 1 ACGV 4
Db 58 ACGV 61

RESULT 227

ABP62928
ID ABP62928 standard; protein; 85 AA.

AC ABP62928;

DT 14-OCT-2002 (first entry)

DE Human polypeptide SEQ ID NO 365.

XX Human; vulnery; dermatological; neuroprotective; nootropic; cancer;
KW antiparkinsonian; immunosuppressant; cytoskeletal; immunosuppressive;
KW antidiabetic; antiallergic; gene therapy; wound healing; tissue repair;
KW burn; central nervous system disorder; Alzheimer's disease;
KW Parkinson's disease; Huntington's disease; immune disorder;
KW autoimmune disorder; multiple sclerosis; diabetes; allergy.

OS Homo sapiens.

PN WO200218424-A2.

PD 07-MAR-2002.

PF 31-AUG-2001; 2001WO-US027093.

PR 01-SEP-2000; 2000US-00654935.

PA (HYSE-) HYSEQ INC.

XX Tang YT, Asundi V, Zhou P, Xue AJ, Ren F, Zhang J, Wang J;
PI Zhao QA, Wang D, Liu C, Drmanac RT, Wehrman T;
XX WPI; 2002-583321/62.
DR N-PSDB; ABQ93407.
XX
PT New polynucleotide and polypeptides, useful for treatment and diagnosis
PT of Alzheimer's, Parkinson's, Huntington's, amyotrophic lateral
PT sclerosis, immune deficiencies, cancer, autoimmune disorders, multiple
PT sclerosis, diabetes and allergies.
PS
PS Claim 20; SEQ ID NO 365; 284bp + Sequence Listing; English.
XX
XX The invention relates to an isolated polynucleotide (I) comprising one of
CC 245 sequences (ABQ93288-ABQ93532). Treating a condition comprising
CC administering to a mammalian subject a composition comprising the protein
CC (II) encoded by (I) (ABP62809-ABP63053) or an antibody (III) to (II).
CC (I), (II) and (III) are useful for diagnostic evaluation of disorders.
CC (I) is useful for gene therapy of diseases and (II) can be used for
CC therapeutic treatment. Diseases that may be treated include wound healing
CC and tissue repair, burns, central nervous system disorders (e.g.
CC Alzheimer's, Parkinson's, Huntington's and amyotrophic lateral
CC sclerosis), immune deficiencies, cancer, autoimmune disorders, multiple
CC sclerosis, diabetes and allergies. Note: The sequence data for this
CC patent did not form part of the printed specification, but was obtained
CC in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 85 AA;
Query Match 100.0%; Score 19; DB 5; Length 85;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 AOGV 4
Db 44 AOGV 47
RESULT 228
ABM48865
ID ABM48865 standard; protein; 85 AA.
XX
AC ABM48865;
XX
DT 20-OCT-2003 (first entry)
XX
DE Propionibacterium acnes predicted ORF-encoded polypeptide #13541.
XX
KW Acne vulgaris; antiacneborrhoelc; dermatological; antibacterial;
KW immunostimulant; immune response; vaccine.
XX
OS Propionibacterium acnes.
XX
PN WO2003033515-A1.
XX
PD 24-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032727.
XX
PR 15-OCT-2001; 2001US-00978825.
XX
PA (CORI-) CORIXA CORP.
XX
PI Mitcham JL, Skeiky YAW, Persing DH, Bhattacharya A, Maisonneuve JL;
PI Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
PI Barch B, Vallee-Douglas J;
XX WPI; 2003-381789/36.
XX N-PSDB; ACF64483.
DR
XX New Propionibacterium acnes polypeptides and polynucleotides encoding the

PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT or for stimulating an immune response specific for a P. acnes protein.
XX
XX Example 1; SEQ ID NO 13541; 1481bp; English.
PS
XX The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
CC encoding a Propionibacterium acnes protein. The invention also relates to
CC polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
CC immunogenic fragments of P. acnes polypeptides. The invention
CC additionally encompasses expression vectors and host cells comprising a
CC polynucleotide of the invention; antibodies against polypeptides of the
CC invention; fusion proteins comprising a polypeptide of the invention; a
CC method for stimulating an immune response specific for a P. acnes
CC polypeptide and an isolated T cell population comprising T cells prepared
CC via this method; a vaccine composition (comprising P. acnes polypeptides,
CC polynucleotides, antibodies, fusion proteins, T cell populations, or
CC antigen-presenting cells that express the polypeptide); a method and kit
CC for detecting or determining the presence or absence of P. acnes in a
CC patient; and a method for inhibiting the development of P. acnes in a
CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC proteins, T cell populations or antigen-presenting cells that express the
CC polypeptides are useful for diagnosing, preventing or treating acne
CC vulgaris, or for stimulating an immune response specific for a P. acnes
CC protein. The polynucleotides can also be used as probes or primers for
CC nucleic acid hybridisation. The vaccine composition is useful for the
CC stimulation of an immune response against P. acnes, or for treating acne,
CC and the kit is useful for performing a diagnostic assay. The present
CC sequence represents a polypeptide predicted to be encoded by an ORF (open
CC reading frame) contained within the P. acnes polynucleotides of the
CC invention. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 85 AA;
Query Match 100.0%; Score 19; DB 6; Length 85;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 AOGV 4
Db 58 AOGV 61
RESULT 229
ADQ75906
ID ADQ75906 standard; protein; 85 AA.
XX
AC ADQ75906;
XX
DT 23-SEP-2004 (first entry)
XX
DE Lysine decarboxylase fragment used to create consensus protein #15.
XX
KW amino acid production; threonine; lysine; food; animal feed; cosmetics;
KW enzyme; lysine decarboxylase.
XX
OS Unidentified.
XX
PN WO2004057003-A2.
XX
PD 08-JUL-2004.
XX
PF 19-DEC-2003; 2003WO-EP014649.
XX
PR 20-DEC-2002; 2002DR-01061188.
XX
PA (META-) METANOMICS GMBH & CO KGAA.
XX
PI Schmitz O, Puzio P, Blau A, Looser R, Wendel B, Kamlage B;
PI Plesch G;
XX WPI; 2004-517685/49.
DR

XX Method for preparing amino acids, useful e.g. in foods, cosmetics and
PT pharmaceuticals, by growing transgenic organisms that express a protein
PT that degrades threonine and/or lysine.
XX
XX Disclosure; Fig 2; 110pp; German.
XX
CC The present invention relates to a method for preparing amino acids in
CC transgenic organisms by introducing and expressing a nucleic acid that
CC encodes a protein able to degrade threonine (Thr) and/or lysine (Lys), or
CC increases degradation of Thr and/or Lys in the organism. The amino acids,
CC preferably methionine, homoserine and lysine, or the organisms that
CC produce them, are used in preparation of foods, animal feeds, cosmetic or
CC pharmaceuticals (e.g. Met has antidepressant activity), also as synthetic
CC intermediates. The present sequence is a fragment of a lysine
CC decarboxylase enzyme used to create a consensus sequence for the protein.
CC
SQ Sequence 85 AA;

Query Match 100.0%; Score 19; DB 8; Length 85;
Best Local Similarity 100.0%; Pred. No. 3.6e+03; Mismatches 0; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ACGV 4
12 ACGV 15
Db

RESULT 230
ADQ75905
ID ADQ75905 standard; protein; 85 AA.
XX
XX ADQ75905;
AC
XX
XX 23-SEP-2004 (first entry)
DT
XX
XX Lysine decarboxylase fragment used to create consensus protein #14.
DE
XX
XX amino acid production; threonine; lysine; food; animal feed; cosmetics;
KW enzyme; lysine decarboxylase.
XX
XX Unidentified.
OS
XX
XX WO2004057003-A2.
PN
XX
XX 08-JUL-2004.
PD
XX
XX 19-DEC-2003; 2003WO-EP014649.
PF
XX
XX 20-DEC-2002; 2002DE-01061188.
PR
XX
XX (META-) METANOMICS GMBH & CO KGAA.
PA
XX
PI Schmitz O, Puzio P, Blau A, Looser R, Wendel B, Kamlage B;
PI Plesch G;
PI
XX
XX WPI; 2004-517685/49.
DR
XX
XX Method for preparing amino acids, useful e.g. in foods, cosmetics and
PT pharmaceuticals, by growing transgenic organisms that express a protein
PT that degrades threonine and/or lysine.
XX
XX
XX Disclosure; Fig 2; 110pp; German.
XX
XX The present invention relates to a method for preparing amino acids in
CC transgenic organisms by introducing and expressing a nucleic acid that
CC encodes a protein able to degrade Threonine (Thr) and/or Lysine (Lys), or
CC increases degradation of Thr and/or Lys in the organism. The amino acids,
CC preferably methionine, homoserine and lysine, or the organisms that
CC produce them, are used in preparation of foods, animal feeds, cosmetic or
CC pharmaceuticals (e.g. Met has antidepressant activity), also as synthetic
CC intermediates. The present sequence is a fragment of a lysine
CC decarboxylase enzyme used to create a consensus sequence for the protein.
CC

XX
SQ Sequence 85 AA;

Query Match 100.0%; Score 19; DB 8; Length 85;
Best Local Similarity 100.0%; Pred. No. 3.6e+03; Mismatches 0; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ACGV 4
12 ACGV 15
Db

RESULT 231
ADY12627
ID ADY12627 standard; protein; 85 AA.
XX
XX ADY12627;
AC
XX
XX 21-APR-2005 (first entry)
DT
XX
XX Plant full length insert polypeptide seqid 68442.
DE
XX
XX plant protectant; plant growth regulant; gene therapy; plant;
KW recombinant DNA construct; physical array; plant breeding marker;
KW cold tolerance; heat tolerance; drought tolerance; herbicide tolerance;
KW extreme osmotic condition; pathogen tolerance; pest tolerance;
KW growth rate; cell cycle pathway; disease resistance;
KW galactomanan production; lignin production; plant growth regulator;
KW yield; plant growth; plant development; seed oil; protein yield;
KW protein content.
XX
XX Unidentified.
OS
XX
XX US2004034888-A1.
PN
XX
XX 19-FEB-2004.
PD
XX
XX 28-APR-2003; 2003US-00425114.
PF
XX
XX 06-MAY-1999; 99US-00304517.
PR
XX
XX 05-NOV-2001; 2001US-00985678.
PR
XX
XX (LIU/) LIU J.
PA (ZHOU/) ZHOU Y.
PA (KOVA/) KOVALIC D K.
PA (SCRE/) SCREEN S E.
PA (TABAS/) TABASKA J E.
PA (CAOY/) CAO Y.
XX
XX
PI Liu J, Zhou Y, Kovalic DK, Screen SE, Tabaska JE, Cao Y;
PI
XX
XX WPI; 2004-180133/17.
DR
XX
XX New recombinant DNA construct, useful for improving plant tolerance to
PT cold, heat, drought, herbicides, extreme osmotic conditions, pathogens or
PT pests, for conferring increased resistance to plant disease, or for
PT improving yield.
XX
XX
XX Claim 1; SEQ ID NO 68442; 15pp; English.
PS
XX
XX The invention describes a recombinant DNA construct comprising a
CC polynucleotide consisting of a sequence encoding an amino acid sequence
CC available in electronic form from the US patent office at
CC ftp.segdata.uspfo.gov/sequence.html?DocID:2004034888. The polynucleotide
CC of the invention are also useful in physical arrays of molecules and as
CC plant breeding markers. The recombinant DNA construct is useful for
CC improving plant tolerance to cold, heat, drought, herbicides, extreme
CC osmotic conditions, pathogens or pests, for manipulating growth rate in
CC plant cells by modification of the cell cycle pathway, for conferring
CC increased resistance to plant disease, for producing galactomanan,
CC lignin or plant growth regulators, for increasing the rate of homologous
CC recombination in plants, for improving yield by modification of
CC photosynthesis or carbohydrate, nitrogen or phosphorus use and/or uptake
CC

CC or by providing improved plant growth and development under at least one
CC stress condition or for modifying seed oil or protein yield and/or
CC content. This is the amino acid sequence of a plant full length insert
CC polypeptide that can be used in the recombinant DNA construct of the
CC invention.

XX
SQ Sequence 85 AA;

Query Match 100.0%; Score 19; DB 8; Length 85;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||
Db 8 AOGV 11

RESULT 232

ABM94141
ID ABM94141 standard; protein, 85 AA.

XX
AC ABM94141;

XX
DT 02-JUN-2005 (first entry)

XX
DE M. xanthus protein sequence, seq id 13340.

XX
KM Transgenic plant; DNA replication; gene regulation; gene expression.

XX
OS Myxococcus xanthus.

XX
PN US6833447-B1.

XX
PD 21-DEC-2004.

XX
PF 10-JUL-2001; 2001US-00902540.

XX
PR 10-JUL-2000; 2000US-0217883P.

XX
PA (MONS) MONSANTO TECHNOLOGY LLC.

XX
PI Goldman BS, Hinkle GJ, Slater SC, Wiegand RC;

XX
DR WPI; 2005-028716/03.

XX
PT New substantially purified Myxococcus xanthus nucleic acid molecule
PT encoding a nitrite reductase, useful for determining gene expression,
PT identifying mutations in a gene of interest, and for constructing
PT mutations in a gene of interest.

XX
PS Example 2; SEQ ID NO 13340; 25pp; English.

XX
CC The invention relates to a substantially purified nucleic acid molecule
CC encoding a nitrite reductase of SEQ ID NO. 11926. Further disclosed is a
CC recombinant DNA construct for expression of a nitrite reductase gene in a
CC plant cell, and a plant cell comprising the recombinant DNA construct.
CC The nucleic acid is useful for determining gene expression, identifying
CC mutations in a gene of interest, and for constructing mutations in a gene
CC of interest. Sequences given in records for SEQ IDs 9692-16825 represent
CC a group of 7134 Myxococcus xanthus proteins and peptides. Note: The
CC sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from USPTO
XX

XX
SQ Sequence 85 AA;

Query Match 100.0%; Score 19; DB 9; Length 85;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||
Db 55 AOGV 58

RESULT 233

AAU47746
ID AAU47746 standard; protein, 86 AA.

XX
AC AAU47746;

XX
DT 27-FEB-2002 (first entry)

XX
DE Propionibacterium acnes immunogenic protein #8642.

XX
KM SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KM uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KM inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KM dermatological; osteopathic; neuroprotectant.

XX
OS Propionibacterium acnes.

XX
PN WO200181581-A2.

XX
PD 01-NOV-2001.

XX
PF 20-APR-2001; 2001WO-US012865.

XX
PR 21-APR-2000; 2000US-0199047P.

XX
PR 02-JUN-2000; 2000US-0208841P.

XX
PR 07-JUL-2000; 2000US-0216747P.

XX
PA (CORI-) CORIXA CORP.

XX
PI Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;

XX
PI L'malsonneuve J, Zhang Y, Jen S, Carter D;

XX
DR WPI; 2001-616774/71.

XX
DR N-PSDB; AAS59539.

XX
PS Example 1; SEQ ID NO 8941; 1069pp; English.

XX
CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

XX
SQ Sequence 86 AA;

Query Match 100.0%; Score 19; DB 4; Length 86;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AOGV 4
|||
Db 9 AOGV 12

RESULT 234
 ABB78149
 ID ABB78149 standard; protein; 86 AA.
 XX
 AC ABB78149;
 XX
 DT 05-NOV-2002 (first entry)
 XX
 XX Amino acid sequence of a YggX homologue.
 DE
 XX Superoxide damage; cell; YggX; *Salmonella enterica* serovar typhimurium;
 KM hydroxyl radical; DNA damage; yggX homologue.
 XX
 OS *Bordetella bronchiseptica*.
 XX
 PN US2002072118-A1.
 PD 13-JUN-2002.
 XX
 PF 18-SEP-2001; 2001US-00955502.
 XX
 PR 22-SEP-2000; 2000US-0234588P.
 XX
 PA (DOWN/) DOWNS D.
 PA (GRAL/) GRALNICK J A.
 XX
 PI Downs D, Gralnick JA;
 XX
 DR WPI; 2002-589476/63.
 XX
 XX Reducing superoxide damage to a cell, e.g. bacterial, mammalian or plant
 PT cell, comprises engineering the cell to produce more YggX protein, a
 PT protein identified from *Salmonella enterica* serovar typhimurium.
 XX
 XX Example; Fig 1A; 16pp; English.
 XX
 CC The specification describes a method for reducing superoxide damage to a
 CC cell. The method comprises engineering the cell to produce more than the
 CC native amount of YggX protein (a protein identified from *Salmonella*
 CC *enterica* serovar typhimurium) or its homolog, where the cells are
 CC rendered more resistant to superoxide damage. YggX reduces the oxidation
 CC of (Fe-S) clusters, and thus reduces the loss of Fe(II) ions from
 CC clusters. The resulting decrease in free-iron levels generates fewer
 CC hydroxyl radicals and thus reduced DNA damage. The method is useful for
 CC reducing superoxide damage in a bacterial, yeast, mammalian or plant
 CC cell. ABB78147-78 represent YggX homologues
 CC
 XX
 SQ Sequence 86 AA;
 Query Match 100.0%; Score 19; DB 5; Length 86;
 Best Local Similarity 100.0%; Pred. No. 3.7e+03; Mismatches 0; Gaps 0;
 Matches 4; Conservative 0; Indels 0;
 QY 1 AOGV 4
 ||||
 Db 82 AOGV 85
 RESULT 235
 ABB32375
 ID ABB32375 standard; protein; 86 AA.
 XX
 AC ABB32375;
 XX
 DT 08-JUL-2002 (first entry)
 XX
 XX Human ORF1348 protein, SEQ ID NO:2696.
 DE
 XX Human, ORF, open reading frame; ORF; drug screening; diagnosis;
 KM disease monitoring; cytokine; cell proliferation; cell differentiation;
 KM immune modulation; haematopoiesis regulation; tissue growth;
 KM angiogenesis; activin; inhibin; chemotactic; chemokinetic; haemostatic;

KM thrombolytic; tumour inhibition; bodily characteristic; fertility;
 KM behaviour; cancer; proliferative disorder; neurological disorder;
 KM cardiovascular disease; immune system disorder; organ transplantation;
 KM tissue growth disorder; tissue regeneration disorder; diabetes mellitus;
 KM hypothyroidism; cholesterol ester storage disease; infection; vulnery;
 KM vasotropic; antiproliferative; antidiabetic; cytotoxic; nocrotic;
 KM neuroprotective; antiatherosclerotic; anticoagulant; thrombolytic;
 KM cardiant; hypotensive; antithyroid; antiinflammatory; immunomodulator;
 KM dermatological; analgesic; virucide; antibacterial; fungicide.
 XX
 OS *Homo sapiens*.
 XX
 PN WO200190366-A2.
 XX
 PD 29-NOV-2001.
 XX
 PF 24-MAY-2001; 2001WO-US017076.
 XX
 PR 24-MAY-2000; 2000US-0206690P.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 PI Leach MD, Shinkets RA;
 XX
 DR WPI; 2002-106200/14.
 DR N-PSDB; ABB76401.
 XX
 XX Novel human polypeptides and polynucleotides useful for diagnosing,
 PT preventing and treating cardiovascular disease, neurodegenerative,
 PT hyperproliferative disorders and disorders related to organ
 PT transplantation.
 XX
 PS Claim 10; Page 934; 2508pp; English.
 XX
 CC Sequences ABB31028-ABB35561 represent 4534 novel human proteins
 CC designated ORF (open reading frame) 1-4534, and sequences ABB75054-
 CC ABB79587 represent cDNAs encoding them. The invention also encompasses
 CC polypeptides at least 80% identical to the ORF1-ORF4534 (collectively
 CC referred to as ORFX) proteins, polynucleotides at least 85% identical to
 CC the ORFX nucleic acid sequences, vectors and host cells comprising ORFX
 CC polynucleotides, the recombinant production of ORFX proteins, antibodies
 CC specific for ORFX proteins, methods of detecting ORFX polynucleotides and
 CC polypeptides, methods of screening for modulators of ORFX expression or
 CC activity, and methods of screening individuals for a predisposition to an
 CC ORFX-associated disorder. The ORFX proteins of the invention have a wide
 CC range of biological activities, such as cytokine, cell proliferation,
 CC cell differentiation, immune modulation, haematopoiesis regulation,
 CC tissue growth, angiogenesis, activin or inhibin activity, chemotactic/
 CC chemokinetic activity, haemostatic activity, thrombolytic activity,
 CC receptor/ligand, antiinflammatory activity, tumour inhibition activity,
 CC and antinfective activity, and may also be involved in the determination
 CC of bodily characteristics, fertility and behaviour. ORFX proteins,
 CC nucleic acids and antibodies may be used in the treatment of cancers,
 CC other proliferative disorders such as psoriasis and benign tumour,
 CC neurological disorders such as epilepsy and Alzheimer's disease,
 CC cardiovascular diseases, immune system disorders, disorders related to
 CC organ transplantation, disorders of tissue growth and regeneration,
 CC diseases such as diabetes mellitus, hypothyroidism, and cholesterol ester
 CC storage disease, and infectious diseases caused by viral, bacterial,
 CC fungal and other pathogens. ORFX nucleic acids may also be used as a
 CC source of primers and probes, in the detection of ORFX genomic sequences
 CC or transcripts, in the identification and cloning of homologous
 CC sequences, in genetic diagnosis, and in forensic biology. The ORFX
 CC nucleic acids may additionally be used to produce transgenic animals
 CC which may be useful for studying the function and/or activity of ORFX
 CC protein, and in drug screening. The ORFX proteins may also be used as
 CC immunogens to generate specific antibodies, which are useful in the
 CC diagnosis, treatment and monitoring of ORFX-associated diseases
 CC
 XX
 SQ Sequence 86 AA;
 Query Match 100.0%; Score 19; DB 5; Length 86;
 Best Local Similarity 100.0%; Pred. No. 3.7e+03;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 75 AOGV 78

RESULT 236
ABM44265
ID ABM44265 standard; protein; 86 AA.
XX
XX ABM44265;
XX
XX 20-OCT-2003 (first entry)
XX
XX Propionibacterium acnes predicted ORF-encoded polypeptide #8941.
XX
XX Acne vulgaris; antiseborrheic; dermatological; antibacterial;
XX KW immunostimulant; immune response; vaccine.
XX
XX Propionibacterium acnes.
XX
XX WO2003033515-A1.
XX
XX 24-APR-2003.
XX
XX 11-OCT-2002; 2002WO-US032727.
XX PF
XX 15-OCT-2001; 2001US-00978825.
XX PR
XX
XX (CORI-) CORIXA CORP.
XX
XX Mitcham JL, Skeiky YAW, Persing DH, Bhatia A, Maisonneuve JL;
PI Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
PI Barth B, Vailieve-Douglass J;
XX
XX WPI; 2003-381789/36.
XX DR N-PSDB; ACF64468.
XX
XX
XX New Propionibacterium acnes polypeptides and polynucleotides encoding the
PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT or for stimulating an immune response specific for a P. acnes protein.
PT
XX
XX Example 1; SEQ ID NO 8941; 1481bp; English.
XX
XX The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
CC encoding a Propionibacterium acnes protein. The invention also relates to
CC polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
CC immunogenic fragments of P. acnes polypeptides. The invention
CC additionally encompasses expression vectors and host cells comprising a
CC polynucleotide of the invention; antibodies against polypeptides of the
CC invention; fusion proteins comprising a polypeptide of the invention; a
CC method for stimulating an immune response specific for a P. acnes
CC polypeptide and an isolated T cell population comprising T cells prepared
CC via this method; a vaccine composition (comprising P. acnes polypeptides,
CC polynucleotides, antibodies, fusion proteins, T cell populations, or
CC antigen-presenting cells that express the polypeptide); a method and kit
CC for detecting or determining the presence or absence of P. acnes in a
CC patient; and a method for inhibiting the development of P. acnes in a
CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC proteins, T cell populations or antigen-presenting cells that express the
CC polypeptides are useful for diagnosing, preventing or treating acne
CC vulgaris, or for stimulating an immune response specific for a P. acnes
CC protein. The polynucleotides can also be used as probes or primers for
CC nucleic acid hybridization. The vaccine composition is useful for the
CC stimulation of an immune response against P. acnes, or for treating acne,
CC and the kit is useful for performing a diagnostic assay. The present
CC sequence represents a polypeptide predicted to be encoded by an ORF (open
CC reading frame) contained within the P. acnes polynucleotides of the
CC invention. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX

SEQ Sequence 86 AA;

QY 1 AOGV 4
|||
Db 9 AOGV 12

RESULT 237
ADR87224
ID ADR87224 standard; protein; 86 AA.
XX
XX ADR87224;
XX
XX 16-DEC-2004 (first entry)
XX
XX Dust mite allergen Der p 1 fragment SEQ ID NO:13.
XX DE
XX Dust mite allergen; Der p 1; T-cell response; IgE; immunoglobulin E;
XX KW dust mite; allergen; Der p 1; T-cell response; IgE; immunoglobulin E;
XX KW immune response; antiallergic; gene therapy; vaccine.
XX
XX Dermatophagoides sp.
XX OS
XX WO2004081028-A2.
XX PN
XX 23-SEP-2004.
XX PD
XX 15-MAR-2004; 2004WO-IB001300.
XX PF
XX 14-MAR-2003; 2003US-0455004P.
XX PR 12-MAR-2004; 2004US-00799514.
XX PR
XX (UWLA-) UNIV LAUSANNE.
XX PA
XX Sperini F;
XX PI
XX WPI; 2004-668931/65.
XX DR
XX
XX New compositions including contiguous overlapping peptide fragments that
PT form an entire amino acid sequence of an allergen (e.g. Bee venom or
PT birch pollen allergen), useful for preventing or treating IgE-mediated
PT allergies.
XX
XX Claim 4; SEQ ID NO 13; 82bp; English.
XX
XX The invention relates to novel compositions including contiguous
CC overlapping peptide fragments which together form an entire amino acid
CC sequence of an allergen, where the fragments are capable of inducing a T-
CC cell response in patients who are hypersensitive to the allergen. The
CC contiguous overlapping peptide fragments further result in lower levels
CC of IgE stimulation activity. The lower levels of IgE stimulation activity
CC are zero or weak. The contiguous overlapping peptide fragments further
CC result in a decrease in T-cell response upon subsequent exposure to the
CC allergen, thus, modulating an immune response in the patients, who are
CC hypersensitive to the allergen. A composition of the invention has
CC antiallergic activity, and may have a use in gene therapy, and as a
CC vaccine. The composition and methods are useful for preventing or
CC treating IgE-mediated allergies. The present sequence represents a
CC fragment of an allergen of the invention, dust mite Der p 1.
XX
XX Sequence 86 AA;
SQ

.. Query Match 100.0%; Score 19; DB 8; Length 86;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
|||
Db 44 AOGV 47

RESULT 238
 ID AUA62248
 ID AUA62248 standard; protein; 87 AA.
 XX AUA62248;
 DT 27-FEB-2002 (first entry)
 DE Propionibacterium acnes immunogenic protein #23144.
 KW SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
 KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
 KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
 KW dermatological; osteopathic; neuroprotectant.
 OS Propionibacterium acnes.
 PN MO200181581-A2.
 XX
 PD 01-NOV-2001.
 XX
 PF 20-APR-2001; 2001WO-US012865.
 XX
 PR 21-APR-2000; 2000US-0199047P.
 PR 02-JUN-2000; 2000US-0208841P.
 PR 07-JUL-2000; 2000US-0216747P.
 PA (CORI-) CORIXA CORP.
 XX
 XX SKEIKY YAM, PERSING DH, MITCHEM JL, WANG SS, BHATIA A;
 P1 L'maisonneuve J, Zhang Y, Jen S, Carter D;
 P1 WPI, 2001-616774/71.
 DR N-PSDB; AAS59624.
 XX
 PT Propionibacterium acnes polypeptides and nucleic acids useful for
 PT vaccinating against and diagnosing infections, especially useful for
 PT treating acne vulgaris.
 PS
 XX Example 1; SEQ ID NO 23443; 1069pp; English.
 PS
 CC Sequences AUA39105-AUA68017 represent Propionibacterium acnes immunogenic
 CC polypeptides. The proteins and their associated DNA sequences are used in
 CC the treatment, prevention and diagnosis of medical conditions caused by
 CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
 CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
 CC P. acnes is also involved in infections of bone, joints and the central
 CC nervous system, however it is particularly involved in the inflammatory
 CC lesions associated with acne vulgaris. A method for detecting the
 CC presence or absence of P. acnes in a patient comprises contacting a
 CC sample with a binding agent that binds to the proteins of the invention
 CC and determining the amount of bound protein in the sample. The
 CC polypeptides may be used as antigens in the production of antibodies
 CC specific for P. acnes proteins. These antibodies can be used to
 CC downregulate expression and activity of P. acnes polypeptides and
 CC therefore treat P. acnes infections. The antibodies may also be used as
 CC diagnostic agents for determining P. acnes presence, for example, by
 CC enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
 CC this patent did not form part of the printed specification, but was
 CC obtained in electronic format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 Q0 Sequence 87 AA;

Query Match	100.0%	Score 19;	DB 4;	Length 87;
Best Local Similarity	100.0%;	Pred. No. 3.7e+03;		
Matches 4; Conservative	0;	Mismatches 0;	Indels 0;	Gaps 0

Qy	1	AOGV	4
Db	4	2	AOGV 4.5

XX	ABM58767 standard; protein; 87 AA.
ID	ABM58767
XX	ABM58767;
AC	ABM58767;
XX	20-OCT-2003 (first entry)
DT	20-OCT-2003
DE	Propionibacterium acnes predicted ORF-encoded polypeptide #23443.
XX	Propionibacterium acnes predicted ORF-encoded polypeptide #23443.
KW	Acne vulgaris; antiseborrheic; dermatological; antibacterial;
RN	immunostimulant; immune response; vaccine.
OS	Propionibacterium acnes.
XX	MO2003033515-A1.
FN	24-APR-2003.
PD	24-APR-2003.
PD	11-OCT-2002; 2002WO-US032727.
PF	11-OCT-2002; 2002WO-US032727.
XX	15-OCT-2001; 2001US-00978825.
PR	15-OCT-2001; 2001US-00978825.
PA	(CORI-) CORIXA CORP.
PI	Mitcham JL, Skeiky YAW, Persing DH, Bhatia A, Maisonneuve JL;
PI	Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
PI	Barch B, Vallieve-Douglass J;
XX	WPI; 2003-381789/36.
DR	N-PSDB; ACF64553.
PT	New Propionibacterium acnes polypeptides and polynucleotides encoding the
PT	polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
FT	or for stimulating an immune response specific for a P. acnes protein.
XX	
XX	Example 1; SEQ ID NO 23443; 1481bp; English.
PS	The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
XX	encoding a Propionibacterium acnes protein. The invention also relates to
CC	polypeptides encoded by the polynucleotides (ABM5624-ABM64536) and to
CC	immunogenic fragments of P. acnes polypeptides. The invention
CC	additionally encompasses expression vectors and host cells comprising a
CC	polynucleotide of the invention; antibodies against polypeptides of the
CC	invention; fusion proteins comprising a polypeptide of the invention; a
CC	method for stimulating an immune response specific for a P. acnes
CC	polypeptide and an isolated T cell population comprising T cells prepared
CC	via this method; a vaccine composition (comprising P. acnes polypeptides,
CC	polynucleotides, antibodies, fusion proteins, T cell populations, or
CC	antigen-presenting cells that express the polypeptide); a method and kit
CC	for detecting or determining the presence or absence of P. acnes in a
CC	patient; and a method for inhibiting the development of P. acnes in a
CC	patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC	proteins, T cell populations or antigen-presenting cells that express them
CC	polypeptides are useful for diagnosing, preventing or treating acne
CC	vulgaris, or for stimulating an immune response specific for a P. acnes
CC	protein. The polynucleotides can also be used as probes or primers for
CC	nucleic acid hybridization. The vaccine composition is useful for the
CC	stimulation of an immune response against P. acnes, or for treating acne,
CC	and the kit is useful for performing a diagnostic assay. The present
CC	sequence represents a polypeptide predicted to be encoded by an ORF (open
CC	reading frame) contained within the P. acnes polynucleotides of the
CC	invention. Note: The sequence data for this patent did not form part of
CC	the printed specification, but was obtained in electronic format directly
CC	from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX	
XQ	Sequence 87 AA:

Query Match	100.0%;	Score 19;	DB 6;	Length 87;
Best Local Similarity	100.0%;	Pred. No. 3.7e+03;		
Matches	4;	Conservative	0;	Mismatches 0;
				Indels 0;
				Gaps 0

QY 1 AOGV 4
 ||||
 DB 42 AOGV 45

RESULT 240

AAU54801

ID AAU54801 standard; protein; 88 AA.

AC AAU54801;

DT 27-FEB-2002 (first entry)

XX Propionibacterium acnes immunogenic protein #15697.

XX SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
 KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
 KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
 KW dermatological; osteopathic; neuroprotectant.

OS Propionibacterium acnes.

PN WO200181581-A2.

XX 01-NOV-2001.

XX 20-APR-2001; 2001WO-US012865.

XX 21-APR-2000; 2000US-0199047P.

XX 02-JUN-2000; 2000US-0208841P.

XX 07-JUL-2000; 2000US-0216747P.

XX (CORI-) CORIXA CORP.

XX Skeiky YAM, Persing DH, Mitcham JL, Wang SS, Bhatia A;

XX L'maisonmeuve J, Zhang Y, Jen S, Carter D;

XX WPI; 2001-616774/71.

XX N-PSDB; AAS59566.

XX Propionibacterium acnes polypeptides and nucleic acids useful for

XX treating against and diagnosing infections, especially useful for

XX treating acne vulgaris.

XX Example 1; SEQ ID NO 15996; 10699P; English.

XX Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic

XX polypeptides. The proteins and their associated DNA sequences are used in

XX the treatment, prevention and diagnosis of medical conditions caused by

XX P. acnes. The disorders include SAPHO syndrome (synovitis, acne,

XX pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.

XX P. acnes is also involved in infections of bone, joints and the inflammatory

XX nervous system, however it is particularly involved in the inflammatory

XX lesions associated with acne vulgaris. A method for detecting the

XX presence or absence of P. acnes in a patient comprises contacting a

XX sample with a binding agent that binds to the proteins of the invention

XX and determining the amount of bound protein in the sample. The

XX polypeptides may be used as antigens in the production of antibodies

XX specific for P. acnes proteins. These antibodies can be used to

XX downregulate expression and activity of P. acnes polypeptides and

XX therefore treat P. acnes infections. The antibodies may also be used as

XX diagnostic agents for determining P. acnes presence, for example, by

XX enzyme linked immunosorbent assay (ELISA). Note: The sequence data for

XX this patent did not form part of the printed specification, but was

XX obtained in electronic format directly from WIPO at

XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 88 AA;

XX Query Match 100.0%; Score 19; DB 4; Length 88;

XX Best Local Similarity 100.0%; Pred. No. 3.8e+03; Indels 0; Gaps 0;

XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AOGV 4
 ||||
 DB 82 AOGV 85

RESULT 241

ABU60929

ID ABU60929 standard; protein; 88 AA.

AC ABU60929;

DT 08-MAY-2003 (first entry)

XX Lung specific protein (LSP) #32.

XX Human; gene therapy; vaccine; lung specific antigen; cancer diagnosis;
 KW cancer monitoring; cancer staging; cancer imaging; lung cancer;
 KW non-cancerous diseases of the lung; transgenic animal.

OS Homo sapiens.

PN WO200268633-A2.

XX 06-SEP-2002.

XX 21-NOV-2001; 2001WO-US043612.

XX 22-NOV-2000; 2000US-0252500P.

XX (DIAD-) DIADENXUS INC.

XX Maclna RA, Recipon H, Chen S, Sun Y, Liu C;

XX WPI; 2002-713376/77.

XX New isolated human nucleic acid molecule and polypeptide, useful for

XX identifying, diagnosing, monitoring, staging, imaging and treating lung

XX cancer and non-cancerous diseases of the lung.

XX Claim 11; Page 328; 3899P; English.

XX The invention describes an isolated human nucleic acid (1) encoding any

XX of 120 10-1533 residue amino acid sequences (S1), given in the

XX specification, comprising any of 164 179-12421 base pair sequences (S2),

XX given in the specification. The methods and compositions of the present

XX invention are useful for identifying, diagnosing, monitoring, staging,

XX imaging and treating lung cancer and non-cancerous diseases of the lung.

XX They are also used for identifying lung tissue, monitoring and

XX identifying and/or designing antagonists of the polypeptide of the

XX invention, gene therapy, production of transgenic animals and production

XX of engineered lung tissue for treatment and research. This is the amino

XX acid sequence of a lung specific nucleic acid

XX Sequence 88 AA;

XX Query Match 100.0%; Score 19; DB 5; Length 88;

XX Best Local Similarity 100.0%; Pred. No. 3.8e+03; Indels 0; Gaps 0;

XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Query Match 100.0%; Score 19; DB 4; Length 88;

XX Best Local Similarity 100.0%; Pred. No. 3.8e+03; Indels 0; Gaps 0;

XX Sequence 88 AA;

XX Query Match 100.0%; Score 19; DB 4; Length 88;

XX Best Local Similarity 100.0%; Pred. No. 3.8e+03; Indels 0; Gaps 0;

XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Query Match 100.0%; Score 19; DB 4; Length 88;

XX Best Local Similarity 100.0%; Pred. No. 3.8e+03; Indels 0; Gaps 0;

```

XX  Acne vulgaris; antiseborrheic; dermatological; antibacterial;
KM  immunostimulant; immune response; vaccine.
XX
XX  Propionibacterium acne.
XX
XX  WO2003033515-A1.
XX
XX  24-APR-2003.
XX
XX  11-OCT-2002; 2002MO-US032727.
XX
XX  15-OCT-2001; 2001US-00978825.
XX
XX  (CORI-) CORIXA CORP.
XX
XX  Mitcham JL, Skeiky YAW, Persing DH, Bhatia A, Maisonneuve JL;
PI  Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
PI  Barth B, Vallette-Doulaas J;
XX
XX  WPI; 2003-381789/36.
XX  N-PSDB; ACF64495.
XX
XX  New Propionibacterium acne polypeptides and polynucleotides encoding the
PT  polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT  or for stimulating an immune response specific for a P. acne protein.
XX
XX  Example 1; SEQ ID NO 15996; 1481pp; English.
XX
XX  The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
XX  encoding a Propionibacterium acne protein. The invention also relates to
XX  polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
XX  immunogenic fragments of P. acne polypeptides. The invention
XX  additionally encompasses expression vectors and host cells comprising a
XX  polynucleotide of the invention; antibodies against polypeptides of the
XX  invention; fusion proteins comprising a polypeptide of the invention; a
XX  method for stimulating an immune response specific for a P. acne
XX  polypeptide and an isolated T cell population comprising T cells prepared
XX  via this method; a vaccine composition (comprising P. acne polypeptides,
XX  polynucleotides, antibodies, fusion proteins, T cell populations, or
XX  antigen-presenting cells that express the polypeptide); a method and kit
XX  for detecting or determining the presence or absence of P. acne in a
XX  patient; and a method for inhibiting the development of P. acne in a
XX  patient. The P. acne polypeptides, polynucleotides, antibodies, fusion
XX  proteins, T cell populations or antigen-presenting cells that express the
XX  polypeptides are useful for diagnosing, preventing or treating acne
XX  vulgaris, or for stimulating an immune response specific for a P. acne
XX  protein. The polynucleotides can also be used as probes or primers for
XX  nucleic acid hybridisation. The vaccine composition is useful for the
XX  stimulation of an immune response against P. acne, or for treating acne,
XX  and the kit is useful for performing a diagnostic assay. The present
XX  sequence represents a polypeptide predicted to be encoded by an ORF (open
XX  reading frame) contained within the P. acne polynucleotides of the
XX  invention. Note: The sequence data for this patent did not form part of
XX  the printed specification, but was obtained in electronic format directly
XX  from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX  Sequence 88 AA;
SQ

```

```

Query Match      100.0%; Score 19; DB 6; Length 88;
Best Local Similarity 100.0%; Pred. No. 3.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

OY  1 ACGV 4
    ||||
DB  82 ACGV 85

```

```

RESULT 243
AAV74147
ID  AAV74147 standard; protein; 89 AA.
XX
XX  AAV74147;
AC

```

```

XX  14-MAR-2000 (first entry)
XX
XX  Human prostate tumor EST fragment derived protein #334.
XX
XX  Pancreas; tumor; EST; expressed sequence tag; human; cytosolic;
XX  treatment.
XX
XX  Homo sapiens.
XX
XX  DB19820190-A1.
XX
XX  04-NOV-1999.
XX
XX  28-APR-1998; 98DE-01020190.
XX
XX  28-APR-1998; 98DE-01020190.
XX
XX  (META-) METAGEN GES GENOMFORSCHUNG MBH.
XX
XX  Rosenthal A, Specht T, Hinzmann B, Schmitt A, Pilarsky C, Dahl E;
PI  WPI; 1999-621386/54.
XX  N-PSDB; AAZ52968.
XX
XX  New human nucleic acid sequences from pancreatic tumors, and related
PT  proteins.
XX
XX  Claim 23; Page 448; 502pp; German.
XX
XX  This invention describes novel polypeptides and their encoding nucleic
XX  acids derived from human pancreatic tumor tissue which have cytostatic
XX  activity. The sequences are also useful in producing pharmaceutical
XX  compositions for treatment of pancreatic tumors. AAT73814-774252
XX  represent protein fragments encoded by the human pancreatic tumor cDNA
XX  library derived expressed sequence tag (EST) sequences represented in
XX  AAZ52858-253014
XX
XX  Sequence 89 AA;
SQ

```

```

Query Match      100.0%; Score 19; DB 2; Length 89;
Best Local Similarity 100.0%; Pred. No. 3.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

OY  1 ACGV 4
    ||||
DB  32 ACGV 35

```

```

RESULT 244
AAV59139
ID  AAV59139 standard; protein; 89 AA.
XX
XX  AAV59139;
AC

```

```

DT  08-MAR-2000 (first entry)
XX
XX

```

```

DE  Mouse serine/threonine kinase, PAK4 partial protein sequence.
XX
XX  PAK4; serine/threonine kinase; GTPase; intracellular signal cascade; Rac;
XX  Cdc42h; morphogenesis; mitogenesis; JNK; p38 MAP kinase; mouse;
XX  actin polymerization; filopodia; cancer; arthritis.
XX
XX  Mus sp.
XX
XX  WO9963073-A1.
XX
XX  09-DEC-1999.
XX
XX  21-MAY-1999; 99MO-US011341.
XX
XX  21-MAY-1998; 98US-00082737.
XX

```

PA (UYCO) UNIV COLUMBIA NEW YORK.
 XX
 PI Minden A;
 XX
 DR WPI: 2000-072881/06.
 DR N-PSDB; AA240658.
 XX
 PT Novel mammalian nucleic acid useful for treating cancer and arthritis.
 XX
 PS Disclosure; Page 44; 95pp; English.
 XX
 CC The invention relates to an isolated mammalian nucleic acid that encodes
 CC PAK4, a novel serine/threonine kinase or its mutant homolog. PAK4 is an
 CC effector for the GTPases Rac and Cdc42Hs which are involved in
 CC intracellular signal cascades, morphogenesis and mitogenesis, and
 CC activate the JNK and p38 MAP kinase pathways. Inhibiting interaction of
 CC PAK4 with these enzymes will thus result in inhibition of actin
 CC polymerization and formation of filopodia. The PAK4 nucleic acid used for
 CC recombinant production of the protein, and as a source of probes for
 CC identifying homologous sequences and of (anti)sense oligonucleotides for
 CC inhibiting PAK4 expression. The protein, or its fragments, are used to
 CC raise specific antibodies and these are useful as ligands for therapeutic
 CC inhibition of interaction between PAK4 and its native binding partners.
 CC Inhibition of PAK4 activity or expression is used for treatment of cancer
 CC and arthritis. The present sequence represents the partial sequence of
 CC mouse PAK4
 XX
 SQ Sequence 89 AA;
 XX
 QY 1 ACGV 4
 DB 78 ACGV 81
 XX
 Query Match 100.0%; Score 19; DB 3; Length 89;
 Best Local Similarity 100.0%; Pred. No. 3.8e+03; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 RESULT 245
 ADP56448
 ID ADP56448 standard; protein; 89 AA.
 XX
 AC ADP56448;
 XX
 DT 18-NOV-2004 (first entry)
 XX
 DE Human PRO protein sequence SEQ ID NO:2424.
 XX
 KW human; PRO; immune related disease; inflammatory immune response;
 KW immune response stimulation; antiallergic; antianemic; antiarthritic;
 KW antidiabetic; antidiabetic; antiinflammatory; antiproliferative;
 KW antineumatic; antihypoid; CNS; dermatological; gastrointestinal;
 KW haemostatic; hepatotropic; immunostimulant; immunosuppressive; muscular;
 KW nephrotropic; neuroprotective; osteopathic; respiratory; vasotropic;
 KW virucide; gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN WO2004039956-A2.
 XX
 PD 13-MAY-2004.
 XX
 PP 28-OCT-2003; 2003WO-US034381.
 XX
 PR 29-OCT-2002; 2002US-0422472P.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Aggarwal S, Clark H, Gurney AL, Schoenfeld J, Williams PM;
 PI Wood WI, Wu TD;
 XX
 DR WPI: 2004-376182/35.
 DR N-PSDB; ADP56447.

XX
 PT New PRO polynucleotides and polypeptides, useful in useful in diagnosing
 PT and treating an immune related disease, e.g. systemic lupus
 PT erythematosus, rheumatoid arthritis, diabetes mellitus or asthma and in
 PT stimulating an immune response.
 XX
 PS Claim 1; SEQ ID NO 2424; 3009pp; English.
 XX
 CC The present invention describes an isolated PRO nucleic acid (1). Also
 CC described: (1) a vector comprising (1); (2) a host cell comprising the
 CC vector of (1); (3) a process for producing a PRO polypeptide; (4) an
 CC isolated PRO polypeptide; (5) a chimeric molecule comprising the
 CC polypeptide of (4) fused to a heterologous amino acid sequence; (6) an
 CC antibody which specifically binds to a polypeptide of (4); (7) a
 CC composition of matter comprising a polypeptide of (4), an agonist or
 CC antagonist of the polypeptide or an antibody that binds to the
 CC polypeptide in combination with a carrier; (8) an article of manufacture
 CC comprising a container, a label on the container and a composition of
 CC matter of (7); (9) a method of treating an immune related disease in a
 CC mammal; (10) a method for determining the presence of a PRO polypeptide
 CC in a sample suspected of having the polypeptide; (11) a method of
 CC diagnosing an immune related disease or an inflammatory immune response
 CC in mammal; (12) a method of identifying a compound that inhibits or
 CC mimics the activity of or expression of a gene encoding a PRO polypeptide
 CC; and (13) a method of stimulating the immune response in a mammal. The
 CC PRO sequences have antiallergic, antianemic, antiarthritic,
 CC antidiabetic, antidiabetic, antiinflammatory, antiproliferative,
 CC antineumatic, antihypoid, CNS, dermatological, gastrointestinal,
 CC haemostatic, hepatotropic, immunostimulant, immunosuppressive, muscular,
 CC nephrotropic, neuroprotective, osteopathic, respiratory, vasotropic and
 CC virucide activities, and can be used in gene therapy. The nucleic acid
 CC (1) and the encoded polypeptides, compositions, kits and methods are
 CC useful in diagnosing and treating an immune related disease and in
 CC stimulating an immune response. The present sequence represents a human
 CC PRO protein from the present invention.
 XX
 SQ Sequence 89 AA;
 XX
 QY 1 ACGV 4
 DB 62 ACGV 65
 XX
 Query Match 100.0%; Score 19; DB 8; Length 89;
 Best Local Similarity 100.0%; Pred. No. 3.8e+03; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 RESULT 246
 AAU14672
 ID AAU14672 standard; protein; 91 AA.
 XX
 AC AAU14672;
 XX
 DT 24-OCT-2001 (first entry)
 XX
 DE Novel bone marrow polypeptide #71.
 XX
 KW Bone marrow; diagnostic; therapeutic; gene therapy; antigenic;
 KW haematopoiesis; myeloid; lymph cell disorder; tissue regeneration;
 KW wound healing; nutritional supplement; immune disorder;
 KW severe combined immunodeficiency; SCID.
 XX
 OS Homo sapiens.
 XX
 PN WO200157187-A2.
 XX
 PD 09-AUG-2001.
 XX
 PP 05-FEB-2001; 2001WO-US003782.
 XX
 PR 03-FEB-2000; 2000US-00496914.
 PR 20-JUN-2000; 2000US-00598075.
 PR 19-JUL-2000; 2000US-00620325.

PR 30-NOV-2000; 2000US-0250683P.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Ford JE, Boyle BJ, Tang YT, Liu C, Asundi V, Zhou P, Xue AJ,
 PI Ren F, Drmanac RT;
 XX
 DR WPI; 2001-488875/53.
 DR N-PSDB; AAS22977.
 XX
 PT Nucleic acids encoding bone marrow polypeptides, useful in diagnostic and
 PT gene therapy.
 XX
 PS Claim 10; Page 245; 392pp; English.
 XX
 CC AAU14602-AAU14794 represent novel bone marrow polypeptides of the
 CC invention. The proteins and corresponding coding sequences may be used in
 CC the prevention, diagnosis and treatment of diseases associated with
 CC inappropriate bone marrow polypeptide expression. For example, to treat
 CC disorders associated with decreased expression by rectifying mutations or
 CC deletions in a patient's genome that affect the activity of the
 CC polypeptides by expressing inactive proteins or to supplement the
 CC patient's own production of the polypeptides. Additionally, the nucleic
 CC acids may be used to produce the polypeptides, by inserting the nucleic
 CC acids into a host cell and culturing the cell to express the protein. The
 CC nucleic acid and its complementary sequences may also be used as DNA
 CC probes in diagnostic assays to detect and quantitate the presence of
 CC similar nucleic acid sequences in samples, and therefore which patients
 CC may be in need of restorative therapy. The proteins may also be used as
 CC antigens in the production of antibodies against bone marrow proteins and
 CC in assays to identify modulators of their expression and activity. The
 CC anti-bone marrow protein antibodies and antagonists may also be used to
 CC down regulate expression and activity. The antibodies may also be used as
 CC diagnostic agents for detecting the presence of the protein in samples
 CC (e.g. by enzyme linked immunosorbent assay (ELISA)). The proteins may be
 CC used to regulate haemtopoiesis activity, and consequently in the
 CC treatment of myeloid or lymph cell disorders; in tissue regeneration,
 CC such as wound healing; as a nutritional supplement; and in treatment of
 CC immune disorders such as severe combined immunodeficiency (SCID)
 XX
 SQ Sequence 91 AA;
 XX
 QY 1 ACGV 4
 Db 9 ACGV 12
 ||||
 Query Match 100.0%; Score 19; DB 4; Length 91;
 Best Local Similarity 100.0%; Pred. No. 3.9e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 247
 ABG04651
 ID ABG04651 standard; protein; 91 AA.
 XX
 AC ABG04651;
 XX
 DT 13-FEB-2002 (first entry)
 XX
 DE Novel human diagnostic protein #4642.
 XX
 KW Human, chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder.
 XX
 OS Homo sapiens.
 XX
 PN MO200175067-A2.
 XX
 PD 11-OCT-2001.
 XX
 PF 30-MAR-2001; 2001WO-US008631.
 XX
 PR 31-MAR-2000; 2000US-00540217.

PR 23-AUG-2000; 2000US-00649167.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Drmanac RT, Liu C, Tang YT;
 XX
 DR WPI; 2001-639362/73.
 DR N-PSDB; AAS68838.
 XX
 PT New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity.
 XX
 PS Claim 20; SEQ ID NO 35010; 103pp; English.
 XX
 CC The invention relates to isolated polynucleotide (I) and polypeptide (II)
 CC sequences. (I) is useful as hybridisation probes, polymerase chain
 CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,
 CC and in recombinant production of (II). The polynucleotides are also used
 CC in diagnostics as expressed sequence tags for identifying expressed
 CC genes. (I) is useful in gene therapy techniques to restore normal
 CC activity of (II) or to treat disease states involving (II). (II) is
 CC useful for generating antibodies against it, detecting or quantitating a
 CC polypeptide in tissue, as molecular weight markers and as a food
 CC supplement. (II) and its binding partners are useful in medical imaging
 CC of sites expressing (II). (I) and (II) are useful for treating disorders
 CC involving aberrant protein expression or biological activity. The
 CC polynucleotide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic
 CC amino acid sequences of the invention. Note: The sequence data for this
 CC patent did not appear in the printed specification, but was obtained in
 CC electronic format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 91 AA;
 XX
 QY 1 ACGV 4
 Db 24 ACGV 27
 ||||
 Query Match 100.0%; Score 19; DB 4; Length 91;
 Best Local Similarity 100.0%; Pred. No. 3.9e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 248
 ABP09720
 ID ABP09720 standard; protein; 91 AA.
 XX
 AC ABP09720;
 XX
 DT 24-JUN-2002 (first entry)
 XX
 DE Human ORFX protein sequence SEQ ID NO:19422.
 XX
 KW Human, open reading frame; ORFX; gene therapy; cancer; cirrhosis;
 KW hyperproliferative disorder; psoriasis; benign tumor; haemorrhage;
 KW degenerative disorder; osteoarthritis; neurodegenerative disorder;
 KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
 KW hypertension; hypothyroidism; cholesterol ester storage disease;
 KW immune deficiency; immune disorder; infectious disease;
 KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
 KW myasthenia gravis.
 XX
 OS Homo sapiens.
 XX
 PN WO200192523-A2.
 XX
 PD 06-DEC-2001.

XX 29-MAY-2001; 2001WO-US010836.
 PF 30-MAY-2000; 2000US-0206132P.
 PR 29-AUG-2000; 2000US-0228716P.
 XX (CURA-) CURAGEN CORP.
 PA Shinkets RA, Leach MD;
 PI WPI; 2002-106308/14.
 DR N-PSDB; ABN25472.
 XX Novel human polypeptides and polynucleotides useful for diagnosing,
 PT preventing and treating cardiovascular disease, neurodegenerative,
 PT hyperproliferative disorders and autoimmune disorders.
 PS Disclosure; SEQ ID NO 19422; 1037bp; English.

XX The present invention describes substantially purified human proteins
 CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
 CC in the specification). ABN15762 to ABN27252 encode the human ORFX
 CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
 CC treating or preventing a pathology associated with an ORFX-associated
 CC disorder in humans, and in the manufacture of a medicament for treating a
 CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
 CC sequences can be used in gene therapy. ORFX sequences can be used in the
 CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
 CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
 CC osteoarthritis, neurodegenerative disorders, disorders related to organ
 CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
 CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
 CC storage disease, various immune deficiencies and disorders, infectious
 CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
 CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
 CC disease and autoimmune inflammatory eye disease. ORFX proteins are also
 CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
 CC bone degenerative disorders, or periodontal disease, and for gut
 CC protection or regeneration and treatment of lung or liver fibrosis,
 CC reperfusion injury in various tissues and conditions resulting from
 CC systemic cytokine damage. N.B. The sequence data for this patent did not
 CC form part of the printed specification, but was obtained in electronic
 CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 91 AA;
 Query Match 100.0%; Score 19; DB 5; Length 91;
 Best Local Similarity 100.0%; Pred. No. 3.9e+03; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0;

QY 1 AOGV 4
 Db 10 AOGV 13

RESULT 249
 ABP11499
 ID ABP11499 standard; protein; 91 AA.
 XX
 AC ABP11499;
 XX
 DT 24-JUN-2002 (first entry)
 XX
 DE Human ORFX protein sequence SEQ ID NO:22980.
 XX
 KM Human, open reading frame; ORFX; gene therapy; cancer; cirrhosis;
 KM hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
 KM degenerative disorder; osteoarthritis; neurodegenerative disorder;
 KM cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
 KM hyperensism; hypothyroidism; cholesterol ester storage disease;
 KM immune deficiency; immune disorder; infectious disease;
 KM autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
 KM myasthenia gravis.

XX Homo sapiens.
 OS
 XX W0200192523-A2.
 XX
 XX 06-DEC-2001.
 PD
 XX 29-MAY-2001; 2001WO-US010836.
 PF 30-MAY-2000; 2000US-0206132P.
 PR 29-AUG-2000; 2000US-0228716P.
 XX (CURA-) CURAGEN CORP.
 PA Shinkets RA, Leach MD;
 PI WPI; 2002-106308/14.
 DR N-PSDB; ABN27251.
 XX Novel human polypeptides and polynucleotides useful for diagnosing,
 PT preventing and treating cardiovascular disease, neurodegenerative,
 PT hyperproliferative disorders and autoimmune disorders.
 PS Disclosure; SEQ ID NO 22980; 1037bp; English.

XX The present invention describes substantially purified human proteins
 CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
 CC in the specification). ABN15762 to ABN27252 encode the human ORFX
 CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
 CC treating or preventing a pathology associated with an ORFX-associated
 CC disorder in humans, and in the manufacture of a medicament for treating a
 CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
 CC sequences can be used in gene therapy. ORFX sequences can be used in the
 CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
 CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
 CC osteoarthritis, neurodegenerative disorders, disorders related to organ
 CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
 CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
 CC storage disease, various immune deficiencies and disorders, infectious
 CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
 CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
 CC disease and autoimmune inflammatory eye disease. ORFX proteins are also
 CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
 CC bone degenerative disorders, or periodontal disease, and for gut
 CC protection or regeneration and treatment of lung or liver fibrosis,
 CC reperfusion injury in various tissues and conditions resulting from
 CC systemic cytokine damage. N.B. The sequence data for this patent did not
 CC form part of the printed specification, but was obtained in electronic
 CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 91 AA;
 Query Match 100.0%; Score 19; DB 5; Length 91;
 Best Local Similarity 100.0%; Pred. No. 3.9e+03; Indels 0; Gaps 0;
 Matches 4; Conservative 0; Mismatches 0;

QY 1 AOGV 4
 Db 16 AOGV 19

RESULT 250
 ABP79711
 ID ABP79711 standard; protein; 92 AA.
 XX
 AC ABP79711;
 XX
 DT 07-MAR-2003 (first entry)
 XX
 DE N. gonorrhoeae amino acid sequence SEQ ID 5952.
 XX
 KM Antibacterial; infection; vaccine; gene therapy.

OS Neisseria gonorrhoeae.
 XX
 PN W0200279243-A2.
 XX
 PD 10-OCT-2002.
 XX
 PF 12-FEB-2002; 2002WO-1B002069.
 XX
 PR 12-FEB-2001; 2001GB-00003424.
 XX
 PA (CHIR-) CHIRON SPA.
 XX
 PI Fontana MR, Pizsa M, Maignani V, Monaci E;
 XX
 XX WPI; 2003-058415/05.
 DR N-PSDB; AB240681.
 XX
 XX
 PT New protein from Neisseria gonorrhoeae, useful for the manufacture of a
 PT medicament for treating or preventing N. gonorrhoeae infection.
 XX
 PS Disclosure; Page 622; 815pp; English.
 XX
 CC The present invention relates to proteins from Neisseria gonorrhoeae.
 CC Also disclosed are the nucleic acid molecules encoding the proteins and
 CC antibodies that specifically bind to the proteins. The composition
 CC comprising the protein, nucleic acid or antibody is useful for the
 CC manufacture of a medicament for treating or preventing N. gonorrhoeae
 CC infection, this may be in the form of a vaccine or gene therapy.
 CC Sequences given in records ABP76736-ABP81046 represent nucleic acid
 CC molecules of the invention
 XX
 SQ Sequence 92 AA;
 Query Match 100.0%; Score 19; DB 6; Length 92;
 Best Local Similarity 100.0%; Pred. No. 3.9e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ACGV 4
 Db 49 ACGV 52

Search completed: February 21, 2006, 09:02:39
 Job time : 156 secs